{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 12,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "J9CHuoaAqP-L",
        "outputId": "35b80f6e-d357-46d5-f2bf-92325d139b4e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: langchain in /usr/local/lib/python3.10/dist-packages (0.3.9)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.0.36)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (3.11.2)\n",
            "Requirement already satisfied: async-timeout<5.0.0,>=4.0.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (4.0.3)\n",
            "Requirement already satisfied: langchain-core<0.4.0,>=0.3.21 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.3.21)\n",
            "Requirement already satisfied: langchain-text-splitters<0.4.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.3.2)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.17 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.1.143)\n",
            "Requirement already satisfied: numpy<2,>=1.22.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (1.26.4)\n",
            "Requirement already satisfied: pydantic<3.0.0,>=2.7.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.9.2)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<10,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (9.0.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (2.4.3)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (24.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.5.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (6.1.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (0.2.0)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.17.2)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain) (24.2)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (3.10.11)\n",
            "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (1.0.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain) (2.23.4)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2024.8.30)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain) (3.1.1)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.0.7)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.4.0,>=0.3.21->langchain) (3.0.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.2.2)\n",
            "\u001b[33mWARNING: Retrying (Retry(total=4, connect=None, read=None, redirect=None, status=None)) after connection broken by 'ReadTimeoutError(\"HTTPSConnectionPool(host='pypi.org', port=443): Read timed out. (read timeout=15)\")': /simple/lanchain-core/\u001b[0m\u001b[33m\n",
            "\u001b[0m\u001b[33mWARNING: Retrying (Retry(total=0, connect=None, read=None, redirect=None, status=None)) after connection broken by 'ReadTimeoutError(\"HTTPSConnectionPool(host='pypi.org', port=443): Read timed out. (read timeout=15)\")': /simple/lanchain-core/\u001b[0m\u001b[33m\n",
            "\u001b[0m\u001b[31mERROR: Could not find a version that satisfies the requirement lanchain-core (from versions: none)\u001b[0m\u001b[31m\n",
            "\u001b[0m\u001b[31mERROR: No matching distribution found for lanchain-core\u001b[0m\u001b[31m\n",
            "\u001b[0mRequirement already satisfied: langchain-community in /usr/local/lib/python3.10/dist-packages (0.3.9)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.0.36)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (3.11.2)\n",
            "Requirement already satisfied: dataclasses-json<0.7,>=0.5.7 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.6.7)\n",
            "Requirement already satisfied: httpx-sse<0.5.0,>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.4.0)\n",
            "Requirement already satisfied: langchain<0.4.0,>=0.3.8 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.3.9)\n",
            "Requirement already satisfied: langchain-core<0.4.0,>=0.3.21 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.3.21)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.125 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.1.143)\n",
            "Requirement already satisfied: numpy<2,>=1.22.4 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (1.26.4)\n",
            "Requirement already satisfied: pydantic-settings<3.0.0,>=2.4.0 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.6.1)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<10,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (9.0.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (2.4.3)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (24.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.5.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (6.1.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (0.2.0)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.17.2)\n",
            "Requirement already satisfied: async-timeout<6.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (4.0.3)\n",
            "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community) (3.23.1)\n",
            "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community) (0.9.0)\n",
            "Requirement already satisfied: langchain-text-splitters<0.4.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from langchain<0.4.0,>=0.3.8->langchain-community) (0.3.2)\n",
            "Requirement already satisfied: pydantic<3.0.0,>=2.7.4 in /usr/local/lib/python3.10/dist-packages (from langchain<0.4.0,>=0.3.8->langchain-community) (2.9.2)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain-community) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain-community) (24.2)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain-community) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-community) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-community) (3.10.11)\n",
            "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-community) (1.0.0)\n",
            "Requirement already satisfied: python-dotenv>=0.21.0 in /usr/local/lib/python3.10/dist-packages (from pydantic-settings<3.0.0,>=2.4.0->langchain-community) (1.0.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (2024.8.30)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain-community) (3.1.1)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (1.0.7)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.4.0,>=0.3.21->langchain-community) (3.0.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.8->langchain-community) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.8->langchain-community) (2.23.4)\n",
            "Requirement already satisfied: mypy-extensions>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain-community) (1.0.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (1.2.2)\n"
          ]
        }
      ],
      "source": [
        "!pip install langchain\n",
        "!pip install lanchain-core\n",
        "!pip install langchain-community"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 13,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "P37_3XBhqlvB",
        "outputId": "301aa6df-d501-4f84-8190-b01316edf0a4"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: colab-xterm in /usr/local/lib/python3.10/dist-packages (0.2.0)\n",
            "Requirement already satisfied: ptyprocess~=0.7.0 in /usr/local/lib/python3.10/dist-packages (from colab-xterm) (0.7.0)\n",
            "Requirement already satisfied: tornado>5.1 in /usr/local/lib/python3.10/dist-packages (from colab-xterm) (6.3.3)\n"
          ]
        }
      ],
      "source": [
        "!pip install colab-xterm"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 14,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "wwN-HWMjrpbp",
        "outputId": "97b4c977-d07c-46b7-a58c-0ed416f1f349"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "The colabxterm extension is already loaded. To reload it, use:\n",
            "  %reload_ext colabxterm\n"
          ]
        }
      ],
      "source": [
        "%load_ext colabxterm"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 15,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 838,
          "resources": {
            "https://localhost:10000/": {
              "data": "PCFkb2N0eXBlIGh0bWw+PGh0bWw+PGhlYWQ+PG1ldGEgY2hhcnNldD0idXRmLTgiLz48c2NyaXB0IGRlZmVyPSJkZWZlciIgc3JjPSJtYWluLmpzIj48L3NjcmlwdD48L2hlYWQ+PGJvZHk+PGRpdiBpZD0idGVybWluYWwiPjwvZGl2PjwvYm9keT48L2h0bWw+",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "147"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/main.js": {
              "data": "/*! For license information please see main.js.LICENSE.txt */
(()=>{var e={102:(e,t,r)=>{"use strict";r.d(t,{Z:()=>a});var i=r(81),n=r.n(i),o=r(645),s=r.n(o)()(n());s.push([e.id,'/**\n * Copyright (c) 2014 The xterm.js authors. All rights reserved.\n * Copyright (c) 2012-2013, Christopher Jeffrey (MIT License)\n * https://github.com/chjj/term.js\n * @license MIT\n *\n * Permission is hereby granted, free of charge, to any person obtaining a copy\n * of this software and associated documentation files (the "Software"), to deal\n * in the Software without restriction, including without limitation the rights\n * to use, copy, modify, merge, publish, distribute, sublicense, and/or sell\n * copies of the Software, and to permit persons to whom the Software is\n * furnished to do so, subject to the following conditions:\n *\n * The above copyright notice and this permission notice shall be included in\n * all copies or substantial portions of the Software.\n *\n * THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR\n * IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,\n * FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE\n * AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER\n * LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,\n * OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN\n * THE SOFTWARE.\n *\n * Originally forked from (with the author\'s permission):\n *   Fabrice Bellard\'s javascript vt100 for jslinux:\n *   http://bellard.org/jslinux/\n *   Copyright (c) 2011 Fabrice Bellard\n *   The original design remains. The terminal itself\n *   has been extended to include xterm CSI codes, among\n *   other features.\n */\n\n/**\n *  Default styles for xterm.js\n */\n\n.xterm {\n    position: relative;\n    -moz-user-select: none;\n         user-select: none;\n    -ms-user-select: none;\n    -webkit-user-select: none;\n}\n\n.xterm.focus,\n.xterm:focus {\n    outline: none;\n}\n\n.xterm .xterm-helpers {\n    position: absolute;\n    top: 0;\n    /**\n     * The z-index of the helpers must be higher than the canvases in order for\n     * IMEs to appear on top.\n     */\n    z-index: 5;\n}\n\n.xterm .xterm-helper-textarea {\n    padding: 0;\n    border: 0;\n    margin: 0;\n    /* Move textarea out of the screen to the far left, so that the cursor is not visible */\n    position: absolute;\n    opacity: 0;\n    left: -9999em;\n    top: 0;\n    width: 0;\n    height: 0;\n    z-index: -5;\n    /** Prevent wrapping so the IME appears against the textarea at the correct position */\n    white-space: nowrap;\n    overflow: hidden;\n    resize: none;\n}\n\n.xterm .composition-view {\n    /* TODO: Composition position got messed up somewhere */\n    background: #000;\n    color: #FFF;\n    display: none;\n    position: absolute;\n    white-space: nowrap;\n    z-index: 1;\n}\n\n.xterm .composition-view.active {\n    display: block;\n}\n\n.xterm .xterm-viewport {\n    /* On OS X this is required in order for the scroll bar to appear fully opaque */\n    background-color: #000;\n    overflow-y: scroll;\n    cursor: default;\n    position: absolute;\n    right: 0;\n    left: 0;\n    top: 0;\n    bottom: 0;\n}\n\n.xterm .xterm-screen {\n    position: relative;\n}\n\n.xterm .xterm-screen canvas {\n    position: absolute;\n    left: 0;\n    top: 0;\n}\n\n.xterm .xterm-scroll-area {\n    visibility: hidden;\n}\n\n.xterm-char-measure-element {\n    display: inline-block;\n    visibility: hidden;\n    position: absolute;\n    top: 0;\n    left: -9999em;\n    line-height: normal;\n}\n\n.xterm {\n    cursor: text;\n}\n\n.xterm.enable-mouse-events {\n    /* When mouse events are enabled (eg. tmux), revert to the standard pointer cursor */\n    cursor: default;\n}\n\n.xterm.xterm-cursor-pointer,\n.xterm .xterm-cursor-pointer {\n    cursor: pointer;\n}\n\n.xterm.column-select.focus {\n    /* Column selection mode */\n    cursor: crosshair;\n}\n\n.xterm .xterm-accessibility,\n.xterm .xterm-message {\n    position: absolute;\n    left: 0;\n    top: 0;\n    bottom: 0;\n    right: 0;\n    z-index: 10;\n    color: transparent;\n}\n\n.xterm .live-region {\n    position: absolute;\n    left: -9999px;\n    width: 1px;\n    height: 1px;\n    overflow: hidden;\n}\n\n.xterm-dim {\n    opacity: 0.5;\n}\n\n.xterm-underline {\n    text-decoration: underline;\n}\n\n.xterm-strikethrough {\n    text-decoration: line-through;\n}\n',""]);const a=s},645:e=>{"use strict";e.exports=function(e){var t=[];return t.toString=function(){return this.map((function(t){var r="",i=void 0!==t[5];return t[4]&&(r+="@supports (".concat(t[4],") {")),t[2]&&(r+="@media ".concat(t[2]," {")),i&&(r+="@layer".concat(t[5].length>0?" ".concat(t[5]):""," {")),r+=e(t),i&&(r+="}"),t[2]&&(r+="}"),t[4]&&(r+="}"),r})).join("")},t.i=function(e,r,i,n,o){"string"==typeof e&&(e=[[null,e,void 0]]);var s={};if(i)for(var a=0;a<this.length;a++){var c=this[a][0];null!=c&&(s[c]=!0)}for(var l=0;l<e.length;l++){var u=[].concat(e[l]);i&&s[u[0]]||(void 0!==o&&(void 0===u[5]||(u[1]="@layer".concat(u[5].length>0?" ".concat(u[5]):""," {").concat(u[1],"}")),u[5]=o),r&&(u[2]?(u[1]="@media ".concat(u[2]," {").concat(u[1],"}"),u[2]=r):u[2]=r),n&&(u[4]?(u[1]="@supports (".concat(u[4],") {").concat(u[1],"}"),u[4]=n):u[4]="".concat(n)),t.push(u))}},t}},81:e=>{"use strict";e.exports=function(e){return e[1]}},486:function(e,t,r){var i;e=r.nmd(e),function(){var n,o="Expected a function",s="__lodash_hash_undefined__",a="__lodash_placeholder__",c=32,l=128,u=1/0,h=9007199254740991,f=NaN,_=4294967295,d=[["ary",l],["bind",1],["bindKey",2],["curry",8],["curryRight",16],["flip",512],["partial",c],["partialRight",64],["rearg",256]],p="[object Arguments]",v="[object Array]",g="[object Boolean]",y="[object Date]",m="[object Error]",b="[object Function]",S="[object GeneratorFunction]",C="[object Map]",w="[object Number]",L="[object Object]",E="[object Promise]",x="[object RegExp]",A="[object Set]",k="[object String]",M="[object Symbol]",R="[object WeakMap]",T="[object ArrayBuffer]",O="[object DataView]",B="[object Float32Array]",D="[object Float64Array]",P="[object Int8Array]",I="[object Int16Array]",H="[object Int32Array]",j="[object Uint8Array]",F="[object Uint8ClampedArray]",W="[object Uint16Array]",U="[object Uint32Array]",q=/\b__p \+= '';/g,N=/\b(__p \+=) '' \+/g,z=/(__e\(.*?\)|\b__t\)) \+\n'';/g,K=/&(?:amp|lt|gt|quot|#39);/g,V=/[&<>"']/g,G=RegExp(K.source),Y=RegExp(V.source),X=/<%-([\s\S]+?)%>/g,Z=/<%([\s\S]+?)%>/g,J=/<%=([\s\S]+?)%>/g,$=/\.|\[(?:[^[\]]*|(["'])(?:(?!\1)[^\\]|\\.)*?\1)\]/,Q=/^\w*$/,ee=/[^.[\]]+|\[(?:(-?\d+(?:\.\d+)?)|(["'])((?:(?!\2)[^\\]|\\.)*?)\2)\]|(?=(?:\.|\[\])(?:\.|\[\]|$))/g,te=/[\\^$.*+?()[\]{}|]/g,re=RegExp(te.source),ie=/^\s+/,ne=/\s/,oe=/\{(?:\n\/\* \[wrapped with .+\] \*\/)?\n?/,se=/\{\n\/\* \[wrapped with (.+)\] \*/,ae=/,? & /,ce=/[^\x00-\x2f\x3a-\x40\x5b-\x60\x7b-\x7f]+/g,le=/[()=,{}\[\]\/\s]/,ue=/\\(\\)?/g,he=/\$\{([^\\}]*(?:\\.[^\\}]*)*)\}/g,fe=/\w*$/,_e=/^[-+]0x[0-9a-f]+$/i,de=/^0b[01]+$/i,pe=/^\[object .+?Constructor\]$/,ve=/^0o[0-7]+$/i,ge=/^(?:0|[1-9]\d*)$/,ye=/[\xc0-\xd6\xd8-\xf6\xf8-\xff\u0100-\u017f]/g,me=/($^)/,be=/['\n\r\u2028\u2029\\]/g,Se="\\u0300-\\u036f\\ufe20-\\ufe2f\\u20d0-\\u20ff",Ce="a-z\\xdf-\\xf6\\xf8-\\xff",we="A-Z\\xc0-\\xd6\\xd8-\\xde",Le="\\xac\\xb1\\xd7\\xf7\\x00-\\x2f\\x3a-\\x40\\x5b-\\x60\\x7b-\\xbf\\u2000-\\u206f \\t\\x0b\\f\\xa0\\ufeff\\n\\r\\u2028\\u2029\\u1680\\u180e\\u2000\\u2001\\u2002\\u2003\\u2004\\u2005\\u2006\\u2007\\u2008\\u2009\\u200a\\u202f\\u205f\\u3000",Ee="["+Le+"]",xe="["+Se+"]",Ae="\\d+",ke="["+Ce+"]",Me="[^\\ud800-\\udfff"+Le+Ae+"\\u2700-\\u27bf"+Ce+we+"]",Re="\\ud83c[\\udffb-\\udfff]",Te="[^\\ud800-\\udfff]",Oe="(?:\\ud83c[\\udde6-\\uddff]){2}",Be="[\\ud800-\\udbff][\\udc00-\\udfff]",De="["+we+"]",Pe="(?:"+ke+"|"+Me+")",Ie="(?:"+De+"|"+Me+")",He="(?:['’](?:d|ll|m|re|s|t|ve))?",je="(?:['’](?:D|LL|M|RE|S|T|VE))?",Fe="(?:"+xe+"|"+Re+")?",We="[\\ufe0e\\ufe0f]?",Ue=We+Fe+"(?:\\u200d(?:"+[Te,Oe,Be].join("|")+")"+We+Fe+")*",qe="(?:"+["[\\u2700-\\u27bf]",Oe,Be].join("|")+")"+Ue,Ne="(?:"+[Te+xe+"?",xe,Oe,Be,"[\\ud800-\\udfff]"].join("|")+")",ze=RegExp("['’]","g"),Ke=RegExp(xe,"g"),Ve=RegExp(Re+"(?="+Re+")|"+Ne+Ue,"g"),Ge=RegExp([De+"?"+ke+"+"+He+"(?="+[Ee,De,"$"].join("|")+")",Ie+"+"+je+"(?="+[Ee,De+Pe,"$"].join("|")+")",De+"?"+Pe+"+"+He,De+"+"+je,"\\d*(?:1ST|2ND|3RD|(?![123])\\dTH)(?=\\b|[a-z_])","\\d*(?:1st|2nd|3rd|(?![123])\\dth)(?=\\b|[A-Z_])",Ae,qe].join("|"),"g"),Ye=RegExp("[\\u200d\\ud800-\\udfff"+Se+"\\ufe0e\\ufe0f]"),Xe=/[a-z][A-Z]|[A-Z]{2}[a-z]|[0-9][a-zA-Z]|[a-zA-Z][0-9]|[^a-zA-Z0-9 ]/,Ze=["Array","Buffer","DataView","Date","Error","Float32Array","Float64Array","Function","Int8Array","Int16Array","Int32Array","Map","Math","Object","Promise","RegExp","Set","String","Symbol","TypeError","Uint8Array","Uint8ClampedArray","Uint16Array","Uint32Array","WeakMap","_","clearTimeout","isFinite","parseInt","setTimeout"],Je=-1,$e={};$e[B]=$e[D]=$e[P]=$e[I]=$e[H]=$e[j]=$e[F]=$e[W]=$e[U]=!0,$e[p]=$e[v]=$e[T]=$e[g]=$e[O]=$e[y]=$e[m]=$e[b]=$e[C]=$e[w]=$e[L]=$e[x]=$e[A]=$e[k]=$e[R]=!1;var Qe={};Qe[p]=Qe[v]=Qe[T]=Qe[O]=Qe[g]=Qe[y]=Qe[B]=Qe[D]=Qe[P]=Qe[I]=Qe[H]=Qe[C]=Qe[w]=Qe[L]=Qe[x]=Qe[A]=Qe[k]=Qe[M]=Qe[j]=Qe[F]=Qe[W]=Qe[U]=!0,Qe[m]=Qe[b]=Qe[R]=!1;var et={"\\":"\\","'":"'","\n":"n","\r":"r","\u2028":"u2028","\u2029":"u2029"},tt=parseFloat,rt=parseInt,it="object"==typeof r.g&&r.g&&r.g.Object===Object&&r.g,nt="object"==typeof self&&self&&self.Object===Object&&self,ot=it||nt||Function("return this")(),st=t&&!t.nodeType&&t,at=st&&e&&!e.nodeType&&e,ct=at&&at.exports===st,lt=ct&&it.process,ut=function(){try{return at&&at.require&&at.require("util").types||lt&&lt.binding&&lt.binding("util")}catch(e){}}(),ht=ut&&ut.isArrayBuffer,ft=ut&&ut.isDate,_t=ut&&ut.isMap,dt=ut&&ut.isRegExp,pt=ut&&ut.isSet,vt=ut&&ut.isTypedArray;function gt(e,t,r){switch(r.length){case 0:return e.call(t);case 1:return e.call(t,r[0]);case 2:return e.call(t,r[0],r[1]);case 3:return e.call(t,r[0],r[1],r[2])}return e.apply(t,r)}function yt(e,t,r,i){for(var n=-1,o=null==e?0:e.length;++n<o;){var s=e[n];t(i,s,r(s),e)}return i}function mt(e,t){for(var r=-1,i=null==e?0:e.length;++r<i&&!1!==t(e[r],r,e););return e}function bt(e,t){for(var r=null==e?0:e.length;r--&&!1!==t(e[r],r,e););return e}function St(e,t){for(var r=-1,i=null==e?0:e.length;++r<i;)if(!t(e[r],r,e))return!1;return!0}function Ct(e,t){for(var r=-1,i=null==e?0:e.length,n=0,o=[];++r<i;){var s=e[r];t(s,r,e)&&(o[n++]=s)}return o}function wt(e,t){return!(null==e||!e.length)&&Bt(e,t,0)>-1}function Lt(e,t,r){for(var i=-1,n=null==e?0:e.length;++i<n;)if(r(t,e[i]))return!0;return!1}function Et(e,t){for(var r=-1,i=null==e?0:e.length,n=Array(i);++r<i;)n[r]=t(e[r],r,e);return n}function xt(e,t){for(var r=-1,i=t.length,n=e.length;++r<i;)e[n+r]=t[r];return e}function At(e,t,r,i){var n=-1,o=null==e?0:e.length;for(i&&o&&(r=e[++n]);++n<o;)r=t(r,e[n],n,e);return r}function kt(e,t,r,i){var n=null==e?0:e.length;for(i&&n&&(r=e[--n]);n--;)r=t(r,e[n],n,e);return r}function Mt(e,t){for(var r=-1,i=null==e?0:e.length;++r<i;)if(t(e[r],r,e))return!0;return!1}var Rt=Ht("length");function Tt(e,t,r){var i;return r(e,(function(e,r,n){if(t(e,r,n))return i=r,!1})),i}function Ot(e,t,r,i){for(var n=e.length,o=r+(i?1:-1);i?o--:++o<n;)if(t(e[o],o,e))return o;return-1}function Bt(e,t,r){return t==t?function(e,t,r){for(var i=r-1,n=e.length;++i<n;)if(e[i]===t)return i;return-1}(e,t,r):Ot(e,Pt,r)}function Dt(e,t,r,i){for(var n=r-1,o=e.length;++n<o;)if(i(e[n],t))return n;return-1}function Pt(e){return e!=e}function It(e,t){var r=null==e?0:e.length;return r?Wt(e,t)/r:f}function Ht(e){return function(t){return null==t?n:t[e]}}function jt(e){return function(t){return null==e?n:e[t]}}function Ft(e,t,r,i,n){return n(e,(function(e,n,o){r=i?(i=!1,e):t(r,e,n,o)})),r}function Wt(e,t){for(var r,i=-1,o=e.length;++i<o;){var s=t(e[i]);s!==n&&(r=r===n?s:r+s)}return r}function Ut(e,t){for(var r=-1,i=Array(e);++r<e;)i[r]=t(r);return i}function qt(e){return e?e.slice(0,sr(e)+1).replace(ie,""):e}function Nt(e){return function(t){return e(t)}}function zt(e,t){return Et(t,(function(t){return e[t]}))}function Kt(e,t){return e.has(t)}function Vt(e,t){for(var r=-1,i=e.length;++r<i&&Bt(t,e[r],0)>-1;);return r}function Gt(e,t){for(var r=e.length;r--&&Bt(t,e[r],0)>-1;);return r}function Yt(e,t){for(var r=e.length,i=0;r--;)e[r]===t&&++i;return i}var Xt=jt({À:"A",Á:"A",Â:"A",Ã:"A",Ä:"A",Å:"A",à:"a",á:"a",â:"a",ã:"a",ä:"a",å:"a",Ç:"C",ç:"c",Ð:"D",ð:"d",È:"E",É:"E",Ê:"E",Ë:"E",è:"e",é:"e",ê:"e",ë:"e",Ì:"I",Í:"I",Î:"I",Ï:"I",ì:"i",í:"i",î:"i",ï:"i",Ñ:"N",ñ:"n",Ò:"O",Ó:"O",Ô:"O",Õ:"O",Ö:"O",Ø:"O",ò:"o",ó:"o",ô:"o",õ:"o",ö:"o",ø:"o",Ù:"U",Ú:"U",Û:"U",Ü:"U",ù:"u",ú:"u",û:"u",ü:"u",Ý:"Y",ý:"y",ÿ:"y",Æ:"Ae",æ:"ae",Þ:"Th",þ:"th",ß:"ss",Ā:"A",Ă:"A",Ą:"A",ā:"a",ă:"a",ą:"a",Ć:"C",Ĉ:"C",Ċ:"C",Č:"C",ć:"c",ĉ:"c",ċ:"c",č:"c",Ď:"D",Đ:"D",ď:"d",đ:"d",Ē:"E",Ĕ:"E",Ė:"E",Ę:"E",Ě:"E",ē:"e",ĕ:"e",ė:"e",ę:"e",ě:"e",Ĝ:"G",Ğ:"G",Ġ:"G",Ģ:"G",ĝ:"g",ğ:"g",ġ:"g",ģ:"g",Ĥ:"H",Ħ:"H",ĥ:"h",ħ:"h",Ĩ:"I",Ī:"I",Ĭ:"I",Į:"I",İ:"I",ĩ:"i",ī:"i",ĭ:"i",į:"i",ı:"i",Ĵ:"J",ĵ:"j",Ķ:"K",ķ:"k",ĸ:"k",Ĺ:"L",Ļ:"L",Ľ:"L",Ŀ:"L",Ł:"L",ĺ:"l",ļ:"l",ľ:"l",ŀ:"l",ł:"l",Ń:"N",Ņ:"N",Ň:"N",Ŋ:"N",ń:"n",ņ:"n",ň:"n",ŋ:"n",Ō:"O",Ŏ:"O",Ő:"O",ō:"o",ŏ:"o",ő:"o",Ŕ:"R",Ŗ:"R",Ř:"R",ŕ:"r",ŗ:"r",ř:"r",Ś:"S",Ŝ:"S",Ş:"S",Š:"S",ś:"s",ŝ:"s",ş:"s",š:"s",Ţ:"T",Ť:"T",Ŧ:"T",ţ:"t",ť:"t",ŧ:"t",Ũ:"U",Ū:"U",Ŭ:"U",Ů:"U",Ű:"U",Ų:"U",ũ:"u",ū:"u",ŭ:"u",ů:"u",ű:"u",ų:"u",Ŵ:"W",ŵ:"w",Ŷ:"Y",ŷ:"y",Ÿ:"Y",Ź:"Z",Ż:"Z",Ž:"Z",ź:"z",ż:"z",ž:"z",Ĳ:"IJ",ĳ:"ij",Œ:"Oe",œ:"oe",ŉ:"'n",ſ:"s"}),Zt=jt({"&":"&amp;","<":"&lt;",">":"&gt;",'"':"&quot;","'":"&#39;"});function Jt(e){return"\\"+et[e]}function $t(e){return Ye.test(e)}function Qt(e){var t=-1,r=Array(e.size);return e.forEach((function(e,i){r[++t]=[i,e]})),r}function er(e,t){return function(r){return e(t(r))}}function tr(e,t){for(var r=-1,i=e.length,n=0,o=[];++r<i;){var s=e[r];s!==t&&s!==a||(e[r]=a,o[n++]=r)}return o}function rr(e){var t=-1,r=Array(e.size);return e.forEach((function(e){r[++t]=e})),r}function ir(e){var t=-1,r=Array(e.size);return e.forEach((function(e){r[++t]=[e,e]})),r}function nr(e){return $t(e)?function(e){for(var t=Ve.lastIndex=0;Ve.test(e);)++t;return t}(e):Rt(e)}function or(e){return $t(e)?function(e){return e.match(Ve)||[]}(e):function(e){return e.split("")}(e)}function sr(e){for(var t=e.length;t--&&ne.test(e.charAt(t)););return t}var ar=jt({"&amp;":"&","&lt;":"<","&gt;":">","&quot;":'"',"&#39;":"'"}),cr=function e(t){var r,i=(t=null==t?ot:cr.defaults(ot.Object(),t,cr.pick(ot,Ze))).Array,ne=t.Date,Se=t.Error,Ce=t.Function,we=t.Math,Le=t.Object,Ee=t.RegExp,xe=t.String,Ae=t.TypeError,ke=i.prototype,Me=Ce.prototype,Re=Le.prototype,Te=t["__core-js_shared__"],Oe=Me.toString,Be=Re.hasOwnProperty,De=0,Pe=(r=/[^.]+$/.exec(Te&&Te.keys&&Te.keys.IE_PROTO||""))?"Symbol(src)_1."+r:"",Ie=Re.toString,He=Oe.call(Le),je=ot._,Fe=Ee("^"+Oe.call(Be).replace(te,"\\$&").replace(/hasOwnProperty|(function).*?(?=\\\()| for .+?(?=\\\])/g,"$1.*?")+"$"),We=ct?t.Buffer:n,Ue=t.Symbol,qe=t.Uint8Array,Ne=We?We.allocUnsafe:n,Ve=er(Le.getPrototypeOf,Le),Ye=Le.create,et=Re.propertyIsEnumerable,it=ke.splice,nt=Ue?Ue.isConcatSpreadable:n,st=Ue?Ue.iterator:n,at=Ue?Ue.toStringTag:n,lt=function(){try{var e=lo(Le,"defineProperty");return e({},"",{}),e}catch(e){}}(),ut=t.clearTimeout!==ot.clearTimeout&&t.clearTimeout,Rt=ne&&ne.now!==ot.Date.now&&ne.now,jt=t.setTimeout!==ot.setTimeout&&t.setTimeout,lr=we.ceil,ur=we.floor,hr=Le.getOwnPropertySymbols,fr=We?We.isBuffer:n,_r=t.isFinite,dr=ke.join,pr=er(Le.keys,Le),vr=we.max,gr=we.min,yr=ne.now,mr=t.parseInt,br=we.random,Sr=ke.reverse,Cr=lo(t,"DataView"),wr=lo(t,"Map"),Lr=lo(t,"Promise"),Er=lo(t,"Set"),xr=lo(t,"WeakMap"),Ar=lo(Le,"create"),kr=xr&&new xr,Mr={},Rr=Fo(Cr),Tr=Fo(wr),Or=Fo(Lr),Br=Fo(Er),Dr=Fo(xr),Pr=Ue?Ue.prototype:n,Ir=Pr?Pr.valueOf:n,Hr=Pr?Pr.toString:n;function jr(e){if(ra(e)&&!Ks(e)&&!(e instanceof qr)){if(e instanceof Ur)return e;if(Be.call(e,"__wrapped__"))return Wo(e)}return new Ur(e)}var Fr=function(){function e(){}return function(t){if(!ta(t))return{};if(Ye)return Ye(t);e.prototype=t;var r=new e;return e.prototype=n,r}}();function Wr(){}function Ur(e,t){this.__wrapped__=e,this.__actions__=[],this.__chain__=!!t,this.__index__=0,this.__values__=n}function qr(e){this.__wrapped__=e,this.__actions__=[],this.__dir__=1,this.__filtered__=!1,this.__iteratees__=[],this.__takeCount__=_,this.__views__=[]}function Nr(e){var t=-1,r=null==e?0:e.length;for(this.clear();++t<r;){var i=e[t];this.set(i[0],i[1])}}function zr(e){var t=-1,r=null==e?0:e.length;for(this.clear();++t<r;){var i=e[t];this.set(i[0],i[1])}}function Kr(e){var t=-1,r=null==e?0:e.length;for(this.clear();++t<r;){var i=e[t];this.set(i[0],i[1])}}function Vr(e){var t=-1,r=null==e?0:e.length;for(this.__data__=new Kr;++t<r;)this.add(e[t])}function Gr(e){var t=this.__data__=new zr(e);this.size=t.size}function Yr(e,t){var r=Ks(e),i=!r&&zs(e),n=!r&&!i&&Xs(e),o=!r&&!i&&!n&&ua(e),s=r||i||n||o,a=s?Ut(e.length,xe):[],c=a.length;for(var l in e)!t&&!Be.call(e,l)||s&&("length"==l||n&&("offset"==l||"parent"==l)||o&&("buffer"==l||"byteLength"==l||"byteOffset"==l)||go(l,c))||a.push(l);return a}function Xr(e){var t=e.length;return t?e[Ki(0,t-1)]:n}function Zr(e,t){return Do(An(e),oi(t,0,e.length))}function Jr(e){return Do(An(e))}function $r(e,t,r){(r!==n&&!Us(e[t],r)||r===n&&!(t in e))&&ii(e,t,r)}function Qr(e,t,r){var i=e[t];Be.call(e,t)&&Us(i,r)&&(r!==n||t in e)||ii(e,t,r)}function ei(e,t){for(var r=e.length;r--;)if(Us(e[r][0],t))return r;return-1}function ti(e,t,r,i){return ui(e,(function(e,n,o){t(i,e,r(e),o)})),i}function ri(e,t){return e&&kn(t,Oa(t),e)}function ii(e,t,r){"__proto__"==t&&lt?lt(e,t,{configurable:!0,enumerable:!0,value:r,writable:!0}):e[t]=r}function ni(e,t){for(var r=-1,o=t.length,s=i(o),a=null==e;++r<o;)s[r]=a?n:Aa(e,t[r]);return s}function oi(e,t,r){return e==e&&(r!==n&&(e=e<=r?e:r),t!==n&&(e=e>=t?e:t)),e}function si(e,t,r,i,o,s){var a,c=1&t,l=2&t,u=4&t;if(r&&(a=o?r(e,i,o,s):r(e)),a!==n)return a;if(!ta(e))return e;var h=Ks(e);if(h){if(a=function(e){var t=e.length,r=new e.constructor(t);return t&&"string"==typeof e[0]&&Be.call(e,"index")&&(r.index=e.index,r.input=e.input),r}(e),!c)return An(e,a)}else{var f=fo(e),_=f==b||f==S;if(Xs(e))return Sn(e,c);if(f==L||f==p||_&&!o){if(a=l||_?{}:po(e),!c)return l?function(e,t){return kn(e,ho(e),t)}(e,function(e,t){return e&&kn(t,Ba(t),e)}(a,e)):function(e,t){return kn(e,uo(e),t)}(e,ri(a,e))}else{if(!Qe[f])return o?e:{};a=function(e,t,r){var i,n=e.constructor;switch(t){case T:return Cn(e);case g:case y:return new n(+e);case O:return function(e,t){var r=t?Cn(e.buffer):e.buffer;return new e.constructor(r,e.byteOffset,e.byteLength)}(e,r);case B:case D:case P:case I:case H:case j:case F:case W:case U:return wn(e,r);case C:return new n;case w:case k:return new n(e);case x:return function(e){var t=new e.constructor(e.source,fe.exec(e));return t.lastIndex=e.lastIndex,t}(e);case A:return new n;case M:return i=e,Ir?Le(Ir.call(i)):{}}}(e,f,c)}}s||(s=new Gr);var d=s.get(e);if(d)return d;s.set(e,a),aa(e)?e.forEach((function(i){a.add(si(i,t,r,i,e,s))})):ia(e)&&e.forEach((function(i,n){a.set(n,si(i,t,r,n,e,s))}));var v=h?n:(u?l?ro:to:l?Ba:Oa)(e);return mt(v||e,(function(i,n){v&&(i=e[n=i]),Qr(a,n,si(i,t,r,n,e,s))})),a}function ai(e,t,r){var i=r.length;if(null==e)return!i;for(e=Le(e);i--;){var o=r[i],s=t[o],a=e[o];if(a===n&&!(o in e)||!s(a))return!1}return!0}function ci(e,t,r){if("function"!=typeof e)throw new Ae(o);return Ro((function(){e.apply(n,r)}),t)}function li(e,t,r,i){var n=-1,o=wt,s=!0,a=e.length,c=[],l=t.length;if(!a)return c;r&&(t=Et(t,Nt(r))),i?(o=Lt,s=!1):t.length>=200&&(o=Kt,s=!1,t=new Vr(t));e:for(;++n<a;){var u=e[n],h=null==r?u:r(u);if(u=i||0!==u?u:0,s&&h==h){for(var f=l;f--;)if(t[f]===h)continue e;c.push(u)}else o(t,h,i)||c.push(u)}return c}jr.templateSettings={escape:X,evaluate:Z,interpolate:J,variable:"",imports:{_:jr}},jr.prototype=Wr.prototype,jr.prototype.constructor=jr,Ur.prototype=Fr(Wr.prototype),Ur.prototype.constructor=Ur,qr.prototype=Fr(Wr.prototype),qr.prototype.constructor=qr,Nr.prototype.clear=function(){this.__data__=Ar?Ar(null):{},this.size=0},Nr.prototype.delete=function(e){var t=this.has(e)&&delete this.__data__[e];return this.size-=t?1:0,t},Nr.prototype.get=function(e){var t=this.__data__;if(Ar){var r=t[e];return r===s?n:r}return Be.call(t,e)?t[e]:n},Nr.prototype.has=function(e){var t=this.__data__;return Ar?t[e]!==n:Be.call(t,e)},Nr.prototype.set=function(e,t){var r=this.__data__;return this.size+=this.has(e)?0:1,r[e]=Ar&&t===n?s:t,this},zr.prototype.clear=function(){this.__data__=[],this.size=0},zr.prototype.delete=function(e){var t=this.__data__,r=ei(t,e);return!(r<0||(r==t.length-1?t.pop():it.call(t,r,1),--this.size,0))},zr.prototype.get=function(e){var t=this.__data__,r=ei(t,e);return r<0?n:t[r][1]},zr.prototype.has=function(e){return ei(this.__data__,e)>-1},zr.prototype.set=function(e,t){var r=this.__data__,i=ei(r,e);return i<0?(++this.size,r.push([e,t])):r[i][1]=t,this},Kr.prototype.clear=function(){this.size=0,this.__data__={hash:new Nr,map:new(wr||zr),string:new Nr}},Kr.prototype.delete=function(e){var t=ao(this,e).delete(e);return this.size-=t?1:0,t},Kr.prototype.get=function(e){return ao(this,e).get(e)},Kr.prototype.has=function(e){return ao(this,e).has(e)},Kr.prototype.set=function(e,t){var r=ao(this,e),i=r.size;return r.set(e,t),this.size+=r.size==i?0:1,this},Vr.prototype.add=Vr.prototype.push=function(e){return this.__data__.set(e,s),this},Vr.prototype.has=function(e){return this.__data__.has(e)},Gr.prototype.clear=function(){this.__data__=new zr,this.size=0},Gr.prototype.delete=function(e){var t=this.__data__,r=t.delete(e);return this.size=t.size,r},Gr.prototype.get=function(e){return this.__data__.get(e)},Gr.prototype.has=function(e){return this.__data__.has(e)},Gr.prototype.set=function(e,t){var r=this.__data__;if(r instanceof zr){var i=r.__data__;if(!wr||i.length<199)return i.push([e,t]),this.size=++r.size,this;r=this.__data__=new Kr(i)}return r.set(e,t),this.size=r.size,this};var ui=Tn(yi),hi=Tn(mi,!0);function fi(e,t){var r=!0;return ui(e,(function(e,i,n){return r=!!t(e,i,n)})),r}function _i(e,t,r){for(var i=-1,o=e.length;++i<o;){var s=e[i],a=t(s);if(null!=a&&(c===n?a==a&&!la(a):r(a,c)))var c=a,l=s}return l}function di(e,t){var r=[];return ui(e,(function(e,i,n){t(e,i,n)&&r.push(e)})),r}function pi(e,t,r,i,n){var o=-1,s=e.length;for(r||(r=vo),n||(n=[]);++o<s;){var a=e[o];t>0&&r(a)?t>1?pi(a,t-1,r,i,n):xt(n,a):i||(n[n.length]=a)}return n}var vi=On(),gi=On(!0);function yi(e,t){return e&&vi(e,t,Oa)}function mi(e,t){return e&&gi(e,t,Oa)}function bi(e,t){return Ct(t,(function(t){return $s(e[t])}))}function Si(e,t){for(var r=0,i=(t=gn(t,e)).length;null!=e&&r<i;)e=e[jo(t[r++])];return r&&r==i?e:n}function Ci(e,t,r){var i=t(e);return Ks(e)?i:xt(i,r(e))}function wi(e){return null==e?e===n?"[object Undefined]":"[object Null]":at&&at in Le(e)?function(e){var t=Be.call(e,at),r=e[at];try{e[at]=n;var i=!0}catch(e){}var o=Ie.call(e);return i&&(t?e[at]=r:delete e[at]),o}(e):function(e){return Ie.call(e)}(e)}function Li(e,t){return e>t}function Ei(e,t){return null!=e&&Be.call(e,t)}function xi(e,t){return null!=e&&t in Le(e)}function Ai(e,t,r){for(var o=r?Lt:wt,s=e[0].length,a=e.length,c=a,l=i(a),u=1/0,h=[];c--;){var f=e[c];c&&t&&(f=Et(f,Nt(t))),u=gr(f.length,u),l[c]=!r&&(t||s>=120&&f.length>=120)?new Vr(c&&f):n}f=e[0];var _=-1,d=l[0];e:for(;++_<s&&h.length<u;){var p=f[_],v=t?t(p):p;if(p=r||0!==p?p:0,!(d?Kt(d,v):o(h,v,r))){for(c=a;--c;){var g=l[c];if(!(g?Kt(g,v):o(e[c],v,r)))continue e}d&&d.push(v),h.push(p)}}return h}function ki(e,t,r){var i=null==(e=xo(e,t=gn(t,e)))?e:e[jo(Jo(t))];return null==i?n:gt(i,e,r)}function Mi(e){return ra(e)&&wi(e)==p}function Ri(e,t,r,i,o){return e===t||(null==e||null==t||!ra(e)&&!ra(t)?e!=e&&t!=t:function(e,t,r,i,o,s){var a=Ks(e),c=Ks(t),l=a?v:fo(e),u=c?v:fo(t),h=(l=l==p?L:l)==L,f=(u=u==p?L:u)==L,_=l==u;if(_&&Xs(e)){if(!Xs(t))return!1;a=!0,h=!1}if(_&&!h)return s||(s=new Gr),a||ua(e)?Qn(e,t,r,i,o,s):function(e,t,r,i,n,o,s){switch(r){case O:if(e.byteLength!=t.byteLength||e.byteOffset!=t.byteOffset)return!1;e=e.buffer,t=t.buffer;case T:return!(e.byteLength!=t.byteLength||!o(new qe(e),new qe(t)));case g:case y:case w:return Us(+e,+t);case m:return e.name==t.name&&e.message==t.message;case x:case k:return e==t+"";case C:var a=Qt;case A:var c=1&i;if(a||(a=rr),e.size!=t.size&&!c)return!1;var l=s.get(e);if(l)return l==t;i|=2,s.set(e,t);var u=Qn(a(e),a(t),i,n,o,s);return s.delete(e),u;case M:if(Ir)return Ir.call(e)==Ir.call(t)}return!1}(e,t,l,r,i,o,s);if(!(1&r)){var d=h&&Be.call(e,"__wrapped__"),b=f&&Be.call(t,"__wrapped__");if(d||b){var S=d?e.value():e,E=b?t.value():t;return s||(s=new Gr),o(S,E,r,i,s)}}return!!_&&(s||(s=new Gr),function(e,t,r,i,o,s){var a=1&r,c=to(e),l=c.length;if(l!=to(t).length&&!a)return!1;for(var u=l;u--;){var h=c[u];if(!(a?h in t:Be.call(t,h)))return!1}var f=s.get(e),_=s.get(t);if(f&&_)return f==t&&_==e;var d=!0;s.set(e,t),s.set(t,e);for(var p=a;++u<l;){var v=e[h=c[u]],g=t[h];if(i)var y=a?i(g,v,h,t,e,s):i(v,g,h,e,t,s);if(!(y===n?v===g||o(v,g,r,i,s):y)){d=!1;break}p||(p="constructor"==h)}if(d&&!p){var m=e.constructor,b=t.constructor;m==b||!("constructor"in e)||!("constructor"in t)||"function"==typeof m&&m instanceof m&&"function"==typeof b&&b instanceof b||(d=!1)}return s.delete(e),s.delete(t),d}(e,t,r,i,o,s))}(e,t,r,i,Ri,o))}function Ti(e,t,r,i){var o=r.length,s=o,a=!i;if(null==e)return!s;for(e=Le(e);o--;){var c=r[o];if(a&&c[2]?c[1]!==e[c[0]]:!(c[0]in e))return!1}for(;++o<s;){var l=(c=r[o])[0],u=e[l],h=c[1];if(a&&c[2]){if(u===n&&!(l in e))return!1}else{var f=new Gr;if(i)var _=i(u,h,l,e,t,f);if(!(_===n?Ri(h,u,3,i,f):_))return!1}}return!0}function Oi(e){return!(!ta(e)||(t=e,Pe&&Pe in t))&&($s(e)?Fe:pe).test(Fo(e));var t}function Bi(e){return"function"==typeof e?e:null==e?nc:"object"==typeof e?Ks(e)?ji(e[0],e[1]):Hi(e):_c(e)}function Di(e){if(!Co(e))return pr(e);var t=[];for(var r in Le(e))Be.call(e,r)&&"constructor"!=r&&t.push(r);return t}function Pi(e,t){return e<t}function Ii(e,t){var r=-1,n=Gs(e)?i(e.length):[];return ui(e,(function(e,i,o){n[++r]=t(e,i,o)})),n}function Hi(e){var t=co(e);return 1==t.length&&t[0][2]?Lo(t[0][0],t[0][1]):function(r){return r===e||Ti(r,e,t)}}function ji(e,t){return mo(e)&&wo(t)?Lo(jo(e),t):function(r){var i=Aa(r,e);return i===n&&i===t?ka(r,e):Ri(t,i,3)}}function Fi(e,t,r,i,o){e!==t&&vi(t,(function(s,a){if(o||(o=new Gr),ta(s))!function(e,t,r,i,o,s,a){var c=ko(e,r),l=ko(t,r),u=a.get(l);if(u)$r(e,r,u);else{var h=s?s(c,l,r+"",e,t,a):n,f=h===n;if(f){var _=Ks(l),d=!_&&Xs(l),p=!_&&!d&&ua(l);h=l,_||d||p?Ks(c)?h=c:Ys(c)?h=An(c):d?(f=!1,h=Sn(l,!0)):p?(f=!1,h=wn(l,!0)):h=[]:oa(l)||zs(l)?(h=c,zs(c)?h=ya(c):ta(c)&&!$s(c)||(h=po(l))):f=!1}f&&(a.set(l,h),o(h,l,i,s,a),a.delete(l)),$r(e,r,h)}}(e,t,a,r,Fi,i,o);else{var c=i?i(ko(e,a),s,a+"",e,t,o):n;c===n&&(c=s),$r(e,a,c)}}),Ba)}function Wi(e,t){var r=e.length;if(r)return go(t+=t<0?r:0,r)?e[t]:n}function Ui(e,t,r){t=t.length?Et(t,(function(e){return Ks(e)?function(t){return Si(t,1===e.length?e[0]:e)}:e})):[nc];var i=-1;t=Et(t,Nt(so()));var n=Ii(e,(function(e,r,n){var o=Et(t,(function(t){return t(e)}));return{criteria:o,index:++i,value:e}}));return function(e,t){var i=e.length;for(e.sort((function(e,t){return function(e,t,r){for(var i=-1,n=e.criteria,o=t.criteria,s=n.length,a=r.length;++i<s;){var c=Ln(n[i],o[i]);if(c)return i>=a?c:c*("desc"==r[i]?-1:1)}return e.index-t.index}(e,t,r)}));i--;)e[i]=e[i].value;return e}(n)}function qi(e,t,r){for(var i=-1,n=t.length,o={};++i<n;){var s=t[i],a=Si(e,s);r(a,s)&&Zi(o,gn(s,e),a)}return o}function Ni(e,t,r,i){var n=i?Dt:Bt,o=-1,s=t.length,a=e;for(e===t&&(t=An(t)),r&&(a=Et(e,Nt(r)));++o<s;)for(var c=0,l=t[o],u=r?r(l):l;(c=n(a,u,c,i))>-1;)a!==e&&it.call(a,c,1),it.call(e,c,1);return e}function zi(e,t){for(var r=e?t.length:0,i=r-1;r--;){var n=t[r];if(r==i||n!==o){var o=n;go(n)?it.call(e,n,1):ln(e,n)}}return e}function Ki(e,t){return e+ur(br()*(t-e+1))}function Vi(e,t){var r="";if(!e||t<1||t>h)return r;do{t%2&&(r+=e),(t=ur(t/2))&&(e+=e)}while(t);return r}function Gi(e,t){return To(Eo(e,t,nc),e+"")}function Yi(e){return Xr(Ua(e))}function Xi(e,t){var r=Ua(e);return Do(r,oi(t,0,r.length))}function Zi(e,t,r,i){if(!ta(e))return e;for(var o=-1,s=(t=gn(t,e)).length,a=s-1,c=e;null!=c&&++o<s;){var l=jo(t[o]),u=r;if("__proto__"===l||"constructor"===l||"prototype"===l)return e;if(o!=a){var h=c[l];(u=i?i(h,l,c):n)===n&&(u=ta(h)?h:go(t[o+1])?[]:{})}Qr(c,l,u),c=c[l]}return e}var Ji=kr?function(e,t){return kr.set(e,t),e}:nc,$i=lt?function(e,t){return lt(e,"toString",{configurable:!0,enumerable:!1,value:tc(t),writable:!0})}:nc;function Qi(e){return Do(Ua(e))}function en(e,t,r){var n=-1,o=e.length;t<0&&(t=-t>o?0:o+t),(r=r>o?o:r)<0&&(r+=o),o=t>r?0:r-t>>>0,t>>>=0;for(var s=i(o);++n<o;)s[n]=e[n+t];return s}function tn(e,t){var r;return ui(e,(function(e,i,n){return!(r=t(e,i,n))})),!!r}function rn(e,t,r){var i=0,n=null==e?i:e.length;if("number"==typeof t&&t==t&&n<=2147483647){for(;i<n;){var o=i+n>>>1,s=e[o];null!==s&&!la(s)&&(r?s<=t:s<t)?i=o+1:n=o}return n}return nn(e,t,nc,r)}function nn(e,t,r,i){var o=0,s=null==e?0:e.length;if(0===s)return 0;for(var a=(t=r(t))!=t,c=null===t,l=la(t),u=t===n;o<s;){var h=ur((o+s)/2),f=r(e[h]),_=f!==n,d=null===f,p=f==f,v=la(f);if(a)var g=i||p;else g=u?p&&(i||_):c?p&&_&&(i||!d):l?p&&_&&!d&&(i||!v):!d&&!v&&(i?f<=t:f<t);g?o=h+1:s=h}return gr(s,4294967294)}function on(e,t){for(var r=-1,i=e.length,n=0,o=[];++r<i;){var s=e[r],a=t?t(s):s;if(!r||!Us(a,c)){var c=a;o[n++]=0===s?0:s}}return o}function sn(e){return"number"==typeof e?e:la(e)?f:+e}function an(e){if("string"==typeof e)return e;if(Ks(e))return Et(e,an)+"";if(la(e))return Hr?Hr.call(e):"";var t=e+"";return"0"==t&&1/e==-1/0?"-0":t}function cn(e,t,r){var i=-1,n=wt,o=e.length,s=!0,a=[],c=a;if(r)s=!1,n=Lt;else if(o>=200){var l=t?null:Gn(e);if(l)return rr(l);s=!1,n=Kt,c=new Vr}else c=t?[]:a;e:for(;++i<o;){var u=e[i],h=t?t(u):u;if(u=r||0!==u?u:0,s&&h==h){for(var f=c.length;f--;)if(c[f]===h)continue e;t&&c.push(h),a.push(u)}else n(c,h,r)||(c!==a&&c.push(h),a.push(u))}return a}function ln(e,t){return null==(e=xo(e,t=gn(t,e)))||delete e[jo(Jo(t))]}function un(e,t,r,i){return Zi(e,t,r(Si(e,t)),i)}function hn(e,t,r,i){for(var n=e.length,o=i?n:-1;(i?o--:++o<n)&&t(e[o],o,e););return r?en(e,i?0:o,i?o+1:n):en(e,i?o+1:0,i?n:o)}function fn(e,t){var r=e;return r instanceof qr&&(r=r.value()),At(t,(function(e,t){return t.func.apply(t.thisArg,xt([e],t.args))}),r)}function _n(e,t,r){var n=e.length;if(n<2)return n?cn(e[0]):[];for(var o=-1,s=i(n);++o<n;)for(var a=e[o],c=-1;++c<n;)c!=o&&(s[o]=li(s[o]||a,e[c],t,r));return cn(pi(s,1),t,r)}function dn(e,t,r){for(var i=-1,o=e.length,s=t.length,a={};++i<o;){var c=i<s?t[i]:n;r(a,e[i],c)}return a}function pn(e){return Ys(e)?e:[]}function vn(e){return"function"==typeof e?e:nc}function gn(e,t){return Ks(e)?e:mo(e,t)?[e]:Ho(ma(e))}var yn=Gi;function mn(e,t,r){var i=e.length;return r=r===n?i:r,!t&&r>=i?e:en(e,t,r)}var bn=ut||function(e){return ot.clearTimeout(e)};function Sn(e,t){if(t)return e.slice();var r=e.length,i=Ne?Ne(r):new e.constructor(r);return e.copy(i),i}function Cn(e){var t=new e.constructor(e.byteLength);return new qe(t).set(new qe(e)),t}function wn(e,t){var r=t?Cn(e.buffer):e.buffer;return new e.constructor(r,e.byteOffset,e.length)}function Ln(e,t){if(e!==t){var r=e!==n,i=null===e,o=e==e,s=la(e),a=t!==n,c=null===t,l=t==t,u=la(t);if(!c&&!u&&!s&&e>t||s&&a&&l&&!c&&!u||i&&a&&l||!r&&l||!o)return 1;if(!i&&!s&&!u&&e<t||u&&r&&o&&!i&&!s||c&&r&&o||!a&&o||!l)return-1}return 0}function En(e,t,r,n){for(var o=-1,s=e.length,a=r.length,c=-1,l=t.length,u=vr(s-a,0),h=i(l+u),f=!n;++c<l;)h[c]=t[c];for(;++o<a;)(f||o<s)&&(h[r[o]]=e[o]);for(;u--;)h[c++]=e[o++];return h}function xn(e,t,r,n){for(var o=-1,s=e.length,a=-1,c=r.length,l=-1,u=t.length,h=vr(s-c,0),f=i(h+u),_=!n;++o<h;)f[o]=e[o];for(var d=o;++l<u;)f[d+l]=t[l];for(;++a<c;)(_||o<s)&&(f[d+r[a]]=e[o++]);return f}function An(e,t){var r=-1,n=e.length;for(t||(t=i(n));++r<n;)t[r]=e[r];return t}function kn(e,t,r,i){var o=!r;r||(r={});for(var s=-1,a=t.length;++s<a;){var c=t[s],l=i?i(r[c],e[c],c,r,e):n;l===n&&(l=e[c]),o?ii(r,c,l):Qr(r,c,l)}return r}function Mn(e,t){return function(r,i){var n=Ks(r)?yt:ti,o=t?t():{};return n(r,e,so(i,2),o)}}function Rn(e){return Gi((function(t,r){var i=-1,o=r.length,s=o>1?r[o-1]:n,a=o>2?r[2]:n;for(s=e.length>3&&"function"==typeof s?(o--,s):n,a&&yo(r[0],r[1],a)&&(s=o<3?n:s,o=1),t=Le(t);++i<o;){var c=r[i];c&&e(t,c,i,s)}return t}))}function Tn(e,t){return function(r,i){if(null==r)return r;if(!Gs(r))return e(r,i);for(var n=r.length,o=t?n:-1,s=Le(r);(t?o--:++o<n)&&!1!==i(s[o],o,s););return r}}function On(e){return function(t,r,i){for(var n=-1,o=Le(t),s=i(t),a=s.length;a--;){var c=s[e?a:++n];if(!1===r(o[c],c,o))break}return t}}function Bn(e){return function(t){var r=$t(t=ma(t))?or(t):n,i=r?r[0]:t.charAt(0),o=r?mn(r,1).join(""):t.slice(1);return i[e]()+o}}function Dn(e){return function(t){return At($a(za(t).replace(ze,"")),e,"")}}function Pn(e){return function(){var t=arguments;switch(t.length){case 0:return new e;case 1:return new e(t[0]);case 2:return new e(t[0],t[1]);case 3:return new e(t[0],t[1],t[2]);case 4:return new e(t[0],t[1],t[2],t[3]);case 5:return new e(t[0],t[1],t[2],t[3],t[4]);case 6:return new e(t[0],t[1],t[2],t[3],t[4],t[5]);case 7:return new e(t[0],t[1],t[2],t[3],t[4],t[5],t[6])}var r=Fr(e.prototype),i=e.apply(r,t);return ta(i)?i:r}}function In(e){return function(t,r,i){var o=Le(t);if(!Gs(t)){var s=so(r,3);t=Oa(t),r=function(e){return s(o[e],e,o)}}var a=e(t,r,i);return a>-1?o[s?t[a]:a]:n}}function Hn(e){return eo((function(t){var r=t.length,i=r,s=Ur.prototype.thru;for(e&&t.reverse();i--;){var a=t[i];if("function"!=typeof a)throw new Ae(o);if(s&&!c&&"wrapper"==no(a))var c=new Ur([],!0)}for(i=c?i:r;++i<r;){var l=no(a=t[i]),u="wrapper"==l?io(a):n;c=u&&bo(u[0])&&424==u[1]&&!u[4].length&&1==u[9]?c[no(u[0])].apply(c,u[3]):1==a.length&&bo(a)?c[l]():c.thru(a)}return function(){var e=arguments,i=e[0];if(c&&1==e.length&&Ks(i))return c.plant(i).value();for(var n=0,o=r?t[n].apply(this,e):i;++n<r;)o=t[n].call(this,o);return o}}))}function jn(e,t,r,o,s,a,c,u,h,f){var _=t&l,d=1&t,p=2&t,v=24&t,g=512&t,y=p?n:Pn(e);return function n(){for(var l=arguments.length,m=i(l),b=l;b--;)m[b]=arguments[b];if(v)var S=oo(n),C=Yt(m,S);if(o&&(m=En(m,o,s,v)),a&&(m=xn(m,a,c,v)),l-=C,v&&l<f){var w=tr(m,S);return Kn(e,t,jn,n.placeholder,r,m,w,u,h,f-l)}var L=d?r:this,E=p?L[e]:e;return l=m.length,u?m=Ao(m,u):g&&l>1&&m.reverse(),_&&h<l&&(m.length=h),this&&this!==ot&&this instanceof n&&(E=y||Pn(E)),E.apply(L,m)}}function Fn(e,t){return function(r,i){return function(e,t,r,i){return yi(e,(function(e,n,o){t(i,r(e),n,o)})),i}(r,e,t(i),{})}}function Wn(e,t){return function(r,i){var o;if(r===n&&i===n)return t;if(r!==n&&(o=r),i!==n){if(o===n)return i;"string"==typeof r||"string"==typeof i?(r=an(r),i=an(i)):(r=sn(r),i=sn(i)),o=e(r,i)}return o}}function Un(e){return eo((function(t){return t=Et(t,Nt(so())),Gi((function(r){var i=this;return e(t,(function(e){return gt(e,i,r)}))}))}))}function qn(e,t){var r=(t=t===n?" ":an(t)).length;if(r<2)return r?Vi(t,e):t;var i=Vi(t,lr(e/nr(t)));return $t(t)?mn(or(i),0,e).join(""):i.slice(0,e)}function Nn(e){return function(t,r,o){return o&&"number"!=typeof o&&yo(t,r,o)&&(r=o=n),t=da(t),r===n?(r=t,t=0):r=da(r),function(e,t,r,n){for(var o=-1,s=vr(lr((t-e)/(r||1)),0),a=i(s);s--;)a[n?s:++o]=e,e+=r;return a}(t,r,o=o===n?t<r?1:-1:da(o),e)}}function zn(e){return function(t,r){return"string"==typeof t&&"string"==typeof r||(t=ga(t),r=ga(r)),e(t,r)}}function Kn(e,t,r,i,o,s,a,l,u,h){var f=8&t;t|=f?c:64,4&(t&=~(f?64:c))||(t&=-4);var _=[e,t,o,f?s:n,f?a:n,f?n:s,f?n:a,l,u,h],d=r.apply(n,_);return bo(e)&&Mo(d,_),d.placeholder=i,Oo(d,e,t)}function Vn(e){var t=we[e];return function(e,r){if(e=ga(e),(r=null==r?0:gr(pa(r),292))&&_r(e)){var i=(ma(e)+"e").split("e");return+((i=(ma(t(i[0]+"e"+(+i[1]+r)))+"e").split("e"))[0]+"e"+(+i[1]-r))}return t(e)}}var Gn=Er&&1/rr(new Er([,-0]))[1]==u?function(e){return new Er(e)}:lc;function Yn(e){return function(t){var r=fo(t);return r==C?Qt(t):r==A?ir(t):function(e,t){return Et(t,(function(t){return[t,e[t]]}))}(t,e(t))}}function Xn(e,t,r,s,u,h,f,_){var d=2&t;if(!d&&"function"!=typeof e)throw new Ae(o);var p=s?s.length:0;if(p||(t&=-97,s=u=n),f=f===n?f:vr(pa(f),0),_=_===n?_:pa(_),p-=u?u.length:0,64&t){var v=s,g=u;s=u=n}var y=d?n:io(e),m=[e,t,r,s,u,v,g,h,f,_];if(y&&function(e,t){var r=e[1],i=t[1],n=r|i,o=n<131,s=i==l&&8==r||i==l&&256==r&&e[7].length<=t[8]||384==i&&t[7].length<=t[8]&&8==r;if(!o&&!s)return e;1&i&&(e[2]=t[2],n|=1&r?0:4);var c=t[3];if(c){var u=e[3];e[3]=u?En(u,c,t[4]):c,e[4]=u?tr(e[3],a):t[4]}(c=t[5])&&(u=e[5],e[5]=u?xn(u,c,t[6]):c,e[6]=u?tr(e[5],a):t[6]),(c=t[7])&&(e[7]=c),i&l&&(e[8]=null==e[8]?t[8]:gr(e[8],t[8])),null==e[9]&&(e[9]=t[9]),e[0]=t[0],e[1]=n}(m,y),e=m[0],t=m[1],r=m[2],s=m[3],u=m[4],!(_=m[9]=m[9]===n?d?0:e.length:vr(m[9]-p,0))&&24&t&&(t&=-25),t&&1!=t)b=8==t||16==t?function(e,t,r){var o=Pn(e);return function s(){for(var a=arguments.length,c=i(a),l=a,u=oo(s);l--;)c[l]=arguments[l];var h=a<3&&c[0]!==u&&c[a-1]!==u?[]:tr(c,u);return(a-=h.length)<r?Kn(e,t,jn,s.placeholder,n,c,h,n,n,r-a):gt(this&&this!==ot&&this instanceof s?o:e,this,c)}}(e,t,_):t!=c&&33!=t||u.length?jn.apply(n,m):function(e,t,r,n){var o=1&t,s=Pn(e);return function t(){for(var a=-1,c=arguments.length,l=-1,u=n.length,h=i(u+c),f=this&&this!==ot&&this instanceof t?s:e;++l<u;)h[l]=n[l];for(;c--;)h[l++]=arguments[++a];return gt(f,o?r:this,h)}}(e,t,r,s);else var b=function(e,t,r){var i=1&t,n=Pn(e);return function t(){return(this&&this!==ot&&this instanceof t?n:e).apply(i?r:this,arguments)}}(e,t,r);return Oo((y?Ji:Mo)(b,m),e,t)}function Zn(e,t,r,i){return e===n||Us(e,Re[r])&&!Be.call(i,r)?t:e}function Jn(e,t,r,i,o,s){return ta(e)&&ta(t)&&(s.set(t,e),Fi(e,t,n,Jn,s),s.delete(t)),e}function $n(e){return oa(e)?n:e}function Qn(e,t,r,i,o,s){var a=1&r,c=e.length,l=t.length;if(c!=l&&!(a&&l>c))return!1;var u=s.get(e),h=s.get(t);if(u&&h)return u==t&&h==e;var f=-1,_=!0,d=2&r?new Vr:n;for(s.set(e,t),s.set(t,e);++f<c;){var p=e[f],v=t[f];if(i)var g=a?i(v,p,f,t,e,s):i(p,v,f,e,t,s);if(g!==n){if(g)continue;_=!1;break}if(d){if(!Mt(t,(function(e,t){if(!Kt(d,t)&&(p===e||o(p,e,r,i,s)))return d.push(t)}))){_=!1;break}}else if(p!==v&&!o(p,v,r,i,s)){_=!1;break}}return s.delete(e),s.delete(t),_}function eo(e){return To(Eo(e,n,Vo),e+"")}function to(e){return Ci(e,Oa,uo)}function ro(e){return Ci(e,Ba,ho)}var io=kr?function(e){return kr.get(e)}:lc;function no(e){for(var t=e.name+"",r=Mr[t],i=Be.call(Mr,t)?r.length:0;i--;){var n=r[i],o=n.func;if(null==o||o==e)return n.name}return t}function oo(e){return(Be.call(jr,"placeholder")?jr:e).placeholder}function so(){var e=jr.iteratee||oc;return e=e===oc?Bi:e,arguments.length?e(arguments[0],arguments[1]):e}function ao(e,t){var r,i,n=e.__data__;return("string"==(i=typeof(r=t))||"number"==i||"symbol"==i||"boolean"==i?"__proto__"!==r:null===r)?n["string"==typeof t?"string":"hash"]:n.map}function co(e){for(var t=Oa(e),r=t.length;r--;){var i=t[r],n=e[i];t[r]=[i,n,wo(n)]}return t}function lo(e,t){var r=function(e,t){return null==e?n:e[t]}(e,t);return Oi(r)?r:n}var uo=hr?function(e){return null==e?[]:(e=Le(e),Ct(hr(e),(function(t){return et.call(e,t)})))}:vc,ho=hr?function(e){for(var t=[];e;)xt(t,uo(e)),e=Ve(e);return t}:vc,fo=wi;function _o(e,t,r){for(var i=-1,n=(t=gn(t,e)).length,o=!1;++i<n;){var s=jo(t[i]);if(!(o=null!=e&&r(e,s)))break;e=e[s]}return o||++i!=n?o:!!(n=null==e?0:e.length)&&ea(n)&&go(s,n)&&(Ks(e)||zs(e))}function po(e){return"function"!=typeof e.constructor||Co(e)?{}:Fr(Ve(e))}function vo(e){return Ks(e)||zs(e)||!!(nt&&e&&e[nt])}function go(e,t){var r=typeof e;return!!(t=null==t?h:t)&&("number"==r||"symbol"!=r&&ge.test(e))&&e>-1&&e%1==0&&e<t}function yo(e,t,r){if(!ta(r))return!1;var i=typeof t;return!!("number"==i?Gs(r)&&go(t,r.length):"string"==i&&t in r)&&Us(r[t],e)}function mo(e,t){if(Ks(e))return!1;var r=typeof e;return!("number"!=r&&"symbol"!=r&&"boolean"!=r&&null!=e&&!la(e))||Q.test(e)||!$.test(e)||null!=t&&e in Le(t)}function bo(e){var t=no(e),r=jr[t];if("function"!=typeof r||!(t in qr.prototype))return!1;if(e===r)return!0;var i=io(r);return!!i&&e===i[0]}(Cr&&fo(new Cr(new ArrayBuffer(1)))!=O||wr&&fo(new wr)!=C||Lr&&fo(Lr.resolve())!=E||Er&&fo(new Er)!=A||xr&&fo(new xr)!=R)&&(fo=function(e){var t=wi(e),r=t==L?e.constructor:n,i=r?Fo(r):"";if(i)switch(i){case Rr:return O;case Tr:return C;case Or:return E;case Br:return A;case Dr:return R}return t});var So=Te?$s:gc;function Co(e){var t=e&&e.constructor;return e===("function"==typeof t&&t.prototype||Re)}function wo(e){return e==e&&!ta(e)}function Lo(e,t){return function(r){return null!=r&&r[e]===t&&(t!==n||e in Le(r))}}function Eo(e,t,r){return t=vr(t===n?e.length-1:t,0),function(){for(var n=arguments,o=-1,s=vr(n.length-t,0),a=i(s);++o<s;)a[o]=n[t+o];o=-1;for(var c=i(t+1);++o<t;)c[o]=n[o];return c[t]=r(a),gt(e,this,c)}}function xo(e,t){return t.length<2?e:Si(e,en(t,0,-1))}function Ao(e,t){for(var r=e.length,i=gr(t.length,r),o=An(e);i--;){var s=t[i];e[i]=go(s,r)?o[s]:n}return e}function ko(e,t){if(("constructor"!==t||"function"!=typeof e[t])&&"__proto__"!=t)return e[t]}var Mo=Bo(Ji),Ro=jt||function(e,t){return ot.setTimeout(e,t)},To=Bo($i);function Oo(e,t,r){var i=t+"";return To(e,function(e,t){var r=t.length;if(!r)return e;var i=r-1;return t[i]=(r>1?"& ":"")+t[i],t=t.join(r>2?", ":" "),e.replace(oe,"{\n/* [wrapped with "+t+"] */\n")}(i,function(e,t){return mt(d,(function(r){var i="_."+r[0];t&r[1]&&!wt(e,i)&&e.push(i)})),e.sort()}(function(e){var t=e.match(se);return t?t[1].split(ae):[]}(i),r)))}function Bo(e){var t=0,r=0;return function(){var i=yr(),o=16-(i-r);if(r=i,o>0){if(++t>=800)return arguments[0]}else t=0;return e.apply(n,arguments)}}function Do(e,t){var r=-1,i=e.length,o=i-1;for(t=t===n?i:t;++r<t;){var s=Ki(r,o),a=e[s];e[s]=e[r],e[r]=a}return e.length=t,e}var Po,Io,Ho=(Po=Ps((function(e){var t=[];return 46===e.charCodeAt(0)&&t.push(""),e.replace(ee,(function(e,r,i,n){t.push(i?n.replace(ue,"$1"):r||e)})),t}),(function(e){return 500===Io.size&&Io.clear(),e})),Io=Po.cache,Po);function jo(e){if("string"==typeof e||la(e))return e;var t=e+"";return"0"==t&&1/e==-1/0?"-0":t}function Fo(e){if(null!=e){try{return Oe.call(e)}catch(e){}try{return e+""}catch(e){}}return""}function Wo(e){if(e instanceof qr)return e.clone();var t=new Ur(e.__wrapped__,e.__chain__);return t.__actions__=An(e.__actions__),t.__index__=e.__index__,t.__values__=e.__values__,t}var Uo=Gi((function(e,t){return Ys(e)?li(e,pi(t,1,Ys,!0)):[]})),qo=Gi((function(e,t){var r=Jo(t);return Ys(r)&&(r=n),Ys(e)?li(e,pi(t,1,Ys,!0),so(r,2)):[]})),No=Gi((function(e,t){var r=Jo(t);return Ys(r)&&(r=n),Ys(e)?li(e,pi(t,1,Ys,!0),n,r):[]}));function zo(e,t,r){var i=null==e?0:e.length;if(!i)return-1;var n=null==r?0:pa(r);return n<0&&(n=vr(i+n,0)),Ot(e,so(t,3),n)}function Ko(e,t,r){var i=null==e?0:e.length;if(!i)return-1;var o=i-1;return r!==n&&(o=pa(r),o=r<0?vr(i+o,0):gr(o,i-1)),Ot(e,so(t,3),o,!0)}function Vo(e){return null!=e&&e.length?pi(e,1):[]}function Go(e){return e&&e.length?e[0]:n}var Yo=Gi((function(e){var t=Et(e,pn);return t.length&&t[0]===e[0]?Ai(t):[]})),Xo=Gi((function(e){var t=Jo(e),r=Et(e,pn);return t===Jo(r)?t=n:r.pop(),r.length&&r[0]===e[0]?Ai(r,so(t,2)):[]})),Zo=Gi((function(e){var t=Jo(e),r=Et(e,pn);return(t="function"==typeof t?t:n)&&r.pop(),r.length&&r[0]===e[0]?Ai(r,n,t):[]}));function Jo(e){var t=null==e?0:e.length;return t?e[t-1]:n}var $o=Gi(Qo);function Qo(e,t){return e&&e.length&&t&&t.length?Ni(e,t):e}var es=eo((function(e,t){var r=null==e?0:e.length,i=ni(e,t);return zi(e,Et(t,(function(e){return go(e,r)?+e:e})).sort(Ln)),i}));function ts(e){return null==e?e:Sr.call(e)}var rs=Gi((function(e){return cn(pi(e,1,Ys,!0))})),is=Gi((function(e){var t=Jo(e);return Ys(t)&&(t=n),cn(pi(e,1,Ys,!0),so(t,2))})),ns=Gi((function(e){var t=Jo(e);return t="function"==typeof t?t:n,cn(pi(e,1,Ys,!0),n,t)}));function os(e){if(!e||!e.length)return[];var t=0;return e=Ct(e,(function(e){if(Ys(e))return t=vr(e.length,t),!0})),Ut(t,(function(t){return Et(e,Ht(t))}))}function ss(e,t){if(!e||!e.length)return[];var r=os(e);return null==t?r:Et(r,(function(e){return gt(t,n,e)}))}var as=Gi((function(e,t){return Ys(e)?li(e,t):[]})),cs=Gi((function(e){return _n(Ct(e,Ys))})),ls=Gi((function(e){var t=Jo(e);return Ys(t)&&(t=n),_n(Ct(e,Ys),so(t,2))})),us=Gi((function(e){var t=Jo(e);return t="function"==typeof t?t:n,_n(Ct(e,Ys),n,t)})),hs=Gi(os),fs=Gi((function(e){var t=e.length,r=t>1?e[t-1]:n;return r="function"==typeof r?(e.pop(),r):n,ss(e,r)}));function _s(e){var t=jr(e);return t.__chain__=!0,t}function ds(e,t){return t(e)}var ps=eo((function(e){var t=e.length,r=t?e[0]:0,i=this.__wrapped__,o=function(t){return ni(t,e)};return!(t>1||this.__actions__.length)&&i instanceof qr&&go(r)?((i=i.slice(r,+r+(t?1:0))).__actions__.push({func:ds,args:[o],thisArg:n}),new Ur(i,this.__chain__).thru((function(e){return t&&!e.length&&e.push(n),e}))):this.thru(o)})),vs=Mn((function(e,t,r){Be.call(e,r)?++e[r]:ii(e,r,1)})),gs=In(zo),ys=In(Ko);function ms(e,t){return(Ks(e)?mt:ui)(e,so(t,3))}function bs(e,t){return(Ks(e)?bt:hi)(e,so(t,3))}var Ss=Mn((function(e,t,r){Be.call(e,r)?e[r].push(t):ii(e,r,[t])})),Cs=Gi((function(e,t,r){var n=-1,o="function"==typeof t,s=Gs(e)?i(e.length):[];return ui(e,(function(e){s[++n]=o?gt(t,e,r):ki(e,t,r)})),s})),ws=Mn((function(e,t,r){ii(e,r,t)}));function Ls(e,t){return(Ks(e)?Et:Ii)(e,so(t,3))}var Es=Mn((function(e,t,r){e[r?0:1].push(t)}),(function(){return[[],[]]})),xs=Gi((function(e,t){if(null==e)return[];var r=t.length;return r>1&&yo(e,t[0],t[1])?t=[]:r>2&&yo(t[0],t[1],t[2])&&(t=[t[0]]),Ui(e,pi(t,1),[])})),As=Rt||function(){return ot.Date.now()};function ks(e,t,r){return t=r?n:t,t=e&&null==t?e.length:t,Xn(e,l,n,n,n,n,t)}function Ms(e,t){var r;if("function"!=typeof t)throw new Ae(o);return e=pa(e),function(){return--e>0&&(r=t.apply(this,arguments)),e<=1&&(t=n),r}}var Rs=Gi((function(e,t,r){var i=1;if(r.length){var n=tr(r,oo(Rs));i|=c}return Xn(e,i,t,r,n)})),Ts=Gi((function(e,t,r){var i=3;if(r.length){var n=tr(r,oo(Ts));i|=c}return Xn(t,i,e,r,n)}));function Os(e,t,r){var i,s,a,c,l,u,h=0,f=!1,_=!1,d=!0;if("function"!=typeof e)throw new Ae(o);function p(t){var r=i,o=s;return i=s=n,h=t,c=e.apply(o,r)}function v(e){return h=e,l=Ro(y,t),f?p(e):c}function g(e){var r=e-u;return u===n||r>=t||r<0||_&&e-h>=a}function y(){var e=As();if(g(e))return m(e);l=Ro(y,function(e){var r=t-(e-u);return _?gr(r,a-(e-h)):r}(e))}function m(e){return l=n,d&&i?p(e):(i=s=n,c)}function b(){var e=As(),r=g(e);if(i=arguments,s=this,u=e,r){if(l===n)return v(u);if(_)return bn(l),l=Ro(y,t),p(u)}return l===n&&(l=Ro(y,t)),c}return t=ga(t)||0,ta(r)&&(f=!!r.leading,a=(_="maxWait"in r)?vr(ga(r.maxWait)||0,t):a,d="trailing"in r?!!r.trailing:d),b.cancel=function(){l!==n&&bn(l),h=0,i=u=s=l=n},b.flush=function(){return l===n?c:m(As())},b}var Bs=Gi((function(e,t){return ci(e,1,t)})),Ds=Gi((function(e,t,r){return ci(e,ga(t)||0,r)}));function Ps(e,t){if("function"!=typeof e||null!=t&&"function"!=typeof t)throw new Ae(o);var r=function(){var i=arguments,n=t?t.apply(this,i):i[0],o=r.cache;if(o.has(n))return o.get(n);var s=e.apply(this,i);return r.cache=o.set(n,s)||o,s};return r.cache=new(Ps.Cache||Kr),r}function Is(e){if("function"!=typeof e)throw new Ae(o);return function(){var t=arguments;switch(t.length){case 0:return!e.call(this);case 1:return!e.call(this,t[0]);case 2:return!e.call(this,t[0],t[1]);case 3:return!e.call(this,t[0],t[1],t[2])}return!e.apply(this,t)}}Ps.Cache=Kr;var Hs=yn((function(e,t){var r=(t=1==t.length&&Ks(t[0])?Et(t[0],Nt(so())):Et(pi(t,1),Nt(so()))).length;return Gi((function(i){for(var n=-1,o=gr(i.length,r);++n<o;)i[n]=t[n].call(this,i[n]);return gt(e,this,i)}))})),js=Gi((function(e,t){var r=tr(t,oo(js));return Xn(e,c,n,t,r)})),Fs=Gi((function(e,t){var r=tr(t,oo(Fs));return Xn(e,64,n,t,r)})),Ws=eo((function(e,t){return Xn(e,256,n,n,n,t)}));function Us(e,t){return e===t||e!=e&&t!=t}var qs=zn(Li),Ns=zn((function(e,t){return e>=t})),zs=Mi(function(){return arguments}())?Mi:function(e){return ra(e)&&Be.call(e,"callee")&&!et.call(e,"callee")},Ks=i.isArray,Vs=ht?Nt(ht):function(e){return ra(e)&&wi(e)==T};function Gs(e){return null!=e&&ea(e.length)&&!$s(e)}function Ys(e){return ra(e)&&Gs(e)}var Xs=fr||gc,Zs=ft?Nt(ft):function(e){return ra(e)&&wi(e)==y};function Js(e){if(!ra(e))return!1;var t=wi(e);return t==m||"[object DOMException]"==t||"string"==typeof e.message&&"string"==typeof e.name&&!oa(e)}function $s(e){if(!ta(e))return!1;var t=wi(e);return t==b||t==S||"[object AsyncFunction]"==t||"[object Proxy]"==t}function Qs(e){return"number"==typeof e&&e==pa(e)}function ea(e){return"number"==typeof e&&e>-1&&e%1==0&&e<=h}function ta(e){var t=typeof e;return null!=e&&("object"==t||"function"==t)}function ra(e){return null!=e&&"object"==typeof e}var ia=_t?Nt(_t):function(e){return ra(e)&&fo(e)==C};function na(e){return"number"==typeof e||ra(e)&&wi(e)==w}function oa(e){if(!ra(e)||wi(e)!=L)return!1;var t=Ve(e);if(null===t)return!0;var r=Be.call(t,"constructor")&&t.constructor;return"function"==typeof r&&r instanceof r&&Oe.call(r)==He}var sa=dt?Nt(dt):function(e){return ra(e)&&wi(e)==x},aa=pt?Nt(pt):function(e){return ra(e)&&fo(e)==A};function ca(e){return"string"==typeof e||!Ks(e)&&ra(e)&&wi(e)==k}function la(e){return"symbol"==typeof e||ra(e)&&wi(e)==M}var ua=vt?Nt(vt):function(e){return ra(e)&&ea(e.length)&&!!$e[wi(e)]},ha=zn(Pi),fa=zn((function(e,t){return e<=t}));function _a(e){if(!e)return[];if(Gs(e))return ca(e)?or(e):An(e);if(st&&e[st])return function(e){for(var t,r=[];!(t=e.next()).done;)r.push(t.value);return r}(e[st]());var t=fo(e);return(t==C?Qt:t==A?rr:Ua)(e)}function da(e){return e?(e=ga(e))===u||e===-1/0?17976931348623157e292*(e<0?-1:1):e==e?e:0:0===e?e:0}function pa(e){var t=da(e),r=t%1;return t==t?r?t-r:t:0}function va(e){return e?oi(pa(e),0,_):0}function ga(e){if("number"==typeof e)return e;if(la(e))return f;if(ta(e)){var t="function"==typeof e.valueOf?e.valueOf():e;e=ta(t)?t+"":t}if("string"!=typeof e)return 0===e?e:+e;e=qt(e);var r=de.test(e);return r||ve.test(e)?rt(e.slice(2),r?2:8):_e.test(e)?f:+e}function ya(e){return kn(e,Ba(e))}function ma(e){return null==e?"":an(e)}var ba=Rn((function(e,t){if(Co(t)||Gs(t))kn(t,Oa(t),e);else for(var r in t)Be.call(t,r)&&Qr(e,r,t[r])})),Sa=Rn((function(e,t){kn(t,Ba(t),e)})),Ca=Rn((function(e,t,r,i){kn(t,Ba(t),e,i)})),wa=Rn((function(e,t,r,i){kn(t,Oa(t),e,i)})),La=eo(ni),Ea=Gi((function(e,t){e=Le(e);var r=-1,i=t.length,o=i>2?t[2]:n;for(o&&yo(t[0],t[1],o)&&(i=1);++r<i;)for(var s=t[r],a=Ba(s),c=-1,l=a.length;++c<l;){var u=a[c],h=e[u];(h===n||Us(h,Re[u])&&!Be.call(e,u))&&(e[u]=s[u])}return e})),xa=Gi((function(e){return e.push(n,Jn),gt(Pa,n,e)}));function Aa(e,t,r){var i=null==e?n:Si(e,t);return i===n?r:i}function ka(e,t){return null!=e&&_o(e,t,xi)}var Ma=Fn((function(e,t,r){null!=t&&"function"!=typeof t.toString&&(t=Ie.call(t)),e[t]=r}),tc(nc)),Ra=Fn((function(e,t,r){null!=t&&"function"!=typeof t.toString&&(t=Ie.call(t)),Be.call(e,t)?e[t].push(r):e[t]=[r]}),so),Ta=Gi(ki);function Oa(e){return Gs(e)?Yr(e):Di(e)}function Ba(e){return Gs(e)?Yr(e,!0):function(e){if(!ta(e))return function(e){var t=[];if(null!=e)for(var r in Le(e))t.push(r);return t}(e);var t=Co(e),r=[];for(var i in e)("constructor"!=i||!t&&Be.call(e,i))&&r.push(i);return r}(e)}var Da=Rn((function(e,t,r){Fi(e,t,r)})),Pa=Rn((function(e,t,r,i){Fi(e,t,r,i)})),Ia=eo((function(e,t){var r={};if(null==e)return r;var i=!1;t=Et(t,(function(t){return t=gn(t,e),i||(i=t.length>1),t})),kn(e,ro(e),r),i&&(r=si(r,7,$n));for(var n=t.length;n--;)ln(r,t[n]);return r})),Ha=eo((function(e,t){return null==e?{}:function(e,t){return qi(e,t,(function(t,r){return ka(e,r)}))}(e,t)}));function ja(e,t){if(null==e)return{};var r=Et(ro(e),(function(e){return[e]}));return t=so(t),qi(e,r,(function(e,r){return t(e,r[0])}))}var Fa=Yn(Oa),Wa=Yn(Ba);function Ua(e){return null==e?[]:zt(e,Oa(e))}var qa=Dn((function(e,t,r){return t=t.toLowerCase(),e+(r?Na(t):t)}));function Na(e){return Ja(ma(e).toLowerCase())}function za(e){return(e=ma(e))&&e.replace(ye,Xt).replace(Ke,"")}var Ka=Dn((function(e,t,r){return e+(r?"-":"")+t.toLowerCase()})),Va=Dn((function(e,t,r){return e+(r?" ":"")+t.toLowerCase()})),Ga=Bn("toLowerCase"),Ya=Dn((function(e,t,r){return e+(r?"_":"")+t.toLowerCase()})),Xa=Dn((function(e,t,r){return e+(r?" ":"")+Ja(t)})),Za=Dn((function(e,t,r){return e+(r?" ":"")+t.toUpperCase()})),Ja=Bn("toUpperCase");function $a(e,t,r){return e=ma(e),(t=r?n:t)===n?function(e){return Xe.test(e)}(e)?function(e){return e.match(Ge)||[]}(e):function(e){return e.match(ce)||[]}(e):e.match(t)||[]}var Qa=Gi((function(e,t){try{return gt(e,n,t)}catch(e){return Js(e)?e:new Se(e)}})),ec=eo((function(e,t){return mt(t,(function(t){t=jo(t),ii(e,t,Rs(e[t],e))})),e}));function tc(e){return function(){return e}}var rc=Hn(),ic=Hn(!0);function nc(e){return e}function oc(e){return Bi("function"==typeof e?e:si(e,1))}var sc=Gi((function(e,t){return function(r){return ki(r,e,t)}})),ac=Gi((function(e,t){return function(r){return ki(e,r,t)}}));function cc(e,t,r){var i=Oa(t),n=bi(t,i);null!=r||ta(t)&&(n.length||!i.length)||(r=t,t=e,e=this,n=bi(t,Oa(t)));var o=!(ta(r)&&"chain"in r&&!r.chain),s=$s(e);return mt(n,(function(r){var i=t[r];e[r]=i,s&&(e.prototype[r]=function(){var t=this.__chain__;if(o||t){var r=e(this.__wrapped__),n=r.__actions__=An(this.__actions__);return n.push({func:i,args:arguments,thisArg:e}),r.__chain__=t,r}return i.apply(e,xt([this.value()],arguments))})})),e}function lc(){}var uc=Un(Et),hc=Un(St),fc=Un(Mt);function _c(e){return mo(e)?Ht(jo(e)):function(e){return function(t){return Si(t,e)}}(e)}var dc=Nn(),pc=Nn(!0);function vc(){return[]}function gc(){return!1}var yc,mc=Wn((function(e,t){return e+t}),0),bc=Vn("ceil"),Sc=Wn((function(e,t){return e/t}),1),Cc=Vn("floor"),wc=Wn((function(e,t){return e*t}),1),Lc=Vn("round"),Ec=Wn((function(e,t){return e-t}),0);return jr.after=function(e,t){if("function"!=typeof t)throw new Ae(o);return e=pa(e),function(){if(--e<1)return t.apply(this,arguments)}},jr.ary=ks,jr.assign=ba,jr.assignIn=Sa,jr.assignInWith=Ca,jr.assignWith=wa,jr.at=La,jr.before=Ms,jr.bind=Rs,jr.bindAll=ec,jr.bindKey=Ts,jr.castArray=function(){if(!arguments.length)return[];var e=arguments[0];return Ks(e)?e:[e]},jr.chain=_s,jr.chunk=function(e,t,r){t=(r?yo(e,t,r):t===n)?1:vr(pa(t),0);var o=null==e?0:e.length;if(!o||t<1)return[];for(var s=0,a=0,c=i(lr(o/t));s<o;)c[a++]=en(e,s,s+=t);return c},jr.compact=function(e){for(var t=-1,r=null==e?0:e.length,i=0,n=[];++t<r;){var o=e[t];o&&(n[i++]=o)}return n},jr.concat=function(){var e=arguments.length;if(!e)return[];for(var t=i(e-1),r=arguments[0],n=e;n--;)t[n-1]=arguments[n];return xt(Ks(r)?An(r):[r],pi(t,1))},jr.cond=function(e){var t=null==e?0:e.length,r=so();return e=t?Et(e,(function(e){if("function"!=typeof e[1])throw new Ae(o);return[r(e[0]),e[1]]})):[],Gi((function(r){for(var i=-1;++i<t;){var n=e[i];if(gt(n[0],this,r))return gt(n[1],this,r)}}))},jr.conforms=function(e){return function(e){var t=Oa(e);return function(r){return ai(r,e,t)}}(si(e,1))},jr.constant=tc,jr.countBy=vs,jr.create=function(e,t){var r=Fr(e);return null==t?r:ri(r,t)},jr.curry=function e(t,r,i){var o=Xn(t,8,n,n,n,n,n,r=i?n:r);return o.placeholder=e.placeholder,o},jr.curryRight=function e(t,r,i){var o=Xn(t,16,n,n,n,n,n,r=i?n:r);return o.placeholder=e.placeholder,o},jr.debounce=Os,jr.defaults=Ea,jr.defaultsDeep=xa,jr.defer=Bs,jr.delay=Ds,jr.difference=Uo,jr.differenceBy=qo,jr.differenceWith=No,jr.drop=function(e,t,r){var i=null==e?0:e.length;return i?en(e,(t=r||t===n?1:pa(t))<0?0:t,i):[]},jr.dropRight=function(e,t,r){var i=null==e?0:e.length;return i?en(e,0,(t=i-(t=r||t===n?1:pa(t)))<0?0:t):[]},jr.dropRightWhile=function(e,t){return e&&e.length?hn(e,so(t,3),!0,!0):[]},jr.dropWhile=function(e,t){return e&&e.length?hn(e,so(t,3),!0):[]},jr.fill=function(e,t,r,i){var o=null==e?0:e.length;return o?(r&&"number"!=typeof r&&yo(e,t,r)&&(r=0,i=o),function(e,t,r,i){var o=e.length;for((r=pa(r))<0&&(r=-r>o?0:o+r),(i=i===n||i>o?o:pa(i))<0&&(i+=o),i=r>i?0:va(i);r<i;)e[r++]=t;return e}(e,t,r,i)):[]},jr.filter=function(e,t){return(Ks(e)?Ct:di)(e,so(t,3))},jr.flatMap=function(e,t){return pi(Ls(e,t),1)},jr.flatMapDeep=function(e,t){return pi(Ls(e,t),u)},jr.flatMapDepth=function(e,t,r){return r=r===n?1:pa(r),pi(Ls(e,t),r)},jr.flatten=Vo,jr.flattenDeep=function(e){return null!=e&&e.length?pi(e,u):[]},jr.flattenDepth=function(e,t){return null!=e&&e.length?pi(e,t=t===n?1:pa(t)):[]},jr.flip=function(e){return Xn(e,512)},jr.flow=rc,jr.flowRight=ic,jr.fromPairs=function(e){for(var t=-1,r=null==e?0:e.length,i={};++t<r;){var n=e[t];i[n[0]]=n[1]}return i},jr.functions=function(e){return null==e?[]:bi(e,Oa(e))},jr.functionsIn=function(e){return null==e?[]:bi(e,Ba(e))},jr.groupBy=Ss,jr.initial=function(e){return null!=e&&e.length?en(e,0,-1):[]},jr.intersection=Yo,jr.intersectionBy=Xo,jr.intersectionWith=Zo,jr.invert=Ma,jr.invertBy=Ra,jr.invokeMap=Cs,jr.iteratee=oc,jr.keyBy=ws,jr.keys=Oa,jr.keysIn=Ba,jr.map=Ls,jr.mapKeys=function(e,t){var r={};return t=so(t,3),yi(e,(function(e,i,n){ii(r,t(e,i,n),e)})),r},jr.mapValues=function(e,t){var r={};return t=so(t,3),yi(e,(function(e,i,n){ii(r,i,t(e,i,n))})),r},jr.matches=function(e){return Hi(si(e,1))},jr.matchesProperty=function(e,t){return ji(e,si(t,1))},jr.memoize=Ps,jr.merge=Da,jr.mergeWith=Pa,jr.method=sc,jr.methodOf=ac,jr.mixin=cc,jr.negate=Is,jr.nthArg=function(e){return e=pa(e),Gi((function(t){return Wi(t,e)}))},jr.omit=Ia,jr.omitBy=function(e,t){return ja(e,Is(so(t)))},jr.once=function(e){return Ms(2,e)},jr.orderBy=function(e,t,r,i){return null==e?[]:(Ks(t)||(t=null==t?[]:[t]),Ks(r=i?n:r)||(r=null==r?[]:[r]),Ui(e,t,r))},jr.over=uc,jr.overArgs=Hs,jr.overEvery=hc,jr.overSome=fc,jr.partial=js,jr.partialRight=Fs,jr.partition=Es,jr.pick=Ha,jr.pickBy=ja,jr.property=_c,jr.propertyOf=function(e){return function(t){return null==e?n:Si(e,t)}},jr.pull=$o,jr.pullAll=Qo,jr.pullAllBy=function(e,t,r){return e&&e.length&&t&&t.length?Ni(e,t,so(r,2)):e},jr.pullAllWith=function(e,t,r){return e&&e.length&&t&&t.length?Ni(e,t,n,r):e},jr.pullAt=es,jr.range=dc,jr.rangeRight=pc,jr.rearg=Ws,jr.reject=function(e,t){return(Ks(e)?Ct:di)(e,Is(so(t,3)))},jr.remove=function(e,t){var r=[];if(!e||!e.length)return r;var i=-1,n=[],o=e.length;for(t=so(t,3);++i<o;){var s=e[i];t(s,i,e)&&(r.push(s),n.push(i))}return zi(e,n),r},jr.rest=function(e,t){if("function"!=typeof e)throw new Ae(o);return Gi(e,t=t===n?t:pa(t))},jr.reverse=ts,jr.sampleSize=function(e,t,r){return t=(r?yo(e,t,r):t===n)?1:pa(t),(Ks(e)?Zr:Xi)(e,t)},jr.set=function(e,t,r){return null==e?e:Zi(e,t,r)},jr.setWith=function(e,t,r,i){return i="function"==typeof i?i:n,null==e?e:Zi(e,t,r,i)},jr.shuffle=function(e){return(Ks(e)?Jr:Qi)(e)},jr.slice=function(e,t,r){var i=null==e?0:e.length;return i?(r&&"number"!=typeof r&&yo(e,t,r)?(t=0,r=i):(t=null==t?0:pa(t),r=r===n?i:pa(r)),en(e,t,r)):[]},jr.sortBy=xs,jr.sortedUniq=function(e){return e&&e.length?on(e):[]},jr.sortedUniqBy=function(e,t){return e&&e.length?on(e,so(t,2)):[]},jr.split=function(e,t,r){return r&&"number"!=typeof r&&yo(e,t,r)&&(t=r=n),(r=r===n?_:r>>>0)?(e=ma(e))&&("string"==typeof t||null!=t&&!sa(t))&&!(t=an(t))&&$t(e)?mn(or(e),0,r):e.split(t,r):[]},jr.spread=function(e,t){if("function"!=typeof e)throw new Ae(o);return t=null==t?0:vr(pa(t),0),Gi((function(r){var i=r[t],n=mn(r,0,t);return i&&xt(n,i),gt(e,this,n)}))},jr.tail=function(e){var t=null==e?0:e.length;return t?en(e,1,t):[]},jr.take=function(e,t,r){return e&&e.length?en(e,0,(t=r||t===n?1:pa(t))<0?0:t):[]},jr.takeRight=function(e,t,r){var i=null==e?0:e.length;return i?en(e,(t=i-(t=r||t===n?1:pa(t)))<0?0:t,i):[]},jr.takeRightWhile=function(e,t){return e&&e.length?hn(e,so(t,3),!1,!0):[]},jr.takeWhile=function(e,t){return e&&e.length?hn(e,so(t,3)):[]},jr.tap=function(e,t){return t(e),e},jr.throttle=function(e,t,r){var i=!0,n=!0;if("function"!=typeof e)throw new Ae(o);return ta(r)&&(i="leading"in r?!!r.leading:i,n="trailing"in r?!!r.trailing:n),Os(e,t,{leading:i,maxWait:t,trailing:n})},jr.thru=ds,jr.toArray=_a,jr.toPairs=Fa,jr.toPairsIn=Wa,jr.toPath=function(e){return Ks(e)?Et(e,jo):la(e)?[e]:An(Ho(ma(e)))},jr.toPlainObject=ya,jr.transform=function(e,t,r){var i=Ks(e),n=i||Xs(e)||ua(e);if(t=so(t,4),null==r){var o=e&&e.constructor;r=n?i?new o:[]:ta(e)&&$s(o)?Fr(Ve(e)):{}}return(n?mt:yi)(e,(function(e,i,n){return t(r,e,i,n)})),r},jr.unary=function(e){return ks(e,1)},jr.union=rs,jr.unionBy=is,jr.unionWith=ns,jr.uniq=function(e){return e&&e.length?cn(e):[]},jr.uniqBy=function(e,t){return e&&e.length?cn(e,so(t,2)):[]},jr.uniqWith=function(e,t){return t="function"==typeof t?t:n,e&&e.length?cn(e,n,t):[]},jr.unset=function(e,t){return null==e||ln(e,t)},jr.unzip=os,jr.unzipWith=ss,jr.update=function(e,t,r){return null==e?e:un(e,t,vn(r))},jr.updateWith=function(e,t,r,i){return i="function"==typeof i?i:n,null==e?e:un(e,t,vn(r),i)},jr.values=Ua,jr.valuesIn=function(e){return null==e?[]:zt(e,Ba(e))},jr.without=as,jr.words=$a,jr.wrap=function(e,t){return js(vn(t),e)},jr.xor=cs,jr.xorBy=ls,jr.xorWith=us,jr.zip=hs,jr.zipObject=function(e,t){return dn(e||[],t||[],Qr)},jr.zipObjectDeep=function(e,t){return dn(e||[],t||[],Zi)},jr.zipWith=fs,jr.entries=Fa,jr.entriesIn=Wa,jr.extend=Sa,jr.extendWith=Ca,cc(jr,jr),jr.add=mc,jr.attempt=Qa,jr.camelCase=qa,jr.capitalize=Na,jr.ceil=bc,jr.clamp=function(e,t,r){return r===n&&(r=t,t=n),r!==n&&(r=(r=ga(r))==r?r:0),t!==n&&(t=(t=ga(t))==t?t:0),oi(ga(e),t,r)},jr.clone=function(e){return si(e,4)},jr.cloneDeep=function(e){return si(e,5)},jr.cloneDeepWith=function(e,t){return si(e,5,t="function"==typeof t?t:n)},jr.cloneWith=function(e,t){return si(e,4,t="function"==typeof t?t:n)},jr.conformsTo=function(e,t){return null==t||ai(e,t,Oa(t))},jr.deburr=za,jr.defaultTo=function(e,t){return null==e||e!=e?t:e},jr.divide=Sc,jr.endsWith=function(e,t,r){e=ma(e),t=an(t);var i=e.length,o=r=r===n?i:oi(pa(r),0,i);return(r-=t.length)>=0&&e.slice(r,o)==t},jr.eq=Us,jr.escape=function(e){return(e=ma(e))&&Y.test(e)?e.replace(V,Zt):e},jr.escapeRegExp=function(e){return(e=ma(e))&&re.test(e)?e.replace(te,"\\$&"):e},jr.every=function(e,t,r){var i=Ks(e)?St:fi;return r&&yo(e,t,r)&&(t=n),i(e,so(t,3))},jr.find=gs,jr.findIndex=zo,jr.findKey=function(e,t){return Tt(e,so(t,3),yi)},jr.findLast=ys,jr.findLastIndex=Ko,jr.findLastKey=function(e,t){return Tt(e,so(t,3),mi)},jr.floor=Cc,jr.forEach=ms,jr.forEachRight=bs,jr.forIn=function(e,t){return null==e?e:vi(e,so(t,3),Ba)},jr.forInRight=function(e,t){return null==e?e:gi(e,so(t,3),Ba)},jr.forOwn=function(e,t){return e&&yi(e,so(t,3))},jr.forOwnRight=function(e,t){return e&&mi(e,so(t,3))},jr.get=Aa,jr.gt=qs,jr.gte=Ns,jr.has=function(e,t){return null!=e&&_o(e,t,Ei)},jr.hasIn=ka,jr.head=Go,jr.identity=nc,jr.includes=function(e,t,r,i){e=Gs(e)?e:Ua(e),r=r&&!i?pa(r):0;var n=e.length;return r<0&&(r=vr(n+r,0)),ca(e)?r<=n&&e.indexOf(t,r)>-1:!!n&&Bt(e,t,r)>-1},jr.indexOf=function(e,t,r){var i=null==e?0:e.length;if(!i)return-1;var n=null==r?0:pa(r);return n<0&&(n=vr(i+n,0)),Bt(e,t,n)},jr.inRange=function(e,t,r){return t=da(t),r===n?(r=t,t=0):r=da(r),function(e,t,r){return e>=gr(t,r)&&e<vr(t,r)}(e=ga(e),t,r)},jr.invoke=Ta,jr.isArguments=zs,jr.isArray=Ks,jr.isArrayBuffer=Vs,jr.isArrayLike=Gs,jr.isArrayLikeObject=Ys,jr.isBoolean=function(e){return!0===e||!1===e||ra(e)&&wi(e)==g},jr.isBuffer=Xs,jr.isDate=Zs,jr.isElement=function(e){return ra(e)&&1===e.nodeType&&!oa(e)},jr.isEmpty=function(e){if(null==e)return!0;if(Gs(e)&&(Ks(e)||"string"==typeof e||"function"==typeof e.splice||Xs(e)||ua(e)||zs(e)))return!e.length;var t=fo(e);if(t==C||t==A)return!e.size;if(Co(e))return!Di(e).length;for(var r in e)if(Be.call(e,r))return!1;return!0},jr.isEqual=function(e,t){return Ri(e,t)},jr.isEqualWith=function(e,t,r){var i=(r="function"==typeof r?r:n)?r(e,t):n;return i===n?Ri(e,t,n,r):!!i},jr.isError=Js,jr.isFinite=function(e){return"number"==typeof e&&_r(e)},jr.isFunction=$s,jr.isInteger=Qs,jr.isLength=ea,jr.isMap=ia,jr.isMatch=function(e,t){return e===t||Ti(e,t,co(t))},jr.isMatchWith=function(e,t,r){return r="function"==typeof r?r:n,Ti(e,t,co(t),r)},jr.isNaN=function(e){return na(e)&&e!=+e},jr.isNative=function(e){if(So(e))throw new Se("Unsupported core-js use. Try https://npms.io/search?q=ponyfill.");return Oi(e)},jr.isNil=function(e){return null==e},jr.isNull=function(e){return null===e},jr.isNumber=na,jr.isObject=ta,jr.isObjectLike=ra,jr.isPlainObject=oa,jr.isRegExp=sa,jr.isSafeInteger=function(e){return Qs(e)&&e>=-9007199254740991&&e<=h},jr.isSet=aa,jr.isString=ca,jr.isSymbol=la,jr.isTypedArray=ua,jr.isUndefined=function(e){return e===n},jr.isWeakMap=function(e){return ra(e)&&fo(e)==R},jr.isWeakSet=function(e){return ra(e)&&"[object WeakSet]"==wi(e)},jr.join=function(e,t){return null==e?"":dr.call(e,t)},jr.kebabCase=Ka,jr.last=Jo,jr.lastIndexOf=function(e,t,r){var i=null==e?0:e.length;if(!i)return-1;var o=i;return r!==n&&(o=(o=pa(r))<0?vr(i+o,0):gr(o,i-1)),t==t?function(e,t,r){for(var i=r+1;i--;)if(e[i]===t)return i;return i}(e,t,o):Ot(e,Pt,o,!0)},jr.lowerCase=Va,jr.lowerFirst=Ga,jr.lt=ha,jr.lte=fa,jr.max=function(e){return e&&e.length?_i(e,nc,Li):n},jr.maxBy=function(e,t){return e&&e.length?_i(e,so(t,2),Li):n},jr.mean=function(e){return It(e,nc)},jr.meanBy=function(e,t){return It(e,so(t,2))},jr.min=function(e){return e&&e.length?_i(e,nc,Pi):n},jr.minBy=function(e,t){return e&&e.length?_i(e,so(t,2),Pi):n},jr.stubArray=vc,jr.stubFalse=gc,jr.stubObject=function(){return{}},jr.stubString=function(){return""},jr.stubTrue=function(){return!0},jr.multiply=wc,jr.nth=function(e,t){return e&&e.length?Wi(e,pa(t)):n},jr.noConflict=function(){return ot._===this&&(ot._=je),this},jr.noop=lc,jr.now=As,jr.pad=function(e,t,r){e=ma(e);var i=(t=pa(t))?nr(e):0;if(!t||i>=t)return e;var n=(t-i)/2;return qn(ur(n),r)+e+qn(lr(n),r)},jr.padEnd=function(e,t,r){e=ma(e);var i=(t=pa(t))?nr(e):0;return t&&i<t?e+qn(t-i,r):e},jr.padStart=function(e,t,r){e=ma(e);var i=(t=pa(t))?nr(e):0;return t&&i<t?qn(t-i,r)+e:e},jr.parseInt=function(e,t,r){return r||null==t?t=0:t&&(t=+t),mr(ma(e).replace(ie,""),t||0)},jr.random=function(e,t,r){if(r&&"boolean"!=typeof r&&yo(e,t,r)&&(t=r=n),r===n&&("boolean"==typeof t?(r=t,t=n):"boolean"==typeof e&&(r=e,e=n)),e===n&&t===n?(e=0,t=1):(e=da(e),t===n?(t=e,e=0):t=da(t)),e>t){var i=e;e=t,t=i}if(r||e%1||t%1){var o=br();return gr(e+o*(t-e+tt("1e-"+((o+"").length-1))),t)}return Ki(e,t)},jr.reduce=function(e,t,r){var i=Ks(e)?At:Ft,n=arguments.length<3;return i(e,so(t,4),r,n,ui)},jr.reduceRight=function(e,t,r){var i=Ks(e)?kt:Ft,n=arguments.length<3;return i(e,so(t,4),r,n,hi)},jr.repeat=function(e,t,r){return t=(r?yo(e,t,r):t===n)?1:pa(t),Vi(ma(e),t)},jr.replace=function(){var e=arguments,t=ma(e[0]);return e.length<3?t:t.replace(e[1],e[2])},jr.result=function(e,t,r){var i=-1,o=(t=gn(t,e)).length;for(o||(o=1,e=n);++i<o;){var s=null==e?n:e[jo(t[i])];s===n&&(i=o,s=r),e=$s(s)?s.call(e):s}return e},jr.round=Lc,jr.runInContext=e,jr.sample=function(e){return(Ks(e)?Xr:Yi)(e)},jr.size=function(e){if(null==e)return 0;if(Gs(e))return ca(e)?nr(e):e.length;var t=fo(e);return t==C||t==A?e.size:Di(e).length},jr.snakeCase=Ya,jr.some=function(e,t,r){var i=Ks(e)?Mt:tn;return r&&yo(e,t,r)&&(t=n),i(e,so(t,3))},jr.sortedIndex=function(e,t){return rn(e,t)},jr.sortedIndexBy=function(e,t,r){return nn(e,t,so(r,2))},jr.sortedIndexOf=function(e,t){var r=null==e?0:e.length;if(r){var i=rn(e,t);if(i<r&&Us(e[i],t))return i}return-1},jr.sortedLastIndex=function(e,t){return rn(e,t,!0)},jr.sortedLastIndexBy=function(e,t,r){return nn(e,t,so(r,2),!0)},jr.sortedLastIndexOf=function(e,t){if(null!=e&&e.length){var r=rn(e,t,!0)-1;if(Us(e[r],t))return r}return-1},jr.startCase=Xa,jr.startsWith=function(e,t,r){return e=ma(e),r=null==r?0:oi(pa(r),0,e.length),t=an(t),e.slice(r,r+t.length)==t},jr.subtract=Ec,jr.sum=function(e){return e&&e.length?Wt(e,nc):0},jr.sumBy=function(e,t){return e&&e.length?Wt(e,so(t,2)):0},jr.template=function(e,t,r){var i=jr.templateSettings;r&&yo(e,t,r)&&(t=n),e=ma(e),t=Ca({},t,i,Zn);var o,s,a=Ca({},t.imports,i.imports,Zn),c=Oa(a),l=zt(a,c),u=0,h=t.interpolate||me,f="__p += '",_=Ee((t.escape||me).source+"|"+h.source+"|"+(h===J?he:me).source+"|"+(t.evaluate||me).source+"|$","g"),d="//# sourceURL="+(Be.call(t,"sourceURL")?(t.sourceURL+"").replace(/\s/g," "):"lodash.templateSources["+ ++Je+"]")+"\n";e.replace(_,(function(t,r,i,n,a,c){return i||(i=n),f+=e.slice(u,c).replace(be,Jt),r&&(o=!0,f+="' +\n__e("+r+") +\n'"),a&&(s=!0,f+="';\n"+a+";\n__p += '"),i&&(f+="' +\n((__t = ("+i+")) == null ? '' : __t) +\n'"),u=c+t.length,t})),f+="';\n";var p=Be.call(t,"variable")&&t.variable;if(p){if(le.test(p))throw new Se("Invalid `variable` option passed into `_.template`")}else f="with (obj) {\n"+f+"\n}\n";f=(s?f.replace(q,""):f).replace(N,"$1").replace(z,"$1;"),f="function("+(p||"obj")+") {\n"+(p?"":"obj || (obj = {});\n")+"var __t, __p = ''"+(o?", __e = _.escape":"")+(s?", __j = Array.prototype.join;\nfunction print() { __p += __j.call(arguments, '') }\n":";\n")+f+"return __p\n}";var v=Qa((function(){return Ce(c,d+"return "+f).apply(n,l)}));if(v.source=f,Js(v))throw v;return v},jr.times=function(e,t){if((e=pa(e))<1||e>h)return[];var r=_,i=gr(e,_);t=so(t),e-=_;for(var n=Ut(i,t);++r<e;)t(r);return n},jr.toFinite=da,jr.toInteger=pa,jr.toLength=va,jr.toLower=function(e){return ma(e).toLowerCase()},jr.toNumber=ga,jr.toSafeInteger=function(e){return e?oi(pa(e),-9007199254740991,h):0===e?e:0},jr.toString=ma,jr.toUpper=function(e){return ma(e).toUpperCase()},jr.trim=function(e,t,r){if((e=ma(e))&&(r||t===n))return qt(e);if(!e||!(t=an(t)))return e;var i=or(e),o=or(t);return mn(i,Vt(i,o),Gt(i,o)+1).join("")},jr.trimEnd=function(e,t,r){if((e=ma(e))&&(r||t===n))return e.slice(0,sr(e)+1);if(!e||!(t=an(t)))return e;var i=or(e);return mn(i,0,Gt(i,or(t))+1).join("")},jr.trimStart=function(e,t,r){if((e=ma(e))&&(r||t===n))return e.replace(ie,"");if(!e||!(t=an(t)))return e;var i=or(e);return mn(i,Vt(i,or(t))).join("")},jr.truncate=function(e,t){var r=30,i="...";if(ta(t)){var o="separator"in t?t.separator:o;r="length"in t?pa(t.length):r,i="omission"in t?an(t.omission):i}var s=(e=ma(e)).length;if($t(e)){var a=or(e);s=a.length}if(r>=s)return e;var c=r-nr(i);if(c<1)return i;var l=a?mn(a,0,c).join(""):e.slice(0,c);if(o===n)return l+i;if(a&&(c+=l.length-c),sa(o)){if(e.slice(c).search(o)){var u,h=l;for(o.global||(o=Ee(o.source,ma(fe.exec(o))+"g")),o.lastIndex=0;u=o.exec(h);)var f=u.index;l=l.slice(0,f===n?c:f)}}else if(e.indexOf(an(o),c)!=c){var _=l.lastIndexOf(o);_>-1&&(l=l.slice(0,_))}return l+i},jr.unescape=function(e){return(e=ma(e))&&G.test(e)?e.replace(K,ar):e},jr.uniqueId=function(e){var t=++De;return ma(e)+t},jr.upperCase=Za,jr.upperFirst=Ja,jr.each=ms,jr.eachRight=bs,jr.first=Go,cc(jr,(yc={},yi(jr,(function(e,t){Be.call(jr.prototype,t)||(yc[t]=e)})),yc),{chain:!1}),jr.VERSION="4.17.21",mt(["bind","bindKey","curry","curryRight","partial","partialRight"],(function(e){jr[e].placeholder=jr})),mt(["drop","take"],(function(e,t){qr.prototype[e]=function(r){r=r===n?1:vr(pa(r),0);var i=this.__filtered__&&!t?new qr(this):this.clone();return i.__filtered__?i.__takeCount__=gr(r,i.__takeCount__):i.__views__.push({size:gr(r,_),type:e+(i.__dir__<0?"Right":"")}),i},qr.prototype[e+"Right"]=function(t){return this.reverse()[e](t).reverse()}})),mt(["filter","map","takeWhile"],(function(e,t){var r=t+1,i=1==r||3==r;qr.prototype[e]=function(e){var t=this.clone();return t.__iteratees__.push({iteratee:so(e,3),type:r}),t.__filtered__=t.__filtered__||i,t}})),mt(["head","last"],(function(e,t){var r="take"+(t?"Right":"");qr.prototype[e]=function(){return this[r](1).value()[0]}})),mt(["initial","tail"],(function(e,t){var r="drop"+(t?"":"Right");qr.prototype[e]=function(){return this.__filtered__?new qr(this):this[r](1)}})),qr.prototype.compact=function(){return this.filter(nc)},qr.prototype.find=function(e){return this.filter(e).head()},qr.prototype.findLast=function(e){return this.reverse().find(e)},qr.prototype.invokeMap=Gi((function(e,t){return"function"==typeof e?new qr(this):this.map((function(r){return ki(r,e,t)}))})),qr.prototype.reject=function(e){return this.filter(Is(so(e)))},qr.prototype.slice=function(e,t){e=pa(e);var r=this;return r.__filtered__&&(e>0||t<0)?new qr(r):(e<0?r=r.takeRight(-e):e&&(r=r.drop(e)),t!==n&&(r=(t=pa(t))<0?r.dropRight(-t):r.take(t-e)),r)},qr.prototype.takeRightWhile=function(e){return this.reverse().takeWhile(e).reverse()},qr.prototype.toArray=function(){return this.take(_)},yi(qr.prototype,(function(e,t){var r=/^(?:filter|find|map|reject)|While$/.test(t),i=/^(?:head|last)$/.test(t),o=jr[i?"take"+("last"==t?"Right":""):t],s=i||/^find/.test(t);o&&(jr.prototype[t]=function(){var t=this.__wrapped__,a=i?[1]:arguments,c=t instanceof qr,l=a[0],u=c||Ks(t),h=function(e){var t=o.apply(jr,xt([e],a));return i&&f?t[0]:t};u&&r&&"function"==typeof l&&1!=l.length&&(c=u=!1);var f=this.__chain__,_=!!this.__actions__.length,d=s&&!f,p=c&&!_;if(!s&&u){t=p?t:new qr(this);var v=e.apply(t,a);return v.__actions__.push({func:ds,args:[h],thisArg:n}),new Ur(v,f)}return d&&p?e.apply(this,a):(v=this.thru(h),d?i?v.value()[0]:v.value():v)})})),mt(["pop","push","shift","sort","splice","unshift"],(function(e){var t=ke[e],r=/^(?:push|sort|unshift)$/.test(e)?"tap":"thru",i=/^(?:pop|shift)$/.test(e);jr.prototype[e]=function(){var e=arguments;if(i&&!this.__chain__){var n=this.value();return t.apply(Ks(n)?n:[],e)}return this[r]((function(r){return t.apply(Ks(r)?r:[],e)}))}})),yi(qr.prototype,(function(e,t){var r=jr[t];if(r){var i=r.name+"";Be.call(Mr,i)||(Mr[i]=[]),Mr[i].push({name:t,func:r})}})),Mr[jn(n,2).name]=[{name:"wrapper",func:n}],qr.prototype.clone=function(){var e=new qr(this.__wrapped__);return e.__actions__=An(this.__actions__),e.__dir__=this.__dir__,e.__filtered__=this.__filtered__,e.__iteratees__=An(this.__iteratees__),e.__takeCount__=this.__takeCount__,e.__views__=An(this.__views__),e},qr.prototype.reverse=function(){if(this.__filtered__){var e=new qr(this);e.__dir__=-1,e.__filtered__=!0}else(e=this.clone()).__dir__*=-1;return e},qr.prototype.value=function(){var e=this.__wrapped__.value(),t=this.__dir__,r=Ks(e),i=t<0,n=r?e.length:0,o=function(e,t,r){for(var i=-1,n=r.length;++i<n;){var o=r[i],s=o.size;switch(o.type){case"drop":e+=s;break;case"dropRight":t-=s;break;case"take":t=gr(t,e+s);break;case"takeRight":e=vr(e,t-s)}}return{start:e,end:t}}(0,n,this.__views__),s=o.start,a=o.end,c=a-s,l=i?a:s-1,u=this.__iteratees__,h=u.length,f=0,_=gr(c,this.__takeCount__);if(!r||!i&&n==c&&_==c)return fn(e,this.__actions__);var d=[];e:for(;c--&&f<_;){for(var p=-1,v=e[l+=t];++p<h;){var g=u[p],y=g.iteratee,m=g.type,b=y(v);if(2==m)v=b;else if(!b){if(1==m)continue e;break e}}d[f++]=v}return d},jr.prototype.at=ps,jr.prototype.chain=function(){return _s(this)},jr.prototype.commit=function(){return new Ur(this.value(),this.__chain__)},jr.prototype.next=function(){this.__values__===n&&(this.__values__=_a(this.value()));var e=this.__index__>=this.__values__.length;return{done:e,value:e?n:this.__values__[this.__index__++]}},jr.prototype.plant=function(e){for(var t,r=this;r instanceof Wr;){var i=Wo(r);i.__index__=0,i.__values__=n,t?o.__wrapped__=i:t=i;var o=i;r=r.__wrapped__}return o.__wrapped__=e,t},jr.prototype.reverse=function(){var e=this.__wrapped__;if(e instanceof qr){var t=e;return this.__actions__.length&&(t=new qr(this)),(t=t.reverse()).__actions__.push({func:ds,args:[ts],thisArg:n}),new Ur(t,this.__chain__)}return this.thru(ts)},jr.prototype.toJSON=jr.prototype.valueOf=jr.prototype.value=function(){return fn(this.__wrapped__,this.__actions__)},jr.prototype.first=jr.prototype.head,st&&(jr.prototype[st]=function(){return this}),jr}();ot._=cr,(i=function(){return cr}.call(t,r,t,e))===n||(e.exports=i)}.call(this)},379:e=>{"use strict";var t=[];function r(e){for(var r=-1,i=0;i<t.length;i++)if(t[i].identifier===e){r=i;break}return r}function i(e,i){for(var o={},s=[],a=0;a<e.length;a++){var c=e[a],l=i.base?c[0]+i.base:c[0],u=o[l]||0,h="".concat(l," ").concat(u);o[l]=u+1;var f=r(h),_={css:c[1],media:c[2],sourceMap:c[3],supports:c[4],layer:c[5]};if(-1!==f)t[f].references++,t[f].updater(_);else{var d=n(_,i);i.byIndex=a,t.splice(a,0,{identifier:h,updater:d,references:1})}s.push(h)}return s}function n(e,t){var r=t.domAPI(t);return r.update(e),function(t){if(t){if(t.css===e.css&&t.media===e.media&&t.sourceMap===e.sourceMap&&t.supports===e.supports&&t.layer===e.layer)return;r.update(e=t)}else r.remove()}}e.exports=function(e,n){var o=i(e=e||[],n=n||{});return function(e){e=e||[];for(var s=0;s<o.length;s++){var a=r(o[s]);t[a].references--}for(var c=i(e,n),l=0;l<o.length;l++){var u=r(o[l]);0===t[u].references&&(t[u].updater(),t.splice(u,1))}o=c}}},569:e=>{"use strict";var t={};e.exports=function(e,r){var i=function(e){if(void 0===t[e]){var r=document.querySelector(e);if(window.HTMLIFrameElement&&r instanceof window.HTMLIFrameElement)try{r=r.contentDocument.head}catch(e){r=null}t[e]=r}return t[e]}(e);if(!i)throw new Error("Couldn't find a style target. This probably means that the value for the 'insert' parameter is invalid.");i.appendChild(r)}},216:e=>{"use strict";e.exports=function(e){var t=document.createElement("style");return e.setAttributes(t,e.attributes),e.insert(t,e.options),t}},565:(e,t,r)=>{"use strict";e.exports=function(e){var t=r.nc;t&&e.setAttribute("nonce",t)}},795:e=>{"use strict";e.exports=function(e){var t=e.insertStyleElement(e);return{update:function(r){!function(e,t,r){var i="";r.supports&&(i+="@supports (".concat(r.supports,") {")),r.media&&(i+="@media ".concat(r.media," {"));var n=void 0!==r.layer;n&&(i+="@layer".concat(r.layer.length>0?" ".concat(r.layer):""," {")),i+=r.css,n&&(i+="}"),r.media&&(i+="}"),r.supports&&(i+="}");var o=r.sourceMap;o&&"undefined"!=typeof btoa&&(i+="\n/*# sourceMappingURL=data:application/json;base64,".concat(btoa(unescape(encodeURIComponent(JSON.stringify(o))))," */")),t.styleTagTransform(i,e,t.options)}(t,e,r)},remove:function(){!function(e){if(null===e.parentNode)return!1;e.parentNode.removeChild(e)}(t)}}}},589:e=>{"use strict";e.exports=function(e,t){if(t.styleSheet)t.styleSheet.cssText=e;else{for(;t.firstChild;)t.removeChild(t.firstChild);t.appendChild(document.createTextNode(e))}}},617:e=>{self,e.exports=(()=>{"use strict";var e={775:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.FitAddon=void 0;var r=function(){function e(){}return e.prototype.activate=function(e){this._terminal=e},e.prototype.dispose=function(){},e.prototype.fit=function(){var e=this.proposeDimensions();if(e&&this._terminal){var t=this._terminal._core;this._terminal.rows===e.rows&&this._terminal.cols===e.cols||(t._renderService.clear(),this._terminal.resize(e.cols,e.rows))}},e.prototype.proposeDimensions=function(){if(this._terminal&&this._terminal.element&&this._terminal.element.parentElement){var e=this._terminal._core;if(0!==e._renderService.dimensions.actualCellWidth&&0!==e._renderService.dimensions.actualCellHeight){var t=window.getComputedStyle(this._terminal.element.parentElement),r=parseInt(t.getPropertyValue("height")),i=Math.max(0,parseInt(t.getPropertyValue("width"))),n=window.getComputedStyle(this._terminal.element),o=r-(parseInt(n.getPropertyValue("padding-top"))+parseInt(n.getPropertyValue("padding-bottom"))),s=i-(parseInt(n.getPropertyValue("padding-right"))+parseInt(n.getPropertyValue("padding-left")))-e.viewport.scrollBarWidth;return{cols:Math.max(2,Math.floor(s/e._renderService.dimensions.actualCellWidth)),rows:Math.max(1,Math.floor(o/e._renderService.dimensions.actualCellHeight))}}}},e}();t.FitAddon=r}},t={};return function r(i){if(t[i])return t[i].exports;var n=t[i]={exports:{}};return e[i](n,n.exports,r),n.exports}(775)})()},320:e=>{self,e.exports=(()=>{"use strict";var e={4567:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.AccessibilityManager=void 0;var o=r(9042),s=r(6114),a=r(9924),c=r(3656),l=r(844),u=r(5596),h=r(9631),f=function(e){function t(t,r){var i=e.call(this)||this;i._terminal=t,i._renderService=r,i._liveRegionLineCount=0,i._charsToConsume=[],i._charsToAnnounce="",i._accessibilityTreeRoot=document.createElement("div"),i._accessibilityTreeRoot.setAttribute("role","document"),i._accessibilityTreeRoot.classList.add("xterm-accessibility"),i._accessibilityTreeRoot.tabIndex=0,i._rowContainer=document.createElement("div"),i._rowContainer.setAttribute("role","list"),i._rowContainer.classList.add("xterm-accessibility-tree"),i._rowElements=[];for(var n=0;n<i._terminal.rows;n++)i._rowElements[n]=i._createAccessibilityTreeNode(),i._rowContainer.appendChild(i._rowElements[n]);if(i._topBoundaryFocusListener=function(e){return i._onBoundaryFocus(e,0)},i._bottomBoundaryFocusListener=function(e){return i._onBoundaryFocus(e,1)},i._rowElements[0].addEventListener("focus",i._topBoundaryFocusListener),i._rowElements[i._rowElements.length-1].addEventListener("focus",i._bottomBoundaryFocusListener),i._refreshRowsDimensions(),i._accessibilityTreeRoot.appendChild(i._rowContainer),i._renderRowsDebouncer=new a.TimeBasedDebouncer(i._renderRows.bind(i)),i._refreshRows(),i._liveRegion=document.createElement("div"),i._liveRegion.classList.add("live-region"),i._liveRegion.setAttribute("aria-live","assertive"),i._accessibilityTreeRoot.appendChild(i._liveRegion),!i._terminal.element)throw new Error("Cannot enable accessibility before Terminal.open");return i._terminal.element.insertAdjacentElement("afterbegin",i._accessibilityTreeRoot),i.register(i._renderRowsDebouncer),i.register(i._terminal.onResize((function(e){return i._onResize(e.rows)}))),i.register(i._terminal.onRender((function(e){return i._refreshRows(e.start,e.end)}))),i.register(i._terminal.onScroll((function(){return i._refreshRows()}))),i.register(i._terminal.onA11yChar((function(e){return i._onChar(e)}))),i.register(i._terminal.onLineFeed((function(){return i._onChar("\n")}))),i.register(i._terminal.onA11yTab((function(e){return i._onTab(e)}))),i.register(i._terminal.onKey((function(e){return i._onKey(e.key)}))),i.register(i._terminal.onBlur((function(){return i._clearLiveRegion()}))),i.register(i._renderService.onDimensionsChange((function(){return i._refreshRowsDimensions()}))),i._screenDprMonitor=new u.ScreenDprMonitor,i.register(i._screenDprMonitor),i._screenDprMonitor.setListener((function(){return i._refreshRowsDimensions()})),i.register((0,c.addDisposableDomListener)(window,"resize",(function(){return i._refreshRowsDimensions()}))),i}return n(t,e),t.prototype.dispose=function(){e.prototype.dispose.call(this),(0,h.removeElementFromParent)(this._accessibilityTreeRoot),this._rowElements.length=0},t.prototype._onBoundaryFocus=function(e,t){var r=e.target,i=this._rowElements[0===t?1:this._rowElements.length-2];if(r.getAttribute("aria-posinset")!==(0===t?"1":""+this._terminal.buffer.lines.length)&&e.relatedTarget===i){var n,o;if(0===t?(n=r,o=this._rowElements.pop(),this._rowContainer.removeChild(o)):(n=this._rowElements.shift(),o=r,this._rowContainer.removeChild(n)),n.removeEventListener("focus",this._topBoundaryFocusListener),o.removeEventListener("focus",this._bottomBoundaryFocusListener),0===t){var s=this._createAccessibilityTreeNode();this._rowElements.unshift(s),this._rowContainer.insertAdjacentElement("afterbegin",s)}else s=this._createAccessibilityTreeNode(),this._rowElements.push(s),this._rowContainer.appendChild(s);this._rowElements[0].addEventListener("focus",this._topBoundaryFocusListener),this._rowElements[this._rowElements.length-1].addEventListener("focus",this._bottomBoundaryFocusListener),this._terminal.scrollLines(0===t?-1:1),this._rowElements[0===t?1:this._rowElements.length-2].focus(),e.preventDefault(),e.stopImmediatePropagation()}},t.prototype._onResize=function(e){this._rowElements[this._rowElements.length-1].removeEventListener("focus",this._bottomBoundaryFocusListener);for(var t=this._rowContainer.children.length;t<this._terminal.rows;t++)this._rowElements[t]=this._createAccessibilityTreeNode(),this._rowContainer.appendChild(this._rowElements[t]);for(;this._rowElements.length>e;)this._rowContainer.removeChild(this._rowElements.pop());this._rowElements[this._rowElements.length-1].addEventListener("focus",this._bottomBoundaryFocusListener),this._refreshRowsDimensions()},t.prototype._createAccessibilityTreeNode=function(){var e=document.createElement("div");return e.setAttribute("role","listitem"),e.tabIndex=-1,this._refreshRowDimensions(e),e},t.prototype._onTab=function(e){for(var t=0;t<e;t++)this._onChar(" ")},t.prototype._onChar=function(e){var t=this;this._liveRegionLineCount<21&&(this._charsToConsume.length>0?this._charsToConsume.shift()!==e&&(this._charsToAnnounce+=e):this._charsToAnnounce+=e,"\n"===e&&(this._liveRegionLineCount++,21===this._liveRegionLineCount&&(this._liveRegion.textContent+=o.tooMuchOutput)),s.isMac&&this._liveRegion.textContent&&this._liveRegion.textContent.length>0&&!this._liveRegion.parentNode&&setTimeout((function(){t._accessibilityTreeRoot.appendChild(t._liveRegion)}),0))},t.prototype._clearLiveRegion=function(){this._liveRegion.textContent="",this._liveRegionLineCount=0,s.isMac&&(0,h.removeElementFromParent)(this._liveRegion)},t.prototype._onKey=function(e){this._clearLiveRegion(),this._charsToConsume.push(e)},t.prototype._refreshRows=function(e,t){this._renderRowsDebouncer.refresh(e,t,this._terminal.rows)},t.prototype._renderRows=function(e,t){for(var r=this._terminal.buffer,i=r.lines.length.toString(),n=e;n<=t;n++){var o=r.translateBufferLineToString(r.ydisp+n,!0),s=(r.ydisp+n+1).toString(),a=this._rowElements[n];a&&(0===o.length?a.innerText=" ":a.textContent=o,a.setAttribute("aria-posinset",s),a.setAttribute("aria-setsize",i))}this._announceCharacters()},t.prototype._refreshRowsDimensions=function(){if(this._renderService.dimensions.actualCellHeight){this._rowElements.length!==this._terminal.rows&&this._onResize(this._terminal.rows);for(var e=0;e<this._terminal.rows;e++)this._refreshRowDimensions(this._rowElements[e])}},t.prototype._refreshRowDimensions=function(e){e.style.height=this._renderService.dimensions.actualCellHeight+"px"},t.prototype._announceCharacters=function(){0!==this._charsToAnnounce.length&&(this._liveRegion.textContent+=this._charsToAnnounce,this._charsToAnnounce="")},t}(l.Disposable);t.AccessibilityManager=f},3614:(e,t)=>{function r(e){return e.replace(/\r?\n/g,"\r")}function i(e,t){return t?"[200~"+e+"[201~":e}function n(e,t,n){e=i(e=r(e),n.decPrivateModes.bracketedPasteMode),n.triggerDataEvent(e,!0),t.value=""}function o(e,t,r){var i=r.getBoundingClientRect(),n=e.clientX-i.left-10,o=e.clientY-i.top-10;t.style.width="20px",t.style.height="20px",t.style.left=n+"px",t.style.top=o+"px",t.style.zIndex="1000",t.focus()}Object.defineProperty(t,"__esModule",{value:!0}),t.rightClickHandler=t.moveTextAreaUnderMouseCursor=t.paste=t.handlePasteEvent=t.copyHandler=t.bracketTextForPaste=t.prepareTextForTerminal=void 0,t.prepareTextForTerminal=r,t.bracketTextForPaste=i,t.copyHandler=function(e,t){e.clipboardData&&e.clipboardData.setData("text/plain",t.selectionText),e.preventDefault()},t.handlePasteEvent=function(e,t,r){e.stopPropagation(),e.clipboardData&&n(e.clipboardData.getData("text/plain"),t,r)},t.paste=n,t.moveTextAreaUnderMouseCursor=o,t.rightClickHandler=function(e,t,r,i,n){o(e,t,r),n&&i.rightClickSelect(e),t.value=i.selectionText,t.select()}},4774:(e,t)=>{var r,i,n,o;function s(e){var t=e.toString(16);return t.length<2?"0"+t:t}function a(e,t){return e<t?(t+.05)/(e+.05):(e+.05)/(t+.05)}Object.defineProperty(t,"__esModule",{value:!0}),t.contrastRatio=t.toPaddedHex=t.rgba=t.rgb=t.css=t.color=t.channels=void 0,function(e){e.toCss=function(e,t,r,i){return void 0!==i?"#"+s(e)+s(t)+s(r)+s(i):"#"+s(e)+s(t)+s(r)},e.toRgba=function(e,t,r,i){return void 0===i&&(i=255),(e<<24|t<<16|r<<8|i)>>>0}}(r=t.channels||(t.channels={})),(i=t.color||(t.color={})).blend=function(e,t){var i=(255&t.rgba)/255;if(1===i)return{css:t.css,rgba:t.rgba};var n=t.rgba>>24&255,o=t.rgba>>16&255,s=t.rgba>>8&255,a=e.rgba>>24&255,c=e.rgba>>16&255,l=e.rgba>>8&255,u=a+Math.round((n-a)*i),h=c+Math.round((o-c)*i),f=l+Math.round((s-l)*i);return{css:r.toCss(u,h,f),rgba:r.toRgba(u,h,f)}},i.isOpaque=function(e){return 255==(255&e.rgba)},i.ensureContrastRatio=function(e,t,r){var i=o.ensureContrastRatio(e.rgba,t.rgba,r);if(i)return o.toColor(i>>24&255,i>>16&255,i>>8&255)},i.opaque=function(e){var t=(255|e.rgba)>>>0,i=o.toChannels(t),n=i[0],s=i[1],a=i[2];return{css:r.toCss(n,s,a),rgba:t}},i.opacity=function(e,t){var i=Math.round(255*t),n=o.toChannels(e.rgba),s=n[0],a=n[1],c=n[2];return{css:r.toCss(s,a,c,i),rgba:r.toRgba(s,a,c,i)}},i.toColorRGB=function(e){return[e.rgba>>24&255,e.rgba>>16&255,e.rgba>>8&255]},(t.css||(t.css={})).toColor=function(e){switch(e.length){case 7:return{css:e,rgba:(parseInt(e.slice(1),16)<<8|255)>>>0};case 9:return{css:e,rgba:parseInt(e.slice(1),16)>>>0}}throw new Error("css.toColor: Unsupported css format")},function(e){function t(e,t,r){var i=e/255,n=t/255,o=r/255;return.2126*(i<=.03928?i/12.92:Math.pow((i+.055)/1.055,2.4))+.7152*(n<=.03928?n/12.92:Math.pow((n+.055)/1.055,2.4))+.0722*(o<=.03928?o/12.92:Math.pow((o+.055)/1.055,2.4))}e.relativeLuminance=function(e){return t(e>>16&255,e>>8&255,255&e)},e.relativeLuminance2=t}(n=t.rgb||(t.rgb={})),function(e){function t(e,t,r){for(var i=e>>24&255,o=e>>16&255,s=e>>8&255,c=t>>24&255,l=t>>16&255,u=t>>8&255,h=a(n.relativeLuminance2(c,u,l),n.relativeLuminance2(i,o,s));h<r&&(c>0||l>0||u>0);)c-=Math.max(0,Math.ceil(.1*c)),l-=Math.max(0,Math.ceil(.1*l)),u-=Math.max(0,Math.ceil(.1*u)),h=a(n.relativeLuminance2(c,u,l),n.relativeLuminance2(i,o,s));return(c<<24|l<<16|u<<8|255)>>>0}function i(e,t,r){for(var i=e>>24&255,o=e>>16&255,s=e>>8&255,c=t>>24&255,l=t>>16&255,u=t>>8&255,h=a(n.relativeLuminance2(c,u,l),n.relativeLuminance2(i,o,s));h<r&&(c<255||l<255||u<255);)c=Math.min(255,c+Math.ceil(.1*(255-c))),l=Math.min(255,l+Math.ceil(.1*(255-l))),u=Math.min(255,u+Math.ceil(.1*(255-u))),h=a(n.relativeLuminance2(c,u,l),n.relativeLuminance2(i,o,s));return(c<<24|l<<16|u<<8|255)>>>0}e.ensureContrastRatio=function(e,r,o){var s=n.relativeLuminance(e>>8),c=n.relativeLuminance(r>>8);if(a(s,c)<o)return c<s?t(e,r,o):i(e,r,o)},e.reduceLuminance=t,e.increaseLuminance=i,e.toChannels=function(e){return[e>>24&255,e>>16&255,e>>8&255,255&e]},e.toColor=function(e,t,i){return{css:r.toCss(e,t,i),rgba:r.toRgba(e,t,i)}}}(o=t.rgba||(t.rgba={})),t.toPaddedHex=s,t.contrastRatio=a},7239:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.ColorContrastCache=void 0;var r=function(){function e(){this._color={},this._rgba={}}return e.prototype.clear=function(){this._color={},this._rgba={}},e.prototype.setCss=function(e,t,r){this._rgba[e]||(this._rgba[e]={}),this._rgba[e][t]=r},e.prototype.getCss=function(e,t){return this._rgba[e]?this._rgba[e][t]:void 0},e.prototype.setColor=function(e,t,r){this._color[e]||(this._color[e]={}),this._color[e][t]=r},e.prototype.getColor=function(e,t){return this._color[e]?this._color[e][t]:void 0},e}();t.ColorContrastCache=r},5680:function(e,t,r){var i=this&&this.__spreadArray||function(e,t,r){if(r||2===arguments.length)for(var i,n=0,o=t.length;n<o;n++)!i&&n in t||(i||(i=Array.prototype.slice.call(t,0,n)),i[n]=t[n]);return e.concat(i||Array.prototype.slice.call(t))};Object.defineProperty(t,"__esModule",{value:!0}),t.ColorManager=t.DEFAULT_ANSI_COLORS=void 0;var n=r(4774),o=r(7239),s=n.css.toColor("#ffffff"),a=n.css.toColor("#000000"),c=n.css.toColor("#ffffff"),l=n.css.toColor("#000000"),u={css:"rgba(255, 255, 255, 0.3)",rgba:4294967117};t.DEFAULT_ANSI_COLORS=Object.freeze(function(){for(var e=[n.css.toColor("#2e3436"),n.css.toColor("#cc0000"),n.css.toColor("#4e9a06"),n.css.toColor("#c4a000"),n.css.toColor("#3465a4"),n.css.toColor("#75507b"),n.css.toColor("#06989a"),n.css.toColor("#d3d7cf"),n.css.toColor("#555753"),n.css.toColor("#ef2929"),n.css.toColor("#8ae234"),n.css.toColor("#fce94f"),n.css.toColor("#729fcf"),n.css.toColor("#ad7fa8"),n.css.toColor("#34e2e2"),n.css.toColor("#eeeeec")],t=[0,95,135,175,215,255],r=0;r<216;r++){var i=t[r/36%6|0],o=t[r/6%6|0],s=t[r%6];e.push({css:n.channels.toCss(i,o,s),rgba:n.channels.toRgba(i,o,s)})}for(r=0;r<24;r++){var a=8+10*r;e.push({css:n.channels.toCss(a,a,a),rgba:n.channels.toRgba(a,a,a)})}return e}());var h=function(){function e(e,r){this.allowTransparency=r;var i=e.createElement("canvas");i.width=1,i.height=1;var h=i.getContext("2d");if(!h)throw new Error("Could not get rendering context");this._ctx=h,this._ctx.globalCompositeOperation="copy",this._litmusColor=this._ctx.createLinearGradient(0,0,1,1),this._contrastCache=new o.ColorContrastCache,this.colors={foreground:s,background:a,cursor:c,cursorAccent:l,selectionTransparent:u,selectionOpaque:n.color.blend(a,u),ansi:t.DEFAULT_ANSI_COLORS.slice(),contrastCache:this._contrastCache},this._updateRestoreColors()}return e.prototype.onOptionsChange=function(e){"minimumContrastRatio"===e&&this._contrastCache.clear()},e.prototype.setTheme=function(e){void 0===e&&(e={}),this.colors.foreground=this._parseColor(e.foreground,s),this.colors.background=this._parseColor(e.background,a),this.colors.cursor=this._parseColor(e.cursor,c,!0),this.colors.cursorAccent=this._parseColor(e.cursorAccent,l,!0),this.colors.selectionTransparent=this._parseColor(e.selection,u,!0),this.colors.selectionOpaque=n.color.blend(this.colors.background,this.colors.selectionTransparent),n.color.isOpaque(this.colors.selectionTransparent)&&(this.colors.selectionTransparent=n.color.opacity(this.colors.selectionTransparent,.3)),this.colors.ansi[0]=this._parseColor(e.black,t.DEFAULT_ANSI_COLORS[0]),this.colors.ansi[1]=this._parseColor(e.red,t.DEFAULT_ANSI_COLORS[1]),this.colors.ansi[2]=this._parseColor(e.green,t.DEFAULT_ANSI_COLORS[2]),this.colors.ansi[3]=this._parseColor(e.yellow,t.DEFAULT_ANSI_COLORS[3]),this.colors.ansi[4]=this._parseColor(e.blue,t.DEFAULT_ANSI_COLORS[4]),this.colors.ansi[5]=this._parseColor(e.magenta,t.DEFAULT_ANSI_COLORS[5]),this.colors.ansi[6]=this._parseColor(e.cyan,t.DEFAULT_ANSI_COLORS[6]),this.colors.ansi[7]=this._parseColor(e.white,t.DEFAULT_ANSI_COLORS[7]),this.colors.ansi[8]=this._parseColor(e.brightBlack,t.DEFAULT_ANSI_COLORS[8]),this.colors.ansi[9]=this._parseColor(e.brightRed,t.DEFAULT_ANSI_COLORS[9]),this.colors.ansi[10]=this._parseColor(e.brightGreen,t.DEFAULT_ANSI_COLORS[10]),this.colors.ansi[11]=this._parseColor(e.brightYellow,t.DEFAULT_ANSI_COLORS[11]),this.colors.ansi[12]=this._parseColor(e.brightBlue,t.DEFAULT_ANSI_COLORS[12]),this.colors.ansi[13]=this._parseColor(e.brightMagenta,t.DEFAULT_ANSI_COLORS[13]),this.colors.ansi[14]=this._parseColor(e.brightCyan,t.DEFAULT_ANSI_COLORS[14]),this.colors.ansi[15]=this._parseColor(e.brightWhite,t.DEFAULT_ANSI_COLORS[15]),this._contrastCache.clear(),this._updateRestoreColors()},e.prototype.restoreColor=function(e){if(void 0!==e)switch(e){case 256:this.colors.foreground=this._restoreColors.foreground;break;case 257:this.colors.background=this._restoreColors.background;break;case 258:this.colors.cursor=this._restoreColors.cursor;break;default:this.colors.ansi[e]=this._restoreColors.ansi[e]}else for(var t=0;t<this._restoreColors.ansi.length;++t)this.colors.ansi[t]=this._restoreColors.ansi[t]},e.prototype._updateRestoreColors=function(){this._restoreColors={foreground:this.colors.foreground,background:this.colors.background,cursor:this.colors.cursor,ansi:i([],this.colors.ansi,!0)}},e.prototype._parseColor=function(e,t,r){if(void 0===r&&(r=this.allowTransparency),void 0===e)return t;if(this._ctx.fillStyle=this._litmusColor,this._ctx.fillStyle=e,"string"!=typeof this._ctx.fillStyle)return console.warn("Color: "+e+" is invalid using fallback "+t.css),t;this._ctx.fillRect(0,0,1,1);var i=this._ctx.getImageData(0,0,1,1).data;if(255!==i[3]){if(!r)return console.warn("Color: "+e+" is using transparency, but allowTransparency is false. Using fallback "+t.css+"."),t;var o=this._ctx.fillStyle.substring(5,this._ctx.fillStyle.length-1).split(",").map((function(e){return Number(e)})),s=o[0],a=o[1],c=o[2],l=o[3],u=Math.round(255*l);return{rgba:n.channels.toRgba(s,a,c,u),css:e}}return{css:this._ctx.fillStyle,rgba:n.channels.toRgba(i[0],i[1],i[2],i[3])}},e}();t.ColorManager=h},9631:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.removeElementFromParent=void 0,t.removeElementFromParent=function(){for(var e,t=[],r=0;r<arguments.length;r++)t[r]=arguments[r];for(var i=0,n=t;i<n.length;i++){var o=n[i];null===(e=null==o?void 0:o.parentElement)||void 0===e||e.removeChild(o)}}},3656:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.addDisposableDomListener=void 0,t.addDisposableDomListener=function(e,t,r,i){e.addEventListener(t,r,i);var n=!1;return{dispose:function(){n||(n=!0,e.removeEventListener(t,r,i))}}}},3551:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.MouseZone=t.Linkifier=void 0;var o=r(8460),s=r(2585),a=function(){function e(e,t,r){this._bufferService=e,this._logService=t,this._unicodeService=r,this._linkMatchers=[],this._nextLinkMatcherId=0,this._onShowLinkUnderline=new o.EventEmitter,this._onHideLinkUnderline=new o.EventEmitter,this._onLinkTooltip=new o.EventEmitter,this._rowsToLinkify={start:void 0,end:void 0}}return Object.defineProperty(e.prototype,"onShowLinkUnderline",{get:function(){return this._onShowLinkUnderline.event},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onHideLinkUnderline",{get:function(){return this._onHideLinkUnderline.event},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onLinkTooltip",{get:function(){return this._onLinkTooltip.event},enumerable:!1,configurable:!0}),e.prototype.attachToDom=function(e,t){this._element=e,this._mouseZoneManager=t},e.prototype.linkifyRows=function(t,r){var i=this;this._mouseZoneManager&&(void 0===this._rowsToLinkify.start||void 0===this._rowsToLinkify.end?(this._rowsToLinkify.start=t,this._rowsToLinkify.end=r):(this._rowsToLinkify.start=Math.min(this._rowsToLinkify.start,t),this._rowsToLinkify.end=Math.max(this._rowsToLinkify.end,r)),this._mouseZoneManager.clearAll(t,r),this._rowsTimeoutId&&clearTimeout(this._rowsTimeoutId),this._rowsTimeoutId=setTimeout((function(){return i._linkifyRows()}),e._timeBeforeLatency))},e.prototype._linkifyRows=function(){this._rowsTimeoutId=void 0;var e=this._bufferService.buffer;if(void 0!==this._rowsToLinkify.start&&void 0!==this._rowsToLinkify.end){var t=e.ydisp+this._rowsToLinkify.start;if(!(t>=e.lines.length)){for(var r=e.ydisp+Math.min(this._rowsToLinkify.end,this._bufferService.rows)+1,i=Math.ceil(2e3/this._bufferService.cols),n=this._bufferService.buffer.iterator(!1,t,r,i,i);n.hasNext();)for(var o=n.next(),s=0;s<this._linkMatchers.length;s++)this._doLinkifyRow(o.range.first,o.content,this._linkMatchers[s]);this._rowsToLinkify.start=void 0,this._rowsToLinkify.end=void 0}}else this._logService.debug("_rowToLinkify was unset before _linkifyRows was called")},e.prototype.registerLinkMatcher=function(e,t,r){if(void 0===r&&(r={}),!t)throw new Error("handler must be defined");var i={id:this._nextLinkMatcherId++,regex:e,handler:t,matchIndex:r.matchIndex,validationCallback:r.validationCallback,hoverTooltipCallback:r.tooltipCallback,hoverLeaveCallback:r.leaveCallback,willLinkActivate:r.willLinkActivate,priority:r.priority||0};return this._addLinkMatcherToList(i),i.id},e.prototype._addLinkMatcherToList=function(e){if(0!==this._linkMatchers.length){for(var t=this._linkMatchers.length-1;t>=0;t--)if(e.priority<=this._linkMatchers[t].priority)return void this._linkMatchers.splice(t+1,0,e);this._linkMatchers.splice(0,0,e)}else this._linkMatchers.push(e)},e.prototype.deregisterLinkMatcher=function(e){for(var t=0;t<this._linkMatchers.length;t++)if(this._linkMatchers[t].id===e)return this._linkMatchers.splice(t,1),!0;return!1},e.prototype._doLinkifyRow=function(e,t,r){for(var i,n=this,o=new RegExp(r.regex.source,(r.regex.flags||"")+"g"),s=-1,a=function(){var a=i["number"!=typeof r.matchIndex?0:r.matchIndex];if(!a)return c._logService.debug("match found without corresponding matchIndex",i,r),"break";if(s=t.indexOf(a,s+1),o.lastIndex=s+a.length,s<0)return"break";var l=c._bufferService.buffer.stringIndexToBufferIndex(e,s);if(l[0]<0)return"break";var u=c._bufferService.buffer.lines.get(l[0]);if(!u)return"break";var h=u.getFg(l[1]),f=h?h>>9&511:void 0;r.validationCallback?r.validationCallback(a,(function(e){n._rowsTimeoutId||e&&n._addLink(l[1],l[0]-n._bufferService.buffer.ydisp,a,r,f)})):c._addLink(l[1],l[0]-c._bufferService.buffer.ydisp,a,r,f)},c=this;null!==(i=o.exec(t))&&"break"!==a(););},e.prototype._addLink=function(e,t,r,i,n){var o=this;if(this._mouseZoneManager&&this._element){var s=this._unicodeService.getStringCellWidth(r),a=e%this._bufferService.cols,l=t+Math.floor(e/this._bufferService.cols),u=(a+s)%this._bufferService.cols,h=l+Math.floor((a+s)/this._bufferService.cols);0===u&&(u=this._bufferService.cols,h--),this._mouseZoneManager.add(new c(a+1,l+1,u+1,h+1,(function(e){if(i.handler)return i.handler(e,r);var t=window.open();t?(t.opener=null,t.location.href=r):console.warn("Opening link blocked as opener could not be cleared")}),(function(){o._onShowLinkUnderline.fire(o._createLinkHoverEvent(a,l,u,h,n)),o._element.classList.add("xterm-cursor-pointer")}),(function(e){o._onLinkTooltip.fire(o._createLinkHoverEvent(a,l,u,h,n)),i.hoverTooltipCallback&&i.hoverTooltipCallback(e,r,{start:{x:a,y:l},end:{x:u,y:h}})}),(function(){o._onHideLinkUnderline.fire(o._createLinkHoverEvent(a,l,u,h,n)),o._element.classList.remove("xterm-cursor-pointer"),i.hoverLeaveCallback&&i.hoverLeaveCallback()}),(function(e){return!i.willLinkActivate||i.willLinkActivate(e,r)})))}},e.prototype._createLinkHoverEvent=function(e,t,r,i,n){return{x1:e,y1:t,x2:r,y2:i,cols:this._bufferService.cols,fg:n}},e._timeBeforeLatency=200,e=i([n(0,s.IBufferService),n(1,s.ILogService),n(2,s.IUnicodeService)],e)}();t.Linkifier=a;var c=function(e,t,r,i,n,o,s,a,c){this.x1=e,this.y1=t,this.x2=r,this.y2=i,this.clickCallback=n,this.hoverCallback=o,this.tooltipCallback=s,this.leaveCallback=a,this.willLinkActivate=c};t.MouseZone=c},6465:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.Linkifier2=void 0;var a=r(2585),c=r(8460),l=r(844),u=r(3656),h=function(e){function t(t){var r=e.call(this)||this;return r._bufferService=t,r._linkProviders=[],r._linkCacheDisposables=[],r._isMouseOut=!0,r._activeLine=-1,r._onShowLinkUnderline=r.register(new c.EventEmitter),r._onHideLinkUnderline=r.register(new c.EventEmitter),r.register((0,l.getDisposeArrayDisposable)(r._linkCacheDisposables)),r}return n(t,e),Object.defineProperty(t.prototype,"currentLink",{get:function(){return this._currentLink},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onShowLinkUnderline",{get:function(){return this._onShowLinkUnderline.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onHideLinkUnderline",{get:function(){return this._onHideLinkUnderline.event},enumerable:!1,configurable:!0}),t.prototype.registerLinkProvider=function(e){var t=this;return this._linkProviders.push(e),{dispose:function(){var r=t._linkProviders.indexOf(e);-1!==r&&t._linkProviders.splice(r,1)}}},t.prototype.attachToDom=function(e,t,r){var i=this;this._element=e,this._mouseService=t,this._renderService=r,this.register((0,u.addDisposableDomListener)(this._element,"mouseleave",(function(){i._isMouseOut=!0,i._clearCurrentLink()}))),this.register((0,u.addDisposableDomListener)(this._element,"mousemove",this._onMouseMove.bind(this))),this.register((0,u.addDisposableDomListener)(this._element,"click",this._onClick.bind(this)))},t.prototype._onMouseMove=function(e){if(this._lastMouseEvent=e,this._element&&this._mouseService){var t=this._positionFromMouseEvent(e,this._element,this._mouseService);if(t){this._isMouseOut=!1;for(var r=e.composedPath(),i=0;i<r.length;i++){var n=r[i];if(n.classList.contains("xterm"))break;if(n.classList.contains("xterm-hover"))return}this._lastBufferCell&&t.x===this._lastBufferCell.x&&t.y===this._lastBufferCell.y||(this._onHover(t),this._lastBufferCell=t)}}},t.prototype._onHover=function(e){if(this._activeLine!==e.y)return this._clearCurrentLink(),void this._askForLink(e,!1);this._currentLink&&this._linkAtPosition(this._currentLink.link,e)||(this._clearCurrentLink(),this._askForLink(e,!0))},t.prototype._askForLink=function(e,t){var r,i=this;this._activeProviderReplies&&t||(null===(r=this._activeProviderReplies)||void 0===r||r.forEach((function(e){null==e||e.forEach((function(e){e.link.dispose&&e.link.dispose()}))})),this._activeProviderReplies=new Map,this._activeLine=e.y);var n=!1;this._linkProviders.forEach((function(r,o){var s;t?(null===(s=i._activeProviderReplies)||void 0===s?void 0:s.get(o))&&(n=i._checkLinkProviderResult(o,e,n)):r.provideLinks(e.y,(function(t){var r,s;if(!i._isMouseOut){var a=null==t?void 0:t.map((function(e){return{link:e}}));null===(r=i._activeProviderReplies)||void 0===r||r.set(o,a),n=i._checkLinkProviderResult(o,e,n),(null===(s=i._activeProviderReplies)||void 0===s?void 0:s.size)===i._linkProviders.length&&i._removeIntersectingLinks(e.y,i._activeProviderReplies)}}))}))},t.prototype._removeIntersectingLinks=function(e,t){for(var r=new Set,i=0;i<t.size;i++){var n=t.get(i);if(n)for(var o=0;o<n.length;o++)for(var s=n[o],a=s.link.range.start.y<e?0:s.link.range.start.x,c=s.link.range.end.y>e?this._bufferService.cols:s.link.range.end.x,l=a;l<=c;l++){if(r.has(l)){n.splice(o--,1);break}r.add(l)}}},t.prototype._checkLinkProviderResult=function(e,t,r){var i,n=this;if(!this._activeProviderReplies)return r;for(var o=this._activeProviderReplies.get(e),s=!1,a=0;a<e;a++)this._activeProviderReplies.has(a)&&!this._activeProviderReplies.get(a)||(s=!0);if(!s&&o){var c=o.find((function(e){return n._linkAtPosition(e.link,t)}));c&&(r=!0,this._handleNewLink(c))}if(this._activeProviderReplies.size===this._linkProviders.length&&!r)for(a=0;a<this._activeProviderReplies.size;a++){var l=null===(i=this._activeProviderReplies.get(a))||void 0===i?void 0:i.find((function(e){return n._linkAtPosition(e.link,t)}));if(l){r=!0,this._handleNewLink(l);break}}return r},t.prototype._onClick=function(e){if(this._element&&this._mouseService&&this._currentLink){var t=this._positionFromMouseEvent(e,this._element,this._mouseService);t&&this._linkAtPosition(this._currentLink.link,t)&&this._currentLink.link.activate(e,this._currentLink.link.text)}},t.prototype._clearCurrentLink=function(e,t){this._element&&this._currentLink&&this._lastMouseEvent&&(!e||!t||this._currentLink.link.range.start.y>=e&&this._currentLink.link.range.end.y<=t)&&(this._linkLeave(this._element,this._currentLink.link,this._lastMouseEvent),this._currentLink=void 0,(0,l.disposeArray)(this._linkCacheDisposables))},t.prototype._handleNewLink=function(e){var t=this;if(this._element&&this._lastMouseEvent&&this._mouseService){var r=this._positionFromMouseEvent(this._lastMouseEvent,this._element,this._mouseService);r&&this._linkAtPosition(e.link,r)&&(this._currentLink=e,this._currentLink.state={decorations:{underline:void 0===e.link.decorations||e.link.decorations.underline,pointerCursor:void 0===e.link.decorations||e.link.decorations.pointerCursor},isHovered:!0},this._linkHover(this._element,e.link,this._lastMouseEvent),e.link.decorations={},Object.defineProperties(e.link.decorations,{pointerCursor:{get:function(){var e,r;return null===(r=null===(e=t._currentLink)||void 0===e?void 0:e.state)||void 0===r?void 0:r.decorations.pointerCursor},set:function(e){var r,i;(null===(r=t._currentLink)||void 0===r?void 0:r.state)&&t._currentLink.state.decorations.pointerCursor!==e&&(t._currentLink.state.decorations.pointerCursor=e,t._currentLink.state.isHovered&&(null===(i=t._element)||void 0===i||i.classList.toggle("xterm-cursor-pointer",e)))}},underline:{get:function(){var e,r;return null===(r=null===(e=t._currentLink)||void 0===e?void 0:e.state)||void 0===r?void 0:r.decorations.underline},set:function(r){var i,n,o;(null===(i=t._currentLink)||void 0===i?void 0:i.state)&&(null===(o=null===(n=t._currentLink)||void 0===n?void 0:n.state)||void 0===o?void 0:o.decorations.underline)!==r&&(t._currentLink.state.decorations.underline=r,t._currentLink.state.isHovered&&t._fireUnderlineEvent(e.link,r))}}}),this._renderService&&this._linkCacheDisposables.push(this._renderService.onRenderedBufferChange((function(e){var r=0===e.start?0:e.start+1+t._bufferService.buffer.ydisp;t._clearCurrentLink(r,e.end+1+t._bufferService.buffer.ydisp)}))))}},t.prototype._linkHover=function(e,t,r){var i;(null===(i=this._currentLink)||void 0===i?void 0:i.state)&&(this._currentLink.state.isHovered=!0,this._currentLink.state.decorations.underline&&this._fireUnderlineEvent(t,!0),this._currentLink.state.decorations.pointerCursor&&e.classList.add("xterm-cursor-pointer")),t.hover&&t.hover(r,t.text)},t.prototype._fireUnderlineEvent=function(e,t){var r=e.range,i=this._bufferService.buffer.ydisp,n=this._createLinkUnderlineEvent(r.start.x-1,r.start.y-i-1,r.end.x,r.end.y-i-1,void 0);(t?this._onShowLinkUnderline:this._onHideLinkUnderline).fire(n)},t.prototype._linkLeave=function(e,t,r){var i;(null===(i=this._currentLink)||void 0===i?void 0:i.state)&&(this._currentLink.state.isHovered=!1,this._currentLink.state.decorations.underline&&this._fireUnderlineEvent(t,!1),this._currentLink.state.decorations.pointerCursor&&e.classList.remove("xterm-cursor-pointer")),t.leave&&t.leave(r,t.text)},t.prototype._linkAtPosition=function(e,t){var r=e.range.start.y===e.range.end.y,i=e.range.start.y<t.y,n=e.range.end.y>t.y;return(r&&e.range.start.x<=t.x&&e.range.end.x>=t.x||i&&e.range.end.x>=t.x||n&&e.range.start.x<=t.x||i&&n)&&e.range.start.y<=t.y&&e.range.end.y>=t.y},t.prototype._positionFromMouseEvent=function(e,t,r){var i=r.getCoords(e,t,this._bufferService.cols,this._bufferService.rows);if(i)return{x:i[0],y:i[1]+this._bufferService.buffer.ydisp}},t.prototype._createLinkUnderlineEvent=function(e,t,r,i,n){return{x1:e,y1:t,x2:r,y2:i,cols:this._bufferService.cols,fg:n}},o([s(0,a.IBufferService)],t)}(l.Disposable);t.Linkifier2=h},9042:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.tooMuchOutput=t.promptLabel=void 0,t.promptLabel="Terminal input",t.tooMuchOutput="Too much output to announce, navigate to rows manually to read"},6954:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.MouseZoneManager=void 0;var a=r(844),c=r(3656),l=r(4725),u=r(2585),h=function(e){function t(t,r,i,n,o,s){var a=e.call(this)||this;return a._element=t,a._screenElement=r,a._bufferService=i,a._mouseService=n,a._selectionService=o,a._optionsService=s,a._zones=[],a._areZonesActive=!1,a._lastHoverCoords=[void 0,void 0],a._initialSelectionLength=0,a.register((0,c.addDisposableDomListener)(a._element,"mousedown",(function(e){return a._onMouseDown(e)}))),a._mouseMoveListener=function(e){return a._onMouseMove(e)},a._mouseLeaveListener=function(e){return a._onMouseLeave(e)},a._clickListener=function(e){return a._onClick(e)},a}return n(t,e),t.prototype.dispose=function(){e.prototype.dispose.call(this),this._deactivate()},t.prototype.add=function(e){this._zones.push(e),1===this._zones.length&&this._activate()},t.prototype.clearAll=function(e,t){if(0!==this._zones.length){e&&t||(e=0,t=this._bufferService.rows-1);for(var r=0;r<this._zones.length;r++){var i=this._zones[r];(i.y1>e&&i.y1<=t+1||i.y2>e&&i.y2<=t+1||i.y1<e&&i.y2>t+1)&&(this._currentZone&&this._currentZone===i&&(this._currentZone.leaveCallback(),this._currentZone=void 0),this._zones.splice(r--,1))}0===this._zones.length&&this._deactivate()}},t.prototype._activate=function(){this._areZonesActive||(this._areZonesActive=!0,this._element.addEventListener("mousemove",this._mouseMoveListener),this._element.addEventListener("mouseleave",this._mouseLeaveListener),this._element.addEventListener("click",this._clickListener))},t.prototype._deactivate=function(){this._areZonesActive&&(this._areZonesActive=!1,this._element.removeEventListener("mousemove",this._mouseMoveListener),this._element.removeEventListener("mouseleave",this._mouseLeaveListener),this._element.removeEventListener("click",this._clickListener))},t.prototype._onMouseMove=function(e){this._lastHoverCoords[0]===e.pageX&&this._lastHoverCoords[1]===e.pageY||(this._onHover(e),this._lastHoverCoords=[e.pageX,e.pageY])},t.prototype._onHover=function(e){var t=this,r=this._findZoneEventAt(e);r!==this._currentZone&&(this._currentZone&&(this._currentZone.leaveCallback(),this._currentZone=void 0,this._tooltipTimeout&&clearTimeout(this._tooltipTimeout)),r&&(this._currentZone=r,r.hoverCallback&&r.hoverCallback(e),this._tooltipTimeout=window.setTimeout((function(){return t._onTooltip(e)}),this._optionsService.options.linkTooltipHoverDuration)))},t.prototype._onTooltip=function(e){this._tooltipTimeout=void 0;var t=this._findZoneEventAt(e);null==t||t.tooltipCallback(e)},t.prototype._onMouseDown=function(e){if(this._initialSelectionLength=this._getSelectionLength(),this._areZonesActive){var t=this._findZoneEventAt(e);(null==t?void 0:t.willLinkActivate(e))&&(e.preventDefault(),e.stopImmediatePropagation())}},t.prototype._onMouseLeave=function(e){this._currentZone&&(this._currentZone.leaveCallback(),this._currentZone=void 0,this._tooltipTimeout&&clearTimeout(this._tooltipTimeout))},t.prototype._onClick=function(e){var t=this._findZoneEventAt(e),r=this._getSelectionLength();t&&r===this._initialSelectionLength&&(t.clickCallback(e),e.preventDefault(),e.stopImmediatePropagation())},t.prototype._getSelectionLength=function(){var e=this._selectionService.selectionText;return e?e.length:0},t.prototype._findZoneEventAt=function(e){var t=this._mouseService.getCoords(e,this._screenElement,this._bufferService.cols,this._bufferService.rows);if(t)for(var r=t[0],i=t[1],n=0;n<this._zones.length;n++){var o=this._zones[n];if(o.y1===o.y2){if(i===o.y1&&r>=o.x1&&r<o.x2)return o}else if(i===o.y1&&r>=o.x1||i===o.y2&&r<o.x2||i>o.y1&&i<o.y2)return o}},o([s(2,u.IBufferService),s(3,l.IMouseService),s(4,l.ISelectionService),s(5,u.IOptionsService)],t)}(a.Disposable);t.MouseZoneManager=h},6193:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.RenderDebouncer=void 0;var r=function(){function e(e){this._renderCallback=e}return e.prototype.dispose=function(){this._animationFrame&&(window.cancelAnimationFrame(this._animationFrame),this._animationFrame=void 0)},e.prototype.refresh=function(e,t,r){var i=this;this._rowCount=r,e=void 0!==e?e:0,t=void 0!==t?t:this._rowCount-1,this._rowStart=void 0!==this._rowStart?Math.min(this._rowStart,e):e,this._rowEnd=void 0!==this._rowEnd?Math.max(this._rowEnd,t):t,this._animationFrame||(this._animationFrame=window.requestAnimationFrame((function(){return i._innerRefresh()})))},e.prototype._innerRefresh=function(){if(void 0!==this._rowStart&&void 0!==this._rowEnd&&void 0!==this._rowCount){var e=Math.max(this._rowStart,0),t=Math.min(this._rowEnd,this._rowCount-1);this._rowStart=void 0,this._rowEnd=void 0,this._animationFrame=void 0,this._renderCallback(e,t)}},e}();t.RenderDebouncer=r},5596:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.ScreenDprMonitor=void 0;var o=function(e){function t(){var t=null!==e&&e.apply(this,arguments)||this;return t._currentDevicePixelRatio=window.devicePixelRatio,t}return n(t,e),t.prototype.setListener=function(e){var t=this;this._listener&&this.clearListener(),this._listener=e,this._outerListener=function(){t._listener&&(t._listener(window.devicePixelRatio,t._currentDevicePixelRatio),t._updateDpr())},this._updateDpr()},t.prototype.dispose=function(){e.prototype.dispose.call(this),this.clearListener()},t.prototype._updateDpr=function(){var e;this._outerListener&&(null===(e=this._resolutionMediaMatchList)||void 0===e||e.removeListener(this._outerListener),this._currentDevicePixelRatio=window.devicePixelRatio,this._resolutionMediaMatchList=window.matchMedia("screen and (resolution: "+window.devicePixelRatio+"dppx)"),this._resolutionMediaMatchList.addListener(this._outerListener))},t.prototype.clearListener=function(){this._resolutionMediaMatchList&&this._listener&&this._outerListener&&(this._resolutionMediaMatchList.removeListener(this._outerListener),this._resolutionMediaMatchList=void 0,this._listener=void 0,this._outerListener=void 0)},t}(r(844).Disposable);t.ScreenDprMonitor=o},3236:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.Terminal=void 0;var o=r(2950),s=r(1680),a=r(3614),c=r(2584),l=r(5435),u=r(3525),h=r(3551),f=r(9312),_=r(6114),d=r(3656),p=r(9042),v=r(357),g=r(6954),y=r(4567),m=r(1296),b=r(7399),S=r(8460),C=r(8437),w=r(5680),L=r(3230),E=r(4725),x=r(428),A=r(8934),k=r(6465),M=r(5114),R=r(8969),T=r(4774),O=r(4269),B=r(5941),D="undefined"!=typeof window?window.document:null,P=function(e){function t(t){void 0===t&&(t={});var r=e.call(this,t)||this;return r.browser=_,r._keyDownHandled=!1,r._keyPressHandled=!1,r._unprocessedDeadKey=!1,r._onCursorMove=new S.EventEmitter,r._onKey=new S.EventEmitter,r._onRender=new S.EventEmitter,r._onSelectionChange=new S.EventEmitter,r._onTitleChange=new S.EventEmitter,r._onBell=new S.EventEmitter,r._onFocus=new S.EventEmitter,r._onBlur=new S.EventEmitter,r._onA11yCharEmitter=new S.EventEmitter,r._onA11yTabEmitter=new S.EventEmitter,r._setup(),r.linkifier=r._instantiationService.createInstance(h.Linkifier),r.linkifier2=r.register(r._instantiationService.createInstance(k.Linkifier2)),r.register(r._inputHandler.onRequestBell((function(){return r.bell()}))),r.register(r._inputHandler.onRequestRefreshRows((function(e,t){return r.refresh(e,t)}))),r.register(r._inputHandler.onRequestSendFocus((function(){return r._reportFocus()}))),r.register(r._inputHandler.onRequestReset((function(){return r.reset()}))),r.register(r._inputHandler.onRequestWindowsOptionsReport((function(e){return r._reportWindowsOptions(e)}))),r.register(r._inputHandler.onColor((function(e){return r._handleColorEvent(e)}))),r.register((0,S.forwardEvent)(r._inputHandler.onCursorMove,r._onCursorMove)),r.register((0,S.forwardEvent)(r._inputHandler.onTitleChange,r._onTitleChange)),r.register((0,S.forwardEvent)(r._inputHandler.onA11yChar,r._onA11yCharEmitter)),r.register((0,S.forwardEvent)(r._inputHandler.onA11yTab,r._onA11yTabEmitter)),r.register(r._bufferService.onResize((function(e){return r._afterResize(e.cols,e.rows)}))),r}return n(t,e),Object.defineProperty(t.prototype,"onCursorMove",{get:function(){return this._onCursorMove.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onKey",{get:function(){return this._onKey.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRender",{get:function(){return this._onRender.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onSelectionChange",{get:function(){return this._onSelectionChange.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onTitleChange",{get:function(){return this._onTitleChange.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onBell",{get:function(){return this._onBell.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onFocus",{get:function(){return this._onFocus.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onBlur",{get:function(){return this._onBlur.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onA11yChar",{get:function(){return this._onA11yCharEmitter.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onA11yTab",{get:function(){return this._onA11yTabEmitter.event},enumerable:!1,configurable:!0}),t.prototype._handleColorEvent=function(e){var t,r;if(this._colorManager){for(var i=0,n=e;i<n.length;i++){var o=n[i],s=void 0,a="";switch(o.index){case 256:s="foreground",a="10";break;case 257:s="background",a="11";break;case 258:s="cursor",a="12";break;default:s="ansi",a="4;"+o.index}if(s)switch(o.type){case 0:var l=T.color.toColorRGB("ansi"===s?this._colorManager.colors.ansi[o.index]:this._colorManager.colors[s]);this.coreService.triggerDataEvent(c.C0.ESC+"]"+a+";"+(0,B.toRgbString)(l)+c.C0.BEL);break;case 1:"ansi"===s?this._colorManager.colors.ansi[o.index]=T.rgba.toColor.apply(T.rgba,o.color):this._colorManager.colors[s]=T.rgba.toColor.apply(T.rgba,o.color);break;case 2:this._colorManager.restoreColor(o.index)}}null===(t=this._renderService)||void 0===t||t.setColors(this._colorManager.colors),null===(r=this.viewport)||void 0===r||r.onThemeChange(this._colorManager.colors)}},t.prototype.dispose=function(){var t,r,i;this._isDisposed||(e.prototype.dispose.call(this),null===(t=this._renderService)||void 0===t||t.dispose(),this._customKeyEventHandler=void 0,this.write=function(){},null===(i=null===(r=this.element)||void 0===r?void 0:r.parentNode)||void 0===i||i.removeChild(this.element))},t.prototype._setup=function(){e.prototype._setup.call(this),this._customKeyEventHandler=void 0},Object.defineProperty(t.prototype,"buffer",{get:function(){return this.buffers.active},enumerable:!1,configurable:!0}),t.prototype.focus=function(){this.textarea&&this.textarea.focus({preventScroll:!0})},t.prototype._updateOptions=function(t){var r,i,n,o;switch(e.prototype._updateOptions.call(this,t),t){case"fontFamily":case"fontSize":null===(r=this._renderService)||void 0===r||r.clear(),null===(i=this._charSizeService)||void 0===i||i.measure();break;case"cursorBlink":case"cursorStyle":this.refresh(this.buffer.y,this.buffer.y);break;case"customGlyphs":case"drawBoldTextInBrightColors":case"letterSpacing":case"lineHeight":case"fontWeight":case"fontWeightBold":case"minimumContrastRatio":this._renderService&&(this._renderService.clear(),this._renderService.onResize(this.cols,this.rows),this.refresh(0,this.rows-1));break;case"rendererType":this._renderService&&(this._renderService.setRenderer(this._createRenderer()),this._renderService.onResize(this.cols,this.rows));break;case"scrollback":null===(n=this.viewport)||void 0===n||n.syncScrollArea();break;case"screenReaderMode":this.optionsService.options.screenReaderMode?!this._accessibilityManager&&this._renderService&&(this._accessibilityManager=new y.AccessibilityManager(this,this._renderService)):(null===(o=this._accessibilityManager)||void 0===o||o.dispose(),this._accessibilityManager=void 0);break;case"tabStopWidth":this.buffers.setupTabStops();break;case"theme":this._setTheme(this.optionsService.options.theme)}},t.prototype._onTextAreaFocus=function(e){this.coreService.decPrivateModes.sendFocus&&this.coreService.triggerDataEvent(c.C0.ESC+"[I"),this.updateCursorStyle(e),this.element.classList.add("focus"),this._showCursor(),this._onFocus.fire()},t.prototype.blur=function(){var e;return null===(e=this.textarea)||void 0===e?void 0:e.blur()},t.prototype._onTextAreaBlur=function(){this.textarea.value="",this.refresh(this.buffer.y,this.buffer.y),this.coreService.decPrivateModes.sendFocus&&this.coreService.triggerDataEvent(c.C0.ESC+"[O"),this.element.classList.remove("focus"),this._onBlur.fire()},t.prototype._syncTextArea=function(){if(this.textarea&&this.buffer.isCursorInViewport&&!this._compositionHelper.isComposing&&this._renderService){var e=this.buffer.ybase+this.buffer.y,t=this.buffer.lines.get(e);if(t){var r=Math.min(this.buffer.x,this.cols-1),i=this._renderService.dimensions.actualCellHeight,n=t.getWidth(r),o=this._renderService.dimensions.actualCellWidth*n,s=this.buffer.y*this._renderService.dimensions.actualCellHeight,a=r*this._renderService.dimensions.actualCellWidth;this.textarea.style.left=a+"px",this.textarea.style.top=s+"px",this.textarea.style.width=o+"px",this.textarea.style.height=i+"px",this.textarea.style.lineHeight=i+"px",this.textarea.style.zIndex="-5"}}},t.prototype._initGlobal=function(){var e=this;this._bindKeys(),this.register((0,d.addDisposableDomListener)(this.element,"copy",(function(t){e.hasSelection()&&(0,a.copyHandler)(t,e._selectionService)})));var t=function(t){return(0,a.handlePasteEvent)(t,e.textarea,e.coreService)};this.register((0,d.addDisposableDomListener)(this.textarea,"paste",t)),this.register((0,d.addDisposableDomListener)(this.element,"paste",t)),_.isFirefox?this.register((0,d.addDisposableDomListener)(this.element,"mousedown",(function(t){2===t.button&&(0,a.rightClickHandler)(t,e.textarea,e.screenElement,e._selectionService,e.options.rightClickSelectsWord)}))):this.register((0,d.addDisposableDomListener)(this.element,"contextmenu",(function(t){(0,a.rightClickHandler)(t,e.textarea,e.screenElement,e._selectionService,e.options.rightClickSelectsWord)}))),_.isLinux&&this.register((0,d.addDisposableDomListener)(this.element,"auxclick",(function(t){1===t.button&&(0,a.moveTextAreaUnderMouseCursor)(t,e.textarea,e.screenElement)})))},t.prototype._bindKeys=function(){var e=this;this.register((0,d.addDisposableDomListener)(this.textarea,"keyup",(function(t){return e._keyUp(t)}),!0)),this.register((0,d.addDisposableDomListener)(this.textarea,"keydown",(function(t){return e._keyDown(t)}),!0)),this.register((0,d.addDisposableDomListener)(this.textarea,"keypress",(function(t){return e._keyPress(t)}),!0)),this.register((0,d.addDisposableDomListener)(this.textarea,"compositionstart",(function(){return e._compositionHelper.compositionstart()}))),this.register((0,d.addDisposableDomListener)(this.textarea,"compositionupdate",(function(t){return e._compositionHelper.compositionupdate(t)}))),this.register((0,d.addDisposableDomListener)(this.textarea,"compositionend",(function(){return e._compositionHelper.compositionend()}))),this.register((0,d.addDisposableDomListener)(this.textarea,"input",(function(t){return e._inputEvent(t)}),!0)),this.register(this.onRender((function(){return e._compositionHelper.updateCompositionElements()}))),this.register(this.onRender((function(t){return e._queueLinkification(t.start,t.end)})))},t.prototype.open=function(e){var t=this;if(!e)throw new Error("Terminal requires a parent element.");e.isConnected||this._logService.debug("Terminal.open was called on an element that was not attached to the DOM"),this._document=e.ownerDocument,this.element=this._document.createElement("div"),this.element.dir="ltr",this.element.classList.add("terminal"),this.element.classList.add("xterm"),this.element.setAttribute("tabindex","0"),e.appendChild(this.element);var r=D.createDocumentFragment();this._viewportElement=D.createElement("div"),this._viewportElement.classList.add("xterm-viewport"),r.appendChild(this._viewportElement),this._viewportScrollArea=D.createElement("div"),this._viewportScrollArea.classList.add("xterm-scroll-area"),this._viewportElement.appendChild(this._viewportScrollArea),this.screenElement=D.createElement("div"),this.screenElement.classList.add("xterm-screen"),this._helperContainer=D.createElement("div"),this._helperContainer.classList.add("xterm-helpers"),this.screenElement.appendChild(this._helperContainer),r.appendChild(this.screenElement),this.textarea=D.createElement("textarea"),this.textarea.classList.add("xterm-helper-textarea"),this.textarea.setAttribute("aria-label",p.promptLabel),this.textarea.setAttribute("aria-multiline","false"),this.textarea.setAttribute("autocorrect","off"),this.textarea.setAttribute("autocapitalize","off"),this.textarea.setAttribute("spellcheck","false"),this.textarea.tabIndex=0,this.register((0,d.addDisposableDomListener)(this.textarea,"focus",(function(e){return t._onTextAreaFocus(e)}))),this.register((0,d.addDisposableDomListener)(this.textarea,"blur",(function(){return t._onTextAreaBlur()}))),this._helperContainer.appendChild(this.textarea);var i=this._instantiationService.createInstance(M.CoreBrowserService,this.textarea);this._instantiationService.setService(E.ICoreBrowserService,i),this._charSizeService=this._instantiationService.createInstance(x.CharSizeService,this._document,this._helperContainer),this._instantiationService.setService(E.ICharSizeService,this._charSizeService),this._theme=this.options.theme||this._theme,this._colorManager=new w.ColorManager(D,this.options.allowTransparency),this.register(this.optionsService.onOptionChange((function(e){return t._colorManager.onOptionsChange(e)}))),this._colorManager.setTheme(this._theme),this._characterJoinerService=this._instantiationService.createInstance(O.CharacterJoinerService),this._instantiationService.setService(E.ICharacterJoinerService,this._characterJoinerService);var n=this._createRenderer();this._renderService=this.register(this._instantiationService.createInstance(L.RenderService,n,this.rows,this.screenElement)),this._instantiationService.setService(E.IRenderService,this._renderService),this.register(this._renderService.onRenderedBufferChange((function(e){return t._onRender.fire(e)}))),this.onResize((function(e){return t._renderService.resize(e.cols,e.rows)})),this._compositionView=D.createElement("div"),this._compositionView.classList.add("composition-view"),this._compositionHelper=this._instantiationService.createInstance(o.CompositionHelper,this.textarea,this._compositionView),this._helperContainer.appendChild(this._compositionView),this.element.appendChild(r),this._soundService=this._instantiationService.createInstance(v.SoundService),this._instantiationService.setService(E.ISoundService,this._soundService),this._mouseService=this._instantiationService.createInstance(A.MouseService),this._instantiationService.setService(E.IMouseService,this._mouseService),this.viewport=this._instantiationService.createInstance(s.Viewport,(function(e){return t.scrollLines(e,!0,1)}),this._viewportElement,this._viewportScrollArea,this.element),this.viewport.onThemeChange(this._colorManager.colors),this.register(this._inputHandler.onRequestSyncScrollBar((function(){return t.viewport.syncScrollArea()}))),this.register(this.viewport),this.register(this.onCursorMove((function(){t._renderService.onCursorMove(),t._syncTextArea()}))),this.register(this.onResize((function(){return t._renderService.onResize(t.cols,t.rows)}))),this.register(this.onBlur((function(){return t._renderService.onBlur()}))),this.register(this.onFocus((function(){return t._renderService.onFocus()}))),this.register(this._renderService.onDimensionsChange((function(){return t.viewport.syncScrollArea()}))),this._selectionService=this.register(this._instantiationService.createInstance(f.SelectionService,this.element,this.screenElement,this.linkifier2)),this._instantiationService.setService(E.ISelectionService,this._selectionService),this.register(this._selectionService.onRequestScrollLines((function(e){return t.scrollLines(e.amount,e.suppressScrollEvent)}))),this.register(this._selectionService.onSelectionChange((function(){return t._onSelectionChange.fire()}))),this.register(this._selectionService.onRequestRedraw((function(e){return t._renderService.onSelectionChanged(e.start,e.end,e.columnSelectMode)}))),this.register(this._selectionService.onLinuxMouseSelection((function(e){t.textarea.value=e,t.textarea.focus(),t.textarea.select()}))),this.register(this._onScroll.event((function(e){t.viewport.syncScrollArea(),t._selectionService.refresh()}))),this.register((0,d.addDisposableDomListener)(this._viewportElement,"scroll",(function(){return t._selectionService.refresh()}))),this._mouseZoneManager=this._instantiationService.createInstance(g.MouseZoneManager,this.element,this.screenElement),this.register(this._mouseZoneManager),this.register(this.onScroll((function(){return t._mouseZoneManager.clearAll()}))),this.linkifier.attachToDom(this.element,this._mouseZoneManager),this.linkifier2.attachToDom(this.screenElement,this._mouseService,this._renderService),this.register((0,d.addDisposableDomListener)(this.element,"mousedown",(function(e){return t._selectionService.onMouseDown(e)}))),this.coreMouseService.areMouseEventsActive?(this._selectionService.disable(),this.element.classList.add("enable-mouse-events")):this._selectionService.enable(),this.options.screenReaderMode&&(this._accessibilityManager=new y.AccessibilityManager(this,this._renderService)),this._charSizeService.measure(),this.refresh(0,this.rows-1),this._initGlobal(),this.bindMouse()},t.prototype._createRenderer=function(){switch(this.options.rendererType){case"canvas":return this._instantiationService.createInstance(u.Renderer,this._colorManager.colors,this.screenElement,this.linkifier,this.linkifier2);case"dom":return this._instantiationService.createInstance(m.DomRenderer,this._colorManager.colors,this.element,this.screenElement,this._viewportElement,this.linkifier,this.linkifier2);default:throw new Error('Unrecognized rendererType "'+this.options.rendererType+'"')}},t.prototype._setTheme=function(e){var t,r,i;this._theme=e,null===(t=this._colorManager)||void 0===t||t.setTheme(e),null===(r=this._renderService)||void 0===r||r.setColors(this._colorManager.colors),null===(i=this.viewport)||void 0===i||i.onThemeChange(this._colorManager.colors)},t.prototype.bindMouse=function(){var e=this,t=this,r=this.element;function i(e){var r,i,n=t._mouseService.getRawByteCoords(e,t.screenElement,t.cols,t.rows);if(!n)return!1;switch(e.overrideType||e.type){case"mousemove":i=32,void 0===e.buttons?(r=3,void 0!==e.button&&(r=e.button<3?e.button:3)):r=1&e.buttons?0:4&e.buttons?1:2&e.buttons?2:3;break;case"mouseup":i=0,r=e.button<3?e.button:3;break;case"mousedown":i=1,r=e.button<3?e.button:3;break;case"wheel":0!==e.deltaY&&(i=e.deltaY<0?0:1),r=4;break;default:return!1}return!(void 0===i||void 0===r||r>4)&&t.coreMouseService.triggerMouseEvent({col:n.x-33,row:n.y-33,button:r,action:i,ctrl:e.ctrlKey,alt:e.altKey,shift:e.shiftKey})}var n={mouseup:null,wheel:null,mousedrag:null,mousemove:null},o=function(t){return i(t),t.buttons||(e._document.removeEventListener("mouseup",n.mouseup),n.mousedrag&&e._document.removeEventListener("mousemove",n.mousedrag)),e.cancel(t)},s=function(t){return i(t),e.cancel(t,!0)},a=function(e){e.buttons&&i(e)},l=function(e){e.buttons||i(e)};this.register(this.coreMouseService.onProtocolChange((function(t){t?("debug"===e.optionsService.options.logLevel&&e._logService.debug("Binding to mouse events:",e.coreMouseService.explainEvents(t)),e.element.classList.add("enable-mouse-events"),e._selectionService.disable()):(e._logService.debug("Unbinding from mouse events."),e.element.classList.remove("enable-mouse-events"),e._selectionService.enable()),8&t?n.mousemove||(r.addEventListener("mousemove",l),n.mousemove=l):(r.removeEventListener("mousemove",n.mousemove),n.mousemove=null),16&t?n.wheel||(r.addEventListener("wheel",s,{passive:!1}),n.wheel=s):(r.removeEventListener("wheel",n.wheel),n.wheel=null),2&t?n.mouseup||(n.mouseup=o):(e._document.removeEventListener("mouseup",n.mouseup),n.mouseup=null),4&t?n.mousedrag||(n.mousedrag=a):(e._document.removeEventListener("mousemove",n.mousedrag),n.mousedrag=null)}))),this.coreMouseService.activeProtocol=this.coreMouseService.activeProtocol,this.register((0,d.addDisposableDomListener)(r,"mousedown",(function(t){if(t.preventDefault(),e.focus(),e.coreMouseService.areMouseEventsActive&&!e._selectionService.shouldForceSelection(t))return i(t),n.mouseup&&e._document.addEventListener("mouseup",n.mouseup),n.mousedrag&&e._document.addEventListener("mousemove",n.mousedrag),e.cancel(t)}))),this.register((0,d.addDisposableDomListener)(r,"wheel",(function(t){if(!n.wheel){if(!e.buffer.hasScrollback){var r=e.viewport.getLinesScrolled(t);if(0===r)return;for(var i=c.C0.ESC+(e.coreService.decPrivateModes.applicationCursorKeys?"O":"[")+(t.deltaY<0?"A":"B"),o="",s=0;s<Math.abs(r);s++)o+=i;return e.coreService.triggerDataEvent(o,!0),e.cancel(t,!0)}return e.viewport.onWheel(t)?e.cancel(t):void 0}}),{passive:!1})),this.register((0,d.addDisposableDomListener)(r,"touchstart",(function(t){if(!e.coreMouseService.areMouseEventsActive)return e.viewport.onTouchStart(t),e.cancel(t)}),{passive:!0})),this.register((0,d.addDisposableDomListener)(r,"touchmove",(function(t){if(!e.coreMouseService.areMouseEventsActive)return e.viewport.onTouchMove(t)?void 0:e.cancel(t)}),{passive:!1}))},t.prototype.refresh=function(e,t){var r;null===(r=this._renderService)||void 0===r||r.refreshRows(e,t)},t.prototype._queueLinkification=function(e,t){var r;null===(r=this.linkifier)||void 0===r||r.linkifyRows(e,t)},t.prototype.updateCursorStyle=function(e){var t;(null===(t=this._selectionService)||void 0===t?void 0:t.shouldColumnSelect(e))?this.element.classList.add("column-select"):this.element.classList.remove("column-select")},t.prototype._showCursor=function(){this.coreService.isCursorInitialized||(this.coreService.isCursorInitialized=!0,this.refresh(this.buffer.y,this.buffer.y))},t.prototype.scrollLines=function(t,r,i){void 0===i&&(i=0),e.prototype.scrollLines.call(this,t,r,i),this.refresh(0,this.rows-1)},t.prototype.paste=function(e){(0,a.paste)(e,this.textarea,this.coreService)},t.prototype.attachCustomKeyEventHandler=function(e){this._customKeyEventHandler=e},t.prototype.registerLinkMatcher=function(e,t,r){var i=this.linkifier.registerLinkMatcher(e,t,r);return this.refresh(0,this.rows-1),i},t.prototype.deregisterLinkMatcher=function(e){this.linkifier.deregisterLinkMatcher(e)&&this.refresh(0,this.rows-1)},t.prototype.registerLinkProvider=function(e){return this.linkifier2.registerLinkProvider(e)},t.prototype.registerCharacterJoiner=function(e){if(!this._characterJoinerService)throw new Error("Terminal must be opened first");var t=this._characterJoinerService.register(e);return this.refresh(0,this.rows-1),t},t.prototype.deregisterCharacterJoiner=function(e){if(!this._characterJoinerService)throw new Error("Terminal must be opened first");this._characterJoinerService.deregister(e)&&this.refresh(0,this.rows-1)},Object.defineProperty(t.prototype,"markers",{get:function(){return this.buffer.markers},enumerable:!1,configurable:!0}),t.prototype.addMarker=function(e){if(this.buffer===this.buffers.normal)return this.buffer.addMarker(this.buffer.ybase+this.buffer.y+e)},t.prototype.hasSelection=function(){return!!this._selectionService&&this._selectionService.hasSelection},t.prototype.select=function(e,t,r){this._selectionService.setSelection(e,t,r)},t.prototype.getSelection=function(){return this._selectionService?this._selectionService.selectionText:""},t.prototype.getSelectionPosition=function(){if(this._selectionService&&this._selectionService.hasSelection)return{startColumn:this._selectionService.selectionStart[0],startRow:this._selectionService.selectionStart[1],endColumn:this._selectionService.selectionEnd[0],endRow:this._selectionService.selectionEnd[1]}},t.prototype.clearSelection=function(){var e;null===(e=this._selectionService)||void 0===e||e.clearSelection()},t.prototype.selectAll=function(){var e;null===(e=this._selectionService)||void 0===e||e.selectAll()},t.prototype.selectLines=function(e,t){var r;null===(r=this._selectionService)||void 0===r||r.selectLines(e,t)},t.prototype._keyDown=function(e){if(this._keyDownHandled=!1,this._customKeyEventHandler&&!1===this._customKeyEventHandler(e))return!1;if(!this._compositionHelper.keydown(e))return this.buffer.ybase!==this.buffer.ydisp&&this._bufferService.scrollToBottom(),!1;"Dead"!==e.key&&"AltGraph"!==e.key||(this._unprocessedDeadKey=!0);var t=(0,b.evaluateKeyboardEvent)(e,this.coreService.decPrivateModes.applicationCursorKeys,this.browser.isMac,this.options.macOptionIsMeta);if(this.updateCursorStyle(e),3===t.type||2===t.type){var r=this.rows-1;return this.scrollLines(2===t.type?-r:r),this.cancel(e,!0)}return 1===t.type&&this.selectAll(),!!this._isThirdLevelShift(this.browser,e)||(t.cancel&&this.cancel(e,!0),!t.key||(this._unprocessedDeadKey?(this._unprocessedDeadKey=!1,!0):(t.key!==c.C0.ETX&&t.key!==c.C0.CR||(this.textarea.value=""),this._onKey.fire({key:t.key,domEvent:e}),this._showCursor(),this.coreService.triggerDataEvent(t.key,!0),this.optionsService.options.screenReaderMode?void(this._keyDownHandled=!0):this.cancel(e,!0))))},t.prototype._isThirdLevelShift=function(e,t){var r=e.isMac&&!this.options.macOptionIsMeta&&t.altKey&&!t.ctrlKey&&!t.metaKey||e.isWindows&&t.altKey&&t.ctrlKey&&!t.metaKey||e.isWindows&&t.getModifierState("AltGraph");return"keypress"===t.type?r:r&&(!t.keyCode||t.keyCode>47)},t.prototype._keyUp=function(e){this._customKeyEventHandler&&!1===this._customKeyEventHandler(e)||(function(e){return 16===e.keyCode||17===e.keyCode||18===e.keyCode}(e)||this.focus(),this.updateCursorStyle(e),this._keyPressHandled=!1)},t.prototype._keyPress=function(e){var t;if(this._keyPressHandled=!1,this._keyDownHandled)return!1;if(this._customKeyEventHandler&&!1===this._customKeyEventHandler(e))return!1;if(this.cancel(e),e.charCode)t=e.charCode;else if(null===e.which||void 0===e.which)t=e.keyCode;else{if(0===e.which||0===e.charCode)return!1;t=e.which}return!(!t||(e.altKey||e.ctrlKey||e.metaKey)&&!this._isThirdLevelShift(this.browser,e)||(t=String.fromCharCode(t),this._onKey.fire({key:t,domEvent:e}),this._showCursor(),this.coreService.triggerDataEvent(t,!0),this._keyPressHandled=!0,this._unprocessedDeadKey=!1,0))},t.prototype._inputEvent=function(e){if(e.data&&"insertText"===e.inputType&&!e.composed&&!this.optionsService.options.screenReaderMode){if(this._keyPressHandled)return!1;this._unprocessedDeadKey=!1;var t=e.data;return this.coreService.triggerDataEvent(t,!0),this.cancel(e),!0}return!1},t.prototype.bell=function(){var e;this._soundBell()&&(null===(e=this._soundService)||void 0===e||e.playBellSound()),this._onBell.fire()},t.prototype.resize=function(t,r){t!==this.cols||r!==this.rows?e.prototype.resize.call(this,t,r):this._charSizeService&&!this._charSizeService.hasValidSize&&this._charSizeService.measure()},t.prototype._afterResize=function(e,t){var r,i;null===(r=this._charSizeService)||void 0===r||r.measure(),null===(i=this.viewport)||void 0===i||i.syncScrollArea(!0)},t.prototype.clear=function(){if(0!==this.buffer.ybase||0!==this.buffer.y){this.buffer.lines.set(0,this.buffer.lines.get(this.buffer.ybase+this.buffer.y)),this.buffer.lines.length=1,this.buffer.ydisp=0,this.buffer.ybase=0,this.buffer.y=0;for(var e=1;e<this.rows;e++)this.buffer.lines.push(this.buffer.getBlankLine(C.DEFAULT_ATTR_DATA));this.refresh(0,this.rows-1),this._onScroll.fire({position:this.buffer.ydisp,source:0})}},t.prototype.reset=function(){var t,r;this.options.rows=this.rows,this.options.cols=this.cols;var i=this._customKeyEventHandler;this._setup(),e.prototype.reset.call(this),null===(t=this._selectionService)||void 0===t||t.reset(),this._customKeyEventHandler=i,this.refresh(0,this.rows-1),null===(r=this.viewport)||void 0===r||r.syncScrollArea()},t.prototype.clearTextureAtlas=function(){var e;null===(e=this._renderService)||void 0===e||e.clearTextureAtlas()},t.prototype._reportFocus=function(){var e;(null===(e=this.element)||void 0===e?void 0:e.classList.contains("focus"))?this.coreService.triggerDataEvent(c.C0.ESC+"[I"):this.coreService.triggerDataEvent(c.C0.ESC+"[O")},t.prototype._reportWindowsOptions=function(e){if(this._renderService)switch(e){case l.WindowsOptionsReportType.GET_WIN_SIZE_PIXELS:var t=this._renderService.dimensions.scaledCanvasWidth.toFixed(0),r=this._renderService.dimensions.scaledCanvasHeight.toFixed(0);this.coreService.triggerDataEvent(c.C0.ESC+"[4;"+r+";"+t+"t");break;case l.WindowsOptionsReportType.GET_CELL_SIZE_PIXELS:var i=this._renderService.dimensions.scaledCellWidth.toFixed(0),n=this._renderService.dimensions.scaledCellHeight.toFixed(0);this.coreService.triggerDataEvent(c.C0.ESC+"[6;"+n+";"+i+"t")}},t.prototype.cancel=function(e,t){if(this.options.cancelEvents||t)return e.preventDefault(),e.stopPropagation(),!1},t.prototype._visualBell=function(){return!1},t.prototype._soundBell=function(){return"sound"===this.options.bellStyle},t}(R.CoreTerminal);t.Terminal=P},9924:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.TimeBasedDebouncer=void 0;var r=function(){function e(e,t){void 0===t&&(t=1e3),this._renderCallback=e,this._debounceThresholdMS=t,this._lastRefreshMs=0,this._additionalRefreshRequested=!1}return e.prototype.dispose=function(){this._refreshTimeoutID&&clearTimeout(this._refreshTimeoutID)},e.prototype.refresh=function(e,t,r){var i=this;this._rowCount=r,e=void 0!==e?e:0,t=void 0!==t?t:this._rowCount-1,this._rowStart=void 0!==this._rowStart?Math.min(this._rowStart,e):e,this._rowEnd=void 0!==this._rowEnd?Math.max(this._rowEnd,t):t;var n=Date.now();if(n-this._lastRefreshMs>=this._debounceThresholdMS)this._lastRefreshMs=n,this._innerRefresh();else if(!this._additionalRefreshRequested){var o=n-this._lastRefreshMs,s=this._debounceThresholdMS-o;this._additionalRefreshRequested=!0,this._refreshTimeoutID=window.setTimeout((function(){i._lastRefreshMs=Date.now(),i._innerRefresh(),i._additionalRefreshRequested=!1,i._refreshTimeoutID=void 0}),s)}},e.prototype._innerRefresh=function(){if(void 0!==this._rowStart&&void 0!==this._rowEnd&&void 0!==this._rowCount){var e=Math.max(this._rowStart,0),t=Math.min(this._rowEnd,this._rowCount-1);this._rowStart=void 0,this._rowEnd=void 0,this._renderCallback(e,t)}},e}();t.TimeBasedDebouncer=r},1680:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.Viewport=void 0;var a=r(844),c=r(3656),l=r(4725),u=r(2585),h=function(e){function t(t,r,i,n,o,s,a,l){var u=e.call(this)||this;return u._scrollLines=t,u._viewportElement=r,u._scrollArea=i,u._element=n,u._bufferService=o,u._optionsService=s,u._charSizeService=a,u._renderService=l,u.scrollBarWidth=0,u._currentRowHeight=0,u._currentScaledCellHeight=0,u._lastRecordedBufferLength=0,u._lastRecordedViewportHeight=0,u._lastRecordedBufferHeight=0,u._lastTouchY=0,u._lastScrollTop=0,u._lastHadScrollBar=!1,u._wheelPartialScroll=0,u._refreshAnimationFrame=null,u._ignoreNextScrollEvent=!1,u.scrollBarWidth=u._viewportElement.offsetWidth-u._scrollArea.offsetWidth||15,u._lastHadScrollBar=!0,u.register((0,c.addDisposableDomListener)(u._viewportElement,"scroll",u._onScroll.bind(u))),u._activeBuffer=u._bufferService.buffer,u.register(u._bufferService.buffers.onBufferActivate((function(e){return u._activeBuffer=e.activeBuffer}))),u._renderDimensions=u._renderService.dimensions,u.register(u._renderService.onDimensionsChange((function(e){return u._renderDimensions=e}))),setTimeout((function(){return u.syncScrollArea()}),0),u}return n(t,e),t.prototype.onThemeChange=function(e){this._viewportElement.style.backgroundColor=e.background.css},t.prototype._refresh=function(e){var t=this;if(e)return this._innerRefresh(),void(null!==this._refreshAnimationFrame&&cancelAnimationFrame(this._refreshAnimationFrame));null===this._refreshAnimationFrame&&(this._refreshAnimationFrame=requestAnimationFrame((function(){return t._innerRefresh()})))},t.prototype._innerRefresh=function(){if(this._charSizeService.height>0){this._currentRowHeight=this._renderService.dimensions.scaledCellHeight/window.devicePixelRatio,this._currentScaledCellHeight=this._renderService.dimensions.scaledCellHeight,this._lastRecordedViewportHeight=this._viewportElement.offsetHeight;var e=Math.round(this._currentRowHeight*this._lastRecordedBufferLength)+(this._lastRecordedViewportHeight-this._renderService.dimensions.canvasHeight);this._lastRecordedBufferHeight!==e&&(this._lastRecordedBufferHeight=e,this._scrollArea.style.height=this._lastRecordedBufferHeight+"px")}var t=this._bufferService.buffer.ydisp*this._currentRowHeight;this._viewportElement.scrollTop!==t&&(this._ignoreNextScrollEvent=!0,this._viewportElement.scrollTop=t),0===this._optionsService.options.scrollback?this.scrollBarWidth=0:this.scrollBarWidth=this._viewportElement.offsetWidth-this._scrollArea.offsetWidth||15,this._lastHadScrollBar=this.scrollBarWidth>0;var r=window.getComputedStyle(this._element),i=parseInt(r.paddingLeft)+parseInt(r.paddingRight);this._viewportElement.style.width=(this._renderService.dimensions.actualCellWidth*this._bufferService.cols+this.scrollBarWidth+(this._lastHadScrollBar?i:0)).toString()+"px",this._refreshAnimationFrame=null},t.prototype.syncScrollArea=function(e){if(void 0===e&&(e=!1),this._lastRecordedBufferLength!==this._bufferService.buffer.lines.length)return this._lastRecordedBufferLength=this._bufferService.buffer.lines.length,void this._refresh(e);this._lastRecordedViewportHeight===this._renderService.dimensions.canvasHeight&&this._lastScrollTop===this._activeBuffer.ydisp*this._currentRowHeight&&this._renderDimensions.scaledCellHeight===this._currentScaledCellHeight?this._lastHadScrollBar!==this._optionsService.options.scrollback>0&&this._refresh(e):this._refresh(e)},t.prototype._onScroll=function(e){if(this._lastScrollTop=this._viewportElement.scrollTop,this._viewportElement.offsetParent){if(this._ignoreNextScrollEvent)return this._ignoreNextScrollEvent=!1,void this._scrollLines(0);var t=Math.round(this._lastScrollTop/this._currentRowHeight)-this._bufferService.buffer.ydisp;this._scrollLines(t)}},t.prototype._bubbleScroll=function(e,t){var r=this._viewportElement.scrollTop+this._lastRecordedViewportHeight;return!(t<0&&0!==this._viewportElement.scrollTop||t>0&&r<this._lastRecordedBufferHeight)||(e.cancelable&&e.preventDefault(),!1)},t.prototype.onWheel=function(e){var t=this._getPixelsScrolled(e);return 0!==t&&(this._viewportElement.scrollTop+=t,this._bubbleScroll(e,t))},t.prototype._getPixelsScrolled=function(e){if(0===e.deltaY||e.shiftKey)return 0;var t=this._applyScrollModifier(e.deltaY,e);return e.deltaMode===WheelEvent.DOM_DELTA_LINE?t*=this._currentRowHeight:e.deltaMode===WheelEvent.DOM_DELTA_PAGE&&(t*=this._currentRowHeight*this._bufferService.rows),t},t.prototype.getLinesScrolled=function(e){if(0===e.deltaY||e.shiftKey)return 0;var t=this._applyScrollModifier(e.deltaY,e);return e.deltaMode===WheelEvent.DOM_DELTA_PIXEL?(t/=this._currentRowHeight+0,this._wheelPartialScroll+=t,t=Math.floor(Math.abs(this._wheelPartialScroll))*(this._wheelPartialScroll>0?1:-1),this._wheelPartialScroll%=1):e.deltaMode===WheelEvent.DOM_DELTA_PAGE&&(t*=this._bufferService.rows),t},t.prototype._applyScrollModifier=function(e,t){var r=this._optionsService.options.fastScrollModifier;return"alt"===r&&t.altKey||"ctrl"===r&&t.ctrlKey||"shift"===r&&t.shiftKey?e*this._optionsService.options.fastScrollSensitivity*this._optionsService.options.scrollSensitivity:e*this._optionsService.options.scrollSensitivity},t.prototype.onTouchStart=function(e){this._lastTouchY=e.touches[0].pageY},t.prototype.onTouchMove=function(e){var t=this._lastTouchY-e.touches[0].pageY;return this._lastTouchY=e.touches[0].pageY,0!==t&&(this._viewportElement.scrollTop+=t,this._bubbleScroll(e,t))},o([s(4,u.IBufferService),s(5,u.IOptionsService),s(6,l.ICharSizeService),s(7,l.IRenderService)],t)}(a.Disposable);t.Viewport=h},2950:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.CompositionHelper=void 0;var o=r(4725),s=r(2585),a=function(){function e(e,t,r,i,n,o){this._textarea=e,this._compositionView=t,this._bufferService=r,this._optionsService=i,this._coreService=n,this._renderService=o,this._isComposing=!1,this._isSendingComposition=!1,this._compositionPosition={start:0,end:0},this._dataAlreadySent=""}return Object.defineProperty(e.prototype,"isComposing",{get:function(){return this._isComposing},enumerable:!1,configurable:!0}),e.prototype.compositionstart=function(){this._isComposing=!0,this._compositionPosition.start=this._textarea.value.length,this._compositionView.textContent="",this._dataAlreadySent="",this._compositionView.classList.add("active")},e.prototype.compositionupdate=function(e){var t=this;this._compositionView.textContent=e.data,this.updateCompositionElements(),setTimeout((function(){t._compositionPosition.end=t._textarea.value.length}),0)},e.prototype.compositionend=function(){this._finalizeComposition(!0)},e.prototype.keydown=function(e){if(this._isComposing||this._isSendingComposition){if(229===e.keyCode)return!1;if(16===e.keyCode||17===e.keyCode||18===e.keyCode)return!1;this._finalizeComposition(!1)}return 229!==e.keyCode||(this._handleAnyTextareaChanges(),!1)},e.prototype._finalizeComposition=function(e){var t=this;if(this._compositionView.classList.remove("active"),this._isComposing=!1,e){var r={start:this._compositionPosition.start,end:this._compositionPosition.end};this._isSendingComposition=!0,setTimeout((function(){var e;t._isSendingComposition&&(t._isSendingComposition=!1,r.start+=t._dataAlreadySent.length,(e=t._isComposing?t._textarea.value.substring(r.start,r.end):t._textarea.value.substring(r.start)).length>0&&t._coreService.triggerDataEvent(e,!0))}),0)}else{this._isSendingComposition=!1;var i=this._textarea.value.substring(this._compositionPosition.start,this._compositionPosition.end);this._coreService.triggerDataEvent(i,!0)}},e.prototype._handleAnyTextareaChanges=function(){var e=this,t=this._textarea.value;setTimeout((function(){if(!e._isComposing){var r=e._textarea.value.replace(t,"");r.length>0&&(e._dataAlreadySent=r,e._coreService.triggerDataEvent(r,!0))}}),0)},e.prototype.updateCompositionElements=function(e){var t=this;if(this._isComposing){if(this._bufferService.buffer.isCursorInViewport){var r=Math.min(this._bufferService.buffer.x,this._bufferService.cols-1),i=this._renderService.dimensions.actualCellHeight,n=this._bufferService.buffer.y*this._renderService.dimensions.actualCellHeight,o=r*this._renderService.dimensions.actualCellWidth;this._compositionView.style.left=o+"px",this._compositionView.style.top=n+"px",this._compositionView.style.height=i+"px",this._compositionView.style.lineHeight=i+"px",this._compositionView.style.fontFamily=this._optionsService.options.fontFamily,this._compositionView.style.fontSize=this._optionsService.options.fontSize+"px";var s=this._compositionView.getBoundingClientRect();this._textarea.style.left=o+"px",this._textarea.style.top=n+"px",this._textarea.style.width=Math.max(s.width,1)+"px",this._textarea.style.height=Math.max(s.height,1)+"px",this._textarea.style.lineHeight=s.height+"px"}e||setTimeout((function(){return t.updateCompositionElements(!0)}),0)}},i([n(2,s.IBufferService),n(3,s.IOptionsService),n(4,s.ICoreService),n(5,o.IRenderService)],e)}();t.CompositionHelper=a},9806:(e,t)=>{function r(e,t){var r=t.getBoundingClientRect();return[e.clientX-r.left,e.clientY-r.top]}Object.defineProperty(t,"__esModule",{value:!0}),t.getRawByteCoords=t.getCoords=t.getCoordsRelativeToElement=void 0,t.getCoordsRelativeToElement=r,t.getCoords=function(e,t,i,n,o,s,a,c){if(o){var l=r(e,t);if(l)return l[0]=Math.ceil((l[0]+(c?s/2:0))/s),l[1]=Math.ceil(l[1]/a),l[0]=Math.min(Math.max(l[0],1),i+(c?1:0)),l[1]=Math.min(Math.max(l[1],1),n),l}},t.getRawByteCoords=function(e){if(e)return{x:e[0]+32,y:e[1]+32}}},9504:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.moveToCellSequence=void 0;var i=r(2584);function n(e,t,r,i){var n=e-o(r,e),a=t-o(r,t),u=Math.abs(n-a)-function(e,t,r){for(var i=0,n=e-o(r,e),a=t-o(r,t),c=0;c<Math.abs(n-a);c++){var l="A"===s(e,t)?-1:1,u=r.buffer.lines.get(n+l*c);(null==u?void 0:u.isWrapped)&&i++}return i}(e,t,r);return l(u,c(s(e,t),i))}function o(e,t){for(var r=0,i=e.buffer.lines.get(t),n=null==i?void 0:i.isWrapped;n&&t>=0&&t<e.rows;)r++,n=null==(i=e.buffer.lines.get(--t))?void 0:i.isWrapped;return r}function s(e,t){return e>t?"A":"B"}function a(e,t,r,i,n,o){for(var s=e,a=t,c="";s!==r||a!==i;)s+=n?1:-1,n&&s>o.cols-1?(c+=o.buffer.translateBufferLineToString(a,!1,e,s),s=0,e=0,a++):!n&&s<0&&(c+=o.buffer.translateBufferLineToString(a,!1,0,e+1),e=s=o.cols-1,a--);return c+o.buffer.translateBufferLineToString(a,!1,e,s)}function c(e,t){var r=t?"O":"[";return i.C0.ESC+r+e}function l(e,t){e=Math.floor(e);for(var r="",i=0;i<e;i++)r+=t;return r}t.moveToCellSequence=function(e,t,r,i){var s,u=r.buffer.x,h=r.buffer.y;if(!r.buffer.hasScrollback)return function(e,t,r,i,s,u){return 0===n(t,i,s,u).length?"":l(a(e,t,e,t-o(s,t),!1,s).length,c("D",u))}(u,h,0,t,r,i)+n(h,t,r,i)+function(e,t,r,i,s,u){var h;h=n(t,i,s,u).length>0?i-o(s,i):t;var f=i,_=function(e,t,r,i,s,a){var c;return c=n(r,i,s,a).length>0?i-o(s,i):t,e<r&&c<=i||e>=r&&c<i?"C":"D"}(e,t,r,i,s,u);return l(a(e,h,r,f,"C"===_,s).length,c(_,u))}(u,h,e,t,r,i);if(h===t)return s=u>e?"D":"C",l(Math.abs(u-e),c(s,i));s=h>t?"D":"C";var f=Math.abs(h-t);return l(function(e,t){return t.cols-e}(h>t?e:u,r)+(f-1)*r.cols+1+((h>t?u:e)-1),c(s,i))}},1546:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.BaseRenderLayer=void 0;var i=r(643),n=r(8803),o=r(1420),s=r(3734),a=r(1752),c=r(4774),l=r(9631),u=r(8978),h=function(){function e(e,t,r,i,n,o,s,a){this._container=e,this._alpha=i,this._colors=n,this._rendererId=o,this._bufferService=s,this._optionsService=a,this._scaledCharWidth=0,this._scaledCharHeight=0,this._scaledCellWidth=0,this._scaledCellHeight=0,this._scaledCharLeft=0,this._scaledCharTop=0,this._currentGlyphIdentifier={chars:"",code:0,bg:0,fg:0,bold:!1,dim:!1,italic:!1},this._canvas=document.createElement("canvas"),this._canvas.classList.add("xterm-"+t+"-layer"),this._canvas.style.zIndex=r.toString(),this._initCanvas(),this._container.appendChild(this._canvas)}return e.prototype.dispose=function(){var e;(0,l.removeElementFromParent)(this._canvas),null===(e=this._charAtlas)||void 0===e||e.dispose()},e.prototype._initCanvas=function(){this._ctx=(0,a.throwIfFalsy)(this._canvas.getContext("2d",{alpha:this._alpha})),this._alpha||this._clearAll()},e.prototype.onOptionsChanged=function(){},e.prototype.onBlur=function(){},e.prototype.onFocus=function(){},e.prototype.onCursorMove=function(){},e.prototype.onGridChanged=function(e,t){},e.prototype.onSelectionChanged=function(e,t,r){void 0===r&&(r=!1)},e.prototype.setColors=function(e){this._refreshCharAtlas(e)},e.prototype._setTransparency=function(e){if(e!==this._alpha){var t=this._canvas;this._alpha=e,this._canvas=this._canvas.cloneNode(),this._initCanvas(),this._container.replaceChild(this._canvas,t),this._refreshCharAtlas(this._colors),this.onGridChanged(0,this._bufferService.rows-1)}},e.prototype._refreshCharAtlas=function(e){this._scaledCharWidth<=0&&this._scaledCharHeight<=0||(this._charAtlas=(0,o.acquireCharAtlas)(this._optionsService.options,this._rendererId,e,this._scaledCharWidth,this._scaledCharHeight),this._charAtlas.warmUp())},e.prototype.resize=function(e){this._scaledCellWidth=e.scaledCellWidth,this._scaledCellHeight=e.scaledCellHeight,this._scaledCharWidth=e.scaledCharWidth,this._scaledCharHeight=e.scaledCharHeight,this._scaledCharLeft=e.scaledCharLeft,this._scaledCharTop=e.scaledCharTop,this._canvas.width=e.scaledCanvasWidth,this._canvas.height=e.scaledCanvasHeight,this._canvas.style.width=e.canvasWidth+"px",this._canvas.style.height=e.canvasHeight+"px",this._alpha||this._clearAll(),this._refreshCharAtlas(this._colors)},e.prototype.clearTextureAtlas=function(){var e;null===(e=this._charAtlas)||void 0===e||e.clear()},e.prototype._fillCells=function(e,t,r,i){this._ctx.fillRect(e*this._scaledCellWidth,t*this._scaledCellHeight,r*this._scaledCellWidth,i*this._scaledCellHeight)},e.prototype._fillMiddleLineAtCells=function(e,t,r){void 0===r&&(r=1);var i=Math.ceil(.5*this._scaledCellHeight);this._ctx.fillRect(e*this._scaledCellWidth,(t+1)*this._scaledCellHeight-i-window.devicePixelRatio,r*this._scaledCellWidth,window.devicePixelRatio)},e.prototype._fillBottomLineAtCells=function(e,t,r){void 0===r&&(r=1),this._ctx.fillRect(e*this._scaledCellWidth,(t+1)*this._scaledCellHeight-window.devicePixelRatio-1,r*this._scaledCellWidth,window.devicePixelRatio)},e.prototype._fillLeftLineAtCell=function(e,t,r){this._ctx.fillRect(e*this._scaledCellWidth,t*this._scaledCellHeight,window.devicePixelRatio*r,this._scaledCellHeight)},e.prototype._strokeRectAtCell=function(e,t,r,i){this._ctx.lineWidth=window.devicePixelRatio,this._ctx.strokeRect(e*this._scaledCellWidth+window.devicePixelRatio/2,t*this._scaledCellHeight+window.devicePixelRatio/2,r*this._scaledCellWidth-window.devicePixelRatio,i*this._scaledCellHeight-window.devicePixelRatio)},e.prototype._clearAll=function(){this._alpha?this._ctx.clearRect(0,0,this._canvas.width,this._canvas.height):(this._ctx.fillStyle=this._colors.background.css,this._ctx.fillRect(0,0,this._canvas.width,this._canvas.height))},e.prototype._clearCells=function(e,t,r,i){this._alpha?this._ctx.clearRect(e*this._scaledCellWidth,t*this._scaledCellHeight,r*this._scaledCellWidth,i*this._scaledCellHeight):(this._ctx.fillStyle=this._colors.background.css,this._ctx.fillRect(e*this._scaledCellWidth,t*this._scaledCellHeight,r*this._scaledCellWidth,i*this._scaledCellHeight))},e.prototype._fillCharTrueColor=function(e,t,r){this._ctx.font=this._getFont(!1,!1),this._ctx.textBaseline=n.TEXT_BASELINE,this._clipRow(r);var i=!1;!1!==this._optionsService.options.customGlyphs&&(i=(0,u.tryDrawCustomChar)(this._ctx,e.getChars(),t*this._scaledCellWidth,r*this._scaledCellHeight,this._scaledCellWidth,this._scaledCellHeight)),i||this._ctx.fillText(e.getChars(),t*this._scaledCellWidth+this._scaledCharLeft,r*this._scaledCellHeight+this._scaledCharTop+this._scaledCharHeight)},e.prototype._drawChars=function(e,t,r){var o,s,a,c=this._getContrastColor(e);c||e.isFgRGB()||e.isBgRGB()?this._drawUncachedChars(e,t,r,c):(e.isInverse()?(s=e.isBgDefault()?n.INVERTED_DEFAULT_COLOR:e.getBgColor(),a=e.isFgDefault()?n.INVERTED_DEFAULT_COLOR:e.getFgColor()):(a=e.isBgDefault()?i.DEFAULT_COLOR:e.getBgColor(),s=e.isFgDefault()?i.DEFAULT_COLOR:e.getFgColor()),s+=this._optionsService.options.drawBoldTextInBrightColors&&e.isBold()&&s<8?8:0,this._currentGlyphIdentifier.chars=e.getChars()||i.WHITESPACE_CELL_CHAR,this._currentGlyphIdentifier.code=e.getCode()||i.WHITESPACE_CELL_CODE,this._currentGlyphIdentifier.bg=a,this._currentGlyphIdentifier.fg=s,this._currentGlyphIdentifier.bold=!!e.isBold(),this._currentGlyphIdentifier.dim=!!e.isDim(),this._currentGlyphIdentifier.italic=!!e.isItalic(),(null===(o=this._charAtlas)||void 0===o?void 0:o.draw(this._ctx,this._currentGlyphIdentifier,t*this._scaledCellWidth+this._scaledCharLeft,r*this._scaledCellHeight+this._scaledCharTop))||this._drawUncachedChars(e,t,r))},e.prototype._drawUncachedChars=function(e,t,r,i){if(this._ctx.save(),this._ctx.font=this._getFont(!!e.isBold(),!!e.isItalic()),this._ctx.textBaseline=n.TEXT_BASELINE,e.isInverse())if(i)this._ctx.fillStyle=i.css;else if(e.isBgDefault())this._ctx.fillStyle=c.color.opaque(this._colors.background).css;else if(e.isBgRGB())this._ctx.fillStyle="rgb("+s.AttributeData.toColorRGB(e.getBgColor()).join(",")+")";else{var o=e.getBgColor();this._optionsService.options.drawBoldTextInBrightColors&&e.isBold()&&o<8&&(o+=8),this._ctx.fillStyle=this._colors.ansi[o].css}else if(i)this._ctx.fillStyle=i.css;else if(e.isFgDefault())this._ctx.fillStyle=this._colors.foreground.css;else if(e.isFgRGB())this._ctx.fillStyle="rgb("+s.AttributeData.toColorRGB(e.getFgColor()).join(",")+")";else{var a=e.getFgColor();this._optionsService.options.drawBoldTextInBrightColors&&e.isBold()&&a<8&&(a+=8),this._ctx.fillStyle=this._colors.ansi[a].css}this._clipRow(r),e.isDim()&&(this._ctx.globalAlpha=n.DIM_OPACITY);var l=!1;!1!==this._optionsService.options.customGlyphs&&(l=(0,u.tryDrawCustomChar)(this._ctx,e.getChars(),t*this._scaledCellWidth,r*this._scaledCellHeight,this._scaledCellWidth,this._scaledCellHeight)),l||this._ctx.fillText(e.getChars(),t*this._scaledCellWidth+this._scaledCharLeft,r*this._scaledCellHeight+this._scaledCharTop+this._scaledCharHeight),this._ctx.restore()},e.prototype._clipRow=function(e){this._ctx.beginPath(),this._ctx.rect(0,e*this._scaledCellHeight,this._bufferService.cols*this._scaledCellWidth,this._scaledCellHeight),this._ctx.clip()},e.prototype._getFont=function(e,t){return(t?"italic":"")+" "+(e?this._optionsService.options.fontWeightBold:this._optionsService.options.fontWeight)+" "+this._optionsService.options.fontSize*window.devicePixelRatio+"px "+this._optionsService.options.fontFamily},e.prototype._getContrastColor=function(e){if(1!==this._optionsService.options.minimumContrastRatio){var t=this._colors.contrastCache.getColor(e.bg,e.fg);if(void 0!==t)return t||void 0;var r=e.getFgColor(),i=e.getFgColorMode(),n=e.getBgColor(),o=e.getBgColorMode(),s=!!e.isInverse(),a=!!e.isInverse();if(s){var l=r;r=n,n=l;var u=i;i=o,o=u}var h=this._resolveBackgroundRgba(o,n,s),f=this._resolveForegroundRgba(i,r,s,a),_=c.rgba.ensureContrastRatio(h,f,this._optionsService.options.minimumContrastRatio);if(_){var d={css:c.channels.toCss(_>>24&255,_>>16&255,_>>8&255),rgba:_};return this._colors.contrastCache.setColor(e.bg,e.fg,d),d}this._colors.contrastCache.setColor(e.bg,e.fg,null)}},e.prototype._resolveBackgroundRgba=function(e,t,r){switch(e){case 16777216:case 33554432:return this._colors.ansi[t].rgba;case 50331648:return t<<8;default:return r?this._colors.foreground.rgba:this._colors.background.rgba}},e.prototype._resolveForegroundRgba=function(e,t,r,i){switch(e){case 16777216:case 33554432:return this._optionsService.options.drawBoldTextInBrightColors&&i&&t<8&&(t+=8),this._colors.ansi[t].rgba;case 50331648:return t<<8;default:return r?this._colors.background.rgba:this._colors.foreground.rgba}},e}();t.BaseRenderLayer=h},2512:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.CursorRenderLayer=void 0;var a=r(1546),c=r(511),l=r(2585),u=r(4725),h=600,f=function(e){function t(t,r,i,n,o,s,a,l,u){var h=e.call(this,t,"cursor",r,!0,i,n,s,a)||this;return h._onRequestRedraw=o,h._coreService=l,h._coreBrowserService=u,h._cell=new c.CellData,h._state={x:0,y:0,isFocused:!1,style:"",width:0},h._cursorRenderers={bar:h._renderBarCursor.bind(h),block:h._renderBlockCursor.bind(h),underline:h._renderUnderlineCursor.bind(h)},h}return n(t,e),t.prototype.dispose=function(){this._cursorBlinkStateManager&&(this._cursorBlinkStateManager.dispose(),this._cursorBlinkStateManager=void 0),e.prototype.dispose.call(this)},t.prototype.resize=function(t){e.prototype.resize.call(this,t),this._state={x:0,y:0,isFocused:!1,style:"",width:0}},t.prototype.reset=function(){var e;this._clearCursor(),null===(e=this._cursorBlinkStateManager)||void 0===e||e.restartBlinkAnimation(),this.onOptionsChanged()},t.prototype.onBlur=function(){var e;null===(e=this._cursorBlinkStateManager)||void 0===e||e.pause(),this._onRequestRedraw.fire({start:this._bufferService.buffer.y,end:this._bufferService.buffer.y})},t.prototype.onFocus=function(){var e;null===(e=this._cursorBlinkStateManager)||void 0===e||e.resume(),this._onRequestRedraw.fire({start:this._bufferService.buffer.y,end:this._bufferService.buffer.y})},t.prototype.onOptionsChanged=function(){var e,t=this;this._optionsService.options.cursorBlink?this._cursorBlinkStateManager||(this._cursorBlinkStateManager=new _(this._coreBrowserService.isFocused,(function(){t._render(!0)}))):(null===(e=this._cursorBlinkStateManager)||void 0===e||e.dispose(),this._cursorBlinkStateManager=void 0),this._onRequestRedraw.fire({start:this._bufferService.buffer.y,end:this._bufferService.buffer.y})},t.prototype.onCursorMove=function(){var e;null===(e=this._cursorBlinkStateManager)||void 0===e||e.restartBlinkAnimation()},t.prototype.onGridChanged=function(e,t){!this._cursorBlinkStateManager||this._cursorBlinkStateManager.isPaused?this._render(!1):this._cursorBlinkStateManager.restartBlinkAnimation()},t.prototype._render=function(e){if(this._coreService.isCursorInitialized&&!this._coreService.isCursorHidden){var t=this._bufferService.buffer.ybase+this._bufferService.buffer.y,r=t-this._bufferService.buffer.ydisp;if(r<0||r>=this._bufferService.rows)this._clearCursor();else{var i=Math.min(this._bufferService.buffer.x,this._bufferService.cols-1);if(this._bufferService.buffer.lines.get(t).loadCell(i,this._cell),void 0!==this._cell.content){if(!this._coreBrowserService.isFocused){this._clearCursor(),this._ctx.save(),this._ctx.fillStyle=this._colors.cursor.css;var n=this._optionsService.options.cursorStyle;return n&&"block"!==n?this._cursorRenderers[n](i,r,this._cell):this._renderBlurCursor(i,r,this._cell),this._ctx.restore(),this._state.x=i,this._state.y=r,this._state.isFocused=!1,this._state.style=n,void(this._state.width=this._cell.getWidth())}if(!this._cursorBlinkStateManager||this._cursorBlinkStateManager.isCursorVisible){if(this._state){if(this._state.x===i&&this._state.y===r&&this._state.isFocused===this._coreBrowserService.isFocused&&this._state.style===this._optionsService.options.cursorStyle&&this._state.width===this._cell.getWidth())return;this._clearCursor()}this._ctx.save(),this._cursorRenderers[this._optionsService.options.cursorStyle||"block"](i,r,this._cell),this._ctx.restore(),this._state.x=i,this._state.y=r,this._state.isFocused=!1,this._state.style=this._optionsService.options.cursorStyle,this._state.width=this._cell.getWidth()}else this._clearCursor()}}}else this._clearCursor()},t.prototype._clearCursor=function(){this._state&&(window.devicePixelRatio<1?this._clearAll():this._clearCells(this._state.x,this._state.y,this._state.width,1),this._state={x:0,y:0,isFocused:!1,style:"",width:0})},t.prototype._renderBarCursor=function(e,t,r){this._ctx.save(),this._ctx.fillStyle=this._colors.cursor.css,this._fillLeftLineAtCell(e,t,this._optionsService.options.cursorWidth),this._ctx.restore()},t.prototype._renderBlockCursor=function(e,t,r){this._ctx.save(),this._ctx.fillStyle=this._colors.cursor.css,this._fillCells(e,t,r.getWidth(),1),this._ctx.fillStyle=this._colors.cursorAccent.css,this._fillCharTrueColor(r,e,t),this._ctx.restore()},t.prototype._renderUnderlineCursor=function(e,t,r){this._ctx.save(),this._ctx.fillStyle=this._colors.cursor.css,this._fillBottomLineAtCells(e,t),this._ctx.restore()},t.prototype._renderBlurCursor=function(e,t,r){this._ctx.save(),this._ctx.strokeStyle=this._colors.cursor.css,this._strokeRectAtCell(e,t,r.getWidth(),1),this._ctx.restore()},o([s(5,l.IBufferService),s(6,l.IOptionsService),s(7,l.ICoreService),s(8,u.ICoreBrowserService)],t)}(a.BaseRenderLayer);t.CursorRenderLayer=f;var _=function(){function e(e,t){this._renderCallback=t,this.isCursorVisible=!0,e&&this._restartInterval()}return Object.defineProperty(e.prototype,"isPaused",{get:function(){return!(this._blinkStartTimeout||this._blinkInterval)},enumerable:!1,configurable:!0}),e.prototype.dispose=function(){this._blinkInterval&&(window.clearInterval(this._blinkInterval),this._blinkInterval=void 0),this._blinkStartTimeout&&(window.clearTimeout(this._blinkStartTimeout),this._blinkStartTimeout=void 0),this._animationFrame&&(window.cancelAnimationFrame(this._animationFrame),this._animationFrame=void 0)},e.prototype.restartBlinkAnimation=function(){var e=this;this.isPaused||(this._animationTimeRestarted=Date.now(),this.isCursorVisible=!0,this._animationFrame||(this._animationFrame=window.requestAnimationFrame((function(){e._renderCallback(),e._animationFrame=void 0}))))},e.prototype._restartInterval=function(e){var t=this;void 0===e&&(e=h),this._blinkInterval&&(window.clearInterval(this._blinkInterval),this._blinkInterval=void 0),this._blinkStartTimeout=window.setTimeout((function(){if(t._animationTimeRestarted){var e=h-(Date.now()-t._animationTimeRestarted);if(t._animationTimeRestarted=void 0,e>0)return void t._restartInterval(e)}t.isCursorVisible=!1,t._animationFrame=window.requestAnimationFrame((function(){t._renderCallback(),t._animationFrame=void 0})),t._blinkInterval=window.setInterval((function(){if(t._animationTimeRestarted){var e=h-(Date.now()-t._animationTimeRestarted);return t._animationTimeRestarted=void 0,void t._restartInterval(e)}t.isCursorVisible=!t.isCursorVisible,t._animationFrame=window.requestAnimationFrame((function(){t._renderCallback(),t._animationFrame=void 0}))}),h)}),e)},e.prototype.pause=function(){this.isCursorVisible=!0,this._blinkInterval&&(window.clearInterval(this._blinkInterval),this._blinkInterval=void 0),this._blinkStartTimeout&&(window.clearTimeout(this._blinkStartTimeout),this._blinkStartTimeout=void 0),this._animationFrame&&(window.cancelAnimationFrame(this._animationFrame),this._animationFrame=void 0)},e.prototype.resume=function(){this.pause(),this._animationTimeRestarted=void 0,this._restartInterval(),this.restartBlinkAnimation()},e}()},8978:(e,t,r)=>{var i,n,o,s,a,c,l,u,h,f,_,d,p,v,g,y,m,b,S,C,w,L,E,x,A,k,M,R,T,O,B,D,P,I,H,j,F,W,U,q,N,z,K,V,G,Y,X,Z,J,$,Q,ee,te,re,ie,ne,oe,se,ae,ce,le,ue,he,fe,_e,de,pe,ve,ge,ye,me,be,Se,Ce,we,Le,Ee,xe,Ae,ke,Me,Re,Te,Oe,Be,De,Pe,Ie,He,je,Fe,We,Ue,qe,Ne,ze,Ke,Ve,Ge,Ye,Xe,Ze,Je,$e,Qe,et,tt,rt,it,nt,ot,st,at,ct,lt,ut,ht,ft,_t,dt,pt,vt,gt,yt,mt,bt,St,Ct;Object.defineProperty(t,"__esModule",{value:!0}),t.tryDrawCustomChar=t.boxDrawingDefinitions=t.blockElementDefinitions=void 0;var wt=r(1752);t.blockElementDefinitions={"▀":[{x:0,y:0,w:8,h:4}],"▁":[{x:0,y:7,w:8,h:1}],"▂":[{x:0,y:6,w:8,h:2}],"▃":[{x:0,y:5,w:8,h:3}],"▄":[{x:0,y:4,w:8,h:4}],"▅":[{x:0,y:3,w:8,h:5}],"▆":[{x:0,y:2,w:8,h:6}],"▇":[{x:0,y:1,w:8,h:7}],"█":[{x:0,y:0,w:8,h:8}],"▉":[{x:0,y:0,w:7,h:8}],"▊":[{x:0,y:0,w:6,h:8}],"▋":[{x:0,y:0,w:5,h:8}],"▌":[{x:0,y:0,w:4,h:8}],"▍":[{x:0,y:0,w:3,h:8}],"▎":[{x:0,y:0,w:2,h:8}],"▏":[{x:0,y:0,w:1,h:8}],"▐":[{x:4,y:0,w:4,h:8}],"▔":[{x:0,y:0,w:9,h:1}],"▕":[{x:7,y:0,w:1,h:8}],"▖":[{x:0,y:4,w:4,h:4}],"▗":[{x:4,y:4,w:4,h:4}],"▘":[{x:0,y:0,w:4,h:4}],"▙":[{x:0,y:0,w:4,h:8},{x:0,y:4,w:8,h:4}],"▚":[{x:0,y:0,w:4,h:4},{x:4,y:4,w:4,h:4}],"▛":[{x:0,y:0,w:4,h:8},{x:0,y:0,w:4,h:8}],"▜":[{x:0,y:0,w:8,h:4},{x:4,y:0,w:4,h:8}],"▝":[{x:4,y:0,w:4,h:4}],"▞":[{x:4,y:0,w:4,h:4},{x:0,y:4,w:4,h:4}],"▟":[{x:4,y:0,w:4,h:8},{x:0,y:4,w:8,h:4}],"🭰":[{x:1,y:0,w:1,h:8}],"🭱":[{x:2,y:0,w:1,h:8}],"🭲":[{x:3,y:0,w:1,h:8}],"🭳":[{x:4,y:0,w:1,h:8}],"🭴":[{x:5,y:0,w:1,h:8}],"🭵":[{x:6,y:0,w:1,h:8}],"🭶":[{x:0,y:1,w:8,h:1}],"🭷":[{x:0,y:2,w:8,h:1}],"🭸":[{x:0,y:3,w:8,h:1}],"🭹":[{x:0,y:4,w:8,h:1}],"🭺":[{x:0,y:5,w:8,h:1}],"🭻":[{x:0,y:6,w:8,h:1}],"🭼":[{x:0,y:0,w:1,h:8},{x:0,y:7,w:8,h:1}],"🭽":[{x:0,y:0,w:1,h:8},{x:0,y:0,w:8,h:1}],"🭾":[{x:7,y:0,w:1,h:8},{x:0,y:0,w:8,h:1}],"🭿":[{x:7,y:0,w:1,h:8},{x:0,y:7,w:8,h:1}],"🮀":[{x:0,y:0,w:8,h:1},{x:0,y:7,w:8,h:1}],"🮁":[{x:0,y:0,w:8,h:1},{x:0,y:2,w:8,h:1},{x:0,y:4,w:8,h:1},{x:0,y:7,w:8,h:1}],"🮂":[{x:0,y:0,w:8,h:2}],"🮃":[{x:0,y:0,w:8,h:3}],"🮄":[{x:0,y:0,w:8,h:5}],"🮅":[{x:0,y:0,w:8,h:6}],"🮆":[{x:0,y:0,w:8,h:7}],"🮇":[{x:6,y:0,w:2,h:8}],"🮈":[{x:5,y:0,w:3,h:8}],"🮉":[{x:3,y:0,w:5,h:8}],"🮊":[{x:2,y:0,w:6,h:8}],"🮋":[{x:1,y:0,w:7,h:8}],"🮕":[{x:0,y:0,w:2,h:2},{x:4,y:0,w:2,h:2},{x:2,y:2,w:2,h:2},{x:6,y:2,w:2,h:2},{x:0,y:4,w:2,h:2},{x:4,y:4,w:2,h:2},{x:2,y:6,w:2,h:2},{x:6,y:6,w:2,h:2}],"🮖":[{x:2,y:0,w:2,h:2},{x:6,y:0,w:2,h:2},{x:0,y:2,w:2,h:2},{x:4,y:2,w:2,h:2},{x:2,y:4,w:2,h:2},{x:6,y:4,w:2,h:2},{x:0,y:6,w:2,h:2},{x:4,y:6,w:2,h:2}],"🮗":[{x:0,y:2,w:8,h:2},{x:0,y:6,w:8,h:2}]};var Lt={"░":[[1,0,0,0],[0,0,0,0],[0,0,1,0],[0,0,0,0]],"▒":[[1,0],[0,0],[0,1],[0,0]],"▓":[[0,1],[1,1],[1,0],[1,1]]};t.boxDrawingDefinitions={"─":(i={},i[1]="M0,.5 L1,.5",i),"━":(n={},n[3]="M0,.5 L1,.5",n),"│":(o={},o[1]="M.5,0 L.5,1",o),"┃":(s={},s[3]="M.5,0 L.5,1",s),"┌":(a={},a[1]="M0.5,1 L.5,.5 L1,.5",a),"┏":(c={},c[3]="M0.5,1 L.5,.5 L1,.5",c),"┐":(l={},l[1]="M0,.5 L.5,.5 L.5,1",l),"┓":(u={},u[3]="M0,.5 L.5,.5 L.5,1",u),"└":(h={},h[1]="M.5,0 L.5,.5 L1,.5",h),"┗":(f={},f[3]="M.5,0 L.5,.5 L1,.5",f),"┘":(_={},_[1]="M.5,0 L.5,.5 L0,.5",_),"┛":(d={},d[3]="M.5,0 L.5,.5 L0,.5",d),"├":(p={},p[1]="M.5,0 L.5,1 M.5,.5 L1,.5",p),"┣":(v={},v[3]="M.5,0 L.5,1 M.5,.5 L1,.5",v),"┤":(g={},g[1]="M.5,0 L.5,1 M.5,.5 L0,.5",g),"┫":(y={},y[3]="M.5,0 L.5,1 M.5,.5 L0,.5",y),"┬":(m={},m[1]="M0,.5 L1,.5 M.5,.5 L.5,1",m),"┳":(b={},b[3]="M0,.5 L1,.5 M.5,.5 L.5,1",b),"┴":(S={},S[1]="M0,.5 L1,.5 M.5,.5 L.5,0",S),"┻":(C={},C[3]="M0,.5 L1,.5 M.5,.5 L.5,0",C),"┼":(w={},w[1]="M0,.5 L1,.5 M.5,0 L.5,1",w),"╋":(L={},L[3]="M0,.5 L1,.5 M.5,0 L.5,1",L),"╴":(E={},E[1]="M.5,.5 L0,.5",E),"╸":(x={},x[3]="M.5,.5 L0,.5",x),"╵":(A={},A[1]="M.5,.5 L.5,0",A),"╹":(k={},k[3]="M.5,.5 L.5,0",k),"╶":(M={},M[1]="M.5,.5 L1,.5",M),"╺":(R={},R[3]="M.5,.5 L1,.5",R),"╷":(T={},T[1]="M.5,.5 L.5,1",T),"╻":(O={},O[3]="M.5,.5 L.5,1",O),"═":(B={},B[1]=function(e,t){return"M0,"+(.5-t)+" L1,"+(.5-t)+" M0,"+(.5+t)+" L1,"+(.5+t)},B),"║":(D={},D[1]=function(e,t){return"M"+(.5-e)+",0 L"+(.5-e)+",1 M"+(.5+e)+",0 L"+(.5+e)+",1"},D),"╒":(P={},P[1]=function(e,t){return"M.5,1 L.5,"+(.5-t)+" L1,"+(.5-t)+" M.5,"+(.5+t)+" L1,"+(.5+t)},P),"╓":(I={},I[1]=function(e,t){return"M"+(.5-e)+",1 L"+(.5-e)+",.5 L1,.5 M"+(.5+e)+",.5 L"+(.5+e)+",1"},I),"╔":(H={},H[1]=function(e,t){return"M1,"+(.5-t)+" L"+(.5-e)+","+(.5-t)+" L"+(.5-e)+",1 M1,"+(.5+t)+" L"+(.5+e)+","+(.5+t)+" L"+(.5+e)+",1"},H),"╕":(j={},j[1]=function(e,t){return"M0,"+(.5-t)+" L.5,"+(.5-t)+" L.5,1 M0,"+(.5+t)+" L.5,"+(.5+t)},j),"╖":(F={},F[1]=function(e,t){return"M"+(.5+e)+",1 L"+(.5+e)+",.5 L0,.5 M"+(.5-e)+",.5 L"+(.5-e)+",1"},F),"╗":(W={},W[1]=function(e,t){return"M0,"+(.5+t)+" L"+(.5-e)+","+(.5+t)+" L"+(.5-e)+",1 M0,"+(.5-t)+" L"+(.5+e)+","+(.5-t)+" L"+(.5+e)+",1"},W),"╘":(U={},U[1]=function(e,t){return"M.5,0 L.5,"+(.5+t)+" L1,"+(.5+t)+" M.5,"+(.5-t)+" L1,"+(.5-t)},U),"╙":(q={},q[1]=function(e,t){return"M1,.5 L"+(.5-e)+",.5 L"+(.5-e)+",0 M"+(.5+e)+",.5 L"+(.5+e)+",0"},q),"╚":(N={},N[1]=function(e,t){return"M1,"+(.5-t)+" L"+(.5+e)+","+(.5-t)+" L"+(.5+e)+",0 M1,"+(.5+t)+" L"+(.5-e)+","+(.5+t)+" L"+(.5-e)+",0"},N),"╛":(z={},z[1]=function(e,t){return"M0,"+(.5+t)+" L.5,"+(.5+t)+" L.5,0 M0,"+(.5-t)+" L.5,"+(.5-t)},z),"╜":(K={},K[1]=function(e,t){return"M0,.5 L"+(.5+e)+",.5 L"+(.5+e)+",0 M"+(.5-e)+",.5 L"+(.5-e)+",0"},K),"╝":(V={},V[1]=function(e,t){return"M0,"+(.5-t)+" L"+(.5-e)+","+(.5-t)+" L"+(.5-e)+",0 M0,"+(.5+t)+" L"+(.5+e)+","+(.5+t)+" L"+(.5+e)+",0"},V),"╞":(G={},G[1]=function(e,t){return"M.5,0 L.5,1 M.5,"+(.5-t)+" L1,"+(.5-t)+" M.5,"+(.5+t)+" L1,"+(.5+t)},G),"╟":(Y={},Y[1]=function(e,t){return"M"+(.5-e)+",0 L"+(.5-e)+",1 M"+(.5+e)+",0 L"+(.5+e)+",1 M"+(.5+e)+",.5 L1,.5"},Y),"╠":(X={},X[1]=function(e,t){return"M"+(.5-e)+",0 L"+(.5-e)+",1 M1,"+(.5+t)+" L"+(.5+e)+","+(.5+t)+" L"+(.5+e)+",1 M1,"+(.5-t)+" L"+(.5+e)+","+(.5-t)+" L"+(.5+e)+",0"},X),"╡":(Z={},Z[1]=function(e,t){return"M.5,0 L.5,1 M0,"+(.5-t)+" L.5,"+(.5-t)+" M0,"+(.5+t)+" L.5,"+(.5+t)},Z),"╢":(J={},J[1]=function(e,t){return"M0,.5 L"+(.5-e)+",.5 M"+(.5-e)+",0 L"+(.5-e)+",1 M"+(.5+e)+",0 L"+(.5+e)+",1"},J),"╣":($={},$[1]=function(e,t){return"M"+(.5+e)+",0 L"+(.5+e)+",1 M0,"+(.5+t)+" L"+(.5-e)+","+(.5+t)+" L"+(.5-e)+",1 M0,"+(.5-t)+" L"+(.5-e)+","+(.5-t)+" L"+(.5-e)+",0"},$),"╤":(Q={},Q[1]=function(e,t){return"M0,"+(.5-t)+" L1,"+(.5-t)+" M0,"+(.5+t)+" L1,"+(.5+t)+" M.5,"+(.5+t)+" L.5,1"},Q),"╥":(ee={},ee[1]=function(e,t){return"M0,.5 L1,.5 M"+(.5-e)+",.5 L"+(.5-e)+",1 M"+(.5+e)+",.5 L"+(.5+e)+",1"},ee),"╦":(te={},te[1]=function(e,t){return"M0,"+(.5-t)+" L1,"+(.5-t)+" M0,"+(.5+t)+" L"+(.5-e)+","+(.5+t)+" L"+(.5-e)+",1 M1,"+(.5+t)+" L"+(.5+e)+","+(.5+t)+" L"+(.5+e)+",1"},te),"╧":(re={},re[1]=function(e,t){return"M.5,0 L.5,"+(.5-t)+" M0,"+(.5-t)+" L1,"+(.5-t)+" M0,"+(.5+t)+" L1,"+(.5+t)},re),"╨":(ie={},ie[1]=function(e,t){return"M0,.5 L1,.5 M"+(.5-e)+",.5 L"+(.5-e)+",0 M"+(.5+e)+",.5 L"+(.5+e)+",0"},ie),"╩":(ne={},ne[1]=function(e,t){return"M0,"+(.5+t)+" L1,"+(.5+t)+" M0,"+(.5-t)+" L"+(.5-e)+","+(.5-t)+" L"+(.5-e)+",0 M1,"+(.5-t)+" L"+(.5+e)+","+(.5-t)+" L"+(.5+e)+",0"},ne),"╪":(oe={},oe[1]=function(e,t){return"M.5,0 L.5,1 M0,"+(.5-t)+" L1,"+(.5-t)+" M0,"+(.5+t)+" L1,"+(.5+t)},oe),"╫":(se={},se[1]=function(e,t){return"M0,.5 L1,.5 M"+(.5-e)+",0 L"+(.5-e)+",1 M"+(.5+e)+",0 L"+(.5+e)+",1"},se),"╬":(ae={},ae[1]=function(e,t){return"M0,"+(.5+t)+" L"+(.5-e)+","+(.5+t)+" L"+(.5-e)+",1 M1,"+(.5+t)+" L"+(.5+e)+","+(.5+t)+" L"+(.5+e)+",1 M0,"+(.5-t)+" L"+(.5-e)+","+(.5-t)+" L"+(.5-e)+",0 M1,"+(.5-t)+" L"+(.5+e)+","+(.5-t)+" L"+(.5+e)+",0"},ae),"╱":(ce={},ce[1]="M1,0 L0,1",ce),"╲":(le={},le[1]="M0,0 L1,1",le),"╳":(ue={},ue[1]="M1,0 L0,1 M0,0 L1,1",ue),"╼":(he={},he[1]="M.5,.5 L0,.5",he[3]="M.5,.5 L1,.5",he),"╽":(fe={},fe[1]="M.5,.5 L.5,0",fe[3]="M.5,.5 L.5,1",fe),"╾":(_e={},_e[1]="M.5,.5 L1,.5",_e[3]="M.5,.5 L0,.5",_e),"╿":(de={},de[1]="M.5,.5 L.5,1",de[3]="M.5,.5 L.5,0",de),"┍":(pe={},pe[1]="M.5,.5 L.5,1",pe[3]="M.5,.5 L1,.5",pe),"┎":(ve={},ve[1]="M.5,.5 L1,.5",ve[3]="M.5,.5 L.5,1",ve),"┑":(ge={},ge[1]="M.5,.5 L.5,1",ge[3]="M.5,.5 L0,.5",ge),"┒":(ye={},ye[1]="M.5,.5 L0,.5",ye[3]="M.5,.5 L.5,1",ye),"┕":(me={},me[1]="M.5,.5 L.5,0",me[3]="M.5,.5 L1,.5",me),"┖":(be={},be[1]="M.5,.5 L1,.5",be[3]="M.5,.5 L.5,0",be),"┙":(Se={},Se[1]="M.5,.5 L.5,0",Se[3]="M.5,.5 L0,.5",Se),"┚":(Ce={},Ce[1]="M.5,.5 L0,.5",Ce[3]="M.5,.5 L.5,0",Ce),"┝":(we={},we[1]="M.5,0 L.5,1",we[3]="M.5,.5 L1,.5",we),"┞":(Le={},Le[1]="M0.5,1 L.5,.5 L1,.5",Le[3]="M.5,.5 L.5,0",Le),"┟":(Ee={},Ee[1]="M.5,0 L.5,.5 L1,.5",Ee[3]="M.5,.5 L.5,1",Ee),"┠":(xe={},xe[1]="M.5,.5 L1,.5",xe[3]="M.5,0 L.5,1",xe),"┡":(Ae={},Ae[1]="M.5,.5 L.5,1",Ae[3]="M.5,0 L.5,.5 L1,.5",Ae),"┢":(ke={},ke[1]="M.5,.5 L.5,0",ke[3]="M0.5,1 L.5,.5 L1,.5",ke),"┥":(Me={},Me[1]="M.5,0 L.5,1",Me[3]="M.5,.5 L0,.5",Me),"┦":(Re={},Re[1]="M0,.5 L.5,.5 L.5,1",Re[3]="M.5,.5 L.5,0",Re),"┧":(Te={},Te[1]="M.5,0 L.5,.5 L0,.5",Te[3]="M.5,.5 L.5,1",Te),"┨":(Oe={},Oe[1]="M.5,.5 L0,.5",Oe[3]="M.5,0 L.5,1",Oe),"┩":(Be={},Be[1]="M.5,.5 L.5,1",Be[3]="M.5,0 L.5,.5 L0,.5",Be),"┪":(De={},De[1]="M.5,.5 L.5,0",De[3]="M0,.5 L.5,.5 L.5,1",De),"┭":(Pe={},Pe[1]="M0.5,1 L.5,.5 L1,.5",Pe[3]="M.5,.5 L0,.5",Pe),"┮":(Ie={},Ie[1]="M0,.5 L.5,.5 L.5,1",Ie[3]="M.5,.5 L1,.5",Ie),"┯":(He={},He[1]="M.5,.5 L.5,1",He[3]="M0,.5 L1,.5",He),"┰":(je={},je[1]="M0,.5 L1,.5",je[3]="M.5,.5 L.5,1",je),"┱":(Fe={},Fe[1]="M.5,.5 L1,.5",Fe[3]="M0,.5 L.5,.5 L.5,1",Fe),"┲":(We={},We[1]="M.5,.5 L0,.5",We[3]="M0.5,1 L.5,.5 L1,.5",We),"┵":(Ue={},Ue[1]="M.5,0 L.5,.5 L1,.5",Ue[3]="M.5,.5 L0,.5",Ue),"┶":(qe={},qe[1]="M.5,0 L.5,.5 L0,.5",qe[3]="M.5,.5 L1,.5",qe),"┷":(Ne={},Ne[1]="M.5,.5 L.5,0",Ne[3]="M0,.5 L1,.5",Ne),"┸":(ze={},ze[1]="M0,.5 L1,.5",ze[3]="M.5,.5 L.5,0",ze),"┹":(Ke={},Ke[1]="M.5,.5 L1,.5",Ke[3]="M.5,0 L.5,.5 L0,.5",Ke),"┺":(Ve={},Ve[1]="M.5,.5 L0,.5",Ve[3]="M.5,0 L.5,.5 L1,.5",Ve),"┽":(Ge={},Ge[1]="M.5,0 L.5,1 M.5,.5 L1,.5",Ge[3]="M.5,.5 L0,.5",Ge),"┾":(Ye={},Ye[1]="M.5,0 L.5,1 M.5,.5 L0,.5",Ye[3]="M.5,.5 L1,.5",Ye),"┿":(Xe={},Xe[1]="M.5,0 L.5,1",Xe[3]="M0,.5 L1,.5",Xe),"╀":(Ze={},Ze[1]="M0,.5 L1,.5 M.5,.5 L.5,1",Ze[3]="M.5,.5 L.5,0",Ze),"╁":(Je={},Je[1]="M.5,.5 L.5,0 M0,.5 L1,.5",Je[3]="M.5,.5 L.5,1",Je),"╂":($e={},$e[1]="M0,.5 L1,.5",$e[3]="M.5,0 L.5,1",$e),"╃":(Qe={},Qe[1]="M0.5,1 L.5,.5 L1,.5",Qe[3]="M.5,0 L.5,.5 L0,.5",Qe),"╄":(et={},et[1]="M0,.5 L.5,.5 L.5,1",et[3]="M.5,0 L.5,.5 L1,.5",et),"╅":(tt={},tt[1]="M.5,0 L.5,.5 L1,.5",tt[3]="M0,.5 L.5,.5 L.5,1",tt),"╆":(rt={},rt[1]="M.5,0 L.5,.5 L0,.5",rt[3]="M0.5,1 L.5,.5 L1,.5",rt),"╇":(it={},it[1]="M.5,.5 L.5,1",it[3]="M.5,.5 L.5,0 M0,.5 L1,.5",it),"╈":(nt={},nt[1]="M.5,.5 L.5,0",nt[3]="M0,.5 L1,.5 M.5,.5 L.5,1",nt),"╉":(ot={},ot[1]="M.5,.5 L1,.5",ot[3]="M.5,0 L.5,1 M.5,.5 L0,.5",ot),"╊":(st={},st[1]="M.5,.5 L0,.5",st[3]="M.5,0 L.5,1 M.5,.5 L1,.5",st),"╌":(at={},at[1]="M.1,.5 L.4,.5 M.6,.5 L.9,.5",at),"╍":(ct={},ct[3]="M.1,.5 L.4,.5 M.6,.5 L.9,.5",ct),"┄":(lt={},lt[1]="M.0667,.5 L.2667,.5 M.4,.5 L.6,.5 M.7333,.5 L.9333,.5",lt),"┅":(ut={},ut[3]="M.0667,.5 L.2667,.5 M.4,.5 L.6,.5 M.7333,.5 L.9333,.5",ut),"┈":(ht={},ht[1]="M.05,.5 L.2,.5 M.3,.5 L.45,.5 M.55,.5 L.7,.5 M.8,.5 L.95,.5",ht),"┉":(ft={},ft[3]="M.05,.5 L.2,.5 M.3,.5 L.45,.5 M.55,.5 L.7,.5 M.8,.5 L.95,.5",ft),"╎":(_t={},_t[1]="M.5,.1 L.5,.4 M.5,.6 L.5,.9",_t),"╏":(dt={},dt[3]="M.5,.1 L.5,.4 M.5,.6 L.5,.9",dt),"┆":(pt={},pt[1]="M.5,.0667 L.5,.2667 M.5,.4 L.5,.6 M.5,.7333 L.5,.9333",pt),"┇":(vt={},vt[3]="M.5,.0667 L.5,.2667 M.5,.4 L.5,.6 M.5,.7333 L.5,.9333",vt),"┊":(gt={},gt[1]="M.5,.05 L.5,.2 M.5,.3 L.5,.45 L.5,.55 M.5,.7 L.5,.95",gt),"┋":(yt={},yt[3]="M.5,.05 L.5,.2 M.5,.3 L.5,.45 L.5,.55 M.5,.7 L.5,.95",yt),"╭":(mt={},mt[1]="C.5,1,.5,.5,1,.5",mt),"╮":(bt={},bt[1]="C.5,1,.5,.5,0,.5",bt),"╯":(St={},St[1]="C.5,0,.5,.5,0,.5",St),"╰":(Ct={},Ct[1]="C.5,0,.5,.5,1,.5",Ct)},t.tryDrawCustomChar=function(e,r,i,n,o,s){var a=t.blockElementDefinitions[r];if(a)return function(e,t,r,i,n,o){for(var s=0;s<t.length;s++){var a=t[s],c=n/8,l=o/8;e.fillRect(r+a.x*c,i+a.y*l,a.w*c,a.h*l)}}(e,a,i,n,o,s),!0;var c=Lt[r];if(c)return function(e,t,r,i,n,o){var s,a=Et.get(t);a||(a=new Map,Et.set(t,a));var c=e.fillStyle;if("string"!=typeof c)throw new Error('Unexpected fillStyle type "'+c+'"');var l=a.get(c);if(!l){var u=t[0].length,h=t.length,f=document.createElement("canvas");f.width=u,f.height=h;var _=(0,wt.throwIfFalsy)(f.getContext("2d")),d=new ImageData(u,h),p=void 0,v=void 0,g=void 0,y=void 0;if(c.startsWith("#"))p=parseInt(c.substr(1,2),16),v=parseInt(c.substr(3,2),16),g=parseInt(c.substr(5,2),16),y=c.length>7&&parseInt(c.substr(7,2),16)||1;else{if(!c.startsWith("rgba"))throw new Error('Unexpected fillStyle color format "'+c+'" when drawing pattern glyph');p=(s=c.substring(5,c.length-1).split(",").map((function(e){return parseFloat(e)})))[0],v=s[1],g=s[2],y=s[3]}for(var m=0;m<h;m++)for(var b=0;b<u;b++)d.data[4*(m*u+b)]=p,d.data[4*(m*u+b)+1]=v,d.data[4*(m*u+b)+2]=g,d.data[4*(m*u+b)+3]=t[m][b]*(255*y);_.putImageData(d,0,0),l=(0,wt.throwIfFalsy)(e.createPattern(f,null)),a.set(c,l)}e.fillStyle=l,e.fillRect(r,i,n,o)}(e,c,i,n,o,s),!0;var l=t.boxDrawingDefinitions[r];return!!l&&(function(e,t,r,i,n,o){e.strokeStyle=e.fillStyle;for(var s=0,a=Object.entries(t);s<a.length;s++){var c=a[s],l=c[0],u=c[1];e.beginPath(),e.lineWidth=window.devicePixelRatio*Number.parseInt(l);for(var h=0,f=("function"==typeof u?u(.15,.15/o*n):u).split(" ");h<f.length;h++){var _=f[h],d=_[0],p=At[d];if(p){var v=_.substring(1).split(",");v[0]&&v[1]&&p(e,kt(v,n,o,r,i))}else console.error('Could not find drawing instructions for "'+d+'"')}e.stroke(),e.closePath()}}(e,l,i,n,o,s),!0)};var Et=new Map;function xt(e,t,r){return void 0===r&&(r=0),Math.max(Math.min(e,t),r)}var At={C:function(e,t){return e.bezierCurveTo(t[0],t[1],t[2],t[3],t[4],t[5])},L:function(e,t){return e.lineTo(t[0],t[1])},M:function(e,t){return e.moveTo(t[0],t[1])}};function kt(e,t,r,i,n){var o=e.map((function(e){return parseFloat(e)||parseInt(e)}));if(o.length<2)throw new Error("Too few arguments for instruction");for(var s=0;s<o.length;s+=2)o[s]*=t,0!==o[s]&&(o[s]=xt(Math.round(o[s]+.5)-.5,t,0)),o[s]+=i;for(var a=1;a<o.length;a+=2)o[a]*=r,0!==o[a]&&(o[a]=xt(Math.round(o[a]+.5)-.5,r,0)),o[a]+=n;return o}},3700:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.GridCache=void 0;var r=function(){function e(){this.cache=[]}return e.prototype.resize=function(e,t){for(var r=0;r<e;r++){this.cache.length<=r&&this.cache.push([]);for(var i=this.cache[r].length;i<t;i++)this.cache[r].push(void 0);this.cache[r].length=t}this.cache.length=e},e.prototype.clear=function(){for(var e=0;e<this.cache.length;e++)for(var t=0;t<this.cache[e].length;t++)this.cache[e][t]=void 0},e}();t.GridCache=r},5098:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.LinkRenderLayer=void 0;var a=r(1546),c=r(8803),l=r(2040),u=r(2585),h=function(e){function t(t,r,i,n,o,s,a,c){var l=e.call(this,t,"link",r,!0,i,n,a,c)||this;return o.onShowLinkUnderline((function(e){return l._onShowLinkUnderline(e)})),o.onHideLinkUnderline((function(e){return l._onHideLinkUnderline(e)})),s.onShowLinkUnderline((function(e){return l._onShowLinkUnderline(e)})),s.onHideLinkUnderline((function(e){return l._onHideLinkUnderline(e)})),l}return n(t,e),t.prototype.resize=function(t){e.prototype.resize.call(this,t),this._state=void 0},t.prototype.reset=function(){this._clearCurrentLink()},t.prototype._clearCurrentLink=function(){if(this._state){this._clearCells(this._state.x1,this._state.y1,this._state.cols-this._state.x1,1);var e=this._state.y2-this._state.y1-1;e>0&&this._clearCells(0,this._state.y1+1,this._state.cols,e),this._clearCells(0,this._state.y2,this._state.x2,1),this._state=void 0}},t.prototype._onShowLinkUnderline=function(e){if(e.fg===c.INVERTED_DEFAULT_COLOR?this._ctx.fillStyle=this._colors.background.css:e.fg&&(0,l.is256Color)(e.fg)?this._ctx.fillStyle=this._colors.ansi[e.fg].css:this._ctx.fillStyle=this._colors.foreground.css,e.y1===e.y2)this._fillBottomLineAtCells(e.x1,e.y1,e.x2-e.x1);else{this._fillBottomLineAtCells(e.x1,e.y1,e.cols-e.x1);for(var t=e.y1+1;t<e.y2;t++)this._fillBottomLineAtCells(0,t,e.cols);this._fillBottomLineAtCells(0,e.y2,e.x2)}this._state=e},t.prototype._onHideLinkUnderline=function(e){this._clearCurrentLink()},o([s(6,u.IBufferService),s(7,u.IOptionsService)],t)}(a.BaseRenderLayer);t.LinkRenderLayer=h},3525:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.Renderer=void 0;var a=r(9596),c=r(4149),l=r(2512),u=r(5098),h=r(844),f=r(4725),_=r(2585),d=r(1420),p=r(8460),v=1,g=function(e){function t(t,r,i,n,o,s,h,f){var _=e.call(this)||this;_._colors=t,_._screenElement=r,_._bufferService=s,_._charSizeService=h,_._optionsService=f,_._id=v++,_._onRequestRedraw=new p.EventEmitter;var d=_._optionsService.options.allowTransparency;return _._renderLayers=[o.createInstance(a.TextRenderLayer,_._screenElement,0,_._colors,d,_._id),o.createInstance(c.SelectionRenderLayer,_._screenElement,1,_._colors,_._id),o.createInstance(u.LinkRenderLayer,_._screenElement,2,_._colors,_._id,i,n),o.createInstance(l.CursorRenderLayer,_._screenElement,3,_._colors,_._id,_._onRequestRedraw)],_.dimensions={scaledCharWidth:0,scaledCharHeight:0,scaledCellWidth:0,scaledCellHeight:0,scaledCharLeft:0,scaledCharTop:0,scaledCanvasWidth:0,scaledCanvasHeight:0,canvasWidth:0,canvasHeight:0,actualCellWidth:0,actualCellHeight:0},_._devicePixelRatio=window.devicePixelRatio,_._updateDimensions(),_.onOptionsChanged(),_}return n(t,e),Object.defineProperty(t.prototype,"onRequestRedraw",{get:function(){return this._onRequestRedraw.event},enumerable:!1,configurable:!0}),t.prototype.dispose=function(){for(var t=0,r=this._renderLayers;t<r.length;t++)r[t].dispose();e.prototype.dispose.call(this),(0,d.removeTerminalFromCache)(this._id)},t.prototype.onDevicePixelRatioChange=function(){this._devicePixelRatio!==window.devicePixelRatio&&(this._devicePixelRatio=window.devicePixelRatio,this.onResize(this._bufferService.cols,this._bufferService.rows))},t.prototype.setColors=function(e){this._colors=e;for(var t=0,r=this._renderLayers;t<r.length;t++){var i=r[t];i.setColors(this._colors),i.reset()}},t.prototype.onResize=function(e,t){this._updateDimensions();for(var r=0,i=this._renderLayers;r<i.length;r++)i[r].resize(this.dimensions);this._screenElement.style.width=this.dimensions.canvasWidth+"px",this._screenElement.style.height=this.dimensions.canvasHeight+"px"},t.prototype.onCharSizeChanged=function(){this.onResize(this._bufferService.cols,this._bufferService.rows)},t.prototype.onBlur=function(){this._runOperation((function(e){return e.onBlur()}))},t.prototype.onFocus=function(){this._runOperation((function(e){return e.onFocus()}))},t.prototype.onSelectionChanged=function(e,t,r){void 0===r&&(r=!1),this._runOperation((function(i){return i.onSelectionChanged(e,t,r)}))},t.prototype.onCursorMove=function(){this._runOperation((function(e){return e.onCursorMove()}))},t.prototype.onOptionsChanged=function(){this._runOperation((function(e){return e.onOptionsChanged()}))},t.prototype.clear=function(){this._runOperation((function(e){return e.reset()}))},t.prototype._runOperation=function(e){for(var t=0,r=this._renderLayers;t<r.length;t++)e(r[t])},t.prototype.renderRows=function(e,t){for(var r=0,i=this._renderLayers;r<i.length;r++)i[r].onGridChanged(e,t)},t.prototype.clearTextureAtlas=function(){for(var e=0,t=this._renderLayers;e<t.length;e++)t[e].clearTextureAtlas()},t.prototype._updateDimensions=function(){this._charSizeService.hasValidSize&&(this.dimensions.scaledCharWidth=Math.floor(this._charSizeService.width*window.devicePixelRatio),this.dimensions.scaledCharHeight=Math.ceil(this._charSizeService.height*window.devicePixelRatio),this.dimensions.scaledCellHeight=Math.floor(this.dimensions.scaledCharHeight*this._optionsService.options.lineHeight),this.dimensions.scaledCharTop=1===this._optionsService.options.lineHeight?0:Math.round((this.dimensions.scaledCellHeight-this.dimensions.scaledCharHeight)/2),this.dimensions.scaledCellWidth=this.dimensions.scaledCharWidth+Math.round(this._optionsService.options.letterSpacing),this.dimensions.scaledCharLeft=Math.floor(this._optionsService.options.letterSpacing/2),this.dimensions.scaledCanvasHeight=this._bufferService.rows*this.dimensions.scaledCellHeight,this.dimensions.scaledCanvasWidth=this._bufferService.cols*this.dimensions.scaledCellWidth,this.dimensions.canvasHeight=Math.round(this.dimensions.scaledCanvasHeight/window.devicePixelRatio),this.dimensions.canvasWidth=Math.round(this.dimensions.scaledCanvasWidth/window.devicePixelRatio),this.dimensions.actualCellHeight=this.dimensions.canvasHeight/this._bufferService.rows,this.dimensions.actualCellWidth=this.dimensions.canvasWidth/this._bufferService.cols)},o([s(4,_.IInstantiationService),s(5,_.IBufferService),s(6,f.ICharSizeService),s(7,_.IOptionsService)],t)}(h.Disposable);t.Renderer=g},1752:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.throwIfFalsy=void 0,t.throwIfFalsy=function(e){if(!e)throw new Error("value must not be falsy");return e}},4149:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.SelectionRenderLayer=void 0;var a=r(1546),c=r(2585),l=function(e){function t(t,r,i,n,o,s){var a=e.call(this,t,"selection",r,!0,i,n,o,s)||this;return a._clearState(),a}return n(t,e),t.prototype._clearState=function(){this._state={start:void 0,end:void 0,columnSelectMode:void 0,ydisp:void 0}},t.prototype.resize=function(t){e.prototype.resize.call(this,t),this._clearState()},t.prototype.reset=function(){this._state.start&&this._state.end&&(this._clearState(),this._clearAll())},t.prototype.onSelectionChanged=function(e,t,r){if(this._didStateChange(e,t,r,this._bufferService.buffer.ydisp))if(this._clearAll(),e&&t){var i=e[1]-this._bufferService.buffer.ydisp,n=t[1]-this._bufferService.buffer.ydisp,o=Math.max(i,0),s=Math.min(n,this._bufferService.rows-1);if(o>=this._bufferService.rows||s<0)this._state.ydisp=this._bufferService.buffer.ydisp;else{if(this._ctx.fillStyle=this._colors.selectionTransparent.css,r){var a=e[0],c=t[0]-a,l=s-o+1;this._fillCells(a,o,c,l)}else{a=i===o?e[0]:0;var u=o===n?t[0]:this._bufferService.cols;this._fillCells(a,o,u-a,1);var h=Math.max(s-o-1,0);if(this._fillCells(0,o+1,this._bufferService.cols,h),o!==s){var f=n===s?t[0]:this._bufferService.cols;this._fillCells(0,s,f,1)}}this._state.start=[e[0],e[1]],this._state.end=[t[0],t[1]],this._state.columnSelectMode=r,this._state.ydisp=this._bufferService.buffer.ydisp}}else this._clearState()},t.prototype._didStateChange=function(e,t,r,i){return!this._areCoordinatesEqual(e,this._state.start)||!this._areCoordinatesEqual(t,this._state.end)||r!==this._state.columnSelectMode||i!==this._state.ydisp},t.prototype._areCoordinatesEqual=function(e,t){return!(!e||!t)&&e[0]===t[0]&&e[1]===t[1]},o([s(4,c.IBufferService),s(5,c.IOptionsService)],t)}(a.BaseRenderLayer);t.SelectionRenderLayer=l},9596:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.TextRenderLayer=void 0;var a=r(3700),c=r(1546),l=r(3734),u=r(643),h=r(511),f=r(2585),_=r(4725),d=r(4269),p=function(e){function t(t,r,i,n,o,s,c,l){var u=e.call(this,t,"text",r,n,i,o,s,c)||this;return u._characterJoinerService=l,u._characterWidth=0,u._characterFont="",u._characterOverlapCache={},u._workCell=new h.CellData,u._state=new a.GridCache,u}return n(t,e),t.prototype.resize=function(t){e.prototype.resize.call(this,t);var r=this._getFont(!1,!1);this._characterWidth===t.scaledCharWidth&&this._characterFont===r||(this._characterWidth=t.scaledCharWidth,this._characterFont=r,this._characterOverlapCache={}),this._state.clear(),this._state.resize(this._bufferService.cols,this._bufferService.rows)},t.prototype.reset=function(){this._state.clear(),this._clearAll()},t.prototype._forEachCell=function(e,t,r){for(var i=e;i<=t;i++)for(var n=i+this._bufferService.buffer.ydisp,o=this._bufferService.buffer.lines.get(n),s=this._characterJoinerService.getJoinedCharacters(n),a=0;a<this._bufferService.cols;a++){o.loadCell(a,this._workCell);var c=this._workCell,l=!1,h=a;if(0!==c.getWidth()){if(s.length>0&&a===s[0][0]){l=!0;var f=s.shift();c=new d.JoinedCellData(this._workCell,o.translateToString(!0,f[0],f[1]),f[1]-f[0]),h=f[1]-1}!l&&this._isOverlapping(c)&&h<o.length-1&&o.getCodePoint(h+1)===u.NULL_CELL_CODE&&(c.content&=-12582913,c.content|=2<<22),r(c,a,i),a=h}}},t.prototype._drawBackground=function(e,t){var r=this,i=this._ctx,n=this._bufferService.cols,o=0,s=0,a=null;i.save(),this._forEachCell(e,t,(function(e,t,c){var u=null;e.isInverse()?u=e.isFgDefault()?r._colors.foreground.css:e.isFgRGB()?"rgb("+l.AttributeData.toColorRGB(e.getFgColor()).join(",")+")":r._colors.ansi[e.getFgColor()].css:e.isBgRGB()?u="rgb("+l.AttributeData.toColorRGB(e.getBgColor()).join(",")+")":e.isBgPalette()&&(u=r._colors.ansi[e.getBgColor()].css),null===a&&(o=t,s=c),c!==s?(i.fillStyle=a||"",r._fillCells(o,s,n-o,1),o=t,s=c):a!==u&&(i.fillStyle=a||"",r._fillCells(o,s,t-o,1),o=t,s=c),a=u})),null!==a&&(i.fillStyle=a,this._fillCells(o,s,n-o,1)),i.restore()},t.prototype._drawForeground=function(e,t){var r=this;this._forEachCell(e,t,(function(e,t,i){if(!e.isInvisible()&&(r._drawChars(e,t,i),e.isUnderline()||e.isStrikethrough())){if(r._ctx.save(),e.isInverse())if(e.isBgDefault())r._ctx.fillStyle=r._colors.background.css;else if(e.isBgRGB())r._ctx.fillStyle="rgb("+l.AttributeData.toColorRGB(e.getBgColor()).join(",")+")";else{var n=e.getBgColor();r._optionsService.options.drawBoldTextInBrightColors&&e.isBold()&&n<8&&(n+=8),r._ctx.fillStyle=r._colors.ansi[n].css}else if(e.isFgDefault())r._ctx.fillStyle=r._colors.foreground.css;else if(e.isFgRGB())r._ctx.fillStyle="rgb("+l.AttributeData.toColorRGB(e.getFgColor()).join(",")+")";else{var o=e.getFgColor();r._optionsService.options.drawBoldTextInBrightColors&&e.isBold()&&o<8&&(o+=8),r._ctx.fillStyle=r._colors.ansi[o].css}e.isStrikethrough()&&r._fillMiddleLineAtCells(t,i,e.getWidth()),e.isUnderline()&&r._fillBottomLineAtCells(t,i,e.getWidth()),r._ctx.restore()}}))},t.prototype.onGridChanged=function(e,t){0!==this._state.cache.length&&(this._charAtlas&&this._charAtlas.beginFrame(),this._clearCells(0,e,this._bufferService.cols,t-e+1),this._drawBackground(e,t),this._drawForeground(e,t))},t.prototype.onOptionsChanged=function(){this._setTransparency(this._optionsService.options.allowTransparency)},t.prototype._isOverlapping=function(e){if(1!==e.getWidth())return!1;if(e.getCode()<256)return!1;var t=e.getChars();if(this._characterOverlapCache.hasOwnProperty(t))return this._characterOverlapCache[t];this._ctx.save(),this._ctx.font=this._characterFont;var r=Math.floor(this._ctx.measureText(t).width)>this._characterWidth;return this._ctx.restore(),this._characterOverlapCache[t]=r,r},o([s(5,f.IBufferService),s(6,f.IOptionsService),s(7,_.ICharacterJoinerService)],t)}(c.BaseRenderLayer);t.TextRenderLayer=p},9616:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.BaseCharAtlas=void 0;var r=function(){function e(){this._didWarmUp=!1}return e.prototype.dispose=function(){},e.prototype.warmUp=function(){this._didWarmUp||(this._doWarmUp(),this._didWarmUp=!0)},e.prototype._doWarmUp=function(){},e.prototype.clear=function(){},e.prototype.beginFrame=function(){},e}();t.BaseCharAtlas=r},1420:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.removeTerminalFromCache=t.acquireCharAtlas=void 0;var i=r(2040),n=r(1906),o=[];t.acquireCharAtlas=function(e,t,r,s,a){for(var c=(0,i.generateConfig)(s,a,e,r),l=0;l<o.length;l++){var u=(h=o[l]).ownedBy.indexOf(t);if(u>=0){if((0,i.configEquals)(h.config,c))return h.atlas;1===h.ownedBy.length?(h.atlas.dispose(),o.splice(l,1)):h.ownedBy.splice(u,1);break}}for(l=0;l<o.length;l++){var h=o[l];if((0,i.configEquals)(h.config,c))return h.ownedBy.push(t),h.atlas}var f={atlas:new n.DynamicCharAtlas(document,c),config:c,ownedBy:[t]};return o.push(f),f.atlas},t.removeTerminalFromCache=function(e){for(var t=0;t<o.length;t++){var r=o[t].ownedBy.indexOf(e);if(-1!==r){1===o[t].ownedBy.length?(o[t].atlas.dispose(),o.splice(t,1)):o[t].ownedBy.splice(r,1);break}}}},2040:function(e,t,r){var i=this&&this.__spreadArray||function(e,t,r){if(r||2===arguments.length)for(var i,n=0,o=t.length;n<o;n++)!i&&n in t||(i||(i=Array.prototype.slice.call(t,0,n)),i[n]=t[n]);return e.concat(i||Array.prototype.slice.call(t))};Object.defineProperty(t,"__esModule",{value:!0}),t.is256Color=t.configEquals=t.generateConfig=void 0;var n=r(643);t.generateConfig=function(e,t,r,n){var o={foreground:n.foreground,background:n.background,cursor:void 0,cursorAccent:void 0,selection:void 0,ansi:i([],n.ansi,!0)};return{devicePixelRatio:window.devicePixelRatio,scaledCharWidth:e,scaledCharHeight:t,fontFamily:r.fontFamily,fontSize:r.fontSize,fontWeight:r.fontWeight,fontWeightBold:r.fontWeightBold,allowTransparency:r.allowTransparency,colors:o}},t.configEquals=function(e,t){for(var r=0;r<e.colors.ansi.length;r++)if(e.colors.ansi[r].rgba!==t.colors.ansi[r].rgba)return!1;return e.devicePixelRatio===t.devicePixelRatio&&e.fontFamily===t.fontFamily&&e.fontSize===t.fontSize&&e.fontWeight===t.fontWeight&&e.fontWeightBold===t.fontWeightBold&&e.allowTransparency===t.allowTransparency&&e.scaledCharWidth===t.scaledCharWidth&&e.scaledCharHeight===t.scaledCharHeight&&e.colors.foreground===t.colors.foreground&&e.colors.background===t.colors.background},t.is256Color=function(e){return e<n.DEFAULT_COLOR}},8803:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.CHAR_ATLAS_CELL_SPACING=t.TEXT_BASELINE=t.DIM_OPACITY=t.INVERTED_DEFAULT_COLOR=void 0;var i=r(6114);t.INVERTED_DEFAULT_COLOR=257,t.DIM_OPACITY=.5,t.TEXT_BASELINE=i.isFirefox?"bottom":"ideographic",t.CHAR_ATLAS_CELL_SPACING=1},1906:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.NoneCharAtlas=t.DynamicCharAtlas=t.getGlyphCacheKey=void 0;var o=r(8803),s=r(9616),a=r(5680),c=r(7001),l=r(6114),u=r(1752),h=r(4774),f=1024,_=1024,d={css:"rgba(0, 0, 0, 0)",rgba:0};function p(e){return e.code<<21|e.bg<<12|e.fg<<3|(e.bold?0:4)+(e.dim?0:2)+(e.italic?0:1)}t.getGlyphCacheKey=p;var v=function(e){function t(t,r){var i=e.call(this)||this;i._config=r,i._drawToCacheCount=0,i._glyphsWaitingOnBitmap=[],i._bitmapCommitTimeout=null,i._bitmap=null,i._cacheCanvas=t.createElement("canvas"),i._cacheCanvas.width=f,i._cacheCanvas.height=_,i._cacheCtx=(0,u.throwIfFalsy)(i._cacheCanvas.getContext("2d",{alpha:!0}));var n=t.createElement("canvas");n.width=i._config.scaledCharWidth,n.height=i._config.scaledCharHeight,i._tmpCtx=(0,u.throwIfFalsy)(n.getContext("2d",{alpha:i._config.allowTransparency})),i._width=Math.floor(f/i._config.scaledCharWidth),i._height=Math.floor(_/i._config.scaledCharHeight);var o=i._width*i._height;return i._cacheMap=new c.LRUMap(o),i._cacheMap.prealloc(o),i}return n(t,e),t.prototype.dispose=function(){null!==this._bitmapCommitTimeout&&(window.clearTimeout(this._bitmapCommitTimeout),this._bitmapCommitTimeout=null)},t.prototype.beginFrame=function(){this._drawToCacheCount=0},t.prototype.clear=function(){if(this._cacheMap.size>0){var e=this._width*this._height;this._cacheMap=new c.LRUMap(e),this._cacheMap.prealloc(e)}this._cacheCtx.clearRect(0,0,f,_),this._tmpCtx.clearRect(0,0,this._config.scaledCharWidth,this._config.scaledCharHeight)},t.prototype.draw=function(e,t,r,i){if(32===t.code)return!0;if(!this._canCache(t))return!1;var n=p(t),o=this._cacheMap.get(n);if(null!=o)return this._drawFromCache(e,o,r,i),!0;if(this._drawToCacheCount<100){var s;s=this._cacheMap.size<this._cacheMap.capacity?this._cacheMap.size:this._cacheMap.peek().index;var a=this._drawToCache(t,s);return this._cacheMap.set(n,a),this._drawFromCache(e,a,r,i),!0}return!1},t.prototype._canCache=function(e){return e.code<256},t.prototype._toCoordinateX=function(e){return e%this._width*this._config.scaledCharWidth},t.prototype._toCoordinateY=function(e){return Math.floor(e/this._width)*this._config.scaledCharHeight},t.prototype._drawFromCache=function(e,t,r,i){if(!t.isEmpty){var n=this._toCoordinateX(t.index),o=this._toCoordinateY(t.index);e.drawImage(t.inBitmap?this._bitmap:this._cacheCanvas,n,o,this._config.scaledCharWidth,this._config.scaledCharHeight,r,i,this._config.scaledCharWidth,this._config.scaledCharHeight)}},t.prototype._getColorFromAnsiIndex=function(e){return e<this._config.colors.ansi.length?this._config.colors.ansi[e]:a.DEFAULT_ANSI_COLORS[e]},t.prototype._getBackgroundColor=function(e){return this._config.allowTransparency?d:e.bg===o.INVERTED_DEFAULT_COLOR?this._config.colors.foreground:e.bg<256?this._getColorFromAnsiIndex(e.bg):this._config.colors.background},t.prototype._getForegroundColor=function(e){return e.fg===o.INVERTED_DEFAULT_COLOR?h.color.opaque(this._config.colors.background):e.fg<256?this._getColorFromAnsiIndex(e.fg):this._config.colors.foreground},t.prototype._drawToCache=function(e,t){this._drawToCacheCount++,this._tmpCtx.save();var r=this._getBackgroundColor(e);this._tmpCtx.globalCompositeOperation="copy",this._tmpCtx.fillStyle=r.css,this._tmpCtx.fillRect(0,0,this._config.scaledCharWidth,this._config.scaledCharHeight),this._tmpCtx.globalCompositeOperation="source-over";var i=e.bold?this._config.fontWeightBold:this._config.fontWeight,n=e.italic?"italic":"";this._tmpCtx.font=n+" "+i+" "+this._config.fontSize*this._config.devicePixelRatio+"px "+this._config.fontFamily,this._tmpCtx.textBaseline=o.TEXT_BASELINE,this._tmpCtx.fillStyle=this._getForegroundColor(e).css,e.dim&&(this._tmpCtx.globalAlpha=o.DIM_OPACITY),this._tmpCtx.fillText(e.chars,0,this._config.scaledCharHeight);var s=this._tmpCtx.getImageData(0,0,this._config.scaledCharWidth,this._config.scaledCharHeight),a=!1;if(this._config.allowTransparency||(a=y(s,r)),a&&"_"===e.chars&&!this._config.allowTransparency)for(var c=1;c<=5&&(this._tmpCtx.fillText(e.chars,0,this._config.scaledCharHeight-c),a=y(s=this._tmpCtx.getImageData(0,0,this._config.scaledCharWidth,this._config.scaledCharHeight),r));c++);this._tmpCtx.restore();var l=this._toCoordinateX(t),u=this._toCoordinateY(t);this._cacheCtx.putImageData(s,l,u);var h={index:t,isEmpty:a,inBitmap:!1};return this._addGlyphToBitmap(h),h},t.prototype._addGlyphToBitmap=function(e){var t=this;!("createImageBitmap"in window)||l.isFirefox||l.isSafari||(this._glyphsWaitingOnBitmap.push(e),null===this._bitmapCommitTimeout&&(this._bitmapCommitTimeout=window.setTimeout((function(){return t._generateBitmap()}),100)))},t.prototype._generateBitmap=function(){var e=this,t=this._glyphsWaitingOnBitmap;this._glyphsWaitingOnBitmap=[],window.createImageBitmap(this._cacheCanvas).then((function(r){e._bitmap=r;for(var i=0;i<t.length;i++)t[i].inBitmap=!0})),this._bitmapCommitTimeout=null},t}(s.BaseCharAtlas);t.DynamicCharAtlas=v;var g=function(e){function t(t,r){return e.call(this)||this}return n(t,e),t.prototype.draw=function(e,t,r,i){return!1},t}(s.BaseCharAtlas);function y(e,t){for(var r=!0,i=t.rgba>>>24,n=t.rgba>>>16&255,o=t.rgba>>>8&255,s=0;s<e.data.length;s+=4)e.data[s]===i&&e.data[s+1]===n&&e.data[s+2]===o?e.data[s+3]=0:r=!1;return r}t.NoneCharAtlas=g},7001:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.LRUMap=void 0;var r=function(){function e(e){this.capacity=e,this._map={},this._head=null,this._tail=null,this._nodePool=[],this.size=0}return e.prototype._unlinkNode=function(e){var t=e.prev,r=e.next;e===this._head&&(this._head=r),e===this._tail&&(this._tail=t),null!==t&&(t.next=r),null!==r&&(r.prev=t)},e.prototype._appendNode=function(e){var t=this._tail;null!==t&&(t.next=e),e.prev=t,e.next=null,this._tail=e,null===this._head&&(this._head=e)},e.prototype.prealloc=function(e){for(var t=this._nodePool,r=0;r<e;r++)t.push({prev:null,next:null,key:null,value:null})},e.prototype.get=function(e){var t=this._map[e];return void 0!==t?(this._unlinkNode(t),this._appendNode(t),t.value):null},e.prototype.peekValue=function(e){var t=this._map[e];return void 0!==t?t.value:null},e.prototype.peek=function(){var e=this._head;return null===e?null:e.value},e.prototype.set=function(e,t){var r=this._map[e];if(void 0!==r)r=this._map[e],this._unlinkNode(r),r.value=t;else if(this.size>=this.capacity)r=this._head,this._unlinkNode(r),delete this._map[r.key],r.key=e,r.value=t,this._map[e]=r;else{var i=this._nodePool;i.length>0?((r=i.pop()).key=e,r.value=t):r={prev:null,next:null,key:e,value:t},this._map[e]=r,this.size++}this._appendNode(r)},e}();t.LRUMap=r},1296:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.DomRenderer=void 0;var a=r(3787),c=r(8803),l=r(844),u=r(4725),h=r(2585),f=r(8460),_=r(4774),d=r(9631),p="xterm-dom-renderer-owner-",v="xterm-fg-",g="xterm-bg-",y="xterm-focus",m=1,b=function(e){function t(t,r,i,n,o,s,c,l,u,h){var f=e.call(this)||this;return f._colors=t,f._element=r,f._screenElement=i,f._viewportElement=n,f._linkifier=o,f._linkifier2=s,f._charSizeService=l,f._optionsService=u,f._bufferService=h,f._terminalClass=m++,f._rowElements=[],f._rowContainer=document.createElement("div"),f._rowContainer.classList.add("xterm-rows"),f._rowContainer.style.lineHeight="normal",f._rowContainer.setAttribute("aria-hidden","true"),f._refreshRowElements(f._bufferService.cols,f._bufferService.rows),f._selectionContainer=document.createElement("div"),f._selectionContainer.classList.add("xterm-selection"),f._selectionContainer.setAttribute("aria-hidden","true"),f.dimensions={scaledCharWidth:0,scaledCharHeight:0,scaledCellWidth:0,scaledCellHeight:0,scaledCharLeft:0,scaledCharTop:0,scaledCanvasWidth:0,scaledCanvasHeight:0,canvasWidth:0,canvasHeight:0,actualCellWidth:0,actualCellHeight:0},f._updateDimensions(),f._injectCss(),f._rowFactory=c.createInstance(a.DomRendererRowFactory,document,f._colors),f._element.classList.add(p+f._terminalClass),f._screenElement.appendChild(f._rowContainer),f._screenElement.appendChild(f._selectionContainer),f._linkifier.onShowLinkUnderline((function(e){return f._onLinkHover(e)})),f._linkifier.onHideLinkUnderline((function(e){return f._onLinkLeave(e)})),f._linkifier2.onShowLinkUnderline((function(e){return f._onLinkHover(e)})),f._linkifier2.onHideLinkUnderline((function(e){return f._onLinkLeave(e)})),f}return n(t,e),Object.defineProperty(t.prototype,"onRequestRedraw",{get:function(){return(new f.EventEmitter).event},enumerable:!1,configurable:!0}),t.prototype.dispose=function(){this._element.classList.remove(p+this._terminalClass),(0,d.removeElementFromParent)(this._rowContainer,this._selectionContainer,this._themeStyleElement,this._dimensionsStyleElement),e.prototype.dispose.call(this)},t.prototype._updateDimensions=function(){this.dimensions.scaledCharWidth=this._charSizeService.width*window.devicePixelRatio,this.dimensions.scaledCharHeight=Math.ceil(this._charSizeService.height*window.devicePixelRatio),this.dimensions.scaledCellWidth=this.dimensions.scaledCharWidth+Math.round(this._optionsService.options.letterSpacing),this.dimensions.scaledCellHeight=Math.floor(this.dimensions.scaledCharHeight*this._optionsService.options.lineHeight),this.dimensions.scaledCharLeft=0,this.dimensions.scaledCharTop=0,this.dimensions.scaledCanvasWidth=this.dimensions.scaledCellWidth*this._bufferService.cols,this.dimensions.scaledCanvasHeight=this.dimensions.scaledCellHeight*this._bufferService.rows,this.dimensions.canvasWidth=Math.round(this.dimensions.scaledCanvasWidth/window.devicePixelRatio),this.dimensions.canvasHeight=Math.round(this.dimensions.scaledCanvasHeight/window.devicePixelRatio),this.dimensions.actualCellWidth=this.dimensions.canvasWidth/this._bufferService.cols,this.dimensions.actualCellHeight=this.dimensions.canvasHeight/this._bufferService.rows;for(var e=0,t=this._rowElements;e<t.length;e++){var r=t[e];r.style.width=this.dimensions.canvasWidth+"px",r.style.height=this.dimensions.actualCellHeight+"px",r.style.lineHeight=this.dimensions.actualCellHeight+"px",r.style.overflow="hidden"}this._dimensionsStyleElement||(this._dimensionsStyleElement=document.createElement("style"),this._screenElement.appendChild(this._dimensionsStyleElement));var i=this._terminalSelector+" .xterm-rows span { display: inline-block; height: 100%; vertical-align: top; width: "+this.dimensions.actualCellWidth+"px}";this._dimensionsStyleElement.textContent=i,this._selectionContainer.style.height=this._viewportElement.style.height,this._screenElement.style.width=this.dimensions.canvasWidth+"px",this._screenElement.style.height=this.dimensions.canvasHeight+"px"},t.prototype.setColors=function(e){this._colors=e,this._injectCss()},t.prototype._injectCss=function(){var e=this;this._themeStyleElement||(this._themeStyleElement=document.createElement("style"),this._screenElement.appendChild(this._themeStyleElement));var t=this._terminalSelector+" .xterm-rows { color: "+this._colors.foreground.css+"; font-family: "+this._optionsService.options.fontFamily+"; font-size: "+this._optionsService.options.fontSize+"px;}";t+=this._terminalSelector+" span:not(."+a.BOLD_CLASS+") { font-weight: "+this._optionsService.options.fontWeight+";}"+this._terminalSelector+" span."+a.BOLD_CLASS+" { font-weight: "+this._optionsService.options.fontWeightBold+";}"+this._terminalSelector+" span."+a.ITALIC_CLASS+" { font-style: italic;}",t+="@keyframes blink_box_shadow_"+this._terminalClass+" { 50% {  box-shadow: none; }}",t+="@keyframes blink_block_"+this._terminalClass+" { 0% {  background-color: "+this._colors.cursor.css+";  color: "+this._colors.cursorAccent.css+"; } 50% {  background-color: "+this._colors.cursorAccent.css+";  color: "+this._colors.cursor.css+"; }}",t+=this._terminalSelector+" .xterm-rows:not(.xterm-focus) ."+a.CURSOR_CLASS+"."+a.CURSOR_STYLE_BLOCK_CLASS+" { outline: 1px solid "+this._colors.cursor.css+"; outline-offset: -1px;}"+this._terminalSelector+" .xterm-rows.xterm-focus ."+a.CURSOR_CLASS+"."+a.CURSOR_BLINK_CLASS+":not(."+a.CURSOR_STYLE_BLOCK_CLASS+") { animation: blink_box_shadow_"+this._terminalClass+" 1s step-end infinite;}"+this._terminalSelector+" .xterm-rows.xterm-focus ."+a.CURSOR_CLASS+"."+a.CURSOR_BLINK_CLASS+"."+a.CURSOR_STYLE_BLOCK_CLASS+" { animation: blink_block_"+this._terminalClass+" 1s step-end infinite;}"+this._terminalSelector+" .xterm-rows.xterm-focus ."+a.CURSOR_CLASS+"."+a.CURSOR_STYLE_BLOCK_CLASS+" { background-color: "+this._colors.cursor.css+"; color: "+this._colors.cursorAccent.css+";}"+this._terminalSelector+" .xterm-rows ."+a.CURSOR_CLASS+"."+a.CURSOR_STYLE_BAR_CLASS+" { box-shadow: "+this._optionsService.options.cursorWidth+"px 0 0 "+this._colors.cursor.css+" inset;}"+this._terminalSelector+" .xterm-rows ."+a.CURSOR_CLASS+"."+a.CURSOR_STYLE_UNDERLINE_CLASS+" { box-shadow: 0 -1px 0 "+this._colors.cursor.css+" inset;}",t+=this._terminalSelector+" .xterm-selection { position: absolute; top: 0; left: 0; z-index: 1; pointer-events: none;}"+this._terminalSelector+" .xterm-selection div { position: absolute; background-color: "+this._colors.selectionTransparent.css+";}",this._colors.ansi.forEach((function(r,i){t+=e._terminalSelector+" ."+v+i+" { color: "+r.css+"; }"+e._terminalSelector+" ."+g+i+" { background-color: "+r.css+"; }"})),t+=this._terminalSelector+" ."+v+c.INVERTED_DEFAULT_COLOR+" { color: "+_.color.opaque(this._colors.background).css+"; }"+this._terminalSelector+" ."+g+c.INVERTED_DEFAULT_COLOR+" { background-color: "+this._colors.foreground.css+"; }",this._themeStyleElement.textContent=t},t.prototype.onDevicePixelRatioChange=function(){this._updateDimensions()},t.prototype._refreshRowElements=function(e,t){for(var r=this._rowElements.length;r<=t;r++){var i=document.createElement("div");this._rowContainer.appendChild(i),this._rowElements.push(i)}for(;this._rowElements.length>t;)this._rowContainer.removeChild(this._rowElements.pop())},t.prototype.onResize=function(e,t){this._refreshRowElements(e,t),this._updateDimensions()},t.prototype.onCharSizeChanged=function(){this._updateDimensions()},t.prototype.onBlur=function(){this._rowContainer.classList.remove(y)},t.prototype.onFocus=function(){this._rowContainer.classList.add(y)},t.prototype.onSelectionChanged=function(e,t,r){for(;this._selectionContainer.children.length;)this._selectionContainer.removeChild(this._selectionContainer.children[0]);if(e&&t){var i=e[1]-this._bufferService.buffer.ydisp,n=t[1]-this._bufferService.buffer.ydisp,o=Math.max(i,0),s=Math.min(n,this._bufferService.rows-1);if(!(o>=this._bufferService.rows||s<0)){var a=document.createDocumentFragment();if(r)a.appendChild(this._createSelectionElement(o,e[0],t[0],s-o+1));else{var c=i===o?e[0]:0,l=o===n?t[0]:this._bufferService.cols;a.appendChild(this._createSelectionElement(o,c,l));var u=s-o-1;if(a.appendChild(this._createSelectionElement(o+1,0,this._bufferService.cols,u)),o!==s){var h=n===s?t[0]:this._bufferService.cols;a.appendChild(this._createSelectionElement(s,0,h))}}this._selectionContainer.appendChild(a)}}},t.prototype._createSelectionElement=function(e,t,r,i){void 0===i&&(i=1);var n=document.createElement("div");return n.style.height=i*this.dimensions.actualCellHeight+"px",n.style.top=e*this.dimensions.actualCellHeight+"px",n.style.left=t*this.dimensions.actualCellWidth+"px",n.style.width=this.dimensions.actualCellWidth*(r-t)+"px",n},t.prototype.onCursorMove=function(){},t.prototype.onOptionsChanged=function(){this._updateDimensions(),this._injectCss()},t.prototype.clear=function(){for(var e=0,t=this._rowElements;e<t.length;e++)t[e].innerText=""},t.prototype.renderRows=function(e,t){for(var r=this._bufferService.buffer.ybase+this._bufferService.buffer.y,i=Math.min(this._bufferService.buffer.x,this._bufferService.cols-1),n=this._optionsService.options.cursorBlink,o=e;o<=t;o++){var s=this._rowElements[o];s.innerText="";var a=o+this._bufferService.buffer.ydisp,c=this._bufferService.buffer.lines.get(a),l=this._optionsService.options.cursorStyle;s.appendChild(this._rowFactory.createRow(c,a,a===r,l,i,n,this.dimensions.actualCellWidth,this._bufferService.cols))}},Object.defineProperty(t.prototype,"_terminalSelector",{get:function(){return"."+p+this._terminalClass},enumerable:!1,configurable:!0}),t.prototype._onLinkHover=function(e){this._setCellUnderline(e.x1,e.x2,e.y1,e.y2,e.cols,!0)},t.prototype._onLinkLeave=function(e){this._setCellUnderline(e.x1,e.x2,e.y1,e.y2,e.cols,!1)},t.prototype._setCellUnderline=function(e,t,r,i,n,o){for(;e!==t||r!==i;){var s=this._rowElements[r];if(!s)return;var a=s.children[e];a&&(a.style.textDecoration=o?"underline":"none"),++e>=n&&(e=0,r++)}},o([s(6,h.IInstantiationService),s(7,u.ICharSizeService),s(8,h.IOptionsService),s(9,h.IBufferService)],t)}(l.Disposable);t.DomRenderer=b},3787:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.DomRendererRowFactory=t.CURSOR_STYLE_UNDERLINE_CLASS=t.CURSOR_STYLE_BAR_CLASS=t.CURSOR_STYLE_BLOCK_CLASS=t.CURSOR_BLINK_CLASS=t.CURSOR_CLASS=t.STRIKETHROUGH_CLASS=t.UNDERLINE_CLASS=t.ITALIC_CLASS=t.DIM_CLASS=t.BOLD_CLASS=void 0;var o=r(8803),s=r(643),a=r(511),c=r(2585),l=r(4774),u=r(4725),h=r(4269);t.BOLD_CLASS="xterm-bold",t.DIM_CLASS="xterm-dim",t.ITALIC_CLASS="xterm-italic",t.UNDERLINE_CLASS="xterm-underline",t.STRIKETHROUGH_CLASS="xterm-strikethrough",t.CURSOR_CLASS="xterm-cursor",t.CURSOR_BLINK_CLASS="xterm-cursor-blink",t.CURSOR_STYLE_BLOCK_CLASS="xterm-cursor-block",t.CURSOR_STYLE_BAR_CLASS="xterm-cursor-bar",t.CURSOR_STYLE_UNDERLINE_CLASS="xterm-cursor-underline";var f=function(){function e(e,t,r,i,n){this._document=e,this._colors=t,this._characterJoinerService=r,this._optionsService=i,this._coreService=n,this._workCell=new a.CellData}return e.prototype.setColors=function(e){this._colors=e},e.prototype.createRow=function(e,r,i,n,a,c,u,f){for(var d=this._document.createDocumentFragment(),p=this._characterJoinerService.getJoinedCharacters(r),v=0,g=Math.min(e.length,f)-1;g>=0;g--)if(e.loadCell(g,this._workCell).getCode()!==s.NULL_CELL_CODE||i&&g===a){v=g+1;break}for(g=0;g<v;g++){e.loadCell(g,this._workCell);var y=this._workCell.getWidth();if(0!==y){var m=!1,b=g,S=this._workCell;if(p.length>0&&g===p[0][0]){m=!0;var C=p.shift();S=new h.JoinedCellData(this._workCell,e.translateToString(!0,C[0],C[1]),C[1]-C[0]),b=C[1]-1,y=S.getWidth()}var w=this._document.createElement("span");if(y>1&&(w.style.width=u*y+"px"),m&&(w.style.display="inline",a>=g&&a<=b&&(a=g)),!this._coreService.isCursorHidden&&i&&g===a)switch(w.classList.add(t.CURSOR_CLASS),c&&w.classList.add(t.CURSOR_BLINK_CLASS),n){case"bar":w.classList.add(t.CURSOR_STYLE_BAR_CLASS);break;case"underline":w.classList.add(t.CURSOR_STYLE_UNDERLINE_CLASS);break;default:w.classList.add(t.CURSOR_STYLE_BLOCK_CLASS)}S.isBold()&&w.classList.add(t.BOLD_CLASS),S.isItalic()&&w.classList.add(t.ITALIC_CLASS),S.isDim()&&w.classList.add(t.DIM_CLASS),S.isUnderline()&&w.classList.add(t.UNDERLINE_CLASS),S.isInvisible()?w.textContent=s.WHITESPACE_CELL_CHAR:w.textContent=S.getChars()||s.WHITESPACE_CELL_CHAR,S.isStrikethrough()&&w.classList.add(t.STRIKETHROUGH_CLASS);var L=S.getFgColor(),E=S.getFgColorMode(),x=S.getBgColor(),A=S.getBgColorMode(),k=!!S.isInverse();if(k){var M=L;L=x,x=M;var R=E;E=A,A=R}switch(E){case 16777216:case 33554432:S.isBold()&&L<8&&this._optionsService.options.drawBoldTextInBrightColors&&(L+=8),this._applyMinimumContrast(w,this._colors.background,this._colors.ansi[L])||w.classList.add("xterm-fg-"+L);break;case 50331648:var T=l.rgba.toColor(L>>16&255,L>>8&255,255&L);this._applyMinimumContrast(w,this._colors.background,T)||this._addStyle(w,"color:#"+_(L.toString(16),"0",6));break;default:this._applyMinimumContrast(w,this._colors.background,this._colors.foreground)||k&&w.classList.add("xterm-fg-"+o.INVERTED_DEFAULT_COLOR)}switch(A){case 16777216:case 33554432:w.classList.add("xterm-bg-"+x);break;case 50331648:this._addStyle(w,"background-color:#"+_(x.toString(16),"0",6));break;default:k&&w.classList.add("xterm-bg-"+o.INVERTED_DEFAULT_COLOR)}d.appendChild(w),g=b}}return d},e.prototype._applyMinimumContrast=function(e,t,r){if(1===this._optionsService.options.minimumContrastRatio)return!1;var i=this._colors.contrastCache.getColor(this._workCell.bg,this._workCell.fg);return void 0===i&&(i=l.color.ensureContrastRatio(t,r,this._optionsService.options.minimumContrastRatio),this._colors.contrastCache.setColor(this._workCell.bg,this._workCell.fg,null!=i?i:null)),!!i&&(this._addStyle(e,"color:"+i.css),!0)},e.prototype._addStyle=function(e,t){e.setAttribute("style",""+(e.getAttribute("style")||"")+t+";")},i([n(2,u.ICharacterJoinerService),n(3,c.IOptionsService),n(4,c.ICoreService)],e)}();function _(e,t,r){for(;e.length<r;)e=t+e;return e}t.DomRendererRowFactory=f},456:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.SelectionModel=void 0;var r=function(){function e(e){this._bufferService=e,this.isSelectAllActive=!1,this.selectionStartLength=0}return e.prototype.clearSelection=function(){this.selectionStart=void 0,this.selectionEnd=void 0,this.isSelectAllActive=!1,this.selectionStartLength=0},Object.defineProperty(e.prototype,"finalSelectionStart",{get:function(){return this.isSelectAllActive?[0,0]:this.selectionEnd&&this.selectionStart&&this.areSelectionValuesReversed()?this.selectionEnd:this.selectionStart},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"finalSelectionEnd",{get:function(){if(this.isSelectAllActive)return[this._bufferService.cols,this._bufferService.buffer.ybase+this._bufferService.rows-1];if(this.selectionStart){if(!this.selectionEnd||this.areSelectionValuesReversed()){var e=this.selectionStart[0]+this.selectionStartLength;return e>this._bufferService.cols?e%this._bufferService.cols==0?[this._bufferService.cols,this.selectionStart[1]+Math.floor(e/this._bufferService.cols)-1]:[e%this._bufferService.cols,this.selectionStart[1]+Math.floor(e/this._bufferService.cols)]:[e,this.selectionStart[1]]}return this.selectionStartLength&&this.selectionEnd[1]===this.selectionStart[1]?[Math.max(this.selectionStart[0]+this.selectionStartLength,this.selectionEnd[0]),this.selectionEnd[1]]:this.selectionEnd}},enumerable:!1,configurable:!0}),e.prototype.areSelectionValuesReversed=function(){var e=this.selectionStart,t=this.selectionEnd;return!(!e||!t)&&(e[1]>t[1]||e[1]===t[1]&&e[0]>t[0])},e.prototype.onTrim=function(e){return this.selectionStart&&(this.selectionStart[1]-=e),this.selectionEnd&&(this.selectionEnd[1]-=e),this.selectionEnd&&this.selectionEnd[1]<0?(this.clearSelection(),!0):(this.selectionStart&&this.selectionStart[1]<0&&(this.selectionStart[1]=0),!1)},e}();t.SelectionModel=r},428:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.CharSizeService=void 0;var o=r(2585),s=r(8460),a=function(){function e(e,t,r){this._optionsService=r,this.width=0,this.height=0,this._onCharSizeChange=new s.EventEmitter,this._measureStrategy=new c(e,t,this._optionsService)}return Object.defineProperty(e.prototype,"hasValidSize",{get:function(){return this.width>0&&this.height>0},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onCharSizeChange",{get:function(){return this._onCharSizeChange.event},enumerable:!1,configurable:!0}),e.prototype.measure=function(){var e=this._measureStrategy.measure();e.width===this.width&&e.height===this.height||(this.width=e.width,this.height=e.height,this._onCharSizeChange.fire())},i([n(2,o.IOptionsService)],e)}();t.CharSizeService=a;var c=function(){function e(e,t,r){this._document=e,this._parentElement=t,this._optionsService=r,this._result={width:0,height:0},this._measureElement=this._document.createElement("span"),this._measureElement.classList.add("xterm-char-measure-element"),this._measureElement.textContent="W",this._measureElement.setAttribute("aria-hidden","true"),this._parentElement.appendChild(this._measureElement)}return e.prototype.measure=function(){this._measureElement.style.fontFamily=this._optionsService.options.fontFamily,this._measureElement.style.fontSize=this._optionsService.options.fontSize+"px";var e=this._measureElement.getBoundingClientRect();return 0!==e.width&&0!==e.height&&(this._result.width=e.width,this._result.height=Math.ceil(e.height)),this._result},e}()},4269:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.CharacterJoinerService=t.JoinedCellData=void 0;var a=r(3734),c=r(643),l=r(511),u=r(2585),h=function(e){function t(t,r,i){var n=e.call(this)||this;return n.content=0,n.combinedData="",n.fg=t.fg,n.bg=t.bg,n.combinedData=r,n._width=i,n}return n(t,e),t.prototype.isCombined=function(){return 2097152},t.prototype.getWidth=function(){return this._width},t.prototype.getChars=function(){return this.combinedData},t.prototype.getCode=function(){return 2097151},t.prototype.setFromCharData=function(e){throw new Error("not implemented")},t.prototype.getAsCharData=function(){return[this.fg,this.getChars(),this.getWidth(),this.getCode()]},t}(a.AttributeData);t.JoinedCellData=h;var f=function(){function e(e){this._bufferService=e,this._characterJoiners=[],this._nextCharacterJoinerId=0,this._workCell=new l.CellData}return e.prototype.register=function(e){var t={id:this._nextCharacterJoinerId++,handler:e};return this._characterJoiners.push(t),t.id},e.prototype.deregister=function(e){for(var t=0;t<this._characterJoiners.length;t++)if(this._characterJoiners[t].id===e)return this._characterJoiners.splice(t,1),!0;return!1},e.prototype.getJoinedCharacters=function(e){if(0===this._characterJoiners.length)return[];var t=this._bufferService.buffer.lines.get(e);if(!t||0===t.length)return[];for(var r=[],i=t.translateToString(!0),n=0,o=0,s=0,a=t.getFg(0),l=t.getBg(0),u=0;u<t.getTrimmedLength();u++)if(t.loadCell(u,this._workCell),0!==this._workCell.getWidth()){if(this._workCell.fg!==a||this._workCell.bg!==l){if(u-n>1)for(var h=this._getJoinedRanges(i,s,o,t,n),f=0;f<h.length;f++)r.push(h[f]);n=u,s=o,a=this._workCell.fg,l=this._workCell.bg}o+=this._workCell.getChars().length||c.WHITESPACE_CELL_CHAR.length}if(this._bufferService.cols-n>1)for(h=this._getJoinedRanges(i,s,o,t,n),f=0;f<h.length;f++)r.push(h[f]);return r},e.prototype._getJoinedRanges=function(t,r,i,n,o){var s=t.substring(r,i),a=[];try{a=this._characterJoiners[0].handler(s)}catch(e){console.error(e)}for(var c=1;c<this._characterJoiners.length;c++)try{for(var l=this._characterJoiners[c].handler(s),u=0;u<l.length;u++)e._mergeRanges(a,l[u])}catch(e){console.error(e)}return this._stringRangesToCellRanges(a,n,o),a},e.prototype._stringRangesToCellRanges=function(e,t,r){var i=0,n=!1,o=0,s=e[i];if(s){for(var a=r;a<this._bufferService.cols;a++){var l=t.getWidth(a),u=t.getString(a).length||c.WHITESPACE_CELL_CHAR.length;if(0!==l){if(!n&&s[0]<=o&&(s[0]=a,n=!0),s[1]<=o){if(s[1]=a,!(s=e[++i]))break;s[0]<=o?(s[0]=a,n=!0):n=!1}o+=u}}s&&(s[1]=this._bufferService.cols)}},e._mergeRanges=function(e,t){for(var r=!1,i=0;i<e.length;i++){var n=e[i];if(r){if(t[1]<=n[0])return e[i-1][1]=t[1],e;if(t[1]<=n[1])return e[i-1][1]=Math.max(t[1],n[1]),e.splice(i,1),e;e.splice(i,1),i--}else{if(t[1]<=n[0])return e.splice(i,0,t),e;if(t[1]<=n[1])return n[0]=Math.min(t[0],n[0]),e;t[0]<n[1]&&(n[0]=Math.min(t[0],n[0]),r=!0)}}return r?e[e.length-1][1]=t[1]:e.push(t),e},e=o([s(0,u.IBufferService)],e)}();t.CharacterJoinerService=f},5114:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.CoreBrowserService=void 0;var r=function(){function e(e){this._textarea=e}return Object.defineProperty(e.prototype,"isFocused",{get:function(){return(this._textarea.getRootNode?this._textarea.getRootNode():document).activeElement===this._textarea&&document.hasFocus()},enumerable:!1,configurable:!0}),e}();t.CoreBrowserService=r},8934:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.MouseService=void 0;var o=r(4725),s=r(9806),a=function(){function e(e,t){this._renderService=e,this._charSizeService=t}return e.prototype.getCoords=function(e,t,r,i,n){return(0,s.getCoords)(e,t,r,i,this._charSizeService.hasValidSize,this._renderService.dimensions.actualCellWidth,this._renderService.dimensions.actualCellHeight,n)},e.prototype.getRawByteCoords=function(e,t,r,i){var n=this.getCoords(e,t,r,i);return(0,s.getRawByteCoords)(n)},i([n(0,o.IRenderService),n(1,o.ICharSizeService)],e)}();t.MouseService=a},3230:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.RenderService=void 0;var a=r(6193),c=r(8460),l=r(844),u=r(5596),h=r(3656),f=r(2585),_=r(4725),d=function(e){function t(t,r,i,n,o,s){var l=e.call(this)||this;if(l._renderer=t,l._rowCount=r,l._charSizeService=o,l._isPaused=!1,l._needsFullRefresh=!1,l._isNextRenderRedrawOnly=!0,l._needsSelectionRefresh=!1,l._canvasWidth=0,l._canvasHeight=0,l._selectionState={start:void 0,end:void 0,columnSelectMode:!1},l._onDimensionsChange=new c.EventEmitter,l._onRender=new c.EventEmitter,l._onRefreshRequest=new c.EventEmitter,l.register({dispose:function(){return l._renderer.dispose()}}),l._renderDebouncer=new a.RenderDebouncer((function(e,t){return l._renderRows(e,t)})),l.register(l._renderDebouncer),l._screenDprMonitor=new u.ScreenDprMonitor,l._screenDprMonitor.setListener((function(){return l.onDevicePixelRatioChange()})),l.register(l._screenDprMonitor),l.register(s.onResize((function(e){return l._fullRefresh()}))),l.register(n.onOptionChange((function(){return l._renderer.onOptionsChanged()}))),l.register(l._charSizeService.onCharSizeChange((function(){return l.onCharSizeChanged()}))),l._renderer.onRequestRedraw((function(e){return l.refreshRows(e.start,e.end,!0)})),l.register((0,h.addDisposableDomListener)(window,"resize",(function(){return l.onDevicePixelRatioChange()}))),"IntersectionObserver"in window){var f=new IntersectionObserver((function(e){return l._onIntersectionChange(e[e.length-1])}),{threshold:0});f.observe(i),l.register({dispose:function(){return f.disconnect()}})}return l}return n(t,e),Object.defineProperty(t.prototype,"onDimensionsChange",{get:function(){return this._onDimensionsChange.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRenderedBufferChange",{get:function(){return this._onRender.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRefreshRequest",{get:function(){return this._onRefreshRequest.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"dimensions",{get:function(){return this._renderer.dimensions},enumerable:!1,configurable:!0}),t.prototype._onIntersectionChange=function(e){this._isPaused=void 0===e.isIntersecting?0===e.intersectionRatio:!e.isIntersecting,this._isPaused||this._charSizeService.hasValidSize||this._charSizeService.measure(),!this._isPaused&&this._needsFullRefresh&&(this.refreshRows(0,this._rowCount-1),this._needsFullRefresh=!1)},t.prototype.refreshRows=function(e,t,r){void 0===r&&(r=!1),this._isPaused?this._needsFullRefresh=!0:(r||(this._isNextRenderRedrawOnly=!1),this._renderDebouncer.refresh(e,t,this._rowCount))},t.prototype._renderRows=function(e,t){this._renderer.renderRows(e,t),this._needsSelectionRefresh&&(this._renderer.onSelectionChanged(this._selectionState.start,this._selectionState.end,this._selectionState.columnSelectMode),this._needsSelectionRefresh=!1),this._isNextRenderRedrawOnly||this._onRender.fire({start:e,end:t}),this._isNextRenderRedrawOnly=!0},t.prototype.resize=function(e,t){this._rowCount=t,this._fireOnCanvasResize()},t.prototype.changeOptions=function(){this._renderer.onOptionsChanged(),this.refreshRows(0,this._rowCount-1),this._fireOnCanvasResize()},t.prototype._fireOnCanvasResize=function(){this._renderer.dimensions.canvasWidth===this._canvasWidth&&this._renderer.dimensions.canvasHeight===this._canvasHeight||this._onDimensionsChange.fire(this._renderer.dimensions)},t.prototype.dispose=function(){e.prototype.dispose.call(this)},t.prototype.setRenderer=function(e){var t=this;this._renderer.dispose(),this._renderer=e,this._renderer.onRequestRedraw((function(e){return t.refreshRows(e.start,e.end,!0)})),this._needsSelectionRefresh=!0,this._fullRefresh()},t.prototype._fullRefresh=function(){this._isPaused?this._needsFullRefresh=!0:this.refreshRows(0,this._rowCount-1)},t.prototype.clearTextureAtlas=function(){var e,t;null===(t=null===(e=this._renderer)||void 0===e?void 0:e.clearTextureAtlas)||void 0===t||t.call(e),this._fullRefresh()},t.prototype.setColors=function(e){this._renderer.setColors(e),this._fullRefresh()},t.prototype.onDevicePixelRatioChange=function(){this._charSizeService.measure(),this._renderer.onDevicePixelRatioChange(),this.refreshRows(0,this._rowCount-1)},t.prototype.onResize=function(e,t){this._renderer.onResize(e,t),this._fullRefresh()},t.prototype.onCharSizeChanged=function(){this._renderer.onCharSizeChanged()},t.prototype.onBlur=function(){this._renderer.onBlur()},t.prototype.onFocus=function(){this._renderer.onFocus()},t.prototype.onSelectionChanged=function(e,t,r){this._selectionState.start=e,this._selectionState.end=t,this._selectionState.columnSelectMode=r,this._renderer.onSelectionChanged(e,t,r)},t.prototype.onCursorMove=function(){this._renderer.onCursorMove()},t.prototype.clear=function(){this._renderer.clear()},o([s(3,f.IOptionsService),s(4,_.ICharSizeService),s(5,f.IBufferService)],t)}(l.Disposable);t.RenderService=d},9312:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.SelectionService=void 0;var a=r(6114),c=r(456),l=r(511),u=r(8460),h=r(4725),f=r(2585),_=r(9806),d=r(9504),p=r(844),v=r(4841),g=String.fromCharCode(160),y=new RegExp(g,"g"),m=function(e){function t(t,r,i,n,o,s,a,h){var f=e.call(this)||this;return f._element=t,f._screenElement=r,f._linkifier=i,f._bufferService=n,f._coreService=o,f._mouseService=s,f._optionsService=a,f._renderService=h,f._dragScrollAmount=0,f._enabled=!0,f._workCell=new l.CellData,f._mouseDownTimeStamp=0,f._oldHasSelection=!1,f._oldSelectionStart=void 0,f._oldSelectionEnd=void 0,f._onLinuxMouseSelection=f.register(new u.EventEmitter),f._onRedrawRequest=f.register(new u.EventEmitter),f._onSelectionChange=f.register(new u.EventEmitter),f._onRequestScrollLines=f.register(new u.EventEmitter),f._mouseMoveListener=function(e){return f._onMouseMove(e)},f._mouseUpListener=function(e){return f._onMouseUp(e)},f._coreService.onUserInput((function(){f.hasSelection&&f.clearSelection()})),f._trimListener=f._bufferService.buffer.lines.onTrim((function(e){return f._onTrim(e)})),f.register(f._bufferService.buffers.onBufferActivate((function(e){return f._onBufferActivate(e)}))),f.enable(),f._model=new c.SelectionModel(f._bufferService),f._activeSelectionMode=0,f}return n(t,e),Object.defineProperty(t.prototype,"onLinuxMouseSelection",{get:function(){return this._onLinuxMouseSelection.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRequestRedraw",{get:function(){return this._onRedrawRequest.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onSelectionChange",{get:function(){return this._onSelectionChange.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRequestScrollLines",{get:function(){return this._onRequestScrollLines.event},enumerable:!1,configurable:!0}),t.prototype.dispose=function(){this._removeMouseDownListeners()},t.prototype.reset=function(){this.clearSelection()},t.prototype.disable=function(){this.clearSelection(),this._enabled=!1},t.prototype.enable=function(){this._enabled=!0},Object.defineProperty(t.prototype,"selectionStart",{get:function(){return this._model.finalSelectionStart},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"selectionEnd",{get:function(){return this._model.finalSelectionEnd},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"hasSelection",{get:function(){var e=this._model.finalSelectionStart,t=this._model.finalSelectionEnd;return!(!e||!t||e[0]===t[0]&&e[1]===t[1])},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"selectionText",{get:function(){var e=this._model.finalSelectionStart,t=this._model.finalSelectionEnd;if(!e||!t)return"";var r=this._bufferService.buffer,i=[];if(3===this._activeSelectionMode){if(e[0]===t[0])return"";for(var n=e[1];n<=t[1];n++){var o=r.translateBufferLineToString(n,!0,e[0],t[0]);i.push(o)}}else{var s=e[1]===t[1]?t[0]:void 0;for(i.push(r.translateBufferLineToString(e[1],!0,e[0],s)),n=e[1]+1;n<=t[1]-1;n++){var c=r.lines.get(n);o=r.translateBufferLineToString(n,!0),(null==c?void 0:c.isWrapped)?i[i.length-1]+=o:i.push(o)}e[1]!==t[1]&&(c=r.lines.get(t[1]),o=r.translateBufferLineToString(t[1],!0,0,t[0]),c&&c.isWrapped?i[i.length-1]+=o:i.push(o))}return i.map((function(e){return e.replace(y," ")})).join(a.isWindows?"\r\n":"\n")},enumerable:!1,configurable:!0}),t.prototype.clearSelection=function(){this._model.clearSelection(),this._removeMouseDownListeners(),this.refresh(),this._onSelectionChange.fire()},t.prototype.refresh=function(e){var t=this;this._refreshAnimationFrame||(this._refreshAnimationFrame=window.requestAnimationFrame((function(){return t._refresh()}))),a.isLinux&&e&&this.selectionText.length&&this._onLinuxMouseSelection.fire(this.selectionText)},t.prototype._refresh=function(){this._refreshAnimationFrame=void 0,this._onRedrawRequest.fire({start:this._model.finalSelectionStart,end:this._model.finalSelectionEnd,columnSelectMode:3===this._activeSelectionMode})},t.prototype._isClickInSelection=function(e){var t=this._getMouseBufferCoords(e),r=this._model.finalSelectionStart,i=this._model.finalSelectionEnd;return!!(r&&i&&t)&&this._areCoordsInSelection(t,r,i)},t.prototype._areCoordsInSelection=function(e,t,r){return e[1]>t[1]&&e[1]<r[1]||t[1]===r[1]&&e[1]===t[1]&&e[0]>=t[0]&&e[0]<r[0]||t[1]<r[1]&&e[1]===r[1]&&e[0]<r[0]||t[1]<r[1]&&e[1]===t[1]&&e[0]>=t[0]},t.prototype._selectWordAtCursor=function(e,t){var r,i,n=null===(i=null===(r=this._linkifier.currentLink)||void 0===r?void 0:r.link)||void 0===i?void 0:i.range;if(n)return this._model.selectionStart=[n.start.x-1,n.start.y-1],this._model.selectionStartLength=(0,v.getRangeLength)(n,this._bufferService.cols),this._model.selectionEnd=void 0,!0;var o=this._getMouseBufferCoords(e);return!!o&&(this._selectWordAt(o,t),this._model.selectionEnd=void 0,!0)},t.prototype.selectAll=function(){this._model.isSelectAllActive=!0,this.refresh(),this._onSelectionChange.fire()},t.prototype.selectLines=function(e,t){this._model.clearSelection(),e=Math.max(e,0),t=Math.min(t,this._bufferService.buffer.lines.length-1),this._model.selectionStart=[0,e],this._model.selectionEnd=[this._bufferService.cols,t],this.refresh(),this._onSelectionChange.fire()},t.prototype._onTrim=function(e){this._model.onTrim(e)&&this.refresh()},t.prototype._getMouseBufferCoords=function(e){var t=this._mouseService.getCoords(e,this._screenElement,this._bufferService.cols,this._bufferService.rows,!0);if(t)return t[0]--,t[1]--,t[1]+=this._bufferService.buffer.ydisp,t},t.prototype._getMouseEventScrollAmount=function(e){var t=(0,_.getCoordsRelativeToElement)(e,this._screenElement)[1],r=this._renderService.dimensions.canvasHeight;return t>=0&&t<=r?0:(t>r&&(t-=r),t=Math.min(Math.max(t,-50),50),(t/=50)/Math.abs(t)+Math.round(14*t))},t.prototype.shouldForceSelection=function(e){return a.isMac?e.altKey&&this._optionsService.options.macOptionClickForcesSelection:e.shiftKey},t.prototype.onMouseDown=function(e){if(this._mouseDownTimeStamp=e.timeStamp,(2!==e.button||!this.hasSelection)&&0===e.button){if(!this._enabled){if(!this.shouldForceSelection(e))return;e.stopPropagation()}e.preventDefault(),this._dragScrollAmount=0,this._enabled&&e.shiftKey?this._onIncrementalClick(e):1===e.detail?this._onSingleClick(e):2===e.detail?this._onDoubleClick(e):3===e.detail&&this._onTripleClick(e),this._addMouseDownListeners(),this.refresh(!0)}},t.prototype._addMouseDownListeners=function(){var e=this;this._screenElement.ownerDocument&&(this._screenElement.ownerDocument.addEventListener("mousemove",this._mouseMoveListener),this._screenElement.ownerDocument.addEventListener("mouseup",this._mouseUpListener)),this._dragScrollIntervalTimer=window.setInterval((function(){return e._dragScroll()}),50)},t.prototype._removeMouseDownListeners=function(){this._screenElement.ownerDocument&&(this._screenElement.ownerDocument.removeEventListener("mousemove",this._mouseMoveListener),this._screenElement.ownerDocument.removeEventListener("mouseup",this._mouseUpListener)),clearInterval(this._dragScrollIntervalTimer),this._dragScrollIntervalTimer=void 0},t.prototype._onIncrementalClick=function(e){this._model.selectionStart&&(this._model.selectionEnd=this._getMouseBufferCoords(e))},t.prototype._onSingleClick=function(e){if(this._model.selectionStartLength=0,this._model.isSelectAllActive=!1,this._activeSelectionMode=this.shouldColumnSelect(e)?3:0,this._model.selectionStart=this._getMouseBufferCoords(e),this._model.selectionStart){this._model.selectionEnd=void 0;var t=this._bufferService.buffer.lines.get(this._model.selectionStart[1]);t&&t.length!==this._model.selectionStart[0]&&0===t.hasWidth(this._model.selectionStart[0])&&this._model.selectionStart[0]++}},t.prototype._onDoubleClick=function(e){this._selectWordAtCursor(e,!0)&&(this._activeSelectionMode=1)},t.prototype._onTripleClick=function(e){var t=this._getMouseBufferCoords(e);t&&(this._activeSelectionMode=2,this._selectLineAt(t[1]))},t.prototype.shouldColumnSelect=function(e){return e.altKey&&!(a.isMac&&this._optionsService.options.macOptionClickForcesSelection)},t.prototype._onMouseMove=function(e){if(e.stopImmediatePropagation(),this._model.selectionStart){var t=this._model.selectionEnd?[this._model.selectionEnd[0],this._model.selectionEnd[1]]:null;if(this._model.selectionEnd=this._getMouseBufferCoords(e),this._model.selectionEnd){2===this._activeSelectionMode?this._model.selectionEnd[1]<this._model.selectionStart[1]?this._model.selectionEnd[0]=0:this._model.selectionEnd[0]=this._bufferService.cols:1===this._activeSelectionMode&&this._selectToWordAt(this._model.selectionEnd),this._dragScrollAmount=this._getMouseEventScrollAmount(e),3!==this._activeSelectionMode&&(this._dragScrollAmount>0?this._model.selectionEnd[0]=this._bufferService.cols:this._dragScrollAmount<0&&(this._model.selectionEnd[0]=0));var r=this._bufferService.buffer;if(this._model.selectionEnd[1]<r.lines.length){var i=r.lines.get(this._model.selectionEnd[1]);i&&0===i.hasWidth(this._model.selectionEnd[0])&&this._model.selectionEnd[0]++}t&&t[0]===this._model.selectionEnd[0]&&t[1]===this._model.selectionEnd[1]||this.refresh(!0)}else this.refresh(!0)}},t.prototype._dragScroll=function(){if(this._model.selectionEnd&&this._model.selectionStart&&this._dragScrollAmount){this._onRequestScrollLines.fire({amount:this._dragScrollAmount,suppressScrollEvent:!1});var e=this._bufferService.buffer;this._dragScrollAmount>0?(3!==this._activeSelectionMode&&(this._model.selectionEnd[0]=this._bufferService.cols),this._model.selectionEnd[1]=Math.min(e.ydisp+this._bufferService.rows,e.lines.length-1)):(3!==this._activeSelectionMode&&(this._model.selectionEnd[0]=0),this._model.selectionEnd[1]=e.ydisp),this.refresh()}},t.prototype._onMouseUp=function(e){var t=e.timeStamp-this._mouseDownTimeStamp;if(this._removeMouseDownListeners(),this.selectionText.length<=1&&t<500&&e.altKey&&this._optionsService.getOption("altClickMovesCursor")){if(this._bufferService.buffer.ybase===this._bufferService.buffer.ydisp){var r=this._mouseService.getCoords(e,this._element,this._bufferService.cols,this._bufferService.rows,!1);if(r&&void 0!==r[0]&&void 0!==r[1]){var i=(0,d.moveToCellSequence)(r[0]-1,r[1]-1,this._bufferService,this._coreService.decPrivateModes.applicationCursorKeys);this._coreService.triggerDataEvent(i,!0)}}}else this._fireEventIfSelectionChanged()},t.prototype._fireEventIfSelectionChanged=function(){var e=this._model.finalSelectionStart,t=this._model.finalSelectionEnd,r=!(!e||!t||e[0]===t[0]&&e[1]===t[1]);r?e&&t&&(this._oldSelectionStart&&this._oldSelectionEnd&&e[0]===this._oldSelectionStart[0]&&e[1]===this._oldSelectionStart[1]&&t[0]===this._oldSelectionEnd[0]&&t[1]===this._oldSelectionEnd[1]||this._fireOnSelectionChange(e,t,r)):this._oldHasSelection&&this._fireOnSelectionChange(e,t,r)},t.prototype._fireOnSelectionChange=function(e,t,r){this._oldSelectionStart=e,this._oldSelectionEnd=t,this._oldHasSelection=r,this._onSelectionChange.fire()},t.prototype._onBufferActivate=function(e){var t=this;this.clearSelection(),this._trimListener.dispose(),this._trimListener=e.activeBuffer.lines.onTrim((function(e){return t._onTrim(e)}))},t.prototype._convertViewportColToCharacterIndex=function(e,t){for(var r=t[0],i=0;t[0]>=i;i++){var n=e.loadCell(i,this._workCell).getChars().length;0===this._workCell.getWidth()?r--:n>1&&t[0]!==i&&(r+=n-1)}return r},t.prototype.setSelection=function(e,t,r){this._model.clearSelection(),this._removeMouseDownListeners(),this._model.selectionStart=[e,t],this._model.selectionStartLength=r,this.refresh()},t.prototype.rightClickSelect=function(e){this._isClickInSelection(e)||(this._selectWordAtCursor(e,!1)&&this.refresh(!0),this._fireEventIfSelectionChanged())},t.prototype._getWordAt=function(e,t,r,i){if(void 0===r&&(r=!0),void 0===i&&(i=!0),!(e[0]>=this._bufferService.cols)){var n=this._bufferService.buffer,o=n.lines.get(e[1]);if(o){var s=n.translateBufferLineToString(e[1],!1),a=this._convertViewportColToCharacterIndex(o,e),c=a,l=e[0]-a,u=0,h=0,f=0,_=0;if(" "===s.charAt(a)){for(;a>0&&" "===s.charAt(a-1);)a--;for(;c<s.length&&" "===s.charAt(c+1);)c++}else{var d=e[0],p=e[0];0===o.getWidth(d)&&(u++,d--),2===o.getWidth(p)&&(h++,p++);var v=o.getString(p).length;for(v>1&&(_+=v-1,c+=v-1);d>0&&a>0&&!this._isCharWordSeparator(o.loadCell(d-1,this._workCell));){o.loadCell(d-1,this._workCell);var g=this._workCell.getChars().length;0===this._workCell.getWidth()?(u++,d--):g>1&&(f+=g-1,a-=g-1),a--,d--}for(;p<o.length&&c+1<s.length&&!this._isCharWordSeparator(o.loadCell(p+1,this._workCell));){o.loadCell(p+1,this._workCell);var y=this._workCell.getChars().length;2===this._workCell.getWidth()?(h++,p++):y>1&&(_+=y-1,c+=y-1),c++,p++}}c++;var m=a+l-u+f,b=Math.min(this._bufferService.cols,c-a+u+h-f-_);if(t||""!==s.slice(a,c).trim()){if(r&&0===m&&32!==o.getCodePoint(0)){var S=n.lines.get(e[1]-1);if(S&&o.isWrapped&&32!==S.getCodePoint(this._bufferService.cols-1)){var C=this._getWordAt([this._bufferService.cols-1,e[1]-1],!1,!0,!1);if(C){var w=this._bufferService.cols-C.start;m-=w,b+=w}}}if(i&&m+b===this._bufferService.cols&&32!==o.getCodePoint(this._bufferService.cols-1)){var L=n.lines.get(e[1]+1);if((null==L?void 0:L.isWrapped)&&32!==L.getCodePoint(0)){var E=this._getWordAt([0,e[1]+1],!1,!1,!0);E&&(b+=E.length)}}return{start:m,length:b}}}}},t.prototype._selectWordAt=function(e,t){var r=this._getWordAt(e,t);if(r){for(;r.start<0;)r.start+=this._bufferService.cols,e[1]--;this._model.selectionStart=[r.start,e[1]],this._model.selectionStartLength=r.length}},t.prototype._selectToWordAt=function(e){var t=this._getWordAt(e,!0);if(t){for(var r=e[1];t.start<0;)t.start+=this._bufferService.cols,r--;if(!this._model.areSelectionValuesReversed())for(;t.start+t.length>this._bufferService.cols;)t.length-=this._bufferService.cols,r++;this._model.selectionEnd=[this._model.areSelectionValuesReversed()?t.start:t.start+t.length,r]}},t.prototype._isCharWordSeparator=function(e){return 0!==e.getWidth()&&this._optionsService.options.wordSeparator.indexOf(e.getChars())>=0},t.prototype._selectLineAt=function(e){var t=this._bufferService.buffer.getWrappedRangeForLine(e);this._model.selectionStart=[0,t.first],this._model.selectionEnd=[this._bufferService.cols,t.last],this._model.selectionStartLength=0},o([s(3,f.IBufferService),s(4,f.ICoreService),s(5,h.IMouseService),s(6,f.IOptionsService),s(7,h.IRenderService)],t)}(p.Disposable);t.SelectionService=m},4725:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.ICharacterJoinerService=t.ISoundService=t.ISelectionService=t.IRenderService=t.IMouseService=t.ICoreBrowserService=t.ICharSizeService=void 0;var i=r(8343);t.ICharSizeService=(0,i.createDecorator)("CharSizeService"),t.ICoreBrowserService=(0,i.createDecorator)("CoreBrowserService"),t.IMouseService=(0,i.createDecorator)("MouseService"),t.IRenderService=(0,i.createDecorator)("RenderService"),t.ISelectionService=(0,i.createDecorator)("SelectionService"),t.ISoundService=(0,i.createDecorator)("SoundService"),t.ICharacterJoinerService=(0,i.createDecorator)("CharacterJoinerService")},357:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.SoundService=void 0;var o=r(2585),s=function(){function e(e){this._optionsService=e}return Object.defineProperty(e,"audioContext",{get:function(){if(!e._audioContext){var t=window.AudioContext||window.webkitAudioContext;if(!t)return console.warn("Web Audio API is not supported by this browser. Consider upgrading to the latest version"),null;e._audioContext=new t}return e._audioContext},enumerable:!1,configurable:!0}),e.prototype.playBellSound=function(){var t=e.audioContext;if(t){var r=t.createBufferSource();t.decodeAudioData(this._base64ToArrayBuffer(this._removeMimeType(this._optionsService.options.bellSound)),(function(e){r.buffer=e,r.connect(t.destination),r.start(0)}))}},e.prototype._base64ToArrayBuffer=function(e){for(var t=window.atob(e),r=t.length,i=new Uint8Array(r),n=0;n<r;n++)i[n]=t.charCodeAt(n);return i.buffer},e.prototype._removeMimeType=function(e){return e.split(",")[1]},e=i([n(0,o.IOptionsService)],e)}();t.SoundService=s},6349:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.CircularList=void 0;var i=r(8460),n=function(){function e(e){this._maxLength=e,this.onDeleteEmitter=new i.EventEmitter,this.onInsertEmitter=new i.EventEmitter,this.onTrimEmitter=new i.EventEmitter,this._array=new Array(this._maxLength),this._startIndex=0,this._length=0}return Object.defineProperty(e.prototype,"onDelete",{get:function(){return this.onDeleteEmitter.event},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onInsert",{get:function(){return this.onInsertEmitter.event},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onTrim",{get:function(){return this.onTrimEmitter.event},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"maxLength",{get:function(){return this._maxLength},set:function(e){if(this._maxLength!==e){for(var t=new Array(e),r=0;r<Math.min(e,this.length);r++)t[r]=this._array[this._getCyclicIndex(r)];this._array=t,this._maxLength=e,this._startIndex=0}},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"length",{get:function(){return this._length},set:function(e){if(e>this._length)for(var t=this._length;t<e;t++)this._array[t]=void 0;this._length=e},enumerable:!1,configurable:!0}),e.prototype.get=function(e){return this._array[this._getCyclicIndex(e)]},e.prototype.set=function(e,t){this._array[this._getCyclicIndex(e)]=t},e.prototype.push=function(e){this._array[this._getCyclicIndex(this._length)]=e,this._length===this._maxLength?(this._startIndex=++this._startIndex%this._maxLength,this.onTrimEmitter.fire(1)):this._length++},e.prototype.recycle=function(){if(this._length!==this._maxLength)throw new Error("Can only recycle when the buffer is full");return this._startIndex=++this._startIndex%this._maxLength,this.onTrimEmitter.fire(1),this._array[this._getCyclicIndex(this._length-1)]},Object.defineProperty(e.prototype,"isFull",{get:function(){return this._length===this._maxLength},enumerable:!1,configurable:!0}),e.prototype.pop=function(){return this._array[this._getCyclicIndex(this._length---1)]},e.prototype.splice=function(e,t){for(var r=[],i=2;i<arguments.length;i++)r[i-2]=arguments[i];if(t){for(var n=e;n<this._length-t;n++)this._array[this._getCyclicIndex(n)]=this._array[this._getCyclicIndex(n+t)];this._length-=t,this.onDeleteEmitter.fire({index:e,amount:t})}for(n=this._length-1;n>=e;n--)this._array[this._getCyclicIndex(n+r.length)]=this._array[this._getCyclicIndex(n)];for(n=0;n<r.length;n++)this._array[this._getCyclicIndex(e+n)]=r[n];if(r.length&&this.onInsertEmitter.fire({index:e,amount:r.length}),this._length+r.length>this._maxLength){var o=this._length+r.length-this._maxLength;this._startIndex+=o,this._length=this._maxLength,this.onTrimEmitter.fire(o)}else this._length+=r.length},e.prototype.trimStart=function(e){e>this._length&&(e=this._length),this._startIndex+=e,this._length-=e,this.onTrimEmitter.fire(e)},e.prototype.shiftElements=function(e,t,r){if(!(t<=0)){if(e<0||e>=this._length)throw new Error("start argument out of range");if(e+r<0)throw new Error("Cannot shift elements in list beyond index 0");if(r>0){for(var i=t-1;i>=0;i--)this.set(e+i+r,this.get(e+i));var n=e+t+r-this._length;if(n>0)for(this._length+=n;this._length>this._maxLength;)this._length--,this._startIndex++,this.onTrimEmitter.fire(1)}else for(i=0;i<t;i++)this.set(e+i+r,this.get(e+i))}},e.prototype._getCyclicIndex=function(e){return(this._startIndex+e)%this._maxLength},e}();t.CircularList=n},1439:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.clone=void 0,t.clone=function e(t,r){if(void 0===r&&(r=5),"object"!=typeof t)return t;var i=Array.isArray(t)?[]:{};for(var n in t)i[n]=r<=1?t[n]:t[n]&&e(t[n],r-1);return i}},8969:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.CoreTerminal=void 0;var o=r(844),s=r(2585),a=r(4348),c=r(7866),l=r(744),u=r(7302),h=r(6975),f=r(8460),_=r(1753),d=r(3730),p=r(1480),v=r(7994),g=r(9282),y=r(5435),m=r(5981),b=!1,S=function(e){function t(t){var r=e.call(this)||this;return r._onBinary=new f.EventEmitter,r._onData=new f.EventEmitter,r._onLineFeed=new f.EventEmitter,r._onResize=new f.EventEmitter,r._onScroll=new f.EventEmitter,r._instantiationService=new a.InstantiationService,r.optionsService=new u.OptionsService(t),r._instantiationService.setService(s.IOptionsService,r.optionsService),r._bufferService=r.register(r._instantiationService.createInstance(l.BufferService)),r._instantiationService.setService(s.IBufferService,r._bufferService),r._logService=r._instantiationService.createInstance(c.LogService),r._instantiationService.setService(s.ILogService,r._logService),r.coreService=r.register(r._instantiationService.createInstance(h.CoreService,(function(){return r.scrollToBottom()}))),r._instantiationService.setService(s.ICoreService,r.coreService),r.coreMouseService=r._instantiationService.createInstance(_.CoreMouseService),r._instantiationService.setService(s.ICoreMouseService,r.coreMouseService),r._dirtyRowService=r._instantiationService.createInstance(d.DirtyRowService),r._instantiationService.setService(s.IDirtyRowService,r._dirtyRowService),r.unicodeService=r._instantiationService.createInstance(p.UnicodeService),r._instantiationService.setService(s.IUnicodeService,r.unicodeService),r._charsetService=r._instantiationService.createInstance(v.CharsetService),r._instantiationService.setService(s.ICharsetService,r._charsetService),r._inputHandler=new y.InputHandler(r._bufferService,r._charsetService,r.coreService,r._dirtyRowService,r._logService,r.optionsService,r.coreMouseService,r.unicodeService),r.register((0,f.forwardEvent)(r._inputHandler.onLineFeed,r._onLineFeed)),r.register(r._inputHandler),r.register((0,f.forwardEvent)(r._bufferService.onResize,r._onResize)),r.register((0,f.forwardEvent)(r.coreService.onData,r._onData)),r.register((0,f.forwardEvent)(r.coreService.onBinary,r._onBinary)),r.register(r.optionsService.onOptionChange((function(e){return r._updateOptions(e)}))),r.register(r._bufferService.onScroll((function(e){r._onScroll.fire({position:r._bufferService.buffer.ydisp,source:0}),r._dirtyRowService.markRangeDirty(r._bufferService.buffer.scrollTop,r._bufferService.buffer.scrollBottom)}))),r.register(r._inputHandler.onScroll((function(e){r._onScroll.fire({position:r._bufferService.buffer.ydisp,source:0}),r._dirtyRowService.markRangeDirty(r._bufferService.buffer.scrollTop,r._bufferService.buffer.scrollBottom)}))),r._writeBuffer=new m.WriteBuffer((function(e,t){return r._inputHandler.parse(e,t)})),r}return n(t,e),Object.defineProperty(t.prototype,"onBinary",{get:function(){return this._onBinary.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onData",{get:function(){return this._onData.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onLineFeed",{get:function(){return this._onLineFeed.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onResize",{get:function(){return this._onResize.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onScroll",{get:function(){var e=this;return this._onScrollApi||(this._onScrollApi=new f.EventEmitter,this.register(this._onScroll.event((function(t){var r;null===(r=e._onScrollApi)||void 0===r||r.fire(t.position)})))),this._onScrollApi.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"cols",{get:function(){return this._bufferService.cols},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"rows",{get:function(){return this._bufferService.rows},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"buffers",{get:function(){return this._bufferService.buffers},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"options",{get:function(){return this.optionsService.options},set:function(e){for(var t in e)this.optionsService.options[t]=e[t]},enumerable:!1,configurable:!0}),t.prototype.dispose=function(){var t;this._isDisposed||(e.prototype.dispose.call(this),null===(t=this._windowsMode)||void 0===t||t.dispose(),this._windowsMode=void 0)},t.prototype.write=function(e,t){this._writeBuffer.write(e,t)},t.prototype.writeSync=function(e,t){this._logService.logLevel<=s.LogLevelEnum.WARN&&!b&&(this._logService.warn("writeSync is unreliable and will be removed soon."),b=!0),this._writeBuffer.writeSync(e,t)},t.prototype.resize=function(e,t){isNaN(e)||isNaN(t)||(e=Math.max(e,l.MINIMUM_COLS),t=Math.max(t,l.MINIMUM_ROWS),this._bufferService.resize(e,t))},t.prototype.scroll=function(e,t){void 0===t&&(t=!1),this._bufferService.scroll(e,t)},t.prototype.scrollLines=function(e,t,r){this._bufferService.scrollLines(e,t,r)},t.prototype.scrollPages=function(e){this._bufferService.scrollPages(e)},t.prototype.scrollToTop=function(){this._bufferService.scrollToTop()},t.prototype.scrollToBottom=function(){this._bufferService.scrollToBottom()},t.prototype.scrollToLine=function(e){this._bufferService.scrollToLine(e)},t.prototype.registerEscHandler=function(e,t){return this._inputHandler.registerEscHandler(e,t)},t.prototype.registerDcsHandler=function(e,t){return this._inputHandler.registerDcsHandler(e,t)},t.prototype.registerCsiHandler=function(e,t){return this._inputHandler.registerCsiHandler(e,t)},t.prototype.registerOscHandler=function(e,t){return this._inputHandler.registerOscHandler(e,t)},t.prototype._setup=function(){this.optionsService.options.windowsMode&&this._enableWindowsMode()},t.prototype.reset=function(){this._inputHandler.reset(),this._bufferService.reset(),this._charsetService.reset(),this.coreService.reset(),this.coreMouseService.reset()},t.prototype._updateOptions=function(e){var t;switch(e){case"scrollback":this.buffers.resize(this.cols,this.rows);break;case"windowsMode":this.optionsService.options.windowsMode?this._enableWindowsMode():(null===(t=this._windowsMode)||void 0===t||t.dispose(),this._windowsMode=void 0)}},t.prototype._enableWindowsMode=function(){var e=this;if(!this._windowsMode){var t=[];t.push(this.onLineFeed(g.updateWindowsModeWrappedState.bind(null,this._bufferService))),t.push(this.registerCsiHandler({final:"H"},(function(){return(0,g.updateWindowsModeWrappedState)(e._bufferService),!1}))),this._windowsMode={dispose:function(){for(var e=0,r=t;e<r.length;e++)r[e].dispose()}}}},t}(o.Disposable);t.CoreTerminal=S},8460:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.forwardEvent=t.EventEmitter=void 0;var r=function(){function e(){this._listeners=[],this._disposed=!1}return Object.defineProperty(e.prototype,"event",{get:function(){var e=this;return this._event||(this._event=function(t){return e._listeners.push(t),{dispose:function(){if(!e._disposed)for(var r=0;r<e._listeners.length;r++)if(e._listeners[r]===t)return void e._listeners.splice(r,1)}}}),this._event},enumerable:!1,configurable:!0}),e.prototype.fire=function(e,t){for(var r=[],i=0;i<this._listeners.length;i++)r.push(this._listeners[i]);for(i=0;i<r.length;i++)r[i].call(void 0,e,t)},e.prototype.dispose=function(){this._listeners&&(this._listeners.length=0),this._disposed=!0},e}();t.EventEmitter=r,t.forwardEvent=function(e,t){return e((function(e){return t.fire(e)}))}},5435:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.InputHandler=t.WindowsOptionsReportType=void 0;var o,s=r(2584),a=r(7116),c=r(2015),l=r(844),u=r(8273),h=r(482),f=r(8437),_=r(8460),d=r(643),p=r(511),v=r(3734),g=r(2585),y=r(6242),m=r(6351),b=r(5941),S={"(":0,")":1,"*":2,"+":3,"-":1,".":2},C=131072;function w(e,t){if(e>24)return t.setWinLines||!1;switch(e){case 1:return!!t.restoreWin;case 2:return!!t.minimizeWin;case 3:return!!t.setWinPosition;case 4:return!!t.setWinSizePixels;case 5:return!!t.raiseWin;case 6:return!!t.lowerWin;case 7:return!!t.refreshWin;case 8:return!!t.setWinSizeChars;case 9:return!!t.maximizeWin;case 10:return!!t.fullscreenWin;case 11:return!!t.getWinState;case 13:return!!t.getWinPosition;case 14:return!!t.getWinSizePixels;case 15:return!!t.getScreenSizePixels;case 16:return!!t.getCellSizePixels;case 18:return!!t.getWinSizeChars;case 19:return!!t.getScreenSizeChars;case 20:return!!t.getIconTitle;case 21:return!!t.getWinTitle;case 22:return!!t.pushTitle;case 23:return!!t.popTitle;case 24:return!!t.setWinLines}return!1}!function(e){e[e.GET_WIN_SIZE_PIXELS=0]="GET_WIN_SIZE_PIXELS",e[e.GET_CELL_SIZE_PIXELS=1]="GET_CELL_SIZE_PIXELS"}(o=t.WindowsOptionsReportType||(t.WindowsOptionsReportType={}));var L=function(){function e(e,t,r,i){this._bufferService=e,this._coreService=t,this._logService=r,this._optionsService=i,this._data=new Uint32Array(0)}return e.prototype.hook=function(e){this._data=new Uint32Array(0)},e.prototype.put=function(e,t,r){this._data=(0,u.concat)(this._data,e.subarray(t,r))},e.prototype.unhook=function(e){if(!e)return this._data=new Uint32Array(0),!0;var t=(0,h.utf32ToString)(this._data);switch(this._data=new Uint32Array(0),t){case'"q':this._coreService.triggerDataEvent(s.C0.ESC+'P1$r0"q'+s.C0.ESC+"\\");break;case'"p':this._coreService.triggerDataEvent(s.C0.ESC+'P1$r61;1"p'+s.C0.ESC+"\\");break;case"r":var r=this._bufferService.buffer.scrollTop+1+";"+(this._bufferService.buffer.scrollBottom+1)+"r";this._coreService.triggerDataEvent(s.C0.ESC+"P1$r"+r+s.C0.ESC+"\\");break;case"m":this._coreService.triggerDataEvent(s.C0.ESC+"P1$r0m"+s.C0.ESC+"\\");break;case" q":var i={block:2,underline:4,bar:6}[this._optionsService.options.cursorStyle];i-=this._optionsService.options.cursorBlink?1:0,this._coreService.triggerDataEvent(s.C0.ESC+"P1$r"+i+" q"+s.C0.ESC+"\\");break;default:this._logService.debug("Unknown DCS $q %s",t),this._coreService.triggerDataEvent(s.C0.ESC+"P0$r"+s.C0.ESC+"\\")}return!0},e}(),E=function(e){function t(t,r,i,n,o,l,u,d,v){void 0===v&&(v=new c.EscapeSequenceParser);var g=e.call(this)||this;g._bufferService=t,g._charsetService=r,g._coreService=i,g._dirtyRowService=n,g._logService=o,g._optionsService=l,g._coreMouseService=u,g._unicodeService=d,g._parser=v,g._parseBuffer=new Uint32Array(4096),g._stringDecoder=new h.StringToUtf32,g._utf8Decoder=new h.Utf8ToUtf32,g._workCell=new p.CellData,g._windowTitle="",g._iconName="",g._windowTitleStack=[],g._iconNameStack=[],g._curAttrData=f.DEFAULT_ATTR_DATA.clone(),g._eraseAttrDataInternal=f.DEFAULT_ATTR_DATA.clone(),g._onRequestBell=new _.EventEmitter,g._onRequestRefreshRows=new _.EventEmitter,g._onRequestReset=new _.EventEmitter,g._onRequestSendFocus=new _.EventEmitter,g._onRequestSyncScrollBar=new _.EventEmitter,g._onRequestWindowsOptionsReport=new _.EventEmitter,g._onA11yChar=new _.EventEmitter,g._onA11yTab=new _.EventEmitter,g._onCursorMove=new _.EventEmitter,g._onLineFeed=new _.EventEmitter,g._onScroll=new _.EventEmitter,g._onTitleChange=new _.EventEmitter,g._onColor=new _.EventEmitter,g._parseStack={paused:!1,cursorStartX:0,cursorStartY:0,decodedLength:0,position:0},g._specialColors=[256,257,258],g.register(g._parser),g._activeBuffer=g._bufferService.buffer,g.register(g._bufferService.buffers.onBufferActivate((function(e){return g._activeBuffer=e.activeBuffer}))),g._parser.setCsiHandlerFallback((function(e,t){g._logService.debug("Unknown CSI code: ",{identifier:g._parser.identToString(e),params:t.toArray()})})),g._parser.setEscHandlerFallback((function(e){g._logService.debug("Unknown ESC code: ",{identifier:g._parser.identToString(e)})})),g._parser.setExecuteHandlerFallback((function(e){g._logService.debug("Unknown EXECUTE code: ",{code:e})})),g._parser.setOscHandlerFallback((function(e,t,r){g._logService.debug("Unknown OSC code: ",{identifier:e,action:t,data:r})})),g._parser.setDcsHandlerFallback((function(e,t,r){"HOOK"===t&&(r=r.toArray()),g._logService.debug("Unknown DCS code: ",{identifier:g._parser.identToString(e),action:t,payload:r})})),g._parser.setPrintHandler((function(e,t,r){return g.print(e,t,r)})),g._parser.registerCsiHandler({final:"@"},(function(e){return g.insertChars(e)})),g._parser.registerCsiHandler({intermediates:" ",final:"@"},(function(e){return g.scrollLeft(e)})),g._parser.registerCsiHandler({final:"A"},(function(e){return g.cursorUp(e)})),g._parser.registerCsiHandler({intermediates:" ",final:"A"},(function(e){return g.scrollRight(e)})),g._parser.registerCsiHandler({final:"B"},(function(e){return g.cursorDown(e)})),g._parser.registerCsiHandler({final:"C"},(function(e){return g.cursorForward(e)})),g._parser.registerCsiHandler({final:"D"},(function(e){return g.cursorBackward(e)})),g._parser.registerCsiHandler({final:"E"},(function(e){return g.cursorNextLine(e)})),g._parser.registerCsiHandler({final:"F"},(function(e){return g.cursorPrecedingLine(e)})),g._parser.registerCsiHandler({final:"G"},(function(e){return g.cursorCharAbsolute(e)})),g._parser.registerCsiHandler({final:"H"},(function(e){return g.cursorPosition(e)})),g._parser.registerCsiHandler({final:"I"},(function(e){return g.cursorForwardTab(e)})),g._parser.registerCsiHandler({final:"J"},(function(e){return g.eraseInDisplay(e)})),g._parser.registerCsiHandler({prefix:"?",final:"J"},(function(e){return g.eraseInDisplay(e)})),g._parser.registerCsiHandler({final:"K"},(function(e){return g.eraseInLine(e)})),g._parser.registerCsiHandler({prefix:"?",final:"K"},(function(e){return g.eraseInLine(e)})),g._parser.registerCsiHandler({final:"L"},(function(e){return g.insertLines(e)})),g._parser.registerCsiHandler({final:"M"},(function(e){return g.deleteLines(e)})),g._parser.registerCsiHandler({final:"P"},(function(e){return g.deleteChars(e)})),g._parser.registerCsiHandler({final:"S"},(function(e){return g.scrollUp(e)})),g._parser.registerCsiHandler({final:"T"},(function(e){return g.scrollDown(e)})),g._parser.registerCsiHandler({final:"X"},(function(e){return g.eraseChars(e)})),g._parser.registerCsiHandler({final:"Z"},(function(e){return g.cursorBackwardTab(e)})),g._parser.registerCsiHandler({final:"`"},(function(e){return g.charPosAbsolute(e)})),g._parser.registerCsiHandler({final:"a"},(function(e){return g.hPositionRelative(e)})),g._parser.registerCsiHandler({final:"b"},(function(e){return g.repeatPrecedingCharacter(e)})),g._parser.registerCsiHandler({final:"c"},(function(e){return g.sendDeviceAttributesPrimary(e)})),g._parser.registerCsiHandler({prefix:">",final:"c"},(function(e){return g.sendDeviceAttributesSecondary(e)})),g._parser.registerCsiHandler({final:"d"},(function(e){return g.linePosAbsolute(e)})),g._parser.registerCsiHandler({final:"e"},(function(e){return g.vPositionRelative(e)})),g._parser.registerCsiHandler({final:"f"},(function(e){return g.hVPosition(e)})),g._parser.registerCsiHandler({final:"g"},(function(e){return g.tabClear(e)})),g._parser.registerCsiHandler({final:"h"},(function(e){return g.setMode(e)})),g._parser.registerCsiHandler({prefix:"?",final:"h"},(function(e){return g.setModePrivate(e)})),g._parser.registerCsiHandler({final:"l"},(function(e){return g.resetMode(e)})),g._parser.registerCsiHandler({prefix:"?",final:"l"},(function(e){return g.resetModePrivate(e)})),g._parser.registerCsiHandler({final:"m"},(function(e){return g.charAttributes(e)})),g._parser.registerCsiHandler({final:"n"},(function(e){return g.deviceStatus(e)})),g._parser.registerCsiHandler({prefix:"?",final:"n"},(function(e){return g.deviceStatusPrivate(e)})),g._parser.registerCsiHandler({intermediates:"!",final:"p"},(function(e){return g.softReset(e)})),g._parser.registerCsiHandler({intermediates:" ",final:"q"},(function(e){return g.setCursorStyle(e)})),g._parser.registerCsiHandler({final:"r"},(function(e){return g.setScrollRegion(e)})),g._parser.registerCsiHandler({final:"s"},(function(e){return g.saveCursor(e)})),g._parser.registerCsiHandler({final:"t"},(function(e){return g.windowOptions(e)})),g._parser.registerCsiHandler({final:"u"},(function(e){return g.restoreCursor(e)})),g._parser.registerCsiHandler({intermediates:"'",final:"}"},(function(e){return g.insertColumns(e)})),g._parser.registerCsiHandler({intermediates:"'",final:"~"},(function(e){return g.deleteColumns(e)})),g._parser.setExecuteHandler(s.C0.BEL,(function(){return g.bell()})),g._parser.setExecuteHandler(s.C0.LF,(function(){return g.lineFeed()})),g._parser.setExecuteHandler(s.C0.VT,(function(){return g.lineFeed()})),g._parser.setExecuteHandler(s.C0.FF,(function(){return g.lineFeed()})),g._parser.setExecuteHandler(s.C0.CR,(function(){return g.carriageReturn()})),g._parser.setExecuteHandler(s.C0.BS,(function(){return g.backspace()})),g._parser.setExecuteHandler(s.C0.HT,(function(){return g.tab()})),g._parser.setExecuteHandler(s.C0.SO,(function(){return g.shiftOut()})),g._parser.setExecuteHandler(s.C0.SI,(function(){return g.shiftIn()})),g._parser.setExecuteHandler(s.C1.IND,(function(){return g.index()})),g._parser.setExecuteHandler(s.C1.NEL,(function(){return g.nextLine()})),g._parser.setExecuteHandler(s.C1.HTS,(function(){return g.tabSet()})),g._parser.registerOscHandler(0,new y.OscHandler((function(e){return g.setTitle(e),g.setIconName(e),!0}))),g._parser.registerOscHandler(1,new y.OscHandler((function(e){return g.setIconName(e)}))),g._parser.registerOscHandler(2,new y.OscHandler((function(e){return g.setTitle(e)}))),g._parser.registerOscHandler(4,new y.OscHandler((function(e){return g.setOrReportIndexedColor(e)}))),g._parser.registerOscHandler(10,new y.OscHandler((function(e){return g.setOrReportFgColor(e)}))),g._parser.registerOscHandler(11,new y.OscHandler((function(e){return g.setOrReportBgColor(e)}))),g._parser.registerOscHandler(12,new y.OscHandler((function(e){return g.setOrReportCursorColor(e)}))),g._parser.registerOscHandler(104,new y.OscHandler((function(e){return g.restoreIndexedColor(e)}))),g._parser.registerOscHandler(110,new y.OscHandler((function(e){return g.restoreFgColor(e)}))),g._parser.registerOscHandler(111,new y.OscHandler((function(e){return g.restoreBgColor(e)}))),g._parser.registerOscHandler(112,new y.OscHandler((function(e){return g.restoreCursorColor(e)}))),g._parser.registerEscHandler({final:"7"},(function(){return g.saveCursor()})),g._parser.registerEscHandler({final:"8"},(function(){return g.restoreCursor()})),g._parser.registerEscHandler({final:"D"},(function(){return g.index()})),g._parser.registerEscHandler({final:"E"},(function(){return g.nextLine()})),g._parser.registerEscHandler({final:"H"},(function(){return g.tabSet()})),g._parser.registerEscHandler({final:"M"},(function(){return g.reverseIndex()})),g._parser.registerEscHandler({final:"="},(function(){return g.keypadApplicationMode()})),g._parser.registerEscHandler({final:">"},(function(){return g.keypadNumericMode()})),g._parser.registerEscHandler({final:"c"},(function(){return g.fullReset()})),g._parser.registerEscHandler({final:"n"},(function(){return g.setgLevel(2)})),g._parser.registerEscHandler({final:"o"},(function(){return g.setgLevel(3)})),g._parser.registerEscHandler({final:"|"},(function(){return g.setgLevel(3)})),g._parser.registerEscHandler({final:"}"},(function(){return g.setgLevel(2)})),g._parser.registerEscHandler({final:"~"},(function(){return g.setgLevel(1)})),g._parser.registerEscHandler({intermediates:"%",final:"@"},(function(){return g.selectDefaultCharset()})),g._parser.registerEscHandler({intermediates:"%",final:"G"},(function(){return g.selectDefaultCharset()}));var m=function(e){b._parser.registerEscHandler({intermediates:"(",final:e},(function(){return g.selectCharset("("+e)})),b._parser.registerEscHandler({intermediates:")",final:e},(function(){return g.selectCharset(")"+e)})),b._parser.registerEscHandler({intermediates:"*",final:e},(function(){return g.selectCharset("*"+e)})),b._parser.registerEscHandler({intermediates:"+",final:e},(function(){return g.selectCharset("+"+e)})),b._parser.registerEscHandler({intermediates:"-",final:e},(function(){return g.selectCharset("-"+e)})),b._parser.registerEscHandler({intermediates:".",final:e},(function(){return g.selectCharset("."+e)})),b._parser.registerEscHandler({intermediates:"/",final:e},(function(){return g.selectCharset("/"+e)}))},b=this;for(var S in a.CHARSETS)m(S);return g._parser.registerEscHandler({intermediates:"#",final:"8"},(function(){return g.screenAlignmentPattern()})),g._parser.setErrorHandler((function(e){return g._logService.error("Parsing error: ",e),e})),g._parser.registerDcsHandler({intermediates:"$",final:"q"},new L(g._bufferService,g._coreService,g._logService,g._optionsService)),g}return n(t,e),Object.defineProperty(t.prototype,"onRequestBell",{get:function(){return this._onRequestBell.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRequestRefreshRows",{get:function(){return this._onRequestRefreshRows.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRequestReset",{get:function(){return this._onRequestReset.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRequestSendFocus",{get:function(){return this._onRequestSendFocus.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRequestSyncScrollBar",{get:function(){return this._onRequestSyncScrollBar.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onRequestWindowsOptionsReport",{get:function(){return this._onRequestWindowsOptionsReport.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onA11yChar",{get:function(){return this._onA11yChar.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onA11yTab",{get:function(){return this._onA11yTab.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onCursorMove",{get:function(){return this._onCursorMove.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onLineFeed",{get:function(){return this._onLineFeed.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onScroll",{get:function(){return this._onScroll.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onTitleChange",{get:function(){return this._onTitleChange.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onColor",{get:function(){return this._onColor.event},enumerable:!1,configurable:!0}),t.prototype.dispose=function(){e.prototype.dispose.call(this)},t.prototype._preserveStack=function(e,t,r,i){this._parseStack.paused=!0,this._parseStack.cursorStartX=e,this._parseStack.cursorStartY=t,this._parseStack.decodedLength=r,this._parseStack.position=i},t.prototype._logSlowResolvingAsync=function(e){this._logService.logLevel<=g.LogLevelEnum.WARN&&Promise.race([e,new Promise((function(e,t){return setTimeout((function(){return t("#SLOW_TIMEOUT")}),5e3)}))]).catch((function(e){if("#SLOW_TIMEOUT"!==e)throw e;console.warn("async parser handler taking longer than 5000 ms")}))},t.prototype.parse=function(e,t){var r,i=this._activeBuffer.x,n=this._activeBuffer.y,o=0,s=this._parseStack.paused;if(s){if(r=this._parser.parse(this._parseBuffer,this._parseStack.decodedLength,t))return this._logSlowResolvingAsync(r),r;i=this._parseStack.cursorStartX,n=this._parseStack.cursorStartY,this._parseStack.paused=!1,e.length>C&&(o=this._parseStack.position+C)}if(this._logService.logLevel<=g.LogLevelEnum.DEBUG&&this._logService.debug("parsing data"+("string"==typeof e?' "'+e+'"':""),"string"==typeof e?e.split("").map((function(e){return e.charCodeAt(0)})):e),this._parseBuffer.length<e.length&&this._parseBuffer.length<C&&(this._parseBuffer=new Uint32Array(Math.min(e.length,C))),s||this._dirtyRowService.clearRange(),e.length>C)for(var a=o;a<e.length;a+=C){var c=a+C<e.length?a+C:e.length,l="string"==typeof e?this._stringDecoder.decode(e.substring(a,c),this._parseBuffer):this._utf8Decoder.decode(e.subarray(a,c),this._parseBuffer);if(r=this._parser.parse(this._parseBuffer,l))return this._preserveStack(i,n,l,a),this._logSlowResolvingAsync(r),r}else if(!s&&(l="string"==typeof e?this._stringDecoder.decode(e,this._parseBuffer):this._utf8Decoder.decode(e,this._parseBuffer),r=this._parser.parse(this._parseBuffer,l)))return this._preserveStack(i,n,l,0),this._logSlowResolvingAsync(r),r;this._activeBuffer.x===i&&this._activeBuffer.y===n||this._onCursorMove.fire(),this._onRequestRefreshRows.fire(this._dirtyRowService.start,this._dirtyRowService.end)},t.prototype.print=function(e,t,r){var i,n,o=this._charsetService.charset,s=this._optionsService.options.screenReaderMode,a=this._bufferService.cols,c=this._coreService.decPrivateModes.wraparound,l=this._coreService.modes.insertMode,u=this._curAttrData,f=this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y);this._dirtyRowService.markDirty(this._activeBuffer.y),this._activeBuffer.x&&r-t>0&&2===f.getWidth(this._activeBuffer.x-1)&&f.setCellFromCodePoint(this._activeBuffer.x-1,0,1,u.fg,u.bg,u.extended);for(var _=t;_<r;++_){if(i=e[_],n=this._unicodeService.wcwidth(i),i<127&&o){var p=o[String.fromCharCode(i)];p&&(i=p.charCodeAt(0))}if(s&&this._onA11yChar.fire((0,h.stringFromCodePoint)(i)),n||!this._activeBuffer.x){if(this._activeBuffer.x+n-1>=a)if(c){for(;this._activeBuffer.x<a;)f.setCellFromCodePoint(this._activeBuffer.x++,0,1,u.fg,u.bg,u.extended);this._activeBuffer.x=0,this._activeBuffer.y++,this._activeBuffer.y===this._activeBuffer.scrollBottom+1?(this._activeBuffer.y--,this._bufferService.scroll(this._eraseAttrData(),!0)):(this._activeBuffer.y>=this._bufferService.rows&&(this._activeBuffer.y=this._bufferService.rows-1),this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y).isWrapped=!0),f=this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y)}else if(this._activeBuffer.x=a-1,2===n)continue;if(l&&(f.insertCells(this._activeBuffer.x,n,this._activeBuffer.getNullCell(u),u),2===f.getWidth(a-1)&&f.setCellFromCodePoint(a-1,d.NULL_CELL_CODE,d.NULL_CELL_WIDTH,u.fg,u.bg,u.extended)),f.setCellFromCodePoint(this._activeBuffer.x++,i,n,u.fg,u.bg,u.extended),n>0)for(;--n;)f.setCellFromCodePoint(this._activeBuffer.x++,0,0,u.fg,u.bg,u.extended)}else f.getWidth(this._activeBuffer.x-1)?f.addCodepointToCell(this._activeBuffer.x-1,i):f.addCodepointToCell(this._activeBuffer.x-2,i)}r-t>0&&(f.loadCell(this._activeBuffer.x-1,this._workCell),2===this._workCell.getWidth()||this._workCell.getCode()>65535?this._parser.precedingCodepoint=0:this._workCell.isCombined()?this._parser.precedingCodepoint=this._workCell.getChars().charCodeAt(0):this._parser.precedingCodepoint=this._workCell.content),this._activeBuffer.x<a&&r-t>0&&0===f.getWidth(this._activeBuffer.x)&&!f.hasContent(this._activeBuffer.x)&&f.setCellFromCodePoint(this._activeBuffer.x,0,1,u.fg,u.bg,u.extended),this._dirtyRowService.markDirty(this._activeBuffer.y)},t.prototype.registerCsiHandler=function(e,t){var r=this;return"t"!==e.final||e.prefix||e.intermediates?this._parser.registerCsiHandler(e,t):this._parser.registerCsiHandler(e,(function(e){return!w(e.params[0],r._optionsService.options.windowOptions)||t(e)}))},t.prototype.registerDcsHandler=function(e,t){return this._parser.registerDcsHandler(e,new m.DcsHandler(t))},t.prototype.registerEscHandler=function(e,t){return this._parser.registerEscHandler(e,t)},t.prototype.registerOscHandler=function(e,t){return this._parser.registerOscHandler(e,new y.OscHandler(t))},t.prototype.bell=function(){return this._onRequestBell.fire(),!0},t.prototype.lineFeed=function(){return this._dirtyRowService.markDirty(this._activeBuffer.y),this._optionsService.options.convertEol&&(this._activeBuffer.x=0),this._activeBuffer.y++,this._activeBuffer.y===this._activeBuffer.scrollBottom+1?(this._activeBuffer.y--,this._bufferService.scroll(this._eraseAttrData())):this._activeBuffer.y>=this._bufferService.rows&&(this._activeBuffer.y=this._bufferService.rows-1),this._activeBuffer.x>=this._bufferService.cols&&this._activeBuffer.x--,this._dirtyRowService.markDirty(this._activeBuffer.y),this._onLineFeed.fire(),!0},t.prototype.carriageReturn=function(){return this._activeBuffer.x=0,!0},t.prototype.backspace=function(){var e;if(!this._coreService.decPrivateModes.reverseWraparound)return this._restrictCursor(),this._activeBuffer.x>0&&this._activeBuffer.x--,!0;if(this._restrictCursor(this._bufferService.cols),this._activeBuffer.x>0)this._activeBuffer.x--;else if(0===this._activeBuffer.x&&this._activeBuffer.y>this._activeBuffer.scrollTop&&this._activeBuffer.y<=this._activeBuffer.scrollBottom&&(null===(e=this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y))||void 0===e?void 0:e.isWrapped)){this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y).isWrapped=!1,this._activeBuffer.y--,this._activeBuffer.x=this._bufferService.cols-1;var t=this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y);t.hasWidth(this._activeBuffer.x)&&!t.hasContent(this._activeBuffer.x)&&this._activeBuffer.x--}return this._restrictCursor(),!0},t.prototype.tab=function(){if(this._activeBuffer.x>=this._bufferService.cols)return!0;var e=this._activeBuffer.x;return this._activeBuffer.x=this._activeBuffer.nextStop(),this._optionsService.options.screenReaderMode&&this._onA11yTab.fire(this._activeBuffer.x-e),!0},t.prototype.shiftOut=function(){return this._charsetService.setgLevel(1),!0},t.prototype.shiftIn=function(){return this._charsetService.setgLevel(0),!0},t.prototype._restrictCursor=function(e){void 0===e&&(e=this._bufferService.cols-1),this._activeBuffer.x=Math.min(e,Math.max(0,this._activeBuffer.x)),this._activeBuffer.y=this._coreService.decPrivateModes.origin?Math.min(this._activeBuffer.scrollBottom,Math.max(this._activeBuffer.scrollTop,this._activeBuffer.y)):Math.min(this._bufferService.rows-1,Math.max(0,this._activeBuffer.y)),this._dirtyRowService.markDirty(this._activeBuffer.y)},t.prototype._setCursor=function(e,t){this._dirtyRowService.markDirty(this._activeBuffer.y),this._coreService.decPrivateModes.origin?(this._activeBuffer.x=e,this._activeBuffer.y=this._activeBuffer.scrollTop+t):(this._activeBuffer.x=e,this._activeBuffer.y=t),this._restrictCursor(),this._dirtyRowService.markDirty(this._activeBuffer.y)},t.prototype._moveCursor=function(e,t){this._restrictCursor(),this._setCursor(this._activeBuffer.x+e,this._activeBuffer.y+t)},t.prototype.cursorUp=function(e){var t=this._activeBuffer.y-this._activeBuffer.scrollTop;return t>=0?this._moveCursor(0,-Math.min(t,e.params[0]||1)):this._moveCursor(0,-(e.params[0]||1)),!0},t.prototype.cursorDown=function(e){var t=this._activeBuffer.scrollBottom-this._activeBuffer.y;return t>=0?this._moveCursor(0,Math.min(t,e.params[0]||1)):this._moveCursor(0,e.params[0]||1),!0},t.prototype.cursorForward=function(e){return this._moveCursor(e.params[0]||1,0),!0},t.prototype.cursorBackward=function(e){return this._moveCursor(-(e.params[0]||1),0),!0},t.prototype.cursorNextLine=function(e){return this.cursorDown(e),this._activeBuffer.x=0,!0},t.prototype.cursorPrecedingLine=function(e){return this.cursorUp(e),this._activeBuffer.x=0,!0},t.prototype.cursorCharAbsolute=function(e){return this._setCursor((e.params[0]||1)-1,this._activeBuffer.y),!0},t.prototype.cursorPosition=function(e){return this._setCursor(e.length>=2?(e.params[1]||1)-1:0,(e.params[0]||1)-1),!0},t.prototype.charPosAbsolute=function(e){return this._setCursor((e.params[0]||1)-1,this._activeBuffer.y),!0},t.prototype.hPositionRelative=function(e){return this._moveCursor(e.params[0]||1,0),!0},t.prototype.linePosAbsolute=function(e){return this._setCursor(this._activeBuffer.x,(e.params[0]||1)-1),!0},t.prototype.vPositionRelative=function(e){return this._moveCursor(0,e.params[0]||1),!0},t.prototype.hVPosition=function(e){return this.cursorPosition(e),!0},t.prototype.tabClear=function(e){var t=e.params[0];return 0===t?delete this._activeBuffer.tabs[this._activeBuffer.x]:3===t&&(this._activeBuffer.tabs={}),!0},t.prototype.cursorForwardTab=function(e){if(this._activeBuffer.x>=this._bufferService.cols)return!0;for(var t=e.params[0]||1;t--;)this._activeBuffer.x=this._activeBuffer.nextStop();return!0},t.prototype.cursorBackwardTab=function(e){if(this._activeBuffer.x>=this._bufferService.cols)return!0;for(var t=e.params[0]||1;t--;)this._activeBuffer.x=this._activeBuffer.prevStop();return!0},t.prototype._eraseInBufferLine=function(e,t,r,i){void 0===i&&(i=!1);var n=this._activeBuffer.lines.get(this._activeBuffer.ybase+e);n.replaceCells(t,r,this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),i&&(n.isWrapped=!1)},t.prototype._resetBufferLine=function(e){var t=this._activeBuffer.lines.get(this._activeBuffer.ybase+e);t.fill(this._activeBuffer.getNullCell(this._eraseAttrData())),t.isWrapped=!1},t.prototype.eraseInDisplay=function(e){var t;switch(this._restrictCursor(this._bufferService.cols),e.params[0]){case 0:for(t=this._activeBuffer.y,this._dirtyRowService.markDirty(t),this._eraseInBufferLine(t++,this._activeBuffer.x,this._bufferService.cols,0===this._activeBuffer.x);t<this._bufferService.rows;t++)this._resetBufferLine(t);this._dirtyRowService.markDirty(t);break;case 1:for(t=this._activeBuffer.y,this._dirtyRowService.markDirty(t),this._eraseInBufferLine(t,0,this._activeBuffer.x+1,!0),this._activeBuffer.x+1>=this._bufferService.cols&&(this._activeBuffer.lines.get(t+1).isWrapped=!1);t--;)this._resetBufferLine(t);this._dirtyRowService.markDirty(0);break;case 2:for(t=this._bufferService.rows,this._dirtyRowService.markDirty(t-1);t--;)this._resetBufferLine(t);this._dirtyRowService.markDirty(0);break;case 3:var r=this._activeBuffer.lines.length-this._bufferService.rows;r>0&&(this._activeBuffer.lines.trimStart(r),this._activeBuffer.ybase=Math.max(this._activeBuffer.ybase-r,0),this._activeBuffer.ydisp=Math.max(this._activeBuffer.ydisp-r,0),this._onScroll.fire(0))}return!0},t.prototype.eraseInLine=function(e){switch(this._restrictCursor(this._bufferService.cols),e.params[0]){case 0:this._eraseInBufferLine(this._activeBuffer.y,this._activeBuffer.x,this._bufferService.cols,0===this._activeBuffer.x);break;case 1:this._eraseInBufferLine(this._activeBuffer.y,0,this._activeBuffer.x+1,!1);break;case 2:this._eraseInBufferLine(this._activeBuffer.y,0,this._bufferService.cols,!0)}return this._dirtyRowService.markDirty(this._activeBuffer.y),!0},t.prototype.insertLines=function(e){this._restrictCursor();var t=e.params[0]||1;if(this._activeBuffer.y>this._activeBuffer.scrollBottom||this._activeBuffer.y<this._activeBuffer.scrollTop)return!0;for(var r=this._activeBuffer.ybase+this._activeBuffer.y,i=this._bufferService.rows-1-this._activeBuffer.scrollBottom,n=this._bufferService.rows-1+this._activeBuffer.ybase-i+1;t--;)this._activeBuffer.lines.splice(n-1,1),this._activeBuffer.lines.splice(r,0,this._activeBuffer.getBlankLine(this._eraseAttrData()));return this._dirtyRowService.markRangeDirty(this._activeBuffer.y,this._activeBuffer.scrollBottom),this._activeBuffer.x=0,!0},t.prototype.deleteLines=function(e){this._restrictCursor();var t=e.params[0]||1;if(this._activeBuffer.y>this._activeBuffer.scrollBottom||this._activeBuffer.y<this._activeBuffer.scrollTop)return!0;var r,i=this._activeBuffer.ybase+this._activeBuffer.y;for(r=this._bufferService.rows-1-this._activeBuffer.scrollBottom,r=this._bufferService.rows-1+this._activeBuffer.ybase-r;t--;)this._activeBuffer.lines.splice(i,1),this._activeBuffer.lines.splice(r,0,this._activeBuffer.getBlankLine(this._eraseAttrData()));return this._dirtyRowService.markRangeDirty(this._activeBuffer.y,this._activeBuffer.scrollBottom),this._activeBuffer.x=0,!0},t.prototype.insertChars=function(e){this._restrictCursor();var t=this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y);return t&&(t.insertCells(this._activeBuffer.x,e.params[0]||1,this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),this._dirtyRowService.markDirty(this._activeBuffer.y)),!0},t.prototype.deleteChars=function(e){this._restrictCursor();var t=this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y);return t&&(t.deleteCells(this._activeBuffer.x,e.params[0]||1,this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),this._dirtyRowService.markDirty(this._activeBuffer.y)),!0},t.prototype.scrollUp=function(e){for(var t=e.params[0]||1;t--;)this._activeBuffer.lines.splice(this._activeBuffer.ybase+this._activeBuffer.scrollTop,1),this._activeBuffer.lines.splice(this._activeBuffer.ybase+this._activeBuffer.scrollBottom,0,this._activeBuffer.getBlankLine(this._eraseAttrData()));return this._dirtyRowService.markRangeDirty(this._activeBuffer.scrollTop,this._activeBuffer.scrollBottom),!0},t.prototype.scrollDown=function(e){for(var t=e.params[0]||1;t--;)this._activeBuffer.lines.splice(this._activeBuffer.ybase+this._activeBuffer.scrollBottom,1),this._activeBuffer.lines.splice(this._activeBuffer.ybase+this._activeBuffer.scrollTop,0,this._activeBuffer.getBlankLine(f.DEFAULT_ATTR_DATA));return this._dirtyRowService.markRangeDirty(this._activeBuffer.scrollTop,this._activeBuffer.scrollBottom),!0},t.prototype.scrollLeft=function(e){if(this._activeBuffer.y>this._activeBuffer.scrollBottom||this._activeBuffer.y<this._activeBuffer.scrollTop)return!0;for(var t=e.params[0]||1,r=this._activeBuffer.scrollTop;r<=this._activeBuffer.scrollBottom;++r){var i=this._activeBuffer.lines.get(this._activeBuffer.ybase+r);i.deleteCells(0,t,this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),i.isWrapped=!1}return this._dirtyRowService.markRangeDirty(this._activeBuffer.scrollTop,this._activeBuffer.scrollBottom),!0},t.prototype.scrollRight=function(e){if(this._activeBuffer.y>this._activeBuffer.scrollBottom||this._activeBuffer.y<this._activeBuffer.scrollTop)return!0;for(var t=e.params[0]||1,r=this._activeBuffer.scrollTop;r<=this._activeBuffer.scrollBottom;++r){var i=this._activeBuffer.lines.get(this._activeBuffer.ybase+r);i.insertCells(0,t,this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),i.isWrapped=!1}return this._dirtyRowService.markRangeDirty(this._activeBuffer.scrollTop,this._activeBuffer.scrollBottom),!0},t.prototype.insertColumns=function(e){if(this._activeBuffer.y>this._activeBuffer.scrollBottom||this._activeBuffer.y<this._activeBuffer.scrollTop)return!0;for(var t=e.params[0]||1,r=this._activeBuffer.scrollTop;r<=this._activeBuffer.scrollBottom;++r){var i=this._activeBuffer.lines.get(this._activeBuffer.ybase+r);i.insertCells(this._activeBuffer.x,t,this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),i.isWrapped=!1}return this._dirtyRowService.markRangeDirty(this._activeBuffer.scrollTop,this._activeBuffer.scrollBottom),!0},t.prototype.deleteColumns=function(e){if(this._activeBuffer.y>this._activeBuffer.scrollBottom||this._activeBuffer.y<this._activeBuffer.scrollTop)return!0;for(var t=e.params[0]||1,r=this._activeBuffer.scrollTop;r<=this._activeBuffer.scrollBottom;++r){var i=this._activeBuffer.lines.get(this._activeBuffer.ybase+r);i.deleteCells(this._activeBuffer.x,t,this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),i.isWrapped=!1}return this._dirtyRowService.markRangeDirty(this._activeBuffer.scrollTop,this._activeBuffer.scrollBottom),!0},t.prototype.eraseChars=function(e){this._restrictCursor();var t=this._activeBuffer.lines.get(this._activeBuffer.ybase+this._activeBuffer.y);return t&&(t.replaceCells(this._activeBuffer.x,this._activeBuffer.x+(e.params[0]||1),this._activeBuffer.getNullCell(this._eraseAttrData()),this._eraseAttrData()),this._dirtyRowService.markDirty(this._activeBuffer.y)),!0},t.prototype.repeatPrecedingCharacter=function(e){if(!this._parser.precedingCodepoint)return!0;for(var t=e.params[0]||1,r=new Uint32Array(t),i=0;i<t;++i)r[i]=this._parser.precedingCodepoint;return this.print(r,0,r.length),!0},t.prototype.sendDeviceAttributesPrimary=function(e){return e.params[0]>0||(this._is("xterm")||this._is("rxvt-unicode")||this._is("screen")?this._coreService.triggerDataEvent(s.C0.ESC+"[?1;2c"):this._is("linux")&&this._coreService.triggerDataEvent(s.C0.ESC+"[?6c")),!0},t.prototype.sendDeviceAttributesSecondary=function(e){return e.params[0]>0||(this._is("xterm")?this._coreService.triggerDataEvent(s.C0.ESC+"[>0;276;0c"):this._is("rxvt-unicode")?this._coreService.triggerDataEvent(s.C0.ESC+"[>85;95;0c"):this._is("linux")?this._coreService.triggerDataEvent(e.params[0]+"c"):this._is("screen")&&this._coreService.triggerDataEvent(s.C0.ESC+"[>83;40003;0c")),!0},t.prototype._is=function(e){return 0===(this._optionsService.options.termName+"").indexOf(e)},t.prototype.setMode=function(e){for(var t=0;t<e.length;t++)4===e.params[t]&&(this._coreService.modes.insertMode=!0);return!0},t.prototype.setModePrivate=function(e){for(var t=0;t<e.length;t++)switch(e.params[t]){case 1:this._coreService.decPrivateModes.applicationCursorKeys=!0;break;case 2:this._charsetService.setgCharset(0,a.DEFAULT_CHARSET),this._charsetService.setgCharset(1,a.DEFAULT_CHARSET),this._charsetService.setgCharset(2,a.DEFAULT_CHARSET),this._charsetService.setgCharset(3,a.DEFAULT_CHARSET);break;case 3:this._optionsService.options.windowOptions.setWinLines&&(this._bufferService.resize(132,this._bufferService.rows),this._onRequestReset.fire());break;case 6:this._coreService.decPrivateModes.origin=!0,this._setCursor(0,0);break;case 7:this._coreService.decPrivateModes.wraparound=!0;break;case 12:break;case 45:this._coreService.decPrivateModes.reverseWraparound=!0;break;case 66:this._logService.debug("Serial port requested application keypad."),this._coreService.decPrivateModes.applicationKeypad=!0,this._onRequestSyncScrollBar.fire();break;case 9:this._coreMouseService.activeProtocol="X10";break;case 1e3:this._coreMouseService.activeProtocol="VT200";break;case 1002:this._coreMouseService.activeProtocol="DRAG";break;case 1003:this._coreMouseService.activeProtocol="ANY";break;case 1004:this._coreService.decPrivateModes.sendFocus=!0,this._onRequestSendFocus.fire();break;case 1005:this._logService.debug("DECSET 1005 not supported (see #2507)");break;case 1006:this._coreMouseService.activeEncoding="SGR";break;case 1015:this._logService.debug("DECSET 1015 not supported (see #2507)");break;case 25:this._coreService.isCursorHidden=!1;break;case 1048:this.saveCursor();break;case 1049:this.saveCursor();case 47:case 1047:this._bufferService.buffers.activateAltBuffer(this._eraseAttrData()),this._coreService.isCursorInitialized=!0,this._onRequestRefreshRows.fire(0,this._bufferService.rows-1),this._onRequestSyncScrollBar.fire();break;case 2004:this._coreService.decPrivateModes.bracketedPasteMode=!0}return!0},t.prototype.resetMode=function(e){for(var t=0;t<e.length;t++)4===e.params[t]&&(this._coreService.modes.insertMode=!1);return!0},t.prototype.resetModePrivate=function(e){for(var t=0;t<e.length;t++)switch(e.params[t]){case 1:this._coreService.decPrivateModes.applicationCursorKeys=!1;break;case 3:this._optionsService.options.windowOptions.setWinLines&&(this._bufferService.resize(80,this._bufferService.rows),this._onRequestReset.fire());break;case 6:this._coreService.decPrivateModes.origin=!1,this._setCursor(0,0);break;case 7:this._coreService.decPrivateModes.wraparound=!1;break;case 12:break;case 45:this._coreService.decPrivateModes.reverseWraparound=!1;break;case 66:this._logService.debug("Switching back to normal keypad."),this._coreService.decPrivateModes.applicationKeypad=!1,this._onRequestSyncScrollBar.fire();break;case 9:case 1e3:case 1002:case 1003:this._coreMouseService.activeProtocol="NONE";break;case 1004:this._coreService.decPrivateModes.sendFocus=!1;break;case 1005:this._logService.debug("DECRST 1005 not supported (see #2507)");break;case 1006:this._coreMouseService.activeEncoding="DEFAULT";break;case 1015:this._logService.debug("DECRST 1015 not supported (see #2507)");break;case 25:this._coreService.isCursorHidden=!0;break;case 1048:this.restoreCursor();break;case 1049:case 47:case 1047:this._bufferService.buffers.activateNormalBuffer(),1049===e.params[t]&&this.restoreCursor(),this._coreService.isCursorInitialized=!0,this._onRequestRefreshRows.fire(0,this._bufferService.rows-1),this._onRequestSyncScrollBar.fire();break;case 2004:this._coreService.decPrivateModes.bracketedPasteMode=!1}return!0},t.prototype._updateAttrColor=function(e,t,r,i,n){return 2===t?(e|=50331648,e&=-16777216,e|=v.AttributeData.fromColorRGB([r,i,n])):5===t&&(e&=-50331904,e|=33554432|255&r),e},t.prototype._extractColor=function(e,t,r){var i=[0,0,-1,0,0,0],n=0,o=0;do{if(i[o+n]=e.params[t+o],e.hasSubParams(t+o)){var s=e.getSubParams(t+o),a=0;do{5===i[1]&&(n=1),i[o+a+1+n]=s[a]}while(++a<s.length&&a+o+1+n<i.length);break}if(5===i[1]&&o+n>=2||2===i[1]&&o+n>=5)break;i[1]&&(n=1)}while(++o+t<e.length&&o+n<i.length);for(a=2;a<i.length;++a)-1===i[a]&&(i[a]=0);switch(i[0]){case 38:r.fg=this._updateAttrColor(r.fg,i[1],i[3],i[4],i[5]);break;case 48:r.bg=this._updateAttrColor(r.bg,i[1],i[3],i[4],i[5]);break;case 58:r.extended=r.extended.clone(),r.extended.underlineColor=this._updateAttrColor(r.extended.underlineColor,i[1],i[3],i[4],i[5])}return o},t.prototype._processUnderline=function(e,t){t.extended=t.extended.clone(),(!~e||e>5)&&(e=1),t.extended.underlineStyle=e,t.fg|=268435456,0===e&&(t.fg&=-268435457),t.updateExtended()},t.prototype.charAttributes=function(e){if(1===e.length&&0===e.params[0])return this._curAttrData.fg=f.DEFAULT_ATTR_DATA.fg,this._curAttrData.bg=f.DEFAULT_ATTR_DATA.bg,!0;for(var t,r=e.length,i=this._curAttrData,n=0;n<r;n++)(t=e.params[n])>=30&&t<=37?(i.fg&=-50331904,i.fg|=16777216|t-30):t>=40&&t<=47?(i.bg&=-50331904,i.bg|=16777216|t-40):t>=90&&t<=97?(i.fg&=-50331904,i.fg|=16777224|t-90):t>=100&&t<=107?(i.bg&=-50331904,i.bg|=16777224|t-100):0===t?(i.fg=f.DEFAULT_ATTR_DATA.fg,i.bg=f.DEFAULT_ATTR_DATA.bg):1===t?i.fg|=134217728:3===t?i.bg|=67108864:4===t?(i.fg|=268435456,this._processUnderline(e.hasSubParams(n)?e.getSubParams(n)[0]:1,i)):5===t?i.fg|=536870912:7===t?i.fg|=67108864:8===t?i.fg|=1073741824:9===t?i.fg|=2147483648:2===t?i.bg|=134217728:21===t?this._processUnderline(2,i):22===t?(i.fg&=-134217729,i.bg&=-134217729):23===t?i.bg&=-67108865:24===t?i.fg&=-268435457:25===t?i.fg&=-536870913:27===t?i.fg&=-67108865:28===t?i.fg&=-1073741825:29===t?i.fg&=2147483647:39===t?(i.fg&=-67108864,i.fg|=16777215&f.DEFAULT_ATTR_DATA.fg):49===t?(i.bg&=-67108864,i.bg|=16777215&f.DEFAULT_ATTR_DATA.bg):38===t||48===t||58===t?n+=this._extractColor(e,n,i):59===t?(i.extended=i.extended.clone(),i.extended.underlineColor=-1,i.updateExtended()):100===t?(i.fg&=-67108864,i.fg|=16777215&f.DEFAULT_ATTR_DATA.fg,i.bg&=-67108864,i.bg|=16777215&f.DEFAULT_ATTR_DATA.bg):this._logService.debug("Unknown SGR attribute: %d.",t);return!0},t.prototype.deviceStatus=function(e){switch(e.params[0]){case 5:this._coreService.triggerDataEvent(s.C0.ESC+"[0n");break;case 6:var t=this._activeBuffer.y+1,r=this._activeBuffer.x+1;this._coreService.triggerDataEvent(s.C0.ESC+"["+t+";"+r+"R")}return!0},t.prototype.deviceStatusPrivate=function(e){if(6===e.params[0]){var t=this._activeBuffer.y+1,r=this._activeBuffer.x+1;this._coreService.triggerDataEvent(s.C0.ESC+"[?"+t+";"+r+"R")}return!0},t.prototype.softReset=function(e){return this._coreService.isCursorHidden=!1,this._onRequestSyncScrollBar.fire(),this._activeBuffer.scrollTop=0,this._activeBuffer.scrollBottom=this._bufferService.rows-1,this._curAttrData=f.DEFAULT_ATTR_DATA.clone(),this._coreService.reset(),this._charsetService.reset(),this._activeBuffer.savedX=0,this._activeBuffer.savedY=this._activeBuffer.ybase,this._activeBuffer.savedCurAttrData.fg=this._curAttrData.fg,this._activeBuffer.savedCurAttrData.bg=this._curAttrData.bg,this._activeBuffer.savedCharset=this._charsetService.charset,this._coreService.decPrivateModes.origin=!1,!0},t.prototype.setCursorStyle=function(e){var t=e.params[0]||1;switch(t){case 1:case 2:this._optionsService.options.cursorStyle="block";break;case 3:case 4:this._optionsService.options.cursorStyle="underline";break;case 5:case 6:this._optionsService.options.cursorStyle="bar"}var r=t%2==1;return this._optionsService.options.cursorBlink=r,!0},t.prototype.setScrollRegion=function(e){var t,r=e.params[0]||1;return(e.length<2||(t=e.params[1])>this._bufferService.rows||0===t)&&(t=this._bufferService.rows),t>r&&(this._activeBuffer.scrollTop=r-1,this._activeBuffer.scrollBottom=t-1,this._setCursor(0,0)),!0},t.prototype.windowOptions=function(e){if(!w(e.params[0],this._optionsService.options.windowOptions))return!0;var t=e.length>1?e.params[1]:0;switch(e.params[0]){case 14:2!==t&&this._onRequestWindowsOptionsReport.fire(o.GET_WIN_SIZE_PIXELS);break;case 16:this._onRequestWindowsOptionsReport.fire(o.GET_CELL_SIZE_PIXELS);break;case 18:this._bufferService&&this._coreService.triggerDataEvent(s.C0.ESC+"[8;"+this._bufferService.rows+";"+this._bufferService.cols+"t");break;case 22:0!==t&&2!==t||(this._windowTitleStack.push(this._windowTitle),this._windowTitleStack.length>10&&this._windowTitleStack.shift()),0!==t&&1!==t||(this._iconNameStack.push(this._iconName),this._iconNameStack.length>10&&this._iconNameStack.shift());break;case 23:0!==t&&2!==t||this._windowTitleStack.length&&this.setTitle(this._windowTitleStack.pop()),0!==t&&1!==t||this._iconNameStack.length&&this.setIconName(this._iconNameStack.pop())}return!0},t.prototype.saveCursor=function(e){return this._activeBuffer.savedX=this._activeBuffer.x,this._activeBuffer.savedY=this._activeBuffer.ybase+this._activeBuffer.y,this._activeBuffer.savedCurAttrData.fg=this._curAttrData.fg,this._activeBuffer.savedCurAttrData.bg=this._curAttrData.bg,this._activeBuffer.savedCharset=this._charsetService.charset,!0},t.prototype.restoreCursor=function(e){return this._activeBuffer.x=this._activeBuffer.savedX||0,this._activeBuffer.y=Math.max(this._activeBuffer.savedY-this._activeBuffer.ybase,0),this._curAttrData.fg=this._activeBuffer.savedCurAttrData.fg,this._curAttrData.bg=this._activeBuffer.savedCurAttrData.bg,this._charsetService.charset=this._savedCharset,this._activeBuffer.savedCharset&&(this._charsetService.charset=this._activeBuffer.savedCharset),this._restrictCursor(),!0},t.prototype.setTitle=function(e){return this._windowTitle=e,this._onTitleChange.fire(e),!0},t.prototype.setIconName=function(e){return this._iconName=e,!0},t.prototype.setOrReportIndexedColor=function(e){for(var t=[],r=e.split(";");r.length>1;){var i=r.shift(),n=r.shift();if(/^\d+$/.exec(i)){var o=parseInt(i);if(0<=o&&o<256)if("?"===n)t.push({type:0,index:o});else{var s=(0,b.parseColor)(n);s&&t.push({type:1,index:o,color:s})}}}return t.length&&this._onColor.fire(t),!0},t.prototype._setOrReportSpecialColor=function(e,t){for(var r=e.split(";"),i=0;i<r.length&&!(t>=this._specialColors.length);++i,++t)if("?"===r[i])this._onColor.fire([{type:0,index:this._specialColors[t]}]);else{var n=(0,b.parseColor)(r[i]);n&&this._onColor.fire([{type:1,index:this._specialColors[t],color:n}])}return!0},t.prototype.setOrReportFgColor=function(e){return this._setOrReportSpecialColor(e,0)},t.prototype.setOrReportBgColor=function(e){return this._setOrReportSpecialColor(e,1)},t.prototype.setOrReportCursorColor=function(e){return this._setOrReportSpecialColor(e,2)},t.prototype.restoreIndexedColor=function(e){if(!e)return this._onColor.fire([{type:2}]),!0;for(var t=[],r=e.split(";"),i=0;i<r.length;++i)if(/^\d+$/.exec(r[i])){var n=parseInt(r[i]);0<=n&&n<256&&t.push({type:2,index:n})}return t.length&&this._onColor.fire(t),!0},t.prototype.restoreFgColor=function(e){return this._onColor.fire([{type:2,index:256}]),!0},t.prototype.restoreBgColor=function(e){return this._onColor.fire([{type:2,index:257}]),!0},t.prototype.restoreCursorColor=function(e){return this._onColor.fire([{type:2,index:258}]),!0},t.prototype.nextLine=function(){return this._activeBuffer.x=0,this.index(),!0},t.prototype.keypadApplicationMode=function(){return this._logService.debug("Serial port requested application keypad."),this._coreService.decPrivateModes.applicationKeypad=!0,this._onRequestSyncScrollBar.fire(),!0},t.prototype.keypadNumericMode=function(){return this._logService.debug("Switching back to normal keypad."),this._coreService.decPrivateModes.applicationKeypad=!1,this._onRequestSyncScrollBar.fire(),!0},t.prototype.selectDefaultCharset=function(){return this._charsetService.setgLevel(0),this._charsetService.setgCharset(0,a.DEFAULT_CHARSET),!0},t.prototype.selectCharset=function(e){return 2!==e.length?(this.selectDefaultCharset(),!0):("/"===e[0]||this._charsetService.setgCharset(S[e[0]],a.CHARSETS[e[1]]||a.DEFAULT_CHARSET),!0)},t.prototype.index=function(){return this._restrictCursor(),this._activeBuffer.y++,this._activeBuffer.y===this._activeBuffer.scrollBottom+1?(this._activeBuffer.y--,this._bufferService.scroll(this._eraseAttrData())):this._activeBuffer.y>=this._bufferService.rows&&(this._activeBuffer.y=this._bufferService.rows-1),this._restrictCursor(),!0},t.prototype.tabSet=function(){return this._activeBuffer.tabs[this._activeBuffer.x]=!0,!0},t.prototype.reverseIndex=function(){if(this._restrictCursor(),this._activeBuffer.y===this._activeBuffer.scrollTop){var e=this._activeBuffer.scrollBottom-this._activeBuffer.scrollTop;this._activeBuffer.lines.shiftElements(this._activeBuffer.ybase+this._activeBuffer.y,e,1),this._activeBuffer.lines.set(this._activeBuffer.ybase+this._activeBuffer.y,this._activeBuffer.getBlankLine(this._eraseAttrData())),this._dirtyRowService.markRangeDirty(this._activeBuffer.scrollTop,this._activeBuffer.scrollBottom)}else this._activeBuffer.y--,this._restrictCursor();return!0},t.prototype.fullReset=function(){return this._parser.reset(),this._onRequestReset.fire(),!0},t.prototype.reset=function(){this._curAttrData=f.DEFAULT_ATTR_DATA.clone(),this._eraseAttrDataInternal=f.DEFAULT_ATTR_DATA.clone()},t.prototype._eraseAttrData=function(){return this._eraseAttrDataInternal.bg&=-67108864,this._eraseAttrDataInternal.bg|=67108863&this._curAttrData.bg,this._eraseAttrDataInternal},t.prototype.setgLevel=function(e){return this._charsetService.setgLevel(e),!0},t.prototype.screenAlignmentPattern=function(){var e=new p.CellData;e.content=1<<22|"E".charCodeAt(0),e.fg=this._curAttrData.fg,e.bg=this._curAttrData.bg,this._setCursor(0,0);for(var t=0;t<this._bufferService.rows;++t){var r=this._activeBuffer.ybase+this._activeBuffer.y+t,i=this._activeBuffer.lines.get(r);i&&(i.fill(e),i.isWrapped=!1)}return this._dirtyRowService.markAllDirty(),this._setCursor(0,0),!0},t}(l.Disposable);t.InputHandler=E},844:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.getDisposeArrayDisposable=t.disposeArray=t.Disposable=void 0;var r=function(){function e(){this._disposables=[],this._isDisposed=!1}return e.prototype.dispose=function(){this._isDisposed=!0;for(var e=0,t=this._disposables;e<t.length;e++)t[e].dispose();this._disposables.length=0},e.prototype.register=function(e){return this._disposables.push(e),e},e.prototype.unregister=function(e){var t=this._disposables.indexOf(e);-1!==t&&this._disposables.splice(t,1)},e}();function i(e){for(var t=0,r=e;t<r.length;t++)r[t].dispose();e.length=0}t.Disposable=r,t.disposeArray=i,t.getDisposeArrayDisposable=function(e){return{dispose:function(){return i(e)}}}},6114:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.isLinux=t.isWindows=t.isIphone=t.isIpad=t.isMac=t.isSafari=t.isFirefox=void 0;var r="undefined"==typeof navigator,i=r?"node":navigator.userAgent,n=r?"node":navigator.platform;t.isFirefox=i.includes("Firefox"),t.isSafari=/^((?!chrome|android).)*safari/i.test(i),t.isMac=["Macintosh","MacIntel","MacPPC","Mac68K"].includes(n),t.isIpad="iPad"===n,t.isIphone="iPhone"===n,t.isWindows=["Windows","Win16","Win32","WinCE"].includes(n),t.isLinux=n.indexOf("Linux")>=0},8273:(e,t)=>{function r(e,t,r,i){if(void 0===r&&(r=0),void 0===i&&(i=e.length),r>=e.length)return e;r=(e.length+r)%e.length,i=i>=e.length?e.length:(e.length+i)%e.length;for(var n=r;n<i;++n)e[n]=t;return e}Object.defineProperty(t,"__esModule",{value:!0}),t.concat=t.fillFallback=t.fill=void 0,t.fill=function(e,t,i,n){return e.fill?e.fill(t,i,n):r(e,t,i,n)},t.fillFallback=r,t.concat=function(e,t){var r=new e.constructor(e.length+t.length);return r.set(e),r.set(t,e.length),r}},9282:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.updateWindowsModeWrappedState=void 0;var i=r(643);t.updateWindowsModeWrappedState=function(e){var t=e.buffer.lines.get(e.buffer.ybase+e.buffer.y-1),r=null==t?void 0:t.get(e.cols-1),n=e.buffer.lines.get(e.buffer.ybase+e.buffer.y);n&&r&&(n.isWrapped=r[i.CHAR_DATA_CODE_INDEX]!==i.NULL_CELL_CODE&&r[i.CHAR_DATA_CODE_INDEX]!==i.WHITESPACE_CELL_CODE)}},3734:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.ExtendedAttrs=t.AttributeData=void 0;var r=function(){function e(){this.fg=0,this.bg=0,this.extended=new i}return e.toColorRGB=function(e){return[e>>>16&255,e>>>8&255,255&e]},e.fromColorRGB=function(e){return(255&e[0])<<16|(255&e[1])<<8|255&e[2]},e.prototype.clone=function(){var t=new e;return t.fg=this.fg,t.bg=this.bg,t.extended=this.extended.clone(),t},e.prototype.isInverse=function(){return 67108864&this.fg},e.prototype.isBold=function(){return 134217728&this.fg},e.prototype.isUnderline=function(){return 268435456&this.fg},e.prototype.isBlink=function(){return 536870912&this.fg},e.prototype.isInvisible=function(){return 1073741824&this.fg},e.prototype.isItalic=function(){return 67108864&this.bg},e.prototype.isDim=function(){return 134217728&this.bg},e.prototype.isStrikethrough=function(){return 2147483648&this.fg},e.prototype.getFgColorMode=function(){return 50331648&this.fg},e.prototype.getBgColorMode=function(){return 50331648&this.bg},e.prototype.isFgRGB=function(){return 50331648==(50331648&this.fg)},e.prototype.isBgRGB=function(){return 50331648==(50331648&this.bg)},e.prototype.isFgPalette=function(){return 16777216==(50331648&this.fg)||33554432==(50331648&this.fg)},e.prototype.isBgPalette=function(){return 16777216==(50331648&this.bg)||33554432==(50331648&this.bg)},e.prototype.isFgDefault=function(){return 0==(50331648&this.fg)},e.prototype.isBgDefault=function(){return 0==(50331648&this.bg)},e.prototype.isAttributeDefault=function(){return 0===this.fg&&0===this.bg},e.prototype.getFgColor=function(){switch(50331648&this.fg){case 16777216:case 33554432:return 255&this.fg;case 50331648:return 16777215&this.fg;default:return-1}},e.prototype.getBgColor=function(){switch(50331648&this.bg){case 16777216:case 33554432:return 255&this.bg;case 50331648:return 16777215&this.bg;default:return-1}},e.prototype.hasExtendedAttrs=function(){return 268435456&this.bg},e.prototype.updateExtended=function(){this.extended.isEmpty()?this.bg&=-268435457:this.bg|=268435456},e.prototype.getUnderlineColor=function(){if(268435456&this.bg&&~this.extended.underlineColor)switch(50331648&this.extended.underlineColor){case 16777216:case 33554432:return 255&this.extended.underlineColor;case 50331648:return 16777215&this.extended.underlineColor;default:return this.getFgColor()}return this.getFgColor()},e.prototype.getUnderlineColorMode=function(){return 268435456&this.bg&&~this.extended.underlineColor?50331648&this.extended.underlineColor:this.getFgColorMode()},e.prototype.isUnderlineColorRGB=function(){return 268435456&this.bg&&~this.extended.underlineColor?50331648==(50331648&this.extended.underlineColor):this.isFgRGB()},e.prototype.isUnderlineColorPalette=function(){return 268435456&this.bg&&~this.extended.underlineColor?16777216==(50331648&this.extended.underlineColor)||33554432==(50331648&this.extended.underlineColor):this.isFgPalette()},e.prototype.isUnderlineColorDefault=function(){return 268435456&this.bg&&~this.extended.underlineColor?0==(50331648&this.extended.underlineColor):this.isFgDefault()},e.prototype.getUnderlineStyle=function(){return 268435456&this.fg?268435456&this.bg?this.extended.underlineStyle:1:0},e}();t.AttributeData=r;var i=function(){function e(e,t){void 0===e&&(e=0),void 0===t&&(t=-1),this.underlineStyle=e,this.underlineColor=t}return e.prototype.clone=function(){return new e(this.underlineStyle,this.underlineColor)},e.prototype.isEmpty=function(){return 0===this.underlineStyle},e}();t.ExtendedAttrs=i},9092:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.BufferStringIterator=t.Buffer=t.MAX_BUFFER_SIZE=void 0;var i=r(6349),n=r(8437),o=r(511),s=r(643),a=r(4634),c=r(4863),l=r(7116),u=r(3734);t.MAX_BUFFER_SIZE=4294967295;var h=function(){function e(e,t,r){this._hasScrollback=e,this._optionsService=t,this._bufferService=r,this.ydisp=0,this.ybase=0,this.y=0,this.x=0,this.savedY=0,this.savedX=0,this.savedCurAttrData=n.DEFAULT_ATTR_DATA.clone(),this.savedCharset=l.DEFAULT_CHARSET,this.markers=[],this._nullCell=o.CellData.fromCharData([0,s.NULL_CELL_CHAR,s.NULL_CELL_WIDTH,s.NULL_CELL_CODE]),this._whitespaceCell=o.CellData.fromCharData([0,s.WHITESPACE_CELL_CHAR,s.WHITESPACE_CELL_WIDTH,s.WHITESPACE_CELL_CODE]),this._cols=this._bufferService.cols,this._rows=this._bufferService.rows,this.lines=new i.CircularList(this._getCorrectBufferLength(this._rows)),this.scrollTop=0,this.scrollBottom=this._rows-1,this.setupTabStops()}return e.prototype.getNullCell=function(e){return e?(this._nullCell.fg=e.fg,this._nullCell.bg=e.bg,this._nullCell.extended=e.extended):(this._nullCell.fg=0,this._nullCell.bg=0,this._nullCell.extended=new u.ExtendedAttrs),this._nullCell},e.prototype.getWhitespaceCell=function(e){return e?(this._whitespaceCell.fg=e.fg,this._whitespaceCell.bg=e.bg,this._whitespaceCell.extended=e.extended):(this._whitespaceCell.fg=0,this._whitespaceCell.bg=0,this._whitespaceCell.extended=new u.ExtendedAttrs),this._whitespaceCell},e.prototype.getBlankLine=function(e,t){return new n.BufferLine(this._bufferService.cols,this.getNullCell(e),t)},Object.defineProperty(e.prototype,"hasScrollback",{get:function(){return this._hasScrollback&&this.lines.maxLength>this._rows},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"isCursorInViewport",{get:function(){var e=this.ybase+this.y-this.ydisp;return e>=0&&e<this._rows},enumerable:!1,configurable:!0}),e.prototype._getCorrectBufferLength=function(e){if(!this._hasScrollback)return e;var r=e+this._optionsService.options.scrollback;return r>t.MAX_BUFFER_SIZE?t.MAX_BUFFER_SIZE:r},e.prototype.fillViewportRows=function(e){if(0===this.lines.length){void 0===e&&(e=n.DEFAULT_ATTR_DATA);for(var t=this._rows;t--;)this.lines.push(this.getBlankLine(e))}},e.prototype.clear=function(){this.ydisp=0,this.ybase=0,this.y=0,this.x=0,this.lines=new i.CircularList(this._getCorrectBufferLength(this._rows)),this.scrollTop=0,this.scrollBottom=this._rows-1,this.setupTabStops()},e.prototype.resize=function(e,t){var r=this.getNullCell(n.DEFAULT_ATTR_DATA),i=this._getCorrectBufferLength(t);if(i>this.lines.maxLength&&(this.lines.maxLength=i),this.lines.length>0){if(this._cols<e)for(var o=0;o<this.lines.length;o++)this.lines.get(o).resize(e,r);var s=0;if(this._rows<t)for(var a=this._rows;a<t;a++)this.lines.length<t+this.ybase&&(this._optionsService.options.windowsMode?this.lines.push(new n.BufferLine(e,r)):this.ybase>0&&this.lines.length<=this.ybase+this.y+s+1?(this.ybase--,s++,this.ydisp>0&&this.ydisp--):this.lines.push(new n.BufferLine(e,r)));else for(a=this._rows;a>t;a--)this.lines.length>t+this.ybase&&(this.lines.length>this.ybase+this.y+1?this.lines.pop():(this.ybase++,this.ydisp++));if(i<this.lines.maxLength){var c=this.lines.length-i;c>0&&(this.lines.trimStart(c),this.ybase=Math.max(this.ybase-c,0),this.ydisp=Math.max(this.ydisp-c,0),this.savedY=Math.max(this.savedY-c,0)),this.lines.maxLength=i}this.x=Math.min(this.x,e-1),this.y=Math.min(this.y,t-1),s&&(this.y+=s),this.savedX=Math.min(this.savedX,e-1),this.scrollTop=0}if(this.scrollBottom=t-1,this._isReflowEnabled&&(this._reflow(e,t),this._cols>e))for(o=0;o<this.lines.length;o++)this.lines.get(o).resize(e,r);this._cols=e,this._rows=t},Object.defineProperty(e.prototype,"_isReflowEnabled",{get:function(){return this._hasScrollback&&!this._optionsService.options.windowsMode},enumerable:!1,configurable:!0}),e.prototype._reflow=function(e,t){this._cols!==e&&(e>this._cols?this._reflowLarger(e,t):this._reflowSmaller(e,t))},e.prototype._reflowLarger=function(e,t){var r=(0,a.reflowLargerGetLinesToRemove)(this.lines,this._cols,e,this.ybase+this.y,this.getNullCell(n.DEFAULT_ATTR_DATA));if(r.length>0){var i=(0,a.reflowLargerCreateNewLayout)(this.lines,r);(0,a.reflowLargerApplyNewLayout)(this.lines,i.layout),this._reflowLargerAdjustViewport(e,t,i.countRemoved)}},e.prototype._reflowLargerAdjustViewport=function(e,t,r){for(var i=this.getNullCell(n.DEFAULT_ATTR_DATA),o=r;o-- >0;)0===this.ybase?(this.y>0&&this.y--,this.lines.length<t&&this.lines.push(new n.BufferLine(e,i))):(this.ydisp===this.ybase&&this.ydisp--,this.ybase--);this.savedY=Math.max(this.savedY-r,0)},e.prototype._reflowSmaller=function(e,t){for(var r=this.getNullCell(n.DEFAULT_ATTR_DATA),i=[],o=0,s=this.lines.length-1;s>=0;s--){var c=this.lines.get(s);if(!(!c||!c.isWrapped&&c.getTrimmedLength()<=e)){for(var l=[c];c.isWrapped&&s>0;)c=this.lines.get(--s),l.unshift(c);var u=this.ybase+this.y;if(!(u>=s&&u<s+l.length)){var h,f=l[l.length-1].getTrimmedLength(),_=(0,a.reflowSmallerGetNewLineLengths)(l,this._cols,e),d=_.length-l.length;h=0===this.ybase&&this.y!==this.lines.length-1?Math.max(0,this.y-this.lines.maxLength+d):Math.max(0,this.lines.length-this.lines.maxLength+d);for(var p=[],v=0;v<d;v++){var g=this.getBlankLine(n.DEFAULT_ATTR_DATA,!0);p.push(g)}p.length>0&&(i.push({start:s+l.length+o,newLines:p}),o+=p.length),l.push.apply(l,p);var y=_.length-1,m=_[y];0===m&&(m=_[--y]);for(var b=l.length-d-1,S=f;b>=0;){var C=Math.min(S,m);if(l[y].copyCellsFrom(l[b],S-C,m-C,C,!0),0==(m-=C)&&(m=_[--y]),0==(S-=C)){b--;var w=Math.max(b,0);S=(0,a.getWrappedLineTrimmedLength)(l,w,this._cols)}}for(v=0;v<l.length;v++)_[v]<e&&l[v].setCell(_[v],r);for(var L=d-h;L-- >0;)0===this.ybase?this.y<t-1?(this.y++,this.lines.pop()):(this.ybase++,this.ydisp++):this.ybase<Math.min(this.lines.maxLength,this.lines.length+o)-t&&(this.ybase===this.ydisp&&this.ydisp++,this.ybase++);this.savedY=Math.min(this.savedY+d,this.ybase+t-1)}}}if(i.length>0){var E=[],x=[];for(v=0;v<this.lines.length;v++)x.push(this.lines.get(v));var A=this.lines.length,k=A-1,M=0,R=i[M];this.lines.length=Math.min(this.lines.maxLength,this.lines.length+o);var T=0;for(v=Math.min(this.lines.maxLength-1,A+o-1);v>=0;v--)if(R&&R.start>k+T){for(var O=R.newLines.length-1;O>=0;O--)this.lines.set(v--,R.newLines[O]);v++,E.push({index:k+1,amount:R.newLines.length}),T+=R.newLines.length,R=i[++M]}else this.lines.set(v,x[k--]);var B=0;for(v=E.length-1;v>=0;v--)E[v].index+=B,this.lines.onInsertEmitter.fire(E[v]),B+=E[v].amount;var D=Math.max(0,A+o-this.lines.maxLength);D>0&&this.lines.onTrimEmitter.fire(D)}},e.prototype.stringIndexToBufferIndex=function(e,t,r){for(void 0===r&&(r=!1);t;){var i=this.lines.get(e);if(!i)return[-1,-1];for(var n=r?i.getTrimmedLength():i.length,o=0;o<n;++o)if(i.get(o)[s.CHAR_DATA_WIDTH_INDEX]&&(t-=i.get(o)[s.CHAR_DATA_CHAR_INDEX].length||1),t<0)return[e,o];e++}return[e,0]},e.prototype.translateBufferLineToString=function(e,t,r,i){void 0===r&&(r=0);var n=this.lines.get(e);return n?n.translateToString(t,r,i):""},e.prototype.getWrappedRangeForLine=function(e){for(var t=e,r=e;t>0&&this.lines.get(t).isWrapped;)t--;for(;r+1<this.lines.length&&this.lines.get(r+1).isWrapped;)r++;return{first:t,last:r}},e.prototype.setupTabStops=function(e){for(null!=e?this.tabs[e]||(e=this.prevStop(e)):(this.tabs={},e=0);e<this._cols;e+=this._optionsService.options.tabStopWidth)this.tabs[e]=!0},e.prototype.prevStop=function(e){for(null==e&&(e=this.x);!this.tabs[--e]&&e>0;);return e>=this._cols?this._cols-1:e<0?0:e},e.prototype.nextStop=function(e){for(null==e&&(e=this.x);!this.tabs[++e]&&e<this._cols;);return e>=this._cols?this._cols-1:e<0?0:e},e.prototype.addMarker=function(e){var t=this,r=new c.Marker(e);return this.markers.push(r),r.register(this.lines.onTrim((function(e){r.line-=e,r.line<0&&r.dispose()}))),r.register(this.lines.onInsert((function(e){r.line>=e.index&&(r.line+=e.amount)}))),r.register(this.lines.onDelete((function(e){r.line>=e.index&&r.line<e.index+e.amount&&r.dispose(),r.line>e.index&&(r.line-=e.amount)}))),r.register(r.onDispose((function(){return t._removeMarker(r)}))),r},e.prototype._removeMarker=function(e){this.markers.splice(this.markers.indexOf(e),1)},e.prototype.iterator=function(e,t,r,i,n){return new f(this,e,t,r,i,n)},e}();t.Buffer=h;var f=function(){function e(e,t,r,i,n,o){void 0===r&&(r=0),void 0===i&&(i=e.lines.length),void 0===n&&(n=0),void 0===o&&(o=0),this._buffer=e,this._trimRight=t,this._startIndex=r,this._endIndex=i,this._startOverscan=n,this._endOverscan=o,this._startIndex<0&&(this._startIndex=0),this._endIndex>this._buffer.lines.length&&(this._endIndex=this._buffer.lines.length),this._current=this._startIndex}return e.prototype.hasNext=function(){return this._current<this._endIndex},e.prototype.next=function(){var e=this._buffer.getWrappedRangeForLine(this._current);e.first<this._startIndex-this._startOverscan&&(e.first=this._startIndex-this._startOverscan),e.last>this._endIndex+this._endOverscan&&(e.last=this._endIndex+this._endOverscan),e.first=Math.max(e.first,0),e.last=Math.min(e.last,this._buffer.lines.length);for(var t="",r=e.first;r<=e.last;++r)t+=this._buffer.translateBufferLineToString(r,this._trimRight);return this._current=e.last+1,{range:e,content:t}},e}();t.BufferStringIterator=f},8437:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.BufferLine=t.DEFAULT_ATTR_DATA=void 0;var i=r(482),n=r(643),o=r(511),s=r(3734);t.DEFAULT_ATTR_DATA=Object.freeze(new s.AttributeData);var a=function(){function e(e,t,r){void 0===r&&(r=!1),this.isWrapped=r,this._combined={},this._extendedAttrs={},this._data=new Uint32Array(3*e);for(var i=t||o.CellData.fromCharData([0,n.NULL_CELL_CHAR,n.NULL_CELL_WIDTH,n.NULL_CELL_CODE]),s=0;s<e;++s)this.setCell(s,i);this.length=e}return e.prototype.get=function(e){var t=this._data[3*e+0],r=2097151&t;return[this._data[3*e+1],2097152&t?this._combined[e]:r?(0,i.stringFromCodePoint)(r):"",t>>22,2097152&t?this._combined[e].charCodeAt(this._combined[e].length-1):r]},e.prototype.set=function(e,t){this._data[3*e+1]=t[n.CHAR_DATA_ATTR_INDEX],t[n.CHAR_DATA_CHAR_INDEX].length>1?(this._combined[e]=t[1],this._data[3*e+0]=2097152|e|t[n.CHAR_DATA_WIDTH_INDEX]<<22):this._data[3*e+0]=t[n.CHAR_DATA_CHAR_INDEX].charCodeAt(0)|t[n.CHAR_DATA_WIDTH_INDEX]<<22},e.prototype.getWidth=function(e){return this._data[3*e+0]>>22},e.prototype.hasWidth=function(e){return 12582912&this._data[3*e+0]},e.prototype.getFg=function(e){return this._data[3*e+1]},e.prototype.getBg=function(e){return this._data[3*e+2]},e.prototype.hasContent=function(e){return 4194303&this._data[3*e+0]},e.prototype.getCodePoint=function(e){var t=this._data[3*e+0];return 2097152&t?this._combined[e].charCodeAt(this._combined[e].length-1):2097151&t},e.prototype.isCombined=function(e){return 2097152&this._data[3*e+0]},e.prototype.getString=function(e){var t=this._data[3*e+0];return 2097152&t?this._combined[e]:2097151&t?(0,i.stringFromCodePoint)(2097151&t):""},e.prototype.loadCell=function(e,t){var r=3*e;return t.content=this._data[r+0],t.fg=this._data[r+1],t.bg=this._data[r+2],2097152&t.content&&(t.combinedData=this._combined[e]),268435456&t.bg&&(t.extended=this._extendedAttrs[e]),t},e.prototype.setCell=function(e,t){2097152&t.content&&(this._combined[e]=t.combinedData),268435456&t.bg&&(this._extendedAttrs[e]=t.extended),this._data[3*e+0]=t.content,this._data[3*e+1]=t.fg,this._data[3*e+2]=t.bg},e.prototype.setCellFromCodePoint=function(e,t,r,i,n,o){268435456&n&&(this._extendedAttrs[e]=o),this._data[3*e+0]=t|r<<22,this._data[3*e+1]=i,this._data[3*e+2]=n},e.prototype.addCodepointToCell=function(e,t){var r=this._data[3*e+0];2097152&r?this._combined[e]+=(0,i.stringFromCodePoint)(t):(2097151&r?(this._combined[e]=(0,i.stringFromCodePoint)(2097151&r)+(0,i.stringFromCodePoint)(t),r&=-2097152,r|=2097152):r=t|1<<22,this._data[3*e+0]=r)},e.prototype.insertCells=function(e,t,r,i){if((e%=this.length)&&2===this.getWidth(e-1)&&this.setCellFromCodePoint(e-1,0,1,(null==i?void 0:i.fg)||0,(null==i?void 0:i.bg)||0,(null==i?void 0:i.extended)||new s.ExtendedAttrs),t<this.length-e){for(var n=new o.CellData,a=this.length-e-t-1;a>=0;--a)this.setCell(e+t+a,this.loadCell(e+a,n));for(a=0;a<t;++a)this.setCell(e+a,r)}else for(a=e;a<this.length;++a)this.setCell(a,r);2===this.getWidth(this.length-1)&&this.setCellFromCodePoint(this.length-1,0,1,(null==i?void 0:i.fg)||0,(null==i?void 0:i.bg)||0,(null==i?void 0:i.extended)||new s.ExtendedAttrs)},e.prototype.deleteCells=function(e,t,r,i){if(e%=this.length,t<this.length-e){for(var n=new o.CellData,a=0;a<this.length-e-t;++a)this.setCell(e+a,this.loadCell(e+t+a,n));for(a=this.length-t;a<this.length;++a)this.setCell(a,r)}else for(a=e;a<this.length;++a)this.setCell(a,r);e&&2===this.getWidth(e-1)&&this.setCellFromCodePoint(e-1,0,1,(null==i?void 0:i.fg)||0,(null==i?void 0:i.bg)||0,(null==i?void 0:i.extended)||new s.ExtendedAttrs),0!==this.getWidth(e)||this.hasContent(e)||this.setCellFromCodePoint(e,0,1,(null==i?void 0:i.fg)||0,(null==i?void 0:i.bg)||0,(null==i?void 0:i.extended)||new s.ExtendedAttrs)},e.prototype.replaceCells=function(e,t,r,i){for(e&&2===this.getWidth(e-1)&&this.setCellFromCodePoint(e-1,0,1,(null==i?void 0:i.fg)||0,(null==i?void 0:i.bg)||0,(null==i?void 0:i.extended)||new s.ExtendedAttrs),t<this.length&&2===this.getWidth(t-1)&&this.setCellFromCodePoint(t,0,1,(null==i?void 0:i.fg)||0,(null==i?void 0:i.bg)||0,(null==i?void 0:i.extended)||new s.ExtendedAttrs);e<t&&e<this.length;)this.setCell(e++,r)},e.prototype.resize=function(e,t){if(e!==this.length){if(e>this.length){var r=new Uint32Array(3*e);this.length&&(3*e<this._data.length?r.set(this._data.subarray(0,3*e)):r.set(this._data)),this._data=r;for(var i=this.length;i<e;++i)this.setCell(i,t)}else if(e){(r=new Uint32Array(3*e)).set(this._data.subarray(0,3*e)),this._data=r;var n=Object.keys(this._combined);for(i=0;i<n.length;i++){var o=parseInt(n[i],10);o>=e&&delete this._combined[o]}}else this._data=new Uint32Array(0),this._combined={};this.length=e}},e.prototype.fill=function(e){this._combined={},this._extendedAttrs={};for(var t=0;t<this.length;++t)this.setCell(t,e)},e.prototype.copyFrom=function(e){for(var t in this.length!==e.length?this._data=new Uint32Array(e._data):this._data.set(e._data),this.length=e.length,this._combined={},e._combined)this._combined[t]=e._combined[t];for(var t in this._extendedAttrs={},e._extendedAttrs)this._extendedAttrs[t]=e._extendedAttrs[t];this.isWrapped=e.isWrapped},e.prototype.clone=function(){var t=new e(0);for(var r in t._data=new Uint32Array(this._data),t.length=this.length,this._combined)t._combined[r]=this._combined[r];for(var r in this._extendedAttrs)t._extendedAttrs[r]=this._extendedAttrs[r];return t.isWrapped=this.isWrapped,t},e.prototype.getTrimmedLength=function(){for(var e=this.length-1;e>=0;--e)if(4194303&this._data[3*e+0])return e+(this._data[3*e+0]>>22);return 0},e.prototype.copyCellsFrom=function(e,t,r,i,n){var o=e._data;if(n)for(var s=i-1;s>=0;s--)for(var a=0;a<3;a++)this._data[3*(r+s)+a]=o[3*(t+s)+a];else for(s=0;s<i;s++)for(a=0;a<3;a++)this._data[3*(r+s)+a]=o[3*(t+s)+a];var c=Object.keys(e._combined);for(a=0;a<c.length;a++){var l=parseInt(c[a],10);l>=t&&(this._combined[l-t+r]=e._combined[l])}},e.prototype.translateToString=function(e,t,r){void 0===e&&(e=!1),void 0===t&&(t=0),void 0===r&&(r=this.length),e&&(r=Math.min(r,this.getTrimmedLength()));for(var o="";t<r;){var s=this._data[3*t+0],a=2097151&s;o+=2097152&s?this._combined[t]:a?(0,i.stringFromCodePoint)(a):n.WHITESPACE_CELL_CHAR,t+=s>>22||1}return o},e}();t.BufferLine=a},4841:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.getRangeLength=void 0,t.getRangeLength=function(e,t){if(e.start.y>e.end.y)throw new Error("Buffer range end ("+e.end.x+", "+e.end.y+") cannot be before start ("+e.start.x+", "+e.start.y+")");return t*(e.end.y-e.start.y)+(e.end.x-e.start.x+1)}},4634:(e,t)=>{function r(e,t,r){if(t===e.length-1)return e[t].getTrimmedLength();var i=!e[t].hasContent(r-1)&&1===e[t].getWidth(r-1),n=2===e[t+1].getWidth(0);return i&&n?r-1:r}Object.defineProperty(t,"__esModule",{value:!0}),t.getWrappedLineTrimmedLength=t.reflowSmallerGetNewLineLengths=t.reflowLargerApplyNewLayout=t.reflowLargerCreateNewLayout=t.reflowLargerGetLinesToRemove=void 0,t.reflowLargerGetLinesToRemove=function(e,t,i,n,o){for(var s=[],a=0;a<e.length-1;a++){var c=a,l=e.get(++c);if(l.isWrapped){for(var u=[e.get(a)];c<e.length&&l.isWrapped;)u.push(l),l=e.get(++c);if(n>=a&&n<c)a+=u.length-1;else{for(var h=0,f=r(u,h,t),_=1,d=0;_<u.length;){var p=r(u,_,t),v=p-d,g=i-f,y=Math.min(v,g);u[h].copyCellsFrom(u[_],d,f,y,!1),(f+=y)===i&&(h++,f=0),(d+=y)===p&&(_++,d=0),0===f&&0!==h&&2===u[h-1].getWidth(i-1)&&(u[h].copyCellsFrom(u[h-1],i-1,f++,1,!1),u[h-1].setCell(i-1,o))}u[h].replaceCells(f,i,o);for(var m=0,b=u.length-1;b>0&&(b>h||0===u[b].getTrimmedLength());b--)m++;m>0&&(s.push(a+u.length-m),s.push(m)),a+=u.length-1}}}return s},t.reflowLargerCreateNewLayout=function(e,t){for(var r=[],i=0,n=t[i],o=0,s=0;s<e.length;s++)if(n===s){var a=t[++i];e.onDeleteEmitter.fire({index:s-o,amount:a}),s+=a-1,o+=a,n=t[++i]}else r.push(s);return{layout:r,countRemoved:o}},t.reflowLargerApplyNewLayout=function(e,t){for(var r=[],i=0;i<t.length;i++)r.push(e.get(t[i]));for(i=0;i<r.length;i++)e.set(i,r[i]);e.length=t.length},t.reflowSmallerGetNewLineLengths=function(e,t,i){for(var n=[],o=e.map((function(i,n){return r(e,n,t)})).reduce((function(e,t){return e+t})),s=0,a=0,c=0;c<o;){if(o-c<i){n.push(o-c);break}s+=i;var l=r(e,a,t);s>l&&(s-=l,a++);var u=2===e[a].getWidth(s-1);u&&s--;var h=u?i-1:i;n.push(h),c+=h}return n},t.getWrappedLineTrimmedLength=r},5295:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.BufferSet=void 0;var o=r(9092),s=r(8460),a=function(e){function t(t,r){var i=e.call(this)||this;return i._optionsService=t,i._bufferService=r,i._onBufferActivate=i.register(new s.EventEmitter),i.reset(),i}return n(t,e),Object.defineProperty(t.prototype,"onBufferActivate",{get:function(){return this._onBufferActivate.event},enumerable:!1,configurable:!0}),t.prototype.reset=function(){this._normal=new o.Buffer(!0,this._optionsService,this._bufferService),this._normal.fillViewportRows(),this._alt=new o.Buffer(!1,this._optionsService,this._bufferService),this._activeBuffer=this._normal,this._onBufferActivate.fire({activeBuffer:this._normal,inactiveBuffer:this._alt}),this.setupTabStops()},Object.defineProperty(t.prototype,"alt",{get:function(){return this._alt},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"active",{get:function(){return this._activeBuffer},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"normal",{get:function(){return this._normal},enumerable:!1,configurable:!0}),t.prototype.activateNormalBuffer=function(){this._activeBuffer!==this._normal&&(this._normal.x=this._alt.x,this._normal.y=this._alt.y,this._alt.clear(),this._activeBuffer=this._normal,this._onBufferActivate.fire({activeBuffer:this._normal,inactiveBuffer:this._alt}))},t.prototype.activateAltBuffer=function(e){this._activeBuffer!==this._alt&&(this._alt.fillViewportRows(e),this._alt.x=this._normal.x,this._alt.y=this._normal.y,this._activeBuffer=this._alt,this._onBufferActivate.fire({activeBuffer:this._alt,inactiveBuffer:this._normal}))},t.prototype.resize=function(e,t){this._normal.resize(e,t),this._alt.resize(e,t)},t.prototype.setupTabStops=function(e){this._normal.setupTabStops(e),this._alt.setupTabStops(e)},t}(r(844).Disposable);t.BufferSet=a},511:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.CellData=void 0;var o=r(482),s=r(643),a=r(3734),c=function(e){function t(){var t=null!==e&&e.apply(this,arguments)||this;return t.content=0,t.fg=0,t.bg=0,t.extended=new a.ExtendedAttrs,t.combinedData="",t}return n(t,e),t.fromCharData=function(e){var r=new t;return r.setFromCharData(e),r},t.prototype.isCombined=function(){return 2097152&this.content},t.prototype.getWidth=function(){return this.content>>22},t.prototype.getChars=function(){return 2097152&this.content?this.combinedData:2097151&this.content?(0,o.stringFromCodePoint)(2097151&this.content):""},t.prototype.getCode=function(){return this.isCombined()?this.combinedData.charCodeAt(this.combinedData.length-1):2097151&this.content},t.prototype.setFromCharData=function(e){this.fg=e[s.CHAR_DATA_ATTR_INDEX],this.bg=0;var t=!1;if(e[s.CHAR_DATA_CHAR_INDEX].length>2)t=!0;else if(2===e[s.CHAR_DATA_CHAR_INDEX].length){var r=e[s.CHAR_DATA_CHAR_INDEX].charCodeAt(0);if(55296<=r&&r<=56319){var i=e[s.CHAR_DATA_CHAR_INDEX].charCodeAt(1);56320<=i&&i<=57343?this.content=1024*(r-55296)+i-56320+65536|e[s.CHAR_DATA_WIDTH_INDEX]<<22:t=!0}else t=!0}else this.content=e[s.CHAR_DATA_CHAR_INDEX].charCodeAt(0)|e[s.CHAR_DATA_WIDTH_INDEX]<<22;t&&(this.combinedData=e[s.CHAR_DATA_CHAR_INDEX],this.content=2097152|e[s.CHAR_DATA_WIDTH_INDEX]<<22)},t.prototype.getAsCharData=function(){return[this.fg,this.getChars(),this.getWidth(),this.getCode()]},t}(a.AttributeData);t.CellData=c},643:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.WHITESPACE_CELL_CODE=t.WHITESPACE_CELL_WIDTH=t.WHITESPACE_CELL_CHAR=t.NULL_CELL_CODE=t.NULL_CELL_WIDTH=t.NULL_CELL_CHAR=t.CHAR_DATA_CODE_INDEX=t.CHAR_DATA_WIDTH_INDEX=t.CHAR_DATA_CHAR_INDEX=t.CHAR_DATA_ATTR_INDEX=t.DEFAULT_ATTR=t.DEFAULT_COLOR=void 0,t.DEFAULT_COLOR=256,t.DEFAULT_ATTR=256|t.DEFAULT_COLOR<<9,t.CHAR_DATA_ATTR_INDEX=0,t.CHAR_DATA_CHAR_INDEX=1,t.CHAR_DATA_WIDTH_INDEX=2,t.CHAR_DATA_CODE_INDEX=3,t.NULL_CELL_CHAR="",t.NULL_CELL_WIDTH=1,t.NULL_CELL_CODE=0,t.WHITESPACE_CELL_CHAR=" ",t.WHITESPACE_CELL_WIDTH=1,t.WHITESPACE_CELL_CODE=32},4863:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.Marker=void 0;var o=r(8460),s=function(e){function t(r){var i=e.call(this)||this;return i.line=r,i._id=t._nextId++,i.isDisposed=!1,i._onDispose=new o.EventEmitter,i}return n(t,e),Object.defineProperty(t.prototype,"id",{get:function(){return this._id},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onDispose",{get:function(){return this._onDispose.event},enumerable:!1,configurable:!0}),t.prototype.dispose=function(){this.isDisposed||(this.isDisposed=!0,this.line=-1,this._onDispose.fire(),e.prototype.dispose.call(this))},t._nextId=1,t}(r(844).Disposable);t.Marker=s},7116:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.DEFAULT_CHARSET=t.CHARSETS=void 0,t.CHARSETS={},t.DEFAULT_CHARSET=t.CHARSETS.B,t.CHARSETS[0]={"`":"◆",a:"▒",b:"␉",c:"␌",d:"␍",e:"␊",f:"°",g:"±",h:"␤",i:"␋",j:"┘",k:"┐",l:"┌",m:"└",n:"┼",o:"⎺",p:"⎻",q:"─",r:"⎼",s:"⎽",t:"├",u:"┤",v:"┴",w:"┬",x:"│",y:"≤",z:"≥","{":"π","|":"≠","}":"£","~":"·"},t.CHARSETS.A={"#":"£"},t.CHARSETS.B=void 0,t.CHARSETS[4]={"#":"£","@":"¾","[":"ij","\\":"½","]":"|","{":"¨","|":"f","}":"¼","~":"´"},t.CHARSETS.C=t.CHARSETS[5]={"[":"Ä","\\":"Ö","]":"Å","^":"Ü","`":"é","{":"ä","|":"ö","}":"å","~":"ü"},t.CHARSETS.R={"#":"£","@":"à","[":"°","\\":"ç","]":"§","{":"é","|":"ù","}":"è","~":"¨"},t.CHARSETS.Q={"@":"à","[":"â","\\":"ç","]":"ê","^":"î","`":"ô","{":"é","|":"ù","}":"è","~":"û"},t.CHARSETS.K={"@":"§","[":"Ä","\\":"Ö","]":"Ü","{":"ä","|":"ö","}":"ü","~":"ß"},t.CHARSETS.Y={"#":"£","@":"§","[":"°","\\":"ç","]":"é","`":"ù","{":"à","|":"ò","}":"è","~":"ì"},t.CHARSETS.E=t.CHARSETS[6]={"@":"Ä","[":"Æ","\\":"Ø","]":"Å","^":"Ü","`":"ä","{":"æ","|":"ø","}":"å","~":"ü"},t.CHARSETS.Z={"#":"£","@":"§","[":"¡","\\":"Ñ","]":"¿","{":"°","|":"ñ","}":"ç"},t.CHARSETS.H=t.CHARSETS[7]={"@":"É","[":"Ä","\\":"Ö","]":"Å","^":"Ü","`":"é","{":"ä","|":"ö","}":"å","~":"ü"},t.CHARSETS["="]={"#":"ù","@":"à","[":"é","\\":"ç","]":"ê","^":"î",_:"è","`":"ô","{":"ä","|":"ö","}":"ü","~":"û"}},2584:(e,t)=>{var r,i;Object.defineProperty(t,"__esModule",{value:!0}),t.C1=t.C0=void 0,(i=t.C0||(t.C0={})).NUL="\0",i.SOH="",i.STX="",i.ETX="",i.EOT="",i.ENQ="",i.ACK="",i.BEL="",i.BS="\b",i.HT="\t",i.LF="\n",i.VT="\v",i.FF="\f",i.CR="\r",i.SO="",i.SI="",i.DLE="",i.DC1="",i.DC2="",i.DC3="",i.DC4="",i.NAK="",i.SYN="",i.ETB="",i.CAN="",i.EM="",i.SUB="",i.ESC="",i.FS="",i.GS="",i.RS="",i.US="",i.SP=" ",i.DEL="",(r=t.C1||(t.C1={})).PAD="",r.HOP="",r.BPH="",r.NBH="",r.IND="",r.NEL="",r.SSA="",r.ESA="",r.HTS="",r.HTJ="",r.VTS="",r.PLD="",r.PLU="",r.RI="",r.SS2="",r.SS3="",r.DCS="",r.PU1="",r.PU2="",r.STS="",r.CCH="",r.MW="",r.SPA="",r.EPA="",r.SOS="",r.SGCI="",r.SCI="",r.CSI="",r.ST="",r.OSC="",r.PM="",r.APC=""},7399:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.evaluateKeyboardEvent=void 0;var i=r(2584),n={48:["0",")"],49:["1","!"],50:["2","@"],51:["3","#"],52:["4","$"],53:["5","%"],54:["6","^"],55:["7","&"],56:["8","*"],57:["9","("],186:[";",":"],187:["=","+"],188:[",","<"],189:["-","_"],190:[".",">"],191:["/","?"],192:["`","~"],219:["[","{"],220:["\\","|"],221:["]","}"],222:["'",'"']};t.evaluateKeyboardEvent=function(e,t,r,o){var s={type:0,cancel:!1,key:void 0},a=(e.shiftKey?1:0)|(e.altKey?2:0)|(e.ctrlKey?4:0)|(e.metaKey?8:0);switch(e.keyCode){case 0:"UIKeyInputUpArrow"===e.key?s.key=t?i.C0.ESC+"OA":i.C0.ESC+"[A":"UIKeyInputLeftArrow"===e.key?s.key=t?i.C0.ESC+"OD":i.C0.ESC+"[D":"UIKeyInputRightArrow"===e.key?s.key=t?i.C0.ESC+"OC":i.C0.ESC+"[C":"UIKeyInputDownArrow"===e.key&&(s.key=t?i.C0.ESC+"OB":i.C0.ESC+"[B");break;case 8:if(e.shiftKey){s.key=i.C0.BS;break}if(e.altKey){s.key=i.C0.ESC+i.C0.DEL;break}s.key=i.C0.DEL;break;case 9:if(e.shiftKey){s.key=i.C0.ESC+"[Z";break}s.key=i.C0.HT,s.cancel=!0;break;case 13:s.key=e.altKey?i.C0.ESC+i.C0.CR:i.C0.CR,s.cancel=!0;break;case 27:s.key=i.C0.ESC,e.altKey&&(s.key=i.C0.ESC+i.C0.ESC),s.cancel=!0;break;case 37:if(e.metaKey)break;a?(s.key=i.C0.ESC+"[1;"+(a+1)+"D",s.key===i.C0.ESC+"[1;3D"&&(s.key=i.C0.ESC+(r?"b":"[1;5D"))):s.key=t?i.C0.ESC+"OD":i.C0.ESC+"[D";break;case 39:if(e.metaKey)break;a?(s.key=i.C0.ESC+"[1;"+(a+1)+"C",s.key===i.C0.ESC+"[1;3C"&&(s.key=i.C0.ESC+(r?"f":"[1;5C"))):s.key=t?i.C0.ESC+"OC":i.C0.ESC+"[C";break;case 38:if(e.metaKey)break;a?(s.key=i.C0.ESC+"[1;"+(a+1)+"A",r||s.key!==i.C0.ESC+"[1;3A"||(s.key=i.C0.ESC+"[1;5A")):s.key=t?i.C0.ESC+"OA":i.C0.ESC+"[A";break;case 40:if(e.metaKey)break;a?(s.key=i.C0.ESC+"[1;"+(a+1)+"B",r||s.key!==i.C0.ESC+"[1;3B"||(s.key=i.C0.ESC+"[1;5B")):s.key=t?i.C0.ESC+"OB":i.C0.ESC+"[B";break;case 45:e.shiftKey||e.ctrlKey||(s.key=i.C0.ESC+"[2~");break;case 46:s.key=a?i.C0.ESC+"[3;"+(a+1)+"~":i.C0.ESC+"[3~";break;case 36:s.key=a?i.C0.ESC+"[1;"+(a+1)+"H":t?i.C0.ESC+"OH":i.C0.ESC+"[H";break;case 35:s.key=a?i.C0.ESC+"[1;"+(a+1)+"F":t?i.C0.ESC+"OF":i.C0.ESC+"[F";break;case 33:e.shiftKey?s.type=2:s.key=i.C0.ESC+"[5~";break;case 34:e.shiftKey?s.type=3:s.key=i.C0.ESC+"[6~";break;case 112:s.key=a?i.C0.ESC+"[1;"+(a+1)+"P":i.C0.ESC+"OP";break;case 113:s.key=a?i.C0.ESC+"[1;"+(a+1)+"Q":i.C0.ESC+"OQ";break;case 114:s.key=a?i.C0.ESC+"[1;"+(a+1)+"R":i.C0.ESC+"OR";break;case 115:s.key=a?i.C0.ESC+"[1;"+(a+1)+"S":i.C0.ESC+"OS";break;case 116:s.key=a?i.C0.ESC+"[15;"+(a+1)+"~":i.C0.ESC+"[15~";break;case 117:s.key=a?i.C0.ESC+"[17;"+(a+1)+"~":i.C0.ESC+"[17~";break;case 118:s.key=a?i.C0.ESC+"[18;"+(a+1)+"~":i.C0.ESC+"[18~";break;case 119:s.key=a?i.C0.ESC+"[19;"+(a+1)+"~":i.C0.ESC+"[19~";break;case 120:s.key=a?i.C0.ESC+"[20;"+(a+1)+"~":i.C0.ESC+"[20~";break;case 121:s.key=a?i.C0.ESC+"[21;"+(a+1)+"~":i.C0.ESC+"[21~";break;case 122:s.key=a?i.C0.ESC+"[23;"+(a+1)+"~":i.C0.ESC+"[23~";break;case 123:s.key=a?i.C0.ESC+"[24;"+(a+1)+"~":i.C0.ESC+"[24~";break;default:if(!e.ctrlKey||e.shiftKey||e.altKey||e.metaKey)if(r&&!o||!e.altKey||e.metaKey)!r||e.altKey||e.ctrlKey||e.shiftKey||!e.metaKey?e.key&&!e.ctrlKey&&!e.altKey&&!e.metaKey&&e.keyCode>=48&&1===e.key.length?s.key=e.key:e.key&&e.ctrlKey&&"_"===e.key&&(s.key=i.C0.US):65===e.keyCode&&(s.type=1);else{var c=n[e.keyCode],l=null==c?void 0:c[e.shiftKey?1:0];if(l)s.key=i.C0.ESC+l;else if(e.keyCode>=65&&e.keyCode<=90){var u=e.ctrlKey?e.keyCode-64:e.keyCode+32;s.key=i.C0.ESC+String.fromCharCode(u)}}else e.keyCode>=65&&e.keyCode<=90?s.key=String.fromCharCode(e.keyCode-64):32===e.keyCode?s.key=i.C0.NUL:e.keyCode>=51&&e.keyCode<=55?s.key=String.fromCharCode(e.keyCode-51+27):56===e.keyCode?s.key=i.C0.DEL:219===e.keyCode?s.key=i.C0.ESC:220===e.keyCode?s.key=i.C0.FS:221===e.keyCode&&(s.key=i.C0.GS)}return s}},482:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.Utf8ToUtf32=t.StringToUtf32=t.utf32ToString=t.stringFromCodePoint=void 0,t.stringFromCodePoint=function(e){return e>65535?(e-=65536,String.fromCharCode(55296+(e>>10))+String.fromCharCode(e%1024+56320)):String.fromCharCode(e)},t.utf32ToString=function(e,t,r){void 0===t&&(t=0),void 0===r&&(r=e.length);for(var i="",n=t;n<r;++n){var o=e[n];o>65535?(o-=65536,i+=String.fromCharCode(55296+(o>>10))+String.fromCharCode(o%1024+56320)):i+=String.fromCharCode(o)}return i};var r=function(){function e(){this._interim=0}return e.prototype.clear=function(){this._interim=0},e.prototype.decode=function(e,t){var r=e.length;if(!r)return 0;var i=0,n=0;this._interim&&(56320<=(a=e.charCodeAt(n++))&&a<=57343?t[i++]=1024*(this._interim-55296)+a-56320+65536:(t[i++]=this._interim,t[i++]=a),this._interim=0);for(var o=n;o<r;++o){var s=e.charCodeAt(o);if(55296<=s&&s<=56319){if(++o>=r)return this._interim=s,i;var a;56320<=(a=e.charCodeAt(o))&&a<=57343?t[i++]=1024*(s-55296)+a-56320+65536:(t[i++]=s,t[i++]=a)}else 65279!==s&&(t[i++]=s)}return i},e}();t.StringToUtf32=r;var i=function(){function e(){this.interim=new Uint8Array(3)}return e.prototype.clear=function(){this.interim.fill(0)},e.prototype.decode=function(e,t){var r=e.length;if(!r)return 0;var i,n,o,s,a=0,c=0,l=0;if(this.interim[0]){var u=!1,h=this.interim[0];h&=192==(224&h)?31:224==(240&h)?15:7;for(var f=0,_=void 0;(_=63&this.interim[++f])&&f<4;)h<<=6,h|=_;for(var d=192==(224&this.interim[0])?2:224==(240&this.interim[0])?3:4,p=d-f;l<p;){if(l>=r)return 0;if(128!=(192&(_=e[l++]))){l--,u=!0;break}this.interim[f++]=_,h<<=6,h|=63&_}u||(2===d?h<128?l--:t[a++]=h:3===d?h<2048||h>=55296&&h<=57343||65279===h||(t[a++]=h):h<65536||h>1114111||(t[a++]=h)),this.interim.fill(0)}for(var v=r-4,g=l;g<r;){for(;!(!(g<v)||128&(i=e[g])||128&(n=e[g+1])||128&(o=e[g+2])||128&(s=e[g+3]));)t[a++]=i,t[a++]=n,t[a++]=o,t[a++]=s,g+=4;if((i=e[g++])<128)t[a++]=i;else if(192==(224&i)){if(g>=r)return this.interim[0]=i,a;if(128!=(192&(n=e[g++]))){g--;continue}if((c=(31&i)<<6|63&n)<128){g--;continue}t[a++]=c}else if(224==(240&i)){if(g>=r)return this.interim[0]=i,a;if(128!=(192&(n=e[g++]))){g--;continue}if(g>=r)return this.interim[0]=i,this.interim[1]=n,a;if(128!=(192&(o=e[g++]))){g--;continue}if((c=(15&i)<<12|(63&n)<<6|63&o)<2048||c>=55296&&c<=57343||65279===c)continue;t[a++]=c}else if(240==(248&i)){if(g>=r)return this.interim[0]=i,a;if(128!=(192&(n=e[g++]))){g--;continue}if(g>=r)return this.interim[0]=i,this.interim[1]=n,a;if(128!=(192&(o=e[g++]))){g--;continue}if(g>=r)return this.interim[0]=i,this.interim[1]=n,this.interim[2]=o,a;if(128!=(192&(s=e[g++]))){g--;continue}if((c=(7&i)<<18|(63&n)<<12|(63&o)<<6|63&s)<65536||c>1114111)continue;t[a++]=c}}return a},e}();t.Utf8ToUtf32=i},225:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.UnicodeV6=void 0;var i,n=r(8273),o=[[768,879],[1155,1158],[1160,1161],[1425,1469],[1471,1471],[1473,1474],[1476,1477],[1479,1479],[1536,1539],[1552,1557],[1611,1630],[1648,1648],[1750,1764],[1767,1768],[1770,1773],[1807,1807],[1809,1809],[1840,1866],[1958,1968],[2027,2035],[2305,2306],[2364,2364],[2369,2376],[2381,2381],[2385,2388],[2402,2403],[2433,2433],[2492,2492],[2497,2500],[2509,2509],[2530,2531],[2561,2562],[2620,2620],[2625,2626],[2631,2632],[2635,2637],[2672,2673],[2689,2690],[2748,2748],[2753,2757],[2759,2760],[2765,2765],[2786,2787],[2817,2817],[2876,2876],[2879,2879],[2881,2883],[2893,2893],[2902,2902],[2946,2946],[3008,3008],[3021,3021],[3134,3136],[3142,3144],[3146,3149],[3157,3158],[3260,3260],[3263,3263],[3270,3270],[3276,3277],[3298,3299],[3393,3395],[3405,3405],[3530,3530],[3538,3540],[3542,3542],[3633,3633],[3636,3642],[3655,3662],[3761,3761],[3764,3769],[3771,3772],[3784,3789],[3864,3865],[3893,3893],[3895,3895],[3897,3897],[3953,3966],[3968,3972],[3974,3975],[3984,3991],[3993,4028],[4038,4038],[4141,4144],[4146,4146],[4150,4151],[4153,4153],[4184,4185],[4448,4607],[4959,4959],[5906,5908],[5938,5940],[5970,5971],[6002,6003],[6068,6069],[6071,6077],[6086,6086],[6089,6099],[6109,6109],[6155,6157],[6313,6313],[6432,6434],[6439,6440],[6450,6450],[6457,6459],[6679,6680],[6912,6915],[6964,6964],[6966,6970],[6972,6972],[6978,6978],[7019,7027],[7616,7626],[7678,7679],[8203,8207],[8234,8238],[8288,8291],[8298,8303],[8400,8431],[12330,12335],[12441,12442],[43014,43014],[43019,43019],[43045,43046],[64286,64286],[65024,65039],[65056,65059],[65279,65279],[65529,65531]],s=[[68097,68099],[68101,68102],[68108,68111],[68152,68154],[68159,68159],[119143,119145],[119155,119170],[119173,119179],[119210,119213],[119362,119364],[917505,917505],[917536,917631],[917760,917999]],a=function(){function e(){if(this.version="6",!i){i=new Uint8Array(65536),(0,n.fill)(i,1),i[0]=0,(0,n.fill)(i,0,1,32),(0,n.fill)(i,0,127,160),(0,n.fill)(i,2,4352,4448),i[9001]=2,i[9002]=2,(0,n.fill)(i,2,11904,42192),i[12351]=1,(0,n.fill)(i,2,44032,55204),(0,n.fill)(i,2,63744,64256),(0,n.fill)(i,2,65040,65050),(0,n.fill)(i,2,65072,65136),(0,n.fill)(i,2,65280,65377),(0,n.fill)(i,2,65504,65511);for(var e=0;e<o.length;++e)(0,n.fill)(i,0,o[e][0],o[e][1]+1)}}return e.prototype.wcwidth=function(e){return e<32?0:e<127?1:e<65536?i[e]:function(e,t){var r,i=0,n=t.length-1;if(e<t[0][0]||e>t[n][1])return!1;for(;n>=i;)if(e>t[r=i+n>>1][1])i=r+1;else{if(!(e<t[r][0]))return!0;n=r-1}return!1}(e,s)?0:e>=131072&&e<=196605||e>=196608&&e<=262141?2:1},e}();t.UnicodeV6=a},5981:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.WriteBuffer=void 0;var r="undefined"==typeof queueMicrotask?function(e){Promise.resolve().then(e)}:queueMicrotask,i=function(){function e(e){this._action=e,this._writeBuffer=[],this._callbacks=[],this._pendingData=0,this._bufferOffset=0,this._isSyncWriting=!1,this._syncCalls=0}return e.prototype.writeSync=function(e,t){if(void 0!==t&&this._syncCalls>t)this._syncCalls=0;else if(this._pendingData+=e.length,this._writeBuffer.push(e),this._callbacks.push(void 0),this._syncCalls++,!this._isSyncWriting){var r;for(this._isSyncWriting=!0;r=this._writeBuffer.shift();){this._action(r);var i=this._callbacks.shift();i&&i()}this._pendingData=0,this._bufferOffset=2147483647,this._isSyncWriting=!1,this._syncCalls=0}},e.prototype.write=function(e,t){var r=this;if(this._pendingData>5e7)throw new Error("write data discarded, use flow control to avoid losing data");this._writeBuffer.length||(this._bufferOffset=0,setTimeout((function(){return r._innerWrite()}))),this._pendingData+=e.length,this._writeBuffer.push(e),this._callbacks.push(t)},e.prototype._innerWrite=function(e,t){var i=this;void 0===e&&(e=0),void 0===t&&(t=!0);for(var n=e||Date.now();this._writeBuffer.length>this._bufferOffset;){var o=this._writeBuffer[this._bufferOffset],s=this._action(o,t);if(s)return void s.catch((function(e){return r((function(){throw e})),Promise.resolve(!1)})).then((function(e){return Date.now()-n>=12?setTimeout((function(){return i._innerWrite(0,e)})):i._innerWrite(n,e)}));var a=this._callbacks[this._bufferOffset];if(a&&a(),this._bufferOffset++,this._pendingData-=o.length,Date.now()-n>=12)break}this._writeBuffer.length>this._bufferOffset?(this._bufferOffset>50&&(this._writeBuffer=this._writeBuffer.slice(this._bufferOffset),this._callbacks=this._callbacks.slice(this._bufferOffset),this._bufferOffset=0),setTimeout((function(){return i._innerWrite()}))):(this._writeBuffer.length=0,this._callbacks.length=0,this._pendingData=0,this._bufferOffset=0)},e}();t.WriteBuffer=i},5941:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.toRgbString=t.parseColor=void 0;var r=/^([\da-f]{1})\/([\da-f]{1})\/([\da-f]{1})$|^([\da-f]{2})\/([\da-f]{2})\/([\da-f]{2})$|^([\da-f]{3})\/([\da-f]{3})\/([\da-f]{3})$|^([\da-f]{4})\/([\da-f]{4})\/([\da-f]{4})$/,i=/^[\da-f]+$/;function n(e,t){var r=e.toString(16),i=r.length<2?"0"+r:r;switch(t){case 4:return r[0];case 8:return i;case 12:return(i+i).slice(0,3);default:return i+i}}t.parseColor=function(e){if(e){var t=e.toLowerCase();if(0===t.indexOf("rgb:")){t=t.slice(4);var n=r.exec(t);if(n){var o=n[1]?15:n[4]?255:n[7]?4095:65535;return[Math.round(parseInt(n[1]||n[4]||n[7]||n[10],16)/o*255),Math.round(parseInt(n[2]||n[5]||n[8]||n[11],16)/o*255),Math.round(parseInt(n[3]||n[6]||n[9]||n[12],16)/o*255)]}}else if(0===t.indexOf("#")&&(t=t.slice(1),i.exec(t)&&[3,6,9,12].includes(t.length))){for(var s=t.length/3,a=[0,0,0],c=0;c<3;++c){var l=parseInt(t.slice(s*c,s*c+s),16);a[c]=1===s?l<<4:2===s?l:3===s?l>>4:l>>8}return a}}},t.toRgbString=function(e,t){void 0===t&&(t=16);var r=e[0],i=e[1],o=e[2];return"rgb:"+n(r,t)+"/"+n(i,t)+"/"+n(o,t)}},5770:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.PAYLOAD_LIMIT=void 0,t.PAYLOAD_LIMIT=1e7},6351:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.DcsHandler=t.DcsParser=void 0;var i=r(482),n=r(8742),o=r(5770),s=[],a=function(){function e(){this._handlers=Object.create(null),this._active=s,this._ident=0,this._handlerFb=function(){},this._stack={paused:!1,loopPosition:0,fallThrough:!1}}return e.prototype.dispose=function(){this._handlers=Object.create(null),this._handlerFb=function(){},this._active=s},e.prototype.registerHandler=function(e,t){void 0===this._handlers[e]&&(this._handlers[e]=[]);var r=this._handlers[e];return r.push(t),{dispose:function(){var e=r.indexOf(t);-1!==e&&r.splice(e,1)}}},e.prototype.clearHandler=function(e){this._handlers[e]&&delete this._handlers[e]},e.prototype.setHandlerFallback=function(e){this._handlerFb=e},e.prototype.reset=function(){if(this._active.length)for(var e=this._stack.paused?this._stack.loopPosition-1:this._active.length-1;e>=0;--e)this._active[e].unhook(!1);this._stack.paused=!1,this._active=s,this._ident=0},e.prototype.hook=function(e,t){if(this.reset(),this._ident=e,this._active=this._handlers[e]||s,this._active.length)for(var r=this._active.length-1;r>=0;r--)this._active[r].hook(t);else this._handlerFb(this._ident,"HOOK",t)},e.prototype.put=function(e,t,r){if(this._active.length)for(var n=this._active.length-1;n>=0;n--)this._active[n].put(e,t,r);else this._handlerFb(this._ident,"PUT",(0,i.utf32ToString)(e,t,r))},e.prototype.unhook=function(e,t){if(void 0===t&&(t=!0),this._active.length){var r=!1,i=this._active.length-1,n=!1;if(this._stack.paused&&(i=this._stack.loopPosition-1,r=t,n=this._stack.fallThrough,this._stack.paused=!1),!n&&!1===r){for(;i>=0&&!0!==(r=this._active[i].unhook(e));i--)if(r instanceof Promise)return this._stack.paused=!0,this._stack.loopPosition=i,this._stack.fallThrough=!1,r;i--}for(;i>=0;i--)if((r=this._active[i].unhook(!1))instanceof Promise)return this._stack.paused=!0,this._stack.loopPosition=i,this._stack.fallThrough=!0,r}else this._handlerFb(this._ident,"UNHOOK",e);this._active=s,this._ident=0},e}();t.DcsParser=a;var c=new n.Params;c.addParam(0);var l=function(){function e(e){this._handler=e,this._data="",this._params=c,this._hitLimit=!1}return e.prototype.hook=function(e){this._params=e.length>1||e.params[0]?e.clone():c,this._data="",this._hitLimit=!1},e.prototype.put=function(e,t,r){this._hitLimit||(this._data+=(0,i.utf32ToString)(e,t,r),this._data.length>o.PAYLOAD_LIMIT&&(this._data="",this._hitLimit=!0))},e.prototype.unhook=function(e){var t=this,r=!1;if(this._hitLimit)r=!1;else if(e&&(r=this._handler(this._data,this._params))instanceof Promise)return r.then((function(e){return t._params=c,t._data="",t._hitLimit=!1,e}));return this._params=c,this._data="",this._hitLimit=!1,r},e}();t.DcsHandler=l},2015:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)});Object.defineProperty(t,"__esModule",{value:!0}),t.EscapeSequenceParser=t.VT500_TRANSITION_TABLE=t.TransitionTable=void 0;var o=r(844),s=r(8273),a=r(8742),c=r(6242),l=r(6351),u=function(){function e(e){this.table=new Uint8Array(e)}return e.prototype.setDefault=function(e,t){(0,s.fill)(this.table,e<<4|t)},e.prototype.add=function(e,t,r,i){this.table[t<<8|e]=r<<4|i},e.prototype.addMany=function(e,t,r,i){for(var n=0;n<e.length;n++)this.table[t<<8|e[n]]=r<<4|i},e}();t.TransitionTable=u;var h=160;t.VT500_TRANSITION_TABLE=function(){var e=new u(4095),t=Array.apply(null,Array(256)).map((function(e,t){return t})),r=function(e,r){return t.slice(e,r)},i=r(32,127),n=r(0,24);n.push(25),n.push.apply(n,r(28,32));var o,s=r(0,14);for(o in e.setDefault(1,0),e.addMany(i,0,2,0),s)e.addMany([24,26,153,154],o,3,0),e.addMany(r(128,144),o,3,0),e.addMany(r(144,152),o,3,0),e.add(156,o,0,0),e.add(27,o,11,1),e.add(157,o,4,8),e.addMany([152,158,159],o,0,7),e.add(155,o,11,3),e.add(144,o,11,9);return e.addMany(n,0,3,0),e.addMany(n,1,3,1),e.add(127,1,0,1),e.addMany(n,8,0,8),e.addMany(n,3,3,3),e.add(127,3,0,3),e.addMany(n,4,3,4),e.add(127,4,0,4),e.addMany(n,6,3,6),e.addMany(n,5,3,5),e.add(127,5,0,5),e.addMany(n,2,3,2),e.add(127,2,0,2),e.add(93,1,4,8),e.addMany(i,8,5,8),e.add(127,8,5,8),e.addMany([156,27,24,26,7],8,6,0),e.addMany(r(28,32),8,0,8),e.addMany([88,94,95],1,0,7),e.addMany(i,7,0,7),e.addMany(n,7,0,7),e.add(156,7,0,0),e.add(127,7,0,7),e.add(91,1,11,3),e.addMany(r(64,127),3,7,0),e.addMany(r(48,60),3,8,4),e.addMany([60,61,62,63],3,9,4),e.addMany(r(48,60),4,8,4),e.addMany(r(64,127),4,7,0),e.addMany([60,61,62,63],4,0,6),e.addMany(r(32,64),6,0,6),e.add(127,6,0,6),e.addMany(r(64,127),6,0,0),e.addMany(r(32,48),3,9,5),e.addMany(r(32,48),5,9,5),e.addMany(r(48,64),5,0,6),e.addMany(r(64,127),5,7,0),e.addMany(r(32,48),4,9,5),e.addMany(r(32,48),1,9,2),e.addMany(r(32,48),2,9,2),e.addMany(r(48,127),2,10,0),e.addMany(r(48,80),1,10,0),e.addMany(r(81,88),1,10,0),e.addMany([89,90,92],1,10,0),e.addMany(r(96,127),1,10,0),e.add(80,1,11,9),e.addMany(n,9,0,9),e.add(127,9,0,9),e.addMany(r(28,32),9,0,9),e.addMany(r(32,48),9,9,12),e.addMany(r(48,60),9,8,10),e.addMany([60,61,62,63],9,9,10),e.addMany(n,11,0,11),e.addMany(r(32,128),11,0,11),e.addMany(r(28,32),11,0,11),e.addMany(n,10,0,10),e.add(127,10,0,10),e.addMany(r(28,32),10,0,10),e.addMany(r(48,60),10,8,10),e.addMany([60,61,62,63],10,0,11),e.addMany(r(32,48),10,9,12),e.addMany(n,12,0,12),e.add(127,12,0,12),e.addMany(r(28,32),12,0,12),e.addMany(r(32,48),12,9,12),e.addMany(r(48,64),12,0,11),e.addMany(r(64,127),12,12,13),e.addMany(r(64,127),10,12,13),e.addMany(r(64,127),9,12,13),e.addMany(n,13,13,13),e.addMany(i,13,13,13),e.add(127,13,0,13),e.addMany([27,156,24,26],13,14,0),e.add(h,0,2,0),e.add(h,8,5,8),e.add(h,6,0,6),e.add(h,11,0,11),e.add(h,13,13,13),e}();var f=function(e){function r(r){void 0===r&&(r=t.VT500_TRANSITION_TABLE);var i=e.call(this)||this;return i._transitions=r,i._parseStack={state:0,handlers:[],handlerPos:0,transition:0,chunkPos:0},i.initialState=0,i.currentState=i.initialState,i._params=new a.Params,i._params.addParam(0),i._collect=0,i.precedingCodepoint=0,i._printHandlerFb=function(e,t,r){},i._executeHandlerFb=function(e){},i._csiHandlerFb=function(e,t){},i._escHandlerFb=function(e){},i._errorHandlerFb=function(e){return e},i._printHandler=i._printHandlerFb,i._executeHandlers=Object.create(null),i._csiHandlers=Object.create(null),i._escHandlers=Object.create(null),i._oscParser=new c.OscParser,i._dcsParser=new l.DcsParser,i._errorHandler=i._errorHandlerFb,i.registerEscHandler({final:"\\"},(function(){return!0})),i}return n(r,e),r.prototype._identifier=function(e,t){void 0===t&&(t=[64,126]);var r=0;if(e.prefix){if(e.prefix.length>1)throw new Error("only one byte as prefix supported");if((r=e.prefix.charCodeAt(0))&&60>r||r>63)throw new Error("prefix must be in range 0x3c .. 0x3f")}if(e.intermediates){if(e.intermediates.length>2)throw new Error("only two bytes as intermediates are supported");for(var i=0;i<e.intermediates.length;++i){var n=e.intermediates.charCodeAt(i);if(32>n||n>47)throw new Error("intermediate must be in range 0x20 .. 0x2f");r<<=8,r|=n}}if(1!==e.final.length)throw new Error("final must be a single byte");var o=e.final.charCodeAt(0);if(t[0]>o||o>t[1])throw new Error("final must be in range "+t[0]+" .. "+t[1]);return(r<<=8)|o},r.prototype.identToString=function(e){for(var t=[];e;)t.push(String.fromCharCode(255&e)),e>>=8;return t.reverse().join("")},r.prototype.dispose=function(){this._csiHandlers=Object.create(null),this._executeHandlers=Object.create(null),this._escHandlers=Object.create(null),this._oscParser.dispose(),this._dcsParser.dispose()},r.prototype.setPrintHandler=function(e){this._printHandler=e},r.prototype.clearPrintHandler=function(){this._printHandler=this._printHandlerFb},r.prototype.registerEscHandler=function(e,t){var r=this._identifier(e,[48,126]);void 0===this._escHandlers[r]&&(this._escHandlers[r]=[]);var i=this._escHandlers[r];return i.push(t),{dispose:function(){var e=i.indexOf(t);-1!==e&&i.splice(e,1)}}},r.prototype.clearEscHandler=function(e){this._escHandlers[this._identifier(e,[48,126])]&&delete this._escHandlers[this._identifier(e,[48,126])]},r.prototype.setEscHandlerFallback=function(e){this._escHandlerFb=e},r.prototype.setExecuteHandler=function(e,t){this._executeHandlers[e.charCodeAt(0)]=t},r.prototype.clearExecuteHandler=function(e){this._executeHandlers[e.charCodeAt(0)]&&delete this._executeHandlers[e.charCodeAt(0)]},r.prototype.setExecuteHandlerFallback=function(e){this._executeHandlerFb=e},r.prototype.registerCsiHandler=function(e,t){var r=this._identifier(e);void 0===this._csiHandlers[r]&&(this._csiHandlers[r]=[]);var i=this._csiHandlers[r];return i.push(t),{dispose:function(){var e=i.indexOf(t);-1!==e&&i.splice(e,1)}}},r.prototype.clearCsiHandler=function(e){this._csiHandlers[this._identifier(e)]&&delete this._csiHandlers[this._identifier(e)]},r.prototype.setCsiHandlerFallback=function(e){this._csiHandlerFb=e},r.prototype.registerDcsHandler=function(e,t){return this._dcsParser.registerHandler(this._identifier(e),t)},r.prototype.clearDcsHandler=function(e){this._dcsParser.clearHandler(this._identifier(e))},r.prototype.setDcsHandlerFallback=function(e){this._dcsParser.setHandlerFallback(e)},r.prototype.registerOscHandler=function(e,t){return this._oscParser.registerHandler(e,t)},r.prototype.clearOscHandler=function(e){this._oscParser.clearHandler(e)},r.prototype.setOscHandlerFallback=function(e){this._oscParser.setHandlerFallback(e)},r.prototype.setErrorHandler=function(e){this._errorHandler=e},r.prototype.clearErrorHandler=function(){this._errorHandler=this._errorHandlerFb},r.prototype.reset=function(){this.currentState=this.initialState,this._oscParser.reset(),this._dcsParser.reset(),this._params.reset(),this._params.addParam(0),this._collect=0,this.precedingCodepoint=0,0!==this._parseStack.state&&(this._parseStack.state=2,this._parseStack.handlers=[])},r.prototype._preserveStack=function(e,t,r,i,n){this._parseStack.state=e,this._parseStack.handlers=t,this._parseStack.handlerPos=r,this._parseStack.transition=i,this._parseStack.chunkPos=n},r.prototype.parse=function(e,t,r){var i,n=0,o=0,s=0;if(this._parseStack.state)if(2===this._parseStack.state)this._parseStack.state=0,s=this._parseStack.chunkPos+1;else{if(void 0===r||1===this._parseStack.state)throw this._parseStack.state=1,new Error("improper continuation due to previous async handler, giving up parsing");var a=this._parseStack.handlers,c=this._parseStack.handlerPos-1;switch(this._parseStack.state){case 3:if(!1===r&&c>-1)for(;c>=0&&!0!==(i=a[c](this._params));c--)if(i instanceof Promise)return this._parseStack.handlerPos=c,i;this._parseStack.handlers=[];break;case 4:if(!1===r&&c>-1)for(;c>=0&&!0!==(i=a[c]());c--)if(i instanceof Promise)return this._parseStack.handlerPos=c,i;this._parseStack.handlers=[];break;case 6:if(n=e[this._parseStack.chunkPos],i=this._dcsParser.unhook(24!==n&&26!==n,r))return i;27===n&&(this._parseStack.transition|=1),this._params.reset(),this._params.addParam(0),this._collect=0;break;case 5:if(n=e[this._parseStack.chunkPos],i=this._oscParser.end(24!==n&&26!==n,r))return i;27===n&&(this._parseStack.transition|=1),this._params.reset(),this._params.addParam(0),this._collect=0}this._parseStack.state=0,s=this._parseStack.chunkPos+1,this.precedingCodepoint=0,this.currentState=15&this._parseStack.transition}for(var l=s;l<t;++l){switch(n=e[l],(o=this._transitions.table[this.currentState<<8|(n<160?n:h)])>>4){case 2:for(var u=l+1;;++u){if(u>=t||(n=e[u])<32||n>126&&n<h){this._printHandler(e,l,u),l=u-1;break}if(++u>=t||(n=e[u])<32||n>126&&n<h){this._printHandler(e,l,u),l=u-1;break}if(++u>=t||(n=e[u])<32||n>126&&n<h){this._printHandler(e,l,u),l=u-1;break}if(++u>=t||(n=e[u])<32||n>126&&n<h){this._printHandler(e,l,u),l=u-1;break}}break;case 3:this._executeHandlers[n]?this._executeHandlers[n]():this._executeHandlerFb(n),this.precedingCodepoint=0;break;case 0:break;case 1:if(this._errorHandler({position:l,code:n,currentState:this.currentState,collect:this._collect,params:this._params,abort:!1}).abort)return;break;case 7:for(var f=(a=this._csiHandlers[this._collect<<8|n])?a.length-1:-1;f>=0&&!0!==(i=a[f](this._params));f--)if(i instanceof Promise)return this._preserveStack(3,a,f,o,l),i;f<0&&this._csiHandlerFb(this._collect<<8|n,this._params),this.precedingCodepoint=0;break;case 8:do{switch(n){case 59:this._params.addParam(0);break;case 58:this._params.addSubParam(-1);break;default:this._params.addDigit(n-48)}}while(++l<t&&(n=e[l])>47&&n<60);l--;break;case 9:this._collect<<=8,this._collect|=n;break;case 10:for(var _=this._escHandlers[this._collect<<8|n],d=_?_.length-1:-1;d>=0&&!0!==(i=_[d]());d--)if(i instanceof Promise)return this._preserveStack(4,_,d,o,l),i;d<0&&this._escHandlerFb(this._collect<<8|n),this.precedingCodepoint=0;break;case 11:this._params.reset(),this._params.addParam(0),this._collect=0;break;case 12:this._dcsParser.hook(this._collect<<8|n,this._params);break;case 13:for(var p=l+1;;++p)if(p>=t||24===(n=e[p])||26===n||27===n||n>127&&n<h){this._dcsParser.put(e,l,p),l=p-1;break}break;case 14:if(i=this._dcsParser.unhook(24!==n&&26!==n))return this._preserveStack(6,[],0,o,l),i;27===n&&(o|=1),this._params.reset(),this._params.addParam(0),this._collect=0,this.precedingCodepoint=0;break;case 4:this._oscParser.start();break;case 5:for(var v=l+1;;v++)if(v>=t||(n=e[v])<32||n>127&&n<h){this._oscParser.put(e,l,v),l=v-1;break}break;case 6:if(i=this._oscParser.end(24!==n&&26!==n))return this._preserveStack(5,[],0,o,l),i;27===n&&(o|=1),this._params.reset(),this._params.addParam(0),this._collect=0,this.precedingCodepoint=0}this.currentState=15&o}},r}(o.Disposable);t.EscapeSequenceParser=f},6242:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.OscHandler=t.OscParser=void 0;var i=r(5770),n=r(482),o=[],s=function(){function e(){this._state=0,this._active=o,this._id=-1,this._handlers=Object.create(null),this._handlerFb=function(){},this._stack={paused:!1,loopPosition:0,fallThrough:!1}}return e.prototype.registerHandler=function(e,t){void 0===this._handlers[e]&&(this._handlers[e]=[]);var r=this._handlers[e];return r.push(t),{dispose:function(){var e=r.indexOf(t);-1!==e&&r.splice(e,1)}}},e.prototype.clearHandler=function(e){this._handlers[e]&&delete this._handlers[e]},e.prototype.setHandlerFallback=function(e){this._handlerFb=e},e.prototype.dispose=function(){this._handlers=Object.create(null),this._handlerFb=function(){},this._active=o},e.prototype.reset=function(){if(2===this._state)for(var e=this._stack.paused?this._stack.loopPosition-1:this._active.length-1;e>=0;--e)this._active[e].end(!1);this._stack.paused=!1,this._active=o,this._id=-1,this._state=0},e.prototype._start=function(){if(this._active=this._handlers[this._id]||o,this._active.length)for(var e=this._active.length-1;e>=0;e--)this._active[e].start();else this._handlerFb(this._id,"START")},e.prototype._put=function(e,t,r){if(this._active.length)for(var i=this._active.length-1;i>=0;i--)this._active[i].put(e,t,r);else this._handlerFb(this._id,"PUT",(0,n.utf32ToString)(e,t,r))},e.prototype.start=function(){this.reset(),this._state=1},e.prototype.put=function(e,t,r){if(3!==this._state){if(1===this._state)for(;t<r;){var i=e[t++];if(59===i){this._state=2,this._start();break}if(i<48||57<i)return void(this._state=3);-1===this._id&&(this._id=0),this._id=10*this._id+i-48}2===this._state&&r-t>0&&this._put(e,t,r)}},e.prototype.end=function(e,t){if(void 0===t&&(t=!0),0!==this._state){if(3!==this._state)if(1===this._state&&this._start(),this._active.length){var r=!1,i=this._active.length-1,n=!1;if(this._stack.paused&&(i=this._stack.loopPosition-1,r=t,n=this._stack.fallThrough,this._stack.paused=!1),!n&&!1===r){for(;i>=0&&!0!==(r=this._active[i].end(e));i--)if(r instanceof Promise)return this._stack.paused=!0,this._stack.loopPosition=i,this._stack.fallThrough=!1,r;i--}for(;i>=0;i--)if((r=this._active[i].end(!1))instanceof Promise)return this._stack.paused=!0,this._stack.loopPosition=i,this._stack.fallThrough=!0,r}else this._handlerFb(this._id,"END",e);this._active=o,this._id=-1,this._state=0}},e}();t.OscParser=s;var a=function(){function e(e){this._handler=e,this._data="",this._hitLimit=!1}return e.prototype.start=function(){this._data="",this._hitLimit=!1},e.prototype.put=function(e,t,r){this._hitLimit||(this._data+=(0,n.utf32ToString)(e,t,r),this._data.length>i.PAYLOAD_LIMIT&&(this._data="",this._hitLimit=!0))},e.prototype.end=function(e){var t=this,r=!1;if(this._hitLimit)r=!1;else if(e&&(r=this._handler(this._data))instanceof Promise)return r.then((function(e){return t._data="",t._hitLimit=!1,e}));return this._data="",this._hitLimit=!1,r},e}();t.OscHandler=a},8742:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.Params=void 0;var r=2147483647,i=function(){function e(e,t){if(void 0===e&&(e=32),void 0===t&&(t=32),this.maxLength=e,this.maxSubParamsLength=t,t>256)throw new Error("maxSubParamsLength must not be greater than 256");this.params=new Int32Array(e),this.length=0,this._subParams=new Int32Array(t),this._subParamsLength=0,this._subParamsIdx=new Uint16Array(e),this._rejectDigits=!1,this._rejectSubDigits=!1,this._digitIsSub=!1}return e.fromArray=function(t){var r=new e;if(!t.length)return r;for(var i=Array.isArray(t[0])?1:0;i<t.length;++i){var n=t[i];if(Array.isArray(n))for(var o=0;o<n.length;++o)r.addSubParam(n[o]);else r.addParam(n)}return r},e.prototype.clone=function(){var t=new e(this.maxLength,this.maxSubParamsLength);return t.params.set(this.params),t.length=this.length,t._subParams.set(this._subParams),t._subParamsLength=this._subParamsLength,t._subParamsIdx.set(this._subParamsIdx),t._rejectDigits=this._rejectDigits,t._rejectSubDigits=this._rejectSubDigits,t._digitIsSub=this._digitIsSub,t},e.prototype.toArray=function(){for(var e=[],t=0;t<this.length;++t){e.push(this.params[t]);var r=this._subParamsIdx[t]>>8,i=255&this._subParamsIdx[t];i-r>0&&e.push(Array.prototype.slice.call(this._subParams,r,i))}return e},e.prototype.reset=function(){this.length=0,this._subParamsLength=0,this._rejectDigits=!1,this._rejectSubDigits=!1,this._digitIsSub=!1},e.prototype.addParam=function(e){if(this._digitIsSub=!1,this.length>=this.maxLength)this._rejectDigits=!0;else{if(e<-1)throw new Error("values lesser than -1 are not allowed");this._subParamsIdx[this.length]=this._subParamsLength<<8|this._subParamsLength,this.params[this.length++]=e>r?r:e}},e.prototype.addSubParam=function(e){if(this._digitIsSub=!0,this.length)if(this._rejectDigits||this._subParamsLength>=this.maxSubParamsLength)this._rejectSubDigits=!0;else{if(e<-1)throw new Error("values lesser than -1 are not allowed");this._subParams[this._subParamsLength++]=e>r?r:e,this._subParamsIdx[this.length-1]++}},e.prototype.hasSubParams=function(e){return(255&this._subParamsIdx[e])-(this._subParamsIdx[e]>>8)>0},e.prototype.getSubParams=function(e){var t=this._subParamsIdx[e]>>8,r=255&this._subParamsIdx[e];return r-t>0?this._subParams.subarray(t,r):null},e.prototype.getSubParamsAll=function(){for(var e={},t=0;t<this.length;++t){var r=this._subParamsIdx[t]>>8,i=255&this._subParamsIdx[t];i-r>0&&(e[t]=this._subParams.slice(r,i))}return e},e.prototype.addDigit=function(e){var t;if(!(this._rejectDigits||!(t=this._digitIsSub?this._subParamsLength:this.length)||this._digitIsSub&&this._rejectSubDigits)){var i=this._digitIsSub?this._subParams:this.params,n=i[t-1];i[t-1]=~n?Math.min(10*n+e,r):e}},e}();t.Params=i},5741:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.AddonManager=void 0;var r=function(){function e(){this._addons=[]}return e.prototype.dispose=function(){for(var e=this._addons.length-1;e>=0;e--)this._addons[e].instance.dispose()},e.prototype.loadAddon=function(e,t){var r=this,i={instance:t,dispose:t.dispose,isDisposed:!1};this._addons.push(i),t.dispose=function(){return r._wrappedAddonDispose(i)},t.activate(e)},e.prototype._wrappedAddonDispose=function(e){if(!e.isDisposed){for(var t=-1,r=0;r<this._addons.length;r++)if(this._addons[r]===e){t=r;break}if(-1===t)throw new Error("Could not dispose an addon that has not been loaded");e.isDisposed=!0,e.dispose.apply(e.instance),this._addons.splice(t,1)}},e}();t.AddonManager=r},8771:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.BufferApiView=void 0;var i=r(3785),n=r(511),o=function(){function e(e,t){this._buffer=e,this.type=t}return e.prototype.init=function(e){return this._buffer=e,this},Object.defineProperty(e.prototype,"cursorY",{get:function(){return this._buffer.y},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"cursorX",{get:function(){return this._buffer.x},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"viewportY",{get:function(){return this._buffer.ydisp},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"baseY",{get:function(){return this._buffer.ybase},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"length",{get:function(){return this._buffer.lines.length},enumerable:!1,configurable:!0}),e.prototype.getLine=function(e){var t=this._buffer.lines.get(e);if(t)return new i.BufferLineApiView(t)},e.prototype.getNullCell=function(){return new n.CellData},e}();t.BufferApiView=o},3785:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.BufferLineApiView=void 0;var i=r(511),n=function(){function e(e){this._line=e}return Object.defineProperty(e.prototype,"isWrapped",{get:function(){return this._line.isWrapped},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"length",{get:function(){return this._line.length},enumerable:!1,configurable:!0}),e.prototype.getCell=function(e,t){if(!(e<0||e>=this._line.length))return t?(this._line.loadCell(e,t),t):this._line.loadCell(e,new i.CellData)},e.prototype.translateToString=function(e,t,r){return this._line.translateToString(e,t,r)},e}();t.BufferLineApiView=n},8285:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.BufferNamespaceApi=void 0;var i=r(8771),n=r(8460),o=function(){function e(e){var t=this;this._core=e,this._onBufferChange=new n.EventEmitter,this._normal=new i.BufferApiView(this._core.buffers.normal,"normal"),this._alternate=new i.BufferApiView(this._core.buffers.alt,"alternate"),this._core.buffers.onBufferActivate((function(){return t._onBufferChange.fire(t.active)}))}return Object.defineProperty(e.prototype,"onBufferChange",{get:function(){return this._onBufferChange.event},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"active",{get:function(){if(this._core.buffers.active===this._core.buffers.normal)return this.normal;if(this._core.buffers.active===this._core.buffers.alt)return this.alternate;throw new Error("Active buffer is neither normal nor alternate")},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"normal",{get:function(){return this._normal.init(this._core.buffers.normal)},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"alternate",{get:function(){return this._alternate.init(this._core.buffers.alt)},enumerable:!1,configurable:!0}),e}();t.BufferNamespaceApi=o},7975:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.ParserApi=void 0;var r=function(){function e(e){this._core=e}return e.prototype.registerCsiHandler=function(e,t){return this._core.registerCsiHandler(e,(function(e){return t(e.toArray())}))},e.prototype.addCsiHandler=function(e,t){return this.registerCsiHandler(e,t)},e.prototype.registerDcsHandler=function(e,t){return this._core.registerDcsHandler(e,(function(e,r){return t(e,r.toArray())}))},e.prototype.addDcsHandler=function(e,t){return this.registerDcsHandler(e,t)},e.prototype.registerEscHandler=function(e,t){return this._core.registerEscHandler(e,t)},e.prototype.addEscHandler=function(e,t){return this.registerEscHandler(e,t)},e.prototype.registerOscHandler=function(e,t){return this._core.registerOscHandler(e,t)},e.prototype.addOscHandler=function(e,t){return this.registerOscHandler(e,t)},e}();t.ParserApi=r},7090:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.UnicodeApi=void 0;var r=function(){function e(e){this._core=e}return e.prototype.register=function(e){this._core.unicodeService.register(e)},Object.defineProperty(e.prototype,"versions",{get:function(){return this._core.unicodeService.versions},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"activeVersion",{get:function(){return this._core.unicodeService.activeVersion},set:function(e){this._core.unicodeService.activeVersion=e},enumerable:!1,configurable:!0}),e}();t.UnicodeApi=r},744:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.BufferService=t.MINIMUM_ROWS=t.MINIMUM_COLS=void 0;var a=r(2585),c=r(5295),l=r(8460),u=r(844);t.MINIMUM_COLS=2,t.MINIMUM_ROWS=1;var h=function(e){function r(r){var i=e.call(this)||this;return i._optionsService=r,i.isUserScrolling=!1,i._onResize=new l.EventEmitter,i._onScroll=new l.EventEmitter,i.cols=Math.max(r.options.cols||0,t.MINIMUM_COLS),i.rows=Math.max(r.options.rows||0,t.MINIMUM_ROWS),i.buffers=new c.BufferSet(r,i),i}return n(r,e),Object.defineProperty(r.prototype,"onResize",{get:function(){return this._onResize.event},enumerable:!1,configurable:!0}),Object.defineProperty(r.prototype,"onScroll",{get:function(){return this._onScroll.event},enumerable:!1,configurable:!0}),Object.defineProperty(r.prototype,"buffer",{get:function(){return this.buffers.active},enumerable:!1,configurable:!0}),r.prototype.dispose=function(){e.prototype.dispose.call(this),this.buffers.dispose()},r.prototype.resize=function(e,t){this.cols=e,this.rows=t,this.buffers.resize(e,t),this.buffers.setupTabStops(this.cols),this._onResize.fire({cols:e,rows:t})},r.prototype.reset=function(){this.buffers.reset(),this.isUserScrolling=!1},r.prototype.scroll=function(e,t){void 0===t&&(t=!1);var r,i=this.buffer;(r=this._cachedBlankLine)&&r.length===this.cols&&r.getFg(0)===e.fg&&r.getBg(0)===e.bg||(r=i.getBlankLine(e,t),this._cachedBlankLine=r),r.isWrapped=t;var n=i.ybase+i.scrollTop,o=i.ybase+i.scrollBottom;if(0===i.scrollTop){var s=i.lines.isFull;o===i.lines.length-1?s?i.lines.recycle().copyFrom(r):i.lines.push(r.clone()):i.lines.splice(o+1,0,r.clone()),s?this.isUserScrolling&&(i.ydisp=Math.max(i.ydisp-1,0)):(i.ybase++,this.isUserScrolling||i.ydisp++)}else{var a=o-n+1;i.lines.shiftElements(n+1,a-1,-1),i.lines.set(o,r.clone())}this.isUserScrolling||(i.ydisp=i.ybase),this._onScroll.fire(i.ydisp)},r.prototype.scrollLines=function(e,t,r){var i=this.buffer;if(e<0){if(0===i.ydisp)return;this.isUserScrolling=!0}else e+i.ydisp>=i.ybase&&(this.isUserScrolling=!1);var n=i.ydisp;i.ydisp=Math.max(Math.min(i.ydisp+e,i.ybase),0),n!==i.ydisp&&(t||this._onScroll.fire(i.ydisp))},r.prototype.scrollPages=function(e){this.scrollLines(e*(this.rows-1))},r.prototype.scrollToTop=function(){this.scrollLines(-this.buffer.ydisp)},r.prototype.scrollToBottom=function(){this.scrollLines(this.buffer.ybase-this.buffer.ydisp)},r.prototype.scrollToLine=function(e){var t=e-this.buffer.ydisp;0!==t&&this.scrollLines(t)},o([s(0,a.IOptionsService)],r)}(u.Disposable);t.BufferService=h},7994:(e,t)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.CharsetService=void 0;var r=function(){function e(){this.glevel=0,this._charsets=[]}return e.prototype.reset=function(){this.charset=void 0,this._charsets=[],this.glevel=0},e.prototype.setgLevel=function(e){this.glevel=e,this.charset=this._charsets[e]},e.prototype.setgCharset=function(e,t){this._charsets[e]=t,this.glevel===e&&(this.charset=t)},e}();t.CharsetService=r},1753:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.CoreMouseService=void 0;var o=r(2585),s=r(8460),a={NONE:{events:0,restrict:function(){return!1}},X10:{events:1,restrict:function(e){return 4!==e.button&&1===e.action&&(e.ctrl=!1,e.alt=!1,e.shift=!1,!0)}},VT200:{events:19,restrict:function(e){return 32!==e.action}},DRAG:{events:23,restrict:function(e){return 32!==e.action||3!==e.button}},ANY:{events:31,restrict:function(e){return!0}}};function c(e,t){var r=(e.ctrl?16:0)|(e.shift?4:0)|(e.alt?8:0);return 4===e.button?(r|=64,r|=e.action):(r|=3&e.button,4&e.button&&(r|=64),8&e.button&&(r|=128),32===e.action?r|=32:0!==e.action||t||(r|=3)),r}var l=String.fromCharCode,u={DEFAULT:function(e){var t=[c(e,!1)+32,e.col+32,e.row+32];return t[0]>255||t[1]>255||t[2]>255?"":"[M"+l(t[0])+l(t[1])+l(t[2])},SGR:function(e){var t=0===e.action&&4!==e.button?"m":"M";return"[<"+c(e,!0)+";"+e.col+";"+e.row+t}},h=function(){function e(e,t){this._bufferService=e,this._coreService=t,this._protocols={},this._encodings={},this._activeProtocol="",this._activeEncoding="",this._onProtocolChange=new s.EventEmitter,this._lastEvent=null;for(var r=0,i=Object.keys(a);r<i.length;r++){var n=i[r];this.addProtocol(n,a[n])}for(var o=0,c=Object.keys(u);o<c.length;o++){var l=c[o];this.addEncoding(l,u[l])}this.reset()}return e.prototype.addProtocol=function(e,t){this._protocols[e]=t},e.prototype.addEncoding=function(e,t){this._encodings[e]=t},Object.defineProperty(e.prototype,"activeProtocol",{get:function(){return this._activeProtocol},set:function(e){if(!this._protocols[e])throw new Error('unknown protocol "'+e+'"');this._activeProtocol=e,this._onProtocolChange.fire(this._protocols[e].events)},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"areMouseEventsActive",{get:function(){return 0!==this._protocols[this._activeProtocol].events},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"activeEncoding",{get:function(){return this._activeEncoding},set:function(e){if(!this._encodings[e])throw new Error('unknown encoding "'+e+'"');this._activeEncoding=e},enumerable:!1,configurable:!0}),e.prototype.reset=function(){this.activeProtocol="NONE",this.activeEncoding="DEFAULT",this._lastEvent=null},Object.defineProperty(e.prototype,"onProtocolChange",{get:function(){return this._onProtocolChange.event},enumerable:!1,configurable:!0}),e.prototype.triggerMouseEvent=function(e){if(e.col<0||e.col>=this._bufferService.cols||e.row<0||e.row>=this._bufferService.rows)return!1;if(4===e.button&&32===e.action)return!1;if(3===e.button&&32!==e.action)return!1;if(4!==e.button&&(2===e.action||3===e.action))return!1;if(e.col++,e.row++,32===e.action&&this._lastEvent&&this._compareEvents(this._lastEvent,e))return!1;if(!this._protocols[this._activeProtocol].restrict(e))return!1;var t=this._encodings[this._activeEncoding](e);return t&&("DEFAULT"===this._activeEncoding?this._coreService.triggerBinaryEvent(t):this._coreService.triggerDataEvent(t,!0)),this._lastEvent=e,!0},e.prototype.explainEvents=function(e){return{down:!!(1&e),up:!!(2&e),drag:!!(4&e),move:!!(8&e),wheel:!!(16&e)}},e.prototype._compareEvents=function(e,t){return e.col===t.col&&e.row===t.row&&e.button===t.button&&e.action===t.action&&e.ctrl===t.ctrl&&e.alt===t.alt&&e.shift===t.shift},i([n(0,o.IBufferService),n(1,o.ICoreService)],e)}();t.CoreMouseService=h},6975:function(e,t,r){var i,n=this&&this.__extends||(i=function(e,t){return i=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var r in t)Object.prototype.hasOwnProperty.call(t,r)&&(e[r]=t[r])},i(e,t)},function(e,t){if("function"!=typeof t&&null!==t)throw new TypeError("Class extends value "+String(t)+" is not a constructor or null");function r(){this.constructor=e}i(e,t),e.prototype=null===t?Object.create(t):(r.prototype=t.prototype,new r)}),o=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},s=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.CoreService=void 0;var a=r(2585),c=r(8460),l=r(1439),u=r(844),h=Object.freeze({insertMode:!1}),f=Object.freeze({applicationCursorKeys:!1,applicationKeypad:!1,bracketedPasteMode:!1,origin:!1,reverseWraparound:!1,sendFocus:!1,wraparound:!0}),_=function(e){function t(t,r,i,n){var o=e.call(this)||this;return o._bufferService=r,o._logService=i,o._optionsService=n,o.isCursorInitialized=!1,o.isCursorHidden=!1,o._onData=o.register(new c.EventEmitter),o._onUserInput=o.register(new c.EventEmitter),o._onBinary=o.register(new c.EventEmitter),o._scrollToBottom=t,o.register({dispose:function(){return o._scrollToBottom=void 0}}),o.modes=(0,l.clone)(h),o.decPrivateModes=(0,l.clone)(f),o}return n(t,e),Object.defineProperty(t.prototype,"onData",{get:function(){return this._onData.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onUserInput",{get:function(){return this._onUserInput.event},enumerable:!1,configurable:!0}),Object.defineProperty(t.prototype,"onBinary",{get:function(){return this._onBinary.event},enumerable:!1,configurable:!0}),t.prototype.reset=function(){this.modes=(0,l.clone)(h),this.decPrivateModes=(0,l.clone)(f)},t.prototype.triggerDataEvent=function(e,t){if(void 0===t&&(t=!1),!this._optionsService.options.disableStdin){var r=this._bufferService.buffer;r.ybase!==r.ydisp&&this._scrollToBottom(),t&&this._onUserInput.fire(),this._logService.debug('sending data "'+e+'"',(function(){return e.split("").map((function(e){return e.charCodeAt(0)}))})),this._onData.fire(e)}},t.prototype.triggerBinaryEvent=function(e){this._optionsService.options.disableStdin||(this._logService.debug('sending binary "'+e+'"',(function(){return e.split("").map((function(e){return e.charCodeAt(0)}))})),this._onBinary.fire(e))},o([s(1,a.IBufferService),s(2,a.ILogService),s(3,a.IOptionsService)],t)}(u.Disposable);t.CoreService=_},3730:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}};Object.defineProperty(t,"__esModule",{value:!0}),t.DirtyRowService=void 0;var o=r(2585),s=function(){function e(e){this._bufferService=e,this.clearRange()}return Object.defineProperty(e.prototype,"start",{get:function(){return this._start},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"end",{get:function(){return this._end},enumerable:!1,configurable:!0}),e.prototype.clearRange=function(){this._start=this._bufferService.buffer.y,this._end=this._bufferService.buffer.y},e.prototype.markDirty=function(e){e<this._start?this._start=e:e>this._end&&(this._end=e)},e.prototype.markRangeDirty=function(e,t){if(e>t){var r=e;e=t,t=r}e<this._start&&(this._start=e),t>this._end&&(this._end=t)},e.prototype.markAllDirty=function(){this.markRangeDirty(0,this._bufferService.rows-1)},i([n(0,o.IBufferService)],e)}();t.DirtyRowService=s},4348:function(e,t,r){var i=this&&this.__spreadArray||function(e,t,r){if(r||2===arguments.length)for(var i,n=0,o=t.length;n<o;n++)!i&&n in t||(i||(i=Array.prototype.slice.call(t,0,n)),i[n]=t[n]);return e.concat(i||Array.prototype.slice.call(t))};Object.defineProperty(t,"__esModule",{value:!0}),t.InstantiationService=t.ServiceCollection=void 0;var n=r(2585),o=r(8343),s=function(){function e(){for(var e=[],t=0;t<arguments.length;t++)e[t]=arguments[t];this._entries=new Map;for(var r=0,i=e;r<i.length;r++){var n=i[r],o=n[0],s=n[1];this.set(o,s)}}return e.prototype.set=function(e,t){var r=this._entries.get(e);return this._entries.set(e,t),r},e.prototype.forEach=function(e){this._entries.forEach((function(t,r){return e(r,t)}))},e.prototype.has=function(e){return this._entries.has(e)},e.prototype.get=function(e){return this._entries.get(e)},e}();t.ServiceCollection=s;var a=function(){function e(){this._services=new s,this._services.set(n.IInstantiationService,this)}return e.prototype.setService=function(e,t){this._services.set(e,t)},e.prototype.getService=function(e){return this._services.get(e)},e.prototype.createInstance=function(e){for(var t=[],r=1;r<arguments.length;r++)t[r-1]=arguments[r];for(var n=(0,o.getServiceDependencies)(e).sort((function(e,t){return e.index-t.index})),s=[],a=0,c=n;a<c.length;a++){var l=c[a],u=this._services.get(l.id);if(!u)throw new Error("[createInstance] "+e.name+" depends on UNKNOWN service "+l.id+".");s.push(u)}var h=n.length>0?n[0].index:t.length;if(t.length!==h)throw new Error("[createInstance] First service dependency of "+e.name+" at position "+(h+1)+" conflicts with "+t.length+" static arguments");return new(e.bind.apply(e,i([void 0],i(i([],t,!0),s,!0),!1)))},e}();t.InstantiationService=a},7866:function(e,t,r){var i=this&&this.__decorate||function(e,t,r,i){var n,o=arguments.length,s=o<3?t:null===i?i=Object.getOwnPropertyDescriptor(t,r):i;if("object"==typeof Reflect&&"function"==typeof Reflect.decorate)s=Reflect.decorate(e,t,r,i);else for(var a=e.length-1;a>=0;a--)(n=e[a])&&(s=(o<3?n(s):o>3?n(t,r,s):n(t,r))||s);return o>3&&s&&Object.defineProperty(t,r,s),s},n=this&&this.__param||function(e,t){return function(r,i){t(r,i,e)}},o=this&&this.__spreadArray||function(e,t,r){if(r||2===arguments.length)for(var i,n=0,o=t.length;n<o;n++)!i&&n in t||(i||(i=Array.prototype.slice.call(t,0,n)),i[n]=t[n]);return e.concat(i||Array.prototype.slice.call(t))};Object.defineProperty(t,"__esModule",{value:!0}),t.LogService=void 0;var s=r(2585),a={debug:s.LogLevelEnum.DEBUG,info:s.LogLevelEnum.INFO,warn:s.LogLevelEnum.WARN,error:s.LogLevelEnum.ERROR,off:s.LogLevelEnum.OFF},c=function(){function e(e){var t=this;this._optionsService=e,this.logLevel=s.LogLevelEnum.OFF,this._updateLogLevel(),this._optionsService.onOptionChange((function(e){"logLevel"===e&&t._updateLogLevel()}))}return e.prototype._updateLogLevel=function(){this.logLevel=a[this._optionsService.options.logLevel]},e.prototype._evalLazyOptionalParams=function(e){for(var t=0;t<e.length;t++)"function"==typeof e[t]&&(e[t]=e[t]())},e.prototype._log=function(e,t,r){this._evalLazyOptionalParams(r),e.call.apply(e,o([console,"xterm.js: "+t],r,!1))},e.prototype.debug=function(e){for(var t=[],r=1;r<arguments.length;r++)t[r-1]=arguments[r];this.logLevel<=s.LogLevelEnum.DEBUG&&this._log(console.log,e,t)},e.prototype.info=function(e){for(var t=[],r=1;r<arguments.length;r++)t[r-1]=arguments[r];this.logLevel<=s.LogLevelEnum.INFO&&this._log(console.info,e,t)},e.prototype.warn=function(e){for(var t=[],r=1;r<arguments.length;r++)t[r-1]=arguments[r];this.logLevel<=s.LogLevelEnum.WARN&&this._log(console.warn,e,t)},e.prototype.error=function(e){for(var t=[],r=1;r<arguments.length;r++)t[r-1]=arguments[r];this.logLevel<=s.LogLevelEnum.ERROR&&this._log(console.error,e,t)},i([n(0,s.IOptionsService)],e)}();t.LogService=c},7302:function(e,t,r){var i=this&&this.__assign||function(){return i=Object.assign||function(e){for(var t,r=1,i=arguments.length;r<i;r++)for(var n in t=arguments[r])Object.prototype.hasOwnProperty.call(t,n)&&(e[n]=t[n]);return e},i.apply(this,arguments)};Object.defineProperty(t,"__esModule",{value:!0}),t.OptionsService=t.DEFAULT_OPTIONS=t.DEFAULT_BELL_SOUND=void 0;var n=r(8460),o=r(6114);t.DEFAULT_BELL_SOUND="data:audio/mp3;base64,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",t.DEFAULT_OPTIONS={cols:80,rows:24,cursorBlink:!1,cursorStyle:"block",cursorWidth:1,customGlyphs:!0,bellSound:t.DEFAULT_BELL_SOUND,bellStyle:"none",drawBoldTextInBrightColors:!0,fastScrollModifier:"alt",fastScrollSensitivity:5,fontFamily:"courier-new, courier, monospace",fontSize:15,fontWeight:"normal",fontWeightBold:"bold",lineHeight:1,linkTooltipHoverDuration:500,letterSpacing:0,logLevel:"info",scrollback:1e3,scrollSensitivity:1,screenReaderMode:!1,macOptionIsMeta:!1,macOptionClickForcesSelection:!1,minimumContrastRatio:1,disableStdin:!1,allowProposedApi:!0,allowTransparency:!1,tabStopWidth:8,theme:{},rightClickSelectsWord:o.isMac,rendererType:"canvas",windowOptions:{},windowsMode:!1,wordSeparator:" ()[]{}',\"`",altClickMovesCursor:!0,convertEol:!1,termName:"xterm",cancelEvents:!1};var s=["normal","bold","100","200","300","400","500","600","700","800","900"],a=function(){function e(e){for(var r in this._onOptionChange=new n.EventEmitter,this._options=i({},t.DEFAULT_OPTIONS),e)if(r in this._options)try{var o=e[r];this._options[r]=this._sanitizeAndValidateOption(r,o)}catch(e){console.error(e)}this.options=this._setupOptions(this._options)}return Object.defineProperty(e.prototype,"onOptionChange",{get:function(){return this._onOptionChange.event},enumerable:!1,configurable:!0}),e.prototype._setupOptions=function(e){var r=this,n=i({},e),o=function(e){Object.defineProperty(n,e,{get:function(){if(!(e in t.DEFAULT_OPTIONS))throw new Error('No option with key "'+e+'"');return r._options[e]},set:function(i){if(!(e in t.DEFAULT_OPTIONS))throw new Error('No option with key "'+e+'"');i=r._sanitizeAndValidateOption(e,i),r._options[e]!==i&&(r._options[e]=i,r._onOptionChange.fire(e))}})};for(var s in n)o(s);return n},e.prototype.setOption=function(e,t){this.options[e]=t},e.prototype._sanitizeAndValidateOption=function(e,r){switch(e){case"bellStyle":case"cursorStyle":case"rendererType":case"wordSeparator":r||(r=t.DEFAULT_OPTIONS[e]);break;case"fontWeight":case"fontWeightBold":if("number"==typeof r&&1<=r&&r<=1e3)break;r=s.includes(r)?r:t.DEFAULT_OPTIONS[e];break;case"cursorWidth":r=Math.floor(r);case"lineHeight":case"tabStopWidth":if(r<1)throw new Error(e+" cannot be less than 1, value: "+r);break;case"minimumContrastRatio":r=Math.max(1,Math.min(21,Math.round(10*r)/10));break;case"scrollback":if((r=Math.min(r,4294967295))<0)throw new Error(e+" cannot be less than 0, value: "+r);break;case"fastScrollSensitivity":case"scrollSensitivity":if(r<=0)throw new Error(e+" cannot be less than or equal to 0, value: "+r);case"rows":case"cols":if(!r&&0!==r)throw new Error(e+" must be numeric, value: "+r)}return r},e.prototype.getOption=function(e){return this.options[e]},e}();t.OptionsService=a},8343:(e,t)=>{function r(e,t,r){t.di$target===t?t.di$dependencies.push({id:e,index:r}):(t.di$dependencies=[{id:e,index:r}],t.di$target=t)}Object.defineProperty(t,"__esModule",{value:!0}),t.createDecorator=t.getServiceDependencies=t.serviceRegistry=void 0,t.serviceRegistry=new Map,t.getServiceDependencies=function(e){return e.di$dependencies||[]},t.createDecorator=function(e){if(t.serviceRegistry.has(e))return t.serviceRegistry.get(e);var i=function(e,t,n){if(3!==arguments.length)throw new Error("@IServiceName-decorator can only be used to decorate a parameter");r(i,e,n)};return i.toString=function(){return e},t.serviceRegistry.set(e,i),i}},2585:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.IUnicodeService=t.IOptionsService=t.ILogService=t.LogLevelEnum=t.IInstantiationService=t.IDirtyRowService=t.ICharsetService=t.ICoreService=t.ICoreMouseService=t.IBufferService=void 0;var i,n=r(8343);t.IBufferService=(0,n.createDecorator)("BufferService"),t.ICoreMouseService=(0,n.createDecorator)("CoreMouseService"),t.ICoreService=(0,n.createDecorator)("CoreService"),t.ICharsetService=(0,n.createDecorator)("CharsetService"),t.IDirtyRowService=(0,n.createDecorator)("DirtyRowService"),t.IInstantiationService=(0,n.createDecorator)("InstantiationService"),(i=t.LogLevelEnum||(t.LogLevelEnum={}))[i.DEBUG=0]="DEBUG",i[i.INFO=1]="INFO",i[i.WARN=2]="WARN",i[i.ERROR=3]="ERROR",i[i.OFF=4]="OFF",t.ILogService=(0,n.createDecorator)("LogService"),t.IOptionsService=(0,n.createDecorator)("OptionsService"),t.IUnicodeService=(0,n.createDecorator)("UnicodeService")},1480:(e,t,r)=>{Object.defineProperty(t,"__esModule",{value:!0}),t.UnicodeService=void 0;var i=r(8460),n=r(225),o=function(){function e(){this._providers=Object.create(null),this._active="",this._onChange=new i.EventEmitter;var e=new n.UnicodeV6;this.register(e),this._active=e.version,this._activeProvider=e}return Object.defineProperty(e.prototype,"onChange",{get:function(){return this._onChange.event},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"versions",{get:function(){return Object.keys(this._providers)},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"activeVersion",{get:function(){return this._active},set:function(e){if(!this._providers[e])throw new Error('unknown Unicode version "'+e+'"');this._active=e,this._activeProvider=this._providers[e],this._onChange.fire(e)},enumerable:!1,configurable:!0}),e.prototype.register=function(e){this._providers[e.version]=e},e.prototype.wcwidth=function(e){return this._activeProvider.wcwidth(e)},e.prototype.getStringCellWidth=function(e){for(var t=0,r=e.length,i=0;i<r;++i){var n=e.charCodeAt(i);if(55296<=n&&n<=56319){if(++i>=r)return t+this.wcwidth(n);var o=e.charCodeAt(i);56320<=o&&o<=57343?n=1024*(n-55296)+o-56320+65536:t+=this.wcwidth(o)}t+=this.wcwidth(n)}return t},e}();t.UnicodeService=o}},t={};function r(i){var n=t[i];if(void 0!==n)return n.exports;var o=t[i]={exports:{}};return e[i].call(o.exports,o,o.exports,r),o.exports}var i={};return(()=>{var e=i;Object.defineProperty(e,"__esModule",{value:!0}),e.Terminal=void 0;var t=r(3236),n=r(9042),o=r(7975),s=r(7090),a=r(5741),c=r(8285),l=["cols","rows"],u=function(){function e(e){var r=this;this._core=new t.Terminal(e),this._addonManager=new a.AddonManager,this._publicOptions={};var i=function(e){Object.defineProperty(n._publicOptions,e,{get:function(){return r._core.options[e]},set:function(t){r._checkReadonlyOptions(e),r._core.options[e]=t}})},n=this;for(var o in this._core.options)i(o)}return e.prototype._checkReadonlyOptions=function(e){if(l.includes(e))throw new Error('Option "'+e+'" can only be set in the constructor')},e.prototype._checkProposedApi=function(){if(!this._core.optionsService.options.allowProposedApi)throw new Error("You must set the allowProposedApi option to true to use proposed API")},Object.defineProperty(e.prototype,"onBell",{get:function(){return this._core.onBell},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onBinary",{get:function(){return this._core.onBinary},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onCursorMove",{get:function(){return this._core.onCursorMove},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onData",{get:function(){return this._core.onData},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onKey",{get:function(){return this._core.onKey},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onLineFeed",{get:function(){return this._core.onLineFeed},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onRender",{get:function(){return this._core.onRender},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onResize",{get:function(){return this._core.onResize},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onScroll",{get:function(){return this._core.onScroll},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onSelectionChange",{get:function(){return this._core.onSelectionChange},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"onTitleChange",{get:function(){return this._core.onTitleChange},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"element",{get:function(){return this._core.element},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"parser",{get:function(){return this._checkProposedApi(),this._parser||(this._parser=new o.ParserApi(this._core)),this._parser},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"unicode",{get:function(){return this._checkProposedApi(),new s.UnicodeApi(this._core)},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"textarea",{get:function(){return this._core.textarea},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"rows",{get:function(){return this._core.rows},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"cols",{get:function(){return this._core.cols},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"buffer",{get:function(){return this._checkProposedApi(),this._buffer||(this._buffer=new c.BufferNamespaceApi(this._core)),this._buffer},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"markers",{get:function(){return this._checkProposedApi(),this._core.markers},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"modes",{get:function(){var e=this._core.coreService.decPrivateModes,t="none";switch(this._core.coreMouseService.activeProtocol){case"X10":t="x10";break;case"VT200":t="vt200";break;case"DRAG":t="drag";break;case"ANY":t="any"}return{applicationCursorKeysMode:e.applicationCursorKeys,applicationKeypadMode:e.applicationKeypad,bracketedPasteMode:e.bracketedPasteMode,insertMode:this._core.coreService.modes.insertMode,mouseTrackingMode:t,originMode:e.origin,reverseWraparoundMode:e.reverseWraparound,sendFocusMode:e.sendFocus,wraparoundMode:e.wraparound}},enumerable:!1,configurable:!0}),Object.defineProperty(e.prototype,"options",{get:function(){return this._publicOptions},set:function(e){for(var t in e)this._publicOptions[t]=e[t]},enumerable:!1,configurable:!0}),e.prototype.blur=function(){this._core.blur()},e.prototype.focus=function(){this._core.focus()},e.prototype.resize=function(e,t){this._verifyIntegers(e,t),this._core.resize(e,t)},e.prototype.open=function(e){this._core.open(e)},e.prototype.attachCustomKeyEventHandler=function(e){this._core.attachCustomKeyEventHandler(e)},e.prototype.registerLinkMatcher=function(e,t,r){return this._checkProposedApi(),this._core.registerLinkMatcher(e,t,r)},e.prototype.deregisterLinkMatcher=function(e){this._checkProposedApi(),this._core.deregisterLinkMatcher(e)},e.prototype.registerLinkProvider=function(e){return this._checkProposedApi(),this._core.registerLinkProvider(e)},e.prototype.registerCharacterJoiner=function(e){return this._checkProposedApi(),this._core.registerCharacterJoiner(e)},e.prototype.deregisterCharacterJoiner=function(e){this._checkProposedApi(),this._core.deregisterCharacterJoiner(e)},e.prototype.registerMarker=function(e){return this._checkProposedApi(),this._verifyIntegers(e),this._core.addMarker(e)},e.prototype.addMarker=function(e){return this.registerMarker(e)},e.prototype.hasSelection=function(){return this._core.hasSelection()},e.prototype.select=function(e,t,r){this._verifyIntegers(e,t,r),this._core.select(e,t,r)},e.prototype.getSelection=function(){return this._core.getSelection()},e.prototype.getSelectionPosition=function(){return this._core.getSelectionPosition()},e.prototype.clearSelection=function(){this._core.clearSelection()},e.prototype.selectAll=function(){this._core.selectAll()},e.prototype.selectLines=function(e,t){this._verifyIntegers(e,t),this._core.selectLines(e,t)},e.prototype.dispose=function(){this._addonManager.dispose(),this._core.dispose()},e.prototype.scrollLines=function(e){this._verifyIntegers(e),this._core.scrollLines(e)},e.prototype.scrollPages=function(e){this._verifyIntegers(e),this._core.scrollPages(e)},e.prototype.scrollToTop=function(){this._core.scrollToTop()},e.prototype.scrollToBottom=function(){this._core.scrollToBottom()},e.prototype.scrollToLine=function(e){this._verifyIntegers(e),this._core.scrollToLine(e)},e.prototype.clear=function(){this._core.clear()},e.prototype.write=function(e,t){this._core.write(e,t)},e.prototype.writeUtf8=function(e,t){this._core.write(e,t)},e.prototype.writeln=function(e,t){this._core.write(e),this._core.write("\r\n",t)},e.prototype.paste=function(e){this._core.paste(e)},e.prototype.getOption=function(e){return this._core.optionsService.getOption(e)},e.prototype.setOption=function(e,t){this._checkReadonlyOptions(e),this._core.optionsService.setOption(e,t)},e.prototype.refresh=function(e,t){this._verifyIntegers(e,t),this._core.refresh(e,t)},e.prototype.reset=function(){this._core.reset()},e.prototype.clearTextureAtlas=function(){this._core.clearTextureAtlas()},e.prototype.loadAddon=function(e){return this._addonManager.loadAddon(this,e)},Object.defineProperty(e,"strings",{get:function(){return n},enumerable:!1,configurable:!0}),e.prototype._verifyIntegers=function(){for(var e=[],t=0;t<arguments.length;t++)e[t]=arguments[t];for(var r=0,i=e;r<i.length;r++){var n=i[r];if(n===1/0||isNaN(n)||n%1!=0)throw new Error("This API only accepts integers")}},e}();e.Terminal=u})(),i})()}},t={};function r(i){var n=t[i];if(void 0!==n)return n.exports;var o=t[i]={id:i,loaded:!1,exports:{}};return e[i].call(o.exports,o,o.exports,r),o.loaded=!0,o.exports}r.n=e=>{var t=e&&e.__esModule?()=>e.default:()=>e;return r.d(t,{a:t}),t},r.d=(e,t)=>{for(var i in t)r.o(t,i)&&!r.o(e,i)&&Object.defineProperty(e,i,{enumerable:!0,get:t[i]})},r.g=function(){if("object"==typeof globalThis)return globalThis;try{return this||new Function("return this")()}catch(e){if("object"==typeof window)return window}}(),r.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),r.nmd=e=>(e.paths=[],e.children||(e.children=[]),e),(()=>{"use strict";var e=r(379),t=r.n(e),i=r(795),n=r.n(i),o=r(569),s=r.n(o),a=r(565),c=r.n(a),l=r(216),u=r.n(l),h=r(589),f=r.n(h),_=r(102),d={};d.styleTagTransform=f(),d.setAttributes=c(),d.insert=s().bind(null,"head"),d.domAPI=n(),d.insertStyleElement=u(),t()(_.Z,d),_.Z&&_.Z.locals&&_.Z.locals;var p=r(320),v=r(617),g=r(486),y=r.n(g),m=function(e,t,r,i){return new(r||(r=Promise))((function(n,o){function s(e){try{c(i.next(e))}catch(e){o(e)}}function a(e){try{c(i.throw(e))}catch(e){o(e)}}function c(e){var t;e.done?n(e.value):(t=e.value,t instanceof r?t:new r((function(e){e(t)}))).then(s,a)}c((i=i.apply(e,t||[])).next())}))},b=function(e,t){var r,i,n,o,s={label:0,sent:function(){if(1&n[0])throw n[1];return n[1]},trys:[],ops:[]};return o={next:a(0),throw:a(1),return:a(2)},"function"==typeof Symbol&&(o[Symbol.iterator]=function(){return this}),o;function a(o){return function(a){return function(o){if(r)throw new TypeError("Generator is already executing.");for(;s;)try{if(r=1,i&&(n=2&o[0]?i.return:o[0]?i.throw||((n=i.return)&&n.call(i),0):i.next)&&!(n=n.call(i,o[1])).done)return n;switch(i=0,n&&(o=[2&o[0],n.value]),o[0]){case 0:case 1:n=o;break;case 4:return s.label++,{value:o[1],done:!1};case 5:s.label++,i=o[1],o=[0];continue;case 7:o=s.ops.pop(),s.trys.pop();continue;default:if(!((n=(n=s.trys).length>0&&n[n.length-1])||6!==o[0]&&2!==o[0])){s=0;continue}if(3===o[0]&&(!n||o[1]>n[0]&&o[1]<n[3])){s.label=o[1];break}if(6===o[0]&&s.label<n[1]){s.label=n[1],n=o;break}if(n&&s.label<n[2]){s.label=n[2],s.ops.push(o);break}n[2]&&s.ops.pop(),s.trys.pop();continue}o=t.call(e,s)}catch(e){o=[6,e],i=0}finally{r=n=0}if(5&o[0])throw o[1];return{value:o[0]?o[1]:void 0,done:!0}}([o,a])}}};window.onload=function(){var e=new p.Terminal,t=new v.FitAddon;window.term=e,window.fitAddon=t,e.loadAddon(t),e.open(document.getElementById("terminal"));var r=function(){e.element.parentElement.style.height=window.innerHeight-16+"px",t.fit(),fetch("/resize?rows="+e.rows+"&cols="+e.cols)};r(),window.onresize=r;var i=[];e.onData((function(e){i.push(e)})),m(this,void 0,void 0,(function(){var e,t,r;return b(this,(function(n){switch(n.label){case 0:e=function(e){return new Promise((function(t){return setTimeout(t,e)}))},n.label=1;case 1:n.trys.push([1,,7,8]),n.label=2;case 2:return[4,e(100)];case 3:return n.sent(),y().isEmpty(i)?[3,5]:(t=i.join(""),r=window.btoa(t),i.length=0,[4,fetch("/in/"+r)]);case 4:n.sent(),n.label=5;case 5:return[3,2];case 6:return[3,8];case 7:return console.log("input disconnect!"),[7];case 8:return[2]}}))})),function(){m(this,void 0,void 0,(function(){var t,r,i;return b(this,(function(n){switch(n.label){case 0:n.trys.push([0,,5,6]),n.label=1;case 1:return[4,fetch("/out")];case 2:return t=n.sent(),i=Uint8Array.bind,[4,t.arrayBuffer()];case 3:return r=new(i.apply(Uint8Array,[void 0,n.sent()])),t&&e.write(r),[3,1];case 4:return[3,6];case 5:return console.log("input disconnect!"),[7];case 6:return[2]}}))}))}()}})()})();",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "426644"
                ],
                [
                  "content-type",
                  "text/javascript"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/resize?rows=43&cols=129": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/out": {
              "data": "W0dJTl0gMjAyNC8xMi8wNCAtIDE3OjI5OjA5IHwbWzk3OzQybSAyMDAgG1swbXwgIDguMzQzNjE1Mzk2cyB8ICAgICAgIDEyNy4wLjAuMSB8G1s5Nzs0Nm0gUE9TVCAgICAbWzBtICIvYXBpL2dlbmVyYXRlIg0K",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "120"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/in/G1syMDB+Y3VybCAtZnNTTCBodHRwczovL29sbGFtYS5jb20vaW5zdGFsbC5zaCB8IHNoG1syMDF+": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/in/DQ==": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/in/bw==": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/in/bGxhbWEgcw==": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/in/ZXJ2ZSAmIA==": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/in/G1syMDB+b2xsYW1hIHJ1biBsbGFtYTMuMhtbMjAxfg==": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/in/G1syMDB+b2xsYW1hIHNlcnZlICYgb2xsYW1hIHJ1biBsbGFtYTMuMhtbMjAxfg==": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            },
            "https://localhost:10000/resize?rows=43&cols=92": {
              "data": "",
              "ok": true,
              "headers": [
                [
                  "content-length",
                  "0"
                ],
                [
                  "content-type",
                  "text/html; charset=UTF-8"
                ]
              ],
              "status": 200,
              "status_text": ""
            }
          }
        },
        "id": "M-d7xpgXr5pF",
        "outputId": "ad266c7d-45f3-4404-ae95-9b05e36b5558"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Launching Xterm..."
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "        (async () => {\n",
              "            const url = new URL(await google.colab.kernel.proxyPort(10000, {'cache': true}));\n",
              "            const iframe = document.createElement('iframe');\n",
              "            iframe.src = url;\n",
              "            iframe.setAttribute('width', '100%');\n",
              "            iframe.setAttribute('height', '800');\n",
              "            iframe.setAttribute('frameborder', 0);\n",
              "            document.body.appendChild(iframe);\n",
              "        })();\n",
              "    "
            ]
          },
          "metadata": {}
        }
      ],
      "source": [
        "%xterm"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 16,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "83bB2KdAwanI",
        "outputId": "37b05eb4-263a-4a6e-b602-b75d1bec11bc"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: langchain_ollama in /usr/local/lib/python3.10/dist-packages (0.2.1)\n",
            "Requirement already satisfied: langchain-core<0.4.0,>=0.3.20 in /usr/local/lib/python3.10/dist-packages (from langchain_ollama) (0.3.21)\n",
            "Requirement already satisfied: ollama<1,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from langchain_ollama) (0.4.2)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.20->langchain_ollama) (6.0.2)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.20->langchain_ollama) (1.33)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.125 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.20->langchain_ollama) (0.1.143)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.20->langchain_ollama) (24.2)\n",
            "Requirement already satisfied: pydantic<3.0.0,>=2.5.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.20->langchain_ollama) (2.9.2)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<10.0.0,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.20->langchain_ollama) (9.0.0)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.20->langchain_ollama) (4.12.2)\n",
            "Requirement already satisfied: httpx<0.28.0,>=0.27.0 in /usr/local/lib/python3.10/dist-packages (from ollama<1,>=0.3.0->langchain_ollama) (0.27.2)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<0.28.0,>=0.27.0->ollama<1,>=0.3.0->langchain_ollama) (3.7.1)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx<0.28.0,>=0.27.0->ollama<1,>=0.3.0->langchain_ollama) (2024.8.30)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<0.28.0,>=0.27.0->ollama<1,>=0.3.0->langchain_ollama) (1.0.7)\n",
            "Requirement already satisfied: idna in /usr/local/lib/python3.10/dist-packages (from httpx<0.28.0,>=0.27.0->ollama<1,>=0.3.0->langchain_ollama) (3.10)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<0.28.0,>=0.27.0->ollama<1,>=0.3.0->langchain_ollama) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<0.28.0,>=0.27.0->ollama<1,>=0.3.0->langchain_ollama) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (3.0.0)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (3.10.11)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (2.32.3)\n",
            "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (1.0.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.5.2->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.5.2->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (2.23.4)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langsmith<0.2.0,>=0.1.125->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (3.4.0)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langsmith<0.2.0,>=0.1.125->langchain-core<0.4.0,>=0.3.20->langchain_ollama) (2.2.3)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<0.28.0,>=0.27.0->ollama<1,>=0.3.0->langchain_ollama) (1.2.2)\n"
          ]
        }
      ],
      "source": [
        "!pip install langchain_ollama"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 17,
      "metadata": {
        "id": "ihOAji2uwOss",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 194
        },
        "outputId": "dffc6037-8c3c-47d3-d2f9-d036852ec55f"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "\"Pakistan is a country located in South Asia, bordered by India to the east, Afghanistan to the west, Iran to the south, and China to the north. It has a diverse geography, climate, and culture, making it one of the most fascinating countries in the world.\\n\\n**Geography:**\\n\\nPakistan has a vast territory of over 796,000 square kilometers (308,000 sq mi), with a varied landscape that includes:\\n\\n1. **Himalayas:** The Karakoram range stretches along the northwestern border, featuring some of the highest peaks in the world, including K2 and Nanga Parbat.\\n2. **Indus River Valley:** The Indus River flows through the fertile valleys of northern Pakistan, supporting agriculture and urban centers like Karachi and Lahore.\\n3. **Deserts:** The Thar Desert covers parts of western and central Pakistan, with extreme temperatures and limited water resources.\\n4. **Tropical regions:** The southern region of Sindh is characterized by tropical forests, mangrove swamps, and coral reefs along the Arabian Sea coast.\\n\\n**Climate:**\\n\\nPakistan has a diverse climate, ranging from:\\n\\n1. **Temperate zones:** The northwestern part of the country experiences cold winters and mild summers.\\n2. **Tropical zones:** The southern regions are warm year-round, with heavy monsoon rains during the summer months.\\n3. **Arctic tundra:** The northernmost areas experience harsh, cold conditions.\\n\\n**Culture:**\\n\\nPakistan is a multicultural society, with over 100 languages spoken across the country. The main ethnic groups include:\\n\\n1. **Urdu-speaking population:** The majority of Pakistanis speak Urdu, which is the national language.\\n2. **Balochi and Pashto speakers:** Many people in southern and western provinces speak Balochi or Pashto as their primary language.\\n3. **Punjabi and Sindhi:** These languages are widely spoken in eastern and southern provinces.\\n\\n**History:**\\n\\nPakistan has a rich history, with various empires rising and falling over the centuries:\\n\\n1. **Ancient civilizations:** The Indus Valley Civilization (3300 BCE - 1300 BCE) is one of the earliest known civilizations in South Asia.\\n2. **Islamic conquests:** In the 7th century CE, Arab armies conquered much of India, establishing Islamic rule.\\n3. **British colonial period:** Pakistan was a British province from 1849 to 1947.\\n4. **Partition and independence:** After British rule ended, Pakistan declared its independence in 1947, following the partition of India.\\n\\n**Economy:**\\n\\nPakistan has a diverse economy, with main sectors including:\\n\\n1. **Agriculture:** The country is known for its rice, wheat, cotton, and sugarcane production.\\n2. **Textiles:** The textile industry is significant, producing clothing and fabric exports.\\n3. **Remittances:** Pakistan receives substantial remittances from foreign workers in the Middle East.\\n\\n**Challenges:**\\n\\nPakistan faces several challenges:\\n\\n1. **Poverty:** Despite economic growth, poverty remains widespread, especially in rural areas.\\n2. **Corruption:** Corruption is a major issue in governance and public services.\\n3. **Security concerns:** Pakistan has faced terrorism and security threats for decades, particularly from the Taliban.\\n\\n**Tourism:**\\n\\nPakistan offers many attractions for tourists:\\n\\n1. **Natural wonders:** The country is home to some of the world's highest mountains, the Hunza Valley, and the ancient Indus River Valley.\\n2. **Cultural heritage:** Visit the Lahore Fort, Mughal Gardens in Srinagar, and the historic city of Mohenjo-Daro.\\n3. **Adventure sports:** Enjoy hiking, trekking, skiing, or white-water rafting in various regions.\\n\\n**Education:**\\n\\nPakistan has a well-developed education system, with:\\n\\n1. **Higher education institutions:** Top universities like Quaid-i-Azam University and the Pakistan Institute of Engineering and Applied Sciences (PIEAS).\\n2. **Technical training centers:** Many vocational schools offer specialized training programs.\\n\\n**Sports:**\\n\\nPakistan is known for its passion for sports, particularly:\\n\\n1. **Cricket:** Cricket is the most popular sport in Pakistan, with a strong national team.\\n2. **Squash:** Squash is another favorite sport among Pakistani players and fans.\\n\\nOverall, Pakistan is a country of rich cultural heritage, diverse geography, and challenging circumstances.\""
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 17
        }
      ],
      "source": [
        "from langchain_ollama import OllamaLLM\n",
        "\n",
        "model = OllamaLLM(model=\"llama3.2\")\n",
        "model.invoke(\"tell me about pakistan\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 19,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 88
        },
        "id": "KIniAYjq0nVX",
        "outputId": "41ef14bf-956e-4189-df82-b229e6358b9b"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Here are 10 potential song title ideas about parrots:\\n\\n1. \"Rainbow Wings\"\\n2. \"Flock to My Heart\"\\n3. \"Colorful Soul\"\\n4. \"Parrot\\'s Lament\"\\n5. \"Sunset in the Aviary\"\\n6. \"Tropical Temptation\"\\n7. \"Squawk of Love\"\\n8. \"Feathered Friend Forever\"\\n9. \"Vibrant Voice\"\\n10. \"Cockatoo Serenade\"\\n\\nI hope you find one that sparks your creativity!'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 19
        }
      ],
      "source": [
        "from langchain_ollama import OllamaLLM\n",
        "\n",
        "model = OllamaLLM(model=\"llama3.2\")\n",
        "model.invoke(\"Come up with 10 names for a song about parrots\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 20,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-C0f5dCKKO19",
        "outputId": "27fbec2f-4d66-4b79-d1a3-33a8e7458d29"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: langchain in /usr/local/lib/python3.10/dist-packages (0.3.9)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.0.36)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain) (3.11.2)\n",
            "Requirement already satisfied: async-timeout<5.0.0,>=4.0.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (4.0.3)\n",
            "Requirement already satisfied: langchain-core<0.4.0,>=0.3.21 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.3.21)\n",
            "Requirement already satisfied: langchain-text-splitters<0.4.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.3.2)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.17 in /usr/local/lib/python3.10/dist-packages (from langchain) (0.1.143)\n",
            "Requirement already satisfied: numpy<2,>=1.22.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (1.26.4)\n",
            "Requirement already satisfied: pydantic<3.0.0,>=2.7.4 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.9.2)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<10,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain) (9.0.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (2.4.3)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (24.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.5.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (6.1.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (0.2.0)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain) (1.17.2)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain) (24.2)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (3.10.11)\n",
            "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.17->langchain) (1.0.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain) (2.23.4)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain) (2024.8.30)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain) (3.1.1)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.0.7)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.4.0,>=0.3.21->langchain) (3.0.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.17->langchain) (1.2.2)\n",
            "Requirement already satisfied: langchain-community in /usr/local/lib/python3.10/dist-packages (0.3.9)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.0.36)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (3.11.2)\n",
            "Requirement already satisfied: dataclasses-json<0.7,>=0.5.7 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.6.7)\n",
            "Requirement already satisfied: httpx-sse<0.5.0,>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.4.0)\n",
            "Requirement already satisfied: langchain<0.4.0,>=0.3.8 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.3.9)\n",
            "Requirement already satisfied: langchain-core<0.4.0,>=0.3.21 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.3.21)\n",
            "Requirement already satisfied: langsmith<0.2.0,>=0.1.125 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.1.143)\n",
            "Requirement already satisfied: numpy<2,>=1.22.4 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (1.26.4)\n",
            "Requirement already satisfied: pydantic-settings<3.0.0,>=2.4.0 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.6.1)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<10,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (9.0.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (2.4.3)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.3.1)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (24.2.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.5.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (6.1.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (0.2.0)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.17.2)\n",
            "Requirement already satisfied: async-timeout<6.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (4.0.3)\n",
            "Requirement already satisfied: marshmallow<4.0.0,>=3.18.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community) (3.23.1)\n",
            "Requirement already satisfied: typing-inspect<1,>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from dataclasses-json<0.7,>=0.5.7->langchain-community) (0.9.0)\n",
            "Requirement already satisfied: langchain-text-splitters<0.4.0,>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from langchain<0.4.0,>=0.3.8->langchain-community) (0.3.2)\n",
            "Requirement already satisfied: pydantic<3.0.0,>=2.7.4 in /usr/local/lib/python3.10/dist-packages (from langchain<0.4.0,>=0.3.8->langchain-community) (2.9.2)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain-community) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain-community) (24.2)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.21->langchain-community) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-community) (0.27.2)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-community) (3.10.11)\n",
            "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.2.0,>=0.1.125->langchain-community) (1.0.0)\n",
            "Requirement already satisfied: python-dotenv>=0.21.0 in /usr/local/lib/python3.10/dist-packages (from pydantic-settings<3.0.0,>=2.4.0->langchain-community) (1.0.1)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (2024.8.30)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain-community) (3.1.1)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (1.0.7)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (1.3.1)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.4.0,>=0.3.21->langchain-community) (3.0.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.8->langchain-community) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.8->langchain-community) (2.23.4)\n",
            "Requirement already satisfied: mypy-extensions>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain-community) (1.0.0)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.2.0,>=0.1.125->langchain-community) (1.2.2)\n",
            "Collecting PyPDF2\n",
            "  Downloading pypdf2-3.0.1-py3-none-any.whl.metadata (6.8 kB)\n",
            "Downloading pypdf2-3.0.1-py3-none-any.whl (232 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m232.6/232.6 kB\u001b[0m \u001b[31m16.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: PyPDF2\n",
            "Successfully installed PyPDF2-3.0.1\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (2.32.3)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests) (2024.8.30)\n"
          ]
        }
      ],
      "source": [
        "!pip install langchain\n",
        "!pip install langchain-community\n",
        "!pip install PyPDF2\n",
        "!pip install requests"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 21,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Xy_m5nnkfnIA",
        "outputId": "1ef06e4a-6eca-4b45-d8ae-08dca5871743"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting rapidocr-onnxruntime\n",
            "  Downloading rapidocr_onnxruntime-1.4.1-py3-none-any.whl.metadata (1.3 kB)\n",
            "Collecting pyclipper>=1.2.0 (from rapidocr-onnxruntime)\n",
            "  Downloading pyclipper-1.3.0.post6-cp310-cp310-manylinux_2_12_x86_64.manylinux2010_x86_64.whl.metadata (9.0 kB)\n",
            "Requirement already satisfied: opencv-python>=4.5.1.48 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (4.10.0.84)\n",
            "Requirement already satisfied: numpy<3.0.0,>=1.19.5 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (1.26.4)\n",
            "Requirement already satisfied: six>=1.15.0 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (1.16.0)\n",
            "Requirement already satisfied: Shapely!=2.0.4,>=1.7.1 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (2.0.6)\n",
            "Requirement already satisfied: PyYAML in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (6.0.2)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (11.0.0)\n",
            "Collecting onnxruntime>=1.7.0 (from rapidocr-onnxruntime)\n",
            "  Downloading onnxruntime-1.20.1-cp310-cp310-manylinux_2_27_x86_64.manylinux_2_28_x86_64.whl.metadata (4.5 kB)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (4.66.6)\n",
            "Collecting coloredlogs (from onnxruntime>=1.7.0->rapidocr-onnxruntime)\n",
            "  Downloading coloredlogs-15.0.1-py2.py3-none-any.whl.metadata (12 kB)\n",
            "Requirement already satisfied: flatbuffers in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (24.3.25)\n",
            "Requirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (24.2)\n",
            "Requirement already satisfied: protobuf in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (4.25.5)\n",
            "Requirement already satisfied: sympy in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (1.13.1)\n",
            "Collecting humanfriendly>=9.1 (from coloredlogs->onnxruntime>=1.7.0->rapidocr-onnxruntime)\n",
            "  Downloading humanfriendly-10.0-py2.py3-none-any.whl.metadata (9.2 kB)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from sympy->onnxruntime>=1.7.0->rapidocr-onnxruntime) (1.3.0)\n",
            "Downloading rapidocr_onnxruntime-1.4.1-py3-none-any.whl (14.9 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m14.9/14.9 MB\u001b[0m \u001b[31m42.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading onnxruntime-1.20.1-cp310-cp310-manylinux_2_27_x86_64.manylinux_2_28_x86_64.whl (13.3 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m13.3/13.3 MB\u001b[0m \u001b[31m82.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading pyclipper-1.3.0.post6-cp310-cp310-manylinux_2_12_x86_64.manylinux2010_x86_64.whl (912 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m912.2/912.2 kB\u001b[0m \u001b[31m44.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading coloredlogs-15.0.1-py2.py3-none-any.whl (46 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m46.0/46.0 kB\u001b[0m \u001b[31m4.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading humanfriendly-10.0-py2.py3-none-any.whl (86 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m86.8/86.8 kB\u001b[0m \u001b[31m8.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pyclipper, humanfriendly, coloredlogs, onnxruntime, rapidocr-onnxruntime\n",
            "Successfully installed coloredlogs-15.0.1 humanfriendly-10.0 onnxruntime-1.20.1 pyclipper-1.3.0.post6 rapidocr-onnxruntime-1.4.1\n"
          ]
        }
      ],
      "source": [
        "!pip install rapidocr-onnxruntime"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 22,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KXSSsV5QK09t",
        "outputId": "637758fa-4a36-4927-93fd-74df9912975d"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting pypdf\n",
            "  Downloading pypdf-5.1.0-py3-none-any.whl.metadata (7.2 kB)\n",
            "Requirement already satisfied: typing_extensions>=4.0 in /usr/local/lib/python3.10/dist-packages (from pypdf) (4.12.2)\n",
            "Downloading pypdf-5.1.0-py3-none-any.whl (297 kB)\n",
            "\u001b[?25l   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/298.0 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m298.0/298.0 kB\u001b[0m \u001b[31m18.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pypdf\n",
            "Successfully installed pypdf-5.1.0\n"
          ]
        }
      ],
      "source": [
        "!pip install pypdf"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 23,
      "metadata": {
        "id": "uKdVgbBJjSS3"
      },
      "outputs": [],
      "source": [
        "%pip install -qU langchain-text-splitters"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 24,
      "metadata": {
        "id": "osCM8UunLSJU"
      },
      "outputs": [],
      "source": [
        "from langchain.text_splitter import RecursiveCharacterTextSplitter"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install pymupdf"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "C4eurzfyohOo",
        "outputId": "3c7644d5-f126-40e5-ec32-e3afcd946bf9"
      },
      "execution_count": 29,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting pymupdf\n",
            "  Downloading PyMuPDF-1.24.14-cp39-abi3-manylinux2014_x86_64.manylinux_2_17_x86_64.whl.metadata (3.4 kB)\n",
            "Downloading PyMuPDF-1.24.14-cp39-abi3-manylinux2014_x86_64.manylinux_2_17_x86_64.whl (19.8 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m19.8/19.8 MB\u001b[0m \u001b[31m94.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pymupdf\n",
            "Successfully installed pymupdf-1.24.14\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.document_loaders import PyMuPDFLoader\n",
        "\n",
        "loader = PyMuPDFLoader(\"/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf\")\n",
        "documents = loader.load()\n"
      ],
      "metadata": {
        "id": "n71VLk-soZPf"
      },
      "execution_count": 30,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 31,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "pXt3r0S7oXIr",
        "outputId": "339998ff-9d16-4f11-84f6-0a2f11261db1"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/langchain_community/document_loaders/parsers/pdf.py:154: UserWarning: Unknown PDF Filter!\n",
            "  warnings.warn(\"Unknown PDF Filter!\")\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 0}, page_content='Editor\\nProf. Dr. Sıddık Keskin\\nMedical Diagnosis\\nand\\nTreatment Methods\\nin\\nBasic Medical Sciences\\nMedical Diagnosis and Treatment Methods in Basic Medical Sciences\\nHealth\\nlivredelyon.com\\nlivredelyon\\nlivredelyon\\nlivredelyon\\nISBN: 978-2-38236-061-3'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 1}, page_content='Medical Diagnosis and Treatment Methods  \\nin  \\nBasic Medical Sciences \\n \\n \\n \\n \\n \\nEditor \\nProf. Dr. Sıddık Keskin \\n \\n \\n \\n \\nLyon 2020'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 2}, page_content='Editor • Prof. Dr. Sıddık Keskin                      0000-0001-9355-6558 \\n \\nCover Design • Aruull Raja \\nFirst Published • December 2020, Lyon \\n \\nISBN: 978-2-38236-061-3 \\n \\n \\n \\n \\n© copyright \\nAll rights reserved. No part of this publication may be reproduced, stored \\nin a retrieval system, or transmitted in any form or by an means, \\nelectronic, mechanical, photocopying, recording, or otherwise, without \\nthe publisher’s permission.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 2}, page_content='the publisher’s permission. \\n \\n \\n \\nThe chapters in this book have been checked for plagiarism by \\n \\nPublisher • Livre de Lyon \\nAddress •  37 rue marietton, 69009, Lyon France \\nwebsite •  http://www.livredelyon.com \\ne-mail •  livredelyon@gmail.com'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 3}, page_content='I \\nPREFACE \\n \\nBasic medical sciences are the entire of studies that aim to \\ndiagnose and treatments of diseases in order to maintain healthy life or to \\nprotect health and to treat disorders. Malpractices in health are still an \\nimportant problem for many societie s even for developed societies. The \\nreflection of this problem on patients, relatives of patient and doctors is \\nvery serious financially and morally. It is obvious that this problem can'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 3}, page_content='be reduced substantially by applying the proper diagnosis and treatmen t \\nmethods in Medical Sciences. Today, Evidence -Based Medicine (EBM) \\naims to minimize the problems arising from malpractices in Health \\nSciences and directly affecting the patients, doctors and institution. \\nTherefore, diagnosis and treatment methods in medic al sciences are very \\nimportant in the process of treating the patient and eliminating the \\ndiseases. In order to apply the proper treatment method, the proper'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 3}, page_content='diagnosis of the disease is basic prerequisite. When considering the role \\nof diagnosis and treatme nt for clinicians, well -designed, accurate and \\nreliable diagnostic and treatment methods are needed. Thus, many studies \\nhave been carried out on the diagnosis and treatment methods as well as \\nefficacy and reliability of these methods used in Basic Medical Sciences. \\nIn this framework, the aim of this book is to gather and to present the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 3}, page_content='studies to clinician for easy access and evaluation medical diagnosis and \\ntreatment methods. Thus, our book has 9 chapters. The first and second \\nchapters present conceptual o verview of    biomedical and biochemical \\nhistopathology, respectively. The third chapter is about the review of \\ncancer treatment and the fourth chapter is about the coagulation analysis \\nin diagnosis and treatment. The 5 th chapter is about the prevalence of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 3}, page_content='Palmaris longus. The 6 th chapter is focused on Treatment of erectile \\ndysfunction. The 7 th chapter describes possible effect of pre -eclampsia \\nand eclampsia on pregnancy, and examination of relationship between \\nsmoking and pregnancy is presented in the 8 th chapter. Finally, Chapter 9 \\naddresses the effect of lavender on wound healing as alternative \\nmedicine. \\nWe tried to prepare this book as carefully as possible and by \\nminimizing mistakes as time and possibilities allowed. However, I'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 3}, page_content='apologize to you readers for the mistakes. I would like to thank for all my \\nteammates who contributed to the preparation of this book. We hope that \\nthis book will be useful to our readers and researchers who want to make \\nnew studies. \\nProf. Dr. Sıddık KESKİN'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 4}, page_content='II'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 5}, page_content='CONTENTS \\nPREFACE....………………………………………………………….....I \\nREFEREES……………………………………………………………..V \\nChapter I G. Naz Yazıcı & M. Sunar \\nA BIOMEDICAL TREASURE: NANOFIBERS IN WOUND \\nHEALING………………………………………….…...1 \\nChapter II  G. Naz Yazıcı \\nBIOCHEMICAL AND HISTOPATHOLOGICAL \\nPARAMETERS USED IN EXPERIMENTAL \\nOVARIAN ISCHEMIA / REPERFUSION MODELS IN \\nRECENT YEARS...........................................................13 \\nChapter III  G. Ozcan \\nCLINICAL DEVELOPMENT OF HIF -1α INHIBITORS FOR'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 5}, page_content='CLINICAL DEVELOPMENT OF HIF -1α INHIBITORS FOR \\nCANCER THERAPY....................................................26 \\nChapter IV  M. E. Duz \\nCOAGULATION ANALYSES IN DIAGNOSIS AND \\nTREATMENT................................................................39 \\nChapter V  M. Sunar \\nPREVALENCE OF PALMARIS LONGUS AGENESIS (PLA) \\nAMONG TURKISH MEDICAL STUDENTS..............55 \\nChapter VI  N. Eser \\nTARGETS FOR THE TREATMENT OF ERECTILE'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 5}, page_content='TARGETS FOR THE TREATMENT OF ERECTILE \\nDYSFUNCTION............................................................67 \\nChapter VII  Y. Altuner \\nPOSSIBLE EFFECTS OF PREEKLAMPSY AND EKLAMPSY \\nTHAT MAY OCCUR WITH MATERN AL OBESITY \\nON THE HEALTH OF PREGNANCY: A \\nMETAANALYSIS.........................................................89 \\nChapter VIII  E. Balcıoğlu & H. Yeşil Sarsmaz & G. S. Gürgen \\nAN EXAMINATION OF THE RELATIONSHIP BETWEEN \\nSMOKING DURING -BEFORE PREGNANCY AND'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 5}, page_content='SMOKING DURING -BEFORE PREGNANCY AND \\nNEWBORN BIRTH WEIGHT/PLACENTA WEIGHT \\nAND ITS HISTOPATHOLOGICAL IMPACTS ON \\nTHE PLACENTA TISSUE..........................................115 \\nChapter IX  A. Demiröz & Z. G. Özünal \\nEFFECTS OF LAVENDER OIL ON WOUND HEALING…129'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 6}, page_content='IV'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 7}, page_content='REFEREES \\n \\nAssoc. Prof. Dr. Alper Gümüş,  Başakşehir City Hospital  \\nAssoc. Prof.  Dr. Kemal Sarsmaz , University of Health Sciences Etlik \\nZübeyde Hanım Gynecology Training and Research Hospital \\nAsst. Prof. Dr. Ayhan Güler, Hakkari University'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 8}, page_content='VI'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 9}, page_content='CHAPTER I \\n \\nA BIOMEDICAL TREASURE: NANOFIBERS IN WOUND \\nHEALING \\n \\nGülce Naz Yazıcı1 & Mukadder Sunar2 \\n1(Asst. Prof, PhD) Erzincan Binali Yıldırım University,   \\ne-mail: gulcenazyazici.ank@gmail.com \\n                      0000-0002-6989-997X \\n2(Asst. Prof, PhD) Binali Yıldırım University, e-mail: mukaddersunar@gmail.com \\n                   0000-0002-6744-3848 \\n \\n \\nINTRODUCTION \\nThe skin that covers the body from the outside, protects against'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 9}, page_content='external-environmental factors and has the largest surface;  It is also very \\nprone to damage. The most important function of healthy skin is to provide \\nhomostasis. It acts as a barrier for exogenous substances, chemicals, \\nmoisture loss and pathogens. It is vitally important to quickly and \\neffectively recycle any damage that may occur in the skin. \\nWound is the deterioration of normal anatomical structure and \\nfunctional integrity. Skin; It can be damaged by the effect of many harmful'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 9}, page_content='stimuli such as trauma, surgical applications, heat, cold, radiation, \\ninfection and n eoplasia. In the event of injury, a complex healing and \\nregeneration process occurs in the skin. The healing process firstly aims to \\nrestore homeostasis and within the framework of this process; It covers the \\nsteps of blood coagulation, inflammation, epith elium regeneration, \\ngranulation tissue and tissue reconstruction. \\nNormal wound healing takes place through the regular and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 9}, page_content='sequential work of many cellular and biochemical functions. Under normal \\ncircumstances, these steps result in repairing the damage to the injured skin \\narea. However, as a result of damage repair, a permanent scar formation \\noccurs in the healing area. Scar tissue, unlike normal tissue; It is a texture \\nthat does not contain any leather additions and has lost its appearance - \\nelasticity. While wound healing continues rapidly and regularly in healthy'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 9}, page_content='individuals, it is delayed in cases such as age, infection, diabetes, use of \\nsystemic steroids and cancer treatment. In these cases, chronic and \\nincomplete healing ulcers may occur by disrupting the healing process (1, \\n2, 3). The aim of topical and systemic applications used to prevent this is'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 10}, page_content='2 \\nto provide ideal scar formation by affecting factors such as inflammatory \\ncells, thrombocytes, mediators and extracellular matrix (4). In this context, \\ndifferent treatment methods are tried, new treatment searches are continued \\nto accelerate the healing process, prevent excessive inflammation and \\ninfections, and to prevent any symptoms by monitoring the healing process \\n(5). \\nOpen wounds mean an open door for infection. Therefore, the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 10}, page_content='wound surface should not be left open and should be covered with suitable \\nmaterials. Wound dressings were originally fabricated from natural \\nmaterials such as plant fibers and animal fats to simply cover the wounds. \\nThis has evolved to the present day whereby artificial materials can be \\nfabricated by various advanced technologies to create multifunctional \\nwound dressings. The two essential requirements of suitable modern'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 10}, page_content='wound dressings include rapid hemostasis property and good antibacterial \\nproperty. The purpose of a wound dressing is to achieve rapid hemostasis \\nfunction and it should also possess good antibacterial property to prevent \\ninfections from surrounding bacteria.  \\nElectrospinning has att racted much interest for its versatility to \\nfabricate nanofibrous membranes for a wound dressing which can create a \\nmoist environment around the wound area to promote healing (6). \\nELECTROSPINNING'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 10}, page_content='ELECTROSPINNING \\nHistorically, cells were grown and studied as monolayers on tissue \\nculture plates. In recent years, advances in biomaterial synthesis and \\nmicrofabrication have made it possible to pattern cells into complex, three-\\ndimensional structures by using appropriate scaffolds as the templates  (7, \\n8). \\nElectrospinning is a re markably simple, robust, and versatile \\ntechnique capable of generating fi bers with diameters down to the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 10}, page_content='nanoscale (7, 9). A non-woven mat of electrospun nanofi bers possesses \\nhigh porosity and spatial interconnectivity well -suited for nutrient and \\nwaste t ransport and cell communication  (7, 10). A scaff old based on \\nelectrospun nanofibers also has a large specific surface area for loading of \\nbioactive molecules to facilitate efficient a nd selective cellular responses \\n(9). \\nElectrospinning was first being intro duced in early 1930s for'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 10}, page_content='fabrication of nanofibers as filter materials and textile yarns. Since 1990s, \\nafter Reneker et al. demonstrated the feasibility to produce electrospun \\nnanofibers from many polymers, the number of publications about \\nelectrospinning has grown exponentially , especially for recent ten years  \\n(11, 12, 13).  Electrospinning received  much attention for biomedical \\napplications mainly due to the growing interest in nano -technologies and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 11}, page_content='3 \\nthe unique material properties. Electrospinning is an inexpensive and \\nsimple method to create nanoscale polymer fibers with diameter range \\nfrom 3 –5000 nm  (11, 14).  Nanofibers are suitable to  mimic biological \\nenvironment because they are in the same scale as biological molecules. In \\nfact, nanomaterials like pa rticles, fibrous morphologies or other complex \\nforms, have shown improved interactionswith cells, for example, selective \\nendocytosis, adhesion and orientation (11, 15, 16).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 11}, page_content='A useful wound healing patch should have the following properties \\n(a) antibacterial, (b) able to promote rapid hemostasis and (c) having good \\nbiocompatibility to promote cell growth (6). Nanofibers were usually \\nfabricated by incorporating antibacterial materials in the polymers. To \\ndate, five methods of incorporating active agents in the  fibers; including \\nthe active agent blending with polymer solution before electrospinning,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 11}, page_content='fabricating core/shell structure through coaxial electrospinning, \\nencapsulating the active agent before mixing them with electrospinning \\nsolution, posttreatment of t he fiber after electrospinning to convert a \\nprecursor to its active form or attaching the fiber s urface with the active \\ncompound (6).  \\nThe electrospinning process utilizes high electrostatic forces for \\nnanofiber generation; generally from a polymeric solut ion or melt. The'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 11}, page_content='main assembly of the electrospinning unit comprises of electrical supply \\n(for the generation of high electrical voltage), a syringe (contains solution/ \\nmelt/suspension to be electrospun), a metallic needle (as a capillary), and \\na grounded conductive collector (rotatable drum or static plate type) all \\nenclosed within a chamber (17, 18). During the spinning process, high \\nvoltage (5 –15 kV) is applied between a needle capillary end and a'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 11}, page_content='collector. The polymer solution is electrically charged. At the needle tip, \\nthe polymer solution deforms from a spherical pendant droplet to a conical \\nshape, known as “Taylor cone”. As the electric field is stronger than the \\nsurface tension of the polymer solution, the jet is ejected from the cone \\nsurface. As the jet travels, the solvent evaporates in the air, together with \\nthe stretching and acceleration of the polymer jet, leading to the extremely'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 11}, page_content='thin polymer fibers deposition on the collector (11, 19).  Electrical bending \\ninstability occurs when the distance from the tip to the collector is \\nsufficiently long; in the case of a short distance, the jet is typically straight. \\nUnder the action of the electric field, polymer jets experience bending \\ninstability primarily due to mutual repulsion of the excess electric charges \\ncarried by electrospun jets. The electrospinning process and the formation'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 11}, page_content='of polymer fibers are affected by many parameters. Spinnability, fiber \\ndiameters, fiber uniformity, fiber alignment, defects control (e.g. beads, \\njunctions, and pores), and  other properties are tunable by changing these \\nparameters, (a) substrate -related parameters (polymer concentration,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 12}, page_content='4 \\nviscosity, molecular weight, surface tension); and (b) apparatus -related \\nparameters (flow rate and electric field) (11). \\n \\n \\n \\nFigure 1: Schematic representation of a typical electrospinning apparatus. \\n(Felgueiras, H. P., & Amorim, M. T. P. (2017). Functionalization of \\nelectrospun polymeric wound dressings with antimicrobial \\npeptides. Colloids and Surfaces B: Biointerfaces, 156, 133-148.) \\n \\nElectrospinning has been applied to more than 100 different types of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 12}, page_content='polymers. While preparing a product using the electrospin method, it is \\ngenerally desired to obtain a high effect result by adding an active \\ningredient to a polymer solution. The most used polymer solutions can be \\nlisted as ; PAA (p oly(acrylic acid) ), PVA (p oly(vinyl alcohol) ), PLA \\n(poly(lactic asid )), PAN(p olyacrylonitrile), PCL ( poly(ε-caprolactone)), \\nPVP ( poly(vinyl pyrrolidone) ), PEG ( polyethylene glycol ), PEO'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 12}, page_content='(poly(ethylene oxide)), PLLA (poly(L-lactide)),  and PLGA (Poly (lactic-\\nco-glycolic) acid) for biomedical production (20). For the purpose of the \\nexperimental study to be done on polymer solutions; Antibacterial agents, \\nherbal extracts, various antioxidant agents are added  to these  polymer \\nbased solutions.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 13}, page_content='5 \\n    \\nFigure 2: Diagrammatic illustration to high light the practical applications \\nof E-spun NFs. (Thenmozhi, S., Dharmaraj, N., Kadirvelu, K., & Kim, H. \\nY. (2017). Electrospun nanofibers: New generation materials for advanced \\napplications. Materials Science and Engineering: B, 217, 36-48.) \\nNANOFIBERS (NFs) on WOUND HEALING \\nMany tissues in the human body do not have sufficient \\nregenerative capacity, so damage to these tissues is irreversible. In addition'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 13}, page_content='to poor healing ability, injuries to tissues such as nerves, tendons, cartilage, \\nand myocardium also cause severe pain and disability. At the end of the \\nhealing process that is completed after the injuries, especially the formation \\nof scar tissue on the skin; It is a difficult situation to overcome both in \\nterms of reducing the quality of life and cosmetics. Even with surgery, the \\nreturn of function is often limited, a nd the healing response is scar'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 13}, page_content='mediated rather than regenerative (7, 21). Patients with organ trauma, \\ndisease, or congenital abnormalities should rely on organ transplantation \\nto regain function. Despite its tremendous clinical success, this approach \\ngrapples with post-surgical immune reactions and severe limitations in the \\nnumber of donors available, leaving thousands of patients on waiting lists. \\nThese limitations of organ transplantation have pushed researchers to find \\nsolutions in different areas for decades.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 13}, page_content='solutions in different areas for decades. \\nWOUND DRESSER PROPORTIES of NFs \\nWhen the advantages and disadvantages of wound dressings are \\nevaluated; A good dressing must have some distinctive features.  Wound'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 14}, page_content='6 \\ndressings prepared by electrospin method; It has many prominent features \\nthat will provide advantag es in the wound healing process.  NFs based \\nwound dresses can promote hemostasis without resorting to a haemostatic \\nagent, water adsorption is 8 –92 times superior on electrospun dressings \\ncompared to typical film dressings . The arrangement o f the nanofibers \\nresults in small pores that not only allow cell respiration, oxygen exchange,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 14}, page_content='and to control the moisture at the wounded site preventing dehydration, \\nbut, because of its small size, can also effectively protect the wound from \\ninfection pre venting microorganisms from penetrating.  These wound \\ndresses also comfortable, funct ional because u nlike other commercially \\navailable dressings that use multi-layer technology, which tends to be more \\nunpredictable and less stable, with  electrospinning it is possible to blend'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 14}, page_content='various functional mate rials simultaneously to produce an all -in-one \\nwound dressing.  Use of electrospinning to produce biomimetic \\nnanofibrous structures with good cell conductivity can enhance blood and \\ntissue compatibility, which facil itates wound healing and tissue \\nregeneration and provide scar-free healing (22, 23, 24). \\nANTIBACTERIAL PROPORTIES of NFs \\nMicrobes on the human skin are divided into three general \\ncategories: pathogens, potential pathogens, an d harmless symbiotic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 14}, page_content='organisms (25, 26).  Bacteria are one of these cutaneous microbes. Normal \\nbacteria that are commonly found on the skin include  Staphylococcus \\nepidermidis, corynebacterium, propionibacterium, \\noccasionally Staphylococcus aureus, and peptostreptococcus species (27). \\nSome of the aforementioned cutaneous bacteria, which are known as \\nopportunistic pathogens, can become pathogenic when the human immune \\nsystem is weakened, or when there are concurrent infections and illnesses'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 14}, page_content='such as cancer. They can infect the human body and cause many diseases \\n(25, 28). \\nWhen the human skin barrier is removed or damaged, chances of \\nmore serious infections and issues increase (25). Usually, the polymers \\nused for fabricating antibacterial nanofibers possess inherent abilities such \\nas non -toxicity, goodmechanical properties, biocompatibility and \\nbiodegradability including PCL, PLA, PLGA, PVA and chitosan. The \\ncommon antibacterialmaterials such as antibiotics, triclosan,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 14}, page_content='chlorhexidine, quaternary ammonium compounds (QACs), biguanides, \\nsilver nanoparticles, and metal oxide nanoparticles have been reported to \\nbe used in fabricating antibacterial nanofibers (6). \\nSohrabi A. et al used ampicillin incorporated PMMA (polymethyl \\nmethacrylate)–nylon6 core/shell fibers were fabricated utilizing the coaxial \\nelectrospinning technique for investigate these materials antibacterial \\nactivity in gram-positive Listeria innocua . They confirmed their fibers'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 15}, page_content='7 \\nformation of the core/shell structure and the smooth surface morphology \\nwith TEM and SEM analysis. They design ed drug delivery system for all \\nthe concentrations of the encapsulated drug indicates a three stages drug \\nrelease over a period of 31 days with a sustained manner and suppressed \\nburst release, which occurred only for 6 h. Antibacterial investigations \\nshowed a gradual decrease in the OD (concentration of the bacteria) with'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 15}, page_content='an increase in the concentration of the encapsulated drug from 1% to 20%. \\nA higher amount of drug in the fibers led to enhanced drug release after 18 \\nh incubation which resulted in a higher degree of growth inhibition (29). \\nKhampieng T. et al , used  electrospinning technique and post -\\nspinning sorption method DOXY -h loaded -poly(acrylic acid) (PAA) \\nnanofiber mats (PAA/DOXY -h nanofiber mats) at various doses: \\nPAA/DOXY-h125, PAA/DOXY -h250, PAA/DOXY -h500, and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 15}, page_content='PAA/DOXY-h1000. The morphology, drug content, release \\ncharacteristics, and antibacterial activities of the PAA/DOXY-h nanofiber \\nmats were investigated with SEM, UV–vis spectrophotometry, and disc \\ndiffusion methodology.  They tested these products in gram-positive \\nbacteria, Staphylococcus aureus and Streptococcus agalactiae, and gram-\\nnegative bacteria, Pseudomonas aeruginosa . They found that;  these \\nparticular nanofiber mats demonstrated antibacterial properties against'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 15}, page_content='gram-positive bacteria; S. aureus and S. agalactiae , therewithal appeared \\nto be mor e effective and concentration-dependent against gram-negative \\nbacteria; P. aeruginosa (30). \\nKim SS. et al, producted Polyacrylonitrile (PAN) –chitosan \\ndouble-face films an d nanofibers for investigating their antibacterial \\nactivity. They dissolved PAN and a chitosan salt in dimethyl sulfoxide, and \\nthen thin-layered on a glass plate or electro spun followed by coagulation'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 15}, page_content='in sodium hydroxide solution. The morphology of the PAN –chitosan \\ndouble-face films and nanofibers was analyzed by SEM. The antibacterial \\nefficacy was measured by a swatch test with bacterial suspensions. They \\nconcluded that; the PAN–chitosan nanofibers produced a 5 -log reduction \\n(Log reduction is a mathematical term that is used to express the relative \\nnumber of living microbes that are elimina ted by disinfection) against'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 15}, page_content='Escherichia coli, Staphylococcus aureus, and Micrococcus luteus (31). \\nSarhan WA and Azzazy HME, produced chitosan and honey were \\nco-spun with polyvinyl alcohol (P VA) allowing the fabrication of \\nnanofibers with high honey concentrations up to 40% and high chitosan \\nconcentrations up to 5.5% of the total weight of the fibers using \\nbiocompatible solvents (1% acetic acid). The fabricated nanofibers were \\nfurther chemically crosslinked, by exposure to glutaraldehyde vapor, and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 15}, page_content='physically crosslinked by heating and freezing/thawing. The new HP –\\nchitosan nanofibers showed pronounced antibacterial activity against \\nStaphylococcus aureus but weak antibacterial activity against Escherichia'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 16}, page_content='8 \\ncoli. The developed HP –chitosan nanofibers revealed no cytotoxicity \\neffects on cultured fibroblasts. And they concluded that,  biocompatible, \\nantimicrobial crosslinked honey/polyvinyl alcohol/chitosan nanofibers \\nwere developed which hold potential as an effective wound dressing (31). \\nCONCLUSION \\nDespite their potential for continuous exploration and evolu -tion, \\nantimicrobial dressings are already one of most importantdiscoveries of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 16}, page_content='our century in biomedical research and their thera-peutic abilities are well \\nrecognized (22). Electrospinning is a simple and cost effective but \\nfascinating fiber forming technology with less time consumption under \\noptimized conditions (32). Electrospinning technique, a llows the \\nfabrication of fibers with high -surface area due to their diameters being \\nscalable down to a few nanometers. Electrospin based wound dressers can'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 16}, page_content='be surface functionalized to tune the physical and chemical properties of \\nthe fiber  surface while the fiber structure, morphology, and \\nspatialdistribution can be controlled to achieve specific mechanical  \\nproperties. In addition, electrospinning allows the combination of different \\nsynthetic and natural polymers  to be used to make nanofibers. The \\npossibility of large -scale production combined with simplicity \\nandversatility makes the electrospinning process very attractive for a broad'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 16}, page_content='variety of applications (33). Hundreds of polymer options and hundreds of \\nhealing agents that can be added to these polymer solutions show that this \\nbiomedical research field is in need of much more research.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 17}, page_content='9 \\nREFERENCES \\n1. Meyer, M., Müller, A. K., Yang, J., Moik, D., Ponzio, G., Ornitz, D. M., \\n... & Werner, S. (2012). FGF receptors 1 and 2 are key regulators \\nof keratinocyte migration in vitro and in wounded skin. Journal of \\ncell science, 125(23), 5690-5701. \\n2. Atalan, G., Demirkan, İ., Yaman, H., Cihan, M., Önder, F., & Sözmen, \\nM. (2003). Effect of topical kefir application on open wound \\nhealing an in vivo study.  Kafkas Üniversitesi Veteriner Fakültesi \\nDergisi, 9(1), 43-47.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 17}, page_content='Dergisi, 9(1), 43-47. \\n3. Omeroglu, S., Cam, M., & Erdoğan, D. (2003). Streptozotosin ile \\ndeneysel diyabet oluşturulmuş sıçanlardaki deri yaralarında, \\ninsülin benzeri büyüme faktörü -I’in lokalizasyonunun \\nimmünohistokimyasal olarak gösterilmesi.  Düzce Tıp Fakültesi \\nDergisi, 5, 5-8. \\n4. Kapan, M., Aslanmirza, M. Y., Karip, A. B., Bozkurt, Y., Evsen, M. S., \\nSak, E., & Öngören, A. U. (2008). Lokal fenitoin ve üre \\nuygulamasının yara iyileşmesi üzerine olan etkilerinin'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 17}, page_content='karşılaştırılması. Yeni Tıp Dergisi, 25(4), 209. \\n5. Alpsoy, A., Atasever, S., İlter, K., Özbeser, E., & Öztürk, A. Sıçanlarda \\nlokal midkin tedavisininyara iyileşmesine etkisi.  \\n6. Liu, M., Duan, X. P., Li, Y. M., Yang, D. P., & Long, Y. Z. (2017). \\nElectrospun nanofibers for wound healing. Materials Science and \\nEngineering: C, 76, 1413-1423. \\n7. Liu, W., Thomopoulos, S., & Xia, Y. (2012). Electrospun nanofibers for \\nregenerative medicine. Advanced healthcare materials , 1(1), 10 -\\n25.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 17}, page_content='25. \\n8. Kelleher, C. M., & Vacanti, J. P. (2010). Engineering extracellular \\nmatrix through nan otechnology. Journal of the Royal Society \\nInterface, 7(suppl_6), S717-S729. \\n9. Agarwal, S., Wendorff, J. H., & Greiner, A. (2009). Progress in the field \\nof electrospinning for tissue engineering applications.  Advanced \\nMaterials, 21(32‐33), 3343-3351. \\n10. Pham, Q. P., Sharma, U., & Mikos, A. G. (2006). Electrospinning of \\npolymeric nanofibers for tissue engineering applications: a'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 17}, page_content='review. Tissue engineering, 12(5), 1197-1211. \\n11. Kai, D., Liow, S. S., & Loh, X. J. (2014). Biodegradable polymers for \\nelectrospinning: towards biomedical applications.  Materials \\nScience and Engineering: C, 45, 659-670.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 18}, page_content='10 \\n12. Reneker, D. H., & Chun, I. (1996). Nanometre diameter fibres of \\npolymer, produced by electrospinning.  Nanotechnology, 7(3), \\n216. \\n13. Doshi, J., & Reneker, D. H. (1995). Electrospinning process and \\napplications of electrospun fibers. Journal of electrostatics, 35(2-\\n3), 151-160. \\n14. Subbiah, T., Bhat, G. S., Tock, R. W., Parameswaran, S., & Ramkumar, \\nS. S. (2005). Electrospinning of nanofibers.  Journal of applied \\npolymer science, 96(2), 557-569.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 18}, page_content='polymer science, 96(2), 557-569. \\n15. Jiang, W., Kim, B. Y., Rutka, J. T., & Chan, W. C. (2008). \\nNanoparticle-mediated cellular response is size-dependent. Nature \\nnanotechnology, 3(3), 145-150. \\n16. Kai, D., Jin, G., Prabhakaran, M. P., & Ramakrishna, S. (20 13). \\nElectrospun synthetic and natural nanofibers for regenerative \\nmedicine and stem cells. Biotechnology journal, 8(1), 59-72. \\n17. Thakkar, S., & Misra, M. (2017). Electrospun polymeric nanofibers:'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 18}, page_content='New horizons in drug delivery.  European Journal of \\nPharmaceutical Sciences, 107, 148-167. \\n18. Schiffman, J. D., & Schauer, C. L. (2008). A review: electrospinning \\nof biopolymer nanofibers and their applications.  Polymer \\nreviews, 48(2), 317-352. \\n19. Deitzel, J. M., Kleinmeyer, J., Harris, D. E. A., & Tan, N. B. ( 2001). \\nThe effect of processing variables on the morphology of \\nelectrospun nanofibers and textiles. Polymer, 42(1), 261-272.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 18}, page_content='20. Vilchez, A., Acevedo, F., Cea, M., Seeger, M., & Navia, R. (2020). \\nApplications of electrospun nanofibers with antioxidant \\nproperties: A review. Nanomaterials, 10(1), 175. \\n21. Vacanti, J. P., & Langer, R. (1999). Tissue engineering: the design and \\nfabrication of living replacement devices for surgical \\nreconstruction and transplantation. The lancet, 354, S32-S34. \\n22. Felgueiras, H. P., & Amorim, M. T. P. (2017). Functionalization of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 18}, page_content='electrospun polymeric wound dressings with antimicrobial \\npeptides. Colloids and Surfaces B: Biointerfaces, 156, 133-148. \\n23. Zahedi, P., Rezaeian, I., Ranaei‐Siadat, S. O., Jafari, S. H., & Supaphol, \\nP. (2010). A review on wound dressings with an emphasis on \\nelectrospun nanofibrous polymeric bandages.  Polymers for \\nAdvanced Technologies, 21(2), 77-95. \\n24. Zhang, Y., Lim, C. T., Ramakrishna, S., & Huang, Z. M. (2005). Recent \\ndevelopment of polymer nanofiber s for biomedical and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 19}, page_content='11 \\nbiotechnological applications.  Journal of Materials Science: \\nMaterials in Medicine, 16(10), 933-946. \\n25. Khampieng, T., Wnek, G. E., & Supaphol, P. (2014). Electrospun \\nDOXY-h loaded-poly (acrylic acid) nanofiber mats: in vitro drug \\nrelease and antibacterial properties investigation.  Journal of \\nBiomaterials Science, Polymer Edition, 25(12), 1292-1305. \\n26. Cogen, A. L., Nizet, V., & Gallo, R. L. (2008). Skin microbiota: a \\nsource of disease or defence?.  British Journal of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 19}, page_content='Dermatology, 158(3), 442-455. \\n27. Mackowiak, P. A. (1982). The normal microbial flora.  New England \\nJournal of Medicine, 307(2), 83-93. \\n28. National Institutes of Health (US). Biological Sciences Curriculum \\nStudy. NIH curriculum supplement series [Internet]. Bethesda \\n(MD): National Institutes of Health (US); 2007. Understanding \\nEmerging and Re-emerging Infectious Diseases.  Available from: \\nhttp://www.ncbi.nlm.nih.gov/books/NBK20370/'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 19}, page_content='http://www.ncbi.nlm.nih.gov/books/NBK20370/ \\n29. Sohrabi, A., Shaibani, P. M., Etayash, H., Kaur, K., & Thundat, T. \\n(2013). Sustained drug release and antibacterial activity of \\nampicillin incorporated poly (methyl methacrylate) –nylon6 \\ncore/shell nanofibers. Polymer, 54(11), 2699-2705. \\n30. Kim, S. S., & Lee, J. (2014). Antibacterial activity of polyacrylonitrile–\\nchitosan electrospun nanofibers.  Carbohydrate polymers , 102, \\n231-237.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 19}, page_content='231-237. \\n31. Sarhan, W. A., & Azzazy, H. M. (2015). High concentration honey \\nchitosan electrospun nanofibers: biocompatibility and antibacterial \\neffects. Carbohydrate polymers, 122, 135-143. \\n32. Thenmozhi, S., Dharmaraj, N., Kadirvelu, K., & Kim, H. Y. (2017). \\nElectrospun nanofibers: New generation materials for advanced \\napplications. Materials Science and Engineering: B, 217, 36-48. \\n33. Abrigo, M., M cArthur, S. L., & Kingshott, P. (2014). Electrospun'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 19}, page_content='nanofibers as dressings for chronic wound care: advances, \\nchallenges, and future prospects.  Macromolecular \\nbioscience, 14(6), 772-792.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 20}, page_content='12'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 21}, page_content='CHAPTER II \\n \\nBIOCHEMICAL AND HISTOPATHOLOGICAL \\nPARAMETERS USED IN EXPERIMENTAL OVARIAN \\nISCHEMIA / REPERFUSION MODELS IN RECENT YEARS \\n \\nGülce Naz Yazıcı \\n(Asst. Prof, PhD), Erzincan Binali Yıldırım University,  \\ne-mail: gulcenazyazici.ank@gmail.com \\n                 0000-0002-6989-997X \\n \\nINTRODUCTION \\nOvarian torsion, which  affects females of all ages, is a \\ngynecological emergency (1 ). Adnexal torsion is uncommon, occurring'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 21}, page_content='most often during reproductive years. Torsion of the normal adnexa, which \\nis rare, is more common among children than adults. Typically, one ovary \\nis involved, but sometimes tuba uterina is also involved. Adnexal torsion \\ncauses sudden, severe pelvic pain, and sometimes nausea and vomiting. \\nAdnexal torsion is defined as at least one fu ll turn around the midline of \\nthe adnexa,  ovary or, more rarely, the tuba uterina  alone, including the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 21}, page_content='infundibulopelvic and tubo -ovarian ligaments (2 ). The infundibulopelvic \\nligaments suspend the movable ovary, allowing the ovary to position \\nlaterally or posteriorly to the uterus (1). Adnexal torsion usually indicates \\nan ovarian abnormality. Risk factors for adnexal torsion include; \\npregnancy, induction of ovulation for IVF, ovarian enlargement, \\nparticularly by benign tumors. Benign tumors are more likely to cause'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 21}, page_content='torsion than malignant ones. Because of adnexal tissue is not fixed, a big \\nleading point, such as tumorous growth, can induce twisting ( 1). Adnexal \\ntorsions, which are the fifth most common cause in patients operated on \\ndue to gynecological emerge ncies, constitute 2.7% of gynecological \\nemergencies. Although it is seen in all age groups, its incidence is higher \\nin women of reproductive age . Adnexal torsion (AT) in children is rare,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 21}, page_content='approximately 15% of cases occur during infancy and childhood  (3). In a \\nlarge series by Guthrie et al (4),  the estimated incidence of AT among \\nfemales 1 to 20 years old was estimated to be 4.9 of 100,000 ( 3, \\n5).Although the exact etiology is unknown, an ovarian mass is detected in \\nthe majority of cases. Torsion is very ra re in normal sized ovaries. Its \\nincidence is increasing in pathologies that enlarge the size of the ovary, \\nsuch as polycystic ovary and benign cystic teratoma (6).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 22}, page_content='14 \\nIschemia due to ovarian torsion has been the subject of research \\nin recent years. Ischemia o ccurs when some of them cannot get enough \\nblood and oxygen through a reduction or interruption in blood flow.  The \\ngold standard to treat ovary torsion is surgery, and this is also the only way \\nto confirm the torsion by using the techniques like laparoscopy  and \\nlaparotomy (1). In cases of ovarian torsion, blood flow is provided to the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 22}, page_content='region again with surgical intervention and thus detorsion is performed.  \\nEXPERIMENTAL DESIGN \\nAnimals  \\nMany researchers, who have set up experimental research in \\nrecent years, have focused on supporting the ovarian damage caused by \\ntorsion not only with surgical intervention but also with systemic \\ntherapeutic agent applications. When Wistar albino or Spraque Dawley rats \\nwere evaluated in terms of feeding, housing, cost, response to surgical'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 22}, page_content='intervention; They are among the most suitable laboratory animals to these \\nkind of experiments. While creating the experimental groups, young adult \\n/ adult, healthy, non -pregnant, 200 – 290 g weighing female rats  were \\ngenerally used.  \\nProcedure of experimental ischemia/reperfusion model \\nRats are starved by cutting their access to food, 24 hours before \\nthe operation. Surgical procedures in the rats were performed under \\nanesthesia. Different anesthesia applying protocols and amounts of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 22}, page_content='anesthetic agents used in ovarian ischemia / reperfusion studies conducted \\nin recent years are listed in Table 1. The skin around the incision was \\nshaved and disinfected. After the rats were placed in the dorsal recumbent \\nposition, under sterile conditions; A laparotomy was performed by making \\na 2-cm (7, 8, 9, 10, 11, 12, 13, 14, 15 ) or 2,5-cm (16, 17, 18, 19, 20, 21 ) \\nlongitudinal incision in the midline area of the  lower abdomen and the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 22}, page_content='uterine horns and adnexa were located. The abdomen opened and then \\ngently separated the intestines. After incision in the right / left or bilateral \\nfossa paralumbalis area, adnexa were torsioned 3600 clockwise (13, 18, 22) \\nor 7200 counter clockwise ( 23) and fixed on abdominal wall to stay for  \\nduring the predetermined time as ischemic. Then incision was sutured; re-\\nlaparotomy was performed and adnexa were detorsioned; reperfusion was'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 22}, page_content='allowed for additional predetermined time  after o peration sites were \\nsutured, at the end of experimental time detorsion ovaries were harvested, \\nand blood samples were collected. Rats were sacrificed after collecting \\nsamples. Ischemia / reperfusion times that vary according to studies are \\nshown in the Tab le 2 . The therapeutic agents to be applied in the \\nexperiments are usually administered intraperitoneally or by gavage half'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 22}, page_content='an hour before the detorsion application (with exceptions). Comparison of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 23}, page_content='15 \\nischemia / reperfusion procedures of experimental studies and agents used \\nfor treatment is presented in the Table 2. \\nBIOCHEMICAL PARAMETERS \\nIschemic damage, which is caused by a drop in adnexal \\ncirculation, is one possible cause of adnexal injury resulting from torsion. \\nLevels of lactic acid, hypoxanthine, and lip id peroxide in the tissues \\nincrease because of the hypoxia that is caused by this decreased blood flow'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 23}, page_content='(5). Removing the cause of ischemia and restoring the tissue blood supply \\n(reperfusion/detosion) are significant procedures, unavoidable in cases of \\nischemia. During reperfusion, however, the return of oxygenated blood \\nstarts a reaction that can cause even more damage to the tissue. Reperfusion \\ninjury starts with the formation of reactive oxygen species, triggering a \\nseries of events (24). \\nAmong all possible pathological mechanisms of ischemia -'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 23}, page_content='reperfusion injury, free radical damage (mainly oxidative/nitrosative stress \\ninjury) has been found to play a key role in the process. Free radicals lead \\nto protein dysfunction, DNA damage, and lipid peroxidatio n, resulting in \\ncell death. Free radicals are divided into two main groups: reactive oxygen \\nspecies (ROS) and reactive nitrogen species (RNS). ROS and RNS play \\nkey roles in many pathological processes during ischemia reperfusion.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 23}, page_content='Currently, free radicals’ toxicity in ischemia -reperfusion injury is being \\nintensively studied (25). Lipidoxidation results in the production of toxic \\nsubstances, includingmalondialdehyde (MDA). MDA, a marker of tissue \\ninjury, is a secondary product of oxidative damage formed durin g \\nlipidperoxidation (26, 27) . MDA disrupts ionic transport and \\nenzymaticactivity, severely modifying cell membrane permeability and \\nflu-idity to cause discontinuities and breaks that separate cel ls and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 23}, page_content='organelle contents (7). For this reason, MDA has been chosen as the basic \\nbiochemical parameter among many studies we have examined in this \\nreview. \\nThe cells are protected against ROS damage by various ways \\nsuch as scavenging enzyme systems including Catalase which converts \\nhydrogen peroxide into hydrogen oxide (water) and superoxide dismutase \\n(SOD). SOD catalyzes the partitioning of the superoxide (O2_) radical into \\neither ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 23}, page_content='Superoxide is produced as a by-product of oxygen metabolism. It needs to \\nbe re gulated; otherwise it causes many types of cell damage. Lipid \\nperoxidation which plays a role in decreased binding of hypothalamic \\nhormones to their receptors causes a decline in antioxidant systems (28). \\nThe concentrations of the metabolic intermediates o f ROS are \\nkept under strict control by a complex defense system that includes \\nenzymes such as superoxide dismutase (SOD), catalase (CAT), and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 24}, page_content='16 \\nglutathione peroxidase (GSH-Px) (29, 30) . Excess ROS and their toxic \\nproducts cause DNA damage, lipid peroxidation  in the cellular and \\nmitochondrial membranes, and cellular damage (8).  \\nReactive oxygen species, including hydrogen peroxide, hydroxyl \\nradicals, superoxide anions, and the formation of NO and peroxynitrite are \\nenhanced during reperfusion of the ischemic tissue. These free radicals \\ncause further cellular damage through the pero xidation of lipids in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 24}, page_content='mitochondrial and cell membranes (31).  NO acts in a variety of tissues to \\nregulate a diverse range of physiological processes, but excess of NO can \\nalso be toxic (22).  \\nThe reasons for IR -induced ovarian injury include release of \\ncytokines and free radicals, thrombocyte and neutrophil activation, \\napoptosis, and nitric oxide ( 17). The reactive oxygen species (ROS) are \\nproduced during the ischemia or reperfusion period and release activated'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 24}, page_content='neutrophils such as superoxide, hydrogen peroxide, and hydroxyl radical. \\nIndependent evaluation on these markers would be unpractical and also \\ninsufficient for a wide -ranging assessment. The total antioxidant status \\n(TAS) was employed to assess the general antioxidative status (32). As \\nwell, total oxi dant status (TOS) is obtained to ascertain the overall \\noxidation status (33). Represented as the ratio of TOS to TAS, the oxidative'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 24}, page_content='stress index (OSI) is regarded as a more precise index of oxidative stress \\non the tissue. A number of anti-inflammatory and antioxidant agents were \\nused to prevent I/R injury ( 17). Biochemical parameters frequently \\npreferred in ovarian ischemia / reperfusion studies in recent years are listed \\nin the Table 3. \\nHISTOPATHOLOGICAL CHANGES \\nFor histopathological examinations, tissues are collected \\nimmediately after the lethal dose of anesthesia administered at the end of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 24}, page_content='the experimental procedure. In small -sized organs such as the ovary, at \\nleast half of the organ should be taken into the fixation solution for \\nhistopathological examination. Half of the right ovary of each rat was put \\nseparately into a formaldehyde media. Tissues were detected in the 10% \\nbuffered formalin, after which a routine tissue follow -up was performed \\nand they were placed in paraffin blocks. Slides of 4 –5 μm thickness were'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 24}, page_content='cut from the parafin blocks using a microtome and deparaffinized. The \\nsamples were dyed with hematoxylin –eosin stain and examined under a \\nlight microscope (11). \\nBasic histopathological changes noted in ovarian ischemia / \\nreperfusion studies; cherry like appearance across the tissue ( 5, 8, 18 ), \\ncongestion / dilatation of the vessels, diffuse hemorrhage in the ovarian \\ntissue, leukocyte infiltration, edema, necrosis, and follicular degeneration.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 25}, page_content='17 \\nA healthy evaluation of these histopathological cha nges is only \\npossible with a semiquantitative scoring. A semiquantitative histological \\nevaluation scoring system was used to determine histopathological \\nchanges. These parameterswere evaluated after scoring each individual \\ncriterion between 0 and 3. The cr iteria that were used to evaluate for \\novarian injury were follicular cell degeneration, vascular congestion, \\nhemorrhage, and infiltration by inflammatory cells. Each specimen was'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 25}, page_content='scored using a scale ranging from 0 to 3 (0: none; 1: mild; 2: moderate; 3: \\nsevere) for each criterion (35).  \\nWhen the other strategy is examined, it is seen that the scoring is \\ndone as follows. Five microscopy fields were used to determine the \\npresence or severity of tissue damage. The scoring system used for \\nhistopathologic evaluation of the ovarian tissues was the same as in Sagsöz \\net al (6). According to this system, congestion (vascular dilation),'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 25}, page_content='hemorrhage, and interstitial edema were scored from 0 to 3 according to \\ntheir severity: 0 represented no pathologic findings; and 1,  2, and 3 \\nrepresented pathologic findings of less than 25%, 25%  to 75%, and more \\nthan 75% of the ovarian section, respectively. The total tissue damage \\nscores were calculated by adding the scores for each parameter, and the \\ntotal tissue damage scores were calculated between 0 and 9 for each ovary.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 25}, page_content='Examination and scoring of the ovarian sections were performed in a \\nblinded fashion by the same pathologist (8 , 37). A healthy evaluation of \\nthese histopathological changes is only possible with a semiquantitativ e \\nscoring. In the experimental studies reviewed in this review, the use of \\nscoring system for histopathological changes is about 37%. Apart from \\nstudies using hematoxylin eosin staining, there are also studies evaluating'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 25}, page_content='immunohistochemical parameters, but they are in a minority ( 13, 18, 38, \\n39).  \\nDISCUSSION \\nIschaemia-Reperfusion injury (IRI) is defined as the paradoxical \\nexacerbation of cellular dysfunction and death, following restoration of \\nblood flow to previously ischaemic tissues. Reestablishment of blood flow \\nis essential to salvage ischaemic tissues. However reperfusion itself \\nparadoxically causes further damage, threatening function and viability of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 25}, page_content='the organ. IRI occurs in a wide range of organs including the heart, lung, \\nkidney, gut, skeletal mus cle and brain and may involve not only the \\nischaemic organ itself but may also induce systemic damage to distant \\norgans (34). Medical therapies such as anti-inflammatory and antioxidant \\nfree radical scavengers directed toward the mediators responsible for \\nischemic damage may be used to prevent tissue damage and irreversible'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 25}, page_content='changes (5). This was observed through a reduction in oxidative stress, an \\nincrease in antioxidant enzymes, and less histopathologic damage. These \\nresults agree with earlier experimental  models showing that oxidative'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 26}, page_content='18 \\nstress plays an important role in ovarian torsion (5) and the results of many \\nexperimental studies we gathered from this study show that antioxidants \\nused for therapeutic purposes can reduce ovarian tissue damage. We hope \\nthat our study will be a helpful resource for the design of future ovarian \\nischemia / reperfusion studies. \\nTable 1:  Anesthetics used for surgical procedure in ovaryan torsion \\nstudies. \\n \\n \\nSTUDY\\nANESTHETICS USEDfor THE\\nSURGICALPROCEDURE'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 26}, page_content='STUDY\\nANESTHETICS USEDfor THE\\nSURGICALPROCEDURE\\nCemgil Awkan D.etal(2010),Bozkurt S.et\\nal(2012)\\n60mg/kgKetaminehydrochlorideviaIP\\nAslan MK.etal(2012)\\n80 mg / kg Ketamine hydrochloride via IP\\nCadici E. et al (2010), Kurt A. et al (2011),\\nSengil O.etal(2013),BayirY.etal(2016),\\nUnlubilgin E.et al(2017),Turkler C.et al\\n25 mg / kg Sodium thiopental via IP\\n(2018)\\nAkdemir A. etal (2014), Aslan M. et al\\n50mg/kgKetaminehydrochloride+7mg\\n(2017),1lgen O.et al (2020)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 26}, page_content='(2017),1lgen O.et al (2020)\\nkgXylazinehydrochloridecombinationviaIP\\nErgwn Y.et al (2010), Sak ME.etal (2013),\\n50mg/kgKetaminehydrochloride+10mg/\\nEser A.et al(2015),Incebuyuk A.et al (2015)\\nMelekogluR.etal(2018)\\nkgXylazinehydrochloride.combinationviaIM\\n75mg/kg Ketaminehydrochloride +10mg\\nCakr Gingor AN.et al (2014)\\nkgXylazinehydrochloridecombinationviaIP\\nYurtcuE.etal(2015)\\n40mg/kgKetaminehydrochloride+10mg/\\nkgXylazine hydrochloridecombinationyia IP\\nTopdagYilmazEP.etal(2020)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 26}, page_content='TopdagYilmazEP.etal(2020)\\n45mg/kgKetaminehydrochloride+5mg\\nkgXylazinehydrochloridecombinationviaIP\\nBehroozi-Lak T.etal(2017)\\n90mg/kgKetaminehydrochloride+5mg\\nkg Xylazine hydrochloride.combination via IP'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 27}, page_content='Table 2: Experimental procedures and therapeutic agents used in ovarian ischemia / reperfusion studies in recent years.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 28}, page_content='20 \\nTable 3:  Parameters used for biochemical evaluation in ovarian ischemia / reperfusion studies in recent years. (MDA ( \\nMalondialdehyde), SOD (Superoxide dismutase), GSH/tGSH (Total glutathione),  MPO (Myeloperoxidase), LPO ( \\nLactoperoxidase), CAT (Catalase), GPx (Glutathione peroxidase), NO (Nitric oxide), TAS (Total antioxidant status), TOS (Total \\noxidant status), OSI (Oxidative stability index)).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 29}, page_content='REFERENCES \\n1. Huang C, Hong MK, Ding DC. A review of ovary torsion. Ci Ji Yi Xue \\nZa Zhi. 2017;29(3):143-147. doi:10.4103/tcmj.tcmj_55_17 \\n2. Anne A, Dalley A. Grant’s Atlas of Anatomy. 13th ed. Philadelphia: \\nLippincott Williams & Wilkins; 2012. \\n3. Eskander, R.N., Bristow, R.E. Adnexal Masses in Pediatric and \\nAdolescent Females: A Review of th e Literature.  Curr Obstet \\nGynecol Rep  1, 25–32 (2012). https://doi.org/10.1007/s13669-\\n011-0001-4'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 29}, page_content='011-0001-4 \\n4. Guthrie BD, Adler MD, Powell EC. Incidence and trends of pediatric \\novarian torsion hospitalizations in the United States, 2000 –2006. \\nPediatrics. 2010;125(3):532–8. \\n5. Bozkurt S, Arikan DC, Kurutas EB, Sayar H, Okumus M, Coskun A, \\nBakan V. Selenium has a protective effect on ischemia/reperfusion \\ninjury in a rat ovary model: biochemical an d histopathologic \\nevaluation. J Pediatr Surg. 2012 Sep;47(9):1735 -41. doi: \\n10.1016/j.jpedsurg.2012.03.053. PMID: 22974615.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 29}, page_content='10.1016/j.jpedsurg.2012.03.053. PMID: 22974615. \\n6. Cihangir Mutlu ERCAN, Hakan ÇOKSÜER, Uğur KESKİN, K. Emre \\nKARAŞAHİN, İbrahim ALANBAY, İskender BAŞER.(2011). \\nAdneksiyal torsiyon t edavisinde laparoskopik yaklaşım \\nsonuçlarımız. Gülhane Tıp Dergisi \\n7. Akdemir A, Erbas O, Gode F, Ergenoglu M, Yeniel O, Oltulu F, \\nYavasoglu A, Taskiran D. Protective effect of oxytocin on ovarian \\nischemia-reperfusion injury in rats. Peptides. 2014 May;55:126-'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 29}, page_content='30. doi: 10.1016/j.peptides.2014.02.015. Epub 2014 Mar 11. \\nPMID: 24630974. \\n8. Arikan, Deniz & Bakan, Vedat & Kurutas, Ergul & Sayar, Hamide & \\nCoskun, Ayhan. (2010). Protective effect of tadalafil on \\nischemia/reperfusion injury of rat ovary. Jour nal of pediatric \\nsurgery. 45. 2203-9. 10.1016/j.jpedsurg.2010.07.011. \\n9. Melekoglu, R., Ciftci, O., Eraslan, S., Alan, S., & Basak, N. (2018). The \\nprotective effects of glycyrrhetinic acid and chrysin against'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 29}, page_content='ischemia-reperfusion injury in rat ovaries.  BioMed research \\ninternational, 2018. \\n10. Turkler, C., Kulhan, N. G., Ata, N., Kiremitli, T., Cimen, F. K., & \\nSuleyman, H. (2018). The ameliorative effect of lutein on ovarian \\nischemia-reperfusion injury in rats.  Bratislavske Lekarske \\nListy, 119(11), 713-717.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 30}, page_content='22 \\n11. Yurtcu, E., Togrul, C., Ozyer, S., Uzunlar, O., Karatas, Y. H., Seckin, \\nK. D., ... & Cicek, N. (2015). Dose dependent protective effects of \\nvardenafil on ischemia –reperfusion injury with biochemical and \\nhistopathologic evaluation in rat ovary.  Journal of pediatric \\nsurgery, 50(7), 1205-1209. \\n12. Incebiyik, A., Seker, A., Camuzcuoglu, H., Kocaslan, S., \\nCamuzcuoglu, A., Hilali, N. G., ... & Aksoy, N. (2015). Does \\nsildenafil have protective effects against ovarian ischemia -'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 30}, page_content='reperfusion injury in rats?.  Archives of gynecology and \\nobstetrics, 291(6), 1283-1288. \\n13. Başer, B. G., Taşkın, M. İ., Adalı, E., Öztürk, E., Hısmıoğulları, A. A., \\n& Yay, A. (2018). Does progesterone have protective effects on \\novarian ischemia -reperfusion injury?.  Journal of the Turkish \\nGerman Gynecological Association, 19(2), 87. \\n14. Yilmaz, E. P. T., Un, H., Gundogdu, B., Polat, E., Askin, S., Topdagi, \\nY. E., & Halici, Z. (2020). Protective Effect of Lycopene against'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 30}, page_content='Reperfusion Injury in Rats with Ovarian Torsion: A Biochemical \\nand Hist opathological Evaluation.  Journal of Laboratory \\nPhysicians, 12(1), 32. \\n15. Erbas, O., & Karadadas, N. Effects of Methylene Blue on Ovarian \\nTorsionLDetorsion Injury in a Rat Model. \\n16. Cadirci, E., Oral, A., Odabasoglu, F., Kilic, C., Coskun, K., Halici, Z., \\n... & Unal, B. (2010). Atorvastatin reduces tissue damage in rat \\novaries subjected to torsion and detorsion: biochemical and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 30}, page_content=\"histopathologic evaluation.  Naunyn-Schmiedeberg's archives of \\npharmacology, 381(5), 455-466. \\n17. Sak, M. E., Soydinc, H. E., Sak,  S., Evsen, M. S., Alabalik, U., \\nAkdemir, F., & Gul, T. (2013). The protective effect of curcumin \\non ischemia-reperfusion injury in rat ovary. International Journal \\nof Surgery, 11(9), 967-970. \\n18. Gungor, A. N. C., Gencer, M., Karaca, T., Hacivelioglu, S., Uysal, A., \\nKorkmaz, F., ... & Cosar, E. (2014). The effect of hesperetin on\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 30}, page_content='ischemia–reperfusion injury in rat ovary.  Archives of gynecology \\nand obstetrics, 290(4), 763-769. \\n19. Nayki, C., Nayki, U., Keskin Cimen, F., Kulhan, M., Yapca, O. E., \\nKurt, N., & Bilgin Ozbek, A. (2018). The effect of rutin on ovarian \\nischemia-reperfusion injury in a rat model.  Gynecological \\nEndocrinology, 34(9), 809-814. \\n20. Eser, A., Hizli, D., Haltas, H., Namuslu, M., Kosus, A., Kosus, N., & \\nKafali, H. (2015). Effects of curcum in on ovarian ischemia -'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 31}, page_content='23 \\nreperfusion injury in a rat model.  Biomedical reports, 3(6), 807-\\n813. \\n21. Bayir, Y., Cadirci, E., Polat, B., Kilic Baygutalp, N., Albayrak, A., \\nKarakus, E., ... & Karaca, M. (2016). Aliskiren –a promising \\nstrategy for ovarian ischemia/reperfusion injury protection in rats \\nvia RAAS. Gynecological Endocrinology, 32(8), 675-683. \\n22. Ergun, Y., Koc, A., Dolapcioglu, K., Akaydin, Y., Dogruer, G., Kontas, \\nT., ... & Aslan, E. (2010). The protective effect of erythropoietin'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 31}, page_content='and dimethylsulfoxide on ischemia -reperfusion injury in rat \\novary. European Journal of Obstetrics & Gynecology and \\nReproductive Biology, 152(2), 186-190. \\n23. Aslan, M. K., Boybeyi, Ö., Şenyücel, M. F., Ayva, Ş., Kısa, Ü., Aksoy, \\nN., ... & Çakmak, M. (2012). Protective effect of intraperitoneal \\nozone application in experimental ovarian ischemia/reperfusion \\ninjury. Journal of pediatric surgery, 47(9), 1730-1734.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 31}, page_content='24. Kurt, A., Isaoglu, U., Yilmaz, M., Calik, M., Polat, B., Hakan, H., ... & \\nSuleyman, H. (2011). Biochemical and histological investigation \\nof famotidine effect on postischemic reperfusion injury in the rat \\novary. Journal of pediatric surgery, 46(9), 1817-1823. \\n25. Ming-Shuo Sun, Hang Jin, Xin Sun, Shuo Huang, Fu -Liang Zhang, \\nZhen-Ni Guo, Yi Yang,  \"Free Radical Damage in Ischemia -\\nReperfusion Injury: An Obstacle in Acute Ischemic Stroke after'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 31}, page_content='Revascularization Therapy\",  Oxidative Medicine and Cellular \\nLongevity, vol. 2018, ArticleID 3804979, 17 pages, 2018. https://\\ndoi.org/10.1155/2018/3804979 \\n26. Akdemir A, Erbas¸ O, Ergenoğ lu M, Ozg ür Yeniel A, Oltulu F, \\nYavasoğlu A, et al .Montelukast prevents ischemia/reperfusion -\\ninduced ovarian damage in rats.Eur J Obstet Gynecol Reprod Biol \\n2014;173:71–6. \\n27. Erkanli Senturk G, Erkanli K, Aydin U, Yucel D, Isiksacan N, Ercan'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 31}, page_content='F, et al. The pro-tective effect of oxytocin on ischemia/reperfusion \\ninjury in rat urinary bladder.Peptides 2013;40:82–8. \\n28. Aslan, M., Senturk, G. E., Akkaya, H., Sahin, S., & Yılmaz, B. (2017). \\nThe effect of oxytocin and Kisspeptin -10 in ovary and uterus of \\nischemia-reperfusion injured rats.  Taiwanese Journal of \\nObstetrics and Gynecology, 56(4), 456-462. \\n29. Naziroglu M, Simşek M, Kutlu M. Moderate exercise with a dietary \\nvitamin C and E combination protects against streptozotocin -'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 31}, page_content='induced oxidative damage to the blood and improves fetal \\noutcomes in pregnant rats. Clin Chem Lab Med 2004;42:511-7.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 32}, page_content='24 \\n30. Eren I, Naziroglu M, Demirdas A. Protective effects of lamotrigine, \\naripiprazole and escitalopram on depression -induced oxidative \\nstres in rat brain. Neurochem Res 2007;32:1188-95. \\n31. Somuncu S, Cakmak M, Dikmen G, Akm an H, Kaya M. Ischemia -\\nreperfusion injury of rabbit ovary and protective effect of trapidil: \\nan experimental study. Pediatr Surg Int 2008;24:315 –8. doi: \\n10.1007/s00383-007-2079-3. \\n32. Erel O. A novel automated method to measure total antioxidant'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 32}, page_content='response a gainst potent free radical reactions. Clin Biochem \\n2004;37:112-9. \\n33. Erel O. A new automated colorimetric method for measuring total \\noxidant status. Clin Biochem 2005;38:1103-11. \\n34. Cowled P, Fitridge R. Pathophysiology of Reperfusion Injury. In: \\nFitridge R, Thompson M, editors. Mechanisms of Vascular \\nDisease: A Reference Book for Vascular Specialists [Internet]. \\nAdelaide (AU): University of Adelaide Press; 2011. 18. Available'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 32}, page_content='from: https://www.ncbi.nlm.nih.gov/books/NBK534267/ \\n35. Guven S, Muci E, Unsal MA, et al. The effects of carbon dioxide \\npneumoperitoneum on ovarian blood flow, oxidative stress \\nmarkers, and morphol ogy during laparoscopy: a rabbit model. \\nFertil Steril 2008;93(4). \\n36. Sagsoz N, Kisa U, Apan A. Ischemia -reperfusion injury of rat ovary \\nand the effects of vitamin C, mannitol and verapamil. Hum Reprod \\n2002;17:2972-6. \\n37. Gezer, Ş., & Başaran, M. The prote ctive effect of letrozole in a rat'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 32}, page_content='ovarian ischemia -reperfusion injury model.  Van Medical \\nJournal, 27(4), 407-414. \\n38. Sengul, O., Ferah, I., Polat, B., Halici, Z., Bayir, Y., Yilmaz, M., ... & \\nKeles, O. N. (2013). Blockade of endothelin receptors with \\nbosentan limits ischaemia/reperfusion -induced injury in rat \\novaries. European Journal of Obstetrics & Gynecology and \\nReproductive Biology, 170(2), 458-463. \\n39. Unlubilgin, E., Suleyman, B., Balci, G., Al, R. A., Cankaya, M. U. R.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 32}, page_content='A. T., Nayki, U. A., & Suleym an, H. (2017). Prevention of \\ninfertility induced by ovarian ischemia reperfusion injury by \\nbenidipine in rats: Biochemical, gene expression, \\nhistopathological and immunohistochemical evaluation.  Journal \\nof Gynecology Obstetrics and Human Reproduction , 46(3), 267-\\n273.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 33}, page_content='CHAPTER  III \\n \\nCLINICAL DEVELOPMENT OF HIF-1α INHIBITORS  \\nFOR CANCER THERAPY \\n \\n \\nGülnihal Özcan \\n(Asst. Prof.) Koç University School of Medicine, e-mail:guozcan@ku.edu.tr \\n                  0000-0001-5354-0148 \\n \\n \\nINTRODUCTION \\nHypoxia inducible factors (HIFs) are transcription factors that play \\na central role in adaptation of cells to hypoxia. HIFs are stabilized in the \\nhypoxic environment leading to transcription of many target genes that'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 33}, page_content='induce angiogenesis to re -establish oxy gen homeostasis and regulate \\ncellular energetic metabolism to adapt to hypoxic conditions 1. Cancer cells \\nutilize these mechanisms in their advantage to survive despite unfavorable \\nconditions, gain replicative immortality and stem cell characteristics, \\nescape from apoptotic stimuli and immunosurveillance, metastasize to \\ndifferent areas and resis t anti -cancer therapy. As a result, hypoxia or'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 33}, page_content='increased activity of HIFs bring more malignant characteristics to tumors \\nand worsen patient prognosis 2.  \\nAmong the HIF isoforms HIF -1 come forward w ith its prominent \\ninvolvement in tumor progression and chemoresistance. HIF -1 is a \\nheterodimer of HIF-1α and HIF -1β subunits. HIF -1α is overexpressed in \\nseveral tumors and its expression is associated with poor overall survival \\n3-5. HIF -1α expression was found to be more abundant at the invasive'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 33}, page_content='margins of tumor specimens 6-8. High expression of HIF -1α is also \\nassociated with high a risk of metastasis in cancer 9-11. Therefore, targeting \\nHIF-1α is of prime importance to increase  therapeutic success in cancer \\nchemotherapy. \\nREGULATION OF HIF-1α ACTIVITY \\nIn the presence of oxygen HIF -1α is hydroxylated by prolyl \\nhydroxylases (PHDs). Then hydroxylated HIF-1α is ubiquitinated and \\ndegraded by ubiquitin proteasome system with a reaction dependent on'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 33}, page_content='tumor suppressor protein von Hippel–Lindau (pVHL). On the other hand, \\nin hypoxic conditions HIF-1α cannot be hydroxylated by PHDs and \\nbecomes stable. Then, it translocates to the nucleus and couples with HIF-\\n1β to form HIF-1. After that, HIF-1 binds p300/CBP co-activator forming \\nthe HIF transcription complex which binds to hypoxia response elements'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 34}, page_content='26 \\nand induces the transcription of target genes such as vascular endothelial \\ngrowth facto r (VEGF), glucose transporter -1, epithelial -mesenchymal \\ntransition genes and matrix metalloproteinases 12-14.  \\nThe expression of HIF -1α is also regulated by several other \\nmechanisms besides hypoxia in cancer cells. Reactive oxygen species \\ngenerated by various stimuli stabilize HIF-1α and increases HIF-1 activity. \\nPI3K/Akt/mTOR and RAS/MAPK pathways which are oncogenic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 34}, page_content='pathways overactivated in several cancers are posi tive regulators of HIF-\\n1α expression. Mutations in tumor suppressor genes phosphatase and \\ntensin homologue (PTEN), VHL and p53 are also associated with \\nincreased HIF-1α expression in cancer cells 14,15. \\nHIF-1α INHIBITORS IN CLINICAL TRIALS \\nIn accordance with the importance of HIF-1α in tumor progression \\nand chemoresistance, last 20 years have witnessed the testing of several'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 34}, page_content='direct or indirect inhibitors of HIF-1α in clinical trials for cancer. Some of \\nthese agents such as camptothecins, rapamycin analogs, and \\nanthracyclines, which exhibit antitumor action by mechanisms that does \\nnot directly involve HIF-1α inhibition, have already been approved and \\nwidely us ed for the treatment of several cancers. However, efforts to \\ndevelop new agents that directly inhibit HIF-1α is still growing 16,17. In this'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 34}, page_content='chapter, we present the major HIF-1α inhibitors that were translated to \\nclinical studies so far with registered clinical trials in ClinicalTrials.gov \\n(https://www.clinicaltrials.gov/). Relevant clin ical trial identifiers are \\ngiven for each of the studies in the text. According to their mechanism of \\naction, anti-HIF-1α agents were classified into five in this chapter, namely \\nHIF-1α antisense oligonucleotides, drugs that inhibit HIF -1α translation,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 34}, page_content='drugs that destabilize HIF-1α, inhibitors of HIF-1/DNA binding, and drugs \\nthat inhibitor HIF-1α at multiple levels.  \\n1. HIF-1α Antisense Oligonucleotides \\nEfforts to translate antisense oligonucleotides  into the treatment of \\ncancer patients is growing for the last decade 18. EZN-2968 is a HIF-1α \\nantisense oligonucleotide developed by Enzon Pharmaceuticals. A phase I \\ntrial has been conducted between 2007 and 2011 for determi nation of the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 34}, page_content='safety, pharmacokinetic profile, and anticancer activity of EZN -2968 in \\npatients with advanced solid tumors and lymphoma (NCT00466583). First \\nresults suggested well-tolerability in cancer patients who have undergone \\nprevious treatments 19. In 2010, a second phase I study for EZN-2968 was \\ncommenced under the sponsorship of National Health Institute to \\ndetermine the safety profile and efficacy in advanced solid tumors with'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 34}, page_content='liver metastasis ( NCT01120288). A reduction in HIF-1α expression was \\nobserved in a very limited number of patients enrolled into the study and \\nthe trial was ended early 20. Later in 2016, a phase Ib study was started to'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 35}, page_content='27 \\ntest a synthetic locked nucleic acid form of EZN -2968 (RO7070179) in \\nhepatocellular carcinoma (HCC) ( NCT02564614), since dose limiting \\ntoxicity in the previous studies was hepatotoxicity due to accumulation in \\nliver. Study results suggested that HCC patients may benefit from \\nRO7070179 and, decrease in HIF-1α mRNA during the first cycle may \\nhave predictive value for therapeutic effect 21.  \\n2. Drugs That Inhibit HIF-1α Translation \\n2a. Camptothecins'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 35}, page_content='2a. Camptothecins \\nCamptothecins which act primarily by inhibition of topoisomerase I \\nenzyme, is an important group of chemotherapeutics used in the treatment \\nof cancer. Camptothecin and its derivatives like topotecan has been shown \\nto down -regulate HIF-1α through regulation of the HIF-1α-targeting \\nmiRNAs 22. After the confirmation of its anti-HIF1α activity together with \\nthe anti -angiogenetic and anti -tumorigenic effects in xenograft models,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 35}, page_content='topotecan was evaluated i n a phase I study for its effectiveness in \\nsuppressing HIF -1α expression in advanced solid tumors refractory to \\ntreatment (NCT00117013). Although a median reduction of 7.5% percent \\nwas detected in HIF-1α expression and a correlation was observed between \\nthis reduction and radiological outcomes, the results were not statistically \\nsignificant because of low patient accrual 23. \\nBesides their use as single agents, inclusion of campothecins in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 35}, page_content='combination chemotherapy where an anti -VEGF agent is involved may \\nprevent the increase in HIF-1α due to inhibition of angiogenesis. With this \\nnotion, combination of camptothecins with anti -angiogenetic agents have \\nbeen tested in several clinical trials. Combination of irinotecan with anti -\\nVEGF monoclonal antibody bevacuzimab was tested for its efficacy in \\npediatric patients with recurrent, progressive, or refractory glioma,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 35}, page_content='medulloblastoma, ependymoma, or low -grade glioma in a phase II trial \\nstarted in 2006 (NCT00381797). In another phase II trial started in 2007, \\nefficacy of topotecan in combination with cisplatin and bevacuzimab was \\ntested in patients with recurrent or  persistent cervical can cer \\n(NCT00548418). However, the toxicity profile of this combination was \\ndisappointing 24.  \\nEZN-2208, a pegylated form of SN38, which is the active metabolite'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 35}, page_content='of irinotecan, was combined with bevacuzimab in a phase I trial to test its \\nsafety, efficacy and anti -HIF-1α activity in solid tumors refractory to \\ntreatment (NCT01251926, no posted results). CRLX101, which is a \\nnanoparticle formulation of camptothecin, was tested for its safety and \\nefficacy profile in combination with bevacizumab in patients with ovarian, \\ntubal, and peritoneal cancers resistant to platinium -based therapy'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 35}, page_content='(NCT01652079) 25. The trial was completed in 2018 with no results posted \\nyet. Although the emphasis was not on inhibition of HIF-1α, the efficacy'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 36}, page_content='28 \\nof anti-VEGF aflibercept in combination with the FOLFIRI (folinic acid, \\nfluorouracil, and irinotecan) regimen was investigated in metastatic \\ncolorectal cancer (NCT02129257). The regimen was found to be tolerable. \\nHowever, 6 months of first-line treatment with FOLFIRI + aflibercept was \\nfollowed by aflibercept without accompanying anti-HIF1α treatment and a \\nsubstantial increase in efficacy has not been detected 26. \\n2b. PI3K/AKT/mTOR Pathway Inhibitors'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 36}, page_content='2b. PI3K/AKT/mTOR Pathway Inhibitors \\nPI3K/AKT/mTOR pathway is an important intracellular signaling \\npathways that induces cell proliferation, migration, and tumor progression. \\nSeveral anticancer drugs that inhibit this pathway at distinct molecular \\nlevels have been used or being tested in chemotherapy of several cancers. \\nRapamycin (sirolimus) is the first agent discovered among these, which \\ngives its name to the mTOR protein, the mammalian target of rapamycin'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 36}, page_content='27. Rapamycin analogs (rapalogs), temsirolimus and everolimus are first \\napproved for the treatment of advanced renal car cinoma and have been \\ntested in preclinical and clinical studies for the treatment of several other \\ncancers 28. Besides their primary action on inhibition of cell proliferation \\nand migration, rapalogs also downregulate HIF-1α since \\nPI3K/AKT/mTOR pathway is a positive regulator of  HIF-1α expression'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 36}, page_content='14,17. Due to this action, rapalogs have been started to be tested clinically in \\ncombination with other chemotherapeutics and anti-angiogenic agents.  \\nA phase I study started in 2010  to determine maximum tolerated \\ndose of everolimus (RAD001), in combination with capecitabine and \\noxaliplatin (XELOX) regimen in patients with advanced gastric  cancer \\n(NCT01049620). The same year, another clinical trial started to determine'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 36}, page_content='safety of evero limus and its efficacy in combination with FOLFOX and \\nbevacizumab in the first -line treatment of colorectal cancer \\n(NCT01047293). The combination exhibited a tolerable profile and fair \\nefficacy 29.  Combination of everolimus with sorafenib, which is an anti -\\ntumorigenic and anti -angiogenic agent due to its multi -kinase inhibitor \\naction, was tested in a Phase I -II study for advanced so lid tumors. \\nHowever, the study was suspended early due to toxicity (NCT01226056).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 36}, page_content='Combination of rapamycin and irinotecan has also been tested in refractory \\nsolid tumors in children for the synergistic effect in inhibition of \\nangiogenesis and suppression of HIF-1α (NCT01282697, no results \\nposted).  \\nPerifosine is a multitarget tyrosine kinase inhibitor that has AKT \\ninhibitor activity. It has been extensively tested as a single agent or \\ncombination in several different cancers in tens of different clinical trials'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 36}, page_content='(e.g., NCT00398879, NCT01048580, NCT00398814, NCT00060437, \\nNCT00873457, NCT02238496  and NCT02238496). Due to AKT \\ninhibitory action, perifosine downregulates HIF-1α 16. However, this action'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 37}, page_content='29 \\nwas not the main emphasis in the clinical trials of perifosine conducted so \\nfar. Despite the prom ising results in preclinical studies, its clinical \\neffectiveness in cancer is not fully established yet.    \\n2c. Digoxin \\nSince preclinical studies suggested that digoxin blocks HIF-1α 30, its \\nefficacy in blocking HIF -1α in breast cancer and Kaposi’s Sarcoma  has \\nbeen tested in two different clinical trials. The former o ne aimed to'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 37}, page_content='investigate whether two weeks of digoxin intake starting from the first \\nbiopsy to the time of surgery decreases HIF-1α expression in newly \\ndiagnosed breast cancer (NCT01763931). However the trial stopped to \\nrecruit patients early since accrual goals could not be met  31. HIF-1α has \\nbeen shown to induce lytic life cycle of Human Herpes Virus 8  32. \\nRegarding the efficacy of digoxin in downregulation of HIF -1α, digoxin'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 37}, page_content='may have a potential in the treatment of HHV -8 related Kaposi Sarcoma. \\nA multi -centre phase II study was conducted to test this hypothesis \\n(NCT02212639). The study was expected to be completed in 2019. \\nHowever, the results are not published yet. In addition to these two trials \\nthat put the emphasis on anti -HIF-1α action, there are more than 20 \\ndifferent clinical trials that test digoxin alone or in combination with'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 37}, page_content='chemotherapy in several different cancers as a hypoxia modulator agent or \\np-glycoprotein inhibitor (e.g., NCT04141995, NCT02106845). A Phase II \\nstudy in prostate cancer patients exhibited promising results suggesting \\nthat digoxin can prolong prostate specific antigen doubling  time and may \\nbe effective in androgen -dependent prostate cancer  33 (NCT01162135). \\nNew clinical trials are recruiting patients or will start accrual to evaluate'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 37}, page_content='digoxin in solid tumors and pancreatic cancer (NCT03889795, \\nNCT04141995). \\n2d. 2-Methoxyestradiol \\n2-methoxyestradiol (2ME2) is an estradiol metabolite which inhibits \\nmicrotubule activity and acts as an antitumor agent. 2ME2 inhibits the \\ntranslation of HIF-1α mRNA. Due to this action, 2ME2 was started to be \\nevaluated as an agent to inhibit tumor blood  flow in two different phase I \\ntrials in 2001 and 2002 (NCT00030095, NCT00028821).  Since 2ME2'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 37}, page_content='exhibit inhibitory action on cell proliferation, migration, and angiogenesis \\n17, a nanocrystal colloidal dispersion formulation of 2ME2, Panzem was \\ndeveloped which has higher bioavailability. Panzem entered several phase \\nII trials, starting from 2006 (NCT0039 4810, NCT00306618, \\nNCT00481455, and  NCT00444314). However, the results were \\ndisappointing in terms of anti -tumor activity and tolerability  34,35. Later a \\nnew analogue of 2ME2, ENMD -1198 was developed. ENMD -1198'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 37}, page_content='exhibited potent anti-angiogenic activity in cell models 36. However, to the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 38}, page_content='30 \\nbest of our knowledge, there is no registered clinical trial for ENMD-1198 \\nin clinicaltrials.gov yet.  \\n3. Drugs That Destabilize HIF-1α \\n3a. Geldanamycin and Its Derivatives \\nGeldanamycin and its derivatives are a nsamycin antibiotics with \\nanti-cancer activity. They inhibit heat shock protein 90 (HSP90), leading \\nto degradation of its targets which regulate the activity of several \\nintracellular pathways 37. Geldanamycin and its derivative 17AAG (17-'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 38}, page_content='allylamino 17-demethoxygeldanamycin) or tanespimycin have been tested \\nin clinical trials for the treatment of several cancers since the beginning of \\n2000’s (e.g., NCT00003969, NCT00058253, NCT00093405, \\nNCT00119236, NCT00004065, NCT00019708, NCT00093821, \\nNCT00087386, and  NCT00319930). Since HSP90 takes part in the \\nstabilization of HIF -1α, this makes it an important target to induce \\ndestabilization and degradation of HIF -1α. With the emphasis on this'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 38}, page_content='mechanism, efficacy of 17AAG was evaluated in VHL disease and renal \\ntumors in a phase II trial started in 2004 (NCT00088374). The study could \\nnot achieve accrual goals. However, the evidence that point out to the \\npotential of geldanamycin and its derivatives in cancer th erapy is \\ngrowing38,39.  \\n3b. Histone Deacetylase Inhibitors \\nHistone deacetyla ses (HDAC) play important roles in epigenetic \\nregulation of genes associated with cancer. HDAC inhibitors were'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 38}, page_content='approved for the treatment of several cancers such as lymphoma and \\nmultiple myeloma. They show antitumor effect by inducing cell cycle \\narrest, apoptosis, and anti-angiogenic response 40. HDAC is also important \\nfor the acetylation of HIF -1α/p300 complex and therefore HDAC \\ninhibitors lead to destabilization of HIF-1α 41. Among the HDAC inhibitors \\nromidepsin come forward with this action and there are more than 20 \\ndifferent active clinical trials that assess romidepsin in the treatment of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 38}, page_content='lymphoma and several other cancers (e.g., NCT02512172, NCT04257448, \\nNCT01947140, NCT01755975, and NCT01638533). \\n4. Inhibitors of HIF-1/DNA Binding \\n4a.   Anthracyclines \\nAnthracyclines are among the most widely used and most potent \\nchemotherapeutics in cancer therapy today. They show anti -tumor action \\nby binding to DNA and inhibiting the progression of topoisomerase II  \\nenzyme 42. They also inhibit binding of HIF-1 to DNA. Hence, they inhibit'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 38}, page_content='the expression of HIF -1α regulated genes 43,44. Even though they are \\nalready in use in the treatment of several cancers, their anti-HIF action may'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 39}, page_content='31 \\nincrease the use of anthracyclines further especially in chemotherapy \\nprotocols with anti-VEGF agents.  \\n4b. Echinomycin \\nEchinomycin is a peptide antibiotic with DNA intercalating activity. \\nWith the aim of identifying new drugs which inhibit binding of HIF -1 to \\nDNA, a high -throughput screening was conducted with National Cancer  \\nInstitute’s comprehensive small-molecule library. The screening identified \\nechinomycin as a potent inhibitor of HIF-1/DNA binding 45.  Echinomycin'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 39}, page_content='has been tested in several Phase II trials for the indications of soft tissue \\nsarcoma, endometrial carcinoma, non -small cell lung carcinoma and \\ncolorectal cancer 46-49. However, the clinical efficacy in these trials were \\ndisappointing. Therefore, echinomycin could not progress into the clinic \\nwith the expected speed as an anti-HIF-1 agent.  However, nano-liposomal \\nformulations of echinomycin are being developed, which may offer an'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 39}, page_content='improved efficacy and pharmacokinetic profile for the agent 50,51. \\n5. Drugs That Inhibit HIF-1α at Multiple Levels  \\n5a. Bortezomib \\nThe u biquitin proteasome pathway plays a central role in protein \\nhomeostasis, leading to degradation of misfolded or damaged proteins. \\nProteasome is an attractive target in cancer therapy since inhibition of \\nproteosome induces cell death via endoplasmic reticulum stress, inhibition \\nof survival pathways and stimulation of apoptosis 52. Bortezomib is one of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 39}, page_content='the most prominent proteasome inhibitors evaluated for clinical use in \\ncancer. It was approved by FDA in the treatment of multiple myeloma in \\n2003 53, and there are more than 900 different clinical trials registered that \\nevaluate bortezomib, most ly in combination to conventional \\nchemotherapeutics in a wide spectrum of cancers. Since proteasomal \\ndegradation of HIF-1α has substantial importance in regulation of HIF -1,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 39}, page_content='bortezomib also has an anti -HIF-1 action. In the presence of bortezomib, \\nubiquitinated HIF-1α could not be degraded and accumulates in an inactive \\nform. In this form HIF -1α cannot bind to p300 and induce gene \\nexpression54. Additionally, it was shown that b ortezomib can inhibit \\nPI3K/AKT/mTOR pathway. Moreover, bortezomib was reported to \\nsuppress nuclear translocation of HIF-1α via inhibition of MAPK \\npathway55. With these mechanisms bortezomib exhibits anti-HIF-1 action'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 39}, page_content='at multiple levels which makes it an attractive agent in cancer therapy.  \\n5b. PX-478 \\nPX-478 is a melphalan derivative that downregulates the HIF-1α \\nmRNA and inhibits its translation. It was also reported to inhibit de -\\nubiquitination of HIF-1α to a smaller extent 56. Due to inhibition of HIF -\\n1α, PX-478 may have a potential in cancer treatment. The safety and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 40}, page_content='32 \\nefficacy of PX -478 was evaluated in advanced solid tumors in a phase I \\ntrial conducted in 2007-2010 (NCT00522652).  The results were promising \\nin terms of tolerability and HIF -1α inhibition57. However, a registration \\ncould not be found in clinicaltrial.gov that suggest the further evaluation \\nof PX-478 in clinical studies.  \\nCONCLUSION \\nClinical development of HIF-1α inhibitors for cancer treatment is \\nongoing at a great pace. Till the safety and efficacy of direct HIF -1α'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 40}, page_content='inhibitors is fully established, anti -cancer agents already approved in \\ncancer such as camptothecins, rapalogs, anthracyclines and bortezomib \\nseem to be involved more frequently in combination chemotherapy for \\nHIF-1α inhibitory effect in addition to their primary mechanisms of anti -\\ncancer action.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 41}, page_content='33 \\nREFERENCES \\n1. Semenza GL. Hypoxia-inducible factors in physiology and medicine. \\nCell. 2012;148(3):399-408. \\n2. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human \\ncancer. J Cell Biochem. 2009;107(6):1053-1062. \\n3. Branco-Price C, Zhang N, Schnelle M, et al. Endothel ial cell HIF -1α \\nand HIF-2α differentially regulate metastatic success. Cancer cell. \\n2012;21(1):52-65. \\n4. Kitajima Y, Miyazaki K. The Critical Impact of HIF -1a on Gastric'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 41}, page_content='Cancer Biology. Cancers. 2013;5(1):15-26. \\n5. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer \\nbiology and therapeutics. Oncogene. 2010;29(5):625-634. \\n6. Hao LS, Liu Q, Tian C, et al. Correlation and expression analysis of \\nhypoxia‑inducible factor  1α, glucose transporter 1 and lactate \\ndehydrogenase 5 in human gastric can cer. Oncol Lett. \\n2019;18(2):1431-1441. \\n7. Rohwer N, Lobitz S, Daskalow K, et al. HIF -1α determines the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 41}, page_content='metastatic potential of gastric cancer cells. British Journal of \\nCancer. 2009;100(5):772-781. \\n8. Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM. Is the \\nhypoxia-inducible factor pathway important in gastric cancer? \\nEuropean Journal of Cancer. 2005;41(18):2792-2805. \\n9. Miao ZF, Wang ZN, Zhao TT, et al. Peritoneal milky spots serve as a \\nhypoxic niche and favor gastric cancer stem/progenitor cell \\nperitoneal dissemination through hypoxia -inducible factor 1α.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 41}, page_content='Stem cells (Dayton, Ohio). 2014;32(12):3062-3074. \\n10. Jung J-H, Im S, Jung ES, Kang CS. Clinicopathological Implications of \\nthe Expression of Hypoxia-related Proteins in Gastric Cancer. \\nInternational Journal of Medical Sciences. 2013;10(9):1217-\\n1223. \\n11. Chen L, Shi Y, Yuan J, et al. HIF -1 Alpha Overexpression Correlates \\nwith Poor Overall Survival and Disease -Free Survival in Gastric \\nCancer Pati ents Post -Gastrectomy. PLOS ONE. \\n2014;9(3):e90678.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 41}, page_content='2014;9(3):e90678. \\n12. Kaelin WG, Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central \\nrole of the HIF hydroxylase pathway. Molecular cell. \\n2008;30(4):393-402. \\n13. Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through \\nhypoxia inducible factors and beyond. Nature reviews Molecular \\ncell biology. 2020;21(5):268-283. \\n14. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer \\nprogression, angiogenesis, metastasis, and resistance to therapy.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 41}, page_content='Hypoxia (Auckland, NZ). 2015;3:83-92.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 42}, page_content='34 \\n15. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor \\nangiogenesis by p53 -induced degradation of hypoxia -inducible \\nfactor 1alpha. Genes Dev. 2000;14(1):34-44. \\n16. Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B. \\nHypoxia inducible factor pathway inhibitors as anticancer \\ntherapeutics. Future medicinal chemistry. 2013;5(5):553-572. \\n17. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 42}, page_content='for cancer therapy. Acta pharmaceutica Sinica B. 2015;5(5):378-\\n389. \\n18. Quemener AM, Bachelot L, Forestier A, Donnou -Fournet E, Gilot D, \\nGalibert M-D. The powerful world of antisense oligonucleotides: \\nFrom bench to bedside. Wiley Interdiscip Rev RNA.  \\n2020;11(5):e1594. \\n19. Patnaik A, Chiorean EG, Tolcher A, et al. EZN-2968, a novel hypoxia-\\ninducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) \\nantagonist: Results of a phase I, pharmacokinetic (PK), dose -'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 42}, page_content='escalation study of daily administration in patients (pts) with \\nadvanced malignancies.  Journal of Clinical Oncology  \\n2009;27(15_suppl):2564-2564. \\n20. Jeong W, Rapisarda A, Park SR, et al. Pilot trial of EZN -2968, an \\nantisense oligonucleotide inhibitor of hypoxia -inducible factor-1 \\nalpha (HIF-1α), in patients with refractory solid tumors. Cancer \\nChemother Pharmacol. 2014;73(2):343-348. \\n21. Wu J, Contratto M, Shanbhogue KP, et al. Evaluation of a locked'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 42}, page_content='nucleic acid form of antisense oligo targeting HIF-1α in advanced \\nhepatocellular carcinoma. World journal of c linical oncology. \\n2019;10(3):149-160. \\n22. Bertozzi D, Marinello J, Manzo SG, Fornari F, Gramantieri L, \\nCapranico G. The natural inhibitor of DNA topoisomerase I, \\ncamptothecin, modulates HIF -1α activity by changing miR \\nexpression patterns in human cancer ce lls. Molecular cancer \\ntherapeutics. 2014;13(1):239-248.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 42}, page_content='therapeutics. 2014;13(1):239-248. \\n23. Duffy AG, Melillo G, Turkbey B, et al. A pilot trial of oral topotecan \\n(TPT) in patients with refractory advanced solid neoplasms \\nexpressing HIF -1α. Journal of Clinical Oncology  \\n2010;28(15_suppl):e13518-e13518. \\n24. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of \\ntopotecan, cisplatin and bevacizumab for recurrent or persistent \\ncervical cancer. Gynecologic oncology. 2013;130(1):64-68.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 42}, page_content='25. Krasner CN, Birrer MJ, Berlin ST, et al. Phase II clinical trial evaluating \\nCRLX101 in recurrent ovarian, tubal, and peritoneal cancer. \\nJournal of Clinical Oncology. 2014;32(15_suppl):5581-5581. \\n26. Pentheroudakis G, Kotoula V, Koliou GA, et al. AMALTHEA: \\nProspective, Single -Arm Study of the Hell enic Cooperative'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 43}, page_content='35 \\nOncology Group (HeCOG) Evaluating Efficacy and Safety of \\nFirst-Line FOLFIRI  + Aflibercept for 6 Months Followed by \\nAflibercept Maintenance in Patients With Metastatic Colorectal \\nCancer. Clinical colorectal cancer. 2018;17(4):e631-e637. \\n27. LoRusso PM. Inhibition of the PI3K/AKT/mTOR Pathway in Solid \\nTumors. Journal of clinical oncology. 2016;34(31):3803-3815. \\n28. Tian T, Li X, Zhang J. mTOR Signaling in Cancer and mTOR Inhibitors'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 43}, page_content='in Solid Tumor Targeting Therapy. International journal of \\nmolecular sciences. 2019;20(3). \\n29. Weldon Gilcrease G, Stenehjem DD, Wade ML, et al. Phase I/II study \\nof everolimus combined with mFOLFOX-6 and bevacizumab for \\nfirst-line treatment of metastatic colorectal cancer. Investigational \\nnew drugs. 2019;37(3):482-489. \\n30. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides \\ninhibit HIF-1alpha synthesis and block tumor growth. Proc Natl'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 43}, page_content=\"Acad Sci U S A. 2008;105(50):19579-19586. \\n31. Bardia A, Santa-Maria CA, Jacobs LK, et al. Digoxin as an inhibitor of \\nglobal hypoxia inducible factor -1α (HIF1α) expression and \\ndownstream targets in breast cancer: Dig-HIF1 pharmacodynamic \\ntrial. Journal of clinical oncology . 2013;31(15_suppl):TPS1144-\\nTPS1144. \\n32. Haque M, Wang V, Davis DA, Zheng ZM, Yarchoan R. Genetic \\norganization and hypoxic activation of the Kaposi's sarcoma -\\nassociated herpesvirus ORF34 -37 gene cluster. Journal of\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 43}, page_content='virology. 2006;80(14):7037-7051. \\n33. Lin J, Hoffman -Censits JH, Duffy D, et al. A pilot phase II study of \\ndigoxin in patients with recurrent  prostate cancer as evident by a \\nrising PSA. Journal of Clinical Oncology. \\n2013;31(15_suppl):5061-5061. \\n34. Harrison MR, Hahn NM, Pili R, et al. A phase II study of 2 -\\nmethoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in \\npatients with taxane -refractory, metastatic castrate -resistant \\nprostate cancer (CRPC). Investigational new drugs.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 43}, page_content='2011;29(6):1465-1474. \\n35. Bruce JY, Eickhoff J, Pili R, et al. A phase II study of 2 -\\nmethoxyestradiol nanocrystal colloidal dispersion alone and in \\ncombination with sunitinib malate in patients with metastatic renal \\ncell carcinoma progressing on sunitinib malate. Investigational \\nnew drugs. 2012;30(2):794-802. \\n36. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M. ENMD -1198, a \\nnew analogue of 2-methoxyestradiol, displays both antiangiogenic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 43}, page_content='and vascular -disrupting properties. Molecular cancer \\ntherapeutics. 2010;9(5):1408-1418.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 44}, page_content='36 \\n37. Bisht KS, Bradbury CM, Mattson D, et al. Geldanamycin and 17 -\\nAllylamino-17-demethoxygeldanamycin Potentiate the Radiation \\nResponse of Cervical Tumor Cells via the Heat Shock Protein 90-\\nMediated Intracellular Signaling and Cytotoxicity. Cancer Res.  \\n2003;63(24):8984-8995. \\n38. Weber H, Valbuena JR, Barbhuiya MA, et al. Small molecule inhibitor \\nscreening identifified HSP90 inhibitor 17 -AAG as potential \\ntherapeutic agent for gallbladder cancer. Oncotarget. \\n2017;8(16):26169-26184.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 44}, page_content='2017;8(16):26169-26184. \\n39. Liu H, Lu J, Hua Y, et al. Targeting heat -shock protein 90 with \\nganetespib for molecularly targeted therapy of gastric cancer. Cell \\nDeath Dis. 2015;6(1):e1595. \\n40. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase \\nInhibitors as Anticancer Drugs. International journal of molecular \\nsciences. 2017;18(7). \\n41. Fath DM, Kong X, Liang D, et al. Histone deacetylase inhibitors repress \\nthe transactivation potential of hypoxia -inducible factors'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 44}, page_content='independently of direct acetylation of HIF -alpha. The Journal of \\nbiological chemistry. 2006;281(19):13612-13619. \\n42. Coufal N, Farnaes L. Anthracyclines and Anthracenediones. In: Minev \\nB. (eds) Cancer Management in Man: Chemotherapy, Biological \\nTherapy, Hyperthermia and Supporting Measures. Cancer Growth \\nand Progression, vol 13. Springer, Dordrecht. \\nhttps://doi.org/10.1007/978-90-481-9704-0_5 \\n43. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 44}, page_content='chemotherapy inhibits HIF -1 transcriptional activity and tumor -\\ninduced mobilization of circulating angiogenic cells. Proc Natl \\nAcad Sci U S A. 2009;106(7):2353-2358. \\n44. Tanaka T, Yamaguchi J, Shoji K, Nangaku M. Anthracycline inhibits \\nrecruitment of hypoxia -inducible transcription factors and \\nsuppresses tumor cell migration and cardiac angiogenic response \\nin the host. The Journal of biological c hemistry. \\n2012;287(42):34866-34882.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 44}, page_content='2012;287(42):34866-34882. \\n45. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a Small -Molecule \\nInhibitor of Hypoxia -Inducible Factor-1 DNA-Binding Activity. \\nCancer Res. 2005;65(19):9047-9055. \\n46. Gradishar WJ, Vogelzang NJ, Kilton LJ, et al. A p hase II clinical trial \\nof echinomycin in metastatic soft tissue sarcoma. Investigational \\nnew drugs. 1995;13(2):171-174. \\n47. Muss HB, Blessing JA, DuBeshter B. Echinomycin in recurrent and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 44}, page_content='metastatic endometrial carcinoma. A phase II trial of the \\nGynecologic Oncology Group. Am J Clin Oncol. 1993;16(6):492-\\n493.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 45}, page_content='37 \\n48. Chang AY, Kim K, Boucher H, et al. A randomized Phase II trial of \\nechinomycin, trimetrexate, and cisplatin plus etoposide in patients \\nwith metastatic nonsmall cell lung carcinoma : an Eastern \\nCooperative Oncology Group Study (E1587).  Cancer. \\n1998;82(2):292-300. \\n49. Wadler S, Tenteromano L, Cazenave L, et al. Phase II trial of \\nechinomycin in patients with advanced or recurrent colorectal \\ncancer. Cancer Chemother Pharmacol. 1994;34(3):266-269.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 45}, page_content='50. Bailey CM, Liu Y, Peng G, et al. Liposomal formulation of HIF -1α \\ninhibitor echinomycin eliminates established metastases of triple-\\nnegative breast cancer. Nanomedicine : nanotechnology, biology, \\nand medicine. 2020;29:102278. \\n51. Thomas A, Samykutty A, Gomez-Gutierrez JG, et al. Actively Targeted \\nNanodelivery of Echinomycin Induces Autophagy -Mediated \\nDeath in Chemoresistant Pancreatic Cancer In Vivo. Cancers. \\n2020;12(8).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 45}, page_content='2020;12(8). \\n52. Roeten MSF, Cloos J, Jansen G. Positioning of proteasome inhibitors \\nin therapy of solid malignancies. Cancer Chemother Pharmacol. \\n2018;81(2):227-243. \\n53. Bross PF, Kane R, Farrell AT, et al. Approval Summary for Bortezomib \\nfor Injection in the Treatment of Multiple Myeloma. Clin Cancer \\nRes. 2004;10(12):3954-3964. \\n54. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits \\ntumor adaptation to hypoxia by stimulating the FIH -mediated'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 45}, page_content='repression of hypoxia -inducible factor -1. Blood. \\n2008;111(6):3131-3136. \\n55. Befani CD, Vlachostergios PJ, Hatzidaki E, et al. Bortezomib represses \\nHIF-1α protein expression and nuclear accumulation by inhibiting \\nboth PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. \\nJournal of molecular medicine (Berlin, Germany). 2012;90(1):45-\\n54. \\n56. Koh MY, Spivak -Kroizman T, Venturini S, et al. Molecular \\nmechanisms for the activity of PX -478, an antitumor inhibitor of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 45}, page_content='the hypoxia-inducible factor-1α. Mol Cancer Ther. 2008;7(1):90-\\n100. \\n57. Tibes R, Falchook GS, Hoff DDV, et al. Results from a phase I, dose -\\nescalation study of PX -478, an orally available inhibitor of HIF -\\n1α. Journal of Clinical Oncology. 2010;28(15_suppl):3076-3076.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 46}, page_content='38'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 47}, page_content='CHAPTER IV \\n \\nCOAGULATION ANALYSES IN DIAGNOSIS AND \\nTREATMENT \\n \\nMuhammed Emin Düz \\n(Biochemistry Specialist, MD),. Amasya Sabuncuoğlu Şerefeddin Training and Research \\nHospital, e-mail: cerrahemin@gmail.com \\n              0000-0002-1837-6415 \\n \\nINTRODUCTION \\nIn living macroorganisms, life -long expected and unexpected \\nbleeding and coagulation mechanisms are activated at regular intervals. \\nExcessive coagulation can lead to life -threatening damage resulting from'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 47}, page_content='a blockage in the vessels, and uncontrolled bleedin g can cause serious \\ncomplications, especially death. To prevent bleeding, blood clotting \\n(clotting) occurs a few seconds after the vessel injury. The primary purpose \\nof coagulation is the vascular repair that occurs by collecting thrombocytes \\nat the damage site. Coagulation is known as the clotting of blood or plasma. \\nHemostasis is the procedure that tries to stop bleeding and is the first'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 47}, page_content=\"component of the metabolism's response to vascular injury. As a result of \\nhemostasis, a product called a hemostatic plug or hemostatic clot is formed. \\nThrombosis is an unexpected clot formation in a healthy vascular structure. \\nThrombus formation occurs as a result of thrombosis. Bloo d clotting can \\noccur at an injury site (hemostasis), in a healthy vessel (thrombosis), or on \\na foreign surface such as a laboratory test tube. Still, hemostasis is a\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 47}, page_content='physiological process that can only occur in a living, bleeding organism. \\nHemostasis consists of primary hemostasis, in which platelets are attached \\nand activated to a site of damage, and a fibrin network rigidly structures \\nsecondary hemostasis, in which the primary platelet plug formed. The \\nhemostatic process represents a delicate, well -balanced chain of steps \\nbetween regulatory mechanisms and control that prevent the efficient'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 47}, page_content='activation of local hemostatic agents and improper activation or \\nprolongation of coagulation steps due to vascular damage. The interactions \\nof the protein ingredients of coagulation cascade can be studied in cell-free \\nplasma and characterized as a \"cascade\" of proteolytic reactions. \\nConversely, hemostasis\\'s operation takes place on cell surfaces in a living \\norganism and is dependent on regulation by various biochemical an d'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 47}, page_content='cellular mechanisms. The competence of plasma procoagulant levels can \\nbe defined in the routine plasma clotting assays: prothrombin time (PT) \\nand activated partial thromboplastin time (aPTT). Platelet count and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 48}, page_content=\"40 \\nfunction can be determined in the clinical laboratory. Levels of individual \\nplasma coagulation inhibitors and other regulatory proteins can also be \\nevaluated. However, no laboratory test can provide a general evaluation of \\nhemostasis's competency or thrombosis risk. Each laboratory test offers a \\nsmall fraction of the information required, and the assessment of \\nhemostatic function always requires a comparison of laboratory results \\nwith patients' clinical condition.  \\nHEMOSTASIS\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 48}, page_content=\"with patients' clinical condition.  \\nHEMOSTASIS \\nThe hemostatic system consists of the plasma coagulation system, \\nincluding blood vessels, platelets, fibrinolytic factors, and inhibitory \\nmechanisms. When vessel damage occurs, three local agencies are \\nactivated to control bleeding: (1) vessel wall contraction, (2) platelet \\nadhesion and aggregation (platelet plug formation), and  (3) clot to form \\nfibrin. All these mechanisms need to work, and defects in one or more of\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 48}, page_content='them result in abnormal bleeding. Primary hemostasis is used for rapid \\nplug formation upon damage to the vessel wall, followed by \\nvasoconstriction, platelet adhesion , and aggregation. This stage is for a \\nsudden and quick solution, and fibrin formation is not required. However, \\nprimary hemostasis is transient, and bleeding could begin again, except \\nsecondary hemostasis strengthens the platelet plug by forming a stable'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 48}, page_content=\"fibrin clot. Eventually, the fibrinolytic system 's mechanisms ensure the \\nfibrin clot's dissolution and the restoration of normal blood flow.  \\nPlatelets cannot adhere to the healthy, smooth endothelial surface, \\nand coagulation is not initiated. Endothelial thromboresistance is generated \\nby various antiplatelet and anticoagulant materials produced by the \\nendothelial cells like; prostacyclin (prostaglandin I2, PgI2), nitrite oxide\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 48}, page_content='(NO), thrombomodulin, heparin -like glycosaminoglycans, tissue factor \\npathway inhibitor (TFPI), tissue plasminogen activator (t-PA). Endothelial \\ncells also show procoagulant activity by synthesizing and secreting von \\nWillebrand factor (VWF) and PAI-1. It is crucial that blood not clot inside \\nthe vascular system. In the baseline state, vascular endothelial cells \\nmaintain a nonthrombogenic interface with the circulating blood.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 48}, page_content='Endothelial cells do not ordinarily reveal molecules that promote platelet \\nadhesion or aid activation and activity of the coagulation proteins. After \\nvascular damage, procoagulant factors and tissue factor (TF) are activated, \\nand thrombocyte adhesion, aggregation, and local thrombin formation are \\nachieved.  \\nPlatelets are nucleated cells that are released by the breakdown of \\nmegakaryocytes in the bone marrow. They can be found in circulation for'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 48}, page_content='up to nine days. The approximate number of platelets in peripheral blood \\nis between 150,000 to 400,000 per microliter. On the outer surface of \\nplatelets are various molecules such as integrins and leucine -rich'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 49}, page_content='41 \\nglycoproteins. They mediate platelet adhesion and aggregation as receptors \\nfor adenosine diphosphate (ADP), arachidonic acid, and other agonists.  \\nPlatelet connecting is further intervened by von Willebrand factor (vWF) \\nbridging between collagen and the platelet receptor gl ycoprotein (GP) Ib. \\nThrombin stimulation produced as a result of coagulation reactions is \\nrequired for complete platelet activation. The platelet surface receptor,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 49}, page_content=\"GPIIb / IIIa, rapidly changes platelet formation by stimulating it with \\nfibrinogen. This cha nge in conformation allows platelet aggregates to be \\nconsolidated by connecting to fibrinogen ahead of fibrin conformation. \\nPlatelet activation also launches prostaglandins and thromboxanes ' \\nsynthesis, which regulates platelet activation and assists vasoco nstriction. \\nActivation of platelets motivates several changes resulting in hemostasis \\nincrease via two main mechanisms:\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 49}, page_content='increase via two main mechanisms: \\n1. Production of the hemostatic plug at the site of injury (primary \\nhemostasis). \\n2. Providing of phospholipids as a procoagulant surface  for \\nplasmatic coagulation. \\nEarly platelet plug formation can be divided into separate stages \\nthat are tightly related: platelet adhesion, structural changes, content \\nrelease, and platelet aggregation. Immediately following endothelial \\ndamage, platelets bi nd to adhesive proteins such as collagen via specific'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 49}, page_content='glycoprotein surface receptors (platelet adhesion). In this process, VWF \\nacts as a mediator that first adheres to collagen fibers and then realizes fiber \\nstrength. The platelet then binds to VWF via membrane glycoproteins (GP) \\nIb and IX. After adhesion, the platelets change from disc shape to spherical \\nshape and elongate pseudopods. It accelerates plug formation by releasing \\nADP, serotonin, Thromboxane A2 (TxA2), beta-TG, PF4, and VWF stored'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 49}, page_content='in thrombocyte granules also initiates platelet aggregation. At the end of \\nthe aggregation process, tightly packed degranulated platelets form the \\nhemostatic plug. Fibrinogen, which binds to specific glycoprotein \\nreceptors (GP IIb / IIIa), is required for platelet aggregation. Thromboxane \\nA2 (TXA2) secreted from granules enables vasoconstriction starting with \\nendothelin to continue. ADP stimulates platelet aggregation, while calcium'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 49}, page_content='activates the coagulation system starting with factor XII. \\nTwo congenital blee ding disorders, von Willebrand disease and \\nBernard-Soulier syndrome , are characterized by defective adhesion that \\ncauses a lifelong tendency to bleed due to VWF and GP Ib / IX deficiency. \\nBesides, in Glanzmann thrombasthenia, a disease characterized by the  \\nabsence of GP IIb / IIIa receptors, bleeding time is significantly prolonged,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 49}, page_content='platelet aggregation cannot occur, resulting in a lifelong bleeding tendency.  \\nThe transformation of inactive proenzymes activates coagulation \\nfactors into activated enzymes. En zyme, substrate, and cofactor are'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content=\"42 \\ninvolved in all coagulation steps. These components accumulating on the \\nphospholipid complex require calcium ions for activation, limiting the \\naffected area's reactions. All of the coagulation factors, except factor IV \\n(Ca + 2), are proteins, and most of them are found in the blood as inactive \\nproenzymes (zymogen). Factors V and VIII, on the other hand, are not in \\nthe enzyme structure and are synthesized by megakaryocytes in the bone\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content='marrow. It is stored in platelet granule s and released after activation. \\nVitamin K is required for factor II, VII, IX, X, protein C and S synthesis \\nand function. The only coagulation factor not circulating is tissue factor \\n(Factor III) located in the subendothelial area. The coagulation system is a \\nchain of sequential reactions in which coagulation factors activate each \\nother. It is known to be initiated by two classical ways, extrinsic and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content=\"intrinsic. The intrinsic pathway begins with Hageman factor (factor XII) \\nactivation, and the extrinsic path way begins with the release of tissue \\nfactor. Both paths provide stable clot formation as a result of burst \\nreactions that activate factor X. In the coagulation cascade, many factors \\nintertwine, trigger, and inhibit each other's  work under a single system \\nsimultaneously. The interconnected structure of the system at many points\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content='also allows better control of bleeding and clotting conditions.  The \\ncoagulation system is triggered by the tissue factor released due to \\nendothelial damage or inflammation either by factor XII activated by \\ncollagen. TF then interacts with factor VIIa, activating factors IX and X. \\nFactor Xa also produces a small amount of thrombin from prothrombin. \\nPropagation of coagulation consists of when thrombin repeatedly activates'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content='factors XI, IX, V, and VIII. Thrombin also stimulates the aggregation and \\nactivation of platelets. Coagulation factors, which are frequently activated \\nand multiplied in the system each time, generate too much thrombin from \\nprothrombin. Finally, thrombin transforms fibri nogen into fibrin. Also, \\nthrombin activates factor XIII and forms the desired stable clot with a fibrin \\nfiber network.  \\nThe main initiating pathway of in vivo blood coagulation is the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content='extrinsic system. The crucial component is TF, an intrinsic membrane \\ncomponent expressed by cells in most extravascular tissues. The \\nterminology \"extrinsic\" continues to be used today in terms of education, \\nalthough quite outdated. TF is not frequently extrinsic to the circulatory \\nsystem, but it is also expressed by endothelia l cells and leukocytes under \\ndefinite pathological conditions. TF serves as a cofactor to the significant'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content='factor VII in the extrinsic pathway. TF and factor VII complex provide \\nfactor VIIa activation, whereby factor X is converted into factor Xa, the \\nmain compartment in the common path. The factor VIIa-TF complex also \\nconverts factor IX to factor IXa. Also, as levels of factor Xa increase, the \\nfactor VIIa-TF complex is subject to inhibition by the factor Xa-dependent \\ntissue factor pathway inhibitor (TFPI). The intrinsic pathway earlier begins'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 50}, page_content='with the contact phase. This phase is achieved by factor XII (contact'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 51}, page_content='43 \\nfactor), prekallikrein, and high -molecular-weight (HMW) kininogen. In \\nvitro contact phase is launched by binding factor XII to negative surfaces \\nof g lass and kaolin. This leads to the generation of cofactors XIIa and \\nkallikrein and the release of bradykinin from HMW kininogen. Factor XIIa \\nthen activates factor XI, which converts factor IX to factor IXa, a reaction \\nrequiring calcium presence. After fact or IXa complexes with its cofactor'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 51}, page_content=\"protein factor VIIIa on a negatively charged membrane surface. This \\nenzymatic complex, also referred to as the tenase complex, converts factor \\nX to factor Xa. After both the extrinsic and intrinsic pathways generate \\nfactor Xa, the coagulation pathway 's ensuing reactions are the same and \\nare referred to as the common pathway. Based on the discovery that the \\nfactor VIIa-TF complex also converts factor IX to factor IXa, that is the\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 51}, page_content='privileged reaction, a new modified concept of coagulation was proposed \\nin which factor VIIa -TF complex seems to be the core initiator of \\ncoagulation, but the intrinsic pathway is aforethought essential to pursue \\nthe coagulation response. \\n \\nFigure 1. Coagulation pathway scheme \\n \\nENDOGENOUS ANTICOAGULANTS AND FİBRİNOLYSIS \\nAnticoagulant substances consist of antithrombin III (AT -III), \\nprotein C, protein S, and TFPI. Intact endothelium ensures that the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 51}, page_content='formation of clots is stopped, and if endothelial repair is completed, the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 52}, page_content='44 \\nfibrin is destroyed by fibrinolysis. When clot formation reaches the intact \\nendothelium, it activates the heparin -like molecule AT-III, which runs to \\nthe endothelial surface. Antithrombin III is a potent anticoagulant \\nsubstance produced in the liver and commonly found in body fluids and is \\na significant inhibitor of serine proteases formed during coagulation. \\nAntithrombin III inactivate s all active factors; Xa, XIa, XIIa, IXa,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 52}, page_content='thrombin, and TF -VIIa complex. On the other hand, thrombin binds to \\nthrombomodulin, which is a specific  thrombin (IIa) receptor on the \\nendothelial surface and activates protein C and protein S. Activated protein \\nC neutralizes cofactors such as factor Va and VIIIa. Thus, the coagulation \\nsystem is stopped by inactivating all active and auxiliary factors. \\nPlasminogen is an inactive circulating protein that binds to fibrin during'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 52}, page_content='clot formation. Plasminogen is activated by endothelium produced tissue \\nplasminogen activator (t -PA), urokinase -type plasminogen activator \\n(uPA), and contact factors such as XIa, XIIa, quinine, and kallikrein and \\nconverted to plasmin. tPA is the most effective in activating fibrin -bound \\nplasminogen. Besides, it prevents fibrinolysis from moving beyond the clot \\nformation site. Fibrinogen is a colossal plasma protein with 340 kDa MW.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 52}, page_content='It is produced from the liver, and its concentration range is 200 to 400 \\nmg/dL. Fibrinogen is stable in plasma for about 4 to 5 days. It is a dimeric \\nprotein of highly low solubility designed with two pairs of three \\nnonidentical polypeptide chains covalently connected by disulfide bonds. \\nFibrinolysis event is the breakdown of fibrin strands that hold plasmin, \\nformed by plasminogen, and fibrin. Fibrin is broken down into fibrin'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 52}, page_content='breakdown products by fibrinolysis. The transformation of fibrinogen to \\nfibrin occurs in three stages. First, thrombin splits four small peptides —\\nthe fibrinopeptides A (FPA) and fibrinopeptides B (FPB) —from the \\nfibrinogen molecule, following the formation of a new molecule called \\nfibrin monomer. Secondly, polymerization comprises unconsciou sly by \\nnoncovalent end -to-end and side -to-side relations to develop fibrin'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 52}, page_content='polymers. In the third step, a resistant and consistent fibrin molecule is \\nacquired by the action of factor XIII (fibrin-stabilizing factor) and calcium \\nions. Fibrin degradation pro ducts (FDPs) begin to form while plasmin \\ndiminishes the thrombus. Multiple FDPs, involving fibrinopeptide B and \\nother fibrin degradation monomers and dimers, consist. When fibrin \\npolymers are splitted from the D fragment site, the following D -dimer'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 52}, page_content='fragment pictures thrombosis diffusiveness and plasmin efficiency. D -\\ndimer assays anticipate and have prognostic value in several disease \\nextents, bearing disseminated intravascular coagulation (DIC), pulmonary \\nembolism, deep vein thrombosis, and cancer-associated thrombosis.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 53}, page_content='45 \\nCOAGULATION TESTS \\nNumerous tests assess the risk of bleeding to guide clinical \\ndiagnosis and treatment approaches. Commonly used coagulation tests \\ncontain the following: \\n-CBC \\n-Bleeding time \\n-Platelet function tests \\n-Routine hemostasis tests as prothrombin time (PT), partial \\nthromboplastin time (PTT), thrombin \\ntime (TT), fibrinogen level, and D-dimer \\n- Antithrombin III levels \\n- Private analysis suchlike anti -Xa assay, diluted thrombin time,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 53}, page_content='and tests for heparin-induced thrombocytopenia \\n- Thromboelastography (TEG) \\n-Hypercoagulability and fibrinolysis tests \\nComplete blood count (CBC) is one of the most common \\nlaboratory tests requested by clinicians, and this test is also required before \\nsurgery to evaluate a patient for bleeding risk. Pla telet count and mean \\nplatelet volume are essential parameters in predicting bleeding \\ncomplications, especially in surgical interventions. Performing CBC is for'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 53}, page_content='diagnosing thrombocytopenia when the platelet count is less than 150,000/ \\nµL. Unexpected thrombo cytopenia should be confirmed by peripheral \\nblood smear. The probability of red blood cell fragments or pseudo \\nthrombocytopenia may provide hints for further assessing the patient.  \\nBleeding time is defined as the time between applying a small \\nstandard incision and bleeding stops. Although it is a simple test, many \\nfactors affect bleeding time, making it difficult to standardize. Bleeding'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 53}, page_content=\"time measures platelets ' interaction with the vessel wall, followed by \\nforming the first hemostatic plug. Bleeding time will be prolonged in cases \\nof decreased platelet count, dysfunction, or vascular wall pathology. \\nBesides, when there is a decrease in VWF or fibrinogen, the bleeding time \\nmay be prolonged. The depth, width, and position of the skin incision may \\ndiffer for each application, so its diagnostic utility as an individual test is \\nof limited value.\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 53}, page_content='of limited value. \\nAnalyzers available for platelet function tests include PFA -100, \\nPlateletworks, and VerifyNow. Also, a platelet aggregation test can be \\nperformed. These tests are used to determine platelet function and to decide \\nwhether a platelet transfusion is required. The PFA-100 system is a platelet'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content='46 \\nfunction analyzer that can be used to appraise platelet -related primary \\nhemostasis. If the collagen -epinephrine (CEPI) closure time is extended \\nbut the collagen-adenosine diphosphate (CADP) closure time is standard, \\nthis is presumably due to aspirin. If both CEPI and CADP closure times \\nare prolonged or CEPI closure time is typical and CADP closure time is \\nabnormal, this means platelet dysfunction or von Willebrand disease. PFA-'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content=\"100 is senseless to von Willebrand disease type 2N, clopidogrel, \\nticlopidine, and storage pool disease. PFA -100 results are biased by \\nthrombocytopenia and low hematocrit. VerifyNow is a quick, turbidimetric \\nwhole blood assay able to evaluate platelet aggregation. This assay is based \\non the competence of activated platelets to bind with fibrinogen. If \\nGpIIb/IIIa (glycoprotein IIB/IIIa) competitors are present in patients '\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content='plasma, platelet aggregation lessens. Results a re declared in reactive \\naspirin units (ARU) or clopidogrel, plavix reactive units (PRU).  \\nPlateletworks evaluates platelet function in whole blood. It compares the \\nplatelet count before and after exposure with a selected platelet agonist. In \\nagonist exposur e, functional platelets should be collected, and \\nnonfunctional platelets should not aggregate. A hematology analyzer such'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content='as ICHOR II then measures the number of non -clumped platelets in the \\nEDTA tube and agonist tube. With the difference, platelet functio ns are \\nevaluated. The Plateletworks is useful in monitoring the platelet response \\nin patients using antiplatelet, such as aspirin and clopidogrel. Platelet \\naggregometry is a widely used laboratory test to screen patients with \\ngenetic or obtained platelet f unction defects. Platelet aggregometry'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content=\"evaluates light transmission rising through platelet -rich plasma when \\nplatelets are aggregated due to an agonist 's addition. Diversified agonists \\nused for this test are; AA, collagen, ristocetin, ADP, and epinephrine. The \\nfirst aggregation wave is through the activation of the GpIIb/IIIa receptor. \\nThe secondary wave is due to platelet granule release. Secondary wave \\ndeficit means a storage pool disorder by a reduced number of granules or\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content='faulty release of granule substances. The use of these agonists in advanced \\nconcentrations results in the two waves joining into one aggregation wave. \\nThe prothrombin time (PT) is performed by adding a raw \\npreparation of TF (usually an extract of the brain) to citrate- anticoagulated \\nplasma, recalcification of the plasma, and assessing the clotting time. \\nThromboplastin and CaCl2 are generally added in a single step. Clotting'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content=\"time is established at 37°C using a diversity of methods, including photo -\\noptical and electromechanical detection.  The prothrombin time may be \\nelongated because of the extrinsic coagulation pathway 's deficiency, i.e., \\nfactors II, V, VII, X, and/or fibrinogen. PT is a practical adjustment of the \\nextrinsic pathway and common pathway, and the reference range is 8.8s - \\n11.6 s. A circulating anticoagulant directed against these factors may also\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 54}, page_content=\"provoke the PT's prolongation. However, frequently PT is reported as the \\ninternational normalized ratio (INR). The thromboplastin used may alter\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 55}, page_content=\"47 \\nfrom laboratory to laboratory and fro m country to country. However, \\nreporting results as INR ensures results are comparable among different \\nlaboratories. The INR is calculated as dividing the patient PT by the mean \\nnormal pt and taking the result's power as the ISI (International Sensitivity \\nIndex) value. The INR has two main advantages: it lets a comparison \\nbetween results acquired from several laboratories, and it allows\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 55}, page_content='investigators to standardize anticoagulant therapy in clinical trials and \\nscientific publications.  The normal INR range is  0.8-1.2. Reasons for \\nprolonged PT include coumarin (warfarin), vitamin K deficiency, factor \\ndeficiency (inherited or acquired, e.g., liver disease), or factor inhibitors.  \\nActivated partial prothrombin time (aPTT) is another practical test \\nfor the assessment of secondary homeostasis. Citrated plasma (or oxalate),'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 55}, page_content='surface activating agent (silica, kaolin, celite, or ellagic acid), calcium, and \\nplatelet substitute (rough phospholipid) are mixed and clotting time is \\ndetermined most likely using an automated c oagulation analyzer. It is a \\nuseful measure of the intrinsic pathway as well as the common pathway. It \\ncan evaluate hereditary or acquired faults of the coagulation factors XII, \\nXI, X, IX, VIII, V, prothrombin, and fibrinogen. PTT or aPTT is named'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 55}, page_content='partial thromboplastin time because of the lack of tissue factor \\n(thromboplastin) in the tests. The expected value differs from laboratory to \\nlaboratory but is generally within 25 and 39 s. Causes of extended PTT \\ninclude the following; \\n-Heparin and other direct thrombin inhibitors (DTIs) \\n-Factor deficiency, factor inhibitors, or lupus anticoagulant (LA) \\n-von Willebrand disease \\n-HMWK (Fitzgerald factor) deficiency \\n-Pre-kallikrein (Fletcher factor) deficiency'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 55}, page_content='-Pre-kallikrein (Fletcher factor) deficiency \\nFalsely measured prolonged PT and aPTT reasons contain high \\nhematocrit, underfilling of the citrate tube, and EDTA contamination. \\nDelay in transport and processing may also cause false results.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 56}, page_content=\"48 \\nFigure 2. Clinical evaluation of PT and PTT results \\n \\nThrombin time (TT) is a test that the patient's plasma is mixed with \\nthrombin, and clotting time is measured. It is an assessment of functional \\nfibrinogen. Heparin and abnormal or low fibrinogen molecules prolonges \\nTT. The most performed fibrinogen assay is a modified thrombin test \\nknown as the Clauss fibrinogen assay. This method contains an initial (10-\\nfold) dilution of the plasma sample to guarantee that fibrinogen is rate -\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 56}, page_content='limiting for clotting and the following measurement of the clotting time by \\nsupplementing an excess of thrombin to the sample. T he length of the \\nclotting time is contrarily related to the concentration of fibrinogen. D -\\nDimer forms via fibrin degradation and contains two cross -linked D \\nfragments of the fibrin protein. Elevated levels suggest increased \\nfibrinolysis in DIC and thrombotic states. Antithrombin disables factor Xa'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 56}, page_content='(activated factor X) and activated factor II (thrombin). Therefore, activity \\nis induced by heparin. Low ATIII levels may need additional heparin to \\nobtain the desired anticoagulated state. This is called \"heparin resistance.\" \\nAdipose tissue may release heparin storage back into the circulation a few \\nhours after surgery. This is mentioned as rebound heparin and could result \\nin bleeding. Both heparin resistance and rebound heparin can be prevented'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 56}, page_content='if low ATIII levels are corrected before surgery. Low levels of ATIII levels \\nmay be seen in; inherited deficiency, liver disease, nephrotic syndrome, \\nDIC, and L-Asparaginase therapy.  \\nCoagulation tests may include different approaches other than \\nroutine analysis. PT and aPT T prolongation in individuals may be due to \\nfactor deficiency or factor inhibitors. At this point, mixing studies come to'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 57}, page_content=\"49 \\nthe fore. In this test, the patient's plasma and normal plasma are mixed in \\nequal volume, and PT, PTT, or both are evaluated at 0 and 1-2 hours. \\nProlonged PT / PTT is not shortening, despite factor addition indicates the \\npresence of inhibitors. 0 and 1 -2 hour PTT results mean lupus \\nanticoagulant in the same cases. Results that extend over time reveal the \\npresence of the antibody (typically factor VIII inhibitor). If the PT and PTT\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 57}, page_content='are both prolonged and the mixing study shows correction, the only \\ninference is common pathway problems. Plasma anti -Xa testing can be \\nused to monitor patients receiving unfractionated heparin (UFH) or low \\nmolecular weight heparin (LMWH) therapy. LMWH primarily has anti-Xa \\nactivity, and UFH shows both anti -Xa and anti -IIa activity. Coagulation-\\nbased or chromogenic methods can measure the anti -Xa activity of AT.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 57}, page_content=\"Additionally, a patient who is bleeding but shows typical values of PT/PTT \\nmay be due to; thrombocytopenia and thrombocytopathia, factor XIII \\ndeficiency (clot is not soluble in urea), and increased primary fibrinolysis \\n(e.g., lack of α2 -antiplasmin). The Factor XIII screening test is based on \\nmono chloric a cid's ability to dissolve the fibrin clot in factor XIII \\ndeficiency. Quantitative tests depend on factor XIII transamidase\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 57}, page_content='properties. Although prolonged bleeding time is determinant for von \\nWillebrand disease, it is not specific for the disease. At this p oint, \\nmeasurements of the von Willebrand antigen amount, the functional \\ncapacity of VWF, and the function of the associated factor VIII molecule \\nare valuable. VWF protein is measured by the ELISA method. A decrease \\nin VWF levels is found in most patients. The average VWF antigenic level'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 57}, page_content='in people with blood type 0 is about 25% lower than in other blood groups. \\nThe functionality of VWF is evaluated by calculating the cofactor activity \\nof ristocetin (standardized normal platelet suspension) in the patient \\nplasma. In this assay, the agglutination capacity of VWF in ristocetin -\\nadded plasma is evaluated in terms of the rate or extent of platelet \\nagglutination.  \\nDisruption of coagulation mechanisms may cause bleeding, and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 57}, page_content='impairment of control mechanisms may cause  thrombosis. Control \\nmodulators include AT, protein C and immunological and functional \\nmethods can measure protein S and AT. Functional tests involving \\nchromogenic substrates detect AT as a heparin cofactor. For protein C, \\ntests are available evaluating th e prolongation of aPTT in terms of \\ninactivating activated protein C factors V and VIII. The determination of \\nprotein S is involved in its combination with a free protein S and C4b. Free'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 57}, page_content='protein S acts as the cofactor of active protein C. Protein S assay ca n be \\nevaluated using protein S deficient plasma and activated protein C. In the \\npast, various fibrin/fibrinogen degradation products were determined by \\ndifferent methods. Currently, only D -dimer is measured as a diagnostic \\nparameter for DIC and other throm botic events. Monoclonal antibodies \\nthat can detect D-dimer in plasma were synthesized. The antibody did not'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 58}, page_content='50 \\nreact with fibrinogen, resulting in high sensitivity and specificity of the \\ntest. ELISA can measure prothrombin fragments 1 and 2 (F1 + 2), \\nthrombin-antithrombin complex (TAT), beta -thromboglobulin, and PF 4  \\nto assess hypercoagulability in research laboratories. However, these \\nassays are generally not accepted for evaluating a bleeding patient or a \\npatient with thrombotic disorders. Thromboelastograp hy (TEG) is a'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 58}, page_content='method used to measure the effectiveness of blood coagulation. Although \\nit is used more and more in emergency departments, intensive care units, \\nand resuscitation in delivery rooms, it mainly comes to the fore in surgery \\nand anesthesiology. TEG can also evaluate platelet function, clot strength, \\nand fibrinolysis in addition to known coagulation tests. \\nThromboelastometry (TEM), previously known as rotational \\nthromboelastography (ROTEG) or rotational thromboelastometry'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 58}, page_content='(ROTEM), is a different TE G modeling in which the rotating TEG is the \\nsensor shaft instead of the container. \\nCOAGULATION DISORDERS  \\nLaboratory tests are essential for diagnosing coagulation disorders. \\nHowever, there are no standardized panels required for accurate diagnosis, \\nand measurements can differ significantly between laboratories. Routine \\nlaboratory tests for coagulation disorders include platelet count, \\nprothrombin time (PT), partial thromboplastin time (aPTT), international'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 58}, page_content='normalized ratio (INR), and bleeding time. Platelets should have not only \\nsufficient quantity but also be functional. Bleeding time evaluates the \\nfunction of platelets. Bleeding times may increase in VWF deficiency or \\nantithrombotic substance use (NSAID, aspirin, and valproic acid). PT \\nshows the function of factors II, V, VII, and X, which are vitamin K -\\ndependent factors synthesized from the liver. Drugs that reduce the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 58}, page_content=\"synthesis of vitamin K, such as warfarin, will cause an increase in PT and \\nINR values. INR is a ratio used to predict the percentage of ac tive \\ncoagulation factors. For example, an INR of 2 to 3 means about 10% \\nclotting factor activity. This activity should be at least 30% for standard \\ncoagulation. Partial thromboplastin time evaluates the von Willebrand \\nfactor's activity and factors VIII, IX, XI, and XII. Hemophilia patients have\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 58}, page_content=\"regular PT / INR, bleeding time, and thrombocyte count despite high aPTT. \\nLow FVIII levels will cause prolonged aPTT values through the intrinsic \\npathway. An elevated aPTT requires investigation of factors VIII and I X. \\nWhen evaluating the established factor levels, the amount of factor s \\npresent will determine the disease's severity and prognosis. When \\nprolonged aPTT values raise clinical suspicion, the focus should be on the\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 58}, page_content=\"mother's entire family history, especially the first -degree male relatives. \\nDiagnosis of von Willebrand disease is made with increased bleeding time \\nand decreased vWF levels in ristocetin cofactor analysis, in addition to \\nbleeding history and family history. Since vWF levels are affected by intra-\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 59}, page_content='51 \\nindividual variation, stress, pregnancy, exercise, and inflammatory \\nprocesses, the test should be repeated three times before making a \\ndiagnosis. It can affect gender and blood type levels. Factor multimer tests \\nmay be required to diagnose the specific subtype of the disease. Also, aPTT \\ncan be slightly elevated at second to low factor VIII levels in about 50% of \\npatients with von Willebrand disease.  \\nDisseminated intravascular coagulation (DIC) is a'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 59}, page_content='clinicobiological syndrome defined by excessive clotting activation \\nleading to the accumulation of fibrin into the vessel, organ d isorders, \\nexcessive consumption of coagulation factors and platelets, and bleeding \\nthat can be fatal. DIC can be triggered by different clinical conditions \\n(sepsis, cancer, trauma, and pregnancy complicated by eclampsia or other \\ndiseases). Elimination of t he activation factor and the destruction of the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 59}, page_content='trigger mechanism are the main therapeutic approaches. DIC -specific \\ntreatment strategies aim to limit the activation of blood clotting and the risk \\nof bleeding. Fibrin formation is accompanied by plasminogen activator \\ninhibitor 1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), and \\nfibrinolysis activation due to comorbid diseases and clinical conditions. If \\nfibrinolysis does not occur at the required level, fibrin accumulation will'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 59}, page_content='cause diffuse bl ockages in the microvascular system. Microvascular \\nthrombosis, together with hemodynamic and metabolic disorders, can lead \\nto multiple organ failure. It may have clinical consequences in organ \\nfailure, renal failure, respiratory failure, hypotension, circu latory failure, \\nor impaired brain function. Besides, intravascular coagulation activation \\nmay contribute to macrovascular thrombus formation, leading to venous or'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 59}, page_content='arterial thrombus and embolization. Diagnostic criteria include:  \\n-Presence of additional disease that may predispose to DIC, \\n-Clinical signs (bleeding or organ dysfunction) \\n-Laboratory tests (platelet count, PT, fibrinogen, and \\nfibrin/fibrinogen degradation products [FDPs]) \\nRapidly evolving DIC results in severe thrombocytopenia, \\nprolonged PT and PTT, rapidly decreasing plasma fibrinogen levels, and \\nelevated plasma D-dimer levels. \\nPreanalytical requirements  for routine coagulation'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 59}, page_content='measurements \\nBlue-capped tubes with a citrate concentration of 105-109 mmol / \\nL (3.2%) are recommended for coagulation tests. Laboratory professionals \\nshould keep in mind that there may be a reference range difference \\ndepending on the citrate concentration in the same method and correct \\nreference ranges. In ensuring the correct blood/anticoagulant ratio, care \\nshould be ta ken to ensure that the blood amount corresponds to the tube'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 60}, page_content='52 \\nfilling line specified by the tube manufacturer. It should be noted that the \\ntube filling line is determined to provide the correct blood citrate ratio (9: \\n1), not the volume of the citrated tube.  Blood should be taken into the \\ncitrate tube first in patients who are requested coagulation tests together \\nwith other laboratory tests. Unless the manufacturer specifies a different \\nprocedure, the tubes containing anticoagulants should be mixed by'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 60}, page_content='inverting 3-6 times after blood is taken. Blood should be taken into the \\ncitrate tube first in patients who are requested coagulation tests together \\nwith other laboratory tests. Unless the manufacturer specifies a different \\nprocedure, the tubes containing anticoa gulants should be mixed by \\ninverting 3 -6 times after blood is taken. Coagulation tests at high \\nhematocrit values (> 55%) should be run from plasma with an adjusted'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 60}, page_content='citrate concentration. All coagulation measurements should be performed \\nwithin the first 4 hours after the blood sample is collected. PT and D-dimer \\ntests can be run within 24 hours. However, laboratories must evaluate the \\nsample stability for their system. If the aPTT test is requested for standard \\nheparin monitoring, the whole blood sample should be centrifuged within \\n1 hour after the sample is taken, and the plasma should be separated. To'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 60}, page_content='evaluate protein -S, protein -C, and activated protein C resistance, it is \\nrecommended that these treatments be discontinued two months before \\nwomen receiving combined oral contraceptives and hormone replacement \\ntherapy. When sampling is required for inherited diseases such as vWF, \\nFVIII deficiency, protein S deficiency, samples should be taken when \\nregular menstrual cycles begin or at least two months after birt h. All \\nabnormal values, including pregnancy -associated antiphospholipid'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 60}, page_content='antibodies, should be confirmed by re-drawing.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 61}, page_content='53 \\nREFERENCES \\n1. Doherty TM, Kelley A. Bleeding Disorders. [Updated 2020 Aug 12]. In: \\nStatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; \\n2020 Jan -. Available from: \\nhttps://www.ncbi.nlm.nih.gov/books/NBK541050/ \\n2. Hiller E. (2007) Basic Principles of Hemostasis. In Munker R., Hiller \\nE., Glass J., Paquette R. (eds) Modern Hematology. Contemporary \\nHematology. Humana Press. https://doi.org/10.1007/978-1-\\n59745-149-9_19'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 61}, page_content='59745-149-9_19 \\n3. Harold R. Roberts, Dougald M. Monroe, Miguel A. Escobar, Richard B. \\nWeiskopf; Current  Concepts of Hemostasis: Implications for \\nTherapy. Anesthesiology 2004; 100:722 –730 doi: \\nhttps://doi.org/10.1097/00000542-200403000-00036 \\n4. Antonio Blanco and Gustavo Blanco. Hemostasis. In Medical \\nBiochemistry, 2017 . Pages  781 – 789. doi: \\nhttps://doi.org/10.1016/B978-0-12-803550-4.00031-8 \\n5. Hoffman, Maureen, 2010. Regulation of Hemostasis and Thrombosis.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 61}, page_content='doi: https://doi.org/10.1016/B978-1-4160-3773-6.10009-6 \\n6. Nguyen, Andy & Dasgupta, Amitava & Wahed, Amer. (2016). \\nCoagulation-Based Tests and Their Int erpretation. doi: \\nhttps://doi.org/10.1016/B978-0-12-803531-3.00001-X. \\n7. Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated Intravascular \\nCoagulation: An Update on Pathogenesis, Diagnosis, and \\nTherapeutic Strategies. Clin Appl Thromb Hemost. \\n2018;24(9_suppl):8S-28S. doi: \\nhttps://doi.org/10.1177/1076029618806424'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 61}, page_content='https://doi.org/10.1177/1076029618806424 \\n8. Favaloro EJ, Funk DM, Lippi G. Pre-analytical variables in coagulation \\ntesting associated with diagnostic errors in hemostasis. Lab Med. \\n2012;43:1-10. doi: \\nhttps://doi.org/10.1309/LM749BQETKYPYPVM'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 62}, page_content='54'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 63}, page_content='CHAPTER V \\n \\nPREVALENCE OF PALMARIS LONGUS AGENESIS (PLA) \\nAMONG TURKISH MEDICAL STUDENTS \\n \\nMukadder Sunar1 \\n1(Asst. Prof, PhD) Erzincan Binali Yıldırım University,  \\ne-mail: mukaddersunar@gmail.com \\n                 0000-0002-6744-3848 \\n \\nINTRODUCTION \\nThe palmaris longus  (Figure 1) (1)  is a small, fusiform -shaped \\nmuscle located on the anterior forearm of the human upper extremity. This \\nmuscle belongs to the su perficial forearm flexor group with a most'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 63}, page_content='common proximal attachment at the medial epicondyle of the humerus via \\nthe common forearm flexor tendon and a most common distal attachment \\ninto the connective tissue fibers of the palmar aponeurosis and the flexor \\nretinaculum, a ligamentous structure forming the roof of the carpal tunnel \\nand containing the me dian nerve and digital flexor tendons ( 2, 3 ). The \\npalmaris longus can be morphologically quite variable but most commonly'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 63}, page_content='has a tendinous proximal attachment, a mid-length, spindle-shaped muscle \\nbelly, and a long and thin tendinous distal portion. The majo rity of fibers \\nin the palmaris longus tendon pass superficially to the flexor retinaculum, \\nthe tendon broadens into a flattened collection of fibers, and the fibers \\ninterweave with the palmar aponeurosis (2, 3). The functional contribution \\nof the palmaris longus appears to be minimal, but it has clinical'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 63}, page_content='significance due to its frequent intraoperative harvest for many surgical \\nprocedures, often involving tendon repair in the upper extremity. The thin \\ndistal tendinous portion, superficial location, and lack of functional \\nsignificance make the muscle easily accessible and ideal for intraoperative \\nharvest for tendon reconstruction and other surgical procedures. The \\npalmaris longus muscle is commonly present but may be absent in a small'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 63}, page_content='percentage of the populat ion, ranging from 2.5% to 26% of individuals, \\ndepending on the studied population (2, 3, 4). The palmaris longus tendon \\nis located near the anatomical center of the anterior wrist, medial to the \\ntendon of flexor carpi radialis, and lateral to the tendon of  flexor carpi \\nulnaris (3). The presence of the palmaris longus muscle can be determined \\nthrough noninvasive and standard physical examination of the volar wrist \\n(5, 6).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 64}, page_content='56 \\nMATERIALS AND METHODS \\nSubjects \\nThis is a cross sectional study that involved 712 (429 male, 283 \\nfemale) healthy subjects studying at Atatürk and Erzincan Binali Yıldırım \\nUniversity Faculty of Medicine. We excluded subjects with physically \\ndisabilities, any prior surgery (to upper or lower limbs) and any upper limb \\ninjuries. Subjects with a history of injury /disability (including those \\nresulting from trauma, be it spine, lower or upper limb) , disease or'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 64}, page_content='abnormality of the upper limb which would preclude examination for the \\npresence of the PL tendon. \\nTests  \\nIn our current study, the S cheaffer’s test (7, 8, 9, 10, 11, 12 ), the \\nThompson’s test (5, 8, 11, 13) and the Mishra’s test (7, 8, 9, 11, 13), which \\nare the classical tests frequently used in the studies, were applied to test the \\npresence of Palmaris longus: \\n- The Schaffer’s test: This is the Standard test for the assessment'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 64}, page_content='of the palmaris longus tendon. It involves opposing the thumb to the little \\nfinger and then followed by the flexion of the wrist. Each of the subjects \\nwas asked to oppose the thumb to the little finger and then flexes the wrist \\nslightly (8,11) (Fig. 2). \\n- Thompson’s test: The test involves the flexion of the fingers to \\nform a fist followed by the flexion of the wrist and finally, the thumb is \\nopposed and flexed over the fingers . The subjects were asked to make a'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 64}, page_content='fist and then flex the wrist and finally, the thumb is opposed and flexed \\nover the fingers (8,11) (Fig. 3). \\n- Mishra’s test:  The test involves the abduction of the thumb \\nagainst the resistance with the wrist in slightly palmar flexion. The subjects \\nwere asked to abduct the thumb against resistance with the wrist in slight \\npalmar flexion (8,11) (Fig. 4). \\nStatistical analysis \\nIBM SPSS 22.0 package program was used for statistical analysis'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 64}, page_content='of the data (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, \\nVersion 22.0. Armonk, NY: IBM Corp.). Mean ± standard deviation and \\n(minimum-maximum) value were used when summarizing age, which is a \\ncontinuous variable, and number (n) and percentage (%) for ca tegorical \\nvariables. The Chi -square test was used in the analysis of categorical \\nvariables. Phi coefficient was used to evaluate the PLA relationship'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 64}, page_content='between the right and left sides. For Phi coefficient <0.20 no relationship, \\n0.20-0.29 was considered weak , 0.30 -0.49 moderate, 0.50 -0.69 strong,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 65}, page_content='57 \\n0.70-1.0 very strong (14). Statistical significance was accepted as p <0.05 \\nin all tests. \\nRESULTS \\nStudy was carried out with 712 medical students. There were 283 \\n(39.7%) female and 429 (60.3%) male students. The mean  age \\nwas19.5±1.4 and ranged from 18 to 26 years. \\nFor all students PLA prevalence was found 7.6% (n=54). The \\nprevalence of PLA for females was 6.4% (n=18 out of 283) and for males \\n8.4% (n=36 out of 429). Prevalence was not significantly different between'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 65}, page_content='males and females (p=0.316). \\nOut of 54 students who had PLA was examined for sides according \\nto gender. The percentage of unilateral PLA was 50.0% (n=9 out of 18) for \\nfemale sand 61.1% (n=22 out of 36) in males. Percentage of unilaterality \\nwas not statistically significant for gender (p=0.436). The distribution of \\nagenesis according to gender was shown in (Table 1). \\nWhen the sides were examined for PLA, both for males andf'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 65}, page_content='emales, right and left limbs have strong positive correlation of PL agenesis \\n(φ=0.576, p<0.001). For females correlation between agenesis and sides  \\nwas (φ=0.576, p<0.001) and (φ=0.650, p<0.001) for males. \\n \\n \\nTable 1. PLA distribution according to gender'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 66}, page_content='58 \\nDISCUSSION \\nPalmaris longus (PL) is one of the forearm muscles that lie \\nbetween the flexor carpi ulnaris and the flexor carpi radialis muscles. The \\nabsence of the PL has been shown to vary based on body side, gender, and \\nethnicity in prior studies (7, 11, 15). \\nRoohi et al. studied in 450 healthy subjects (equally distributed \\namong Malaysia’s 3 major ethnic groups) for the presence or absence of \\npalmaris longus. Palmaris longus was found to be absent unilaterally in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 66}, page_content='6.4% of study subjects, and bilaterally in 2.9% of st udy participants. \\nMalays have a high prevalence of palmaris longus absence at 11.3% \\nfollowed closely by Indians at 10.7% whilst Chinese  had a low absence \\nrate of 6.0% (10).  Godwin and Adedayo examined in 600 subjects \\ncomprising 335 males and 265 females aged 8-60years were used to assess \\nthe prevalence of agenesis of the PL in Yoruba tribe. As a result, The \\noverall prevalence of absence both unilaterally and bilaterally in the two'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 66}, page_content='sexes was 6.7%. In males, unilateral absence was 5.4%. The distribution \\non th e right and left were 2.4% and 3.0% respectively. The bilateral \\nabsence was 1.5%. In  females, unilateral absence was 6.0%. The \\ndistribution on the right and left were 2.6% and 3.4% respectively. \\nBilaterally, it was 0.4%. In one subject unilaterally, PL was  observed to \\nhave differentiated from flexor carpi radialis (13). \\nSater MS et al. examined 1,043 subjects, 3–85 years old, from the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 66}, page_content='Kingdom of Bahrain for the presence or absence of the palmaris longus \\nmuscle using the conventional test for the presence of  this muscle. The \\npalmaris longus muscle was absent in 36.8% of subjects. Bilateral absence \\n(19%) was more common than unilateral absence (17.9%) with \\npreponderance in female subjects. The muscle was absent more often on \\nthe left side than the right (P=0.0 03). In the right upper limbs the muscle \\nwas absent in female subjects more than male subjects (P=0.031) (16).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 66}, page_content='Lahiji et al. study on Iranian people and repoted that, the prevalence of the \\nPLA was estimated to be 22.8%; 10.2% agenesis on the right side, 5. 9% \\non the left side, and 6.7% bilaterally PLA. The relationship between PLA \\nand gender did not appear to be significant. Among people with PLA 43% \\nand among people withour PLA 17% were left handed (17). \\nMost standard textbooks of hand surgery quote the pre valence of \\nthe absence of PL at around 15% among Caucasians. The prevalence of its'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 66}, page_content='agenesis has been variously reported  to be from 1.5% in black people to \\n64% in Turkish people (17). \\nAccording to a META analysis performed by 2013, their results \\ndemonstrated that the prevalence of PLA is the lowest among East Asians \\nand Africans, and particularly among the East and South East African \\npopulation (18).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 67}, page_content='59 \\nAlabbat A. et al; studied in 200 normal female students from King \\nFaisal University – Saudi Arabia and resulted that in female subjects; the \\noverall prevalence of absence both unilaterally and bilaterally is 40.5 %. \\nUnilateral absence was 20.5%. The bilateral absence was 20%. The \\ndistribution on the right and left was 29% and 31.5% respectively (5). \\nKikano et al, evaluated 335 Labanese patients including a total of \\n339 by using magnetic resonans imaging (MRI) scans. The Palmaris'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 67}, page_content='longus was present in 221 wrists (65.2%), and bilaterally in only one (25%) \\nout of the 4 bilateral cases. All palmaris longus were locate d using the \\nAxial T1 views. Univariate and multivariate analyses showed no \\ncorrelation with side, gender, or Tesla power. The only morphological \\nvariation was a reversed PL in 2 cases (0.6%). The mean width was 4.24 ± \\n1.2 mm. The mean thickness was 2.75 ± 0.6 mm (19). \\nThe PLM is located superficially, is easily accessible, and is fully'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 67}, page_content='developed at birth, making it one of the most frequently used donor \\nmaterial for tendon and joint reconstructive surgeries in all age groups. As \\nPLM is considered an accessory muscle, its tendon is often used as a graft \\nfor tendon transfer (18, 20) and in other reconstructive surgeries (21, 22). \\nAlso, It is well known that there is a wide variation in the reported \\nprevalence of the PL absence in different ethnic groups. The hi ghest'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 67}, page_content='reported prevalence of absence of the PL tendon is seen in the Turkish \\npopulation with an overall prevalence of absence of 63.9% (7, 23).  \\nConsidering its dispensability, surgeons agree that PL is the best \\nchoice for tendon grafts in tendon reconstru ction, helping the function of \\nparalyzed muscles used for repairing ptosis, treatment of facial paralysis, \\nand urinary incontinence. Plastic surgeons also utilize the PL in lip'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 67}, page_content='augmentation and restoration of lip and chin defects. As its absence is \\nimmaterial to the function of the wrist, PL has the greatest variation in the \\nhuman body and its most common variation is agenesis (PLA) (24). \\nHowever, this muscle variation can lead to median and/or ulnar nerve \\ncompression syndromes in some rare cases (25). \\nA retrospective review of patient charts undergoing endoscopic \\ncarpal tunnel release was performed by Boltuch et al (26). They considered'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 67}, page_content='the rates of palmaris longus agenesis (PLA) and compared to a population \\nmatched data  set by using Schaffers’s test. Study reported that; the \\nPalmaris longus was more prevalent in a population of patients undergoing \\ncarpal tunnel release. These findings can be used to provide further insight \\ninto the pathophysiology of carpal tunnel syndrome (26).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 68}, page_content='60 \\nCONCLUSION \\nIn conclusion, this study demonstrates absence of palmaris longus \\n(PL) muscle in Turkish students compatible with other population studies. \\n \\nACKNOWLEDGEMENTS \\nThe authors of this work wish to thank our mentor Prof. Dr. Samet \\nKAPAKİN a nd all the Students in college of Medicine, Atatürk and \\nErzincan Binali Yıldırım University for their help for collecting the sample \\nand doing the research. \\n \\nFigure 1: Dissected cadaveric forearm with present palmaris longus'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 68}, page_content='muscle (Pękala, P. A., Henry, B. M., Pękala, J. R., Skinningsrud, B., \\nWalocha, J. A., Bonczar, M., & Tomaszewski, K. A. (2017). Congenital \\nabsence of the palmaris longus muscle: A meta-analysis comparing \\ncadaveric and functional studies. Journal of Plastic, Reconstructive & \\nAesthetic Surgery, 70(12), 1715-1724.)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 69}, page_content='61 \\n \\nFigure 2: Schaffer test. (Thidar, A. M., Myint, T. T., Naing, D. K. S., & \\nMustapha, Z. A. (2013). Palmaris Longus Agenesis (PLA) among Dusun \\nand Bajau ethnic groups of Northern Borneo. International Journal of \\nCollaborative Research on Internal Medicine & Public Health, 5(6), 0-\\n0.) \\n \\nFigure 3: Thompson test. (Thidar, A. M., Myint, T. T., Naing, D. K. S., \\n& Mustapha, Z. A. (2013). Palmaris Longus Agenesis (PLA) among \\nDusun and Bajau ethnic groups of Northern Borneo. International'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 69}, page_content='Journal of Collaborative Research on Internal Medicine & Public \\nHealth, 5(6), 0-0.)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 70}, page_content='62 \\n \\nFigure 4: Mischa test. (Thidar, A. M., Myint, T. T., Naing, D. K. S., & \\nMustapha, Z. A. (2013). Palmaris Longus Agenesis (PLA) among Dusun \\nand Bajau ethnic groups of Northern Borneo. International Journal of \\nCollaborative Research on Internal Medicine & Public Health, 5(6), 0-\\n0.)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 71}, page_content='63 \\nREFERENCES \\n1. Pękala, P. A., Henry, B. M., Pękala, J. R., Skinningsrud, B., Walocha, J. \\nA., Bonczar, M., & Tomaszewski, K. A. (2017). Congenital \\nabsence of the palmaris longus muscle: A meta -analysis \\ncomparing cadaveric and functional studies.  Journal of Plastic, \\nReconstructive & Aesthetic Surgery, 70(12), 1715-1724. \\n2. Cooper DW, Burns B. Anatomy, Shoulder and Upper Limb, Hand \\nPalmaris Tendon. [Updated 2020 Sep 15]. In: StatPearls [Internet].'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 71}, page_content='Treasure Island (FL): StatPearls Publishing; 2020 Jan -. Available \\nfrom: https://www.ncbi.nlm.nih.gov/books/NBK519516/ \\n3. Georgiev GP, Iliev AA, Dimitrova IN, Kotov GN, Malinova LG, \\nLandzhov BV. Palmaris Longus Muscle Variations: Clinical \\nSignificance and Proposal of New Classifications.  Folia Med \\n(Plovdiv). 2017 Sep 01;59(3):289-297. [PubMed] \\n4. Cetin A, Genc M, Sevil S, Coban YK. Prevalence of the palmaris longus \\nmuscle and its relationship with grip and pinch strength: a study in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 71}, page_content='a Turkish pediatric population.  Hand (N Y).  2013 Jun;8(2):215 -\\n20. [PMC free article] [PubMed] \\n5. Alabbad, A., Alkhamis, M., Alsultan, M., & Alahmad, S. (2018). The \\nFrequency of Palmaris Longus Absence among Female Students \\nin King Faisal University in Al-Ahsa, Saudi Arabia. The Egyptian \\nJournal of Hospital Medicine, 70(11), 1959-1962. \\n6. Erić M, Koprivčić I, Vučinić N (2 011): Prevalence of the palmaris \\nlongus in relation to the hand dominance. Surgical and Radiologic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 71}, page_content='Anatomy, 33 (6):481–484.  \\n7. Kose, O., Adanir, O., Cirpar, M., Kurklu, M., & Komurcu, M. (2009). \\nThe prevalence of absence of the palmaris longus: a study in \\nTurkish population.  Archives of Orthopaedic and Trauma \\nSurgery, 129(5), 609. \\n8. Thidar, A. M., Myint, T. T., Naing, D. K. S., & Mustapha, Z. A. (2013). \\nPalmaris Longus Agenesis (PLA) among Dusun and Bajau ethnic \\ngroups of Northern Borneo.  International Journal of \\nCollaborative Research on Internal Medicine & Public'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 71}, page_content='Health, 5(6), 0-0. \\n9. Hiz, Ö., Ediz, L., Ceylan, M. F., Gezici, E., Gülcü, E., & Erden, M. \\n(2011). Prevalence of the absence of palmaris longus muscle \\nassessed by a new examination test (Hiz -Ediz Test) in the \\npopulation residing in the area of Van, Turkey. Journal of Clinical \\n& Experimental Investigations/Klinik ve Deneysel Arast irmalar \\nDergisi, 2(3).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 72}, page_content='64 \\n10. Roohi, S. A., Choon-Sian, L., Tan, G. H., Naicker, A. S., & Med Rehab, \\nM. (2007). A study on the absence of palmaris longus in a \\nmultiracial population. Malaysian Orthopaedic Journal, 1(1), 26-\\n28. \\n11. Saxena, S. (2013). A study o n the absence/presence of the muscle \\nPalmaris Longus in an Indian population.  International J of \\nHealthcare & Biomedical Research, 2(1), 48-53. \\n12. Venter, G., Van Schoor, A. N., & Bosman, M. C. (2014). Degenerative'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 72}, page_content='trends of the palmaris longus muscle in a South African \\npopulation. Clinical Anatomy, 27(2), 222-226. \\n13. Mbaka, G. O., & Ejiwunmi, A. B. (2009). Prevalence of palmaris \\nlongus absence –a study in the Yoruba population.  The Ulster \\nmedical journal, 78(2), 90. \\n14. Lewis -Beck, M., Bryman, A. E., & Li ao, T. F. (2003).  The Sage \\nencyclopedia of social science research methods . Sage \\nPublications. \\n15. Wehbé, M. A. (1992). Tendon graft donor sites.  Journal of Hand'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 72}, page_content='Surgery, 17(6), 1130-1132. \\n16. Sater, M. S.,  Dharap, A. S., & Abu‐Hijleh, M. F. (2010). The \\nprevalence of absence of the palmaris longus muscle in the \\nBahraini population. Clinical Anatomy, 23(8), 956-961. \\n17. Lahiji, F. A., Ashoori, K., & Dahmardehei, M. (2013). Prevalence of \\npalmaris longus agenesis in a hospital in Iran. Archives of Iranian \\nmedicine, 16(3), 187. \\n18. Yammine, K. (2013). Clinical prevalence of palmaris longus agenesis:'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 72}, page_content='A systematic review and meta‐analysis.  Clinical Anatomy, 26(6), \\n709-718. \\n19. Kikano, R., Charbel, C., Assi, C., & Yammine, K. (2020). Prevalence, \\nvariants, and morphometrics of Palmaris Longus tendon: a \\nmagnetic resonance imaging study.  Surgical and Radiologic \\nAnatomy, 1-5. \\n20. Raouf, H. A., Kader, G. A., Jaradat, A., Dharap, A., Fadel, R., & Salem, \\nA. H. (2013). Frequ ency of palmaris longus absence and its \\nassociation with other anatomical variations in the Egyptian'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 72}, page_content='population. Clinical Anatomy, 26(5), 572-577. \\n21. Agarwal, P. (2010). Absence of the palmaris longus tendon in Indian \\npopulation. Indian journal of orthopaedics, 44, 212-215.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 73}, page_content='65 \\n22. Ahn, D. S., Yoon, E. S., Koo, S. H., & Park, S. H. (2000). A prospective \\nstudy of the anatomic variations of the median nerve in the carpal \\ntunnel in Asians. Annals of plastic surgery, 44(3), 282-287. \\n23. Kurihara, K., Kojima, T., & Marumo, E. (1984). Frontalis suspension \\nfor blepharoptosis using palmaris longus tendon. Annals of plastic \\nsurgery, 13(4), 274-278. \\n24. Lam, D. S., Ng, J. S., Cheng, G. P., & Li, R. T. (1998). Autogenous'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 73}, page_content='palmaris longus tendon as frontalis suspension material for ptosis \\ncorrection in children.  American journal of \\nophthalmology, 126(1), 109-115. \\n25. Ceyhan, O., & Mavt, A. (1997). Distribution of agenesis of palmaris \\nlongus muscle in 12 to 18 years old age groups.  Indian journal of \\nmedical sciences, 51(5), 156-160. \\n26. Boltuch, A. D., Marcotte, M. A., Treat, C. M., & Marcotte, A. L. \\n(2020). The Palmaris Longus and Its Association with Carpal \\nTunnel Syndrome. Journal of Wrist Surgery.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 74}, page_content='66'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 75}, page_content='CHAPTER VI \\n \\nTARGETS FOR THE TREATMENT OF ERECTILE \\nDYSFUNCTION \\n \\nNadire Eser \\n(Asst. Prof. PhD), Kahramanmaraş Sütçü İmam University,  \\ne-mail: esernadire01@hotmail.com \\n                   0000-0003-1607-5114 \\n \\n1. INTRODUCTION \\n1.1. Epidemiology   \\nErectile dysfunction (ED) is defined as the inability to achieve or \\nmaintain a repetitive /permanent erection for any sexual activity. \\nWorldwide; it is a condition that depends on many factors, where more'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 75}, page_content='than 150 million men are affected, with 39% of men around the age of 40 \\nand 67% of men around the age of 70 1.  \\nThe most important point in terms of the definition is that the \\nerectile problem is not limited to one or more times, this problem must be \\nrepetitive or long -term to be diagnosed with erectile dysfunction. In \\naddition to the age factor, the presence of some chronic diseases (heart \\ndiseases, hypertension, diabetes, and depression), smoking, alcohol use,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 75}, page_content='stress, drug addiction, obesity, and some lifestyles also t rigger the \\nformation of this disorder. In fact, evidence has been shown that there is \\na close relationship between metabolic syndrome, cardiovascular disease \\nand ED 2. Erectile dysfunction can also be caused by psychogenic, \\norganic (vascular, neurogenic, hormonal, anatomical/struct ural), or a \\ncombination of the  organic and psychogenic state  3. Sexual dysfunction'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 75}, page_content='is the most emphasized subject in psychogenic/organic differentiation. It \\nrequires a multidisciplinary approach in both its differential diagnosis \\nand its treatment 4. \\nAlthough ED is a benign disease, this condition is associated \\nwith physical and psychosocial health and has a significant impact on the \\nquality of life of both affected individuals and their partners and families \\n5.  ED is an important problem that impairs the quality of life of men with \\nthis condition all over the world.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 76}, page_content='68 \\n2. NEUROPHYSIOLOGICAL AND MOLECULAR BASES \\nOF PENIS ERECTION \\nThree processes that work synergistically and simultaneously are \\nneeded for normal erectile function:  \\n1) Increased arterial blood flow through the neurogenic way, \\n2) Cavernosal smooth muscle relaxation, \\n3) The restriction of venous return flow.  \\nED occurs due to failure in any of these ways 6. Penis consists of \\n3 anatomical compartments 7. The corp us spongiosum supports and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 76}, page_content='protects the urethra along the ventral face of the penis. On the other \\nhand, located on the dorsal and consists of two adjacent parts the corpus \\ncavernosum, fills with blood at the time of erection and provides a penile \\nerection. The cavernosal compartment consists of a widespread network \\nof vascular sinuses fed by helical arteries. When the penis is flaccid, the \\nsmooth muscle cells supporting the vascular sinuses are tonically'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 76}, page_content='contracted, allowing for low blood circulation. In co ntrast, \\nneuromodulator release, which occurs in response to sexual stimulation \\nand consists of cavernosal nerve terminals and endothelium, causes \\nrelaxation of cavernosal smooth muscles and consequently penile \\nerection. \\nCentral regulation of erectile funct ion includes both spinal and \\nsupraspinal systems. Central supraspinal systems mainly; it is localized \\nin the limbic system (hippocampus, medial preoptic region, nucleus'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 76}, page_content='accumulate), hypothalamus and its nucleus (paraventricular and \\nventromedial nucleus) as well as the nucleus paragigantocellularis of the \\nreticular formation 8. While gamma -aminobutyric acid (GABA), opioid \\npeptides and serotonin reduce sexual responses, oxytocin, nitric oxide, \\nexcitatory amino acids, adrenocorticotropin (ACTH), and alpha -\\nmelanocyte-stimulating hormone (α-MSH) facilitates sexual responses 9.  \\nThe penis is innervated  by autonomic and somatic nerves. Other'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 76}, page_content='factors such as cholinergic nerves, nonadrenergic/noncholinergic nerves \\n(nitric oxide), Vaso -Intestinal Polypeptide (VIP) and Calcitonin Gene \\nRelated Peptide (CGRP) cause smooth muscle relaxation 6,10.  \\nApart from this, shear stress and muscarinic receptors located in \\nthe trabecular endothelium also stimulate nitric oxide production. Nitric \\noxide diffuses i nto smooth muscle cells and interacts with guanylate \\ncyclase to increase intracellular cGMP levels. Increasing cGMP levels'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 76}, page_content='also causes cellular processes that result in smooth muscle relaxation and \\nact through cGMP -dependent protein kinase and ion channels . This \\nmechanism causes the reduction of intracellular Ca +2 levels and the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 77}, page_content='69 \\nopening of Potassium ion channels that cause smooth muscle cell \\nhyperpolarization 11–13. \\nSimilarly; pathways mediated by VIP, CGRP, and Prostaglandin \\nalso cause smooth muscle cell relaxation by increasing intracellular \\ncAMP levels 14. \\nA feature that is very important in all these erection mechanisms \\nand must be remembered is the ion channels known as gap junctions and \\nlocated in the cavernosal smooth muscle cell membrane. Thanks to these'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 77}, page_content='channels that cause tight communication, syncytial relaxation and \\ncontraction can occur, which has a very important role in erectile \\nphysiology 13. \\nThe phosphodiesterase enzyme system is required for \\ndetumescence (reversal of erection): A series of biological events \\ndevelop in the arterial blood, which is filled and stuck in the cavernous \\nbodies, to return to the ve nous system and the penis to regain its flaccid \\nstate. First, the enzyme called \"phosphodiesterase 5\" in the cavernous'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 77}, page_content='structure c -GMP and possibly also enzymes called \"phosphodiesterase \\n2,3,4\" break down c -AMP into GMP and AMP, respectively. Cells in \\nhyperpolarized states are then depolarized, calcium channels open, and \\nmuscular filaments start to contract by interacting with each other as \\ncalcium enters the cell. Blood is pumped into the congested veins, and as \\nthe amount of blood in the cavernous body de creases, the pressure on the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 77}, page_content='veins stuck in the periphery decreases, and a normal venous return begins \\n15. \\nNitric oxide (NO) is a potent peripheral smooth muscle relaxant \\nacting through cyclic guanosine monophosphate (cGMP ). NO released \\nfrom nonadrenergic-noncholinergic nerve endings and endothelium is the \\nmain mediator that provides an erection. NO; It is synthesized from L -\\narginine by nitric oxide synthase (NOS) enzyme in many tissues in the \\nbody. NO synthase; endothelial  (eNOS), neuronal ( nNOS), and induced'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 77}, page_content='(iNOS), it is known that there are 3 isoforms. Mainly, eNOS and nNOS \\nplay a role in penile erection due to NO. NO is synthesized from the \\nendothelium (eNOS) in response to shear stress, from cholinergic nerves \\nas co -transmitter with acetylcholine, and nonadrenergic -noncholinergic \\n(NANK) nerve endings by nNOS, and it activates intracellular guanylate \\ncyclase by diffusing into smooth muscle cells 16. This causes the \\nconversion of GTP to cGMP. Thus, intracellular cGMP concentrations'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 77}, page_content='increase when there is NO stimulation. Increased cGMP concentr ations \\ncause cGMP -dependent protein kinase (PKG) activation and \\nconsequently smooth muscle relaxation. PKG; reduces intracellular Ca +2 \\nlevels by decreasing Ca +2 channel activity, causes smooth muscle cell'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 78}, page_content='70 \\nhyperpolarization by opening Ca +2 dependent K + channels, and also \\ncauses smooth muscle relaxation by providing membrane \\nhyperpolarization by inhibition of calcium sensitizing pathways such as \\nthe Rho-kinase pathway (Figure 1) 11,17. \\n \\nFigure 1: cGMP-mediated smooth muscle cell relaxation in \\ncorpora cavernosa17 \\nNO from nNOS in nitrergic nerves is responsible for most of \\nsmooth muscle relaxation and initiation of relaxation, while NO from'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 78}, page_content='eNOS has been shown to contribute to the maintenance of erection 18. It \\nhas been determined that the activity of nNOS in the penis is regulated \\nby androgens. In castrated rats, it has been shown that the erectile \\nresponse caused by cavernosal nerve stimulation and the nNOS activity \\nin the penis decrease, and these effects ca n be corrected by androgen \\nadministration 18. Molecular oxygen, along with L -arginine, is a \\nnecessary substance for NO synthesis. It has been shown that NO'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 78}, page_content='synthesis in the corpus cavernosum is directly regu lated by oxygen \\nconcentration19. \\n3. POTENTIAL GOALS FOR THE TREATMENT OF \\nERECTILE DYSFUNCTION \\n3.1. Targets Associated with NO-cGMP Pathway  \\n3.1.1. Increasing NO Production  \\nIn the treatment of erectile dysfunction, Tetra hydrobiopterin \\n(BH4), a NOS cofactor, is used as a potential therapeutic agent in the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 79}, page_content='71 \\ntreatment of erectile dysfunction 20. BH4 dysfunction or scarcity, which \\nis the most import ant factor in eNOS dependent NO release, causes \\neNOS dysfunction. This leads to the release of NO -mediated oxygen \\nradicals. Here, with the reaction of NO and free oxygen radicals, NO \\nlevels decrease and peroxynitrite is formed 20. In vitro and in vivo studies \\nhave demonstrated that there is a significant relationship between \\nErectile dysfunction and ROS (Reactive Oxygen Species) production,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 79}, page_content='especially in diabetic animal models 21,22. O , which is a ROS 2\\n-  it turns \\ninto peroxynitrite by reacting with NO. Peroxynitrite; it reacts wi th \\nlipids, proteins, nucleic acids and creates structural damage. They found \\nthat basal O 2\\n- levels increased in the tissue segments of the aging rat \\nmodel compared to the control 23. With the increased O 2\\n- concentration, \\nNO is destroyed and NO -dependent vasodilation is impaire d. Superoxide'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 79}, page_content='dismutase enzyme (SOD) preserves NO activity by preventing the \\nformation of peroxynitrite of ROS. It is known that arginase activity \\nincreases in ED due to age and diabetes 24. Decreased arginase activity in \\nthe penis has been shown to improve endothelial function and restore \\nerectile responses 24,25. Also, pretreatment of diabetic Corpus cavernosum \\nwith arginase (ABH) inhibitors has been shown to partially inhibit the \\ndisruption of NO -mediated corporal relaxation and the enhancement of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 79}, page_content='arginase activity. \\nAn extracellular signal -regulated kinase (ERK), known to \\nmediate cellular responses by growth factors, has  recently been shown to \\nplay a role in vascular reactivity and reduce eNOS activity 26,27. ERK \\ninhibition has b een shown to improve cavernosal relaxation in diabetic \\nmice 28. \\nAnother way to increase intracellular NO concentrations is by \\ninhibiting the endogenous NOS competitive inhibitor asymmetric \\ndimethylarginine (ADMA), the L-arginine analog 29.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 79}, page_content='Inhibition of increasing systemic levels of TNF -α, known to be \\npositively correlated with ED, significantly improves sexual function 30. \\n3.1.2. Increasing the cGMP Level \\n3.1.2.1. PDE-5 (Phosphodiesterase-5) Inhibitors \\nThe PDE5 enzyme has 2 subunits, catalytic, and regulatory. The \\ncatalytic dom ain is the target site for PDE5 inhibitors and contains the \\nbinding unit for cGMP. When the cGMP fills this area, the catalytic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 79}, page_content=\"mechanism located right next to this connection area comes to the closest \\nposition and catalyzes the 5'-GMP by breaking the cyclic phosphate bond \\nof the cGMP. When sildenafil or other PDE5 inhibitors also bind to the \\ncatalytic site, cGMP entry is blocked. These inhibitors, which show\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 80}, page_content='72 \\naffinity to the catalytic region, are competitively prevented from binding \\nof cGMP to reach the cat alytic mechanism. Thus, they inhibit cGMP \\ndegradation. However, PDE5 inhibitors cannot be destroyed by the \\ncatalytic mechanism 31. \\nAlthough the catalytic area is the direct target of PDE5 \\ninhibitors, some features of the regulatory region affect the inhibition \\ndeveloped on it. This area contains allosteric cGMP binding domains and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 80}, page_content='at the same time  phosphorylation sites for enzyme regulation.  Catalytic \\nwhen cGMP is attached to the allosteric domain  does not break down as \\nin the area and enzyme function  It is activated by the reaction that \\ndevelops as a result of binding. In this case binding of cGMP also acts as \\na stimulator for binding of PDE5 inhibitor  to the catalytic site.  In this \\nregard, when the cGMP level increases  in smooth muscle cells after the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 80}, page_content='patient intake silde nafil or other PDE5 inhibitors,  this stimulates t he \\nbinding of more  inhibitors to the catalytic site. In this way  PDE5 \\ninhibitors stimulate their own activity. In addition to binding of cGMP to \\nthe allosteric region Phosphorylation of  PDE5 by cGMP dependent \\nprotein kinase also affect  PDE5 inhibition 31. \\n3.1.2.2. NO Donors  \\nCurrently, r esearchers have focused on a new class of \\ncompounds whose biological and medical significance is recognized.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 80}, page_content='One of these agents is NCX 911, a derivative of sildenafil developed by \\nNixOx, which provides NO release. NCX 911 spontaneously releases \\nNO and increases intracellular cGMP level through PDE5 inhibition and \\nactivation of sGC in the absence of endogenous NO. NCX 911 is more \\npotent than sildenafil both in enhancing tissue relaxation with EFS and \\nreversing contraction in isolated human corpus cavernosum  strips. While \\nsildenafil has minimal effect on increasing tissue cGMP level in the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 80}, page_content='absence of endogenous NO, it increases cGMP level dependent on NCX \\n911 concentration 32. \\n3.1.2.1. Guanilyl Cyclase (sGC) Activity  \\nPrototype of NO -independent sGC activators, initially potent \\nplatelet aggregation  YC-1 known for its inhibitory effect 33. In \\nexperimental studies, it has been shown that YC -1 strengthens the \\nrelaxation phase created by transmural electrical field stimulation (EFS) \\nin the rat corpus cavernosum, reverses the contraction caused by'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 80}, page_content='noradrenaline in the isolated rabbit corpus cavernosum, and this effect is \\nparallel with the tissue cGMP level  34. After that, NO -independent sGC \\nactivators were developed that were more potent than YC -1 (BAY 41 -\\n2272, BAY 41 8543, BAY 58 -2667). Of these three molecules, BAY 41 -\\n2272 and BAY 41 8543 are affiliated to the heme group, and BAY 58 -'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 81}, page_content='73 \\n2667 exerts its effects independently from the heme group. Both \\ndependent sGC activators act synergistically with NO. Therefore, \\nquinoxaline derivative is sensitive to inhibition by sGC inhibitors such as \\nODQ (1H - [1,2,4] oxadiazole [4,3, -a] quinoxaline -1). The efficacy of \\nonly BAY 41 -2272 in erectile tissue has been investigated till this day, \\nand it has been shown to induce relaxation in human and mouse c orpus \\ncavernosum samples contracted with phenylephrine. BAY 41 -2272 was'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 81}, page_content='found to be 32 times more potent than YC -1 and 2 times more than the \\nNO donor. Intravenous and oral administration of the compound \\nproduced weak erections in rabbits, but it was observ ed that the efficacy \\nof BAY 41-2272 was potentiated when administered simultaneously with \\nNO. 35,36. \\n3.1.2.3. Natriuretic Peptides \\nAnother target that inducing penile erection by stimulating \\ncGMP production is the particulate guanylyl cyclase (pGC). PGC'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 81}, page_content='activation by natriuretic peptides enables relaxation of the penile tissue \\nand thus, erection 37.  \\n3.1.2.4. Carbon monoxide (CO) a nd heme -oxygenase (HO) \\ninducers \\nLimited number of studies  shows that CO releasing molecules \\n(CORMs) can be useful in the treatment of ED, and correcting the HO \\nactivity in diabetes-related ED, can improve erectile function 38,39. \\n3.2. Independent Goals from the NO-cGMP Pathway \\n3.2.1. Adenylate Cyclase (AC) -cAMP Pathway'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 81}, page_content='3.2.1. Adenylate Cyclase (AC) -cAMP Pathway \\nActivation of the AC -cAMP pathway is k nown to be beneficial \\nin the treatment of the ED 40. PGE1 (Prostaglandin E1) or PGE 1 is using \\nphosphodiesterase in hibitors specific to mimetic -induced AC activation, \\nsmooth muscle relaxation and penile erection can be induced to increase \\ncAMP pathway activity and cAMP levels 40. PGE1 the use of Alprostadil, \\nits analogue, is known to be useful in the treatment of ED 41.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 81}, page_content='It is thought that the vasointestinal polypeptide (VIP) and its \\nreceptors, which relax corporal tissues through the cAMP signaling \\npathway, may represent the therapeutic target 42,43. \\n3.2.1. Hydrogen sulfide (H2S) Pathway \\nH2S, which plays a role in the control of vascular homeostasis, is \\nseen as a promising target for the development of new therapeutics for \\nED, as it not only promotes corporal dilatation but also allev iates penile \\nfibrosis 44,45.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 82}, page_content='74 \\n3.3. Targets associated with vasoconstriction \\n3.3.1. RhoA/Rho-Kinase Inhibitors \\nMost of the time, smooth muscle cells in the erectile tissue are in \\na contraction and the blood flow into the cavernous sinu ses is minimal. \\nMany studies have reported that RhoA/Rho -kinase-mediated \\nvasoconstriction may be the primary mechanism responsible for penile \\nsmooth muscles to maintain this contracted state 46,47. RhoA/Rho-kinase'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 82}, page_content='actively increases intracellular calcium (Ca 2+) plays a role i n maintaining \\npenile flaccid state as it increases the noradrenergic tone regardless of its \\nconcentration 48. Although there is sufficient conceptual information to \\nsupport the importance of intracellular calcium in the regulation of \\nvascular tone in the penile structure, Ca 2+ sensitization has been recently \\ninvestigated. RhoA is a small protein that binds with the GTP and is'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 82}, page_content='involved in many cellular events such as smooth muscle contraction, cell \\nroof, and morphology and secretion 49. RhoA is inactive when bound to \\nGDP, but with heterotrimeric G protein a ctivation, it is activated by the \\nconversion of GDP to GTP and migrates to the cell membrane. Rho A \\nactivation process is regulated by 3 groups of proteins: \\n1) GDI (guanine nucleotide dissociation inhibitor) inhibits RhoA \\nactivation,  \\n2) GEF (guanine nucle otide exchange factor) regulates the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 82}, page_content='conversion of GDP to GTP, \\n3) GAP (GTPase associated protein) inhibits RhoA activity with \\nintrinsic GTPase activity. \\nTheoretically, factors that stop RhoA activation by affecting the \\nactivity of these proteins will preve nt smooth muscle contraction and \\nallow relaxation. Activated RhoA targets Rho -kinase in penile smooth \\nmuscle. It catalyzes the phosphorylation of MLC phosphatase enzyme, \\nwhich inhibits Rho -kinase enzyme activity. When MLC (myocyte light'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 82}, page_content='chain) phosphotase activity is weak, the MLC predominantly remains in \\nphosphorylated form and smooth muscle contraction  is continued. The \\ninterruption of this process, in which RhoA activates Rho -kinase, leads \\nto the reversal of the flat contraction and the formation of rela xation 49. \\nY-27632, a pyridine derivative, is a selective Rho-kinase inhibitor 50.  \\n3.3.2. Angiotensin receptors \\nIncreased Ang-II activity may contribute to the development of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 82}, page_content='ED by increasing harmful effects such as vasoconstriction, proliferation, \\nfibrosis and oxidative stress 51, in this context, angiotens in converting \\nenzyme inhibitors (ACEIs) and angiotensin r eceptor blockers (ARB; \\nAng-II /AT1) have been shown to have beneficial effe cts on erection in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 83}, page_content='75 \\nrecent years  52. The  view that drugs such as ACEI/ ARBs such as \\ntelmisartan, ramipril, captopril and losartan should reduce these harmful \\neffects and be seen as treatment targets for ED 53–55. \\n3.3.3. Endothelin and Adrenergic receptors \\nDownregulation of ETA receptor expression or activity of \\nEndothelin (ET-1) synthesized by the vascular endothelium in the penis \\nis potentially effective in alleviating ED 26. Studies with drugs such as'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 83}, page_content='tamsulosin, doxazosin, and alfuzosin have shown that α -adrenergic \\nblockade is effective in the ED treatment  56. \\n3.3.4. Transient receptor potential (TRP) channels and Store \\noperated calcium entry \\nIntracellular Ca 2+ is playing an important role in modulating \\nlevels of TRP channels (TRPC6) are see n as a new molecular target for \\nED therapy 57. Recently, transfer of dominant negative genes for 2 \\nproteins, named OR AI1 and STIM1 identified in cavernous smooth'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 83}, page_content='muscle cells has been shown to restore erectile function in diabetic rats \\nand is seen as a new treatment target for ED 58. \\n3.4. Anti-inflammatory and anti-fibrotic treatment targets \\nThis pathway is directed towards the pre vention of collagen \\naccumulation and smooth muscle cell loss in CC  59. Upregulation of the \\nTGF-β1/Smad pathway by inducing fibrous-muscle structural changes 60; \\ninhibition of Poly (adenosine diphosphate ribose) polymerase (PARP),'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 83}, page_content='which is important for DNA re pair, by increasing NO -mediated \\nrelaxation 61; by suppressing IL -6, a pleiotropic cytokine 62. It has been \\nshown to improve erectile function. \\n3.5. Centrally acting drug targets \\nPositive results have been developed in cli nical trials with \\ncentrally acting drugs such as dopamine receptor agonists and \\nmelanocortin receptor agonists. Apomorphine, a centrally -acting non -\\nopioid dopaminergic agonist, induces penile vascular and corporal'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 83}, page_content='smooth muscle relaxation, through the acti vation of the receptors D1 and \\nD2 in the MPOA (Medial Preoptic area) and PVN  (Paraventricular \\nnucleus of  hypothalamus) regions, which maintain the activation of \\ncentral neurogenic pathways in erection 63. \\nMelanocortins such as m elanocyte-stimulating hormone ( MSH) \\nand adrenocorticotropic hormone (ACTH) are involved in important \\nhomeostatic mechanisms controlled by the hypothalamus as well as'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 83}, page_content='sexual functions such as penile erection and sexual motivation 63. \\nMelanocortins act on dopaminergic neurons located in the pro -erectile'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 84}, page_content='76 \\ncenters of the hypothalamus, causing central and spinal oxytocin release. \\nThey show their effects by binding with the MC1 -R to MC5-R receptors. \\nThese receptors have been ide ntified in the skin, gastrointestinal tract, \\nmale and female reproductive system, adrenal cortex, and brain 64,65. \\nEspecially expressed in peripheral tissues, MC5 -R provides the \\nrelationship between central and peripheral control of sexual behavior 64.  \\n3.6. Alternative therapy goals'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 84}, page_content='3.6. Alternative therapy goals \\n3.6.1 Herbs, Toxins and Polyphenols \\nIn recent years, complementary and alternative medicine has \\nbecome increasingly popular and has been used as herbal supplements \\nfor ED. These plants and the  properties of active components in their \\ncontent 66–68 and there are preclinical studies that reveal their mechanisms \\nof action and significant efficacyies are promising 69–71. The mechanism \\nof action of some herbs has been demonstrated by its stimulatory effect'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 84}, page_content='on the NO -cGMP signa ling pathway  71, some aphrodisiac 72 increase \\nfertility and sexual function 73. It has been shown to have such effects.   \\nIt shows that Tx2 -6, a toxin purified from the venom of the P. \\nnigriventer spider, induces erection, by activating the nNOS of the \\nPnTx2-6 toxin, increasing NO production and improving vascular \\nsmooth muscle relaxation that animal v enoms can be potential drugs in \\nED treatment 74,75. \\nThere is some evidence that polyphenols, which have been'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 84}, page_content='shown to be effective in erectile dysfunction, do this by acting as \\nantioxidants that improve the NO/ cGMP p athway and stimulate \\nangiogenesis. Resveratrol, a polyphenol found in red wine, is reported to \\nincrease cGMP in corporal smooth muscle cells, activate eNOS, thereby \\nimproving endothelial function 76. On the other hand, Quercetin is \\nbeneficial on the corpus cavernosum with its anti -inflammatory, anti -\\napoptotic and antioxidant effects 77. \\n3.7. Regenerative medical'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 84}, page_content='3.7. Regenerative medical \\nRegenerative medical especially in the last few decades has \\nincreased in importance, and preclinical trials have shown that growth \\nfactor therapy, gene transfer, stem cell therapy, and tissue engineering \\ncan be beneficial for the restoration of erectile function 78–81.  \\nAlthough human growth hormone (GH) is not considered as the \\nclassic sex hormone, it is involved in the regulation of male reproductive'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 84}, page_content='functions and sexual maturation.  GH has physiological significance not \\nonly in LH and FSH secretion but also in early testosterone stimulation \\n82. It is assumed that the biological effect of growth hormo ne is through \\nthe stimulation of endothelial NO formation mediated by \"insulin -like'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 85}, page_content='77 \\ngrowth factor (IGF -1)\". These data indicate the importance of growth \\nhormone in maintaining erectile capacity 83. Beneficial effect of IGF -1 in \\nendothelial damage caused by spinal cord injury 84 has been shown that \\ntreatment with recombinant GH creates a dose -dependent relaxation on \\nthe erectile tissue and this effect is parallel to the tissue cGMP level 83. \\nGene Transplant Methods:  One of the most im portant conditions'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 85}, page_content='of successful gene therapy is that the genetic material (RNA or DNA) to \\nbe transferred is transported with the appropriate vector or vehicle that \\nwill provide the most effective treatment. Some vectors used to date can \\nbe listed as: nonv iral vectors (naked DNA, plasmid DNA, and \\nliposomes), adenoviruses, adeno-associated viruses, and retroviruses. All \\nof these vectors have specific efficacy and side effects inside the host \\ncell. An ideal vector should be capable of providing efficient'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 85}, page_content='transduction and long -term gene expression with little or no side effects \\nsuch as infection, immunological reaction, and host cell mutation 79.  \\nFirst of all, it is necessary to consider whether gene therapy is a \\nviable treatment method in the treatment of erectile dysfunction. Gene \\ntherapy was initially recommended as an appropr iate treatment option in \\nthe treatment of cardiovascular diseases, and vascular pathologies being'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 85}, page_content='one of the most important causes of the etiology of ED, suggesting that \\nthe same method can be used in ED treatment 80. Preclinical studies in \\nrecent years show that gene transfer has corrective effects on ED 79,80. \\nDue to the structural characteristics of the cardiovascular system, there is \\na drawback in the treatment of diseases in this system: gene therapy can \\neasily reach beyo nd the targeted area. On the other hand, a similar'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 85}, page_content='drawback in ED treatment can be minimized. With a simple tourniquet to \\nbe applied to the root of the penis, the possible systemic effect that may \\noccur after gene injection can be minimized. Another proble m with gene \\ntherapy is that most of the targeted cells need to be transfected in order to \\nachieve therapeutic efficacy. On the other hand, transfecting only a \\ncertain group of cells in the penis is sufficient to provide therapeutic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 85}, page_content='effect. As is known, the re is an interconnection network provided by gap \\njunctions between corpus cavernosum smooth muscle cells. The \\ntherapeutic effect achieved after gene transplantation in a particular cell, \\nthanks to these connections, can spread throughout the penis as if al l \\ncells were transfected 79. Human large conductance, voltage dependent  \\nCa2+ Clinical trials using naked DNA gene therapy with a plasmid (hSlo)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 85}, page_content='expressing the sensitive K channel (hMaxi -K channel) represent the only \\ngene therapy to be evaluated in phase 1 clinical trials to date 85–87  \\nTissue engineering aims to reconstruct the penile tissue. \\nSuccessful monocultures of cavernous endothelial and smooth muscle \\ncells have been reported in recent years. 88.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 86}, page_content='78 \\n4. OTHER GOALS \\nThere are studies showing that physical exercise also contributes \\nto ED treatment as a non -therapeutic approach. Corpus Cavernosum \\nrelaxation in hypertensive rats induced by NO blockade 89 and has been \\nshown to exert anti -inflammatory effects on the hypothalamus and \\ntesticles, increase LH levels, and sup port the primary role of lifestyle \\nmodification in hypogonadism and erectile dysfunction 90. \\n5. CONCLUSION'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 86}, page_content='5. CONCLUSION \\nAs a result, the increasing c oncentration of biochemical, genetic, \\nphysiological, pharmacological and histological research on the erectile \\ndysfunction at the molecular and tissue level will enable a better \\nunderstanding of erectile function mechanism, and the formation of new \\ntreatment targets and clinical treatment protocols in the treatment of ED.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 87}, page_content='79 \\nREFERENCES \\n1.  Mesquita JFP, Ramos TF, Mesquita FP, Netto JMB, Bastos MG, de \\nFigueiredo AA. Prevalence of erectile dysfunction in chronic \\nrenal disease patients on conservative treatment. Clinics. \\n2012;67(2):181-183. doi:10.6061/clinics/2012(02)15 \\n2.  Müller A, Mulhall JP. Cardiovascular disease, metabolic syndrome \\nand erectile dysfunction. Current Opinion in Urology . \\n2006;16(6):435-443. doi:10.1097/01.mou.0000250284.83108.a6'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 87}, page_content='3.  Shamloul R, Ghanem H. Erectile dysfunction. The Lancet . \\n2013;381(9861):153-165. doi:10.1016/S0140-6736(12)60520-0 \\n4.  Perelman MA. Psychosocial evaluation and combination treatment \\nof men with erectile dysfun ction. Urologic Clinics of North \\nAmerica. 2005;32(4):431-445. doi:10.1016/j.ucl.2005.08.010 \\n5.  Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay \\nJB. Impotence and its medical and psychosocial correlates: \\nResults of the Massachusetts Male Aging  Study. Journal of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 87}, page_content='Urology. 1994;151(1):54 -61. doi:10.1016/S0022 -5347(17)34871-\\n1 \\n6.  Lue TF. Erectile Dysfunction. Wood AJJ, ed. New England Journal \\nof Medicine . 2000;342(24):1802 -1813. \\ndoi:10.1056/NEJM200006153422407 \\n7.  Yiee JH, Baskin LS. Penile Embryol ogy and Anatomy. \\nTheScientificWorldJOURNAL. 2010;10:1174 -1179. \\ndoi:10.1100/tsw.2010.112 \\n8.  Giuliano F, Rampin O. Neural control of erection. Physiology and \\nBehavior. 2004;83(2):189 -201. \\ndoi:10.1016/j.physbeh.2004.08.014'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 87}, page_content='doi:10.1016/j.physbeh.2004.08.014 \\n9.  PRIVIERO FBM, LEITE R, WEBB RC,  TEIXEIRA CE. \\nNeurophysiological basis of penile erection. Acta \\nPharmacologica Sinica. 2007;28(6):751-755. doi:10.1111/j.1745-\\n7254.2007.00584.x \\n10.  Stief CG, Noack T, Andersson KE. Signal transduction in cavernous \\nsmooth muscle. World Journal of Urology . 1997;15(1):27-31. \\ndoi:10.1007/BF01275153 \\n11.  Burnett AL, Lowenstein CJ, Bredt DS, Chang TSK, Snyder SH.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 87}, page_content='Nitric oxide: A physiologic mediator of penile erection. Science. \\n1992;257(5068):401-403. doi:10.1126/science.1378650 \\n12.  Rajfer J, Aronson WJ, Bush P A, Dorey FJ, Ignarro LJ. Nitric Oxide'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 88}, page_content='80 \\nas a Mediator of Relaxation of the Corpus Cavernosum in \\nResponse to Nonadrenergic, Noncholinergic Neurotransmission. \\nNew England Journal of Medicine . 1992;326(2):90 -94. \\ndoi:10.1056/nejm199201093260203 \\n13.  Christ GJ. T he “syncytial tissue triad”: A model for understanding \\nhow gap junctions participate in the local control of penile \\nerection. World Journal of Urology . 1997;15(1):36 -44. \\ndoi:10.1007/BF01275155 \\n14.  Bivalacqua TJ, Champion HC, Rajasekaran M, et al. Potentia tion of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 88}, page_content='erectile response and camp accumulation by combınatıon of \\nprostaglandin e 1 and rolipram, a selectıve inhibitor of the type 4 \\nphosphodiesterase (PDE 4). Journal of Urology . \\n1999;162(5):1848-1855. doi:10.1016/S0022-5347(05)68249-3 \\n15.  Lin CS, Lin G , Lue TF. Cyclic nucleotide signaling in cavernous \\nsmooth muscle. Journal of Sexual Medicine . 2005;2(4):478 -491. \\ndoi:10.1111/j.1743-6109.2005.00080.x \\n16.  Nathan C, Xie Q wen. Nitric oxide synthases: Roles, tolls, and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 88}, page_content='controls. Cell. 1994;78(6):915 -918. do i:10.1016/0092-\\n8674(94)90266-6 \\n17.  Morelli A, Filippi S, Vignozzi L, Mancina R, Maggi M. Physiology \\nof Erectile Function: An Update on Intracellular Molecular \\nProcesses{A figure is presented}. EAU-EBU Update Series . \\n2006;4(3-4):96-108. doi:10.1016/j.eeus.2006.03.003 \\n18.  Burnett AL, Tillman SL, Chang TSK, et al. Immunohistochemical \\nlocalization of nitric oxide synthase in the autonomic innervation'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 88}, page_content='of the human penis. Journal of Urology . 1993;150(1):73 -76. \\ndoi:10.1016/S0022-5347(17)35401-0 \\n19.  Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, De Tejada \\nIS. Oxygen tension regulates the nitric oxide pathway. \\nPhysiological role in penile erection. Journal of Clinical \\nInvestigation. 1993;91(2):437-442. doi:10.1172/JCI116220 \\n20.  Sommer F, Klotz T, Steinritz  D, Bloch W. Evaluation of \\ntetrahydrobiopterin (BH4) as a potential therapeutic agent to treat'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 88}, page_content='erectile dysfunction. Asian Journal of Andrology . 2006;8(2):159-\\n167. doi:10.1111/j.1745-7262.2006.00122.x \\n21.  Deng W, Bivalacqua TJ, Champion HC, Hellstrom WJ, Murthy SN, \\nKadowitz PJ. Superoxide dismutase - a target for gene therapeutic \\napproach to reduce oxidative stress in erectile dysfunction. \\nMethods in molecular biology (Clifton, NJ) . 2010;610:213 -227.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 89}, page_content='81 \\ndoi:10.1007/978-1-60327-029-8_13 \\n22.  Long T, Liu G, Wan g Y, Chen Y, Zhang Y, Qin D. TNF -α, Erectile \\nDysfunction, and NADPH Oxidase -Mediated ROS Generation in \\nCorpus Cavernosum in High -Fat Diet/Streptozotocin -Induced \\nDiabetic Rats. Journal of Sexual Medicine . 2012;9(7):1801-1814. \\ndoi:10.1111/j.1743-6109.2012.02739.x \\n23.  Bivalacqua TJ, Armstrong JS, Biggerstaff J, et al. Gene transfer of \\nextracellular SOD to the penis reduces O2 -· and improves erectile'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 89}, page_content='function in aged rats. American Journal of Physiology - Heart \\nand Circulatory Physiology . 2003;284(4 53 -4). \\ndoi:10.1152/ajpheart.00770.2002 \\n24.  Segal R, Hannan JL, Liu X, et al. Chronic Oral Administration of \\nthe Arginase Inhibitor 2(S) -amino-6-boronohexanoic Acid (ABH) \\nImproves Erectile Function in Aged Rats. Journal of Andrology . \\n2012;33(6):1169-1175. doi:10.2164/jandrol.111.015834 \\n25.  Toque HA, Tostes RC, Yao L, et al. Arginase II deletion increases'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 89}, page_content='corpora cavernosa relaxation in diabetic mice. Journal of Sexual \\nMedicine. 2011;8(3):722 -733. doi:10.1111/j.1743 -\\n6109.2010.02098.x \\n26.  Carneiro FS, Nunes KP, Giach ini FRC, et al. Activation of the ET -\\n1/ETA pathway contributes to erectile dysfunction associated \\nwith mineralocorticoid hypertension. Journal of Sexual Medicine . \\n2008;5(12):2793-2807. doi:10.1111/j.1743-6109.2008.01009.x \\n27.  Sommer F, Klotz T, Steinritz D, et al. MAP kinase 1/2 (Erk 1/2) and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 89}, page_content='serine/threonine specific protein kinase Akt/PKB expression and \\nactivity in the human corpus cavernosum. International Journal \\nof Impotence Research . 2002;14(4):217 -225. \\ndoi:10.1038/sj.ijir.3900856 \\n28.  Nunes KP, Toqu e HA, Caldwell RB, Caldwell RW, Webb RC. \\nExtracellular Signal -Regulated Kinase (ERK) Inhibition \\nDecreases Arginase Activity and Improves Corpora Cavernosal \\nRelaxation in Streptozotocin (STZ) -Induced Diabetic Mice. \\nJournal of Sexual Medicine . 2011;8(12):333 5-3344.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 89}, page_content='doi:10.1111/j.1743-6109.2011.02499.x \\n29.  Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine \\ndimethylaminohydrolase (DDAH): Expression, regulation, and \\nfunction in the cardiovascular and renal systems. American \\nJournal of Physiology - Heart and  Circulatory Physiology . \\n2007;293(6):3227-3245. doi:10.1152/ajpheart.00998.2007'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 90}, page_content='82 \\n30.  Oh JS, Heo HM, Kim YG, Lee SG, Lee CK, Yoo B. The effect of \\nanti-tumor necrosis factor agents on sexual dysfunction in male \\npatients with ankylosing spondylitis: A pilot s tudy. International \\nJournal of Impotence Research . 2009;21(6):372 -375. \\ndoi:10.1038/ijir.2009.44 \\n31.  Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: From angina \\nto erectile dysfunction to pulmonary hypertension and beyond. \\nNature Reviews Drug Discovery . 2006;5(8):689 -702. \\ndoi:10.1038/nrd2030'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 90}, page_content='doi:10.1038/nrd2030 \\n32.  Seidler M, Ückert S, Waldkirch E, et al. In vitro effects of a novel \\nclass of nitric oxide (NO) donating compounds on isolated human \\nerectile tissue. European Urology . 2002;42(5):523 -528. \\ndoi:10.1016/S0302-2838(02)00397-4 \\n33.  Friebe A, Müllershausen F, Smolenski A, Walter U, Schultz G, \\nKoesling D. YC-1 potentiates nitric oxide - and carbon monoxide-\\ninduced cyclic GMP effects in human platelets. Molecular'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 90}, page_content='Pharmacology. 1998;54(6):962-967. doi:10.1124/mol.54.6.962 \\n34.  Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson K -E. \\nNitric Oxide Independent Activation of Guanylate Cyclase by \\nYC-1 Causes Erectile Responses in the Rat. Journal of Urology . \\n2002;167(5):2276-2281. doi:10.1016/S0022-5347(05)65142-7 \\n35.  Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41 -\\n2272: A stimulator of soluble guanylyl cyclase induces nitric \\noxide-dependent penile erection in vivo. Urology.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 90}, page_content='2003;61(2):464-467. doi:10.1016/S0090-4295(02)02121-0 \\n36.  Stasch JP, Alonso -Alija C, Apeler H, et al. Pharmacological actions \\nof a novel NO-independent guanylyl cyclase stimulator, BAY 41 -\\n8543: In vitro studies. British Journal of Pharmacology . \\n2002;135(2):333-343. doi:10.1038/sj.bjp.0704484 \\n37.  Fonteles MC, do Nascimento NRF. Guanylin pe ptide family: \\nHistory, interactions with ANP, and new pharmacological \\nperspectives. Canadian Journal of Physiology and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 90}, page_content='perspectives. Canadian Journal of Physiology and \\nPharmacology. 2011;89(8):575-585. doi:10.1139/y11-050 \\n38.  Abdel Aziz MT, El Asmer MF, Mostafa T, et al. Effects of \\nLosartan, HO-1 Inducers or HO -1 inhibitors on erectile signaling \\nin diabetic rats. Journal of Sexual Medicine . 2009;6(12):3254 -\\n3264. doi:10.1111/j.1743-6109.2009.01517.x \\n39.  Abdel Aziz MT, El-asmar MF, Mostafa T, et al. Effect of hemin and \\ncarbon monoxide releasing molecule ( CORM-3) on cGMP in rat'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 91}, page_content='83 \\npenile tissue. Journal of Sexual Medicine . 2008;5(2):336 -343. \\ndoi:10.1111/j.1743-6109.2007.00695.x \\n40.  Hurt KJ, Sezen SF, Lagoda GF, et al. Cyclic AMP -dependent \\nphosphorylation of neuronal nitric oxide synthase mediates penile \\nerection. Proceedings of the National Academy of Sciences of the \\nUnited States of America . 2012;109(41):16624 -16629. \\ndoi:10.1073/pnas.1213790109 \\n41.  Costa P, Potempa AJ. Intraurethral alprostadil for erectile'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 91}, page_content='dysfunction: A review of the literature. Drugs. 2012;72(17):2243-\\n2254. doi:10.2165/11641380-000000000-00000 \\n42.  Decaluwé K, Pauwels B, Verpoest S, Van de Voorde J. New \\nTherapeutic Targets for the Treatment of Erectile Dysfunction. \\nJournal of Sexual Medicine . 2011;8(12):3271 -3290. \\ndoi:10.1111/j.1743-6109.2011.02459.x \\n43.  Burian B, Ortner A, Prassl R, Zimmer A, Mosgoeller W. Clinical \\nPotential of VIP by Modified Pharmaco -kinetics and Delivery'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 91}, page_content='Mechanisms. Endocrine, Metabolic & Immune Disorders -Drug \\nTargets. 2012;12(4):344-350. doi:10.2174/187153012803832594 \\n44.  Shukla N, Rossoni G, Hotston M, et al. Effect of hydrogen sulphide -\\ndonating sildenafil (ACS6) on erectile function and oxidative \\nstress in rabbit isolated corpus cavernosum and in hypertensive \\nrats. BJU International . 2009;103(11):1522 -1529. \\ndoi:10.1111/j.1464-410X.2009.08415.x \\n45.  Meng J, Adaikan PG, Srilatha B. Hydrogen sulfide promotes nitric'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 91}, page_content='oxide production in corpus cavernosum by enhancing expression \\nof endothelial nitric oxide synthase. International Journal of \\nImpotence Research. 2013;25(3):86-90. doi:10.1038/ijir.2012.39 \\n46.  Gur S, Kadowitz PJ, Hellstrom WJG. RhoA/Rho -Kinase as a \\ntherapeutic target for the male urogenital tract. Journal of Sexual \\nMedicine. 2011;8(3):675 -687. doi:10.1111/j.1743 -\\n6109.2010.02084.x \\n47.  Jiang X, Chitaley K. The promise of inhibition of smooth muscle'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 91}, page_content='tone as a treatment for erectile dysfunction: Where are we now. \\nInternational Journal of Impotence Research . 2012;24(2):49 -60. \\ndoi:10.1038/ijir.2011.49 \\n48.  Jin L, Burnett AL. RhoA/Rho -kinase in erectile tissue: Mecha nisms \\nof disease and therapeutic insights. Clinical Science . \\n2006;110(2):153-165. doi:10.1042/CS20050255 \\n49.  Zewdie KA, Ayza MA, Tesfaye BA, Wondafrash DZ, Berhe DF. A'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 92}, page_content='84 \\nsystematic review on rho -kinase as a potential therapeutic target \\nfor the treatment of erectile dysfunction. Research and Reports in \\nUrology. 2020;12:261-272. doi:10.2147/RRU.S255743 \\n50.  Uvin P, Albersen M, Bollen I, et al. Additive effects of the Rho \\nkinase inhibitor Y -27632 and vardenafil on relaxation of the \\ncorpus cavernosum tissue of p atients with erectile dysfunction \\nand clinical phosphodiesterase type 5 inhibitor failure. BJU'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 92}, page_content='International. 2017;119(2):325-332. doi:10.1111/bju.13691 \\n51.  Jin LM. Angiotensin II signaling and its implication in erectile \\ndysfunction. In: Journal of Sexua l Medicine . Vol 6. Blackwell \\nPublishing Ltd; 2009:302 -310. doi:10.1111/j.1743 -\\n6109.2008.01188.x \\n52.  Fraga-Silva RA, Montecucco F, Mach F, Santos RAS, Stergiopulos \\nN. Pathophysiological role of the renin -angiotensin system on \\nerectile dysfunction. European Journal of Clinical Investigation .'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 92}, page_content='2013;43(9):978-985. doi:10.1111/eci.12117 \\n53.  Schlimmer N, Kratz M, Böhm M, Baumhäkel M. Telmisartan, \\nramipril and their combination improve endothelial function in \\ndifferent tissues in a murine model of cholesterol -induced \\natherosclerosis. British Journal of Pharmacology . \\n2011;163(4):804-814. doi:10.1111/j.1476-5381.2011.01267.x \\n54.  Kilarkaje N, Yousif MHM, El -Hashim AZ, Makki B, Akhtar S, \\nBenter IF. Role of angiotensin II and angiotensin -(1-7) in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 92}, page_content='diabetes-induced oxid ative DNA damage in the corpus \\ncavernosum. Fertility and Sterility . 2013;100(1):226 -233. \\ndoi:10.1016/j.fertnstert.2013.02.046 \\n55.  Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction \\nin diabetic patients: A clinical trial. International Jou rnal of \\nImpotence Research. 2012;24(6):217-220. doi:10.1038/ijir.2012.4 \\n56.  Jo HW, Yoo DS, Ju HT, et al. Effect of Patient -Optimized Doses of \\nTamsulosin on Erectile Function in Men With Erectile'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 92}, page_content='Dysfunction and Lower Urinary Tract Symptoms. Korean Journal \\nof Urology. 2013;54(2):100. doi:10.4111/kju.2013.54.2.100 \\n57.  Jung JH, Kim BJ, Chae MR, et al. Gene transfer of TRPC6DN \\n(Dominant negative) restores erectile function in diabetic rats. \\nJournal of Sexual Medicine . 2010;7(3):1126 -1138. \\ndoi:10.1111/j.1743-6109.2009.01634.x \\n58.  Sung HH, Kam SC, Lee JH, et al. Molecular and functional \\ncharacterization of ORAI and STIM in human corporeal smooth'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 93}, page_content='85 \\nmuscle cells and effects of the transfer of their dominant -negative \\nmutant genes into diabetic rats. Journal of Urolo gy. \\n2012;187(5):1903-1910. doi:10.1016/j.juro.2011.12.051 \\n59.  El-Sakka AI, Yassin AA. Amelioration of Penile Fibrosis: Myth or \\nReality. Journal of Andrology . 2010;31(4):324 -335. \\ndoi:10.2164/jandrol.109.008730 \\n60.  Zhou F, Li G -Y, Gao Z -Z, et al. The TGF - 1/Smad/CTGF Pathway \\nand Corpus Cavernosum Fibrous -Muscular Alterations in Rats'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 93}, page_content='With Streptozotocin -Induced Diabetes. Journal of Andrology . \\n2012;33(4):651-659. doi:10.2164/jandrol.111.014456 \\n61.  Li WJ, Zhou J, Li B, Wang H, Peng YB, Wang Z. PARP Inhibition  \\nRestores Erectile Function by Suppressing Corporal Smooth \\nMuscle Apoptosis in Diabetic Rats. Journal of Sexual Medicine . \\n2011;8(4):1072-1082. doi:10.1111/j.1743-6109.2010.02176.x \\n62.  Yamashita S, Kato R, Kobayashi K, Hisasue S ichi, Arai Y, \\nTsukamoto T. inhibition of interleukin -6 attenuates erectile'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 93}, page_content='dysfunction in a rat model of nerve -sparing radical prostatectomy. \\nJournal of Sexual Medicine . 2011;8(7):1957 -1964. \\ndoi:10.1111/j.1743-6109.2011.02283.x \\n63.  Simonsen U, Comerma -Steffensen S, Andersson K -E. M odulation \\nof Dopaminergic Pathways to Treat Erectile Dysfunction. Basic & \\nClinical Pharmacology & Toxicology . 2016;119:63 -74. \\ndoi:10.1111/bcpt.12653 \\n64.  Xu Y, Guan X, Zhou R, Gong R. Melanocortin 5 receptor signaling'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 93}, page_content='pathway in health and disease. Cellular and Molecular Life \\nSciences. 2020;77(19):3831 -3840. doi:10.1007/s00018 -020-\\n03511-0 \\n65.  Dowejko M, Smith C, Getting S, Le TPR, Murray JF. The \\nmelanocortin system in the male reproductive axis. Endocrine \\nAbstracts. Published online March 1, 2014. \\ndoi:10.1530/endoabs.34.p338 \\n66.  Eser N, Yoldas A. Identification of heat -resistant chemical \\ncomponents of Ferula elaeochytris root extracts by gas'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 93}, page_content='chromatography-mass spectrometry. Tropical Journal of \\nPharmaceutical Research . 2019;18(1):55 -60. \\ndoi:10.4314/tjpr.v18i1.9 \\n67.  Eser N, Yolda ş A, Koçer F. GC/FID ile ekstrakte edilen Ferula \\nelaeochytris kök ekstresinden yağ asidlerinin analizi. Sakarya \\nMedical Journal. 2020;10(2):264-269. doi:10.31832/smj.674963'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 94}, page_content='86 \\n68.  Eser N, Kartlaşmış K, Uçar Y, Kökbaş U. Ferula elaeochytris Kök \\nEkstresinin To plam Fenolik Bileşikler ve Glukoz Seviyesi \\nÜzerine Etkisi. Mersin Üniversitesi Tıp Fakültesi Lokman Hekim \\nTıp Tarihi ve Folklorik Tıp Dergisi . 2020;10(2):154 -161. \\ndoi:10.31020/mutftd.648699 \\n69.  Eser N, Buyuknacar HS, Cimentepe OO, et al. The effect of Fer ula \\nelaeochytris root extract on erectile dysfunction in streptozotocin -\\ninduced diabetic rat. International Journal of Impotence'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 94}, page_content='Research. 2020;32(2):186-194. doi:10.1038/s41443-019-0137-8 \\n70.  Eser N, Yoldaş A, Yigin A, et al. The protective effect of Fer ula \\nelaeochytris on age -related erectile dysfunction. Journal of \\nEthnopharmacology. 2020;258:112921. \\ndoi:10.1016/j.jep.2020.112921 \\n71.  Liao H, Jacob R. [Chinese herbal drugs for erectile dysfunction \\nthrough NO -cGMP-PDE5 signaling pathway]. Zhonghua nan ke  \\nxue = National journal of andrology. 2012;18(3):260-265.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 94}, page_content='72.  Goel B, Kumar Maurya N. Aphrodisiac Herbal Therapy for Erectile \\nDysfunction.; 2020. \\n73.  Goswami SK, Inamdar MN, Jamwal R, Dethe S. Effect of \\nCinnamomum cassia Methanol Extract and Sildenafil on Arginase \\nand Sexual Function of Young Male Wistar Rats. Journal of \\nSexual Medicine. 2014;11(6):1475-1483. doi:10.1111/jsm.12535 \\n74.  Nunes KP, Toque HA, Borges MH, Richardson M, Webb RC, de \\nLima ME. Erectile Function Is Improved in Aged Rats by PnTx2 -'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 94}, page_content='6, a Toxin from Phoneutria nigriventer Spider Venom. Journal of \\nSexual Medicine . 2012;9(10):2574 -2581. doi:10.1111/j.1743 -\\n6109.2012.02878.x \\n75.  Nunes KP, Cordeiro MN, Richardson M, et al. Nitric oxide -induced \\nvasorelaxation in response to pntx2 -6 toxin from phoneutria \\nnigriventer spider in rat cavernosal tissue. Journal of Sexual \\nMedicine. 2010;7(12):3879 -3888. doi:10.1111/j.1743 -\\n6109.2010.01978.x \\n76.  Dalaklioglu S, Ozbey G. The potent relaxant effect of resveratrol in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 94}, page_content='rat corpus cavernosum and its underlyin g mechanisms. \\nInternational Journal of Impotence Research . 2013;25(5):188 -\\n193. doi:10.1038/ijir.2013.6 \\n77.  Çevik Ö, Çad ırcı S, Şener TE, et al. Quercetin treatment against \\nischemia/reperfusion injury in rat corpus cavernosum tissue: a \\nrole on apoptosis and oxidative stress. Free Radical Research .'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 95}, page_content='87 \\n2013;47(9):683-691. doi:10.3109/10715762.2013.814912 \\n78.  Aghamir SMK, Guitynavard F. Erectile Dysfunctions. In: Stem Cells \\nin Urology . Springer International Publishing; 2020:75 -88. \\ndoi:10.1007/978-3-030-41476-4_6 \\n79.  Yu Z, Zhang Y, Tang Z, et al. Intracavernosal Adeno -Associated \\nVirus-Mediated S100A1 Gene Transfer Enhances Erect ile \\nFunction in Diabetic Rats by Promoting Cavernous Angiogenesis \\nvia VEGF -A/VEGFR2 Signaling. Journal of Sexual Medicine .'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 95}, page_content='2019;16(9):1344-1354. doi:10.1016/j.jsxm.2019.06.011 \\n80.  Gur S, Abdel -Mageed AB, Sikka SC, Bartolome AR, Hellstrom \\nWJG. Destination Penis? Gene Therapy as a Possible Treatment \\nfor Erectile Dysfunction. Current Gene Therapy. 2018;18(4):225-\\n239. doi:10.2174/1566523218666180730110432 \\n81.  Andersson KE, Christ GJ. Gene Therapy in Erectile Dysfunction: \\nDead or Alive? Journal of Sexual Medic ine. 2020;17(9):1587 -\\n1589. doi:10.1016/j.jsxm.2020.06.012'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 95}, page_content='1589. doi:10.1016/j.jsxm.2020.06.012 \\n82.  Chen Z, Yu Y, He M, et al. Higher growth hormone levels are \\nassociated with erectile dysfunction in male patients with \\nacromegaly. Endocrine Practice . 2019;25(6):562 -571. \\ndoi:10.4158/EP-2018-0518 \\n83.  Galdiero M, Pivonello R, Grasso LFS, Cozzolino A, Colao A. \\nGrowth hormone, prolactin, and sexuality. Journal of \\nEndocrinological Investigation . 2012;35(8):782 -794. \\ndoi:10.1007/BF03345805'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 95}, page_content='doi:10.1007/BF03345805 \\n84.  Li H, Kong R , Wan B, et al. Initiation of PI3K/AKT pathway by \\nIGF-1 decreases spinal cord injury -induced endothelial apoptosis \\nand microvascular damage. Life Sciences . 2020;263:118572. \\ndoi:10.1016/j.lfs.2020.118572 \\n85.  Melman A, Bar -Chama N, McCullough A, Davies K, C hrist G. \\nPlasmid-based gene transfer for treatment of erectile dysfunction \\nand overactive bladder: Results of a phase I trial. In: Israel \\nMedical Association Journal. Vol 9. ; 2007:143-146.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 95}, page_content='86.  Melman A, Bar -Chama N, McCullough A, Davies K, Christ G. \\nhMaxi-K gene transfer in males with erectile dysfunction: Results \\nof the first human trial. Human Gene Therapy. 2006;17(12):1165-\\n1176. doi:10.1089/hum.2006.17.1165 \\n87.  Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. The \\nfirst human trial for gene tra nsfer therapy for the treatment of \\nerectile dysfunction: Preliminary results. European Urology .'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 96}, page_content='88 \\n2005;48(2):314-318. doi:10.1016/j.eururo.2005.05.005 \\n88.  Atala A. Tissue engineering of reproductive tissues and organs. \\nFertility and Sterility . 2012;98(1):21 -29. \\ndoi:10.1016/j.fertnstert.2012.05.038 \\n89.  Ribeiro F, Alves AJ, Duarte JA, Oliveira J. Is exercise training an \\neffective therapy targeting endothelial dysfunction and vascular \\nwall inflammation? International Journal of Cardiology . \\n2010;141(3):214-221. doi:10.1016/j.ijcard.2009.09.548'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 96}, page_content='90.  Morelli A, Filippi S, Comeglio P, et al. Physical activity counteracts \\nmetabolic syndrome -induced hypogonadotropic hypogonadism \\nand erectile dysfunction in the rabbit. American Journal of \\nPhysiology - Endocrinology and Metabolism. 2019;316(3):E519-\\nE535. doi:10.1152/ajpendo.00377.2018'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 97}, page_content='CHAPTER VII \\n \\nPOSSIBLE EFFECTS OF PREEKLAMPSY AND \\nEKLAMPSY THAT MAY OCCUR WITH MATERNAL \\nOBESITY ON THE HEALTH OF PREGNANCY: A \\nMETAANALYSIS \\n \\nYılmaz Altuner \\n(Asst. Prof. Dr..),Karabük University, e-mail:  ayilmaz@karabuk.edu.tr   \\n                0000-0002-8162-2842 \\n \\n1. INTRODUCTION \\nIt has been determined that the prevalence of overweight \"obesity\" \\nhas gradually increased in women in the last 20 years (88). As a result, it'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 97}, page_content='has been suggested that it is associated with obesity during pregnancy, \\ngestational diabetes, hypertensive diseases, preeclampsia -eclampsia, \\ntraumboeubalism diseases, preterm labo b, macrosomia, birth \\ncomplications and increased cesarean delivery (89). In addition, \\nepidemiological studies have shown that excess maternal body we ight \\nincrease during pregnancy causes high birth weight newborns. (90) It has \\nalso been reported that newborns may increase the risk of being overweight'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 97}, page_content='and obese in childhood and adulthood (91). \\nAccording to the data of the World Health Organization (WHO) , \\nit is stated that there are over 400 million obese and 1.6 billion slightly \\nobese individuals in the world. It was stated that in 2015, this rate could \\nreach 2.3 billion per 700 million, respectively (92). 2016 According to the \\ndata of the adult population in the world, approximately 13% were obese, \\nand especially if the prevalence of obesity before pregnancy with an'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 97}, page_content=\"average 0.5 point increased knowledge of literature a year i, in 2000 \\nTurkey's National Diabetes Obesity and Hypertension Epidemiology \\n(TURDEP) that the obesity prevalence according to study data 22.3% It \\nhas been suggested (93). \\nIn particular, increased obesity was found to be associated with \\npregnancy loss and the risk of recurrent pregnancy in the first trimester \\n(94). In overweight and obe se pregnant women, in addition to the\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 97}, page_content='increasing number of undesirable perinatal effects, obviously obesity; It \\nhas also been determined to increase the risk of severe gestational \\nhypertension, preeclapsia-eclipse, gestational diabetes and macrosomia in \\nterms of the mother and fetus (95). In a study involving 1.4 million women \\nwith a large sample, it was found that the risk of preeclapse doubles with'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 98}, page_content='90 \\nevery 5-7 kg / m2 increase in body mass index in pregnant women (96). \\nAgain, when compared with obese and normal body weight women, it was \\nfound that triglyceride, very small density lipoprotein, insulin and leptin \\nlevels were higher in obese pregnant women (97). It has been concluded \\nthat obese women, especially in the postpartum period, breastfeed less than \\nthose of normal weight (98). \\nIt is clear that maternal obesity increases a number of serious'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 98}, page_content='problems such as gestational diabetes, hypertension, preeclapse and eclipse \\nduring pregnancy, as it is associated with short and long -term \\ncomplications in the mother and newborn at the end of pregnancy, delivery \\nand postpartum. \\n2. MATERNAL OBESITY \\nThe alarming increase in the prevalence of obesity worldwide has \\nexplained the importance of the World Health Organization (WHO) \\nconsidering obesity as one of the most se rious global health problems of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 98}, page_content='the 21st century (50). WHO defined obesity and obesity as abnormal or \\nexcessive fat accumulation that harm health and stated that the prevalence \\nof obesity during pregnancy is between 1.8% and 25.3% (25). \\nThe Center for Disease Control (The Center for Disease Control) \\nstated that the prevalence of obesity in pregnant women mirrors obesity in \\nwomen of reproductive age (42); stated that 25% of women of childbearing \\nage are obese and 25% of them are obese especially in the USA a nd'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 98}, page_content='maternal obesity is a major risk factor for maternal and perinatal mortality \\n(40). \\nIt was found that the mother who was overweight and obese during \\npregnancy and at birth was at significant risk in terms of antenatal, \\nintapartum, postpartum and neonatal  complications ( 25). Among the \\nprenatal complications; It has also been determined that recurrent \\nmiscarriages, congenital anomalies cause pregnancy -induced \\nhypertension, preeclampsia, gestational diabetes mellitus (GDM) and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 98}, page_content='venous thromboembolism (29). The risk of induction and cesarean section \\nincreases in obese and obese mothers and it has been stated that the babies \\nof these mothers are mostly macrosomic and stay in the hospital for a \\nlonger time (1).  \\nIt has been emphasized that obesity is a strong ris k factor for \\ngestational diabetes (35) and is effective in the development of diabetes, \\ncardiovascular disease and hypertension in the following years (30).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 98}, page_content='The Royal Collage of Obstetricios and Gynecologist (2004) \\nemphasizes that those with prenatal and postnatal BMI over 30 or body \\nweight over 90 kg carry a significant risk for postpartum troboembolic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 99}, page_content='91 \\nevents (30) Stated that between 2003 -2005, body mass inde x (BMI) was \\nabove 25 in 65% of maternal deaths due to thromboembolism (40). \\nMadan et al. (2010) (28) found that 23% of women were obese and \\n5% were extremely obese; He stated that as the age and parity of women \\nincreased, their BMI increased. Pre -pregnancy diabetes, gestational \\ndiabetes, chronic hypertension and preeclampsia, dysfunctional birth, use \\nof induction, premature rupture of membranes (PROM) and cesarean'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 99}, page_content='delivery were found to be increased in extremely obese patients. In this \\nstudy, premature birth was found in 8% of normal weight women, 8% of \\nobese women, 9% of obese women, and 10% of extremely obese women; \\nIt has been stated that it may be associated with the increased risk of \\npreterm birth in obese patients. Chorioamnionitis, low birth weight ba by \\n(LBW) and placental detachment were observed more frequently as a \\nresult of PROM and preterm delivery in obese pregnant women (29).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 99}, page_content='In a systematic analysis of 13 scientific studies, it was found that \\nincreasing BMI is an independent risk factor for preeclampsia; It has been \\nreported that obese mothers are at twice the risk of preeclampsia than \\nmothers of normal weight. Gestational hypertension is more common in \\nmorbidly obese women who did not have hypertension before; Therefore, \\nmaternal obesity is not only associated with a high risk of preeclampsia,but \\nhas also been associated with gestational hypertension (40).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 99}, page_content='In a randomized controlled study with 1661 women in order to \\nevaluate peripartum and neonatal outcomes in obese and obese mothers; It \\nwas found that 27% of women were obese, 16% were obese, there was an \\nartificial initiation of labor and an increase in cesarean rate, and more \\nantibiotics were used for wound infection in the postpartum period. Again \\nin this study, it was found that the risk of d eveloping gestational diabetes'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 99}, page_content='was two and four times higher in obese and obese than normal weight \\nwomen, respectively; It has been reported that babies born to obese and fat \\nmothers are larger and macrosomic (1). \\nPregnancy outcomes were examined in obese women who gave \\nbirth in a large university hospital in Europe; Singleton pregnancies with \\nbirth weight> 500 g and women whose BMI was calculated in the first \\ntrimester (n = 5824) were included in the study; It was determined that'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 99}, page_content='0.6% of women were morbidl y obese. While the mean age of morbidly \\nobese women was 31, 46.1% of women with normal BMI were found to \\nbe primigravida. While 35.8% of morbidly obese women have \\nhypertension or preeclampsia caused by pregnancy , these problems were \\ndetected in 9.8% of wom en in the normal BMI group. The frequency of \\nfetal macrosomia (birth weight> 4-5 kg) is 1.7% in the normal BMI group \\nand 6.3% in the obese group (13).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 100}, page_content='92 \\n2.1. EFFECT OF MATERNAL OBESITY ON \\nHYPERTENSIVE DISEASES \\nIt has been suggested that hypertensive disorders are  the most \\ncommon medical problems complicating pregnancy in developing and \\ndeveloped countries, and cause significant morbidity and mortality in \\nmother, fetus and newborn, and hypertensive disorders are seen in \\napproximately 10% of pregnancies worldwide (11). Previously, 30 mmHg \\nsystolic blood pressure (SBP) increase or 15 mmHg diastolic blood'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 100}, page_content='pressure (DBP) increase were included in the definition of hypertension \\n(HT) in pregnant women, but it was no longer defined since it was found \\nthat it had no effect on prognosis (6). However, these pregnant women \\nwere followed up more closely in terms of the possibility of developing \\nhypertension (HT). High blood pressure is a symptom and has been the \\nresult of different pathogenesis. Accordingly, its effect on the mo ther and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 100}, page_content='fetus was also different. In addition, hypertension during pregnancy has \\nvaried from mild high blood pressure to severe high blood pressure causing \\nmultiorgan dysfunction. \\nHT can be present before pregnancy as well as detected during \\npregnancy for  the first time. In some, it becomes evident only in the \\nintrapartum or postpartum period. Classification is extremely important in \\nterms of prognosis, management and determination of maternal fetal risks.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 100}, page_content='The National High Blood Pressure Education Program  (NHBPEP) made \\nthe following classification in 2000 (34): \\n1. Preeclampsia-eclampsia \\n2. Chronic hypertension \\n3. Preeclampsia combined with chronic hypertension \\n4.Gestational hypertension \\nPreeclampsia-Eclampsia: It was defined as de novo hypertension \\naccompanied by proteinuria, which emerged after 20 weeks of gestation. \\nHypertension blood pressure was found to be above 140/90 mmHg in at'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 100}, page_content='least two measurements. Proteinuria is defined as 300 mg protein leakage \\nin 24-hour urine. Since edema, which was included in the old definition, is \\nnonspecific and is seen in most normotensive pregnant women, it has not \\nbeen included in the new definition. It has been said that preeclampsia is \\nnot severe if there is no target orga n damage. The definition of severe \\npreeclampsia is defined as excessive elevation in blood pressure or target \\norgan damage.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 100}, page_content='organ damage. \\nChronic Hypertension: Known to be present before pregnancy. \\nIt was detected before or before the 20th week of pregnancy. In the firs t \\nhalf of the pregnancy, despite the increase in intravascular and \\nextravascular volume as well as the increase in cardiac output and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 101}, page_content='93 \\nintrvascular volume, the mean blood pressure decreased as the total \\nperipheral resistance decreased with the increase in v ascular compliance. \\nIncreasing cardiac output plateaued or continued to increase slightly in the \\nsecond half of pregnancy (9). \\nPreeclampsia Added to Chronic Hypertension:  Preeclampsia \\nwas added to the picture of a pregnant woman with chronic hypertension. \\nThe diagnosis of preeclampsia was determined by the emergence or'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 101}, page_content='increase of new proteinuria, increased blood pressure under control, \\nincreased liver enzymes, and thrombocytopenia. \\nGestational hypertension: It is known as hypertension that occurs \\nin the second half of pregnancy or within the first 24 hours postpartum, and \\nreturns to normal within 6 -12 weeks after birth without proteinuria. \\nAlthough the reason is unclear, it has been found that women are very \\nlikely to have HT in the future. It has been esti mated that 15 -25% of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 101}, page_content='women with gestational HT will develop preeclampsia (37). In those who \\nhad gestational HT before 32 weeks, this rate approached 50%. \\n2.2. EFFECT OF MATERNAL OBESITY ON \\nMACROZOMY \\nClinically, macrosomia has been described in several ways. \\nAlthough fetal weight over 4000-5000 gr is a generally accepted definition, \\nit is considered more correct to talk about the baby according to the \\ngestational age (20). The concept of LGA is different from absolute fetal'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 101}, page_content='weight, and the expected fetal weight according to gestational age has been \\nachieved to be above the 90% percentile (11). Although not much, in some \\nstudies, fetuses with a ponderal index above 2.85 were evaluated as LGA \\n(36). \\nPonderal index = Weight (gr) .100 / height cm \\nIn the Preven tion of Macrosomia: Macrosomia observed \\nespecially in diabetes has been reported at a rate of 8-45% despite advanced \\nperinatal medicine practices ( 44). The most important point in the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 101}, page_content='prevention of fetal macrosomia has been the diagnosis of diabetic pregnant \\nwomen. (4) Although patients were aware of their condition in diabetic \\ncases, timely recognition of gestational diabetes, especially seen in risk \\ngroups, was required ( 26). Regardless of the type of diabetes, an \\nappropriate metabolic balance has been maintained throughout pregnancy \\n(23). It was stated that if insulin application will be applied for macrosomia'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 101}, page_content='prophylaxis, the last trimester should be selected and treatment should be \\nstarted as early as possible and before 36th gestational week at the lat est \\n(10).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 102}, page_content='94 \\n2.2. THE EFFECT OF MATERNAL OBESITY ON \\nTHROMBOEMBOLI DISEASES \\nPhysiological and anatomical changes during pregnancy were \\nimportant factors in venous stasis and decreased venous blood flow, uterine \\npressure on inferior vena cava and pelvic veins and immobility thrombus \\nformation. While some coagulation factors increased during pregnancy, \\nthe protein level decreased (41). Age> 35, obesity, cesarean delivery, \\nsevere ovarian hyperstimulation, heart disease, DM, multiparity have been'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 102}, page_content='reported to increase the risk of pulmonary embolism (PE) (18).  \\nPhysiological changes during pregnancy cause PE-like symptoms \\ncausing diagnostic difficulties. Dyspnea, tachypnea, tachycardia and leg \\nswelling occurred during pregnancy. The complaint of shortness of breath \\ngradually increased during pregnancy. In particular, the unusual increase \\nin dyspnea and the accompanying DNT symptoms were among the \\nimportant clues for PE. The most common symptoms were listed as'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 102}, page_content='dyspnea, pleuritic, chest pain and cough (8). \\nThrombolytic Treatment in Pregnant Women:  When \\nthrombolytic therapy in pregnant women is used in patients who are not \\npregnant, it carries a similar risk to the risk of bleeding (3 1). No large \\nstudies have been conducted on the use of pregnancy thrombolytic drugs. \\nTherefore, experience in this matter has been limited ( 33). Tissue -\\nplasminogen activator (tPA) has been recommended in pregnant women'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 102}, page_content='using thrombolytics in the recently published European PE guideline (22). \\n3.PREEKLAMPSİA AND EKLAMSİA \\nPreeclampsia has been a common occurrence in pregnant women. \\nIt has been characterized by protein in the urine accompanying high blood \\npressure. Women with preeclampsia have had swelling in their feet, legs, \\nand hands. If preeclampsia is present, it may occur earlier, and it is usually \\nseen in the second half of pregnancy, the last part of the second trimester, \\nor the third trimester.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 102}, page_content='or the third trimester. \\nEclampsia has been identified as the final and most severe stage of \\npreeclampsia if left untreated. In addition to the previously mentioned \\nfindings of preeclampsia, it was found that women with eclampsia mostly \\nhad a stroke. Eclampsia caused the mother and the baby to go into a coma \\nor even death. In addition, the disease was discovered before, during or \\nafter the birth of the child. \\nIt has been stated that preeclampsia can cause your baby to be born'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 102}, page_content='very small and prevent the placenta from getting enough blood. It has also \\nbeen the main cause of difficulties such as premature birth and \\naccompanying learning defects, epilepsy, cerebral palsy, and he aring and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 103}, page_content='95 \\nvision problems. It has been suggested that the only true cure for \\npreeclampsia and eclampsia is the birth of a baby. \\nOther treatments included: It has been stated as intravenous \\nmagnesium injection to prevent strokes due to eclampsia, Hydralazin e or \\nanother antihypertensive drug to relieve severe spikes in blood pressure, It \\nhas been reported as observing fluid intake (88). \\n3.1. THE RELATIONSHIP OF MATERNAL OBESITY AND \\nPREEKLAMPSY'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 103}, page_content='PREEKLAMPSY \\nPreeclampsia has progressed as a pregnancy -specific syndrome \\naffecting 3-5% of pregnancies. Preeclampsia was defined as the presence \\nof new onset of hypertension and proteinuria or end -organ dysfunction or \\nboth in a woman who was normotensive before pregnancy ( 48). Severe \\nhypertension and end-organ damage signs / symptoms have been accepted \\nas the severe spectrum of the disease (49) \\nEclampsia is a form of new onset, general, tonic clonic seizures or'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 103}, page_content='coma in a woman with preeclampsia, a convulsive sign of preeclampsia, \\nand has been determined by various clinical data seen at the end of severe \\npreeclampsia (50). It occurred in the second half of pregnancy (49). It has \\nbeen suggested that it is a pregnancy -specific syndrome characterized by \\nhypertension and proteinuria (47). It has been reported that it is responsible \\nfor approximately 70,000 maternal deaths and 500,000 infant deaths in the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 103}, page_content='world every year ( 52) and preeclampsia and eclampsia are the second \\n(17%) causes of maternal death, especially in our country (53). Risk factors \\nfor plexus are shown in table 1.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 104}, page_content='96 \\nTable 1. PREEKLAMPSY RISK FACTORS (59, 63, 64, 65) \\nFirst pregnancy     Family history of \\npreeclampsia \\nPreeclampsia in previous pregnancy   Prolonged birth \\ninterval (>10 years) \\nAntiphospholipid syndrome or  Type I Diabetes Mellituda Type \\nDiabetes Mellitus \\nhereditary thrombophilia  \\nChronic hypertension    High body mass index \\n(29) \\nMultiple pregnancy    Systemic lupus erythematosus \\nMaternal age  <18 and >40    Chronic kidney \\ndisease'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 104}, page_content='disease \\nUndisclosed fetal growth retardation   Vascular or \\nconnective tissue diseas \\nFetal growth retardation in previous pregnancy    ablatio placenta or fetal \\nloss Factors associated with the partner \\nMole hydatidiform    Predisposition to genes \\nIn vitro fertilization    Black race \\n \\n3.2. INTERACTIONS OF PLEXUS RISKS \\nFirst pregnancy: It has been suggested that women with a first \\npregnancy may increase the risk of preeclampsia (48, 52, 55). Although it'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 104}, page_content='is not known exactly why the first pregnancy is a predisposing factor, one \\ntheory suggests that these women may have limited exposure to antigens \\nfrom the father, and it has been claimed that this situation may play a role \\nin the pathogenesis of the disease (57). \\nPreeclampsia history in the family:  It has been determined that \\nthe medical history of first -degree close relatives i ncreases the risk of \\npreeclampsia from 2 times to 4 times in those with preeclampsia (51, 55).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 104}, page_content=\"Although this situation suggests a hereditary mechanism, it has been \\nsuggested that the father of the baby may contribute to the increased risk \\nor the father's c ontribution to fetal genes may have a role in insufficient \\nplacentation and subsequent preeclampsia (48). \\nPreeclampsia in previous pregnancy: It has been reported that \\nwomen with a history of preeclampsia in their previous pregnancy increase\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 105}, page_content='97 \\nthe risk of developing preeclampsia 7 times compared to those who do not \\n(Relative Risk (RR): 7.19) (48, 51,55). \\nProlonged birth interval (≥10 years): Too long a period between \\ntwo pregnancies (10 years or more) increased the risk of preeclampsia (52, \\n53,54). \\nMultiple pregnancy: Preeclampsia is more common in multiple \\npregnancies (especially triplets and quadruplets) ( 48, 51, 55). RR in twin \\npregnancies: 2.93 ( 48). Triplet pregnancies have created a higher risk of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 105}, page_content='preeclampsia development compared to twin pregnancy (51). \\nMaternal age  <18 and > 40: Maternal age over 40 increased the \\nrisk of preeclampsia. (RR: 1.96 in multipara, RR: 1.68 in primipara). Older \\nwomen tended to have more risk factors such as diabetes mellitus, obesity, \\nand chronic hypertension. This has been explained by the increase in \\npreeclampsia frequency among older women (48, 51, 55). \\nDiabetes Mellitus: RR in diabetes that exists before pregnancy:'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 105}, page_content='3.56. Various factors such as underlying renal or vascular diseases, high \\nplasma insulin level / insulin resistance, and abnormal lipid metabolism \\nwere thought to affect the risk of preeclampsia. (48,55). \\nChronic kidney disease:  The relative risk has changed in pre -\\npregnancy kidney disease, depending on the degree of reduction in \\nglomerular filtration rate and the presence or absence of hy pertension. \\nThose with advanced chronic kidney disease (grade 47, 48, 49 ) were'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 105}, page_content='diagnosed with preeclampsia after the second half of pregnancy at a rate of \\n40-60%. (48, 55). \\nHigh diastolic blood pressure:  Increased the risk of blood \\npressure ≥130/80 mmHg at the first prenatal visit (RR: 1.38). Women with \\nthe highest risk of superimposed preeclampsia were found to have diastolic \\nblood pressure ≥110 mmHg (RR: 5.2) and ≥100 mmHg (RR: 3.2) before \\nthe 20th gestational week (48). \\nOther: Pre -existing hypertension ( RR: 1.38) (52, 55),'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 105}, page_content='antiphospholipid syndrome (RR: 9.72) (59, 66) and BMI ≥35 (66) were \\namong the other risk factors. It has been controversial that the risk of \\npreeclampsia is higher in adolescents. It has been found that women who \\nsmoke are less likely t o have preeclampsia than non -smokers. (48). The \\nrisk is increased in those who become pregnant with donor egg, embryo \\ndonation or donor insemination (52). It has been difficult to assess the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 105}, page_content='racial differences in the incidence and severity of preeclampsia due to \\nconfounding socioeconomic and cultural factors (51).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 106}, page_content='98 \\n3.3. MATERNAL AND FETAL EFFECTS OF \\nPREECLAMPSIA \\nPreeclampsia has been an important problem affecting maternal \\nand infant health. ( 58). In cases where preeclampsia developed, \\nconvulsion, pulmonary  edema and ablatio placenta were seen. Women \\nwith preeclampsia were found to have a higher risk of hypertension (3.7 \\ntimes), coronary artery disease (2.2 times) and stroke (1.8 times) in their \\nlater life (52). It has been observed that the changes in lipid metabolism of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 106}, page_content='women with preeclampsia (such as increased total cholesterol and \\ntriglyceride levels) are greater than the changes in normotensive pregnant \\nwomen (57, 59). One of the rare complications of preeclampsia is acute \\npancreatitis and can mimic pre eclampsia (6 0, 61 ). Ablatio placenta is \\nrarely seen (less than 1%) in women with preeclampsia without severe \\nsymptoms, while it has been reported that 3% of women have severe \\nsymptoms (48).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 106}, page_content='symptoms (48). \\n Fetal growth retardation and oligohydramnios were observed \\ndue to chronic fetal hypoperfusion in the fetus (48). Severe and early-onset \\npreeclampsia resulted in a serious decrease in fetal birth weight compared \\nto normotensive pregnancies (62). Fetal birth weight was found to be lower \\nthan expected for gestational age by 12% in severe preeclampsia and 23% \\nin early -onset preeclampsia ( 52). Among the long -term effects of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 106}, page_content='preeclampsia on children is an increased risk of stroke and hypertension \\n(52). The frequency of neonatal diseases such as respiratory distress, \\nintraventricular hemorrhage and necrotizing enterocolitis was similar to \\nbabies of preeclamptic pregnant women and babies of non -hypertensive \\nwomen of the same age (48). \\n3.4. TREATMENT METHODS IN PREECLAMPSIA \\nAccording to the long held view, \"childbirth\" has been the only \\nsolution in preeclampsia treatment. In the management of preeclampsia,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 106}, page_content='guided by evidence -based practices, early diagnosis of risk groups, \\nprevention of multiple organ damage in the mother, and effective \\nmanagement of labor or ensuring the safe co ntinuation of pregnancy for \\nmother and baby until fetal lung maturity is achieved (54, 58, 63). \\nWomen deemed to have a high risk of developing preeclampsia \\nwere directed to pre -pregnancy counseling in order to determine \\nchangeable risk factors before pregn ancy. Being at the highest level of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 106}, page_content='health before pregnancy has decreased the risk of developing preeclampsia \\n(51, 52 , 64, 65). It has been found that there is no ideal antenatal care \\nprogram for women with a high risk of preeclampsia. However, when these \\nwomen were diagnosed, antenatal management included more frequent \\nfollow-up, anomaly screening, regular blood pressure and urine controls,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 107}, page_content=\"99 \\nand fetal growth assessments to evaluate fetal growth retardation every 4 \\nweeks (52). \\nIn mild preeclampsia cases, the  mother's life is not in danger and \\nthe continuation of the pregnancy did not put the mother at serious risk and \\ngained time for the baby ( 47). Maternal and fetal risks are well balanced \\nwhen the decision is made for the delivery of a woman with preeclampsia. \\nGenerally, in this case, delivery at the 37th gestational week is\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 107}, page_content='recommended, but if the maternal and fetal condition is stable, a woman \\nwith mild preeclampsia has been followed closely. Laboratory evaluation \\ntwice a week and daily fetal monitoring are generally recommended for the \\nmanagement of all women with preeclampsia by hospitalization. If the \\nwoman was deemed suitable for outpatient follow-up, weekly prenatal visit \\nand twice weekly fetal testing were provided (66). Initiating the emergency'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 107}, page_content='treatment of persistent severe blood pressure to reduce adverse vascular \\nevents has been the main factor in the treatment of severe preeclampsia \\n(67). Another priority in the treatment of severe preeclampsia has been the \\nprevention of eclampsia (51, 66).  \\nAll complications of preeclampsia have been observed especially \\nin the first 48 hours after delivery ( 49). Women with hypertension \\nthroughout pregnancy were followed up after delivery until they were sure'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 107}, page_content='that the hypertension problem was completely resolved. Women who had \\npreeclampsia during pregnancy have been told that their risk of \\ncardiovascular and kidney disease increases in their later life. After \\ndischarge, the woman should be followed up regularly and her blood \\npressure was monitored closely. Those di agnosed with severe \\npreeclampsia were more likely to recur in their next pregnancy (52). \\n3.5. INITIATIVES TO PREVENT PREECLAMPSIA'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 107}, page_content='3.5. INITIATIVES TO PREVENT PREECLAMPSIA \\nThe fact that preeclampsia threatens maternal and infant health \\nsignificantly, and the etiology and pathogenesis are not fully known, draw \\nattention to the importance of preventive approaches. Determining the \\nrisky groups before the development of preeclampsia and taking the \\nnecessary precautions contributed to the improvement of maternal and \\ninfant health. In this context, the development of preeclampsia, which has'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 107}, page_content='widespread and serious consequences, can be stopped, slowed down, \\nreduced in effect or treated early with some simple measures. To prevent \\nthe development of preeclampsia; Life style changes such as physical \\nactivity, dietary regulations, pharmacological methods, and avoidance of \\nstress have been suggested (51, 68, 69). \\nAcetylsalicylic Acid: If there is an early onset of preeclampsia in \\nthe medical history, preterm birth before the 34th week or a history of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 107}, page_content='preeclampsia in more than one pregnancy, it is recommended to start low \\ndose acetylsalicylic acid (60-80 mg) at the end of the first trimester. In the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 108}, page_content='100 \\nmeta-analysis of randomized studies conducted for the prevention of \\npreeclampsia by acetylsalicylic acid and involvin g more than 30,000 \\nwomen, although long-term fetal effects could not be ignored, it was stated \\nthat it provided a small decrease in the rate and morbidity of preeclampsia \\nand there was no evidence against an acute risk (70). \\nAntioxidant Supplements (With V itamins C and E):  \\nAntioxidant support with vitamin C or vitamin E is not recommended for'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 108}, page_content='the prevention or treatment of preeclampsia. ( 70). High-quality evidence \\nof ineffectiveness has been found. In two studies in which antioxidants \\nwere given to women with severe preeclampsia for treatment, no clinical \\nbenefit was found (71, 72). In order to prevent preeclampsia and reduce its \\ncomplications; Although a pilot study found that supplementation of \\n1000mg of vitamin C and 400 IU of vitamin E daily during the second and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 108}, page_content='third trimesters significantly reduced the risk of preeclampsia ( 73), it was \\nbroadly and in multiple, multicenter, randomized women with both low - \\nand high-risk groups. No meaningful results have been achieved in studies \\n(74, 75). \\nFolic Acid Supplement: Although it has been stated that folic acid \\nreduces the risk of preeclampsia, there are studies reporting the opposite \\n(48, 49, 51). \\nAntihypertensive Drugs:  It has not been shown in controlled'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 108}, page_content='studies that lowering blood pressure with antihyperte nsive drugs reduces \\nthe risk of preeclampsia or ablatio placenta or improves fetal and \\npregnancy outcomes. However, treatment has decreased the frequency of \\nmoderate and severe hypertension (50). \\nCalcium Supplement: No benefit of routine calcium supplements \\nhas been observed for the prevention of preeclampsia in healthy \\nnulliparous women whose dietary calcium intake is sufficient. It has been'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 108}, page_content='shown to be beneficial in the prevention of preeclampsia in the high -risk \\ngroup, especially in societies where dieta ry calcium intake is low ( 64). \\nWorld Health Organization (WHO) recommended 1500 -2000 mg of \\ncalcium supplements per day to reduce the risk of preeclampsia for \\npregnant women who are at high risk for developing hypertension in places \\nwhere calcium intake is low ( 51). In a randomized controlled study \\nconducted by WHO in the female population (n: 8325) whose daily'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 108}, page_content='calcium intake is less than 600 mg per day; calcium supplementation \\nprovided a small statistically insignificant reduction in preeclampsia. \\nEclampsia and severe gestational hypertension were significantly lower in \\nthe calcium group. At the same time, the severe maternal mortality and \\nmorbidity index and neonatal mortality rates decreased in the group \\nreceiving calcium. As a result, 1.5 g calcium supple mentation per day'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 109}, page_content='101 \\ncannot prevent preeclampsia, but its severity, maternal 1 morbidity and \\nneonatal mortality have been reduced (65). \\nFish Oil:  There are studies indicating that fish oil supplements \\nhave a protective effect on the vessels, lowers systemic b lood pressure, \\nreduces the incidence of preeclampsia and pregnancy -induced \\nhypertension (52, 53). On the contrary, fish oil supplementation has no \\nThere have been many studies stating that it has no effect (54, 55, 56).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 109}, page_content='Nitric Oxide: There is no sufficient  level of evidence that nitric \\noxide prevents preeclampsia (35). \\nOther Dietary Interventions: There have been only a few small \\nrandomized studies investigating the role of diet in preventing \\npreeclampsia. No beneficial results were found from dietary \\nrecommendations such as protein and energy supplements, protein and \\nenergy restriction (in obese women), magnesium supplementation, and salt \\nrestriction (21, 55, 58, 59).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 109}, page_content='restriction (21, 55, 58, 59). \\nVitamin D Supplementation:  Some observational studies \\nindicate an association between vitamin D deficiency and increased risk of \\npreeclampsia ( 38) and early -onset severe preeclampsia ( 61), while no \\nassociation was found in a prospective cohort study of women with high -\\nrisk preeclampsia (76). As with other nutritional interventions, evidence \\nwas insufficient to prevent preeclampsia (70). \\nWeight Loss: Although there is an increased risk between'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 109}, page_content='maternal obesity and preeclampsia, few studies have evaluated the effect \\nof weight loss on risk. In cohort studies of patients undergoing surgery for \\nweight loss, weight loss was reported to significantly reduce the risk of \\npreeclampsia (76). Additionally, in a cohort study, it was determined that \\nthe risk of recurrent preeclampsia was reduced i n women with \\npreeclampsia who lost weight between pregnancies (62). \\nRest and Physical Activity:  There is no strong evidence that'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 109}, page_content='exercise or physical activity affects the risk of developing preeclampsia. \\n(43). Restriction of bed rest or other physical activities is not recommended \\nprimarily in the prevention of preeclampsia and its complications. (80). It \\nhas been hypothesized that regular exercise prevents preeclampsia by \\nimproving vascular functions. Although bed rest is recommended as a \\npreventive strategy, it has been reported that the evidence for this is limited.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 109}, page_content='Only two small studies evaluated bed rest as a protective strategy, but did \\nnot evaluate perinatal -maternal morbidity and mortality and adverse \\neffects of bed rest (44, 45). \\nModerate activ ity has been found to reduce the risk of \\nhypertension and cardiovascular disease in non -pregnant women. In \\nnormal pregnancy, 30 minutes of moderate activity is not recommended on'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 110}, page_content='102 \\nmost days of the week, if not every day. ( 46). It has been postulated that \\nmoderate activity also stimulates placental angiogenesis and maternal \\nendothelial dysfunction. A few small clinical studies have evaluated the \\neffects of moderate exercise in preventing preeclampsia, but data have \\nbeen limited to make realistic interpretations of the results (47). In addition, \\nlong bed rest during pregnancy increased the risk of thromboembolism'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 110}, page_content='(65). The American Collage of Obstetricians and Gynecologists (ACOG) \\nhas not recommended strict bed rest without severe symptoms for women \\nwith gestational hypertension or preeclampsia (70). \\nCoping with Stress:  According to Çelik and Özdemir ( 70), \\nprolonged stress situations caused a constant high blood pressure. The \\nstress that will be experienced during pregnancy also caused blood \\npressure changes. Hy percortisolemia caused by maternal stress affected'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 110}, page_content='pregnancy by affecting many factors affecting the placenta and fetus. (71). \\nStudies have shown that maternal stress leads to the delivery of low birth \\nweight babies and an increased risk of preeclampsia ( 72, 73). The \\nstimulating effect of stress on the sympathetic nervous system causes \\nchanges in peripheral vascular resistance during pregnancy as well as in \\nthe immune system, and it has been found to be associated with the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 110}, page_content='development of preeclampsia ( 52). Shamsi et al. ( 64) reported that \\nmaternal stress experienced during pregnancy increased the risk of \\npreeclampsia. Vollebregt et al. ( 72) also reported that the risk of \\ndeveloping preeclampsia and hypertensive disorders increased \\napproximately twice in working women compared to non-working women \\nin relation to the tensions experienced in working life. \\nCoping with stress, which is among the lifestyle changes that are'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 110}, page_content='effective in hypertension, has been done with an effective stress \\nmanagement. In stress manag ement, relaxation techniques such as deep \\nbreathing, muscle relaxation exercises and mental relaxation were included \\nin addition to finding a solution to the cause of the stress. It was found that \\nblood pressure decreased with the application of deep breathing exercises. \\nRespiratory exercises have relaxing effects on the cardiovascular system,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 110}, page_content='and mental relaxation has positively affected blood pressure by affecting \\nthe sympathetic nervous system. (53). It is thought that a similar effect can \\nbe seen in pre eclampsia that may develop during pregnancy. Because \\nrhythmic and regular breathing calms the nervous system, people can cope \\nwith stress more easily by deep breathing in stressful situations. As the \\nabdominal muscles are used during deep breathing, the tension in the neck \\nand shoulders is also reduced (54).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 110}, page_content='and shoulders is also reduced (54). \\n4. GESTATIONAL DIABETES \\nGestational diabetes mellitus (GDM) has been described as \\ncarbohydrate intolerance of various degrees, which started during'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 111}, page_content='103 \\npregnancy or was first diagnosed during pregnancy ( 23). This definition \\ndid not exclude the possibility of diabetes, which was also present before \\nconception but was unknown until the first examination during pregnancy. \\nAlthough the American Obstetrics and Gynecological Association \\nstill uses the same terminology, in recent years, the International Diabetic \\nWorking Groups Association (IADPSG), the American Diabetes'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 111}, page_content='Association (ADA), and the World Health Organization (WHO) and others \\nwere first diagnosed during pregnancy but probably previously thought to \\nbe diabetic. stated that transient diabetes due to pregnancy -related insulin \\nresistance should be differentiated (17). These organizations have used the \\nterm gestational diabetes emerging in the second half of pregnancy: overt \\ndiabetes or diabetes mellitus during pregnancy, and the terms for diabetes,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 111}, page_content='which is recognized by standard non -gestational criteria in early \\npregnancy, when insulin resistance is less (45). \\n4.1. PATHOPHYSIOLOGY OF GESTATIONAL DIABETES \\nA subclinical metabolic dysfunction is thought to occur in women \\nwho have normal glucose tolerance during normal pregnancy but develop \\nGDM in the late period of pregnancy. The 60% decrease in insulin \\nsensitivity that occurs during normal pregnancy has led to clinical'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 111}, page_content='hyperglycemia / GDM in these women. Materna l obesity, which is \\nfrequently associated with gestational diabetes, has been associated with \\nincreased inflammation in maternal white adipose tissue and placenta. \\nAdipokines and cytokines such as leptin, adiponectin, TNF-a, interlokin-6 \\nwere secreted from white adipose tissue (5). The placenta showed a similar \\ncytokine gene expression profile except for adinopectin. It is thought that'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 111}, page_content='inflammation caused by secreted cytokines may be related with increased \\ninsulin resistance in pregnant women with gestational diabetes (20). If the \\nmaternal pancreatic B -cells cannot provide enough insulin to meet the \\nincreasing insulin need, GDM has developed (2). \\n4.2. FETAL AND MATERNAL EFFECTS OF \\nGESTATIONAL DIABETES \\nIt is known that both the mother and the fetus are at man y risks \\nassociated with diabetes during pregnancy. There was an increase in risks'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 111}, page_content='(12). While negative consequences in the mother may be short -term \\n(hypertension, preeclampsia), they have also been long-termed, such as the \\nincreased risk of Type 2 DM in later life ( 21). Although postpartum \\nglucose levels return to normal in women with GDM, it has been known \\nthat the risk of developing Type 2 diabetes mellitus (DM) increases 7 times \\nin later life (3, 62). \\nGDM history has also been found to be a determinant for increased'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 111}, page_content='cardiovascular risk and early atherosclerosis (1 4). Hypertensive'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 112}, page_content='104 \\ncomplication rates were found to be higher in diabetic pregnancies \\ncompared to normal pregnancies ( 48). It was found that the risk of \\npreeclampsia increased from 5 -7% to 15 -20% depending on glycemic \\ncontrol, GDM severity and pre-pregnancy body mass index (BMI) (12). In \\nwomen with GDM, the risk of developing type 2 DM in the later years of \\nlife increased by 20 -80% ( 24). Glucose can pass freely from mother to \\nfetus, but maternal i nsulin could not. Maternal glucose in high'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 112}, page_content='concentrations passing through the placenta stimulated insulin secretion in \\nthe fetus, increasing growth factors and causing macrosomia (5). \\n4.3. BIRTH COMPLICATIONS AS A RESULT OF \\nMATERNAL OBESITY AND INCREASE IN CAES ARY \\nDELIVERY \\nMaternal obesity has been a recognized risk factor for serious \\nobstetric complications, which are becoming more common worldwide \\nand include hypertensive disorders, preeclampsia, gestational diabetes,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 112}, page_content='thrombophlebitis, urinary tract infections, chorioamnionitis, preterm labor, \\nfetal macrosomia, shoulder dystosis, and intrauterine fetal death (7). \\nObese women have a high risk of intrapartum complications, and \\nit is thought that various factors may have an effect on this situation. \\nIneffective uterine activity comes first, and macrosomia, which is also a \\nfetal event, reduces the progression of labor; Difficult assessment of fetal'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 112}, page_content='position during delivery in obese women made it difficult to define the \\nbreech presentation precisely (10). Spontaneous pregnancy loss and neural \\ntube defect in the first pregnancy period; gestational diabetes in the second \\ntimester; In the third trimester, the risks of gestational hypertension, \\ndifficulty in fetal follow -up, anesthesia complications, macrosomia, \\nstillbirth and cesarean section increased. In the postpartum period, obese'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 112}, page_content='women have been reported to have bleeding, infection, wound opening, \\nand venous thromboembolism risks ( 25). At the beginning of the \\ndifficulties experienced by obese women during childbirth,  changing \\nposition is the first thing that comes to mind. There have been difficulties \\nin inserting an epidural catheter due to excessive adipose tissue. \\nTransporting the woman to the operating table can also become difficult, \\nand excessive neck, abdominal, and chest weight have made intubation and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 112}, page_content='mechanical ventilation more difficult and complex. Due to the increasing \\nsurgical deliveries, prenatal anesthesia consultation was recommended \\n(19). \\nAlthough there is a relationship between BMI over 30 and \\nprolonged delivery, techniques that stimulate contraction such as nipple \\nstimulation and walking were used. It was important to follow up the \\nfollow-ups for uterine contractions and fetal heart rate just after the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 112}, page_content='induction use. The ability to palpate and record uterine interactions using'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 113}, page_content='105 \\nexcessive abdominal adipose tissue is limited by using a tachodianometer. \\nCalculation of fetal heart rate with dops is also limited in obesity. \\nTherefore, the most a ccurate monitoring was performed with fetal scalp \\nelectrode and internal pressure catheter (19). The first and second stages of \\nmacrosomic deliveries are prolonged, the risk of intervention vaginal birth, \\nthird degree perineal trauma, emergency cesarean se ction, postpartum'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 113}, page_content='hemorrhage, and apgar score below 4 is increased. It was found that he \\nstayed in the hospital for a longer period of time (38). \\nStudies have shown that shoulder dystocia is more common in \\nwomen who are obese and gain excessive weight during pregnancy. It was \\nunderstood that women with a BMI above 40 had a five-fold higher risk of \\nuterine rupture at delivery, prolonged labor and increased risk of fetal \\ndistress during this period, therefore healthcare professionals might have'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 113}, page_content='reservations about trying vaginal delivery after cesarean in obese patients \\n(19). \\nAlthough there is a relationship between prolonged birth and being \\non it, techniques that stimulate contraction such as nipple stimulation and \\nwalking were used. It was important to follow up the follow-ups for uterine \\ncontractions and fetal heart rate just after the induction use. The ability to \\npalpate and record uterine interactions using excessive abdominal adipose'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 113}, page_content='tissue is limited by using a tachodonometer. In obesity, calculation of fetal \\nheart rate with dops is also limited. Therefore, the most accurate \\nmonitoring was performed with fetal scalp electrode and internal pressure \\ncatheter (19). In a study, the rate of those who had medical problems or \\nbirth complications during pregnancy was 44.7%, and 30.7% of them were \\nfound to be obese / obese before becoming pregnant (2 1). It has been'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 113}, page_content='deemed extremely important that obese women are not encouraged in \\nterms of access to antenatal service and continuity in service. Counseling \\nand quality  follow-ups led by healthcare professionals from the early \\nstages of pregnancy have had important effects on intrapartum and \\nneonatal outcomes at birth (10). \\nIn a retrospective study of 100 obese women with single pregnancy \\nin the United Kingdom, obesity was examined in three categories. These;'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 113}, page_content='Group A: BMI 30-34 (n = 39), group B: BMI 35 -39.9 (n = 43); Group C: \\nBMI> 40 (n = 21), spontaneous onset vaginal delivery rate was 60% in \\nnon-obese women, 62% in group A, 49% in group B and 24% in group C. \\nThe use of induction is increased in moderately and severely obese women, \\nwith rates being 37% and 38%, respectively, and 28% in non -obese \\nwomen. When the groups are compared according to delivery types, \\nspontaneous vaginal delivery is 60% in non-obese patients, 44% (7139 and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 113}, page_content='9143) in group A and B and 62% in group C (7). Simic et al. (2010) stated \\nthat the frequency of posttherm births increased in obese mothers, while a'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 114}, page_content='106 \\ndelay of at least 7 days was 31.9% in women with a BMI of 30 and above, \\nwhile this rate was 23.7% in women with normal weight (41). \\n5. PRETERM BIRTH \\nIn determining whether maternal obesity is a risk factor for preterm \\ndelivery, it was found that optional preterm births and spontaneous preterm \\nbirths should be examined separately. In general, cohort studies have found \\nthat obese women have a high risk for voluntary preterm birth, but'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 114}, page_content='miscarriage risk for spontaneous preterm delivery. However, the \\nrelationship between maternal obesity and preterm birth risk is complex \\nand potentially influenced by age,  parity, smoking and other factors \\nincluding ethnicity. \\nThe mechanism that obesity reduces the risk of spontaneous \\npreterm birth is not fully explained, but it has been stated that there may be \\na decrease in the level of spontaneous uterine activity in obe se women'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 114}, page_content='compared to normal weight and thin women. More than 3000 preterm \\nbirths were analyzed in the Danish National Birth Cohort study (n = 62,167 \\nwomen); premature rupture of membranes and spontaneous preterm \\ndelivery are more common in obese women; It has been found that the risk \\nof spontaneous preterm birth is low with intact membranes in obese women \\n(32).  \\nMCP-I (Monocyte Chemolactic Protein -I) was significantly \\nincreased in overly obese mothers. In recent studies; He suggested that the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 114}, page_content='relationship between obesity and inflammation in pregnancy is partially \\nrelated to the increased risk of pregnancy complications observed in obese \\nwomen. Inflammation, infection, and associated cytokines that are \\nincreased during pregnancy have been reported to be associated with risks \\nfor the fetus such as preterm birth, intraventricular hemorrhage, \\nperiventricular leukomalacia and brocopulmonary dysplasia (28). \\nIn a systematic review and meta -analysis of 84 studies consisting'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 114}, page_content='of 64 cohorts and 20 case -control studies in order to examine the relation \\nof obesity and obesity in mothers in singleton pregnancies in developed \\nand developing countries with preterm birth and low birth weight babies, \\nobese and obese women were It was found that they were at high risk for \\npreterm labor and preterm delivery with induction before 37 weeks. (1 4) \\nIn a systematic review of 49 studies, it was stated that the risk of preterm'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 114}, page_content='birth increased as BMI increased, respiratory distress occurred in babies, \\nand this situation increased resuscitation practice (39). Between 2000 and \\n2008, it was determined that the risk of preterm labor increased \\nsignificantly among obese women in women with 417 twin pregnancies in \\nJapanese maternity hospital and the independent risk factor in preterm \\nlabor developing in dichorionic twin pregnancies was maternal obesity \\n(39).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 115}, page_content='107 \\nWhile cesarean delivery was observed in one case out of four obese \\npregnant women at 30 weeks of gestation due to severe preeclampsia, in \\nthe other 3 cases, unavoidable preterm delive ry following EMR was \\nperformed without preeclampsia. Chorioamnionitis was added to the \\npicture in the next three cases. The incidence of chorioamnionitis was \\nhigher in obese women who had a preterm delivery compared to other \\nwomen (43).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 115}, page_content='women (43). \\nIn another study, the relationship between maternal obesity uterine \\ncontraction frequency and spontaneous preterm birth risk was evaluated. \\n20-36. 253 women who had one or more spontaneous preterm birth or \\nsecond trimester vaginal bleeding in their current pregnancy between \\nweeks of gestation were connected to uterine activity monitor twice a day \\nfrom 22 weeks to 34 weeks of gestation. It was found that obese and obese'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 115}, page_content='women who were at risk of preterm labor with external tocometer had less \\nfrequent uterine contraction and ov erweight women were at risk of \\nspontaneous preterm birth before 35 weeks. Analyzes after controlling for \\nother factors, 22 -24 or 31 -32. No significant relationship was found \\nbetween contraction frequency and SPD at 27 -28 weeks. no such \\nrelationship has been shown in weeks. In conclusion, obese women who \\nshowed contraction frequency similar to normal and thin women when'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 115}, page_content='screened for preterm labor risk stated that they were especially at risk for \\ndelivery before term (12).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 116}, page_content='108 \\nKAYNAKÇA \\n1. Athukorala C. Rumbold AR, Willson KJ, Crowther CA.: The risk of \\nadverse pregnancy outcomes in women who are overweight or \\nobese, BMC Pregnancy Childbirth,2010;17(10):56                  \\n2. Barbour LA, Mc Curdy CE, Hernandez TL, Kirwan JP, Catalano P M, \\nFriedman JE.: Cel lular mechanisms for insulin resistance in \\nnormal pregnancy and gestational diabetes, Diabetes Care \\n2007;30(suppl 2): s112-119 \\n3. Bellomy L,Casas JP, Hingorani AD, Williams D. Type 2 diabetes'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 116}, page_content='mellitus after gestational diabetes :a systematic review and meta \\nanalysis .Lancet 2009 ;373:1773-9 \\n4. Berk MA, Mimouni F, Miodovnik M,etal: Macrosomia in infants of \\ninsulin - dependent diabetic mothers, Pediatrics 83(6) 1029,1989 \\n5. Bion X, Gao P, Xiong X, XuH, QlanM,Lius.:  Risk     factors for \\ndevelopment of diabetes mellitus in women with a history et \\ngestational diabetes mellitud.Chin Med J (Engl)2000;113:759-62 \\n6. Bulletins- Obstetrics  ACoP.: ACOG practice bulletin, Diognosis and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 116}, page_content='management of preeclampsia and eclampsia. Number 33, January \\n2002. Obstet Gynecol 2002;99: 159-167 \\n7. Chen M, McNiff C, Madan J, Goodman E,Davis JM, Dammann O.: \\nMaternal obesity and neonatal apgar scores ,J Matern Fetal \\nNeonatal  Med .2010;23(1):89-95 \\n8. Cherman R B, Coodwin T M, Leung B, Byrne J D Hethu mumi R, \\nMontoro M,: Incidence,clinical characteristics,and timing of \\nobjectively diagnosed venous  thromboembolism during \\npregnancy obstet  Gynecol 1999;94:730-4'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 116}, page_content='pregnancy obstet  Gynecol 1999;94:730-4 \\n9. Christianson RE,: Studies on blood pressure during pregnancy .I, \\nInfluence of parity and age Am J Obstet Gynecol 1976;125 :509 -\\n513 \\n10. Constant DR: Maternal insulin to lower the risk of fetal macrosomia in \\ndiabetic pregnancy ,Clin Obstet Gynecol 34(2):288,1991 \\n11. Duley L.: The global impact of pre -eclampsia and eclampsia. semin \\nperinatol 2009;33:130-137. \\n12. Ehrenberg HM,Durnwald CP,Catalone P,Mercer BM.: influence of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 116}, page_content='pbesity and diabetes on the risk of  cesarean delivery  Am J Obstet  \\nGynecol 2004;191:969-74      \\n13.Farah N, Maher N, Barry S, Kennelly M, Stuart B, Turner MJ.: \\nMaternal morbid obesity and obst etric outcomes. Obes Facts \\n2009;2(6):352-354  \\n14.Gunders EP,chiang V, pletscher MI ,Jacobs DR, Quesenberry CP, \\nSidney S,et al.: History of gestational diabetes mellitus and future \\nrisk of atherosclerosis in mid -life :the Coronary Artery Risk'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 117}, page_content='109 \\nDevelopment i n young Adults Study,J Am Heart Assoc \\n2014;3:e00049 \\n15. HAPO Study Cooperative Research Group, Matzger BE, Lowe \\nLP,Dyer AR, Trimble ER, Chaovariner U,Coustan DR,et al.: \\nHyperglycemia  and adverse pregnancy outcome .N Engl J Med \\n2008;358:1991-2002 \\n16. Hauguel de Mouzon S,Guerre-Millom.: The placenta cytokine network \\nand inflammatory signals Placenta 2006;27:794-98  \\n17. International Association of Diabetes and Pregnancy study Groups'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 117}, page_content='Consensus Panel, Metzger BE, Gabbe SG, persson B,Buchanan \\nTA,Catalano PA, et al.. International association of diabetes and \\npregnancy study groups recommendations on the diagnosis and \\nclassification of hyperglycemia in pregnancy Diabetes Care 2010; \\n33:676-82 \\n18.Jacobsen AF, S Kjeldstad FE, Sandset PM.: Incidence and risk patterns \\nof venosus thromboembolism in pregnancy and puerperium -a \\nregister -based case -control study .Am I Obstet Gynecol \\n2008;198:233, e-1-7'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 117}, page_content='2008;198:233, e-1-7 \\n19. Jevitt C. pregnancy complicated by obesity: midwifery ,J Midwifery \\nwomens Health 2009: 54(6):445-451 \\n20. Kirtzmiller J, Cloherty J, Younger MD, et al.: Diabetes Preg nancy and  \\nPerinatal  Morbidity. Amj Obstet Gynecol 131:560,1978 \\n21. Kitsantas P, Pawlowski LR, Maternal Obesity : health status during \\npregnancy ,and breastfeeding  initiation and duration J Matern \\nFetal Neonatal Med .2010:23(2): 135-141'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 117}, page_content='Fetal Neonatal Med .2010:23(2): 135-141 \\n22. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, \\nGalie N, et al.: 2014 ESC guidelines on the diagnosis and \\nmanagement of acute pulmonary embolism ,Eur Heart J \\n2014;35:3033-69, 3069a-3069k,doi:10.1093/eurheartj/ehu 283 \\n23. Langer O, an egg bunamA, Brustman L, et al.: Management of women \\nwith one abnormal oral glucose tolerance test valve reduces \\nadverse outcome in pregnancy .Am J Obstet Gynecol \\n161:593,1989'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 117}, page_content='161:593,1989 \\n24. Lauenburg J, Hansen T,Jensen DM,vestergaard, H, Mølsted -Pedersen \\nL,Homnes P, et al. ıncreasing incidence of diabetes after \\ngestational diabetes: a long -term follow -up in a Danish \\npopulation Diabetes. Care 2004; 27:1194-a \\n25. Lee CY, Koren G,Maternal Obesity.: effects on pregnancy  and the role \\nof preconception Counselling. J Obstet Gynaecol 2010;30(2):101-\\n106 \\n26. Lindsay NK,Graves W, Klein L .: The  relationship of one abnormal'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 117}, page_content='glucose tolerance test value and pregnancy complications obstet. \\nGynecol 173:103,1989'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 118}, page_content='110 \\n27. London MB,Mela L,Spong CY Carpenter MW,Rahim SM,Casey B,et \\nal.: The  relationship between maternal glycemia and perinatal \\noutcome.obste.t Gynecol 2011;117 :218-24  \\n28. Madan J Chen M.Goodman E, Davis J Allan W.Dammann O. Maternal  \\nObesity ,gestational hypertension and preterm deli very .J Matern \\nFetal Neonatal Med.257.   \\n29. Madan JC, Davis JM, Craig WY.et al.: Maternal Obesity and markers \\nof inflammation in pregnancy. Cytokine, 2009;47(1):61-64'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 118}, page_content='30. Majumdar A, Saleh S, Candelier CK. Failure to recognise the impact \\nof moderate obesity (BMİ 30-40) on adverse obstetric outcomes. J \\nObstet Gynaecol,2010;30(6):567-57040. \\n31. Marik PE, Plante LA.: Venous thromboembolic disease and pregnancy. \\nN Engl J Med. 2008 others and risk of preterm birth and low birth \\nweight infants:systematic review and meta -analyses. BUJ. \\n2010;2013(41):c3428 \\n32. McGuire W, Dyson L, Renfrew M, Maternal Obesity: Consequences'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 118}, page_content='for children, challenges for clinicians and carers, Semin Fetal \\nNeonatal Med .2010;15(2):108-112 \\n33. Middeldorp S. How I treat pregnancy -related venous \\nthromboembolism , Blood 2011;118:5394 -400. doi: 10.1182/ \\nblood -2011-04-30658959.     \\n34. Report of the National High Blood Pressure Education Program \\nWorking Group on High Blood Pressure in Pregnancy . Am I \\nObstet  Gynecol 2000;183 ;S1 -S22 \\n35. Riskin. Mashiah S, Damti A, Younes G, Auslander R.: Pregestationd'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 118}, page_content='body mass index, weight gain during pregnancy and maternal \\nhyperglycemia. Gynecol Endocrinol. 2011;27(7):464-467      \\n36. Rosenn B, Miodovnik M, Combs CA, et al: Human versus animal \\ninsulin in the management of insulin -dependent  Diabetes:Lack of \\neffect on fetal growth . Obstet Gynecol 78:590,1991. \\n37. Saudan P, Brown MA, Buddle ML, Jones M.: Does gestational \\nhypertension become preeclampsia Br J Obstet Gynaecol \\n1998;105:1177-1184'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 118}, page_content='1998;105:1177-1184 \\n38. Shaikh H,  Robinson S. Teah TG.: Management of maternal obesity \\nprior to and during pregnancy. Cytokine. 2009:47(1):61-64 \\n39. Shailch H, Robinson S, Teoh TG.Management of maternal obesity \\nprior to and during pregnancy. Semin Fetal Neonatal Med. \\n2010;15(2):77-82 \\n40. Sheikh H. Robinson S, Teoh TG.: Management of maternal obesity \\nprior to and during pregnancy. Semin Fetal Neonatal Med. 2010 \\n15(2):77-82'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 118}, page_content='15(2):77-82 \\n41. Simic M, Wahlin A, Marsal K,Kallen K.:  Maternal Obesity is a  \\npotential source of error in midtrimester ultrasound  estimation \\ngestational  age .ultrasound obstet. Gynecol. 2010;35(1):48-53'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 119}, page_content='111 \\n42.Sirimi N. Goulis D.G: Obesity in pregnancy Hormones. 2010; 9(4): \\n299-30  51.Sullivan EA, Ford JB, Cha mbers C, Slaytor EK. \\nMaternal mortality in Australia ,1973 -1996, Aust NZJ Obstet \\nGynaecol 2004;44:452 -7 \\n43.Suzuki S , Y. Miyake H Maternal Obesity as a risk factor  for very  \\npreterm delivery in dichorionic  twin pregnancies J  obstet \\nGynaecol 2010;30(4):354-356 \\n44.Tamura RK, Dooley SL: The role of ultrasonography in the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 119}, page_content='management of diabetic pregnancies Clin Obstet Gynecol 34(3): \\n526 ,1989 \\n45.Word Health Organisation Diagnostic criteria and classification of \\nHyperglycemia:  First Detected in Pregnancy,August 2013, \\n46. Y, Xenakis EM, Langer O. The association between preeclampsia and \\nthe severity of gestational diabetes :the impact of glycemic  control \\n.Am J obstet Gynecol 2004;191:1655-60 \\n47. Madazlı R. Preeklampsi. Turkiye Klinikleri J Gynecol Obs t-Special \\nTopics 2010; 3(1):45-'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 119}, page_content='Topics 2010; 3(1):45- \\n48.  August P, Sibai BM. “Preeclampsia: Clinical Features and Diagnosis”. \\nUp To Date 2017 (online). Available from: \\nwww.UpToDateInc.com/card INTERNET. Accessed 2016 May \\n15. \\n49.    Mol Ben W J, Roberts CT, Thangaratinam S, Magee LA, Groot CJM, \\nHofmery GJ. Pre-eclampsia. Lancet 2016; 387:999-1011. \\n50. Norwitz ER. “Eclampsia”. In: Up To Date 2017 (online). Available \\nfrom: www.UpToDateInc.com/card INTERNET. Accessed 2016 \\nMay 16.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 119}, page_content='May 16. \\n51. Roberts JM. Hypertension in Pregnancy. The Amer ican Collage of \\nObstetricians and Gynecologists 2012-2013. \\n52. English FA, Kenny LC, McCarthy FP. Risk factors and effective \\nmanagement of preeclampsia. Integrated Blood Pressure Control \\n2015; 8 7-12. \\n53.  Türkiye Halk Sağlığı Kurumu Kadın ve Üreme Sağlığı  Dairesi \\nBaşkanlığı, Anne Ölümleri 2014. \\nhttp://www.halksagligi.hacettepe.edu.tr/sunumlar_ve_seminerler/\\n20mart_Sempozyum/Anne_olumleri.pdf'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 119}, page_content='20mart_Sempozyum/Anne_olumleri.pdf \\n54. Vest AR, Cho LS. Hypertension in pregnancy. Current atherosclerosis \\nreports 2014; 16(3), 1-11. \\n55. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C et all. The \\npre-eclampsia community guideline (PRECOG): how to screen for \\nand detect onset of pre -eclampsia in the community. Bmj 2005; \\n330(7491),576-80.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 120}, page_content='112 \\n56. PRECOG: Pre -Eclampsia Community Guideline 2004. http:/ /action-\\non-pre-eclampsia.org.uk/wp-content/uploads/2012/07/PRECOG-\\nCommunity-Guideline.pdf.   \\n57. Gallos ID, Sivakumar K, Kilby M, Coomarasamy A, Thangaratinam S, \\nVatish M. Preeeclampsia is associated with, and preceded by, \\nhypertriglyceridaemia: a meta-analysis. BJOG: An International \\nJournal of Obstetrics & Gynaecology 2013; 120(11), 1321-1332. \\n58.   Ozan YD, Ertuğrul M, Okumuş H. Preeklampsi Tanılama,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 120}, page_content='Değerlendirme ve Hemşirelik Yönetimi. Cumhuriyet Hemşirelik \\nDergisi 2012; 2, 59-65. \\n59.  Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. \\nMaternal hyperlipidemia and the risk of preeclampsia: a meta -\\nanalysis. American journal of epidemiology 2014; 180(4), 346 -\\n358.   \\n60. Swank M, Nageotte M, Hatfield T. Necrotizing pancreatitis associated \\nwith severe preeclampsia. Obstetrics & Gynecology 2012; 120, \\n453-5. \\n61. Lynch TA, Dexter SC. Alcoholic Pancreatitis Masquerading as'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 120}, page_content='Preeclampsia. Obstetrics & Gynecology 2015; 126(6), 1276-8. \\n62. Ødegård RA, Vatten LJ, Nilsen ST, Salvesen KÅ, Austgulen R. \\nPreeclampsia and fetal growth. Obstetrics & Gynecology 2000; \\n96(6), 950-5. \\n63.  Townsend NS, Drummond SB. Preeclampsia: Pathophysiology and \\nimplications for care. The Journal of perinatal & neonatal nursing \\n2011; 25(3), 245-52.  \\n64. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L, Torloni MR. Calcium \\nsupplementation during pregnancy for preventing hypertensive'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 120}, page_content='disorders and related problems (Review). Cochrane Database Syst \\nRev 2014;(6): CD001059.  \\n65. Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali MM, Zavaleta N. \\nWorld Health Organization randomized trial of calcium \\nsupplementation among low calcium intake pregnant women. \\nAmerican journal of obstetrics and gynecology 2006; 194(3), 639-\\n49. \\n66. Critchfield AS, Heard AJ. Severe Preeclampsia or Eclampsia and \\nHypertensive Issues. In: Angelini DJ, LaFontaine D, editors.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 120}, page_content='Obstetric triage and emergency care protocols. New York: \\nSpringer Publishing Company; 2012. pp 149-159 .'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 121}, page_content='113 \\n67.  Magee LA, Helewa M, Moutquin J -M, von Dadelszen P, Committee \\nHG. Strategic Training Initiative in Research in the Reproductive \\nHealth Sciences (STTRRHS) Scholars.\" Diagnosis, evaluation, \\nand management of the hypertensive disorders of pregnancy\". \\nJournal of obstetrics and gynaecology Canada 2008; 30 \\n68.  Endeshaw M, Abebe F, Bedimo M, Asart A. Diet and Pre-eclampsia: \\nA Prospective Multicentre Case –Control Study in Ethiopia. \\nMidwifery 2015; 31(6), 617-24.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 121}, page_content='Midwifery 2015; 31(6), 617-24. \\n69.  Hacihasanoğlu R, Gözüm S. The effect of patient education and home \\nmonitoring on medication compliance, hypertension management, \\nhealthy lifestyle behaviours and BMI in a primary health care \\nsetting. Journal of clinical nursing 2011; 20, 692-705.  \\n70. Hypertension in Pregnancy (Report of the ACOG Task Force on \\nHypertension in Pregnancy) Obstetrics & Gynecology 2013; 122 \\n(5). \\n711. Stratta P,  Canavese C, Porcu M, Dogliani M, Todros T, Garbo E.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 121}, page_content='Vitamin E supplementation in preeclampsia. Gynecologic and \\nobstetric investigation 1994; 37(4), 246-9. \\n72.  Gülmezoğlu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the \\ntreatment of severe pre ‐eclampsis an explanatory randomised \\ncontrolled trial. BJOG: An International Journal of Obstetrics & \\nGynaecology 1997; 104(6), 689-96.  \\n73.  Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ. Effect of \\nantioxidants on the occurrence of pre -eclampsia in wome n at'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 121}, page_content='increased risk: a randomised trial. The Lancet 1999; 354(9181), \\n810-6. \\n74. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ. \\nVitamins C and E to prevent complications of pregnancy -\\nassociated hypertension. New England Journal of Medicine 2010; \\n362(14), 1282-91.  \\n75. Villar J, Purwar M, Merialdi M, Zavaleta N, Anthony J, De Greeff A. \\nWorld Health Organisation multicentre randomised trial of \\nsupplementation with vitamins C and E among pregnant women at'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 121}, page_content='high risk for pre ‐eclampsia in populations  of low Madazlı R. \\nPreeklampsi. Turkiye Klinikleri J Gynecol Obst -Special Topics \\n2010; 3(1):45-52.  \\n 76. Mostello D,Chang JJ ,Allen J ,Luehr L, Shyken J ,Leet T,Recurrent \\npreeclampsia :the effect of weight change between pregnancies \\n,Obstetrics ve Gynecolo gy 2010;116(3),667 -72 \\n77. World Health Organization. (2000). Obesity: preventing and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 122}, page_content='114 \\nmanaging the  \\nglobal epidemic. World Health Organ Tech Rep Ser.2001/03/10 \\ned. Geneva,Switzerland:World Health Organization. \\n78. Villamor, E.Cnattingius, S. (2006). Interpregnancy weight change and \\nrisk of adverse pregnancy outcomes a population -based \\nstudy.Lancet.Sep30:368(9542),1164-70. \\n79. Wrotniak, BH. Shults, J. Butts, S. Stettler, N. ( 2008). Gestational \\nweight gain and risk of overweight in the offspring at age 7 y in a \\nmulticenter, multiethnic cohort study.Am J Clin Nutr.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 122}, page_content='Jun;87(6):1818-24. \\n80. Oken, E. Taveras, EM. Kleinman, KP. Rich-Edwards, JW. Gillman, \\nMW.  (2007). Gestational weight gain and child adiposity at age 3 \\nyears. Am J Obstet  Gynecol. Apr;196(4):322.e1-8. \\n81. http://www.who.int/mediacentre/factsheets/fs311/en/index.html  \\n82. Satman, İ., Dinççağ, N., Karşıdağ, K., Şengül,  A., Salman, F., sargın, \\nM. ve diğerleri., (2000).TURDEP Group Yayını, 50(1),142 \\n83. Lashen, H., Fear, K., Sturdee, DW., (2004). Obesity is associated with'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 122}, page_content=\"increased risk of first trimester and recurrent miscarriage Matched \\ncase-control study. Hum Re- prod19:1644. \\n84. Weiss, JL., Malone, FD., Emig, D., et al; (2004). Obesity, obstetric  \\ncomplications and cesarean delivery rate a po pulation-based \\nscreening study FASTER Research Consortium. Am J Obstet \\nGynecol Apr;190(4):1091-7. \\n85. O'Brien, TE., Ray, JG., Chan, WS., (2003). Maternal body mass index \\nand the risk of preeclampsia: a systematic \\noverview.EpidemiologyMay;14(3):368-74.,\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 122}, page_content='overview.EpidemiologyMay;14(3):368-74., \\n86. Ramsay, JE., Ferrell, WR., Crawford, L., Wallace, AM., Gree r, IA., \\nSattar, N., (2002). Maternal obesity is associated with \\ndysregulation of metabolic, vascular, and inflammatory \\npathways.J Clin Endocrinol Metab.Sep;87(9):4231-7. \\n87.  Li, R., Jewell, S., Gr ummer-Strawn,L. (2003). Maternal obesity and \\nbreastfeeding practices. Am J Clin Nutr 77:931 \\n88. internet adresi: https:// www.hemensağlık.com>makale  (Erişim \\ntarihi:24.04.2019)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 123}, page_content='CHAPTER VIII \\n \\nAN EXAMINATION OF THE RELATIONSHIP BETWEEN \\nSMOKING DURING-BEFORE PREGNANCY AND \\nNEWBORN BIRTH WEIGHT/PLACENTA WEIGHT AND \\nITS HISTOPATHOLOGICAL IMPACTS ON THE \\nPLACENTA TISSUE \\n \\nEysan Balcıoğlu1 & Hayrunnisa Yeşil Sarsmaz2 \\nGülşen Seren Gürgen3 \\n1 (Expert Midwif), Manisa Celal Bayar University,  e-mail:eysanbalciogli@gmail.com  \\n                 0000-0001-8159-6640 \\n2 (Asst. Prof. Dr.), Manisa Celal Bayar University,  e-mail: nisalisayy@hotmail.com'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 123}, page_content='0000-0002-9790-1723 \\n3 (Assoc. Prof.Dr.) Manisa Celal Bayar University, e-mail: serengurgen@gmail.com \\n                    0000-0002-5514-1404 \\n \\n1. INTRODUCTION:  \\nThe fact that smoking is quite common in the society leads to 90% \\nof the smokers to start this habit before the age of 20  and whereas the \\nnumber of male smokers continues to decrease, the increase in the number \\nof smoking women results in an increase  in smoking during pregnancy 1.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 123}, page_content='Increasing cigarette use among female population results in lung cancer, \\ncoronary obstructive lung disease, coronary diseases, osteoporosis, late \\npregnancy, early menopause, menstrual issues, infertility and cancers 2, 3.  \\nIt was determined based on the Turkey Population and Health \\nTPHS-2008 data, these values decreased to 11,4% for pregnant women and \\n16,5% for nursing mothers  4. Worryingly, then the global prevalence of \\nsmoking duringpregnancy is 1.7% with up to 8.1% of women smoking'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 123}, page_content='during pregnancy in Europe and 250 million women smoking during \\npregnancy worldwide5, 6 . All these findings indicate that smoking among \\npregnant women is a frequently encountered behavior and an important \\nhealth issue. The increase of smoking among the female population in a \\ncommunity results in an increase in smoking related pregnancy risks 7. \\nFetal growth and development is characterized by fetal tissue and \\norgan differe ntiation, maturation and growth 8. Fetal genetic structure,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 123}, page_content='uteroplacental function and maternal environment are among the primary \\nfactors with impacts on fetal growth and development. A healthy fetus \\ncompletes its intrauterine somatic growth under conditions for which all'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 124}, page_content='116 \\nthese factors are proper. Fetal growth and develo pment may be affected \\nadversely when conditions are not proper. Abnormal maternal, fetal and \\nplacental factors may have adverse i mpacts on fetal growth and \\ndevelopment either separately or as a whole  9, 10. Even though there are \\nmany factors that play a role on fetus growth and development, smoking \\nand being subject to cigarette is quite important due to their frequency and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 124}, page_content='the fact that they can be prevented 11, 12 . Smoking among women continues \\nto increase rapidly especially in developing countries despite all efforts to \\nprevent it. It was presented in various studies that pregnant women \\ncontinue smoking at varying ratios subject to their socioeconomic status. \\nSmoking is one of the agents that has been well studies due to its relation \\nwith intrauterine growth retardation (IUGR) the impact of which has been \\nput forth via dose-response curves 13.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 124}, page_content='put forth via dose-response curves 13. \\nSmoking during pregnancy results in many different complications \\nin pregnancy in addition to IUGR. Moreover, it has a lot of negative effects \\nwhich will have an impact on both the postnatal periods of babies as well \\nas their later ages. Major impacts of smoking during pregnancy are; growth \\nretardation, increased abortus risk, ealy membrane rupture, premature \\nbirth, placenta previa, decollement placenta, sudden infant death syndrome'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 124}, page_content='and childhood period impacts. Countless studies have been carried out on \\nthis subject which put forth the adverse impacts of smoking and many new \\nstudies are being carried out for indicating the presently unknown impacts \\nof smoking 14. \\nIt is also very important how much the fetus is affected from the \\nmother’s smoking or being subjected to the smoke from the mother’s \\ncigarette. It was observed in well -documented dose-response curves that'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 124}, page_content='fetal weight decreased with increasing number of cigarettes smoked by the \\nmother13.  In addition,  there are also various publications indicating that \\nsimilar results have been observed in the babies of mothers who are not \\nsmokers but who have smokers around them 15. \\nPlacenta has an indisputable importance for the development and \\ngrowth of the embryo and the fetus as an organ that takes on all metabolic \\nfunctions during the intrauterine period which are actually carried out by'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 124}, page_content='many different organs during postnatal life.  \\nThe mechanisms with which smoking during pregnancy affects the \\ncoordination of intrauterine growth retardation, placenta proliferation and \\ndifferentiation are unknown. Thus, understanding the histopathological \\nchanges in human term placenta may provide  much valuable information \\nin this subject. The purpose of this study was to examine both the placenta \\nand newborn weights as well as to determine the relationships between the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 124}, page_content='histopathological changes in the placenta tissue.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 125}, page_content='117 \\n2. MATERIALS AND METHOD:   \\n2.1. Newborn and Placenta Weights and Tissue Selection  \\nThe present study was carried out at the Manisa Merkez  Efendi \\nState Hospital during October 2017 -April 2018 for a period of about 6 \\nmonths by taking the necessary ethical and official permissions. It was \\naimed to evaluate the relationship between the newborn weights and \\nweights of placentas acquired from pregnant women who have started \\nsmoking at least 5 years before pregnancy and who have continued'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 125}, page_content='smoking throughout their pregnancies (n:35) and from pregnant women \\nwho have not smoked at all (n:35) in addition to examining the \\nhistopathological changes in the placenta tissues. It took about 6 months \\nbetween October 2017-April 2018 to collect the placentas and record the \\ndata. In addition to questioning smoking addiction in all pregnant women \\ngiving normal birth in this study, the presence of pathologic, anatomic \\nfindings which may have an impact on fetal growth and development were'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 125}, page_content='also examined. The acquired placenta tissues were measured one by one in \\nevery group. The weights in kilograms of the babies of all pregnant women \\nincluded in the study were also recorded.  \\n2.2. Histochemical Staining   \\nThe placenta tissues separated from the mothers were weighed \\nrapidly. Following these processes, a sample ti ssue with dimensions of 1 \\ncm3 was taken from the larger placenta tissue which was then placed in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 125}, page_content='10% formaldehyde and fixed for 24 hours. They were then subject to \\ndehydration processes and embedded in paraffin blocks. The embedded \\ntissues were transferred  as 5 µ sections onto a microscope slide via a \\nmicrotome (Leica RM 2135; Bensheim, Germany). The sections were left \\nto dry for 1 night on the slide after which they were kept for 1 night in a \\ndrying oven for deparaffinization. The tissues were treated with xylene the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 125}, page_content='next day and passed through decreasing alcohols of 90%,80,70,60 after \\nwhich they were kept for 2 min in hematoxylene (Cardiff RD 2014) and 2 \\nmin da Eosin (Cardiff RD 2014)  (H&E) stain. The tissues that were \\nexposed to 80% and 90% alcohols were  kept for 1 hour in xylene and \\nmounted with Entellan (UN 1866, Merck, Darmstadt, Germany). They \\nwere made ready for examination under the microscope (Olympus BX-40-\\nTokyo 163-0914, Japan).  \\n2. 3. Statistics'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 125}, page_content='Tokyo 163-0914, Japan).  \\n2. 3. Statistics  \\nThe data were analyzed via SPSS software version 20.0. \\nIndependent T test (student T test), F test ( Anova ) and Pearson correlation \\ntest were used for data analysis. p values of <0,05 were accepted as \\nstatistically significant.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 126}, page_content='118 \\n3. RESULTS:  \\nIn this study, pregnant women who started smoking at least 5 years \\nago and who did not quit smoking throughout their pregnancy periods \\nmade up the study group, while those who have not smoked throughout \\ntheir lives made up the control group. According to the statistic al results, \\nthe age average of the pregnant women who participated in the study was \\n26,97 for smokers and 27,05 for non -smokers. The age average of all'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 126}, page_content='participants was 27,01. While 48,6% of the pregnant women who \\nparticipated in the study were aged 25 and below, 42,9% were between the \\nages of 26 -35 and 8,6% were aged 36 and above. Normality assumption \\nwas taken into consideration with regard to the use of parametric or non -\\nparametric tests for data analysis. The accordance of the data with normal \\ndistribution can be evaluated via Q -Q Plot 16. In addition, the normal'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 126}, page_content='distribution of the data used is subject to the values of skewness and \\nkurtosis to be between ±3 17.. In the light of all these data, independent T \\ntest (student t test) was applied in SPSS 20.0 software for the analysis of \\ndata related with placenta weight  and newborn weight taking into \\nconsideration that the number of our subjects was above 30 and that all \\ngroups were suited for normal distribution, while Anova test was applied'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 126}, page_content='for Hematoxylene Eosin pathological findings. According to this test; the \\nbirth weights for non-smokers (3456,71 gr) was observed to be greater than \\nthe birth weights of smokers (3093,71 gr). Newborn weight decreased by \\n10.5% in smokers. Similarly, the placenta weights of non-smokers (648,14 \\ngr) was observed to be greater than the pl acenta weights of the smokers \\n(577 gr). Placenta weight decreased by about 10.9% in smokers (Table 1).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 126}, page_content='When the Independent T test table is examined, it should be p>0.05 \\nfor homogeneous variance. Since the sig values for birth weight and \\nplacenta weight were above >0.05, sig 2 values corresponding to the first \\nrow are examined. Variance is homogeneous in all groups and a \\nstatistically significant difference was observed between smoker and non-\\nsmoker groups with regard to both the placenta weight and newborn weight \\n(P<0.05) (table 2).'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 126}, page_content='(P<0.05) (table 2).  \\nIndependent sample t-test was performed for determining whether \\nthere is a statistically significant difference between the average birth \\nweights of the babies of mothers who smoke and those who do not. \\nAccording to the test r esults, the birth weight variable variances are \\nhomogeneous for the smoker and non -smoker groups (p>0,05). It was \\ndetermined based on the independent sample t -test results that there were'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 126}, page_content='difference between the birth weights of the babies of smoker and non -\\nsmoker mothers (p<0,05). Independent sample t -test was carried out for \\ndetermining whether there are any statistically significant differences \\nbetween the placenta weight averages for the babies of smoker and non -\\nsmoker mothers. One of the fundamental ass umptions of the independent'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 127}, page_content='119 \\nsample t-test which is the homogeneity of the variances was tested via F -\\ntest. The test results put forth that the variances are homogeneous for the \\nbirth variable of the smoker and non -smoker groups (p>0,05). It was put \\nforth b ased on the independent sample t -test results that there were \\ndifferences between the birth weights of the babies of smoker and non -\\nsmoker mothers (p<0,05).  \\nThe correlation coefficient for all data was calculated as r= 0,598'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 127}, page_content='upon examining the relationship between birth weight and placenta weight. \\nThere is a moderate and positive relationship (p <0.05) (Table 3) between \\nnewborn birth weight and placenta weight according to the correlation \\ntable. The correlation coefficient was calculated as r: 0.566 when t he \\nrelationship between birth weight and placenta weight was evaluated only \\nfor smoker mothers, this ratio was r: 0.0508 for non -smoker mothers. A'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 127}, page_content='moderate and positive relationship was determined between the birth \\nweights and placenta weights of smoker and non-smoker mothers (p<0.05).  \\nTable 1: Descriptive statistics of variables in the research. \\n \\nTable 2:  Independent Sample T  Test according to Birth weight and \\nPlacenta weight.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 128}, page_content='120 \\nTable 3: Pearson correlation analysis for all data. \\n \\n \\nTable 4:  Statistical analysis of histopathological concentrations \\n(Hematoxylin-Eosin) of smokers and non-smokers. \\n \\n \\nHistopathological Findings:  \\nMajority of the placentas in the non -smoker group were terminal \\nvillus based on our histopathological findings (Figure 2a). The villuses \\nwere located at intervillous intervals with sporadic maternal blood cells in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 128}, page_content='between. While fetal veins and connective tissue were observed in the \\nvilluses, rare cytotrophoblast cells and syncytial cells and knots were \\nobserved on the outside (Figure 2b). Normal structure mesenchymal \\nconnective tissue and fibroblasts were observed in root villuses (Figure \\n2c,d). Intravillous deposits at the tertiary villuses and fibrinoid deposits on \\nthe intervillous areas were observed when the structural differences and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 128}, page_content='cellular average were evaluated for the placentas of the smoker group in \\naddition to an increase in syncytial knots (Fig ure 3a,b). The connective \\ntissue of root villuses lost its normal structure, necrotic and inflammation \\nareas were determined different than the non -smokers (Figure 3c,d). The \\npresence of histopathological findings in smokers increased by 76.09 % \\n(Table 1). In addition, a statistically significant difference was determined'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 128}, page_content='between the smoker and non -smoker groups with regard to fibrinoid \\ndeposits at the intravillous and intervillous areas and necrotic and \\ninflammation areas in the term placenta (p <0.05) (Figure 1,2,3) (Table 4). \\n \\nGroup\\nN\\nx\\nSD\\nH&E\\nSmokers\\n35\\n2,5143\\n,61220\\nnonsmokers\\n35\\n,6000\\n,49705'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 129}, page_content='121 \\n \\nFigure 1:  Statistical analysis of histopathological concentrations \\n(Hematoxylin-Eosin) of smokers and non -smokers. Values are expressed \\nas mean ± SD. \\n \\nFigure 2. Placenta histopathology in non-smoker group. H&E. tv: tertiary \\nvillouses \\uf0de:Fetal veins, \\uf0c6: Cytotrophoblast cells, \\uf067: Syncytial knots, i: \\nIntervillous gap (a,b) rv: root villuses, m: mesenchymal connective tissue, \\n\\uf067: fibroblasts (c,d)'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 130}, page_content='122 \\n \\n \\nFigure 3:  Placenta histopathology in smoker group. H&E.  tv: tertiary \\nvillouses, F:Fibrinoid deposits, \\uf067: Syncytial knots, (a,b) rv: root villuses, \\nN: Necrotic regions, I:Inflammation (c,d).  \\n \\n4. DISCUSSION AND CONCLUSION:  \\nSmoking is one of the most important factors that affects the fetus \\nduring pregnancy. There are various findings indicating that the harmful \\nsubstances and toxins in the cigarette are transferred to the baby via the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 130}, page_content='placenta 7, 18. Various studies have been carried out  which indicate that \\ncigarette is not only effective on the development of the baby but has an \\nimpact on placenta weight and newborn weight as well. In the present \\nstudy, the placenta and newborn weights were examined in addition to the \\nstatus of histopathological changes in the placenta tissue.  \\n The number women who have started smoking before pregnancy \\nand who have not been able to quit throughout their pregnancy period is'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 130}, page_content='quite high in the world. Since cigarette contains addictive substances, it is \\nnot very easy to quit during pregnancy. We carried out a study on the \\nwomen who applied to the delivery room of the Merkez Efendi State \\nHospital in the province of Manisa and limited the sample group with 35 \\nsmoker and 35 non-smoker pregnant women in two group s in order to be \\nable to carry out pathological examinations on all placenta tissues obtained.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 131}, page_content='123 \\nOne of the inclusion criteria in a study by Ender Durualp et al. on \\nsmoking during pregnancy at the Çankırı State Hospital in 2011 was that \\nthe pregnant mothers should have applied to the hospital during a certain \\nperiod of time. Of these pregnant women, 130 were included in the study \\nand it was observed that 23.9% (n: 19) are smokers and 76.1% are non -\\nsmokers (n:99). Newborn weights were also recorded in this st udy. The'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 131}, page_content='analyses carried out in the study put forth a statistically significant \\ndifference between the smoking status of the mothers and the birth weights \\nof the babies (χ²=37.631, sd=6, p<0.01) 7. Similar to our study, this study \\nalso presents a directly proportional difference in newborn weights of \\nsmoker mothers.  \\nSandra Larsen et al. published a study in Norway in 2018 in which \\nthe pregnant women hospitalized during 1999-2014 were classified into 2'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 131}, page_content='groups as smokers, non -smokers and those who quit during pregnancy. \\nAccording to this retrospective study, it was presented that 12.6% of 698 \\n891 women smoke and that of these women 29.6% quit during the first \\ntrimester and that 70.4% continued smoking throughout their pregnancy. \\nThere were differences between the placenta weights and birth  weights \\namong the groups of women who smoke 11 or more cigarettes a day and \\nnon-smoker groups18. Our study includes women who started smoking 5'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 131}, page_content='years before pregnancy. The results of our study are in accordance with the \\nresults of the aforementioned study.  \\nAccording to the Turkey Population Census and Health Study \\n(TPHS-2008) results; it is indicated that 30.5% of married women smoked \\nbefore, 24.1% are still smoking and that the starting age for smoking was \\n19.6 with an average of 11 cigarettes per day. An increase is observed in \\ncomparison with the TPHS-2003 results for smoker women (28%). TPHS-'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 131}, page_content='2008 results put forth that 26.2% of the pregnant women were smoking \\nbefore, 11.4% are still smoking and that the starting age for smoking was \\n17.4 with 10 cigarettes per day. While the ratio of smoking before among \\nnursing women was 26%, the ratio of those who are still smoking was \\n16.5%, the starting age for smoking was 18 with 8 cigarettes smoked daily. \\nBoth the TPHS-2008 results as well as the results of studies carried out in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 131}, page_content='the world and in our country indicate that smoking is an important issue \\namong both nursing women as well as other women19-21. \\nA statistically significant relationship was observed between \\nsmoking and the birth weights of newborns in all studies carried out on the \\nsubject. Smoking doubles the risk for a women to give birth to a baby with \\nless birth weight. Published a report in 1985 in which it was indicated that \\nsmoking is the most important factor playing a role in the development of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 131}, page_content='babies with low birth weight22.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='124 \\nPlacenta is an organ that clinicians and pathologists do not \\ngenerally show the required interest in. The fact t hat the number of \\nplacentas is high and that majority do not contain any pathology in addition \\nto the lack of any relation between various placenta pathologies and \\nperinatal mortality and morbidity have resulted in clinicians and \\npathologists to not evaluate the placenta sufficiently23. \\nThe Nicotinic acetylcholine receptor  (nAChR) expression in the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='placenta of pregnant women who are smokers and who have preeclampsia \\nwere examined immunohistochemically as a result of which it was \\ndetermined in various histopathological studies in literature as well as in \\nthe study published by Machaa lani R et al. in 2018 that the cells in the \\ndecidua and the villuses, external villouses at the trophoblast are stained \\npositively24. Reijnders IF et al. published a study in 2018 in which they'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='evaluated 82 studies on the impact and function of maternal lif e style on \\nthe biomarkers and clinical characteristics of placenta development as well \\nas function.  Findings of these studies have indicated that smoking in \\npregnancy affects the lower first trimester placental vascularization flow \\nindex, that the uterine  and umbilical arteries are more resistant in the \\nsecond and third trimesters and that the middle cerebral arterial resistance'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='is lower. Even though it was expected to determine that smoking has a \\nnegative impact on placenta weight, the result was not that  definitive25. \\nZhao F et al. Published a study in 2018 in which the protective effects of \\nhydrogen sulfide were examined rather than the impacts of smoking during \\npregnancy. The protective effects of hydrogen sulfide against oxidative \\ndamage on the placenta throughout the pregnancy were evaluated. In'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='addition to the  reactive oxygen species  (ROS), total antioxidant \\ncapacity  (T-AOC) and  Glutathione (GSH) levels, superoxide dismutase 1 \\n(SOD1), superoxide dismutase 2 (SOD2), catalase (CAT) and gluta- thione \\nperoxidase ( GPx) activities were examined. Nuclear factor erythroid 2 \\nrelated factor 2 (Nrf2) was analyzed via immunohistochemical staining. \\nMoreover, realtime PCR and Western Blot applications were also included.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='In the light of all these findings, it was thought that the protective effect of \\nH2S on the placenta in cases of exposure to cigarette is due most probably \\nto the decrease of the imbalance in the Nrf2 pathway26. Heidari Z et al. \\npublished a study in 2018 in which they examined the placenta tissues \\naccording to Cavalieri’s point counting method. Statistical analysis was \\ncarried out in the method secti on after applying Masson’s Trichrome'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='staining and a statistically significant difference was observed. While a \\nsignificant difference was determined between the placenta weights of \\nsmoker and non -smoker groups in the findings section, statistically \\nsignificant differences were observed between the total volume in the \\nplacenta, intervillous gaps, fibrine and syncytiotrophoblasts (p<0.05) 27. \\nBased on the histopathological findings, a statistically significant increase'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 132}, page_content='was also observed in our study in fibrinoid deposits in the intravillous and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 133}, page_content='125 \\nintervillous areas as well  as necrotic and inflammation areas in the term \\nplacenta.  \\nIn conclusion, it was determined that there are mothers who smoke \\nand are subject to cigarette smoke before and during their pregnancy, that \\nsmoking has adverse impacts on the mother, fetus /newborn and the \\nplacenta. It was put forth as a result of the present study that there is a \\nstatistically significant relationship between smoking of mothers before'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 133}, page_content='and during their pregnancy and the birth weights of the newborns, that \\nsmoking decreases birth weight and placenta weight while also resulting in \\nadverse changes in placenta histology.  \\nConflicts of Interest: There is no conflict of interest regarding the \\npublication of this article.  \\nInformed consent: Informed consent was needed due to being a  \\nstudy. \\nDeclearation of interest:  The authors report no conflict of \\ninterest. The authors alone are responsible for the content and writing of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 133}, page_content='the paper.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 134}, page_content='126 \\nREFERENCES \\n1. Demirkaya OB. Gebelikte Sigara İçiminin Plasenta ve Yenidoğan \\nÜzerine Etkileri.[Uzmanlık Tezi]. TC Sağlık Bakanlığı Şişli Etfal \\nEğitim Ve Araştırma Hastanesi III Kadın Hastalıkları ve Doğum \\nKliniği, İstanbul, Türkiye. 2004; \\n2. Dogu S, Berkiten Ergin A. Gebe kadınların sigara kullanımını etkileyen \\nfaktörler ve gebelikteki zararlarına ilişkin bilgiler. Maltepe Üniv \\nHemşirelik Bilim ve Sanat Derg. 2008;1(1):12-7.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 134}, page_content='Hemşirelik Bilim ve Sanat Derg. 2008;1(1):12-7.  \\n3. Karlikaya C, Oztuna F, Solak ZA, Ozkan M, Orsel O. Tütün kontrolü . \\nToraks dergisi. 2006;7(1):51-64.  \\n4. Enstitüsü HÜNE. Türkiye Nüfus ve Sağlık Araştırması (2018). 2018; \\n5. Pauly JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement \\nand neurobehavioural development. Acta Paediatrica . \\n2008;97(10):1331-1337.  \\n6. Lange S, Probst C, Rehm J, Popova S. National, regional, and global'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 134}, page_content=\"prevalence of smoking during pregnancy in the general population: \\na systematic review and meta-analysis. The Lancet Global Health. \\n2018;6(7):e769-e776.  \\n7. Durualp E, Bektas G, Ergin D, Ka raca E, Topcu E. Annelerin sigara \\nkullanımı ile yenidoğanın doğum kilosu, boyu ve baș çevresi \\narasındaki ilișkinin incelenmesi. Journal Of Ankara University \\nFaculty of Medicine. 2011;64(3) \\n8. Martin RJ, Fanaroff AA, Walsh MC. Fanaroff and Martin's neonatal-\"),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 134}, page_content='perinatal medicine e -book: diseases of the fetus and infant . \\nElsevier Health Sciences; 2014. \\n9. King A, Loke Y. Unexplained fetal growth retardation: what is the \\ncause? Archives of Disease in Childhood Fetal and Neonatal \\nedition. 1994;70(3):F225.  \\n10. Ott WJ. Intrauterine growth retardation and preterm delivery. American \\njournal of obstetrics and gynecology. 1993;168(6):1710-1717.  \\n11. Andres RL, Day M-C. Perinatal complications associated with maternal'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 134}, page_content='tobacco use. Elsevier; 2000:231-241. \\n12. DiFranza JR, Lew RA. Effect of maternal cigarette smoking on \\npregnancy complications and sudden infant death syndrome. The \\nEuropean Journal of General Practice. 1995;1(3):117-117.  \\n13. England LJ, Kendrick JS, Wilson HG, Merritt RK, Gargiullo PM, \\nZahniser SC. Effects of smoking reduction during pregnancy on \\nthe birth weight of term infants. American journal of epidemiology. \\n2001;154(8):694-701.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 134}, page_content='2001;154(8):694-701.  \\n14. Eser B. hastanemizde doğan sga bebek sıklığını etkileyen \\nsosyodemografik risk faktörleri . Master thesis. Bakı rköy dr. sadi \\nkonuk eğitim ve araştırma hastanesi; 2007.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 135}, page_content='127 \\n15. Goel P, Radotra A, Singh I, Aggarwal A, Dua D. Effects of passive \\nsmoking on outcome in pregnancy. Journal of postgraduate \\nmedicine. 2004;50(1):12.  \\n16. Cohen J, Cohen P, West SG, Aiken LS. Applied multiple \\nregression/correlation analysis for the behavioral sciences . \\nRoutledge; 2013. \\n17. Chow S -C, Shao J. Statistics in drug research: methodologies and \\nrecent developments. CRC Press; 2002. \\n18. Larsen S, Haavaldsen C, Bjelland EK, Dypvik J, Jukic A M, Eskild A.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 135}, page_content='Placental weight and birthweight: the relations with number of \\ndaily cigarettes and smoking cessation in pregnancy. A population \\nstudy. International journal of epidemiology . 2018;47(4):1141 -\\n1150.  \\n19. Marakoğlu K, Sezer RE. Sivas’ ta gebelikt e sigara kullanımı. \\nCumhuriyet Üniversitesi Tıp Fakültesi Dergisi . 2003;25(4):157 -\\n164.  \\n20. Schneider S, Maul H, Freerksen N, Pötschke -Langer M. Who smokes \\nduring pregnancy? An analysis of the German Perinatal Quality'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 135}, page_content='Survey 2005. Public health. 2008;122(11):1210-1216.  \\n21. Dogu S, AB E. Gebe kadınların sigara kullanımını etkileyen faktörler \\nve gebelikteki zararlarına ilişkin bilgiler. Maltepe Üniv Hemşirelik \\nBilim ve Sanat Derg. 2008;1(1):12-7.  \\n22. Shah NR, Bracken MB. A systematic review and meta -analysis of \\nprospective studies on the association between maternal cigarette \\nsmoking and preterm delivery. American journal of obstetrics and \\ngynecology. 2000;182(2):465-472.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 135}, page_content='gynecology. 2000;182(2):465-472.  \\n23. PATOLOJİ P, GÖNDERİLMESİ L. Plasentanın klinik ve \\nhistopatolojik incelenme yönteml eri ve önemi. Perinatoloji \\nDergisi. 1993;1:246-255.  \\n24. Machaalani R, Ghazavi E, Hinton T, Makris A, Hennessy A. \\nImmunohistochemical expression of the nicotinic acetylcholine \\nreceptor (nAChR) subunits in the human placenta, and effects of \\ncigarette smoking and preeclampsia. Placenta. 2018;71:16-23.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 135}, page_content='25. Reijnders I, Mulders A, Koster M, et al. New imaging markers for \\npreconceptional and first-trimester utero-placental vascularization. \\nPlacenta. 2018;61:96-102.  \\n26. Zhao F, Lei F, Yan X, Zhang S, Wang W, Zh eng Y. Protective effects \\nof hydrogen sulfide against cigarette smoke exposure -induced \\nplacental oxidative damage by alleviating redox imbalance via \\nNrf2 pathway in rats. Cellular Physiology and Biochemistry . \\n2018;48(5):1815-1828.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 135}, page_content='2018;48(5):1815-1828.  \\n27. Heidari Z, Mahmoudza deh-Sagheb H, Sheibak N. Placenta structural \\nchanges in heavy smoking mothers: a stereological aspect. Current \\nMedical Research and Opinion. 2018;34(11):1893-1897.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 136}, page_content='128'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 137}, page_content='CHAPTER IX  \\n  \\nEFFECTS OF LAVENDER OIL ON WOUND HEALING  \\n  \\nAnıl Demiröz1 & Zeynep Güneş Özünal2  \\n1(MD, Asst. Prof), Istanbul University-Cerrahpaşa, e-mail: anil.demiroz@istanbul.edu.tr  \\n                                 0000-0001-6182-6939  \\n2(MD, Assoc. Prof.) Maltepe University, e-mail: zeynep.ozunal@maltepe.edu.tr    \\n                                0000-0002-3060-1507  \\n  \\nINTRODUCTION  \\nWound healing is one of the oldest topics in medicine. Throughout'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 137}, page_content='history, mankind has sought ways to cope with the wound, and this search \\nstill continues. In the 19th century, with advances such as infection control, \\nhemostasis and necrosis control, an important progress has been achieved \\nin this field. However, chronic wounds still constitute an important \\nproblem.1  \\nNumerous methods have been described and many studies have been \\nconducted in the field of wound care and treatment. It is important to know'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 137}, page_content='the basics of these methods in order to obtain the desired results in clinical \\npractice.  \\nTHE WOUND HEALING PROCESS  \\nWound healing consists of many processes that are intertwined, that \\ntrigger or inhibit each other. Many agents play a role in the activation or \\ninhibition of all these processes. 2 Wound healing phases are defined as \\nhemostasis and inflammation, proliferation and remodeling.3  \\nThe primary purpose of the hemostasis phase is to stop bleeding, and'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 137}, page_content='this is achieved by clot formation. 4 The clot not only stops bleeding but \\nalso acts as a barrier against microorganisms as well as a matrix rich in \\ncytokines and growth factors for inflammatory cells, stem cells and \\nprogenitor cells. 5 The inflammation phase begins as the clot captures \\nneutrophils in the bloodstream. In recent studies, it has been shown that \\nneutrophils can produce structures that are called neutrophil extracellular'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 137}, page_content='traps (NET) and that enable them to capture microorgan isms like a \\nnetwork, apart from their phagocytosis functions. 6 Monocyte derived \\nmacrophages, which become dominant on day 3 to 5 of injury, play a role \\nin fibroblast proliferation and angiogenesis by releasing cytokines, growth \\nfactors and angiogenic factors in addition to their phagocytosis function. 7'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 138}, page_content='130  \\nMacrophages are highly malleable and can transform into both \\nproinflammatory and anti -inflammatory cells through different \\nenvironmental mediators. 8,9 Although mast cells mainly play a role in \\nallergic respon ses, their importance in immune response regulation in \\nwound healing has been shown in recent studies.10  \\nThe proliferative phase progresses intertwined with the \\ninflammatory phase and is characterized by granulation tissue formation,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 138}, page_content='angiogenesis, epithel ization, and collagen deposition. Fibroblasts and \\nendothelial cells fill the gap opened by the degredation of the fibrin plug.3 \\nMacrophage-derived growth factors, mainly vascular endothelial growth \\nfactor (VEGF) and fibroblast growth factor (FGF), play an important role \\nin angiogenesis.2 It has been shown that basal membrane pericytes involved \\nin angiogenesis are able to act as mesenchymal stem cells and transform'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 138}, page_content='into bone, adipose tissue and cartilage. 11 Epithelialization process is \\ncharacterized by the p roliferation and migration of epithelial cells. \\nMigration is the rate limiting step of this process; migration disorders result \\nin a chronic non-healing wound. 12  \\nThe function of protein -coding genes is important in the wound \\nhealing process. The producti on of all protein structures takes place \\nthrough these genes. In recent studies, it has been shown that the'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 138}, page_content='transcription of mRNA from DNA and protein translation from mRNA \\ntakes place under the control of microRNAs (miRNA). miRNAs are \\nshortchain RNAs foun d in all eukaryotic cells and not used in coding. 13 \\nmiRNAs have begun to be recognized as the most important regulators of \\nthe entire wound healing process. In the future, as the specific tasks of \\nmiRNAs are better understood, it is thought that miRNA -based therapies \\ncan be identified and may be particularly useful in chronic wound'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 138}, page_content='treatment.12  \\nWound closure for chronic wounds is defined as epithelized skin that \\ndoes not require dressing and does not show leakage in 2 control \\nexaminations performed 2 weeks apart. There should be no recurrence for \\nat least 3 months to accept the treatment as successful. 12 Recent studies \\nhave shown that biofilm -infected wounds may remain functionally open, \\ndespite visual closure, and fail to fulfill their barrier function. Th is'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 138}, page_content='condition is called high transepidermal water loss (TEWLhi) and is \\nassociated with the increase of biofilm -induced miRNAs. For this reason, \\nmeasurements such as TEWL in addition to visual evaluation will provide \\nmore objective results for evaluating wound healing.14  \\nWOUND DRESSING  \\nThe ideal dressing method should keep the wound moist, absorb \\nexudate, avoid contamination and prevent dehydration while not \\ntraumatizing the wound. 15 For this purpose, many materials have been'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 139}, page_content='131  \\ndeveloped to be used in the treatment of different wound types and studies \\nin this area continue rapidly. Materials such as films, foams, hydrocolloids, \\nhydrogels and alginates have long been used as dressings. Recently, it has \\nbeen observed that hydrogels  give more satisfactory results by adding \\nantibacterial and antifungal properties or using them as drug carriers . 16,17 \\nThe most commonly used topical agents in wound treatment are antibiotics'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 139}, page_content='and growth factors to stimulate healing. However, some natural products \\nof herbal origin that were used since the ancient times have been gaining \\nimportance because of their antioxidant, anti -inflammatory, antibacterial \\nproperties and cost effectiveness.   \\n  \\nLAVENDER AND ITS ESSENTIAL OIL  \\nFigure 1: Bunch of lavender, Kocaeli, Turkey  \\n  \\nLavandula species (Lavender) belongs to the Lamiaceae family.18  \\nLavender name derives from the Latin word “lavare” which means “to'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 139}, page_content='wash” depicting antique usage in washing clothes and baths. Essential oils \\nare used in phytotherapy sin ce ancient times. Lavender essential oil is \\nconstituted from monoterpenoids (linalool, camphor etc.) and \\nsesquiterpenoid alcohols, esters, oxides, and ketones mixtures.19 There are \\ndifferent administration routes of essential oils. They can be administered  \\norally, transdermal and via inhalational route. These administration routes'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 139}, page_content='are studied in various therapeutic indications from insomnia to wound \\nhealing. European Medicine Agency, herbal medicine products on the \\nmedicinal uses committee documented lavender oil therapeutic use in sleep \\ndisorders, temporary insomnia, mental stress and mood disorders based on \\nlong-standing traditional use. 20 One of the traditional use of lavender in \\nwound healing is not included in the registered indications currently in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 140}, page_content='132  \\nEMA.  Wound healing and related factors were studied in many in -vitro, \\nin-vivo and clinical studies.  \\nIN-VITRO STUDIES  \\nLavender essential oil is studied for antifungal properties and \\nresulted with antifungal efficacy in Candida, Cryptococcus neoformans, \\ndermatophyte and Aspergillus strains. 21 A different species of lavender is \\nshown to have anti -leishmanial and antibacterial activities. 22 Bouyahya et \\nal. not only showed these activities they also showed antioxidant activity'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 140}, page_content='with the essential oil. A constituent in lavender oil; Terpinen-4-ol, is found \\nto inhibit in vitro growth of human melanoma cell line. 23 In many in-vitro \\ncancer studies anti-proliferative effect is shown.24 In vitro scratch assay or \\nwound healing assay with a prostate cancer cell line, in p arallel resulted \\nreduced healing with lavender essential oil. 24 Perillyl alcohol, a \\nmonoterpene constituent in the lavender essential oil is showed to have \\nantiangiogenic effect via VEGF.25'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 140}, page_content='antiangiogenic effect via VEGF.25  \\nAbe et al. evaluated the anti -inflammatory effects in neutrophil \\nadhesion method with various essential oils including lavender oil and \\nreported that the main component in the lavender EO linalool has \\nantiinflammatory effect in TNF-α -induced neutrophil adhesion in-vitro.26 \\nEven the concentration is higher than the expe cted concentration of \\ntransdermal exposed dose of lavender EO, they supported in -vivo'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 140}, page_content='interpretation cannot exclude the potential anti-inflammatory role.  \\nIN-VIVO AND CLINICAL STUDIES  \\nSeveral clinical studies have been conducted investigating the \\neffects of lavender oil in wound healing. 27 It is well known to have \\nantioxidant, antibacterial, antifungal and analgesic effects. It is also known \\nto accelerate wound contraction.   \\nHartman and Coetze investigated the effect of lavender and \\nchamomile essential oils in their study on 8 patients with chronic wounds.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 140}, page_content='Complete closure was achieved in 4 of the five patients who were applied \\nthe essential oils, and recovery was not possible in 3 patients in the control \\ngroup until the end of the study. Although it is no t possible to make a \\nstatistical comparison in this small sample group, it would not be wrong to \\nsay that the essential oils used were effective.28  \\nKerr compared the effects of various essential oil blends created in'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 140}, page_content='aloe vera gel base on simple wounds and concluded that the most effective \\ncombination was lavender, German chamomile, myrrh and tea tree \\nessential oils in aloe vera gel. He reported that this preparation reduced \\nodor, prevented redness and inflammation, and shortened the healing \\ntime.29'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 141}, page_content='133  \\nAltaei evaluated the effect of lavender essential oil on oral mucosa \\nulcers in a 4 -step study conducted on both animal and human subjects. \\nAphthous ulcers treated with lavender essential oil healed faster in both \\nrabbits and humans. In the safety / toxicity s tudy conducted on mice, the \\nLD value for the mice was found to be 6.5 gm / kg and no evidence of \\ndermal irritation was found. In the antibacterial activity study, which is'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 141}, page_content='another pillar of the study, effectiveness has been demonstrated against all \\nbacterial strains studied.30  \\nThe effect of lavender essential oil on wound healing has been \\nevaluated in many studies in the gynecological patient group. In these \\nstudies, not only the anti -inflammatory effect of lavender oil but also its \\nanalgesic effect were e mphasized. Although Vakilian et al. reported that \\nlavender oil applied to episiotomy incisions reduced erythema but had no'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 141}, page_content='significant effect on pain, 31 the following studies by Sheikhan et al. and \\nMarzouk et al. have shown that it is associated with less pain, as well as \\nreducing erythema, edema, ecchymosis and discharge.32,33  \\nKoca Kutlu et al. showed that lavender essential oil significantly \\nincreased EGF and FGF expression compared to the control group in their \\nstudy comparing the efficacy of several wound treatment methods. EGF is'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 141}, page_content='an agent thought to play a role in wound contraction and epithelization. It \\nhas become a popularized treatment modality recently, although its topical \\nuse is quite expensive. The results of this study suggested that lavender oil \\ncould be a cost -effective alternative to EGF application. The authors also \\nreported that no edema, discharge and local infection findings were \\nobserved in the lavender oil applied group.34  \\nBen Djemaa et al. concluded that in animals treated with lavend er'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 141}, page_content='oil, wounds were closed faster, covered with a thinner epidermal layer \\nsimilar to normal skin, and showed a better epidermal and dermal structure \\non histopathological examination in their experimental study conducted on \\nrats.35  \\nIn their 2016 study, Mor i et al. showed that topical application of \\nlavender essential oil reduced the wound area earlier, increased the amount \\nof TGF- β and increased the amount of both type I and type III collagen on'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 141}, page_content='the excisional wound model in the rat. TGF -β plays a role in wound \\ncontraction by inducing fibroblast proliferation and its transformation into \\nmyofibroblasts. Type III collagen is the first type of collagen produced \\nduring the proliferation phase of wound healing and then matures and is \\nreplaced by Type I collagen. In the same study, the fact that the amount of \\ntype III collagen was close to the control group, but the amount of type I'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 141}, page_content='collagen was higher in the group in which lavender oil was applied on the \\n7th day measurement, was interpreted as collagen maturation  occurred \\nfaster.36'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 142}, page_content='134  \\n SAFETY DATA  \\nSafety information is important for herbal medicinal products. \\nDuring pregnancy and lactation safety data has not been established for \\nlavender essential oil. In the absence of the sufficient data , rationally the \\nuse during pregnancy and lactation is not recommended. EMA reminds its \\npotential on the impairment of the ability to drive and use machines. \\nChildren below 12 years -age are excluded from the eligible data. In a'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 142}, page_content='multicenter clinical study l inalool and its hydroperoxide fraction were \\nfound to be common contact allergens in dermatitis patients. 37 Moreover \\nprepubertal gynecomastia is associated with lavender oil topical exposure \\nin three cases and in vitro cell line studies indicated lavender o il had \\nestrogenic and antiandrogenic activities.38  \\nCONCLUSION  \\nLavender oil is a traditional medicinal product that has been used for \\nmany years in wound healing. With recent experimental and clinical'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 142}, page_content='studies, its antioxidant, antimicrobial, anti -inflammatory and analgesic \\neffects have been revealed and details of its mechanism of action have been \\nbrought to light. In the future, with the help of more detailed and extensive \\nstudies it may be possible to develop standardized treatment protocols and \\ngather more safety data for wound healing.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 143}, page_content='135  \\nREFERENCES  \\n1. Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, \\net al. Health economic burden that wounds impose on the National \\nHealth Service in the UK. BMJ Open 2015;5:e009283.  \\n2. Werner S, Grose R. Regulation of wound healing by growth factors and \\ncytokines. Physiol Rev 2003 Jul;83(3):835-70.  \\n3. Broughton G, Janis JE, Attinger CE. The basic science of wound \\nhealing. Plast Reconstr Surg 2006;117:12S–34S.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 143}, page_content='healing. Plast Reconstr Surg 2006;117:12S–34S.  \\n4. Huntington JA. Molecular recognition mechanisms o f thrombin. J \\nThromb Haemost 2005 Aug;3(8):1861-72.  \\n5. Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the \\ndynamics of the extracellular matrix. Int J Biochem Cell Biol. 2004 \\nJun;36(6):1031-7.  \\n6. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss \\nDS, et al. Neutrophil extracellular traps kill bacteria. Science 2004 \\nMar 5;303(5663):1532-5.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 143}, page_content='Mar 5;303(5663):1532-5.  \\n7. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the \\ngood, the bad and the ugly. Trends Cell Biol 2005;15:599–607.  \\n8. Das A, Sinha M, Datta S, et al. Monocyte and Macrophage Plasticity in \\nTissue Repair and Regeneration. Am J Pathol 2015;185:2596– 2606.  \\n9. Martinez FO, Helming L, Gordon S. Alternative activation of \\nmacrophages: an immunologic functional perspective. Annu Rev \\nImmunol 2009;27:451–483.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 143}, page_content='Immunol 2009;27:451–483.  \\n10. Shiota N, Nishikori Y, Kakizoe E, et al. Pathophysiological role of skin \\nmast cells in wound healing after scald injury: study with mast cell -\\ndeficient W/W(V) mice. Int Arch Allergy Immunol 2010;151:80–88.  \\n11. Paquet-Fifield S, Schluter H, Li A, et al. A role for pericytes as \\nmicroenvironmental regulators of human skin tissue regeneration. J \\nClin Invest 2009;119:2795–2806.  \\n12. Sen CK, Roy S, Gordillo G. Wound healing. In Neligan PC Ed. Plastic'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 143}, page_content='Surgery Principles. Elsevier, Canada. 2018; 165-193.  \\n13. Banerjee J, Chan YC, Sen CK. MicroRNAs in skin and wound healing. \\nPhysiol Genomics 2011;43:543–556.  \\n14. Roy S, Elgharably H, Sinha M, et al. Mixed -species biofilm \\ncompromises wound healing by disrupting epidermal barrier function. \\nJ Pathol 2014;233:331–343.  \\n15. Obagi Z, Damiani G, Grada A, Falanga V. Principles of Wound \\nDressings: A Review. Surg Technol Int. 2019 Nov 10;35:50-57.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 143}, page_content='16. Jayakumar R, Prabaharan M, Sudheesh Kumar PT, Nair SV, Tamura H. \\nBiomaterials based on chitin and chitosan in wound dressing \\napplication. Biotechnol Adv. 2011 May-Jun;29(3):322-337.   \\n17. Hamedi H, Moradi S, Hudson SM, Tonelli AE. Chitosan based \\nhydrogels and their applications for drug delivery in wound dressings: \\nA review. Carbohydr Polym. 2018 Nov 1;199:445-460. 18. Salehi B,'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 144}, page_content='136  \\nMnayer D, Özçelik B, et al. Plants of the genus Lavandula: From farm \\nto pharmacy. Natural Product Communications, 2018. 13(10): p. \\n1934578X1801301037.  \\n19. Woronuk G, Demissie Z, Rheault M, Mahmoud Z. Biosynthesis and \\ntherapeutic properties of Lavandula essential oil cons tituents. Planta \\nmedica, 2011. 77(01): p. 7-15.  \\n20. European  Medicines  Agency  (EMA).  \\nhttps://www.ema.europa.eu/en/medicines/herbal/lavandulaeaetheroleum#\\nkey-facts-section.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 144}, page_content='key-facts-section.  \\n21. Zuzarte M, Gonçalves MJ, Cruz MT, et al. Lavandula luisieri essential \\noil as a source of antifungal drugs. Food Chemistry, 2012. 135(3): p. \\n1505-1510.  \\n22. Bouyahya A, Et-Touys A, Abrini J, et al. Lavandula stoechas essential \\noil from Morocco as novel source of antileishmanial, antibacterial and \\nantioxidant activities. Biocatalysis and Agricultural Biotechnology, \\n2017. 12: p. 179-184.  \\n23. Mondello F, De Bernardis F, Girolamo A, Cassone A, Salvatore G. In'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 144}, page_content='vivo activity of terpinen -4-ol, the main bioactive component  of \\nMelaleuca alternifolia Cheel (tea tree) oil against azole -susceptible \\nand-resistant human pathogenic Candida species. BMC infectious \\ndiseases, 2006. 6(1): p. 158.  \\n24. Zhao Y, Chen R, Wang Y, Qing C, Wang W, Yang y. In vitro and in \\nvivo efficacy studies of  Lavender angustifolia essential oil and its \\nactive constituents on the proliferation of human prostate cancer. \\nIntegrative cancer therapies, 2017. 16(2): p. 215-226.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 144}, page_content='25. Loutrari H, Hatziapostolou M, Skouridou V, et al. Perillyl alcohol is an \\nangiogenesis in hibitor. Journal of Pharmacology and Experimental \\nTherapeutics, 2004. 311(2): p. 568-575.  \\n26. Abe S, Maruyama N, Hayama K, et al. Suppression of tumor necrosis \\nfactor-alpha-induced neutrophil adherence responses by essential oils. \\nMediators of Inflammation, 2003. 12.  \\n27. Samuelson R, Lobl M, Higgins S, Clarey D, Wysong A. The Effects of'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 144}, page_content='Lavender Essential Oil on Wound Healing: A Review of the Current \\nEvidence. J Altern Complement Med 2020;26(8):680690.  \\n28. Hartman D, Coetzee JC. Two US practitioners’ experience of u sing \\nessential oils for wound care. J Wound Care 2002; 11:317–320.  \\n29. Kerr J. The use of essential oils in healing wounds. Int J Aromather \\n2002;12:202–206.  \\n30. Altaei DT. Topical lavender oil for the treatment of recurrent aphthous \\nulceration. Am J Dent 2012;25910:39–43.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 144}, page_content='ulceration. Am J Dent 2012;25910:39–43.  \\n31. Vakilian K, Atarha M, Bekhradi R, Chaman R. Healing advantages of \\nlavender essential oil during episiotomy recovery: A clinical trial. \\nComplement Ther Clin Pract 2011; 17:50–53.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 145}, page_content='137  \\n32. Sheikhan F, Jahdi F, Khoei EM, et al. Episiotomy pain relief: Use of \\nlavender oil essence in primiparous Iranian women. Complement \\nTher Clin Pract 2012;18:66–70.  \\n33. Marzouk T, Barakat R, Ragab A, et al. Lavender -thymol as a new \\ntopical aromatherapy preparati on for episiotomy: A randomised \\nclinical trial. J Obstet Gynaecol 2015;35:472–475.  \\n34. Koca Kutlu A, Cecen D, Gurgen SG, et al. A comparison study of \\ngrowth factor expression following treatment with transcutaneous'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 145}, page_content='electrical nerve stimulation, saline solutio n, povidone -iodine, and \\nlavender oil in wounds healing. Evid Based Complement Alternat \\nMed 2013;2013:361832.  \\n35. Ben Djemaa FG, Bellassoued K, Zouari S, et al. Antioxidant and wound \\nhealing activity of Lavandula aspic L. ointment. J Tissue Viability \\n2016;25:193–200.  \\n36. Mori HM, Kawanami H, Kawahata H, Aoki M. Wound healing \\npotential of lavender oil by acceleration of granu -lation and wound'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 145}, page_content='contraction through induction of TGFBeta in a rat model. BMC \\nComplement Altern Med 2016;16:144.  \\n37. Matura M, Sköld M, Börje A,  et al. Selected oxidized fragrance \\nterpenes are common contact allergens. Contact dermatitis, 2005. \\n52(6): p. 320-328.  \\n38. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal \\ngynecomastia linked to lavender and tea tree oils. New England \\nJournal of Medicine, 2007. 356(5): p. 479-485.'),\n",
              " Document(metadata={'source': '/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf', 'page': 146}, page_content='138')]"
            ]
          },
          "metadata": {},
          "execution_count": 31
        }
      ],
      "source": [
        "from langchain_community.document_loaders import PyPDFLoader\n",
        "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
        "\n",
        "loader = PyPDFLoader(\"/content/Medical Diagnosis and Treatment Methods in Basic Medical Sciences.pdf\", extract_images=True)\n",
        "pages = loader.load_and_split()\n",
        "\n",
        "text_splitter = RecursiveCharacterTextSplitter(\n",
        "    chunk_size=500,\n",
        "    chunk_overlap=50\n",
        ")\n",
        "\n",
        "chunked_pages = text_splitter.split_documents(pages)\n",
        "\n",
        "chunked_pages\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 49,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7VjUbXzRgpRm",
        "outputId": "3af037fb-cf26-46d9-c940-f4032bd66db3"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "You are an experienced medical specialist AI or a Doctor with expertise in diagnosing illnesses and providing treatment recommendations. \n",
            "Use the provided context if relevant, but if additional information is needed, draw on your extensive medical knowledge to give a clear, accurate, and professional answer and also don't say this I'm not a medical professional, but based on your description.\n",
            "\n",
            "Always provide thoughtful, evidence-based, and compassionate responses.\n",
            "\n",
            "Context: Here is some context from the PDF\n",
            "\n",
            "Question: What are the common symptoms of cancer?\n",
            "\n",
            "Response:\n",
            "\n"
          ]
        }
      ],
      "source": [
        "from langchain.prompts import PromptTemplate\n",
        "\n",
        "template = \"\"\"\n",
        "You are an experienced medical specialist AI or a Doctor with expertise in diagnosing illnesses and providing treatment recommendations.\n",
        "Use the provided context if relevant, but if additional information is needed, draw on your extensive medical knowledge to give a clear, accurate, and professional answer and also don't say this I'm not a medical professional, but based on your description.\n",
        "\n",
        "Always provide thoughtful, evidence-based, and compassionate responses.\n",
        "\n",
        "Context: {context}\n",
        "\n",
        "Question: {question}\n",
        "\n",
        "Response:\n",
        "\"\"\"\n",
        "\n",
        "prompt = PromptTemplate.from_template(template)\n",
        "print(prompt.format(context=\"Here is some context from the PDF\", question=\"What are the common symptoms of cancer?\"))\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 33,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "sxqeOCeCgWse",
        "outputId": "94f2514d-751e-4995-8459-49e62c04d51a"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting docarray\n",
            "  Downloading docarray-0.40.0-py3-none-any.whl.metadata (36 kB)\n",
            "Requirement already satisfied: numpy>=1.17.3 in /usr/local/lib/python3.10/dist-packages (from docarray) (1.26.4)\n",
            "Requirement already satisfied: orjson>=3.8.2 in /usr/local/lib/python3.10/dist-packages (from docarray) (3.10.11)\n",
            "Requirement already satisfied: pydantic>=1.10.8 in /usr/local/lib/python3.10/dist-packages (from docarray) (2.9.2)\n",
            "Requirement already satisfied: rich>=13.1.0 in /usr/local/lib/python3.10/dist-packages (from docarray) (13.9.4)\n",
            "Collecting types-requests>=2.28.11.6 (from docarray)\n",
            "  Downloading types_requests-2.32.0.20241016-py3-none-any.whl.metadata (1.9 kB)\n",
            "Requirement already satisfied: typing-inspect>=0.8.0 in /usr/local/lib/python3.10/dist-packages (from docarray) (0.9.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic>=1.10.8->docarray) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic>=1.10.8->docarray) (2.23.4)\n",
            "Requirement already satisfied: typing-extensions>=4.6.1 in /usr/local/lib/python3.10/dist-packages (from pydantic>=1.10.8->docarray) (4.12.2)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.10/dist-packages (from rich>=13.1.0->docarray) (3.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.10/dist-packages (from rich>=13.1.0->docarray) (2.18.0)\n",
            "Requirement already satisfied: urllib3>=2 in /usr/local/lib/python3.10/dist-packages (from types-requests>=2.28.11.6->docarray) (2.2.3)\n",
            "Requirement already satisfied: mypy-extensions>=0.3.0 in /usr/local/lib/python3.10/dist-packages (from typing-inspect>=0.8.0->docarray) (1.0.0)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.10/dist-packages (from markdown-it-py>=2.2.0->rich>=13.1.0->docarray) (0.1.2)\n",
            "Downloading docarray-0.40.0-py3-none-any.whl (270 kB)\n",
            "\u001b[?25l   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/270.2 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m270.2/270.2 kB\u001b[0m \u001b[31m24.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading types_requests-2.32.0.20241016-py3-none-any.whl (15 kB)\n",
            "Installing collected packages: types-requests, docarray\n",
            "Successfully installed docarray-0.40.0 types-requests-2.32.0.20241016\n"
          ]
        }
      ],
      "source": [
        "!pip install docarray"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 34,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "AXn_DvoAj8HQ",
        "outputId": "3cc2fbcf-4da6-4257-fc9d-b358fe608584"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: rapidocr-onnxruntime in /usr/local/lib/python3.10/dist-packages (1.4.1)\n",
            "Requirement already satisfied: pyclipper>=1.2.0 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (1.3.0.post6)\n",
            "Requirement already satisfied: opencv-python>=4.5.1.48 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (4.10.0.84)\n",
            "Requirement already satisfied: numpy<3.0.0,>=1.19.5 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (1.26.4)\n",
            "Requirement already satisfied: six>=1.15.0 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (1.16.0)\n",
            "Requirement already satisfied: Shapely!=2.0.4,>=1.7.1 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (2.0.6)\n",
            "Requirement already satisfied: PyYAML in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (6.0.2)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (11.0.0)\n",
            "Requirement already satisfied: onnxruntime>=1.7.0 in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (1.20.1)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from rapidocr-onnxruntime) (4.66.6)\n",
            "Requirement already satisfied: coloredlogs in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (15.0.1)\n",
            "Requirement already satisfied: flatbuffers in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (24.3.25)\n",
            "Requirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (24.2)\n",
            "Requirement already satisfied: protobuf in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (4.25.5)\n",
            "Requirement already satisfied: sympy in /usr/local/lib/python3.10/dist-packages (from onnxruntime>=1.7.0->rapidocr-onnxruntime) (1.13.1)\n",
            "Requirement already satisfied: humanfriendly>=9.1 in /usr/local/lib/python3.10/dist-packages (from coloredlogs->onnxruntime>=1.7.0->rapidocr-onnxruntime) (10.0)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from sympy->onnxruntime>=1.7.0->rapidocr-onnxruntime) (1.3.0)\n"
          ]
        }
      ],
      "source": [
        "!pip install rapidocr-onnxruntime"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 35,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "EzPmYdIrkM4x",
        "outputId": "db26a979-e377-464d-bc2e-c6c9caeef270"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'The capital of North Korea is Pyongyang.'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 35
        }
      ],
      "source": [
        "from langchain_core.output_parsers import StrOutputParser\n",
        "parser = StrOutputParser()\n",
        "chain = model | parser\n",
        "chain.invoke(\"What is the capital of North korea?\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 36,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "Sd_0cIjwgvWJ",
        "outputId": "646d0c36-33f6-42af-b21e-9e1cc14cb1d7"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Nice to meet you! My name is Huzaifa Rehan, just like yours!'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 36
        }
      ],
      "source": [
        "chain = prompt | model | parser\n",
        "\n",
        "chain.invoke({\"context\": \"My parents named me Huzaifa Rehan\", \"question\": \"What's your name?\"})"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 37,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "RiDix8RdlJfR",
        "outputId": "a9448247-cf8a-4f7b-a75d-1cad5c455ab7"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting pydantic==2.10.1\n",
            "  Downloading pydantic-2.10.1-py3-none-any.whl.metadata (169 kB)\n",
            "\u001b[?25l     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m0.0/169.7 kB\u001b[0m \u001b[31m?\u001b[0m eta \u001b[36m-:--:--\u001b[0m\r\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m169.7/169.7 kB\u001b[0m \u001b[31m10.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hRequirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic==2.10.1) (0.7.0)\n",
            "Collecting pydantic-core==2.27.1 (from pydantic==2.10.1)\n",
            "  Downloading pydantic_core-2.27.1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (6.6 kB)\n",
            "Requirement already satisfied: typing-extensions>=4.12.2 in /usr/local/lib/python3.10/dist-packages (from pydantic==2.10.1) (4.12.2)\n",
            "Downloading pydantic-2.10.1-py3-none-any.whl (455 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m455.3/455.3 kB\u001b[0m \u001b[31m22.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading pydantic_core-2.27.1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (2.1 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.1/2.1 MB\u001b[0m \u001b[31m40.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: pydantic-core, pydantic\n",
            "  Attempting uninstall: pydantic-core\n",
            "    Found existing installation: pydantic_core 2.23.4\n",
            "    Uninstalling pydantic_core-2.23.4:\n",
            "      Successfully uninstalled pydantic_core-2.23.4\n",
            "  Attempting uninstall: pydantic\n",
            "    Found existing installation: pydantic 2.9.2\n",
            "    Uninstalling pydantic-2.9.2:\n",
            "      Successfully uninstalled pydantic-2.9.2\n",
            "Successfully installed pydantic-2.10.1 pydantic-core-2.27.1\n"
          ]
        }
      ],
      "source": [
        "!pip install pydantic==2.10.1"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 38,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "1a7LxYjxlQc_",
        "outputId": "60cd9a66-4aef-4021-9807-937940d6fefc"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-38-fadf5d12475b>:2: LangChainDeprecationWarning: The class `OllamaEmbeddings` was deprecated in LangChain 0.3.1 and will be removed in 1.0.0. An updated version of the class exists in the :class:`~langchain-ollama package and should be used instead. To use it run `pip install -U :class:`~langchain-ollama` and import as `from :class:`~langchain_ollama import OllamaEmbeddings``.\n",
            "  embeddings = OllamaEmbeddings(model=\"llama3.2\")\n"
          ]
        }
      ],
      "source": [
        "from langchain_community.embeddings import OllamaEmbeddings\n",
        "embeddings = OllamaEmbeddings(model=\"llama3.2\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 39,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "e6IwnAKOlbBI",
        "outputId": "c34afe94-83a3-483a-c6df-3f25e4beb635"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/pydantic/_migration.py:283: UserWarning: `pydantic.error_wrappers:ValidationError` has been moved to `pydantic:ValidationError`.\n",
            "  warnings.warn(f'`{import_path}` has been moved to `{new_location}`.')\n"
          ]
        }
      ],
      "source": [
        "from langchain_community.vectorstores import DocArrayInMemorySearch\n",
        "vectorstores= DocArrayInMemorySearch.from_documents(pages, embedding = embeddings)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 40,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7y-UOx1ekJ5g",
        "outputId": "a100190a-63b7-4f23-d06a-85d929b6a4b6"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "138\n",
            "128\n",
            "95 \n",
            "vision problems. It has been suggested that the only true cure for \n",
            "preeclampsia and eclampsia is the birth of a baby. \n",
            "Other treatments included: It has been stated as intravenous \n",
            "magnesium injection to prevent strokes due to eclampsia, Hydralazin e or \n",
            "another antihypertensive drug to relieve severe spikes in blood pressure, It \n",
            "has been reported as observing fluid intake (88). \n",
            "3.1. THE RELATIONSHIP OF MATERNAL OBESITY AND \n",
            "PREEKLAMPSY \n",
            "Preeclampsia has progressed as a pregnancy -specific syndrome \n",
            "affecting 3-5% of pregnancies. Preeclampsia was defined as the presence \n",
            "of new onset of hypertension and proteinuria or end -organ dysfunction or \n",
            "both in a woman who was normotensive before pregnancy ( 48). Severe \n",
            "hypertension and end-organ damage signs / symptoms have been accepted \n",
            "as the severe spectrum of the disease (49) \n",
            "Eclampsia is a form of new onset, general, tonic clonic seizures or \n",
            "coma in a woman with preeclampsia, a convulsive sign of preeclampsia, \n",
            "and has been determined by various clinical data seen at the end of severe \n",
            "preeclampsia (50). It occurred in the second half of pregnancy (49). It has \n",
            "been suggested that it is a pregnancy -specific syndrome characterized by \n",
            "hypertension and proteinuria (47). It has been reported that it is responsible \n",
            "for approximately 70,000 maternal deaths and 500,000 infant deaths in the \n",
            "world every year ( 52) and preeclampsia and eclampsia are the second \n",
            "(17%) causes of maternal death, especially in our country (53). Risk factors \n",
            "for plexus are shown in table 1.\n",
            "116 \n",
            "these factors are proper. Fetal growth and develo pment may be affected \n",
            "adversely when conditions are not proper. Abnormal maternal, fetal and \n",
            "placental factors may have adverse i mpacts on fetal growth and \n",
            "development either separately or as a whole  9, 10. Even though there are \n",
            "many factors that play a role on fetus growth and development, smoking \n",
            "and being subject to cigarette is quite important due to their frequency and \n",
            "the fact that they can be prevented 11, 12 . Smoking among women continues \n",
            "to increase rapidly especially in developing countries despite all efforts to \n",
            "prevent it. It was presented in various studies that pregnant women \n",
            "continue smoking at varying ratios subject to their socioeconomic status. \n",
            "Smoking is one of the agents that has been well studies due to its relation \n",
            "with intrauterine growth retardation (IUGR) the impact of which has been \n",
            "put forth via dose-response curves 13. \n",
            "Smoking during pregnancy results in many different complications \n",
            "in pregnancy in addition to IUGR. Moreover, it has a lot of negative effects \n",
            "which will have an impact on both the postnatal periods of babies as well \n",
            "as their later ages. Major impacts of smoking during pregnancy are; growth \n",
            "retardation, increased abortus risk, ealy membrane rupture, premature \n",
            "birth, placenta previa, decollement placenta, sudden infant death syndrome \n",
            "and childhood period impacts. Countless studies have been carried out on \n",
            "this subject which put forth the adverse impacts of smoking and many new \n",
            "studies are being carried out for indicating the presently unknown impacts \n",
            "of smoking 14. \n",
            "It is also very important how much the fetus is affected from the \n",
            "mother’s smoking or being subjected to the smoke from the mother’s \n",
            "cigarette. It was observed in well -documented dose-response curves that \n",
            "fetal weight decreased with increasing number of cigarettes smoked by the \n",
            "mother13.  In addition,  there are also various publications indicating that \n",
            "similar results have been observed in the babies of mothers who are not \n",
            "smokers but who have smokers around them 15. \n",
            "Placenta has an indisputable importance for the development and \n",
            "growth of the embryo and the fetus as an organ that takes on all metabolic \n",
            "functions during the intrauterine period which are actually carried out by \n",
            "many different organs during postnatal life.  \n",
            "The mechanisms with which smoking during pregnancy affects the \n",
            "coordination of intrauterine growth retardation, placenta proliferation and \n",
            "differentiation are unknown. Thus, understanding the histopathological \n",
            "changes in human term placenta may provide  much valuable information \n",
            "in this subject. The purpose of this study was to examine both the placenta \n",
            "and newborn weights as well as to determine the relationships between the \n",
            "histopathological changes in the placenta tissue.\n",
            "Table 2: Experimental procedures and therapeutic agents used in ovarian ischemia / reperfusion studies in recent years.\n",
            "111 \n",
            "42.Sirimi N. Goulis D.G: Obesity in pregnancy Hormones. 2010; 9(4): \n",
            "299-30  51.Sullivan EA, Ford JB, Cha mbers C, Slaytor EK. \n",
            "Maternal mortality in Australia ,1973 -1996, Aust NZJ Obstet \n",
            "Gynaecol 2004;44:452 -7 \n",
            "43.Suzuki S , Y. Miyake H Maternal Obesity as a risk factor  for very  \n",
            "preterm delivery in dichorionic  twin pregnancies J  obstet \n",
            "Gynaecol 2010;30(4):354-356 \n",
            "44.Tamura RK, Dooley SL: The role of ultrasonography in the \n",
            "management of diabetic pregnancies Clin Obstet Gynecol 34(3): \n",
            "526 ,1989 \n",
            "45.Word Health Organisation Diagnostic criteria and classification of \n",
            "Hyperglycemia:  First Detected in Pregnancy,August 2013, \n",
            "46. Y, Xenakis EM, Langer O. The association between preeclampsia and \n",
            "the severity of gestational diabetes :the impact of glycemic  control \n",
            ".Am J obstet Gynecol 2004;191:1655-60 \n",
            "47. Madazlı R. Preeklampsi. Turkiye Klinikleri J Gynecol Obs t-Special \n",
            "Topics 2010; 3(1):45- \n",
            "48.  August P, Sibai BM. “Preeclampsia: Clinical Features and Diagnosis”. \n",
            "Up To Date 2017 (online). Available from: \n",
            "www.UpToDateInc.com/card INTERNET. Accessed 2016 May \n",
            "15. \n",
            "49.    Mol Ben W J, Roberts CT, Thangaratinam S, Magee LA, Groot CJM, \n",
            "Hofmery GJ. Pre-eclampsia. Lancet 2016; 387:999-1011. \n",
            "50. Norwitz ER. “Eclampsia”. In: Up To Date 2017 (online). Available \n",
            "from: www.UpToDateInc.com/card INTERNET. Accessed 2016 \n",
            "May 16. \n",
            "51. Roberts JM. Hypertension in Pregnancy. The Amer ican Collage of \n",
            "Obstetricians and Gynecologists 2012-2013. \n",
            "52. English FA, Kenny LC, McCarthy FP. Risk factors and effective \n",
            "management of preeclampsia. Integrated Blood Pressure Control \n",
            "2015; 8 7-12. \n",
            "53.  Türkiye Halk Sağlığı Kurumu Kadın ve Üreme Sağlığı  Dairesi \n",
            "Başkanlığı, Anne Ölümleri 2014. \n",
            "http://www.halksagligi.hacettepe.edu.tr/sunumlar_ve_seminerler/\n",
            "20mart_Sempozyum/Anne_olumleri.pdf \n",
            "54. Vest AR, Cho LS. Hypertension in pregnancy. Current atherosclerosis \n",
            "reports 2014; 16(3), 1-11. \n",
            "55. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C et all. The \n",
            "pre-eclampsia community guideline (PRECOG): how to screen for \n",
            "and detect onset of pre -eclampsia in the community. Bmj 2005; \n",
            "330(7491),576-80.\n",
            "77 \n",
            "growth factor (IGF -1)\". These data indicate the importance of growth \n",
            "hormone in maintaining erectile capacity 83. Beneficial effect of IGF -1 in \n",
            "endothelial damage caused by spinal cord injury 84 has been shown that \n",
            "treatment with recombinant GH creates a dose -dependent relaxation on \n",
            "the erectile tissue and this effect is parallel to the tissue cGMP level 83. \n",
            "Gene Transplant Methods:  One of the most im portant conditions \n",
            "of successful gene therapy is that the genetic material (RNA or DNA) to \n",
            "be transferred is transported with the appropriate vector or vehicle that \n",
            "will provide the most effective treatment. Some vectors used to date can \n",
            "be listed as: nonv iral vectors (naked DNA, plasmid DNA, and \n",
            "liposomes), adenoviruses, adeno-associated viruses, and retroviruses. All \n",
            "of these vectors have specific efficacy and side effects inside the host \n",
            "cell. An ideal vector should be capable of providing efficient \n",
            "transduction and long -term gene expression with little or no side effects \n",
            "such as infection, immunological reaction, and host cell mutation 79.  \n",
            "First of all, it is necessary to consider whether gene therapy is a \n",
            "viable treatment method in the treatment of erectile dysfunction. Gene \n",
            "therapy was initially recommended as an appropr iate treatment option in \n",
            "the treatment of cardiovascular diseases, and vascular pathologies being \n",
            "one of the most important causes of the etiology of ED, suggesting that \n",
            "the same method can be used in ED treatment 80. Preclinical studies in \n",
            "recent years show that gene transfer has corrective effects on ED 79,80. \n",
            "Due to the structural characteristics of the cardiovascular system, there is \n",
            "a drawback in the treatment of diseases in this system: gene therapy can \n",
            "easily reach beyo nd the targeted area. On the other hand, a similar \n",
            "drawback in ED treatment can be minimized. With a simple tourniquet to \n",
            "be applied to the root of the penis, the possible systemic effect that may \n",
            "occur after gene injection can be minimized. Another proble m with gene \n",
            "therapy is that most of the targeted cells need to be transfected in order to \n",
            "achieve therapeutic efficacy. On the other hand, transfecting only a \n",
            "certain group of cells in the penis is sufficient to provide therapeutic \n",
            "effect. As is known, the re is an interconnection network provided by gap \n",
            "junctions between corpus cavernosum smooth muscle cells. The \n",
            "therapeutic effect achieved after gene transplantation in a particular cell, \n",
            "thanks to these connections, can spread throughout the penis as if al l \n",
            "cells were transfected 79. Human large conductance, voltage dependent  \n",
            "Ca2+ Clinical trials using naked DNA gene therapy with a plasmid (hSlo) \n",
            "expressing the sensitive K channel (hMaxi -K channel) represent the only \n",
            "gene therapy to be evaluated in phase 1 clinical trials to date 85–87  \n",
            "Tissue engineering aims to reconstruct the penile tissue. \n",
            "Successful monocultures of cavernous endothelial and smooth muscle \n",
            "cells have been reported in recent years. 88.\n",
            "47 \n",
            "from laboratory to laboratory and fro m country to country. However, \n",
            "reporting results as INR ensures results are comparable among different \n",
            "laboratories. The INR is calculated as dividing the patient PT by the mean \n",
            "normal pt and taking the result's power as the ISI (International Sensitivity \n",
            "Index) value. The INR has two main advantages: it lets a comparison \n",
            "between results acquired from several laboratories, and it allows \n",
            "investigators to standardize anticoagulant therapy in clinical trials and \n",
            "scientific publications.  The normal INR range is  0.8-1.2. Reasons for \n",
            "prolonged PT include coumarin (warfarin), vitamin K deficiency, factor \n",
            "deficiency (inherited or acquired, e.g., liver disease), or factor inhibitors.  \n",
            "Activated partial prothrombin time (aPTT) is another practical test \n",
            "for the assessment of secondary homeostasis. Citrated plasma (or oxalate), \n",
            "surface activating agent (silica, kaolin, celite, or ellagic acid), calcium, and \n",
            "platelet substitute (rough phospholipid) are mixed and clotting time is \n",
            "determined most likely using an automated c oagulation analyzer. It is a \n",
            "useful measure of the intrinsic pathway as well as the common pathway. It \n",
            "can evaluate hereditary or acquired faults of the coagulation factors XII, \n",
            "XI, X, IX, VIII, V, prothrombin, and fibrinogen. PTT or aPTT is named \n",
            "partial thromboplastin time because of the lack of tissue factor \n",
            "(thromboplastin) in the tests. The expected value differs from laboratory to \n",
            "laboratory but is generally within 25 and 39 s. Causes of extended PTT \n",
            "include the following; \n",
            "-Heparin and other direct thrombin inhibitors (DTIs) \n",
            "-Factor deficiency, factor inhibitors, or lupus anticoagulant (LA) \n",
            "-von Willebrand disease \n",
            "-HMWK (Fitzgerald factor) deficiency \n",
            "-Pre-kallikrein (Fletcher factor) deficiency \n",
            "Falsely measured prolonged PT and aPTT reasons contain high \n",
            "hematocrit, underfilling of the citrate tube, and EDTA contamination. \n",
            "Delay in transport and processing may also cause false results.\n",
            "37 \n",
            "48. Chang AY, Kim K, Boucher H, et al. A randomized Phase II trial of \n",
            "echinomycin, trimetrexate, and cisplatin plus etoposide in patients \n",
            "with metastatic nonsmall cell lung carcinoma : an Eastern \n",
            "Cooperative Oncology Group Study (E1587).  Cancer. \n",
            "1998;82(2):292-300. \n",
            "49. Wadler S, Tenteromano L, Cazenave L, et al. Phase II trial of \n",
            "echinomycin in patients with advanced or recurrent colorectal \n",
            "cancer. Cancer Chemother Pharmacol. 1994;34(3):266-269. \n",
            "50. Bailey CM, Liu Y, Peng G, et al. Liposomal formulation of HIF -1α \n",
            "inhibitor echinomycin eliminates established metastases of triple-\n",
            "negative breast cancer. Nanomedicine : nanotechnology, biology, \n",
            "and medicine. 2020;29:102278. \n",
            "51. Thomas A, Samykutty A, Gomez-Gutierrez JG, et al. Actively Targeted \n",
            "Nanodelivery of Echinomycin Induces Autophagy -Mediated \n",
            "Death in Chemoresistant Pancreatic Cancer In Vivo. Cancers. \n",
            "2020;12(8). \n",
            "52. Roeten MSF, Cloos J, Jansen G. Positioning of proteasome inhibitors \n",
            "in therapy of solid malignancies. Cancer Chemother Pharmacol. \n",
            "2018;81(2):227-243. \n",
            "53. Bross PF, Kane R, Farrell AT, et al. Approval Summary for Bortezomib \n",
            "for Injection in the Treatment of Multiple Myeloma. Clin Cancer \n",
            "Res. 2004;10(12):3954-3964. \n",
            "54. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits \n",
            "tumor adaptation to hypoxia by stimulating the FIH -mediated \n",
            "repression of hypoxia -inducible factor -1. Blood. \n",
            "2008;111(6):3131-3136. \n",
            "55. Befani CD, Vlachostergios PJ, Hatzidaki E, et al. Bortezomib represses \n",
            "HIF-1α protein expression and nuclear accumulation by inhibiting \n",
            "both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. \n",
            "Journal of molecular medicine (Berlin, Germany). 2012;90(1):45-\n",
            "54. \n",
            "56. Koh MY, Spivak -Kroizman T, Venturini S, et al. Molecular \n",
            "mechanisms for the activity of PX -478, an antitumor inhibitor of \n",
            "the hypoxia-inducible factor-1α. Mol Cancer Ther. 2008;7(1):90-\n",
            "100. \n",
            "57. Tibes R, Falchook GS, Hoff DDV, et al. Results from a phase I, dose -\n",
            "escalation study of PX -478, an orally available inhibitor of HIF -\n",
            "1α. Journal of Clinical Oncology. 2010;28(15_suppl):3076-3076.\n",
            "36 \n",
            "37. Bisht KS, Bradbury CM, Mattson D, et al. Geldanamycin and 17 -\n",
            "Allylamino-17-demethoxygeldanamycin Potentiate the Radiation \n",
            "Response of Cervical Tumor Cells via the Heat Shock Protein 90-\n",
            "Mediated Intracellular Signaling and Cytotoxicity. Cancer Res.  \n",
            "2003;63(24):8984-8995. \n",
            "38. Weber H, Valbuena JR, Barbhuiya MA, et al. Small molecule inhibitor \n",
            "screening identifified HSP90 inhibitor 17 -AAG as potential \n",
            "therapeutic agent for gallbladder cancer. Oncotarget. \n",
            "2017;8(16):26169-26184. \n",
            "39. Liu H, Lu J, Hua Y, et al. Targeting heat -shock protein 90 with \n",
            "ganetespib for molecularly targeted therapy of gastric cancer. Cell \n",
            "Death Dis. 2015;6(1):e1595. \n",
            "40. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase \n",
            "Inhibitors as Anticancer Drugs. International journal of molecular \n",
            "sciences. 2017;18(7). \n",
            "41. Fath DM, Kong X, Liang D, et al. Histone deacetylase inhibitors repress \n",
            "the transactivation potential of hypoxia -inducible factors \n",
            "independently of direct acetylation of HIF -alpha. The Journal of \n",
            "biological chemistry. 2006;281(19):13612-13619. \n",
            "42. Coufal N, Farnaes L. Anthracyclines and Anthracenediones. In: Minev \n",
            "B. (eds) Cancer Management in Man: Chemotherapy, Biological \n",
            "Therapy, Hyperthermia and Supporting Measures. Cancer Growth \n",
            "and Progression, vol 13. Springer, Dordrecht. \n",
            "https://doi.org/10.1007/978-90-481-9704-0_5 \n",
            "43. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline \n",
            "chemotherapy inhibits HIF -1 transcriptional activity and tumor -\n",
            "induced mobilization of circulating angiogenic cells. Proc Natl \n",
            "Acad Sci U S A. 2009;106(7):2353-2358. \n",
            "44. Tanaka T, Yamaguchi J, Shoji K, Nangaku M. Anthracycline inhibits \n",
            "recruitment of hypoxia -inducible transcription factors and \n",
            "suppresses tumor cell migration and cardiac angiogenic response \n",
            "in the host. The Journal of biological c hemistry. \n",
            "2012;287(42):34866-34882. \n",
            "45. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a Small -Molecule \n",
            "Inhibitor of Hypoxia -Inducible Factor-1 DNA-Binding Activity. \n",
            "Cancer Res. 2005;65(19):9047-9055. \n",
            "46. Gradishar WJ, Vogelzang NJ, Kilton LJ, et al. A p hase II clinical trial \n",
            "of echinomycin in metastatic soft tissue sarcoma. Investigational \n",
            "new drugs. 1995;13(2):171-174. \n",
            "47. Muss HB, Blessing JA, DuBeshter B. Echinomycin in recurrent and \n",
            "metastatic endometrial carcinoma. A phase II trial of the \n",
            "Gynecologic Oncology Group. Am J Clin Oncol. 1993;16(6):492-\n",
            "493.\n",
            "78 \n",
            "4. OTHER GOALS \n",
            "There are studies showing that physical exercise also contributes \n",
            "to ED treatment as a non -therapeutic approach. Corpus Cavernosum \n",
            "relaxation in hypertensive rats induced by NO blockade 89 and has been \n",
            "shown to exert anti -inflammatory effects on the hypothalamus and \n",
            "testicles, increase LH levels, and sup port the primary role of lifestyle \n",
            "modification in hypogonadism and erectile dysfunction 90. \n",
            "5. CONCLUSION \n",
            "As a result, the increasing c oncentration of biochemical, genetic, \n",
            "physiological, pharmacological and histological research on the erectile \n",
            "dysfunction at the molecular and tissue level will enable a better \n",
            "understanding of erectile function mechanism, and the formation of new \n",
            "treatment targets and clinical treatment protocols in the treatment of ED.\n",
            "44 \n",
            "fibrin is destroyed by fibrinolysis. When clot formation reaches the intact \n",
            "endothelium, it activates the heparin -like molecule AT-III, which runs to \n",
            "the endothelial surface. Antithrombin III is a potent anticoagulant \n",
            "substance produced in the liver and commonly found in body fluids and is \n",
            "a significant inhibitor of serine proteases formed during coagulation. \n",
            "Antithrombin III inactivate s all active factors; Xa, XIa, XIIa, IXa, \n",
            "thrombin, and TF -VIIa complex. On the other hand, thrombin binds to \n",
            "thrombomodulin, which is a specific  thrombin (IIa) receptor on the \n",
            "endothelial surface and activates protein C and protein S. Activated protein \n",
            "C neutralizes cofactors such as factor Va and VIIIa. Thus, the coagulation \n",
            "system is stopped by inactivating all active and auxiliary factors. \n",
            "Plasminogen is an inactive circulating protein that binds to fibrin during \n",
            "clot formation. Plasminogen is activated by endothelium produced tissue \n",
            "plasminogen activator (t -PA), urokinase -type plasminogen activator \n",
            "(uPA), and contact factors such as XIa, XIIa, quinine, and kallikrein and \n",
            "converted to plasmin. tPA is the most effective in activating fibrin -bound \n",
            "plasminogen. Besides, it prevents fibrinolysis from moving beyond the clot \n",
            "formation site. Fibrinogen is a colossal plasma protein with 340 kDa MW. \n",
            "It is produced from the liver, and its concentration range is 200 to 400 \n",
            "mg/dL. Fibrinogen is stable in plasma for about 4 to 5 days. It is a dimeric \n",
            "protein of highly low solubility designed with two pairs of three \n",
            "nonidentical polypeptide chains covalently connected by disulfide bonds. \n",
            "Fibrinolysis event is the breakdown of fibrin strands that hold plasmin, \n",
            "formed by plasminogen, and fibrin. Fibrin is broken down into fibrin \n",
            "breakdown products by fibrinolysis. The transformation of fibrinogen to \n",
            "fibrin occurs in three stages. First, thrombin splits four small peptides —\n",
            "the fibrinopeptides A (FPA) and fibrinopeptides B (FPB) —from the \n",
            "fibrinogen molecule, following the formation of a new molecule called \n",
            "fibrin monomer. Secondly, polymerization comprises unconsciou sly by \n",
            "noncovalent end -to-end and side -to-side relations to develop fibrin \n",
            "polymers. In the third step, a resistant and consistent fibrin molecule is \n",
            "acquired by the action of factor XIII (fibrin-stabilizing factor) and calcium \n",
            "ions. Fibrin degradation pro ducts (FDPs) begin to form while plasmin \n",
            "diminishes the thrombus. Multiple FDPs, involving fibrinopeptide B and \n",
            "other fibrin degradation monomers and dimers, consist. When fibrin \n",
            "polymers are splitted from the D fragment site, the following D -dimer \n",
            "fragment pictures thrombosis diffusiveness and plasmin efficiency. D -\n",
            "dimer assays anticipate and have prognostic value in several disease \n",
            "extents, bearing disseminated intravascular coagulation (DIC), pulmonary \n",
            "embolism, deep vein thrombosis, and cancer-associated thrombosis.\n",
            "23 \n",
            "reperfusion injury in a rat model.  Biomedical reports, 3(6), 807-\n",
            "813. \n",
            "21. Bayir, Y., Cadirci, E., Polat, B., Kilic Baygutalp, N., Albayrak, A., \n",
            "Karakus, E., ... & Karaca, M. (2016). Aliskiren –a promising \n",
            "strategy for ovarian ischemia/reperfusion injury protection in rats \n",
            "via RAAS. Gynecological Endocrinology, 32(8), 675-683. \n",
            "22. Ergun, Y., Koc, A., Dolapcioglu, K., Akaydin, Y., Dogruer, G., Kontas, \n",
            "T., ... & Aslan, E. (2010). The protective effect of erythropoietin \n",
            "and dimethylsulfoxide on ischemia -reperfusion injury in rat \n",
            "ovary. European Journal of Obstetrics & Gynecology and \n",
            "Reproductive Biology, 152(2), 186-190. \n",
            "23. Aslan, M. K., Boybeyi, Ö., Şenyücel, M. F., Ayva, Ş., Kısa, Ü., Aksoy, \n",
            "N., ... & Çakmak, M. (2012). Protective effect of intraperitoneal \n",
            "ozone application in experimental ovarian ischemia/reperfusion \n",
            "injury. Journal of pediatric surgery, 47(9), 1730-1734. \n",
            "24. Kurt, A., Isaoglu, U., Yilmaz, M., Calik, M., Polat, B., Hakan, H., ... & \n",
            "Suleyman, H. (2011). Biochemical and histological investigation \n",
            "of famotidine effect on postischemic reperfusion injury in the rat \n",
            "ovary. Journal of pediatric surgery, 46(9), 1817-1823. \n",
            "25. Ming-Shuo Sun, Hang Jin, Xin Sun, Shuo Huang, Fu -Liang Zhang, \n",
            "Zhen-Ni Guo, Yi Yang,  \"Free Radical Damage in Ischemia -\n",
            "Reperfusion Injury: An Obstacle in Acute Ischemic Stroke after \n",
            "Revascularization Therapy\",  Oxidative Medicine and Cellular \n",
            "Longevity, vol. 2018, ArticleID 3804979, 17 pages, 2018. https://\n",
            "doi.org/10.1155/2018/3804979 \n",
            "26. Akdemir A, Erbas¸ O, Ergenoğ lu M, Ozg ür Yeniel A, Oltulu F, \n",
            "Yavasoğlu A, et al .Montelukast prevents ischemia/reperfusion -\n",
            "induced ovarian damage in rats.Eur J Obstet Gynecol Reprod Biol \n",
            "2014;173:71–6. \n",
            "27. Erkanli Senturk G, Erkanli K, Aydin U, Yucel D, Isiksacan N, Ercan \n",
            "F, et al. The pro-tective effect of oxytocin on ischemia/reperfusion \n",
            "injury in rat urinary bladder.Peptides 2013;40:82–8. \n",
            "28. Aslan, M., Senturk, G. E., Akkaya, H., Sahin, S., & Yılmaz, B. (2017). \n",
            "The effect of oxytocin and Kisspeptin -10 in ovary and uterus of \n",
            "ischemia-reperfusion injured rats.  Taiwanese Journal of \n",
            "Obstetrics and Gynecology, 56(4), 456-462. \n",
            "29. Naziroglu M, Simşek M, Kutlu M. Moderate exercise with a dietary \n",
            "vitamin C and E combination protects against streptozotocin -\n",
            "induced oxidative damage to the blood and improves fetal \n",
            "outcomes in pregnant rats. Clin Chem Lab Med 2004;42:511-7.\n",
            "73 \n",
            "2667 exerts its effects independently from the heme group. Both \n",
            "dependent sGC activators act synergistically with NO. Therefore, \n",
            "quinoxaline derivative is sensitive to inhibition by sGC inhibitors such as \n",
            "ODQ (1H - [1,2,4] oxadiazole [4,3, -a] quinoxaline -1). The efficacy of \n",
            "only BAY 41 -2272 in erectile tissue has been investigated till this day, \n",
            "and it has been shown to induce relaxation in human and mouse c orpus \n",
            "cavernosum samples contracted with phenylephrine. BAY 41 -2272 was \n",
            "found to be 32 times more potent than YC -1 and 2 times more than the \n",
            "NO donor. Intravenous and oral administration of the compound \n",
            "produced weak erections in rabbits, but it was observ ed that the efficacy \n",
            "of BAY 41-2272 was potentiated when administered simultaneously with \n",
            "NO. 35,36. \n",
            "3.1.2.3. Natriuretic Peptides \n",
            "Another target that inducing penile erection by stimulating \n",
            "cGMP production is the particulate guanylyl cyclase (pGC). PGC \n",
            "activation by natriuretic peptides enables relaxation of the penile tissue \n",
            "and thus, erection 37.  \n",
            "3.1.2.4. Carbon monoxide (CO) a nd heme -oxygenase (HO) \n",
            "inducers \n",
            "Limited number of studies  shows that CO releasing molecules \n",
            "(CORMs) can be useful in the treatment of ED, and correcting the HO \n",
            "activity in diabetes-related ED, can improve erectile function 38,39. \n",
            "3.2. Independent Goals from the NO-cGMP Pathway \n",
            "3.2.1. Adenylate Cyclase (AC) -cAMP Pathway \n",
            "Activation of the AC -cAMP pathway is k nown to be beneficial \n",
            "in the treatment of the ED 40. PGE1 (Prostaglandin E1) or PGE 1 is using \n",
            "phosphodiesterase in hibitors specific to mimetic -induced AC activation, \n",
            "smooth muscle relaxation and penile erection can be induced to increase \n",
            "cAMP pathway activity and cAMP levels 40. PGE1 the use of Alprostadil, \n",
            "its analogue, is known to be useful in the treatment of ED 41.  \n",
            "It is thought that the vasointestinal polypeptide (VIP) and its \n",
            "receptors, which relax corporal tissues through the cAMP signaling \n",
            "pathway, may represent the therapeutic target 42,43. \n",
            "3.2.1. Hydrogen sulfide (H2S) Pathway \n",
            "H2S, which plays a role in the control of vascular homeostasis, is \n",
            "seen as a promising target for the development of new therapeutics for \n",
            "ED, as it not only promotes corporal dilatation but also allev iates penile \n",
            "fibrosis 44,45.\n",
            "134  \n",
            " SAFETY DATA  \n",
            "Safety information is important for herbal medicinal products. \n",
            "During pregnancy and lactation safety data has not been established for \n",
            "lavender essential oil. In the absence of the sufficient data , rationally the \n",
            "use during pregnancy and lactation is not recommended. EMA reminds its \n",
            "potential on the impairment of the ability to drive and use machines. \n",
            "Children below 12 years -age are excluded from the eligible data. In a \n",
            "multicenter clinical study l inalool and its hydroperoxide fraction were \n",
            "found to be common contact allergens in dermatitis patients. 37 Moreover \n",
            "prepubertal gynecomastia is associated with lavender oil topical exposure \n",
            "in three cases and in vitro cell line studies indicated lavender o il had \n",
            "estrogenic and antiandrogenic activities.38  \n",
            "CONCLUSION  \n",
            "Lavender oil is a traditional medicinal product that has been used for \n",
            "many years in wound healing. With recent experimental and clinical \n",
            "studies, its antioxidant, antimicrobial, anti -inflammatory and analgesic \n",
            "effects have been revealed and details of its mechanism of action have been \n",
            "brought to light. In the future, with the help of more detailed and extensive \n",
            "studies it may be possible to develop standardized treatment protocols and \n",
            "gather more safety data for wound healing.\n",
            "123 \n",
            "One of the inclusion criteria in a study by Ender Durualp et al. on \n",
            "smoking during pregnancy at the Çankırı State Hospital in 2011 was that \n",
            "the pregnant mothers should have applied to the hospital during a certain \n",
            "period of time. Of these pregnant women, 130 were included in the study \n",
            "and it was observed that 23.9% (n: 19) are smokers and 76.1% are non -\n",
            "smokers (n:99). Newborn weights were also recorded in this st udy. The \n",
            "analyses carried out in the study put forth a statistically significant \n",
            "difference between the smoking status of the mothers and the birth weights \n",
            "of the babies (χ²=37.631, sd=6, p<0.01) 7. Similar to our study, this study \n",
            "also presents a directly proportional difference in newborn weights of \n",
            "smoker mothers.  \n",
            "Sandra Larsen et al. published a study in Norway in 2018 in which \n",
            "the pregnant women hospitalized during 1999-2014 were classified into 2 \n",
            "groups as smokers, non -smokers and those who quit during pregnancy. \n",
            "According to this retrospective study, it was presented that 12.6% of 698 \n",
            "891 women smoke and that of these women 29.6% quit during the first \n",
            "trimester and that 70.4% continued smoking throughout their pregnancy. \n",
            "There were differences between the placenta weights and birth  weights \n",
            "among the groups of women who smoke 11 or more cigarettes a day and \n",
            "non-smoker groups18. Our study includes women who started smoking 5 \n",
            "years before pregnancy. The results of our study are in accordance with the \n",
            "results of the aforementioned study.  \n",
            "According to the Turkey Population Census and Health Study \n",
            "(TPHS-2008) results; it is indicated that 30.5% of married women smoked \n",
            "before, 24.1% are still smoking and that the starting age for smoking was \n",
            "19.6 with an average of 11 cigarettes per day. An increase is observed in \n",
            "comparison with the TPHS-2003 results for smoker women (28%). TPHS-\n",
            "2008 results put forth that 26.2% of the pregnant women were smoking \n",
            "before, 11.4% are still smoking and that the starting age for smoking was \n",
            "17.4 with 10 cigarettes per day. While the ratio of smoking before among \n",
            "nursing women was 26%, the ratio of those who are still smoking was \n",
            "16.5%, the starting age for smoking was 18 with 8 cigarettes smoked daily. \n",
            "Both the TPHS-2008 results as well as the results of studies carried out in \n",
            "the world and in our country indicate that smoking is an important issue \n",
            "among both nursing women as well as other women19-21. \n",
            "A statistically significant relationship was observed between \n",
            "smoking and the birth weights of newborns in all studies carried out on the \n",
            "subject. Smoking doubles the risk for a women to give birth to a baby with \n",
            "less birth weight. Published a report in 1985 in which it was indicated that \n",
            "smoking is the most important factor playing a role in the development of \n",
            "babies with low birth weight22.\n",
            "8 \n",
            "coli. The developed HP –chitosan nanofibers revealed no cytotoxicity \n",
            "effects on cultured fibroblasts. And they concluded that,  biocompatible, \n",
            "antimicrobial crosslinked honey/polyvinyl alcohol/chitosan nanofibers \n",
            "were developed which hold potential as an effective wound dressing (31). \n",
            "CONCLUSION \n",
            "Despite their potential for continuous exploration and evolu -tion, \n",
            "antimicrobial dressings are already one of most importantdiscoveries of \n",
            "our century in biomedical research and their thera-peutic abilities are well \n",
            "recognized (22). Electrospinning is a simple and cost effective but \n",
            "fascinating fiber forming technology with less time consumption under \n",
            "optimized conditions (32). Electrospinning technique, a llows the \n",
            "fabrication of fibers with high -surface area due to their diameters being \n",
            "scalable down to a few nanometers. Electrospin based wound dressers can \n",
            "be surface functionalized to tune the physical and chemical properties of \n",
            "the fiber  surface while the fiber structure, morphology, and \n",
            "spatialdistribution can be controlled to achieve specific mechanical  \n",
            "properties. In addition, electrospinning allows the combination of different \n",
            "synthetic and natural polymers  to be used to make nanofibers. The \n",
            "possibility of large -scale production combined with simplicity \n",
            "andversatility makes the electrospinning process very attractive for a broad \n",
            "variety of applications (33). Hundreds of polymer options and hundreds of \n",
            "healing agents that can be added to these polymer solutions show that this \n",
            "biomedical research field is in need of much more research.\n",
            "52 \n",
            "filling line specified by the tube manufacturer. It should be noted that the \n",
            "tube filling line is determined to provide the correct blood citrate ratio (9: \n",
            "1), not the volume of the citrated tube.  Blood should be taken into the \n",
            "citrate tube first in patients who are requested coagulation tests together \n",
            "with other laboratory tests. Unless the manufacturer specifies a different \n",
            "procedure, the tubes containing anticoagulants should be mixed by \n",
            "inverting 3-6 times after blood is taken. Blood should be taken into the \n",
            "citrate tube first in patients who are requested coagulation tests together \n",
            "with other laboratory tests. Unless the manufacturer specifies a different \n",
            "procedure, the tubes containing anticoa gulants should be mixed by \n",
            "inverting 3 -6 times after blood is taken. Coagulation tests at high \n",
            "hematocrit values (> 55%) should be run from plasma with an adjusted \n",
            "citrate concentration. All coagulation measurements should be performed \n",
            "within the first 4 hours after the blood sample is collected. PT and D-dimer \n",
            "tests can be run within 24 hours. However, laboratories must evaluate the \n",
            "sample stability for their system. If the aPTT test is requested for standard \n",
            "heparin monitoring, the whole blood sample should be centrifuged within \n",
            "1 hour after the sample is taken, and the plasma should be separated. To \n",
            "evaluate protein -S, protein -C, and activated protein C resistance, it is \n",
            "recommended that these treatments be discontinued two months before \n",
            "women receiving combined oral contraceptives and hormone replacement \n",
            "therapy. When sampling is required for inherited diseases such as vWF, \n",
            "FVIII deficiency, protein S deficiency, samples should be taken when \n",
            "regular menstrual cycles begin or at least two months after birt h. All \n",
            "abnormal values, including pregnancy -associated antiphospholipid \n",
            "antibodies, should be confirmed by re-drawing.\n",
            "32 \n",
            "efficacy of PX -478 was evaluated in advanced solid tumors in a phase I \n",
            "trial conducted in 2007-2010 (NCT00522652).  The results were promising \n",
            "in terms of tolerability and HIF -1α inhibition57. However, a registration \n",
            "could not be found in clinicaltrial.gov that suggest the further evaluation \n",
            "of PX-478 in clinical studies.  \n",
            "CONCLUSION \n",
            "Clinical development of HIF-1α inhibitors for cancer treatment is \n",
            "ongoing at a great pace. Till the safety and efficacy of direct HIF -1α \n",
            "inhibitors is fully established, anti -cancer agents already approved in \n",
            "cancer such as camptothecins, rapalogs, anthracyclines and bortezomib \n",
            "seem to be involved more frequently in combination chemotherapy for \n",
            "HIF-1α inhibitory effect in addition to their primary mechanisms of anti -\n",
            "cancer action.\n",
            "4 \n",
            "viscosity, molecular weight, surface tension); and (b) apparatus -related \n",
            "parameters (flow rate and electric field) (11). \n",
            " \n",
            " \n",
            " \n",
            "Figure 1: Schematic representation of a typical electrospinning apparatus. \n",
            "(Felgueiras, H. P., & Amorim, M. T. P. (2017). Functionalization of \n",
            "electrospun polymeric wound dressings with antimicrobial \n",
            "peptides. Colloids and Surfaces B: Biointerfaces, 156, 133-148.) \n",
            " \n",
            "Electrospinning has been applied to more than 100 different types of \n",
            "polymers. While preparing a product using the electrospin method, it is \n",
            "generally desired to obtain a high effect result by adding an active \n",
            "ingredient to a polymer solution. The most used polymer solutions can be \n",
            "listed as ; PAA (p oly(acrylic acid) ), PVA (p oly(vinyl alcohol) ), PLA \n",
            "(poly(lactic asid )), PAN(p olyacrylonitrile), PCL ( poly(ε-caprolactone)), \n",
            "PVP ( poly(vinyl pyrrolidone) ), PEG ( polyethylene glycol ), PEO \n",
            "(poly(ethylene oxide)), PLLA (poly(L-lactide)),  and PLGA (Poly (lactic-\n",
            "co-glycolic) acid) for biomedical production (20). For the purpose of the \n",
            "experimental study to be done on polymer solutions; Antibacterial agents, \n",
            "herbal extracts, various antioxidant agents are added  to these  polymer \n",
            "based solutions.\n",
            "125 \n",
            "intervillous areas as well  as necrotic and inflammation areas in the term \n",
            "placenta.  \n",
            "In conclusion, it was determined that there are mothers who smoke \n",
            "and are subject to cigarette smoke before and during their pregnancy, that \n",
            "smoking has adverse impacts on the mother, fetus /newborn and the \n",
            "placenta. It was put forth as a result of the present study that there is a \n",
            "statistically significant relationship between smoking of mothers before \n",
            "and during their pregnancy and the birth weights of the newborns, that \n",
            "smoking decreases birth weight and placenta weight while also resulting in \n",
            "adverse changes in placenta histology.  \n",
            "Conflicts of Interest: There is no conflict of interest regarding the \n",
            "publication of this article.  \n",
            "Informed consent: Informed consent was needed due to being a  \n",
            "study. \n",
            "Declearation of interest:  The authors report no conflict of \n",
            "interest. The authors alone are responsible for the content and writing of \n",
            "the paper.\n",
            "35 \n",
            "Oncology Group (HeCOG) Evaluating Efficacy and Safety of \n",
            "First-Line FOLFIRI  + Aflibercept for 6 Months Followed by \n",
            "Aflibercept Maintenance in Patients With Metastatic Colorectal \n",
            "Cancer. Clinical colorectal cancer. 2018;17(4):e631-e637. \n",
            "27. LoRusso PM. Inhibition of the PI3K/AKT/mTOR Pathway in Solid \n",
            "Tumors. Journal of clinical oncology. 2016;34(31):3803-3815. \n",
            "28. Tian T, Li X, Zhang J. mTOR Signaling in Cancer and mTOR Inhibitors \n",
            "in Solid Tumor Targeting Therapy. International journal of \n",
            "molecular sciences. 2019;20(3). \n",
            "29. Weldon Gilcrease G, Stenehjem DD, Wade ML, et al. Phase I/II study \n",
            "of everolimus combined with mFOLFOX-6 and bevacizumab for \n",
            "first-line treatment of metastatic colorectal cancer. Investigational \n",
            "new drugs. 2019;37(3):482-489. \n",
            "30. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides \n",
            "inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl \n",
            "Acad Sci U S A. 2008;105(50):19579-19586. \n",
            "31. Bardia A, Santa-Maria CA, Jacobs LK, et al. Digoxin as an inhibitor of \n",
            "global hypoxia inducible factor -1α (HIF1α) expression and \n",
            "downstream targets in breast cancer: Dig-HIF1 pharmacodynamic \n",
            "trial. Journal of clinical oncology . 2013;31(15_suppl):TPS1144-\n",
            "TPS1144. \n",
            "32. Haque M, Wang V, Davis DA, Zheng ZM, Yarchoan R. Genetic \n",
            "organization and hypoxic activation of the Kaposi's sarcoma -\n",
            "associated herpesvirus ORF34 -37 gene cluster. Journal of \n",
            "virology. 2006;80(14):7037-7051. \n",
            "33. Lin J, Hoffman -Censits JH, Duffy D, et al. A pilot phase II study of \n",
            "digoxin in patients with recurrent  prostate cancer as evident by a \n",
            "rising PSA. Journal of Clinical Oncology. \n",
            "2013;31(15_suppl):5061-5061. \n",
            "34. Harrison MR, Hahn NM, Pili R, et al. A phase II study of 2 -\n",
            "methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in \n",
            "patients with taxane -refractory, metastatic castrate -resistant \n",
            "prostate cancer (CRPC). Investigational new drugs. \n",
            "2011;29(6):1465-1474. \n",
            "35. Bruce JY, Eickhoff J, Pili R, et al. A phase II study of 2 -\n",
            "methoxyestradiol nanocrystal colloidal dispersion alone and in \n",
            "combination with sunitinib malate in patients with metastatic renal \n",
            "cell carcinoma progressing on sunitinib malate. Investigational \n",
            "new drugs. 2012;30(2):794-802. \n",
            "36. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M. ENMD -1198, a \n",
            "new analogue of 2-methoxyestradiol, displays both antiangiogenic \n",
            "and vascular -disrupting properties. Molecular cancer \n",
            "therapeutics. 2010;9(5):1408-1418.\n",
            "16 \n",
            "glutathione peroxidase (GSH-Px) (29, 30) . Excess ROS and their toxic \n",
            "products cause DNA damage, lipid peroxidation  in the cellular and \n",
            "mitochondrial membranes, and cellular damage (8).  \n",
            "Reactive oxygen species, including hydrogen peroxide, hydroxyl \n",
            "radicals, superoxide anions, and the formation of NO and peroxynitrite are \n",
            "enhanced during reperfusion of the ischemic tissue. These free radicals \n",
            "cause further cellular damage through the pero xidation of lipids in \n",
            "mitochondrial and cell membranes (31).  NO acts in a variety of tissues to \n",
            "regulate a diverse range of physiological processes, but excess of NO can \n",
            "also be toxic (22).  \n",
            "The reasons for IR -induced ovarian injury include release of \n",
            "cytokines and free radicals, thrombocyte and neutrophil activation, \n",
            "apoptosis, and nitric oxide ( 17). The reactive oxygen species (ROS) are \n",
            "produced during the ischemia or reperfusion period and release activated \n",
            "neutrophils such as superoxide, hydrogen peroxide, and hydroxyl radical. \n",
            "Independent evaluation on these markers would be unpractical and also \n",
            "insufficient for a wide -ranging assessment. The total antioxidant status \n",
            "(TAS) was employed to assess the general antioxidative status (32). As \n",
            "well, total oxi dant status (TOS) is obtained to ascertain the overall \n",
            "oxidation status (33). Represented as the ratio of TOS to TAS, the oxidative \n",
            "stress index (OSI) is regarded as a more precise index of oxidative stress \n",
            "on the tissue. A number of anti-inflammatory and antioxidant agents were \n",
            "used to prevent I/R injury ( 17). Biochemical parameters frequently \n",
            "preferred in ovarian ischemia / reperfusion studies in recent years are listed \n",
            "in the Table 3. \n",
            "HISTOPATHOLOGICAL CHANGES \n",
            "For histopathological examinations, tissues are collected \n",
            "immediately after the lethal dose of anesthesia administered at the end of \n",
            "the experimental procedure. In small -sized organs such as the ovary, at \n",
            "least half of the organ should be taken into the fixation solution for \n",
            "histopathological examination. Half of the right ovary of each rat was put \n",
            "separately into a formaldehyde media. Tissues were detected in the 10% \n",
            "buffered formalin, after which a routine tissue follow -up was performed \n",
            "and they were placed in paraffin blocks. Slides of 4 –5 μm thickness were \n",
            "cut from the parafin blocks using a microtome and deparaffinized. The \n",
            "samples were dyed with hematoxylin –eosin stain and examined under a \n",
            "light microscope (11). \n",
            "Basic histopathological changes noted in ovarian ischemia / \n",
            "reperfusion studies; cherry like appearance across the tissue ( 5, 8, 18 ), \n",
            "congestion / dilatation of the vessels, diffuse hemorrhage in the ovarian \n",
            "tissue, leukocyte infiltration, edema, necrosis, and follicular degeneration.\n",
            "65 \n",
            "22. Ahn, D. S., Yoon, E. S., Koo, S. H., & Park, S. H. (2000). A prospective \n",
            "study of the anatomic variations of the median nerve in the carpal \n",
            "tunnel in Asians. Annals of plastic surgery, 44(3), 282-287. \n",
            "23. Kurihara, K., Kojima, T., & Marumo, E. (1984). Frontalis suspension \n",
            "for blepharoptosis using palmaris longus tendon. Annals of plastic \n",
            "surgery, 13(4), 274-278. \n",
            "24. Lam, D. S., Ng, J. S., Cheng, G. P., & Li, R. T. (1998). Autogenous \n",
            "palmaris longus tendon as frontalis suspension material for ptosis \n",
            "correction in children.  American journal of \n",
            "ophthalmology, 126(1), 109-115. \n",
            "25. Ceyhan, O., & Mavt, A. (1997). Distribution of agenesis of palmaris \n",
            "longus muscle in 12 to 18 years old age groups.  Indian journal of \n",
            "medical sciences, 51(5), 156-160. \n",
            "26. Boltuch, A. D., Marcotte, M. A., Treat, C. M., & Marcotte, A. L. \n",
            "(2020). The Palmaris Longus and Its Association with Carpal \n",
            "Tunnel Syndrome. Journal of Wrist Surgery.\n",
            "122 \n",
            " \n",
            " \n",
            "Figure 3:  Placenta histopathology in smoker group. H&E.  tv: tertiary \n",
            "villouses, F:Fibrinoid deposits, : Syncytial knots, (a,b) rv: root villuses, \n",
            "N: Necrotic regions, I:Inflammation (c,d).  \n",
            " \n",
            "4. DISCUSSION AND CONCLUSION:  \n",
            "Smoking is one of the most important factors that affects the fetus \n",
            "during pregnancy. There are various findings indicating that the harmful \n",
            "substances and toxins in the cigarette are transferred to the baby via the \n",
            "placenta 7, 18. Various studies have been carried out  which indicate that \n",
            "cigarette is not only effective on the development of the baby but has an \n",
            "impact on placenta weight and newborn weight as well. In the present \n",
            "study, the placenta and newborn weights were examined in addition to the \n",
            "status of histopathological changes in the placenta tissue.  \n",
            " The number women who have started smoking before pregnancy \n",
            "and who have not been able to quit throughout their pregnancy period is \n",
            "quite high in the world. Since cigarette contains addictive substances, it is \n",
            "not very easy to quit during pregnancy. We carried out a study on the \n",
            "women who applied to the delivery room of the Merkez Efendi State \n",
            "Hospital in the province of Manisa and limited the sample group with 35 \n",
            "smoker and 35 non-smoker pregnant women in two group s in order to be \n",
            "able to carry out pathological examinations on all placenta tissues obtained.\n",
            "107 \n",
            "While cesarean delivery was observed in one case out of four obese \n",
            "pregnant women at 30 weeks of gestation due to severe preeclampsia, in \n",
            "the other 3 cases, unavoidable preterm delive ry following EMR was \n",
            "performed without preeclampsia. Chorioamnionitis was added to the \n",
            "picture in the next three cases. The incidence of chorioamnionitis was \n",
            "higher in obese women who had a preterm delivery compared to other \n",
            "women (43). \n",
            "In another study, the relationship between maternal obesity uterine \n",
            "contraction frequency and spontaneous preterm birth risk was evaluated. \n",
            "20-36. 253 women who had one or more spontaneous preterm birth or \n",
            "second trimester vaginal bleeding in their current pregnancy between \n",
            "weeks of gestation were connected to uterine activity monitor twice a day \n",
            "from 22 weeks to 34 weeks of gestation. It was found that obese and obese \n",
            "women who were at risk of preterm labor with external tocometer had less \n",
            "frequent uterine contraction and ov erweight women were at risk of \n",
            "spontaneous preterm birth before 35 weeks. Analyzes after controlling for \n",
            "other factors, 22 -24 or 31 -32. No significant relationship was found \n",
            "between contraction frequency and SPD at 27 -28 weeks. no such \n",
            "relationship has been shown in weeks. In conclusion, obese women who \n",
            "showed contraction frequency similar to normal and thin women when \n",
            "screened for preterm labor risk stated that they were especially at risk for \n",
            "delivery before term (12).\n",
            "80 \n",
            "as a Mediator of Relaxation of the Corpus Cavernosum in \n",
            "Response to Nonadrenergic, Noncholinergic Neurotransmission. \n",
            "New England Journal of Medicine . 1992;326(2):90 -94. \n",
            "doi:10.1056/nejm199201093260203 \n",
            "13.  Christ GJ. T he “syncytial tissue triad”: A model for understanding \n",
            "how gap junctions participate in the local control of penile \n",
            "erection. World Journal of Urology . 1997;15(1):36 -44. \n",
            "doi:10.1007/BF01275155 \n",
            "14.  Bivalacqua TJ, Champion HC, Rajasekaran M, et al. Potentia tion of \n",
            "erectile response and camp accumulation by combınatıon of \n",
            "prostaglandin e 1 and rolipram, a selectıve inhibitor of the type 4 \n",
            "phosphodiesterase (PDE 4). Journal of Urology . \n",
            "1999;162(5):1848-1855. doi:10.1016/S0022-5347(05)68249-3 \n",
            "15.  Lin CS, Lin G , Lue TF. Cyclic nucleotide signaling in cavernous \n",
            "smooth muscle. Journal of Sexual Medicine . 2005;2(4):478 -491. \n",
            "doi:10.1111/j.1743-6109.2005.00080.x \n",
            "16.  Nathan C, Xie Q wen. Nitric oxide synthases: Roles, tolls, and \n",
            "controls. Cell. 1994;78(6):915 -918. do i:10.1016/0092-\n",
            "8674(94)90266-6 \n",
            "17.  Morelli A, Filippi S, Vignozzi L, Mancina R, Maggi M. Physiology \n",
            "of Erectile Function: An Update on Intracellular Molecular \n",
            "Processes{A figure is presented}. EAU-EBU Update Series . \n",
            "2006;4(3-4):96-108. doi:10.1016/j.eeus.2006.03.003 \n",
            "18.  Burnett AL, Tillman SL, Chang TSK, et al. Immunohistochemical \n",
            "localization of nitric oxide synthase in the autonomic innervation \n",
            "of the human penis. Journal of Urology . 1993;150(1):73 -76. \n",
            "doi:10.1016/S0022-5347(17)35401-0 \n",
            "19.  Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, De Tejada \n",
            "IS. Oxygen tension regulates the nitric oxide pathway. \n",
            "Physiological role in penile erection. Journal of Clinical \n",
            "Investigation. 1993;91(2):437-442. doi:10.1172/JCI116220 \n",
            "20.  Sommer F, Klotz T, Steinritz  D, Bloch W. Evaluation of \n",
            "tetrahydrobiopterin (BH4) as a potential therapeutic agent to treat \n",
            "erectile dysfunction. Asian Journal of Andrology . 2006;8(2):159-\n",
            "167. doi:10.1111/j.1745-7262.2006.00122.x \n",
            "21.  Deng W, Bivalacqua TJ, Champion HC, Hellstrom WJ, Murthy SN, \n",
            "Kadowitz PJ. Superoxide dismutase - a target for gene therapeutic \n",
            "approach to reduce oxidative stress in erectile dysfunction. \n",
            "Methods in molecular biology (Clifton, NJ) . 2010;610:213 -227.\n",
            "24 \n",
            "30. Eren I, Naziroglu M, Demirdas A. Protective effects of lamotrigine, \n",
            "aripiprazole and escitalopram on depression -induced oxidative \n",
            "stres in rat brain. Neurochem Res 2007;32:1188-95. \n",
            "31. Somuncu S, Cakmak M, Dikmen G, Akm an H, Kaya M. Ischemia -\n",
            "reperfusion injury of rabbit ovary and protective effect of trapidil: \n",
            "an experimental study. Pediatr Surg Int 2008;24:315 –8. doi: \n",
            "10.1007/s00383-007-2079-3. \n",
            "32. Erel O. A novel automated method to measure total antioxidant \n",
            "response a gainst potent free radical reactions. Clin Biochem \n",
            "2004;37:112-9. \n",
            "33. Erel O. A new automated colorimetric method for measuring total \n",
            "oxidant status. Clin Biochem 2005;38:1103-11. \n",
            "34. Cowled P, Fitridge R. Pathophysiology of Reperfusion Injury. In: \n",
            "Fitridge R, Thompson M, editors. Mechanisms of Vascular \n",
            "Disease: A Reference Book for Vascular Specialists [Internet]. \n",
            "Adelaide (AU): University of Adelaide Press; 2011. 18. Available \n",
            "from: https://www.ncbi.nlm.nih.gov/books/NBK534267/ \n",
            "35. Guven S, Muci E, Unsal MA, et al. The effects of carbon dioxide \n",
            "pneumoperitoneum on ovarian blood flow, oxidative stress \n",
            "markers, and morphol ogy during laparoscopy: a rabbit model. \n",
            "Fertil Steril 2008;93(4). \n",
            "36. Sagsoz N, Kisa U, Apan A. Ischemia -reperfusion injury of rat ovary \n",
            "and the effects of vitamin C, mannitol and verapamil. Hum Reprod \n",
            "2002;17:2972-6. \n",
            "37. Gezer, Ş., & Başaran, M. The prote ctive effect of letrozole in a rat \n",
            "ovarian ischemia -reperfusion injury model.  Van Medical \n",
            "Journal, 27(4), 407-414. \n",
            "38. Sengul, O., Ferah, I., Polat, B., Halici, Z., Bayir, Y., Yilmaz, M., ... & \n",
            "Keles, O. N. (2013). Blockade of endothelin receptors with \n",
            "bosentan limits ischaemia/reperfusion -induced injury in rat \n",
            "ovaries. European Journal of Obstetrics & Gynecology and \n",
            "Reproductive Biology, 170(2), 458-463. \n",
            "39. Unlubilgin, E., Suleyman, B., Balci, G., Al, R. A., Cankaya, M. U. R. \n",
            "A. T., Nayki, U. A., & Suleym an, H. (2017). Prevention of \n",
            "infertility induced by ovarian ischemia reperfusion injury by \n",
            "benidipine in rats: Biochemical, gene expression, \n",
            "histopathological and immunohistochemical evaluation.  Journal \n",
            "of Gynecology Obstetrics and Human Reproduction , 46(3), 267-\n",
            "273.\n",
            "63 \n",
            "REFERENCES \n",
            "1. Pękala, P. A., Henry, B. M., Pękala, J. R., Skinningsrud, B., Walocha, J. \n",
            "A., Bonczar, M., & Tomaszewski, K. A. (2017). Congenital \n",
            "absence of the palmaris longus muscle: A meta -analysis \n",
            "comparing cadaveric and functional studies.  Journal of Plastic, \n",
            "Reconstructive & Aesthetic Surgery, 70(12), 1715-1724. \n",
            "2. Cooper DW, Burns B. Anatomy, Shoulder and Upper Limb, Hand \n",
            "Palmaris Tendon. [Updated 2020 Sep 15]. In: StatPearls [Internet]. \n",
            "Treasure Island (FL): StatPearls Publishing; 2020 Jan -. Available \n",
            "from: https://www.ncbi.nlm.nih.gov/books/NBK519516/ \n",
            "3. Georgiev GP, Iliev AA, Dimitrova IN, Kotov GN, Malinova LG, \n",
            "Landzhov BV. Palmaris Longus Muscle Variations: Clinical \n",
            "Significance and Proposal of New Classifications.  Folia Med \n",
            "(Plovdiv). 2017 Sep 01;59(3):289-297. [PubMed] \n",
            "4. Cetin A, Genc M, Sevil S, Coban YK. Prevalence of the palmaris longus \n",
            "muscle and its relationship with grip and pinch strength: a study in \n",
            "a Turkish pediatric population.  Hand (N Y).  2013 Jun;8(2):215 -\n",
            "20. [PMC free article] [PubMed] \n",
            "5. Alabbad, A., Alkhamis, M., Alsultan, M., & Alahmad, S. (2018). The \n",
            "Frequency of Palmaris Longus Absence among Female Students \n",
            "in King Faisal University in Al-Ahsa, Saudi Arabia. The Egyptian \n",
            "Journal of Hospital Medicine, 70(11), 1959-1962. \n",
            "6. Erić M, Koprivčić I, Vučinić N (2 011): Prevalence of the palmaris \n",
            "longus in relation to the hand dominance. Surgical and Radiologic \n",
            "Anatomy, 33 (6):481–484.  \n",
            "7. Kose, O., Adanir, O., Cirpar, M., Kurklu, M., & Komurcu, M. (2009). \n",
            "The prevalence of absence of the palmaris longus: a study in \n",
            "Turkish population.  Archives of Orthopaedic and Trauma \n",
            "Surgery, 129(5), 609. \n",
            "8. Thidar, A. M., Myint, T. T., Naing, D. K. S., & Mustapha, Z. A. (2013). \n",
            "Palmaris Longus Agenesis (PLA) among Dusun and Bajau ethnic \n",
            "groups of Northern Borneo.  International Journal of \n",
            "Collaborative Research on Internal Medicine & Public \n",
            "Health, 5(6), 0-0. \n",
            "9. Hiz, Ö., Ediz, L., Ceylan, M. F., Gezici, E., Gülcü, E., & Erden, M. \n",
            "(2011). Prevalence of the absence of palmaris longus muscle \n",
            "assessed by a new examination test (Hiz -Ediz Test) in the \n",
            "population residing in the area of Van, Turkey. Journal of Clinical \n",
            "& Experimental Investigations/Klinik ve Deneysel Arast irmalar \n",
            "Dergisi, 2(3).\n",
            "33 \n",
            "REFERENCES \n",
            "1. Semenza GL. Hypoxia-inducible factors in physiology and medicine. \n",
            "Cell. 2012;148(3):399-408. \n",
            "2. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human \n",
            "cancer. J Cell Biochem. 2009;107(6):1053-1062. \n",
            "3. Branco-Price C, Zhang N, Schnelle M, et al. Endothel ial cell HIF -1α \n",
            "and HIF-2α differentially regulate metastatic success. Cancer cell. \n",
            "2012;21(1):52-65. \n",
            "4. Kitajima Y, Miyazaki K. The Critical Impact of HIF -1a on Gastric \n",
            "Cancer Biology. Cancers. 2013;5(1):15-26. \n",
            "5. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer \n",
            "biology and therapeutics. Oncogene. 2010;29(5):625-634. \n",
            "6. Hao LS, Liu Q, Tian C, et al. Correlation and expression analysis of \n",
            "hypoxia‑inducible factor  1α, glucose transporter 1 and lactate \n",
            "dehydrogenase 5 in human gastric can cer. Oncol Lett. \n",
            "2019;18(2):1431-1441. \n",
            "7. Rohwer N, Lobitz S, Daskalow K, et al. HIF -1α determines the \n",
            "metastatic potential of gastric cancer cells. British Journal of \n",
            "Cancer. 2009;100(5):772-781. \n",
            "8. Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM. Is the \n",
            "hypoxia-inducible factor pathway important in gastric cancer? \n",
            "European Journal of Cancer. 2005;41(18):2792-2805. \n",
            "9. Miao ZF, Wang ZN, Zhao TT, et al. Peritoneal milky spots serve as a \n",
            "hypoxic niche and favor gastric cancer stem/progenitor cell \n",
            "peritoneal dissemination through hypoxia -inducible factor 1α. \n",
            "Stem cells (Dayton, Ohio). 2014;32(12):3062-3074. \n",
            "10. Jung J-H, Im S, Jung ES, Kang CS. Clinicopathological Implications of \n",
            "the Expression of Hypoxia-related Proteins in Gastric Cancer. \n",
            "International Journal of Medical Sciences. 2013;10(9):1217-\n",
            "1223. \n",
            "11. Chen L, Shi Y, Yuan J, et al. HIF -1 Alpha Overexpression Correlates \n",
            "with Poor Overall Survival and Disease -Free Survival in Gastric \n",
            "Cancer Pati ents Post -Gastrectomy. PLOS ONE. \n",
            "2014;9(3):e90678. \n",
            "12. Kaelin WG, Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central \n",
            "role of the HIF hydroxylase pathway. Molecular cell. \n",
            "2008;30(4):393-402. \n",
            "13. Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through \n",
            "hypoxia inducible factors and beyond. Nature reviews Molecular \n",
            "cell biology. 2020;21(5):268-283. \n",
            "14. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer \n",
            "progression, angiogenesis, metastasis, and resistance to therapy. \n",
            "Hypoxia (Auckland, NZ). 2015;3:83-92.\n",
            "64 \n",
            "10. Roohi, S. A., Choon-Sian, L., Tan, G. H., Naicker, A. S., & Med Rehab, \n",
            "M. (2007). A study on the absence of palmaris longus in a \n",
            "multiracial population. Malaysian Orthopaedic Journal, 1(1), 26-\n",
            "28. \n",
            "11. Saxena, S. (2013). A study o n the absence/presence of the muscle \n",
            "Palmaris Longus in an Indian population.  International J of \n",
            "Healthcare & Biomedical Research, 2(1), 48-53. \n",
            "12. Venter, G., Van Schoor, A. N., & Bosman, M. C. (2014). Degenerative \n",
            "trends of the palmaris longus muscle in a South African \n",
            "population. Clinical Anatomy, 27(2), 222-226. \n",
            "13. Mbaka, G. O., & Ejiwunmi, A. B. (2009). Prevalence of palmaris \n",
            "longus absence –a study in the Yoruba population.  The Ulster \n",
            "medical journal, 78(2), 90. \n",
            "14. Lewis -Beck, M., Bryman, A. E., & Li ao, T. F. (2003).  The Sage \n",
            "encyclopedia of social science research methods . Sage \n",
            "Publications. \n",
            "15. Wehbé, M. A. (1992). Tendon graft donor sites.  Journal of Hand \n",
            "Surgery, 17(6), 1130-1132. \n",
            "16. Sater, M. S.,  Dharap, A. S., & Abu‐Hijleh, M. F. (2010). The \n",
            "prevalence of absence of the palmaris longus muscle in the \n",
            "Bahraini population. Clinical Anatomy, 23(8), 956-961. \n",
            "17. Lahiji, F. A., Ashoori, K., & Dahmardehei, M. (2013). Prevalence of \n",
            "palmaris longus agenesis in a hospital in Iran. Archives of Iranian \n",
            "medicine, 16(3), 187. \n",
            "18. Yammine, K. (2013). Clinical prevalence of palmaris longus agenesis: \n",
            "A systematic review and meta‐analysis.  Clinical Anatomy, 26(6), \n",
            "709-718. \n",
            "19. Kikano, R., Charbel, C., Assi, C., & Yammine, K. (2020). Prevalence, \n",
            "variants, and morphometrics of Palmaris Longus tendon: a \n",
            "magnetic resonance imaging study.  Surgical and Radiologic \n",
            "Anatomy, 1-5. \n",
            "20. Raouf, H. A., Kader, G. A., Jaradat, A., Dharap, A., Fadel, R., & Salem, \n",
            "A. H. (2013). Frequ ency of palmaris longus absence and its \n",
            "association with other anatomical variations in the Egyptian \n",
            "population. Clinical Anatomy, 26(5), 572-577. \n",
            "21. Agarwal, P. (2010). Absence of the palmaris longus tendon in Indian \n",
            "population. Indian journal of orthopaedics, 44, 212-215.\n",
            "56 \n",
            "MATERIALS AND METHODS \n",
            "Subjects \n",
            "This is a cross sectional study that involved 712 (429 male, 283 \n",
            "female) healthy subjects studying at Atatürk and Erzincan Binali Yıldırım \n",
            "University Faculty of Medicine. We excluded subjects with physically \n",
            "disabilities, any prior surgery (to upper or lower limbs) and any upper limb \n",
            "injuries. Subjects with a history of injury /disability (including those \n",
            "resulting from trauma, be it spine, lower or upper limb) , disease or \n",
            "abnormality of the upper limb which would preclude examination for the \n",
            "presence of the PL tendon. \n",
            "Tests  \n",
            "In our current study, the S cheaffer’s test (7, 8, 9, 10, 11, 12 ), the \n",
            "Thompson’s test (5, 8, 11, 13) and the Mishra’s test (7, 8, 9, 11, 13), which \n",
            "are the classical tests frequently used in the studies, were applied to test the \n",
            "presence of Palmaris longus: \n",
            "- The Schaffer’s test: This is the Standard test for the assessment \n",
            "of the palmaris longus tendon. It involves opposing the thumb to the little \n",
            "finger and then followed by the flexion of the wrist. Each of the subjects \n",
            "was asked to oppose the thumb to the little finger and then flexes the wrist \n",
            "slightly (8,11) (Fig. 2). \n",
            "- Thompson’s test: The test involves the flexion of the fingers to \n",
            "form a fist followed by the flexion of the wrist and finally, the thumb is \n",
            "opposed and flexed over the fingers . The subjects were asked to make a \n",
            "fist and then flex the wrist and finally, the thumb is opposed and flexed \n",
            "over the fingers (8,11) (Fig. 3). \n",
            "- Mishra’s test:  The test involves the abduction of the thumb \n",
            "against the resistance with the wrist in slightly palmar flexion. The subjects \n",
            "were asked to abduct the thumb against resistance with the wrist in slight \n",
            "palmar flexion (8,11) (Fig. 4). \n",
            "Statistical analysis \n",
            "IBM SPSS 22.0 package program was used for statistical analysis \n",
            "of the data (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, \n",
            "Version 22.0. Armonk, NY: IBM Corp.). Mean ± standard deviation and \n",
            "(minimum-maximum) value were used when summarizing age, which is a \n",
            "continuous variable, and number (n) and percentage (%) for ca tegorical \n",
            "variables. The Chi -square test was used in the analysis of categorical \n",
            "variables. Phi coefficient was used to evaluate the PLA relationship \n",
            "between the right and left sides. For Phi coefficient <0.20 no relationship, \n",
            "0.20-0.29 was considered weak , 0.30 -0.49 moderate, 0.50 -0.69 strong,\n",
            "REFERENCES \n",
            "1. Huang C, Hong MK, Ding DC. A review of ovary torsion. Ci Ji Yi Xue \n",
            "Za Zhi. 2017;29(3):143-147. doi:10.4103/tcmj.tcmj_55_17 \n",
            "2. Anne A, Dalley A. Grant’s Atlas of Anatomy. 13th ed. Philadelphia: \n",
            "Lippincott Williams & Wilkins; 2012. \n",
            "3. Eskander, R.N., Bristow, R.E. Adnexal Masses in Pediatric and \n",
            "Adolescent Females: A Review of th e Literature.  Curr Obstet \n",
            "Gynecol Rep  1, 25–32 (2012). https://doi.org/10.1007/s13669-\n",
            "011-0001-4 \n",
            "4. Guthrie BD, Adler MD, Powell EC. Incidence and trends of pediatric \n",
            "ovarian torsion hospitalizations in the United States, 2000 –2006. \n",
            "Pediatrics. 2010;125(3):532–8. \n",
            "5. Bozkurt S, Arikan DC, Kurutas EB, Sayar H, Okumus M, Coskun A, \n",
            "Bakan V. Selenium has a protective effect on ischemia/reperfusion \n",
            "injury in a rat ovary model: biochemical an d histopathologic \n",
            "evaluation. J Pediatr Surg. 2012 Sep;47(9):1735 -41. doi: \n",
            "10.1016/j.jpedsurg.2012.03.053. PMID: 22974615. \n",
            "6. Cihangir Mutlu ERCAN, Hakan ÇOKSÜER, Uğur KESKİN, K. Emre \n",
            "KARAŞAHİN, İbrahim ALANBAY, İskender BAŞER.(2011). \n",
            "Adneksiyal torsiyon t edavisinde laparoskopik yaklaşım \n",
            "sonuçlarımız. Gülhane Tıp Dergisi \n",
            "7. Akdemir A, Erbas O, Gode F, Ergenoglu M, Yeniel O, Oltulu F, \n",
            "Yavasoglu A, Taskiran D. Protective effect of oxytocin on ovarian \n",
            "ischemia-reperfusion injury in rats. Peptides. 2014 May;55:126-\n",
            "30. doi: 10.1016/j.peptides.2014.02.015. Epub 2014 Mar 11. \n",
            "PMID: 24630974. \n",
            "8. Arikan, Deniz & Bakan, Vedat & Kurutas, Ergul & Sayar, Hamide & \n",
            "Coskun, Ayhan. (2010). Protective effect of tadalafil on \n",
            "ischemia/reperfusion injury of rat ovary. Jour nal of pediatric \n",
            "surgery. 45. 2203-9. 10.1016/j.jpedsurg.2010.07.011. \n",
            "9. Melekoglu, R., Ciftci, O., Eraslan, S., Alan, S., & Basak, N. (2018). The \n",
            "protective effects of glycyrrhetinic acid and chrysin against \n",
            "ischemia-reperfusion injury in rat ovaries.  BioMed research \n",
            "international, 2018. \n",
            "10. Turkler, C., Kulhan, N. G., Ata, N., Kiremitli, T., Cimen, F. K., & \n",
            "Suleyman, H. (2018). The ameliorative effect of lutein on ovarian \n",
            "ischemia-reperfusion injury in rats.  Bratislavske Lekarske \n",
            "Listy, 119(11), 713-717.\n",
            "11 \n",
            "biotechnological applications.  Journal of Materials Science: \n",
            "Materials in Medicine, 16(10), 933-946. \n",
            "25. Khampieng, T., Wnek, G. E., & Supaphol, P. (2014). Electrospun \n",
            "DOXY-h loaded-poly (acrylic acid) nanofiber mats: in vitro drug \n",
            "release and antibacterial properties investigation.  Journal of \n",
            "Biomaterials Science, Polymer Edition, 25(12), 1292-1305. \n",
            "26. Cogen, A. L., Nizet, V., & Gallo, R. L. (2008). Skin microbiota: a \n",
            "source of disease or defence?.  British Journal of \n",
            "Dermatology, 158(3), 442-455. \n",
            "27. Mackowiak, P. A. (1982). The normal microbial flora.  New England \n",
            "Journal of Medicine, 307(2), 83-93. \n",
            "28. National Institutes of Health (US). Biological Sciences Curriculum \n",
            "Study. NIH curriculum supplement series [Internet]. Bethesda \n",
            "(MD): National Institutes of Health (US); 2007. Understanding \n",
            "Emerging and Re-emerging Infectious Diseases.  Available from: \n",
            "http://www.ncbi.nlm.nih.gov/books/NBK20370/ \n",
            "29. Sohrabi, A., Shaibani, P. M., Etayash, H., Kaur, K., & Thundat, T. \n",
            "(2013). Sustained drug release and antibacterial activity of \n",
            "ampicillin incorporated poly (methyl methacrylate) –nylon6 \n",
            "core/shell nanofibers. Polymer, 54(11), 2699-2705. \n",
            "30. Kim, S. S., & Lee, J. (2014). Antibacterial activity of polyacrylonitrile–\n",
            "chitosan electrospun nanofibers.  Carbohydrate polymers , 102, \n",
            "231-237. \n",
            "31. Sarhan, W. A., & Azzazy, H. M. (2015). High concentration honey \n",
            "chitosan electrospun nanofibers: biocompatibility and antibacterial \n",
            "effects. Carbohydrate polymers, 122, 135-143. \n",
            "32. Thenmozhi, S., Dharmaraj, N., Kadirvelu, K., & Kim, H. Y. (2017). \n",
            "Electrospun nanofibers: New generation materials for advanced \n",
            "applications. Materials Science and Engineering: B, 217, 36-48. \n",
            "33. Abrigo, M., M cArthur, S. L., & Kingshott, P. (2014). Electrospun \n",
            "nanofibers as dressings for chronic wound care: advances, \n",
            "challenges, and future prospects.  Macromolecular \n",
            "bioscience, 14(6), 772-792.\n",
            "127 \n",
            "15. Goel P, Radotra A, Singh I, Aggarwal A, Dua D. Effects of passive \n",
            "smoking on outcome in pregnancy. Journal of postgraduate \n",
            "medicine. 2004;50(1):12.  \n",
            "16. Cohen J, Cohen P, West SG, Aiken LS. Applied multiple \n",
            "regression/correlation analysis for the behavioral sciences . \n",
            "Routledge; 2013. \n",
            "17. Chow S -C, Shao J. Statistics in drug research: methodologies and \n",
            "recent developments. CRC Press; 2002. \n",
            "18. Larsen S, Haavaldsen C, Bjelland EK, Dypvik J, Jukic A M, Eskild A. \n",
            "Placental weight and birthweight: the relations with number of \n",
            "daily cigarettes and smoking cessation in pregnancy. A population \n",
            "study. International journal of epidemiology . 2018;47(4):1141 -\n",
            "1150.  \n",
            "19. Marakoğlu K, Sezer RE. Sivas’ ta gebelikt e sigara kullanımı. \n",
            "Cumhuriyet Üniversitesi Tıp Fakültesi Dergisi . 2003;25(4):157 -\n",
            "164.  \n",
            "20. Schneider S, Maul H, Freerksen N, Pötschke -Langer M. Who smokes \n",
            "during pregnancy? An analysis of the German Perinatal Quality \n",
            "Survey 2005. Public health. 2008;122(11):1210-1216.  \n",
            "21. Dogu S, AB E. Gebe kadınların sigara kullanımını etkileyen faktörler \n",
            "ve gebelikteki zararlarına ilişkin bilgiler. Maltepe Üniv Hemşirelik \n",
            "Bilim ve Sanat Derg. 2008;1(1):12-7.  \n",
            "22. Shah NR, Bracken MB. A systematic review and meta -analysis of \n",
            "prospective studies on the association between maternal cigarette \n",
            "smoking and preterm delivery. American journal of obstetrics and \n",
            "gynecology. 2000;182(2):465-472.  \n",
            "23. PATOLOJİ P, GÖNDERİLMESİ L. Plasentanın klinik ve \n",
            "histopatolojik incelenme yönteml eri ve önemi. Perinatoloji \n",
            "Dergisi. 1993;1:246-255.  \n",
            "24. Machaalani R, Ghazavi E, Hinton T, Makris A, Hennessy A. \n",
            "Immunohistochemical expression of the nicotinic acetylcholine \n",
            "receptor (nAChR) subunits in the human placenta, and effects of \n",
            "cigarette smoking and preeclampsia. Placenta. 2018;71:16-23.  \n",
            "25. Reijnders I, Mulders A, Koster M, et al. New imaging markers for \n",
            "preconceptional and first-trimester utero-placental vascularization. \n",
            "Placenta. 2018;61:96-102.  \n",
            "26. Zhao F, Lei F, Yan X, Zhang S, Wang W, Zh eng Y. Protective effects \n",
            "of hydrogen sulfide against cigarette smoke exposure -induced \n",
            "placental oxidative damage by alleviating redox imbalance via \n",
            "Nrf2 pathway in rats. Cellular Physiology and Biochemistry . \n",
            "2018;48(5):1815-1828.  \n",
            "27. Heidari Z, Mahmoudza deh-Sagheb H, Sheibak N. Placenta structural \n",
            "changes in heavy smoking mothers: a stereological aspect. Current \n",
            "Medical Research and Opinion. 2018;34(11):1893-1897.\n",
            "87 \n",
            "2013;47(9):683-691. doi:10.3109/10715762.2013.814912 \n",
            "78.  Aghamir SMK, Guitynavard F. Erectile Dysfunctions. In: Stem Cells \n",
            "in Urology . Springer International Publishing; 2020:75 -88. \n",
            "doi:10.1007/978-3-030-41476-4_6 \n",
            "79.  Yu Z, Zhang Y, Tang Z, et al. Intracavernosal Adeno -Associated \n",
            "Virus-Mediated S100A1 Gene Transfer Enhances Erect ile \n",
            "Function in Diabetic Rats by Promoting Cavernous Angiogenesis \n",
            "via VEGF -A/VEGFR2 Signaling. Journal of Sexual Medicine . \n",
            "2019;16(9):1344-1354. doi:10.1016/j.jsxm.2019.06.011 \n",
            "80.  Gur S, Abdel -Mageed AB, Sikka SC, Bartolome AR, Hellstrom \n",
            "WJG. Destination Penis? Gene Therapy as a Possible Treatment \n",
            "for Erectile Dysfunction. Current Gene Therapy. 2018;18(4):225-\n",
            "239. doi:10.2174/1566523218666180730110432 \n",
            "81.  Andersson KE, Christ GJ. Gene Therapy in Erectile Dysfunction: \n",
            "Dead or Alive? Journal of Sexual Medic ine. 2020;17(9):1587 -\n",
            "1589. doi:10.1016/j.jsxm.2020.06.012 \n",
            "82.  Chen Z, Yu Y, He M, et al. Higher growth hormone levels are \n",
            "associated with erectile dysfunction in male patients with \n",
            "acromegaly. Endocrine Practice . 2019;25(6):562 -571. \n",
            "doi:10.4158/EP-2018-0518 \n",
            "83.  Galdiero M, Pivonello R, Grasso LFS, Cozzolino A, Colao A. \n",
            "Growth hormone, prolactin, and sexuality. Journal of \n",
            "Endocrinological Investigation . 2012;35(8):782 -794. \n",
            "doi:10.1007/BF03345805 \n",
            "84.  Li H, Kong R , Wan B, et al. Initiation of PI3K/AKT pathway by \n",
            "IGF-1 decreases spinal cord injury -induced endothelial apoptosis \n",
            "and microvascular damage. Life Sciences . 2020;263:118572. \n",
            "doi:10.1016/j.lfs.2020.118572 \n",
            "85.  Melman A, Bar -Chama N, McCullough A, Davies K, C hrist G. \n",
            "Plasmid-based gene transfer for treatment of erectile dysfunction \n",
            "and overactive bladder: Results of a phase I trial. In: Israel \n",
            "Medical Association Journal. Vol 9. ; 2007:143-146. \n",
            "86.  Melman A, Bar -Chama N, McCullough A, Davies K, Christ G. \n",
            "hMaxi-K gene transfer in males with erectile dysfunction: Results \n",
            "of the first human trial. Human Gene Therapy. 2006;17(12):1165-\n",
            "1176. doi:10.1089/hum.2006.17.1165 \n",
            "87.  Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. The \n",
            "first human trial for gene tra nsfer therapy for the treatment of \n",
            "erectile dysfunction: Preliminary results. European Urology .\n",
            "9 \n",
            "REFERENCES \n",
            "1. Meyer, M., Müller, A. K., Yang, J., Moik, D., Ponzio, G., Ornitz, D. M., \n",
            "... & Werner, S. (2012). FGF receptors 1 and 2 are key regulators \n",
            "of keratinocyte migration in vitro and in wounded skin. Journal of \n",
            "cell science, 125(23), 5690-5701. \n",
            "2. Atalan, G., Demirkan, İ., Yaman, H., Cihan, M., Önder, F., & Sözmen, \n",
            "M. (2003). Effect of topical kefir application on open wound \n",
            "healing an in vivo study.  Kafkas Üniversitesi Veteriner Fakültesi \n",
            "Dergisi, 9(1), 43-47. \n",
            "3. Omeroglu, S., Cam, M., & Erdoğan, D. (2003). Streptozotosin ile \n",
            "deneysel diyabet oluşturulmuş sıçanlardaki deri yaralarında, \n",
            "insülin benzeri büyüme faktörü -I’in lokalizasyonunun \n",
            "immünohistokimyasal olarak gösterilmesi.  Düzce Tıp Fakültesi \n",
            "Dergisi, 5, 5-8. \n",
            "4. Kapan, M., Aslanmirza, M. Y., Karip, A. B., Bozkurt, Y., Evsen, M. S., \n",
            "Sak, E., & Öngören, A. U. (2008). Lokal fenitoin ve üre \n",
            "uygulamasının yara iyileşmesi üzerine olan etkilerinin \n",
            "karşılaştırılması. Yeni Tıp Dergisi, 25(4), 209. \n",
            "5. Alpsoy, A., Atasever, S., İlter, K., Özbeser, E., & Öztürk, A. Sıçanlarda \n",
            "lokal midkin tedavisininyara iyileşmesine etkisi.  \n",
            "6. Liu, M., Duan, X. P., Li, Y. M., Yang, D. P., & Long, Y. Z. (2017). \n",
            "Electrospun nanofibers for wound healing. Materials Science and \n",
            "Engineering: C, 76, 1413-1423. \n",
            "7. Liu, W., Thomopoulos, S., & Xia, Y. (2012). Electrospun nanofibers for \n",
            "regenerative medicine. Advanced healthcare materials , 1(1), 10 -\n",
            "25. \n",
            "8. Kelleher, C. M., & Vacanti, J. P. (2010). Engineering extracellular \n",
            "matrix through nan otechnology. Journal of the Royal Society \n",
            "Interface, 7(suppl_6), S717-S729. \n",
            "9. Agarwal, S., Wendorff, J. H., & Greiner, A. (2009). Progress in the field \n",
            "of electrospinning for tissue engineering applications.  Advanced \n",
            "Materials, 21(32‐33), 3343-3351. \n",
            "10. Pham, Q. P., Sharma, U., & Mikos, A. G. (2006). Electrospinning of \n",
            "polymeric nanofibers for tissue engineering applications: a \n",
            "review. Tissue engineering, 12(5), 1197-1211. \n",
            "11. Kai, D., Liow, S. S., & Loh, X. J. (2014). Biodegradable polymers for \n",
            "electrospinning: towards biomedical applications.  Materials \n",
            "Science and Engineering: C, 45, 659-670.\n",
            "136  \n",
            "Mnayer D, Özçelik B, et al. Plants of the genus Lavandula: From farm \n",
            "to pharmacy. Natural Product Communications, 2018. 13(10): p. \n",
            "1934578X1801301037.  \n",
            "19. Woronuk G, Demissie Z, Rheault M, Mahmoud Z. Biosynthesis and \n",
            "therapeutic properties of Lavandula essential oil cons tituents. Planta \n",
            "medica, 2011. 77(01): p. 7-15.  \n",
            "20. European  Medicines  Agency  (EMA).  \n",
            "https://www.ema.europa.eu/en/medicines/herbal/lavandulaeaetheroleum#\n",
            "key-facts-section.  \n",
            "21. Zuzarte M, Gonçalves MJ, Cruz MT, et al. Lavandula luisieri essential \n",
            "oil as a source of antifungal drugs. Food Chemistry, 2012. 135(3): p. \n",
            "1505-1510.  \n",
            "22. Bouyahya A, Et-Touys A, Abrini J, et al. Lavandula stoechas essential \n",
            "oil from Morocco as novel source of antileishmanial, antibacterial and \n",
            "antioxidant activities. Biocatalysis and Agricultural Biotechnology, \n",
            "2017. 12: p. 179-184.  \n",
            "23. Mondello F, De Bernardis F, Girolamo A, Cassone A, Salvatore G. In \n",
            "vivo activity of terpinen -4-ol, the main bioactive component  of \n",
            "Melaleuca alternifolia Cheel (tea tree) oil against azole -susceptible \n",
            "and-resistant human pathogenic Candida species. BMC infectious \n",
            "diseases, 2006. 6(1): p. 158.  \n",
            "24. Zhao Y, Chen R, Wang Y, Qing C, Wang W, Yang y. In vitro and in \n",
            "vivo efficacy studies of  Lavender angustifolia essential oil and its \n",
            "active constituents on the proliferation of human prostate cancer. \n",
            "Integrative cancer therapies, 2017. 16(2): p. 215-226.  \n",
            "25. Loutrari H, Hatziapostolou M, Skouridou V, et al. Perillyl alcohol is an \n",
            "angiogenesis in hibitor. Journal of Pharmacology and Experimental \n",
            "Therapeutics, 2004. 311(2): p. 568-575.  \n",
            "26. Abe S, Maruyama N, Hayama K, et al. Suppression of tumor necrosis \n",
            "factor-alpha-induced neutrophil adherence responses by essential oils. \n",
            "Mediators of Inflammation, 2003. 12.  \n",
            "27. Samuelson R, Lobl M, Higgins S, Clarey D, Wysong A. The Effects of \n",
            "Lavender Essential Oil on Wound Healing: A Review of the Current \n",
            "Evidence. J Altern Complement Med 2020;26(8):680690.  \n",
            "28. Hartman D, Coetzee JC. Two US practitioners’ experience of u sing \n",
            "essential oils for wound care. J Wound Care 2002; 11:317–320.  \n",
            "29. Kerr J. The use of essential oils in healing wounds. Int J Aromather \n",
            "2002;12:202–206.  \n",
            "30. Altaei DT. Topical lavender oil for the treatment of recurrent aphthous \n",
            "ulceration. Am J Dent 2012;25910:39–43.  \n",
            "31. Vakilian K, Atarha M, Bekhradi R, Chaman R. Healing advantages of \n",
            "lavender essential oil during episiotomy recovery: A clinical trial. \n",
            "Complement Ther Clin Pract 2011; 17:50–53.\n",
            "CHAPTER VI \n",
            " \n",
            "TARGETS FOR THE TREATMENT OF ERECTILE \n",
            "DYSFUNCTION \n",
            " \n",
            "Nadire Eser \n",
            "(Asst. Prof. PhD), Kahramanmaraş Sütçü İmam University,  \n",
            "e-mail: esernadire01@hotmail.com \n",
            "                   0000-0003-1607-5114 \n",
            " \n",
            "1. INTRODUCTION \n",
            "1.1. Epidemiology   \n",
            "Erectile dysfunction (ED) is defined as the inability to achieve or \n",
            "maintain a repetitive /permanent erection for any sexual activity. \n",
            "Worldwide; it is a condition that depends on many factors, where more \n",
            "than 150 million men are affected, with 39% of men around the age of 40 \n",
            "and 67% of men around the age of 70 1.  \n",
            "The most important point in terms of the definition is that the \n",
            "erectile problem is not limited to one or more times, this problem must be \n",
            "repetitive or long -term to be diagnosed with erectile dysfunction. In \n",
            "addition to the age factor, the presence of some chronic diseases (heart \n",
            "diseases, hypertension, diabetes, and depression), smoking, alcohol use, \n",
            "stress, drug addiction, obesity, and some lifestyles also t rigger the \n",
            "formation of this disorder. In fact, evidence has been shown that there is \n",
            "a close relationship between metabolic syndrome, cardiovascular disease \n",
            "and ED 2. Erectile dysfunction can also be caused by psychogenic, \n",
            "organic (vascular, neurogenic, hormonal, anatomical/struct ural), or a \n",
            "combination of the  organic and psychogenic state  3. Sexual dysfunction \n",
            "is the most emphasized subject in psychogenic/organic differentiation. It \n",
            "requires a multidisciplinary approach in both its differential diagnosis \n",
            "and its treatment 4. \n",
            "Although ED is a benign disease, this condition is associated \n",
            "with physical and psychosocial health and has a significant impact on the \n",
            "quality of life of both affected individuals and their partners and families \n",
            "5.  ED is an important problem that impairs the quality of life of men with \n",
            "this condition all over the world.\n",
            "117 \n",
            "2. MATERIALS AND METHOD:   \n",
            "2.1. Newborn and Placenta Weights and Tissue Selection  \n",
            "The present study was carried out at the Manisa Merkez  Efendi \n",
            "State Hospital during October 2017 -April 2018 for a period of about 6 \n",
            "months by taking the necessary ethical and official permissions. It was \n",
            "aimed to evaluate the relationship between the newborn weights and \n",
            "weights of placentas acquired from pregnant women who have started \n",
            "smoking at least 5 years before pregnancy and who have continued \n",
            "smoking throughout their pregnancies (n:35) and from pregnant women \n",
            "who have not smoked at all (n:35) in addition to examining the \n",
            "histopathological changes in the placenta tissues. It took about 6 months \n",
            "between October 2017-April 2018 to collect the placentas and record the \n",
            "data. In addition to questioning smoking addiction in all pregnant women \n",
            "giving normal birth in this study, the presence of pathologic, anatomic \n",
            "findings which may have an impact on fetal growth and development were \n",
            "also examined. The acquired placenta tissues were measured one by one in \n",
            "every group. The weights in kilograms of the babies of all pregnant women \n",
            "included in the study were also recorded.  \n",
            "2.2. Histochemical Staining   \n",
            "The placenta tissues separated from the mothers were weighed \n",
            "rapidly. Following these processes, a sample ti ssue with dimensions of 1 \n",
            "cm3 was taken from the larger placenta tissue which was then placed in \n",
            "10% formaldehyde and fixed for 24 hours. They were then subject to \n",
            "dehydration processes and embedded in paraffin blocks. The embedded \n",
            "tissues were transferred  as 5 µ sections onto a microscope slide via a \n",
            "microtome (Leica RM 2135; Bensheim, Germany). The sections were left \n",
            "to dry for 1 night on the slide after which they were kept for 1 night in a \n",
            "drying oven for deparaffinization. The tissues were treated with xylene the \n",
            "next day and passed through decreasing alcohols of 90%,80,70,60 after \n",
            "which they were kept for 2 min in hematoxylene (Cardiff RD 2014) and 2 \n",
            "min da Eosin (Cardiff RD 2014)  (H&E) stain. The tissues that were \n",
            "exposed to 80% and 90% alcohols were  kept for 1 hour in xylene and \n",
            "mounted with Entellan (UN 1866, Merck, Darmstadt, Germany). They \n",
            "were made ready for examination under the microscope (Olympus BX-40-\n",
            "Tokyo 163-0914, Japan).  \n",
            "2. 3. Statistics  \n",
            "The data were analyzed via SPSS software version 20.0. \n",
            "Independent T test (student T test), F test ( Anova ) and Pearson correlation \n",
            "test were used for data analysis. p values of <0,05 were accepted as \n",
            "statistically significant.\n",
            "93 \n",
            "intrvascular volume, the mean blood pressure decreased as the total \n",
            "peripheral resistance decreased with the increase in v ascular compliance. \n",
            "Increasing cardiac output plateaued or continued to increase slightly in the \n",
            "second half of pregnancy (9). \n",
            "Preeclampsia Added to Chronic Hypertension:  Preeclampsia \n",
            "was added to the picture of a pregnant woman with chronic hypertension. \n",
            "The diagnosis of preeclampsia was determined by the emergence or \n",
            "increase of new proteinuria, increased blood pressure under control, \n",
            "increased liver enzymes, and thrombocytopenia. \n",
            "Gestational hypertension: It is known as hypertension that occurs \n",
            "in the second half of pregnancy or within the first 24 hours postpartum, and \n",
            "returns to normal within 6 -12 weeks after birth without proteinuria. \n",
            "Although the reason is unclear, it has been found that women are very \n",
            "likely to have HT in the future. It has been esti mated that 15 -25% of \n",
            "women with gestational HT will develop preeclampsia (37). In those who \n",
            "had gestational HT before 32 weeks, this rate approached 50%. \n",
            "2.2. EFFECT OF MATERNAL OBESITY ON \n",
            "MACROZOMY \n",
            "Clinically, macrosomia has been described in several ways. \n",
            "Although fetal weight over 4000-5000 gr is a generally accepted definition, \n",
            "it is considered more correct to talk about the baby according to the \n",
            "gestational age (20). The concept of LGA is different from absolute fetal \n",
            "weight, and the expected fetal weight according to gestational age has been \n",
            "achieved to be above the 90% percentile (11). Although not much, in some \n",
            "studies, fetuses with a ponderal index above 2.85 were evaluated as LGA \n",
            "(36). \n",
            "Ponderal index = Weight (gr) .100 / height cm \n",
            "In the Preven tion of Macrosomia: Macrosomia observed \n",
            "especially in diabetes has been reported at a rate of 8-45% despite advanced \n",
            "perinatal medicine practices ( 44). The most important point in the \n",
            "prevention of fetal macrosomia has been the diagnosis of diabetic pregnant \n",
            "women. (4) Although patients were aware of their condition in diabetic \n",
            "cases, timely recognition of gestational diabetes, especially seen in risk \n",
            "groups, was required ( 26). Regardless of the type of diabetes, an \n",
            "appropriate metabolic balance has been maintained throughout pregnancy \n",
            "(23). It was stated that if insulin application will be applied for macrosomia \n",
            "prophylaxis, the last trimester should be selected and treatment should be \n",
            "started as early as possible and before 36th gestational week at the lat est \n",
            "(10).\n",
            "106 \n",
            "delay of at least 7 days was 31.9% in women with a BMI of 30 and above, \n",
            "while this rate was 23.7% in women with normal weight (41). \n",
            "5. PRETERM BIRTH \n",
            "In determining whether maternal obesity is a risk factor for preterm \n",
            "delivery, it was found that optional preterm births and spontaneous preterm \n",
            "births should be examined separately. In general, cohort studies have found \n",
            "that obese women have a high risk for voluntary preterm birth, but \n",
            "miscarriage risk for spontaneous preterm delivery. However, the \n",
            "relationship between maternal obesity and preterm birth risk is complex \n",
            "and potentially influenced by age,  parity, smoking and other factors \n",
            "including ethnicity. \n",
            "The mechanism that obesity reduces the risk of spontaneous \n",
            "preterm birth is not fully explained, but it has been stated that there may be \n",
            "a decrease in the level of spontaneous uterine activity in obe se women \n",
            "compared to normal weight and thin women. More than 3000 preterm \n",
            "births were analyzed in the Danish National Birth Cohort study (n = 62,167 \n",
            "women); premature rupture of membranes and spontaneous preterm \n",
            "delivery are more common in obese women; It has been found that the risk \n",
            "of spontaneous preterm birth is low with intact membranes in obese women \n",
            "(32).  \n",
            "MCP-I (Monocyte Chemolactic Protein -I) was significantly \n",
            "increased in overly obese mothers. In recent studies; He suggested that the \n",
            "relationship between obesity and inflammation in pregnancy is partially \n",
            "related to the increased risk of pregnancy complications observed in obese \n",
            "women. Inflammation, infection, and associated cytokines that are \n",
            "increased during pregnancy have been reported to be associated with risks \n",
            "for the fetus such as preterm birth, intraventricular hemorrhage, \n",
            "periventricular leukomalacia and brocopulmonary dysplasia (28). \n",
            "In a systematic review and meta -analysis of 84 studies consisting \n",
            "of 64 cohorts and 20 case -control studies in order to examine the relation \n",
            "of obesity and obesity in mothers in singleton pregnancies in developed \n",
            "and developing countries with preterm birth and low birth weight babies, \n",
            "obese and obese women were It was found that they were at high risk for \n",
            "preterm labor and preterm delivery with induction before 37 weeks. (1 4) \n",
            "In a systematic review of 49 studies, it was stated that the risk of preterm \n",
            "birth increased as BMI increased, respiratory distress occurred in babies, \n",
            "and this situation increased resuscitation practice (39). Between 2000 and \n",
            "2008, it was determined that the risk of preterm labor increased \n",
            "significantly among obese women in women with 417 twin pregnancies in \n",
            "Japanese maternity hospital and the independent risk factor in preterm \n",
            "labor developing in dichorionic twin pregnancies was maternal obesity \n",
            "(39).\n",
            "91 \n",
            "events (30) Stated that between 2003 -2005, body mass inde x (BMI) was \n",
            "above 25 in 65% of maternal deaths due to thromboembolism (40). \n",
            "Madan et al. (2010) (28) found that 23% of women were obese and \n",
            "5% were extremely obese; He stated that as the age and parity of women \n",
            "increased, their BMI increased. Pre -pregnancy diabetes, gestational \n",
            "diabetes, chronic hypertension and preeclampsia, dysfunctional birth, use \n",
            "of induction, premature rupture of membranes (PROM) and cesarean \n",
            "delivery were found to be increased in extremely obese patients. In this \n",
            "study, premature birth was found in 8% of normal weight women, 8% of \n",
            "obese women, 9% of obese women, and 10% of extremely obese women; \n",
            "It has been stated that it may be associated with the increased risk of \n",
            "preterm birth in obese patients. Chorioamnionitis, low birth weight ba by \n",
            "(LBW) and placental detachment were observed more frequently as a \n",
            "result of PROM and preterm delivery in obese pregnant women (29). \n",
            "In a systematic analysis of 13 scientific studies, it was found that \n",
            "increasing BMI is an independent risk factor for preeclampsia; It has been \n",
            "reported that obese mothers are at twice the risk of preeclampsia than \n",
            "mothers of normal weight. Gestational hypertension is more common in \n",
            "morbidly obese women who did not have hypertension before; Therefore, \n",
            "maternal obesity is not only associated with a high risk of preeclampsia,but \n",
            "has also been associated with gestational hypertension (40). \n",
            "In a randomized controlled study with 1661 women in order to \n",
            "evaluate peripartum and neonatal outcomes in obese and obese mothers; It \n",
            "was found that 27% of women were obese, 16% were obese, there was an \n",
            "artificial initiation of labor and an increase in cesarean rate, and more \n",
            "antibiotics were used for wound infection in the postpartum period. Again \n",
            "in this study, it was found that the risk of d eveloping gestational diabetes \n",
            "was two and four times higher in obese and obese than normal weight \n",
            "women, respectively; It has been reported that babies born to obese and fat \n",
            "mothers are larger and macrosomic (1). \n",
            "Pregnancy outcomes were examined in obese women who gave \n",
            "birth in a large university hospital in Europe; Singleton pregnancies with \n",
            "birth weight> 500 g and women whose BMI was calculated in the first \n",
            "trimester (n = 5824) were included in the study; It was determined that \n",
            "0.6% of women were morbidl y obese. While the mean age of morbidly \n",
            "obese women was 31, 46.1% of women with normal BMI were found to \n",
            "be primigravida. While 35.8% of morbidly obese women have \n",
            "hypertension or preeclampsia caused by pregnancy , these problems were \n",
            "detected in 9.8% of wom en in the normal BMI group. The frequency of \n",
            "fetal macrosomia (birth weight> 4-5 kg) is 1.7% in the normal BMI group \n",
            "and 6.3% in the obese group (13).\n",
            "59 \n",
            "Alabbat A. et al; studied in 200 normal female students from King \n",
            "Faisal University – Saudi Arabia and resulted that in female subjects; the \n",
            "overall prevalence of absence both unilaterally and bilaterally is 40.5 %. \n",
            "Unilateral absence was 20.5%. The bilateral absence was 20%. The \n",
            "distribution on the right and left was 29% and 31.5% respectively (5). \n",
            "Kikano et al, evaluated 335 Labanese patients including a total of \n",
            "339 by using magnetic resonans imaging (MRI) scans. The Palmaris \n",
            "longus was present in 221 wrists (65.2%), and bilaterally in only one (25%) \n",
            "out of the 4 bilateral cases. All palmaris longus were locate d using the \n",
            "Axial T1 views. Univariate and multivariate analyses showed no \n",
            "correlation with side, gender, or Tesla power. The only morphological \n",
            "variation was a reversed PL in 2 cases (0.6%). The mean width was 4.24 ± \n",
            "1.2 mm. The mean thickness was 2.75 ± 0.6 mm (19). \n",
            "The PLM is located superficially, is easily accessible, and is fully \n",
            "developed at birth, making it one of the most frequently used donor \n",
            "material for tendon and joint reconstructive surgeries in all age groups. As \n",
            "PLM is considered an accessory muscle, its tendon is often used as a graft \n",
            "for tendon transfer (18, 20) and in other reconstructive surgeries (21, 22). \n",
            "Also, It is well known that there is a wide variation in the reported \n",
            "prevalence of the PL absence in different ethnic groups. The hi ghest \n",
            "reported prevalence of absence of the PL tendon is seen in the Turkish \n",
            "population with an overall prevalence of absence of 63.9% (7, 23).  \n",
            "Considering its dispensability, surgeons agree that PL is the best \n",
            "choice for tendon grafts in tendon reconstru ction, helping the function of \n",
            "paralyzed muscles used for repairing ptosis, treatment of facial paralysis, \n",
            "and urinary incontinence. Plastic surgeons also utilize the PL in lip \n",
            "augmentation and restoration of lip and chin defects. As its absence is \n",
            "immaterial to the function of the wrist, PL has the greatest variation in the \n",
            "human body and its most common variation is agenesis (PLA) (24). \n",
            "However, this muscle variation can lead to median and/or ulnar nerve \n",
            "compression syndromes in some rare cases (25). \n",
            "A retrospective review of patient charts undergoing endoscopic \n",
            "carpal tunnel release was performed by Boltuch et al (26). They considered \n",
            "the rates of palmaris longus agenesis (PLA) and compared to a population \n",
            "matched data  set by using Schaffers’s test. Study reported that; the \n",
            "Palmaris longus was more prevalent in a population of patients undergoing \n",
            "carpal tunnel release. These findings can be used to provide further insight \n",
            "into the pathophysiology of carpal tunnel syndrome (26).\n",
            "86 \n",
            "68.  Eser N, Kartlaşmış K, Uçar Y, Kökbaş U. Ferula elaeochytris Kök \n",
            "Ekstresinin To plam Fenolik Bileşikler ve Glukoz Seviyesi \n",
            "Üzerine Etkisi. Mersin Üniversitesi Tıp Fakültesi Lokman Hekim \n",
            "Tıp Tarihi ve Folklorik Tıp Dergisi . 2020;10(2):154 -161. \n",
            "doi:10.31020/mutftd.648699 \n",
            "69.  Eser N, Buyuknacar HS, Cimentepe OO, et al. The effect of Fer ula \n",
            "elaeochytris root extract on erectile dysfunction in streptozotocin -\n",
            "induced diabetic rat. International Journal of Impotence \n",
            "Research. 2020;32(2):186-194. doi:10.1038/s41443-019-0137-8 \n",
            "70.  Eser N, Yoldaş A, Yigin A, et al. The protective effect of Fer ula \n",
            "elaeochytris on age -related erectile dysfunction. Journal of \n",
            "Ethnopharmacology. 2020;258:112921. \n",
            "doi:10.1016/j.jep.2020.112921 \n",
            "71.  Liao H, Jacob R. [Chinese herbal drugs for erectile dysfunction \n",
            "through NO -cGMP-PDE5 signaling pathway]. Zhonghua nan ke  \n",
            "xue = National journal of andrology. 2012;18(3):260-265. \n",
            "72.  Goel B, Kumar Maurya N. Aphrodisiac Herbal Therapy for Erectile \n",
            "Dysfunction.; 2020. \n",
            "73.  Goswami SK, Inamdar MN, Jamwal R, Dethe S. Effect of \n",
            "Cinnamomum cassia Methanol Extract and Sildenafil on Arginase \n",
            "and Sexual Function of Young Male Wistar Rats. Journal of \n",
            "Sexual Medicine. 2014;11(6):1475-1483. doi:10.1111/jsm.12535 \n",
            "74.  Nunes KP, Toque HA, Borges MH, Richardson M, Webb RC, de \n",
            "Lima ME. Erectile Function Is Improved in Aged Rats by PnTx2 -\n",
            "6, a Toxin from Phoneutria nigriventer Spider Venom. Journal of \n",
            "Sexual Medicine . 2012;9(10):2574 -2581. doi:10.1111/j.1743 -\n",
            "6109.2012.02878.x \n",
            "75.  Nunes KP, Cordeiro MN, Richardson M, et al. Nitric oxide -induced \n",
            "vasorelaxation in response to pntx2 -6 toxin from phoneutria \n",
            "nigriventer spider in rat cavernosal tissue. Journal of Sexual \n",
            "Medicine. 2010;7(12):3879 -3888. doi:10.1111/j.1743 -\n",
            "6109.2010.01978.x \n",
            "76.  Dalaklioglu S, Ozbey G. The potent relaxant effect of resveratrol in \n",
            "rat corpus cavernosum and its underlyin g mechanisms. \n",
            "International Journal of Impotence Research . 2013;25(5):188 -\n",
            "193. doi:10.1038/ijir.2013.6 \n",
            "77.  Çevik Ö, Çad ırcı S, Şener TE, et al. Quercetin treatment against \n",
            "ischemia/reperfusion injury in rat corpus cavernosum tissue: a \n",
            "role on apoptosis and oxidative stress. Free Radical Research .\n",
            "62 \n",
            " \n",
            "Figure 4: Mischa test. (Thidar, A. M., Myint, T. T., Naing, D. K. S., & \n",
            "Mustapha, Z. A. (2013). Palmaris Longus Agenesis (PLA) among Dusun \n",
            "and Bajau ethnic groups of Northern Borneo. International Journal of \n",
            "Collaborative Research on Internal Medicine & Public Health, 5(6), 0-\n",
            "0.)\n",
            "72 \n",
            "affinity to the catalytic region, are competitively prevented from binding \n",
            "of cGMP to reach the cat alytic mechanism. Thus, they inhibit cGMP \n",
            "degradation. However, PDE5 inhibitors cannot be destroyed by the \n",
            "catalytic mechanism 31. \n",
            "Although the catalytic area is the direct target of PDE5 \n",
            "inhibitors, some features of the regulatory region affect the inhibition \n",
            "developed on it. This area contains allosteric cGMP binding domains and \n",
            "at the same time  phosphorylation sites for enzyme regulation.  Catalytic \n",
            "when cGMP is attached to the allosteric domain  does not break down as \n",
            "in the area and enzyme function  It is activated by the reaction that \n",
            "develops as a result of binding. In this case binding of cGMP also acts as \n",
            "a stimulator for binding of PDE5 inhibitor  to the catalytic site.  In this \n",
            "regard, when the cGMP level increases  in smooth muscle cells after the \n",
            "patient intake silde nafil or other PDE5 inhibitors,  this stimulates t he \n",
            "binding of more  inhibitors to the catalytic site. In this way  PDE5 \n",
            "inhibitors stimulate their own activity. In addition to binding of cGMP to \n",
            "the allosteric region Phosphorylation of  PDE5 by cGMP dependent \n",
            "protein kinase also affect  PDE5 inhibition 31. \n",
            "3.1.2.2. NO Donors  \n",
            "Currently, r esearchers have focused on a new class of \n",
            "compounds whose biological and medical significance is recognized. \n",
            "One of these agents is NCX 911, a derivative of sildenafil developed by \n",
            "NixOx, which provides NO release. NCX 911 spontaneously releases \n",
            "NO and increases intracellular cGMP level through PDE5 inhibition and \n",
            "activation of sGC in the absence of endogenous NO. NCX 911 is more \n",
            "potent than sildenafil both in enhancing tissue relaxation with EFS and \n",
            "reversing contraction in isolated human corpus cavernosum  strips. While \n",
            "sildenafil has minimal effect on increasing tissue cGMP level in the \n",
            "absence of endogenous NO, it increases cGMP level dependent on NCX \n",
            "911 concentration 32. \n",
            "3.1.2.1. Guanilyl Cyclase (sGC) Activity  \n",
            "Prototype of NO -independent sGC activators, initially potent \n",
            "platelet aggregation  YC-1 known for its inhibitory effect 33. In \n",
            "experimental studies, it has been shown that YC -1 strengthens the \n",
            "relaxation phase created by transmural electrical field stimulation (EFS) \n",
            "in the rat corpus cavernosum, reverses the contraction caused by \n",
            "noradrenaline in the isolated rabbit corpus cavernosum, and this effect is \n",
            "parallel with the tissue cGMP level  34. After that, NO -independent sGC \n",
            "activators were developed that were more potent than YC -1 (BAY 41 -\n",
            "2272, BAY 41 8543, BAY 58 -2667). Of these three molecules, BAY 41 -\n",
            "2272 and BAY 41 8543 are affiliated to the heme group, and BAY 58 -\n",
            "85 \n",
            "muscle cells and effects of the transfer of their dominant -negative \n",
            "mutant genes into diabetic rats. Journal of Urolo gy. \n",
            "2012;187(5):1903-1910. doi:10.1016/j.juro.2011.12.051 \n",
            "59.  El-Sakka AI, Yassin AA. Amelioration of Penile Fibrosis: Myth or \n",
            "Reality. Journal of Andrology . 2010;31(4):324 -335. \n",
            "doi:10.2164/jandrol.109.008730 \n",
            "60.  Zhou F, Li G -Y, Gao Z -Z, et al. The TGF - 1/Smad/CTGF Pathway \n",
            "and Corpus Cavernosum Fibrous -Muscular Alterations in Rats \n",
            "With Streptozotocin -Induced Diabetes. Journal of Andrology . \n",
            "2012;33(4):651-659. doi:10.2164/jandrol.111.014456 \n",
            "61.  Li WJ, Zhou J, Li B, Wang H, Peng YB, Wang Z. PARP Inhibition  \n",
            "Restores Erectile Function by Suppressing Corporal Smooth \n",
            "Muscle Apoptosis in Diabetic Rats. Journal of Sexual Medicine . \n",
            "2011;8(4):1072-1082. doi:10.1111/j.1743-6109.2010.02176.x \n",
            "62.  Yamashita S, Kato R, Kobayashi K, Hisasue S ichi, Arai Y, \n",
            "Tsukamoto T. inhibition of interleukin -6 attenuates erectile \n",
            "dysfunction in a rat model of nerve -sparing radical prostatectomy. \n",
            "Journal of Sexual Medicine . 2011;8(7):1957 -1964. \n",
            "doi:10.1111/j.1743-6109.2011.02283.x \n",
            "63.  Simonsen U, Comerma -Steffensen S, Andersson K -E. M odulation \n",
            "of Dopaminergic Pathways to Treat Erectile Dysfunction. Basic & \n",
            "Clinical Pharmacology & Toxicology . 2016;119:63 -74. \n",
            "doi:10.1111/bcpt.12653 \n",
            "64.  Xu Y, Guan X, Zhou R, Gong R. Melanocortin 5 receptor signaling \n",
            "pathway in health and disease. Cellular and Molecular Life \n",
            "Sciences. 2020;77(19):3831 -3840. doi:10.1007/s00018 -020-\n",
            "03511-0 \n",
            "65.  Dowejko M, Smith C, Getting S, Le TPR, Murray JF. The \n",
            "melanocortin system in the male reproductive axis. Endocrine \n",
            "Abstracts. Published online March 1, 2014. \n",
            "doi:10.1530/endoabs.34.p338 \n",
            "66.  Eser N, Yoldas A. Identification of heat -resistant chemical \n",
            "components of Ferula elaeochytris root extracts by gas \n",
            "chromatography-mass spectrometry. Tropical Journal of \n",
            "Pharmaceutical Research . 2019;18(1):55 -60. \n",
            "doi:10.4314/tjpr.v18i1.9 \n",
            "67.  Eser N, Yolda ş A, Koçer F. GC/FID ile ekstrakte edilen Ferula \n",
            "elaeochytris kök ekstresinden yağ asidlerinin analizi. Sakarya \n",
            "Medical Journal. 2020;10(2):264-269. doi:10.31832/smj.674963\n",
            "66\n",
            "97 \n",
            "the risk of developing preeclampsia 7 times compared to those who do not \n",
            "(Relative Risk (RR): 7.19) (48, 51,55). \n",
            "Prolonged birth interval (≥10 years): Too long a period between \n",
            "two pregnancies (10 years or more) increased the risk of preeclampsia (52, \n",
            "53,54). \n",
            "Multiple pregnancy: Preeclampsia is more common in multiple \n",
            "pregnancies (especially triplets and quadruplets) ( 48, 51, 55). RR in twin \n",
            "pregnancies: 2.93 ( 48). Triplet pregnancies have created a higher risk of \n",
            "preeclampsia development compared to twin pregnancy (51). \n",
            "Maternal age  <18 and > 40: Maternal age over 40 increased the \n",
            "risk of preeclampsia. (RR: 1.96 in multipara, RR: 1.68 in primipara). Older \n",
            "women tended to have more risk factors such as diabetes mellitus, obesity, \n",
            "and chronic hypertension. This has been explained by the increase in \n",
            "preeclampsia frequency among older women (48, 51, 55). \n",
            "Diabetes Mellitus: RR in diabetes that exists before pregnancy: \n",
            "3.56. Various factors such as underlying renal or vascular diseases, high \n",
            "plasma insulin level / insulin resistance, and abnormal lipid metabolism \n",
            "were thought to affect the risk of preeclampsia. (48,55). \n",
            "Chronic kidney disease:  The relative risk has changed in pre -\n",
            "pregnancy kidney disease, depending on the degree of reduction in \n",
            "glomerular filtration rate and the presence or absence of hy pertension. \n",
            "Those with advanced chronic kidney disease (grade 47, 48, 49 ) were \n",
            "diagnosed with preeclampsia after the second half of pregnancy at a rate of \n",
            "40-60%. (48, 55). \n",
            "High diastolic blood pressure:  Increased the risk of blood \n",
            "pressure ≥130/80 mmHg at the first prenatal visit (RR: 1.38). Women with \n",
            "the highest risk of superimposed preeclampsia were found to have diastolic \n",
            "blood pressure ≥110 mmHg (RR: 5.2) and ≥100 mmHg (RR: 3.2) before \n",
            "the 20th gestational week (48). \n",
            "Other: Pre -existing hypertension ( RR: 1.38) (52, 55), \n",
            "antiphospholipid syndrome (RR: 9.72) (59, 66) and BMI ≥35 (66) were \n",
            "among the other risk factors. It has been controversial that the risk of \n",
            "preeclampsia is higher in adolescents. It has been found that women who \n",
            "smoke are less likely t o have preeclampsia than non -smokers. (48). The \n",
            "risk is increased in those who become pregnant with donor egg, embryo \n",
            "donation or donor insemination (52). It has been difficult to assess the \n",
            "racial differences in the incidence and severity of preeclampsia due to \n",
            "confounding socioeconomic and cultural factors (51).\n",
            "137  \n",
            "32. Sheikhan F, Jahdi F, Khoei EM, et al. Episiotomy pain relief: Use of \n",
            "lavender oil essence in primiparous Iranian women. Complement \n",
            "Ther Clin Pract 2012;18:66–70.  \n",
            "33. Marzouk T, Barakat R, Ragab A, et al. Lavender -thymol as a new \n",
            "topical aromatherapy preparati on for episiotomy: A randomised \n",
            "clinical trial. J Obstet Gynaecol 2015;35:472–475.  \n",
            "34. Koca Kutlu A, Cecen D, Gurgen SG, et al. A comparison study of \n",
            "growth factor expression following treatment with transcutaneous \n",
            "electrical nerve stimulation, saline solutio n, povidone -iodine, and \n",
            "lavender oil in wounds healing. Evid Based Complement Alternat \n",
            "Med 2013;2013:361832.  \n",
            "35. Ben Djemaa FG, Bellassoued K, Zouari S, et al. Antioxidant and wound \n",
            "healing activity of Lavandula aspic L. ointment. J Tissue Viability \n",
            "2016;25:193–200.  \n",
            "36. Mori HM, Kawanami H, Kawahata H, Aoki M. Wound healing \n",
            "potential of lavender oil by acceleration of granu -lation and wound \n",
            "contraction through induction of TGFBeta in a rat model. BMC \n",
            "Complement Altern Med 2016;16:144.  \n",
            "37. Matura M, Sköld M, Börje A,  et al. Selected oxidized fragrance \n",
            "terpenes are common contact allergens. Contact dermatitis, 2005. \n",
            "52(6): p. 320-328.  \n",
            "38. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal \n",
            "gynecomastia linked to lavender and tea tree oils. New England \n",
            "Journal of Medicine, 2007. 356(5): p. 479-485.\n",
            "38\n",
            "54\n",
            "IV\n",
            "II\n",
            "58 \n",
            "DISCUSSION \n",
            "Palmaris longus (PL) is one of the forearm muscles that lie \n",
            "between the flexor carpi ulnaris and the flexor carpi radialis muscles. The \n",
            "absence of the PL has been shown to vary based on body side, gender, and \n",
            "ethnicity in prior studies (7, 11, 15). \n",
            "Roohi et al. studied in 450 healthy subjects (equally distributed \n",
            "among Malaysia’s 3 major ethnic groups) for the presence or absence of \n",
            "palmaris longus. Palmaris longus was found to be absent unilaterally in \n",
            "6.4% of study subjects, and bilaterally in 2.9% of st udy participants. \n",
            "Malays have a high prevalence of palmaris longus absence at 11.3% \n",
            "followed closely by Indians at 10.7% whilst Chinese  had a low absence \n",
            "rate of 6.0% (10).  Godwin and Adedayo examined in 600 subjects \n",
            "comprising 335 males and 265 females aged 8-60years were used to assess \n",
            "the prevalence of agenesis of the PL in Yoruba tribe. As a result, The \n",
            "overall prevalence of absence both unilaterally and bilaterally in the two \n",
            "sexes was 6.7%. In males, unilateral absence was 5.4%. The distribution \n",
            "on th e right and left were 2.4% and 3.0% respectively. The bilateral \n",
            "absence was 1.5%. In  females, unilateral absence was 6.0%. The \n",
            "distribution on the right and left were 2.6% and 3.4% respectively. \n",
            "Bilaterally, it was 0.4%. In one subject unilaterally, PL was  observed to \n",
            "have differentiated from flexor carpi radialis (13). \n",
            "Sater MS et al. examined 1,043 subjects, 3–85 years old, from the \n",
            "Kingdom of Bahrain for the presence or absence of the palmaris longus \n",
            "muscle using the conventional test for the presence of  this muscle. The \n",
            "palmaris longus muscle was absent in 36.8% of subjects. Bilateral absence \n",
            "(19%) was more common than unilateral absence (17.9%) with \n",
            "preponderance in female subjects. The muscle was absent more often on \n",
            "the left side than the right (P=0.0 03). In the right upper limbs the muscle \n",
            "was absent in female subjects more than male subjects (P=0.031) (16). \n",
            "Lahiji et al. study on Iranian people and repoted that, the prevalence of the \n",
            "PLA was estimated to be 22.8%; 10.2% agenesis on the right side, 5. 9% \n",
            "on the left side, and 6.7% bilaterally PLA. The relationship between PLA \n",
            "and gender did not appear to be significant. Among people with PLA 43% \n",
            "and among people withour PLA 17% were left handed (17). \n",
            "Most standard textbooks of hand surgery quote the pre valence of \n",
            "the absence of PL at around 15% among Caucasians. The prevalence of its \n",
            "agenesis has been variously reported  to be from 1.5% in black people to \n",
            "64% in Turkish people (17). \n",
            "According to a META analysis performed by 2013, their results \n",
            "demonstrated that the prevalence of PLA is the lowest among East Asians \n",
            "and Africans, and particularly among the East and South East African \n",
            "population (18).\n",
            "126 \n",
            "REFERENCES \n",
            "1. Demirkaya OB. Gebelikte Sigara İçiminin Plasenta ve Yenidoğan \n",
            "Üzerine Etkileri.[Uzmanlık Tezi]. TC Sağlık Bakanlığı Şişli Etfal \n",
            "Eğitim Ve Araştırma Hastanesi III Kadın Hastalıkları ve Doğum \n",
            "Kliniği, İstanbul, Türkiye. 2004; \n",
            "2. Dogu S, Berkiten Ergin A. Gebe kadınların sigara kullanımını etkileyen \n",
            "faktörler ve gebelikteki zararlarına ilişkin bilgiler. Maltepe Üniv \n",
            "Hemşirelik Bilim ve Sanat Derg. 2008;1(1):12-7.  \n",
            "3. Karlikaya C, Oztuna F, Solak ZA, Ozkan M, Orsel O. Tütün kontrolü . \n",
            "Toraks dergisi. 2006;7(1):51-64.  \n",
            "4. Enstitüsü HÜNE. Türkiye Nüfus ve Sağlık Araştırması (2018). 2018; \n",
            "5. Pauly JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement \n",
            "and neurobehavioural development. Acta Paediatrica . \n",
            "2008;97(10):1331-1337.  \n",
            "6. Lange S, Probst C, Rehm J, Popova S. National, regional, and global \n",
            "prevalence of smoking during pregnancy in the general population: \n",
            "a systematic review and meta-analysis. The Lancet Global Health. \n",
            "2018;6(7):e769-e776.  \n",
            "7. Durualp E, Bektas G, Ergin D, Ka raca E, Topcu E. Annelerin sigara \n",
            "kullanımı ile yenidoğanın doğum kilosu, boyu ve baș çevresi \n",
            "arasındaki ilișkinin incelenmesi. Journal Of Ankara University \n",
            "Faculty of Medicine. 2011;64(3) \n",
            "8. Martin RJ, Fanaroff AA, Walsh MC. Fanaroff and Martin's neonatal-\n",
            "perinatal medicine e -book: diseases of the fetus and infant . \n",
            "Elsevier Health Sciences; 2014. \n",
            "9. King A, Loke Y. Unexplained fetal growth retardation: what is the \n",
            "cause? Archives of Disease in Childhood Fetal and Neonatal \n",
            "edition. 1994;70(3):F225.  \n",
            "10. Ott WJ. Intrauterine growth retardation and preterm delivery. American \n",
            "journal of obstetrics and gynecology. 1993;168(6):1710-1717.  \n",
            "11. Andres RL, Day M-C. Perinatal complications associated with maternal \n",
            "tobacco use. Elsevier; 2000:231-241. \n",
            "12. DiFranza JR, Lew RA. Effect of maternal cigarette smoking on \n",
            "pregnancy complications and sudden infant death syndrome. The \n",
            "European Journal of General Practice. 1995;1(3):117-117.  \n",
            "13. England LJ, Kendrick JS, Wilson HG, Merritt RK, Gargiullo PM, \n",
            "Zahniser SC. Effects of smoking reduction during pregnancy on \n",
            "the birth weight of term infants. American journal of epidemiology. \n",
            "2001;154(8):694-701.  \n",
            "14. Eser B. hastanemizde doğan sga bebek sıklığını etkileyen \n",
            "sosyodemografik risk faktörleri . Master thesis. Bakı rköy dr. sadi \n",
            "konuk eğitim ve araştırma hastanesi; 2007.\n",
            "121 \n",
            " \n",
            "Figure 1:  Statistical analysis of histopathological concentrations \n",
            "(Hematoxylin-Eosin) of smokers and non -smokers. Values are expressed \n",
            "as mean ± SD. \n",
            " \n",
            "Figure 2. Placenta histopathology in non-smoker group. H&E. tv: tertiary \n",
            "villouses :Fetal veins, : Cytotrophoblast cells, : Syncytial knots, i: \n",
            "Intervillous gap (a,b) rv: root villuses, m: mesenchymal connective tissue, \n",
            ": fibroblasts (c,d)\n",
            "99 \n",
            "and fetal growth assessments to evaluate fetal growth retardation every 4 \n",
            "weeks (52). \n",
            "In mild preeclampsia cases, the  mother's life is not in danger and \n",
            "the continuation of the pregnancy did not put the mother at serious risk and \n",
            "gained time for the baby ( 47). Maternal and fetal risks are well balanced \n",
            "when the decision is made for the delivery of a woman with preeclampsia. \n",
            "Generally, in this case, delivery at the 37th gestational week is \n",
            "recommended, but if the maternal and fetal condition is stable, a woman \n",
            "with mild preeclampsia has been followed closely. Laboratory evaluation \n",
            "twice a week and daily fetal monitoring are generally recommended for the \n",
            "management of all women with preeclampsia by hospitalization. If the \n",
            "woman was deemed suitable for outpatient follow-up, weekly prenatal visit \n",
            "and twice weekly fetal testing were provided (66). Initiating the emergency \n",
            "treatment of persistent severe blood pressure to reduce adverse vascular \n",
            "events has been the main factor in the treatment of severe preeclampsia \n",
            "(67). Another priority in the treatment of severe preeclampsia has been the \n",
            "prevention of eclampsia (51, 66).  \n",
            "All complications of preeclampsia have been observed especially \n",
            "in the first 48 hours after delivery ( 49). Women with hypertension \n",
            "throughout pregnancy were followed up after delivery until they were sure \n",
            "that the hypertension problem was completely resolved. Women who had \n",
            "preeclampsia during pregnancy have been told that their risk of \n",
            "cardiovascular and kidney disease increases in their later life. After \n",
            "discharge, the woman should be followed up regularly and her blood \n",
            "pressure was monitored closely. Those di agnosed with severe \n",
            "preeclampsia were more likely to recur in their next pregnancy (52). \n",
            "3.5. INITIATIVES TO PREVENT PREECLAMPSIA \n",
            "The fact that preeclampsia threatens maternal and infant health \n",
            "significantly, and the etiology and pathogenesis are not fully known, draw \n",
            "attention to the importance of preventive approaches. Determining the \n",
            "risky groups before the development of preeclampsia and taking the \n",
            "necessary precautions contributed to the improvement of maternal and \n",
            "infant health. In this context, the development of preeclampsia, which has \n",
            "widespread and serious consequences, can be stopped, slowed down, \n",
            "reduced in effect or treated early with some simple measures. To prevent \n",
            "the development of preeclampsia; Life style changes such as physical \n",
            "activity, dietary regulations, pharmacological methods, and avoidance of \n",
            "stress have been suggested (51, 68, 69). \n",
            "Acetylsalicylic Acid: If there is an early onset of preeclampsia in \n",
            "the medical history, preterm birth before the 34th week or a history of \n",
            "preeclampsia in more than one pregnancy, it is recommended to start low \n",
            "dose acetylsalicylic acid (60-80 mg) at the end of the first trimester. In the\n",
            "119 \n",
            "sample t-test which is the homogeneity of the variances was tested via F -\n",
            "test. The test results put forth that the variances are homogeneous for the \n",
            "birth variable of the smoker and non -smoker groups (p>0,05). It was put \n",
            "forth b ased on the independent sample t -test results that there were \n",
            "differences between the birth weights of the babies of smoker and non -\n",
            "smoker mothers (p<0,05).  \n",
            "The correlation coefficient for all data was calculated as r= 0,598 \n",
            "upon examining the relationship between birth weight and placenta weight. \n",
            "There is a moderate and positive relationship (p <0.05) (Table 3) between \n",
            "newborn birth weight and placenta weight according to the correlation \n",
            "table. The correlation coefficient was calculated as r: 0.566 when t he \n",
            "relationship between birth weight and placenta weight was evaluated only \n",
            "for smoker mothers, this ratio was r: 0.0508 for non -smoker mothers. A \n",
            "moderate and positive relationship was determined between the birth \n",
            "weights and placenta weights of smoker and non-smoker mothers (p<0.05).  \n",
            "Table 1: Descriptive statistics of variables in the research. \n",
            " \n",
            "Table 2:  Independent Sample T  Test according to Birth weight and \n",
            "Placenta weight.\n",
            "131  \n",
            "developed to be used in the treatment of different wound types and studies \n",
            "in this area continue rapidly. Materials such as films, foams, hydrocolloids, \n",
            "hydrogels and alginates have long been used as dressings. Recently, it has \n",
            "been observed that hydrogels  give more satisfactory results by adding \n",
            "antibacterial and antifungal properties or using them as drug carriers . 16,17 \n",
            "The most commonly used topical agents in wound treatment are antibiotics \n",
            "and growth factors to stimulate healing. However, some natural products \n",
            "of herbal origin that were used since the ancient times have been gaining \n",
            "importance because of their antioxidant, anti -inflammatory, antibacterial \n",
            "properties and cost effectiveness.   \n",
            "  \n",
            "LAVENDER AND ITS ESSENTIAL OIL  \n",
            "Figure 1: Bunch of lavender, Kocaeli, Turkey  \n",
            "  \n",
            "Lavandula species (Lavender) belongs to the Lamiaceae family.18  \n",
            "Lavender name derives from the Latin word “lavare” which means “to \n",
            "wash” depicting antique usage in washing clothes and baths. Essential oils \n",
            "are used in phytotherapy sin ce ancient times. Lavender essential oil is \n",
            "constituted from monoterpenoids (linalool, camphor etc.) and \n",
            "sesquiterpenoid alcohols, esters, oxides, and ketones mixtures.19 There are \n",
            "different administration routes of essential oils. They can be administered  \n",
            "orally, transdermal and via inhalational route. These administration routes \n",
            "are studied in various therapeutic indications from insomnia to wound \n",
            "healing. European Medicine Agency, herbal medicine products on the \n",
            "medicinal uses committee documented lavender oil therapeutic use in sleep \n",
            "disorders, temporary insomnia, mental stress and mood disorders based on \n",
            "long-standing traditional use. 20 One of the traditional use of lavender in \n",
            "wound healing is not included in the registered indications currently in\n",
            "34 \n",
            "15. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor \n",
            "angiogenesis by p53 -induced degradation of hypoxia -inducible \n",
            "factor 1alpha. Genes Dev. 2000;14(1):34-44. \n",
            "16. Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B. \n",
            "Hypoxia inducible factor pathway inhibitors as anticancer \n",
            "therapeutics. Future medicinal chemistry. 2013;5(5):553-572. \n",
            "17. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention \n",
            "for cancer therapy. Acta pharmaceutica Sinica B. 2015;5(5):378-\n",
            "389. \n",
            "18. Quemener AM, Bachelot L, Forestier A, Donnou -Fournet E, Gilot D, \n",
            "Galibert M-D. The powerful world of antisense oligonucleotides: \n",
            "From bench to bedside. Wiley Interdiscip Rev RNA.  \n",
            "2020;11(5):e1594. \n",
            "19. Patnaik A, Chiorean EG, Tolcher A, et al. EZN-2968, a novel hypoxia-\n",
            "inducible factor-1α (HIF-1α) messenger ribonucleic acid (mRNA) \n",
            "antagonist: Results of a phase I, pharmacokinetic (PK), dose -\n",
            "escalation study of daily administration in patients (pts) with \n",
            "advanced malignancies.  Journal of Clinical Oncology  \n",
            "2009;27(15_suppl):2564-2564. \n",
            "20. Jeong W, Rapisarda A, Park SR, et al. Pilot trial of EZN -2968, an \n",
            "antisense oligonucleotide inhibitor of hypoxia -inducible factor-1 \n",
            "alpha (HIF-1α), in patients with refractory solid tumors. Cancer \n",
            "Chemother Pharmacol. 2014;73(2):343-348. \n",
            "21. Wu J, Contratto M, Shanbhogue KP, et al. Evaluation of a locked \n",
            "nucleic acid form of antisense oligo targeting HIF-1α in advanced \n",
            "hepatocellular carcinoma. World journal of c linical oncology. \n",
            "2019;10(3):149-160. \n",
            "22. Bertozzi D, Marinello J, Manzo SG, Fornari F, Gramantieri L, \n",
            "Capranico G. The natural inhibitor of DNA topoisomerase I, \n",
            "camptothecin, modulates HIF -1α activity by changing miR \n",
            "expression patterns in human cancer ce lls. Molecular cancer \n",
            "therapeutics. 2014;13(1):239-248. \n",
            "23. Duffy AG, Melillo G, Turkbey B, et al. A pilot trial of oral topotecan \n",
            "(TPT) in patients with refractory advanced solid neoplasms \n",
            "expressing HIF -1α. Journal of Clinical Oncology  \n",
            "2010;28(15_suppl):e13518-e13518. \n",
            "24. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of \n",
            "topotecan, cisplatin and bevacizumab for recurrent or persistent \n",
            "cervical cancer. Gynecologic oncology. 2013;130(1):64-68. \n",
            "25. Krasner CN, Birrer MJ, Berlin ST, et al. Phase II clinical trial evaluating \n",
            "CRLX101 in recurrent ovarian, tubal, and peritoneal cancer. \n",
            "Journal of Clinical Oncology. 2014;32(15_suppl):5581-5581. \n",
            "26. Pentheroudakis G, Kotoula V, Koliou GA, et al. AMALTHEA: \n",
            "Prospective, Single -Arm Study of the Hell enic Cooperative\n",
            "12\n",
            "118 \n",
            "3. RESULTS:  \n",
            "In this study, pregnant women who started smoking at least 5 years \n",
            "ago and who did not quit smoking throughout their pregnancy periods \n",
            "made up the study group, while those who have not smoked throughout \n",
            "their lives made up the control group. According to the statistic al results, \n",
            "the age average of the pregnant women who participated in the study was \n",
            "26,97 for smokers and 27,05 for non -smokers. The age average of all \n",
            "participants was 27,01. While 48,6% of the pregnant women who \n",
            "participated in the study were aged 25 and below, 42,9% were between the \n",
            "ages of 26 -35 and 8,6% were aged 36 and above. Normality assumption \n",
            "was taken into consideration with regard to the use of parametric or non -\n",
            "parametric tests for data analysis. The accordance of the data with normal \n",
            "distribution can be evaluated via Q -Q Plot 16. In addition, the normal \n",
            "distribution of the data used is subject to the values of skewness and \n",
            "kurtosis to be between ±3 17.. In the light of all these data, independent T \n",
            "test (student t test) was applied in SPSS 20.0 software for the analysis of \n",
            "data related with placenta weight  and newborn weight taking into \n",
            "consideration that the number of our subjects was above 30 and that all \n",
            "groups were suited for normal distribution, while Anova test was applied \n",
            "for Hematoxylene Eosin pathological findings. According to this test; the \n",
            "birth weights for non-smokers (3456,71 gr) was observed to be greater than \n",
            "the birth weights of smokers (3093,71 gr). Newborn weight decreased by \n",
            "10.5% in smokers. Similarly, the placenta weights of non-smokers (648,14 \n",
            "gr) was observed to be greater than the pl acenta weights of the smokers \n",
            "(577 gr). Placenta weight decreased by about 10.9% in smokers (Table 1).  \n",
            "When the Independent T test table is examined, it should be p>0.05 \n",
            "for homogeneous variance. Since the sig values for birth weight and \n",
            "placenta weight were above >0.05, sig 2 values corresponding to the first \n",
            "row are examined. Variance is homogeneous in all groups and a \n",
            "statistically significant difference was observed between smoker and non-\n",
            "smoker groups with regard to both the placenta weight and newborn weight \n",
            "(P<0.05) (table 2).  \n",
            "Independent sample t-test was performed for determining whether \n",
            "there is a statistically significant difference between the average birth \n",
            "weights of the babies of mothers who smoke and those who do not. \n",
            "According to the test r esults, the birth weight variable variances are \n",
            "homogeneous for the smoker and non -smoker groups (p>0,05). It was \n",
            "determined based on the independent sample t -test results that there were \n",
            "difference between the birth weights of the babies of smoker and non -\n",
            "smoker mothers (p<0,05). Independent sample t -test was carried out for \n",
            "determining whether there are any statistically significant differences \n",
            "between the placenta weight averages for the babies of smoker and non -\n",
            "smoker mothers. One of the fundamental ass umptions of the independent\n",
            "26 \n",
            "and induces the transcription of target genes such as vascular endothelial \n",
            "growth facto r (VEGF), glucose transporter -1, epithelial -mesenchymal \n",
            "transition genes and matrix metalloproteinases 12-14.  \n",
            "The expression of HIF -1α is also regulated by several other \n",
            "mechanisms besides hypoxia in cancer cells. Reactive oxygen species \n",
            "generated by various stimuli stabilize HIF-1α and increases HIF-1 activity. \n",
            "PI3K/Akt/mTOR and RAS/MAPK pathways which are oncogenic \n",
            "pathways overactivated in several cancers are posi tive regulators of HIF-\n",
            "1α expression. Mutations in tumor suppressor genes phosphatase and \n",
            "tensin homologue (PTEN), VHL and p53 are also associated with \n",
            "increased HIF-1α expression in cancer cells 14,15. \n",
            "HIF-1α INHIBITORS IN CLINICAL TRIALS \n",
            "In accordance with the importance of HIF-1α in tumor progression \n",
            "and chemoresistance, last 20 years have witnessed the testing of several \n",
            "direct or indirect inhibitors of HIF-1α in clinical trials for cancer. Some of \n",
            "these agents such as camptothecins, rapamycin analogs, and \n",
            "anthracyclines, which exhibit antitumor action by mechanisms that does \n",
            "not directly involve HIF-1α inhibition, have already been approved and \n",
            "widely us ed for the treatment of several cancers. However, efforts to \n",
            "develop new agents that directly inhibit HIF-1α is still growing 16,17. In this \n",
            "chapter, we present the major HIF-1α inhibitors that were translated to \n",
            "clinical studies so far with registered clinical trials in ClinicalTrials.gov \n",
            "(https://www.clinicaltrials.gov/). Relevant clin ical trial identifiers are \n",
            "given for each of the studies in the text. According to their mechanism of \n",
            "action, anti-HIF-1α agents were classified into five in this chapter, namely \n",
            "HIF-1α antisense oligonucleotides, drugs that inhibit HIF -1α translation, \n",
            "drugs that destabilize HIF-1α, inhibitors of HIF-1/DNA binding, and drugs \n",
            "that inhibitor HIF-1α at multiple levels.  \n",
            "1. HIF-1α Antisense Oligonucleotides \n",
            "Efforts to translate antisense oligonucleotides  into the treatment of \n",
            "cancer patients is growing for the last decade 18. EZN-2968 is a HIF-1α \n",
            "antisense oligonucleotide developed by Enzon Pharmaceuticals. A phase I \n",
            "trial has been conducted between 2007 and 2011 for determi nation of the \n",
            "safety, pharmacokinetic profile, and anticancer activity of EZN -2968 in \n",
            "patients with advanced solid tumors and lymphoma (NCT00466583). First \n",
            "results suggested well-tolerability in cancer patients who have undergone \n",
            "previous treatments 19. In 2010, a second phase I study for EZN-2968 was \n",
            "commenced under the sponsorship of National Health Institute to \n",
            "determine the safety profile and efficacy in advanced solid tumors with \n",
            "liver metastasis ( NCT01120288). A reduction in HIF-1α expression was \n",
            "observed in a very limited number of patients enrolled into the study and \n",
            "the trial was ended early 20. Later in 2016, a phase Ib study was started to\n",
            "14 \n",
            "Ischemia due to ovarian torsion has been the subject of research \n",
            "in recent years. Ischemia o ccurs when some of them cannot get enough \n",
            "blood and oxygen through a reduction or interruption in blood flow.  The \n",
            "gold standard to treat ovary torsion is surgery, and this is also the only way \n",
            "to confirm the torsion by using the techniques like laparoscopy  and \n",
            "laparotomy (1). In cases of ovarian torsion, blood flow is provided to the \n",
            "region again with surgical intervention and thus detorsion is performed.  \n",
            "EXPERIMENTAL DESIGN \n",
            "Animals  \n",
            "Many researchers, who have set up experimental research in \n",
            "recent years, have focused on supporting the ovarian damage caused by \n",
            "torsion not only with surgical intervention but also with systemic \n",
            "therapeutic agent applications. When Wistar albino or Spraque Dawley rats \n",
            "were evaluated in terms of feeding, housing, cost, response to surgical \n",
            "intervention; They are among the most suitable laboratory animals to these \n",
            "kind of experiments. While creating the experimental groups, young adult \n",
            "/ adult, healthy, non -pregnant, 200 – 290 g weighing female rats  were \n",
            "generally used.  \n",
            "Procedure of experimental ischemia/reperfusion model \n",
            "Rats are starved by cutting their access to food, 24 hours before \n",
            "the operation. Surgical procedures in the rats were performed under \n",
            "anesthesia. Different anesthesia applying protocols and amounts of \n",
            "anesthetic agents used in ovarian ischemia / reperfusion studies conducted \n",
            "in recent years are listed in Table 1. The skin around the incision was \n",
            "shaved and disinfected. After the rats were placed in the dorsal recumbent \n",
            "position, under sterile conditions; A laparotomy was performed by making \n",
            "a 2-cm (7, 8, 9, 10, 11, 12, 13, 14, 15 ) or 2,5-cm (16, 17, 18, 19, 20, 21 ) \n",
            "longitudinal incision in the midline area of the  lower abdomen and the \n",
            "uterine horns and adnexa were located. The abdomen opened and then \n",
            "gently separated the intestines. After incision in the right / left or bilateral \n",
            "fossa paralumbalis area, adnexa were torsioned 3600 clockwise (13, 18, 22) \n",
            "or 7200 counter clockwise ( 23) and fixed on abdominal wall to stay for  \n",
            "during the predetermined time as ischemic. Then incision was sutured; re-\n",
            "laparotomy was performed and adnexa were detorsioned; reperfusion was \n",
            "allowed for additional predetermined time  after o peration sites were \n",
            "sutured, at the end of experimental time detorsion ovaries were harvested, \n",
            "and blood samples were collected. Rats were sacrificed after collecting \n",
            "samples. Ischemia / reperfusion times that vary according to studies are \n",
            "shown in the Tab le 2 . The therapeutic agents to be applied in the \n",
            "experiments are usually administered intraperitoneally or by gavage half \n",
            "an hour before the detorsion application (with exceptions). Comparison of\n",
            "81 \n",
            "doi:10.1007/978-1-60327-029-8_13 \n",
            "22.  Long T, Liu G, Wan g Y, Chen Y, Zhang Y, Qin D. TNF -α, Erectile \n",
            "Dysfunction, and NADPH Oxidase -Mediated ROS Generation in \n",
            "Corpus Cavernosum in High -Fat Diet/Streptozotocin -Induced \n",
            "Diabetic Rats. Journal of Sexual Medicine . 2012;9(7):1801-1814. \n",
            "doi:10.1111/j.1743-6109.2012.02739.x \n",
            "23.  Bivalacqua TJ, Armstrong JS, Biggerstaff J, et al. Gene transfer of \n",
            "extracellular SOD to the penis reduces O2 -· and improves erectile \n",
            "function in aged rats. American Journal of Physiology - Heart \n",
            "and Circulatory Physiology . 2003;284(4 53 -4). \n",
            "doi:10.1152/ajpheart.00770.2002 \n",
            "24.  Segal R, Hannan JL, Liu X, et al. Chronic Oral Administration of \n",
            "the Arginase Inhibitor 2(S) -amino-6-boronohexanoic Acid (ABH) \n",
            "Improves Erectile Function in Aged Rats. Journal of Andrology . \n",
            "2012;33(6):1169-1175. doi:10.2164/jandrol.111.015834 \n",
            "25.  Toque HA, Tostes RC, Yao L, et al. Arginase II deletion increases \n",
            "corpora cavernosa relaxation in diabetic mice. Journal of Sexual \n",
            "Medicine. 2011;8(3):722 -733. doi:10.1111/j.1743 -\n",
            "6109.2010.02098.x \n",
            "26.  Carneiro FS, Nunes KP, Giach ini FRC, et al. Activation of the ET -\n",
            "1/ETA pathway contributes to erectile dysfunction associated \n",
            "with mineralocorticoid hypertension. Journal of Sexual Medicine . \n",
            "2008;5(12):2793-2807. doi:10.1111/j.1743-6109.2008.01009.x \n",
            "27.  Sommer F, Klotz T, Steinritz D, et al. MAP kinase 1/2 (Erk 1/2) and \n",
            "serine/threonine specific protein kinase Akt/PKB expression and \n",
            "activity in the human corpus cavernosum. International Journal \n",
            "of Impotence Research . 2002;14(4):217 -225. \n",
            "doi:10.1038/sj.ijir.3900856 \n",
            "28.  Nunes KP, Toqu e HA, Caldwell RB, Caldwell RW, Webb RC. \n",
            "Extracellular Signal -Regulated Kinase (ERK) Inhibition \n",
            "Decreases Arginase Activity and Improves Corpora Cavernosal \n",
            "Relaxation in Streptozotocin (STZ) -Induced Diabetic Mice. \n",
            "Journal of Sexual Medicine . 2011;8(12):333 5-3344. \n",
            "doi:10.1111/j.1743-6109.2011.02499.x \n",
            "29.  Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine \n",
            "dimethylaminohydrolase (DDAH): Expression, regulation, and \n",
            "function in the cardiovascular and renal systems. American \n",
            "Journal of Physiology - Heart and  Circulatory Physiology . \n",
            "2007;293(6):3227-3245. doi:10.1152/ajpheart.00998.2007\n",
            "71 \n",
            "treatment of erectile dysfunction 20. BH4 dysfunction or scarcity, which \n",
            "is the most import ant factor in eNOS dependent NO release, causes \n",
            "eNOS dysfunction. This leads to the release of NO -mediated oxygen \n",
            "radicals. Here, with the reaction of NO and free oxygen radicals, NO \n",
            "levels decrease and peroxynitrite is formed 20. In vitro and in vivo studies \n",
            "have demonstrated that there is a significant relationship between \n",
            "Erectile dysfunction and ROS (Reactive Oxygen Species) production, \n",
            "especially in diabetic animal models 21,22. O , which is a ROS 2\n",
            "-  it turns \n",
            "into peroxynitrite by reacting with NO. Peroxynitrite; it reacts wi th \n",
            "lipids, proteins, nucleic acids and creates structural damage. They found \n",
            "that basal O 2\n",
            "- levels increased in the tissue segments of the aging rat \n",
            "model compared to the control 23. With the increased O 2\n",
            "- concentration, \n",
            "NO is destroyed and NO -dependent vasodilation is impaire d. Superoxide \n",
            "dismutase enzyme (SOD) preserves NO activity by preventing the \n",
            "formation of peroxynitrite of ROS. It is known that arginase activity \n",
            "increases in ED due to age and diabetes 24. Decreased arginase activity in \n",
            "the penis has been shown to improve endothelial function and restore \n",
            "erectile responses 24,25. Also, pretreatment of diabetic Corpus cavernosum \n",
            "with arginase (ABH) inhibitors has been shown to partially inhibit the \n",
            "disruption of NO -mediated corporal relaxation and the enhancement of \n",
            "arginase activity. \n",
            "An extracellular signal -regulated kinase (ERK), known to \n",
            "mediate cellular responses by growth factors, has  recently been shown to \n",
            "play a role in vascular reactivity and reduce eNOS activity 26,27. ERK \n",
            "inhibition has b een shown to improve cavernosal relaxation in diabetic \n",
            "mice 28. \n",
            "Another way to increase intracellular NO concentrations is by \n",
            "inhibiting the endogenous NOS competitive inhibitor asymmetric \n",
            "dimethylarginine (ADMA), the L-arginine analog 29. \n",
            "Inhibition of increasing systemic levels of TNF -α, known to be \n",
            "positively correlated with ED, significantly improves sexual function 30. \n",
            "3.1.2. Increasing the cGMP Level \n",
            "3.1.2.1. PDE-5 (Phosphodiesterase-5) Inhibitors \n",
            "The PDE5 enzyme has 2 subunits, catalytic, and regulatory. The \n",
            "catalytic dom ain is the target site for PDE5 inhibitors and contains the \n",
            "binding unit for cGMP. When the cGMP fills this area, the catalytic \n",
            "mechanism located right next to this connection area comes to the closest \n",
            "position and catalyzes the 5'-GMP by breaking the cyclic phosphate bond \n",
            "of the cGMP. When sildenafil or other PDE5 inhibitors also bind to the \n",
            "catalytic site, cGMP entry is blocked. These inhibitors, which show\n",
            "41 \n",
            "glycoproteins. They mediate platelet adhesion and aggregation as receptors \n",
            "for adenosine diphosphate (ADP), arachidonic acid, and other agonists.  \n",
            "Platelet connecting is further intervened by von Willebrand factor (vWF) \n",
            "bridging between collagen and the platelet receptor gl ycoprotein (GP) Ib. \n",
            "Thrombin stimulation produced as a result of coagulation reactions is \n",
            "required for complete platelet activation. The platelet surface receptor, \n",
            "GPIIb / IIIa, rapidly changes platelet formation by stimulating it with \n",
            "fibrinogen. This cha nge in conformation allows platelet aggregates to be \n",
            "consolidated by connecting to fibrinogen ahead of fibrin conformation. \n",
            "Platelet activation also launches prostaglandins and thromboxanes ' \n",
            "synthesis, which regulates platelet activation and assists vasoco nstriction. \n",
            "Activation of platelets motivates several changes resulting in hemostasis \n",
            "increase via two main mechanisms: \n",
            "1. Production of the hemostatic plug at the site of injury (primary \n",
            "hemostasis). \n",
            "2. Providing of phospholipids as a procoagulant surface  for \n",
            "plasmatic coagulation. \n",
            "Early platelet plug formation can be divided into separate stages \n",
            "that are tightly related: platelet adhesion, structural changes, content \n",
            "release, and platelet aggregation. Immediately following endothelial \n",
            "damage, platelets bi nd to adhesive proteins such as collagen via specific \n",
            "glycoprotein surface receptors (platelet adhesion). In this process, VWF \n",
            "acts as a mediator that first adheres to collagen fibers and then realizes fiber \n",
            "strength. The platelet then binds to VWF via membrane glycoproteins (GP) \n",
            "Ib and IX. After adhesion, the platelets change from disc shape to spherical \n",
            "shape and elongate pseudopods. It accelerates plug formation by releasing \n",
            "ADP, serotonin, Thromboxane A2 (TxA2), beta-TG, PF4, and VWF stored \n",
            "in thrombocyte granules also initiates platelet aggregation. At the end of \n",
            "the aggregation process, tightly packed degranulated platelets form the \n",
            "hemostatic plug. Fibrinogen, which binds to specific glycoprotein \n",
            "receptors (GP IIb / IIIa), is required for platelet aggregation. Thromboxane \n",
            "A2 (TXA2) secreted from granules enables vasoconstriction starting with \n",
            "endothelin to continue. ADP stimulates platelet aggregation, while calcium \n",
            "activates the coagulation system starting with factor XII. \n",
            "Two congenital blee ding disorders, von Willebrand disease and \n",
            "Bernard-Soulier syndrome , are characterized by defective adhesion that \n",
            "causes a lifelong tendency to bleed due to VWF and GP Ib / IX deficiency. \n",
            "Besides, in Glanzmann thrombasthenia, a disease characterized by the  \n",
            "absence of GP IIb / IIIa receptors, bleeding time is significantly prolonged, \n",
            "platelet aggregation cannot occur, resulting in a lifelong bleeding tendency.  \n",
            "The transformation of inactive proenzymes activates coagulation \n",
            "factors into activated enzymes. En zyme, substrate, and cofactor are\n",
            "29 \n",
            "was not the main emphasis in the clinical trials of perifosine conducted so \n",
            "far. Despite the prom ising results in preclinical studies, its clinical \n",
            "effectiveness in cancer is not fully established yet.    \n",
            "2c. Digoxin \n",
            "Since preclinical studies suggested that digoxin blocks HIF-1α 30, its \n",
            "efficacy in blocking HIF -1α in breast cancer and Kaposi’s Sarcoma  has \n",
            "been tested in two different clinical trials. The former o ne aimed to \n",
            "investigate whether two weeks of digoxin intake starting from the first \n",
            "biopsy to the time of surgery decreases HIF-1α expression in newly \n",
            "diagnosed breast cancer (NCT01763931). However the trial stopped to \n",
            "recruit patients early since accrual goals could not be met  31. HIF-1α has \n",
            "been shown to induce lytic life cycle of Human Herpes Virus 8  32. \n",
            "Regarding the efficacy of digoxin in downregulation of HIF -1α, digoxin \n",
            "may have a potential in the treatment of HHV -8 related Kaposi Sarcoma. \n",
            "A multi -centre phase II study was conducted to test this hypothesis \n",
            "(NCT02212639). The study was expected to be completed in 2019. \n",
            "However, the results are not published yet. In addition to these two trials \n",
            "that put the emphasis on anti -HIF-1α action, there are more than 20 \n",
            "different clinical trials that test digoxin alone or in combination with \n",
            "chemotherapy in several different cancers as a hypoxia modulator agent or \n",
            "p-glycoprotein inhibitor (e.g., NCT04141995, NCT02106845). A Phase II \n",
            "study in prostate cancer patients exhibited promising results suggesting \n",
            "that digoxin can prolong prostate specific antigen doubling  time and may \n",
            "be effective in androgen -dependent prostate cancer  33 (NCT01162135). \n",
            "New clinical trials are recruiting patients or will start accrual to evaluate \n",
            "digoxin in solid tumors and pancreatic cancer (NCT03889795, \n",
            "NCT04141995). \n",
            "2d. 2-Methoxyestradiol \n",
            "2-methoxyestradiol (2ME2) is an estradiol metabolite which inhibits \n",
            "microtubule activity and acts as an antitumor agent. 2ME2 inhibits the \n",
            "translation of HIF-1α mRNA. Due to this action, 2ME2 was started to be \n",
            "evaluated as an agent to inhibit tumor blood  flow in two different phase I \n",
            "trials in 2001 and 2002 (NCT00030095, NCT00028821).  Since 2ME2 \n",
            "exhibit inhibitory action on cell proliferation, migration, and angiogenesis \n",
            "17, a nanocrystal colloidal dispersion formulation of 2ME2, Panzem was \n",
            "developed which has higher bioavailability. Panzem entered several phase \n",
            "II trials, starting from 2006 (NCT0039 4810, NCT00306618, \n",
            "NCT00481455, and  NCT00444314). However, the results were \n",
            "disappointing in terms of anti -tumor activity and tolerability  34,35. Later a \n",
            "new analogue of 2ME2, ENMD -1198 was developed. ENMD -1198 \n",
            "exhibited potent anti-angiogenic activity in cell models 36. However, to the\n",
            "VI\n",
            "98 \n",
            "3.3. MATERNAL AND FETAL EFFECTS OF \n",
            "PREECLAMPSIA \n",
            "Preeclampsia has been an important problem affecting maternal \n",
            "and infant health. ( 58). In cases where preeclampsia developed, \n",
            "convulsion, pulmonary  edema and ablatio placenta were seen. Women \n",
            "with preeclampsia were found to have a higher risk of hypertension (3.7 \n",
            "times), coronary artery disease (2.2 times) and stroke (1.8 times) in their \n",
            "later life (52). It has been observed that the changes in lipid metabolism of \n",
            "women with preeclampsia (such as increased total cholesterol and \n",
            "triglyceride levels) are greater than the changes in normotensive pregnant \n",
            "women (57, 59). One of the rare complications of preeclampsia is acute \n",
            "pancreatitis and can mimic pre eclampsia (6 0, 61 ). Ablatio placenta is \n",
            "rarely seen (less than 1%) in women with preeclampsia without severe \n",
            "symptoms, while it has been reported that 3% of women have severe \n",
            "symptoms (48). \n",
            " Fetal growth retardation and oligohydramnios were observed \n",
            "due to chronic fetal hypoperfusion in the fetus (48). Severe and early-onset \n",
            "preeclampsia resulted in a serious decrease in fetal birth weight compared \n",
            "to normotensive pregnancies (62). Fetal birth weight was found to be lower \n",
            "than expected for gestational age by 12% in severe preeclampsia and 23% \n",
            "in early -onset preeclampsia ( 52). Among the long -term effects of \n",
            "preeclampsia on children is an increased risk of stroke and hypertension \n",
            "(52). The frequency of neonatal diseases such as respiratory distress, \n",
            "intraventricular hemorrhage and necrotizing enterocolitis was similar to \n",
            "babies of preeclamptic pregnant women and babies of non -hypertensive \n",
            "women of the same age (48). \n",
            "3.4. TREATMENT METHODS IN PREECLAMPSIA \n",
            "According to the long held view, \"childbirth\" has been the only \n",
            "solution in preeclampsia treatment. In the management of preeclampsia, \n",
            "guided by evidence -based practices, early diagnosis of risk groups, \n",
            "prevention of multiple organ damage in the mother, and effective \n",
            "management of labor or ensuring the safe co ntinuation of pregnancy for \n",
            "mother and baby until fetal lung maturity is achieved (54, 58, 63). \n",
            "Women deemed to have a high risk of developing preeclampsia \n",
            "were directed to pre -pregnancy counseling in order to determine \n",
            "changeable risk factors before pregn ancy. Being at the highest level of \n",
            "health before pregnancy has decreased the risk of developing preeclampsia \n",
            "(51, 52 , 64, 65). It has been found that there is no ideal antenatal care \n",
            "program for women with a high risk of preeclampsia. However, when these \n",
            "women were diagnosed, antenatal management included more frequent \n",
            "follow-up, anomaly screening, regular blood pressure and urine controls,\n",
            "135  \n",
            "REFERENCES  \n",
            "1. Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, \n",
            "et al. Health economic burden that wounds impose on the National \n",
            "Health Service in the UK. BMJ Open 2015;5:e009283.  \n",
            "2. Werner S, Grose R. Regulation of wound healing by growth factors and \n",
            "cytokines. Physiol Rev 2003 Jul;83(3):835-70.  \n",
            "3. Broughton G, Janis JE, Attinger CE. The basic science of wound \n",
            "healing. Plast Reconstr Surg 2006;117:12S–34S.  \n",
            "4. Huntington JA. Molecular recognition mechanisms o f thrombin. J \n",
            "Thromb Haemost 2005 Aug;3(8):1861-72.  \n",
            "5. Midwood KS, Williams LV, Schwarzbauer JE. Tissue repair and the \n",
            "dynamics of the extracellular matrix. Int J Biochem Cell Biol. 2004 \n",
            "Jun;36(6):1031-7.  \n",
            "6. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss \n",
            "DS, et al. Neutrophil extracellular traps kill bacteria. Science 2004 \n",
            "Mar 5;303(5663):1532-5.  \n",
            "7. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the \n",
            "good, the bad and the ugly. Trends Cell Biol 2005;15:599–607.  \n",
            "8. Das A, Sinha M, Datta S, et al. Monocyte and Macrophage Plasticity in \n",
            "Tissue Repair and Regeneration. Am J Pathol 2015;185:2596– 2606.  \n",
            "9. Martinez FO, Helming L, Gordon S. Alternative activation of \n",
            "macrophages: an immunologic functional perspective. Annu Rev \n",
            "Immunol 2009;27:451–483.  \n",
            "10. Shiota N, Nishikori Y, Kakizoe E, et al. Pathophysiological role of skin \n",
            "mast cells in wound healing after scald injury: study with mast cell -\n",
            "deficient W/W(V) mice. Int Arch Allergy Immunol 2010;151:80–88.  \n",
            "11. Paquet-Fifield S, Schluter H, Li A, et al. A role for pericytes as \n",
            "microenvironmental regulators of human skin tissue regeneration. J \n",
            "Clin Invest 2009;119:2795–2806.  \n",
            "12. Sen CK, Roy S, Gordillo G. Wound healing. In Neligan PC Ed. Plastic \n",
            "Surgery Principles. Elsevier, Canada. 2018; 165-193.  \n",
            "13. Banerjee J, Chan YC, Sen CK. MicroRNAs in skin and wound healing. \n",
            "Physiol Genomics 2011;43:543–556.  \n",
            "14. Roy S, Elgharably H, Sinha M, et al. Mixed -species biofilm \n",
            "compromises wound healing by disrupting epidermal barrier function. \n",
            "J Pathol 2014;233:331–343.  \n",
            "15. Obagi Z, Damiani G, Grada A, Falanga V. Principles of Wound \n",
            "Dressings: A Review. Surg Technol Int. 2019 Nov 10;35:50-57.  \n",
            "16. Jayakumar R, Prabaharan M, Sudheesh Kumar PT, Nair SV, Tamura H. \n",
            "Biomaterials based on chitin and chitosan in wound dressing \n",
            "application. Biotechnol Adv. 2011 May-Jun;29(3):322-337.   \n",
            "17. Hamedi H, Moradi S, Hudson SM, Tonelli AE. Chitosan based \n",
            "hydrogels and their applications for drug delivery in wound dressings: \n",
            "A review. Carbohydr Polym. 2018 Nov 1;199:445-460. 18. Salehi B,\n",
            "74 \n",
            "3.3. Targets associated with vasoconstriction \n",
            "3.3.1. RhoA/Rho-Kinase Inhibitors \n",
            "Most of the time, smooth muscle cells in the erectile tissue are in \n",
            "a contraction and the blood flow into the cavernous sinu ses is minimal. \n",
            "Many studies have reported that RhoA/Rho -kinase-mediated \n",
            "vasoconstriction may be the primary mechanism responsible for penile \n",
            "smooth muscles to maintain this contracted state 46,47. RhoA/Rho-kinase \n",
            "actively increases intracellular calcium (Ca 2+) plays a role i n maintaining \n",
            "penile flaccid state as it increases the noradrenergic tone regardless of its \n",
            "concentration 48. Although there is sufficient conceptual information to \n",
            "support the importance of intracellular calcium in the regulation of \n",
            "vascular tone in the penile structure, Ca 2+ sensitization has been recently \n",
            "investigated. RhoA is a small protein that binds with the GTP and is \n",
            "involved in many cellular events such as smooth muscle contraction, cell \n",
            "roof, and morphology and secretion 49. RhoA is inactive when bound to \n",
            "GDP, but with heterotrimeric G protein a ctivation, it is activated by the \n",
            "conversion of GDP to GTP and migrates to the cell membrane. Rho A \n",
            "activation process is regulated by 3 groups of proteins: \n",
            "1) GDI (guanine nucleotide dissociation inhibitor) inhibits RhoA \n",
            "activation,  \n",
            "2) GEF (guanine nucle otide exchange factor) regulates the \n",
            "conversion of GDP to GTP, \n",
            "3) GAP (GTPase associated protein) inhibits RhoA activity with \n",
            "intrinsic GTPase activity. \n",
            "Theoretically, factors that stop RhoA activation by affecting the \n",
            "activity of these proteins will preve nt smooth muscle contraction and \n",
            "allow relaxation. Activated RhoA targets Rho -kinase in penile smooth \n",
            "muscle. It catalyzes the phosphorylation of MLC phosphatase enzyme, \n",
            "which inhibits Rho -kinase enzyme activity. When MLC (myocyte light \n",
            "chain) phosphotase activity is weak, the MLC predominantly remains in \n",
            "phosphorylated form and smooth muscle contraction  is continued. The \n",
            "interruption of this process, in which RhoA activates Rho -kinase, leads \n",
            "to the reversal of the flat contraction and the formation of rela xation 49. \n",
            "Y-27632, a pyridine derivative, is a selective Rho-kinase inhibitor 50.  \n",
            "3.3.2. Angiotensin receptors \n",
            "Increased Ang-II activity may contribute to the development of \n",
            "ED by increasing harmful effects such as vasoconstriction, proliferation, \n",
            "fibrosis and oxidative stress 51, in this context, angiotens in converting \n",
            "enzyme inhibitors (ACEIs) and angiotensin r eceptor blockers (ARB; \n",
            "Ang-II /AT1) have been shown to have beneficial effe cts on erection in\n",
            "20 \n",
            "Table 3:  Parameters used for biochemical evaluation in ovarian ischemia / reperfusion studies in recent years. (MDA ( \n",
            "Malondialdehyde), SOD (Superoxide dismutase), GSH/tGSH (Total glutathione),  MPO (Myeloperoxidase), LPO ( \n",
            "Lactoperoxidase), CAT (Catalase), GPx (Glutathione peroxidase), NO (Nitric oxide), TAS (Total antioxidant status), TOS (Total \n",
            "oxidant status), OSI (Oxidative stability index)).\n",
            "104 \n",
            "complication rates were found to be higher in diabetic pregnancies \n",
            "compared to normal pregnancies ( 48). It was found that the risk of \n",
            "preeclampsia increased from 5 -7% to 15 -20% depending on glycemic \n",
            "control, GDM severity and pre-pregnancy body mass index (BMI) (12). In \n",
            "women with GDM, the risk of developing type 2 DM in the later years of \n",
            "life increased by 20 -80% ( 24). Glucose can pass freely from mother to \n",
            "fetus, but maternal i nsulin could not. Maternal glucose in high \n",
            "concentrations passing through the placenta stimulated insulin secretion in \n",
            "the fetus, increasing growth factors and causing macrosomia (5). \n",
            "4.3. BIRTH COMPLICATIONS AS A RESULT OF \n",
            "MATERNAL OBESITY AND INCREASE IN CAES ARY \n",
            "DELIVERY \n",
            "Maternal obesity has been a recognized risk factor for serious \n",
            "obstetric complications, which are becoming more common worldwide \n",
            "and include hypertensive disorders, preeclampsia, gestational diabetes, \n",
            "thrombophlebitis, urinary tract infections, chorioamnionitis, preterm labor, \n",
            "fetal macrosomia, shoulder dystosis, and intrauterine fetal death (7). \n",
            "Obese women have a high risk of intrapartum complications, and \n",
            "it is thought that various factors may have an effect on this situation. \n",
            "Ineffective uterine activity comes first, and macrosomia, which is also a \n",
            "fetal event, reduces the progression of labor; Difficult assessment of fetal \n",
            "position during delivery in obese women made it difficult to define the \n",
            "breech presentation precisely (10). Spontaneous pregnancy loss and neural \n",
            "tube defect in the first pregnancy period; gestational diabetes in the second \n",
            "timester; In the third trimester, the risks of gestational hypertension, \n",
            "difficulty in fetal follow -up, anesthesia complications, macrosomia, \n",
            "stillbirth and cesarean section increased. In the postpartum period, obese \n",
            "women have been reported to have bleeding, infection, wound opening, \n",
            "and venous thromboembolism risks ( 25). At the beginning of the \n",
            "difficulties experienced by obese women during childbirth,  changing \n",
            "position is the first thing that comes to mind. There have been difficulties \n",
            "in inserting an epidural catheter due to excessive adipose tissue. \n",
            "Transporting the woman to the operating table can also become difficult, \n",
            "and excessive neck, abdominal, and chest weight have made intubation and \n",
            "mechanical ventilation more difficult and complex. Due to the increasing \n",
            "surgical deliveries, prenatal anesthesia consultation was recommended \n",
            "(19). \n",
            "Although there is a relationship between BMI over 30 and \n",
            "prolonged delivery, techniques that stimulate contraction such as nipple \n",
            "stimulation and walking were used. It was important to follow up the \n",
            "follow-ups for uterine contractions and fetal heart rate just after the \n",
            "induction use. The ability to palpate and record uterine interactions using\n",
            "105 \n",
            "excessive abdominal adipose tissue is limited by using a tachodianometer. \n",
            "Calculation of fetal heart rate with dops is also limited in obesity. \n",
            "Therefore, the most a ccurate monitoring was performed with fetal scalp \n",
            "electrode and internal pressure catheter (19). The first and second stages of \n",
            "macrosomic deliveries are prolonged, the risk of intervention vaginal birth, \n",
            "third degree perineal trauma, emergency cesarean se ction, postpartum \n",
            "hemorrhage, and apgar score below 4 is increased. It was found that he \n",
            "stayed in the hospital for a longer period of time (38). \n",
            "Studies have shown that shoulder dystocia is more common in \n",
            "women who are obese and gain excessive weight during pregnancy. It was \n",
            "understood that women with a BMI above 40 had a five-fold higher risk of \n",
            "uterine rupture at delivery, prolonged labor and increased risk of fetal \n",
            "distress during this period, therefore healthcare professionals might have \n",
            "reservations about trying vaginal delivery after cesarean in obese patients \n",
            "(19). \n",
            "Although there is a relationship between prolonged birth and being \n",
            "on it, techniques that stimulate contraction such as nipple stimulation and \n",
            "walking were used. It was important to follow up the follow-ups for uterine \n",
            "contractions and fetal heart rate just after the induction use. The ability to \n",
            "palpate and record uterine interactions using excessive abdominal adipose \n",
            "tissue is limited by using a tachodonometer. In obesity, calculation of fetal \n",
            "heart rate with dops is also limited. Therefore, the most accurate \n",
            "monitoring was performed with fetal scalp electrode and internal pressure \n",
            "catheter (19). In a study, the rate of those who had medical problems or \n",
            "birth complications during pregnancy was 44.7%, and 30.7% of them were \n",
            "found to be obese / obese before becoming pregnant (2 1). It has been \n",
            "deemed extremely important that obese women are not encouraged in \n",
            "terms of access to antenatal service and continuity in service. Counseling \n",
            "and quality  follow-ups led by healthcare professionals from the early \n",
            "stages of pregnancy have had important effects on intrapartum and \n",
            "neonatal outcomes at birth (10). \n",
            "In a retrospective study of 100 obese women with single pregnancy \n",
            "in the United Kingdom, obesity was examined in three categories. These; \n",
            "Group A: BMI 30-34 (n = 39), group B: BMI 35 -39.9 (n = 43); Group C: \n",
            "BMI> 40 (n = 21), spontaneous onset vaginal delivery rate was 60% in \n",
            "non-obese women, 62% in group A, 49% in group B and 24% in group C. \n",
            "The use of induction is increased in moderately and severely obese women, \n",
            "with rates being 37% and 38%, respectively, and 28% in non -obese \n",
            "women. When the groups are compared according to delivery types, \n",
            "spontaneous vaginal delivery is 60% in non-obese patients, 44% (7139 and \n",
            "9143) in group A and B and 62% in group C (7). Simic et al. (2010) stated \n",
            "that the frequency of posttherm births increased in obese mothers, while a\n",
            "46 \n",
            "function analyzer that can be used to appraise platelet -related primary \n",
            "hemostasis. If the collagen -epinephrine (CEPI) closure time is extended \n",
            "but the collagen-adenosine diphosphate (CADP) closure time is standard, \n",
            "this is presumably due to aspirin. If both CEPI and CADP closure times \n",
            "are prolonged or CEPI closure time is typical and CADP closure time is \n",
            "abnormal, this means platelet dysfunction or von Willebrand disease. PFA-\n",
            "100 is senseless to von Willebrand disease type 2N, clopidogrel, \n",
            "ticlopidine, and storage pool disease. PFA -100 results are biased by \n",
            "thrombocytopenia and low hematocrit. VerifyNow is a quick, turbidimetric \n",
            "whole blood assay able to evaluate platelet aggregation. This assay is based \n",
            "on the competence of activated platelets to bind with fibrinogen. If \n",
            "GpIIb/IIIa (glycoprotein IIB/IIIa) competitors are present in patients ' \n",
            "plasma, platelet aggregation lessens. Results a re declared in reactive \n",
            "aspirin units (ARU) or clopidogrel, plavix reactive units (PRU).  \n",
            "Plateletworks evaluates platelet function in whole blood. It compares the \n",
            "platelet count before and after exposure with a selected platelet agonist. In \n",
            "agonist exposur e, functional platelets should be collected, and \n",
            "nonfunctional platelets should not aggregate. A hematology analyzer such \n",
            "as ICHOR II then measures the number of non -clumped platelets in the \n",
            "EDTA tube and agonist tube. With the difference, platelet functio ns are \n",
            "evaluated. The Plateletworks is useful in monitoring the platelet response \n",
            "in patients using antiplatelet, such as aspirin and clopidogrel. Platelet \n",
            "aggregometry is a widely used laboratory test to screen patients with \n",
            "genetic or obtained platelet f unction defects. Platelet aggregometry \n",
            "evaluates light transmission rising through platelet -rich plasma when \n",
            "platelets are aggregated due to an agonist 's addition. Diversified agonists \n",
            "used for this test are; AA, collagen, ristocetin, ADP, and epinephrine. The \n",
            "first aggregation wave is through the activation of the GpIIb/IIIa receptor. \n",
            "The secondary wave is due to platelet granule release. Secondary wave \n",
            "deficit means a storage pool disorder by a reduced number of granules or \n",
            "faulty release of granule substances. The use of these agonists in advanced \n",
            "concentrations results in the two waves joining into one aggregation wave. \n",
            "The prothrombin time (PT) is performed by adding a raw \n",
            "preparation of TF (usually an extract of the brain) to citrate- anticoagulated \n",
            "plasma, recalcification of the plasma, and assessing the clotting time. \n",
            "Thromboplastin and CaCl2 are generally added in a single step. Clotting \n",
            "time is established at 37°C using a diversity of methods, including photo -\n",
            "optical and electromechanical detection.  The prothrombin time may be \n",
            "elongated because of the extrinsic coagulation pathway 's deficiency, i.e., \n",
            "factors II, V, VII, X, and/or fibrinogen. PT is a practical adjustment of the \n",
            "extrinsic pathway and common pathway, and the reference range is 8.8s - \n",
            "11.6 s. A circulating anticoagulant directed against these factors may also \n",
            "provoke the PT's prolongation. However, frequently PT is reported as the \n",
            "international normalized ratio (INR). The thromboplastin used may alter\n",
            "68 \n",
            "2. NEUROPHYSIOLOGICAL AND MOLECULAR BASES \n",
            "OF PENIS ERECTION \n",
            "Three processes that work synergistically and simultaneously are \n",
            "needed for normal erectile function:  \n",
            "1) Increased arterial blood flow through the neurogenic way, \n",
            "2) Cavernosal smooth muscle relaxation, \n",
            "3) The restriction of venous return flow.  \n",
            "ED occurs due to failure in any of these ways 6. Penis consists of \n",
            "3 anatomical compartments 7. The corp us spongiosum supports and \n",
            "protects the urethra along the ventral face of the penis. On the other \n",
            "hand, located on the dorsal and consists of two adjacent parts the corpus \n",
            "cavernosum, fills with blood at the time of erection and provides a penile \n",
            "erection. The cavernosal compartment consists of a widespread network \n",
            "of vascular sinuses fed by helical arteries. When the penis is flaccid, the \n",
            "smooth muscle cells supporting the vascular sinuses are tonically \n",
            "contracted, allowing for low blood circulation. In co ntrast, \n",
            "neuromodulator release, which occurs in response to sexual stimulation \n",
            "and consists of cavernosal nerve terminals and endothelium, causes \n",
            "relaxation of cavernosal smooth muscles and consequently penile \n",
            "erection. \n",
            "Central regulation of erectile funct ion includes both spinal and \n",
            "supraspinal systems. Central supraspinal systems mainly; it is localized \n",
            "in the limbic system (hippocampus, medial preoptic region, nucleus \n",
            "accumulate), hypothalamus and its nucleus (paraventricular and \n",
            "ventromedial nucleus) as well as the nucleus paragigantocellularis of the \n",
            "reticular formation 8. While gamma -aminobutyric acid (GABA), opioid \n",
            "peptides and serotonin reduce sexual responses, oxytocin, nitric oxide, \n",
            "excitatory amino acids, adrenocorticotropin (ACTH), and alpha -\n",
            "melanocyte-stimulating hormone (α-MSH) facilitates sexual responses 9.  \n",
            "The penis is innervated  by autonomic and somatic nerves. Other \n",
            "factors such as cholinergic nerves, nonadrenergic/noncholinergic nerves \n",
            "(nitric oxide), Vaso -Intestinal Polypeptide (VIP) and Calcitonin Gene \n",
            "Related Peptide (CGRP) cause smooth muscle relaxation 6,10.  \n",
            "Apart from this, shear stress and muscarinic receptors located in \n",
            "the trabecular endothelium also stimulate nitric oxide production. Nitric \n",
            "oxide diffuses i nto smooth muscle cells and interacts with guanylate \n",
            "cyclase to increase intracellular cGMP levels. Increasing cGMP levels \n",
            "also causes cellular processes that result in smooth muscle relaxation and \n",
            "act through cGMP -dependent protein kinase and ion channels . This \n",
            "mechanism causes the reduction of intracellular Ca +2 levels and the\n",
            "102 \n",
            "most days of the week, if not every day. ( 46). It has been postulated that \n",
            "moderate activity also stimulates placental angiogenesis and maternal \n",
            "endothelial dysfunction. A few small clinical studies have evaluated the \n",
            "effects of moderate exercise in preventing preeclampsia, but data have \n",
            "been limited to make realistic interpretations of the results (47). In addition, \n",
            "long bed rest during pregnancy increased the risk of thromboembolism \n",
            "(65). The American Collage of Obstetricians and Gynecologists (ACOG) \n",
            "has not recommended strict bed rest without severe symptoms for women \n",
            "with gestational hypertension or preeclampsia (70). \n",
            "Coping with Stress:  According to Çelik and Özdemir ( 70), \n",
            "prolonged stress situations caused a constant high blood pressure. The \n",
            "stress that will be experienced during pregnancy also caused blood \n",
            "pressure changes. Hy percortisolemia caused by maternal stress affected \n",
            "pregnancy by affecting many factors affecting the placenta and fetus. (71). \n",
            "Studies have shown that maternal stress leads to the delivery of low birth \n",
            "weight babies and an increased risk of preeclampsia ( 72, 73). The \n",
            "stimulating effect of stress on the sympathetic nervous system causes \n",
            "changes in peripheral vascular resistance during pregnancy as well as in \n",
            "the immune system, and it has been found to be associated with the \n",
            "development of preeclampsia ( 52). Shamsi et al. ( 64) reported that \n",
            "maternal stress experienced during pregnancy increased the risk of \n",
            "preeclampsia. Vollebregt et al. ( 72) also reported that the risk of \n",
            "developing preeclampsia and hypertensive disorders increased \n",
            "approximately twice in working women compared to non-working women \n",
            "in relation to the tensions experienced in working life. \n",
            "Coping with stress, which is among the lifestyle changes that are \n",
            "effective in hypertension, has been done with an effective stress \n",
            "management. In stress manag ement, relaxation techniques such as deep \n",
            "breathing, muscle relaxation exercises and mental relaxation were included \n",
            "in addition to finding a solution to the cause of the stress. It was found that \n",
            "blood pressure decreased with the application of deep breathing exercises. \n",
            "Respiratory exercises have relaxing effects on the cardiovascular system, \n",
            "and mental relaxation has positively affected blood pressure by affecting \n",
            "the sympathetic nervous system. (53). It is thought that a similar effect can \n",
            "be seen in pre eclampsia that may develop during pregnancy. Because \n",
            "rhythmic and regular breathing calms the nervous system, people can cope \n",
            "with stress more easily by deep breathing in stressful situations. As the \n",
            "abdominal muscles are used during deep breathing, the tension in the neck \n",
            "and shoulders is also reduced (54). \n",
            "4. GESTATIONAL DIABETES \n",
            "Gestational diabetes mellitus (GDM) has been described as \n",
            "carbohydrate intolerance of various degrees, which started during\n",
            "CHAPTER II \n",
            " \n",
            "BIOCHEMICAL AND HISTOPATHOLOGICAL \n",
            "PARAMETERS USED IN EXPERIMENTAL OVARIAN \n",
            "ISCHEMIA / REPERFUSION MODELS IN RECENT YEARS \n",
            " \n",
            "Gülce Naz Yazıcı \n",
            "(Asst. Prof, PhD), Erzincan Binali Yıldırım University,  \n",
            "e-mail: gulcenazyazici.ank@gmail.com \n",
            "                 0000-0002-6989-997X \n",
            " \n",
            "INTRODUCTION \n",
            "Ovarian torsion, which  affects females of all ages, is a \n",
            "gynecological emergency (1 ). Adnexal torsion is uncommon, occurring \n",
            "most often during reproductive years. Torsion of the normal adnexa, which \n",
            "is rare, is more common among children than adults. Typically, one ovary \n",
            "is involved, but sometimes tuba uterina is also involved. Adnexal torsion \n",
            "causes sudden, severe pelvic pain, and sometimes nausea and vomiting. \n",
            "Adnexal torsion is defined as at least one fu ll turn around the midline of \n",
            "the adnexa,  ovary or, more rarely, the tuba uterina  alone, including the \n",
            "infundibulopelvic and tubo -ovarian ligaments (2 ). The infundibulopelvic \n",
            "ligaments suspend the movable ovary, allowing the ovary to position \n",
            "laterally or posteriorly to the uterus (1). Adnexal torsion usually indicates \n",
            "an ovarian abnormality. Risk factors for adnexal torsion include; \n",
            "pregnancy, induction of ovulation for IVF, ovarian enlargement, \n",
            "particularly by benign tumors. Benign tumors are more likely to cause \n",
            "torsion than malignant ones. Because of adnexal tissue is not fixed, a big \n",
            "leading point, such as tumorous growth, can induce twisting ( 1). Adnexal \n",
            "torsions, which are the fifth most common cause in patients operated on \n",
            "due to gynecological emerge ncies, constitute 2.7% of gynecological \n",
            "emergencies. Although it is seen in all age groups, its incidence is higher \n",
            "in women of reproductive age . Adnexal torsion (AT) in children is rare, \n",
            "approximately 15% of cases occur during infancy and childhood  (3). In a \n",
            "large series by Guthrie et al (4),  the estimated incidence of AT among \n",
            "females 1 to 20 years old was estimated to be 4.9 of 100,000 ( 3, \n",
            "5).Although the exact etiology is unknown, an ovarian mass is detected in \n",
            "the majority of cases. Torsion is very ra re in normal sized ovaries. Its \n",
            "incidence is increasing in pathologies that enlarge the size of the ovary, \n",
            "such as polycystic ovary and benign cystic teratoma (6).\n",
            "133  \n",
            "Altaei evaluated the effect of lavender essential oil on oral mucosa \n",
            "ulcers in a 4 -step study conducted on both animal and human subjects. \n",
            "Aphthous ulcers treated with lavender essential oil healed faster in both \n",
            "rabbits and humans. In the safety / toxicity s tudy conducted on mice, the \n",
            "LD value for the mice was found to be 6.5 gm / kg and no evidence of \n",
            "dermal irritation was found. In the antibacterial activity study, which is \n",
            "another pillar of the study, effectiveness has been demonstrated against all \n",
            "bacterial strains studied.30  \n",
            "The effect of lavender essential oil on wound healing has been \n",
            "evaluated in many studies in the gynecological patient group. In these \n",
            "studies, not only the anti -inflammatory effect of lavender oil but also its \n",
            "analgesic effect were e mphasized. Although Vakilian et al. reported that \n",
            "lavender oil applied to episiotomy incisions reduced erythema but had no \n",
            "significant effect on pain, 31 the following studies by Sheikhan et al. and \n",
            "Marzouk et al. have shown that it is associated with less pain, as well as \n",
            "reducing erythema, edema, ecchymosis and discharge.32,33  \n",
            "Koca Kutlu et al. showed that lavender essential oil significantly \n",
            "increased EGF and FGF expression compared to the control group in their \n",
            "study comparing the efficacy of several wound treatment methods. EGF is \n",
            "an agent thought to play a role in wound contraction and epithelization. It \n",
            "has become a popularized treatment modality recently, although its topical \n",
            "use is quite expensive. The results of this study suggested that lavender oil \n",
            "could be a cost -effective alternative to EGF application. The authors also \n",
            "reported that no edema, discharge and local infection findings were \n",
            "observed in the lavender oil applied group.34  \n",
            "Ben Djemaa et al. concluded that in animals treated with lavend er \n",
            "oil, wounds were closed faster, covered with a thinner epidermal layer \n",
            "similar to normal skin, and showed a better epidermal and dermal structure \n",
            "on histopathological examination in their experimental study conducted on \n",
            "rats.35  \n",
            "In their 2016 study, Mor i et al. showed that topical application of \n",
            "lavender essential oil reduced the wound area earlier, increased the amount \n",
            "of TGF- β and increased the amount of both type I and type III collagen on \n",
            "the excisional wound model in the rat. TGF -β plays a role in wound \n",
            "contraction by inducing fibroblast proliferation and its transformation into \n",
            "myofibroblasts. Type III collagen is the first type of collagen produced \n",
            "during the proliferation phase of wound healing and then matures and is \n",
            "replaced by Type I collagen. In the same study, the fact that the amount of \n",
            "type III collagen was close to the control group, but the amount of type I \n",
            "collagen was higher in the group in which lavender oil was applied on the \n",
            "7th day measurement, was interpreted as collagen maturation  occurred \n",
            "faster.36\n",
            "96 \n",
            "Table 1. PREEKLAMPSY RISK FACTORS (59, 63, 64, 65) \n",
            "First pregnancy     Family history of \n",
            "preeclampsia \n",
            "Preeclampsia in previous pregnancy   Prolonged birth \n",
            "interval (>10 years) \n",
            "Antiphospholipid syndrome or  Type I Diabetes Mellituda Type \n",
            "Diabetes Mellitus \n",
            "hereditary thrombophilia  \n",
            "Chronic hypertension    High body mass index \n",
            "(29) \n",
            "Multiple pregnancy    Systemic lupus erythematosus \n",
            "Maternal age  <18 and >40    Chronic kidney \n",
            "disease \n",
            "Undisclosed fetal growth retardation   Vascular or \n",
            "connective tissue diseas \n",
            "Fetal growth retardation in previous pregnancy    ablatio placenta or fetal \n",
            "loss Factors associated with the partner \n",
            "Mole hydatidiform    Predisposition to genes \n",
            "In vitro fertilization    Black race \n",
            " \n",
            "3.2. INTERACTIONS OF PLEXUS RISKS \n",
            "First pregnancy: It has been suggested that women with a first \n",
            "pregnancy may increase the risk of preeclampsia (48, 52, 55). Although it \n",
            "is not known exactly why the first pregnancy is a predisposing factor, one \n",
            "theory suggests that these women may have limited exposure to antigens \n",
            "from the father, and it has been claimed that this situation may play a role \n",
            "in the pathogenesis of the disease (57). \n",
            "Preeclampsia history in the family:  It has been determined that \n",
            "the medical history of first -degree close relatives i ncreases the risk of \n",
            "preeclampsia from 2 times to 4 times in those with preeclampsia (51, 55). \n",
            "Although this situation suggests a hereditary mechanism, it has been \n",
            "suggested that the father of the baby may contribute to the increased risk \n",
            "or the father's c ontribution to fetal genes may have a role in insufficient \n",
            "placentation and subsequent preeclampsia (48). \n",
            "Preeclampsia in previous pregnancy: It has been reported that \n",
            "women with a history of preeclampsia in their previous pregnancy increase\n",
            "CHAPTER V \n",
            " \n",
            "PREVALENCE OF PALMARIS LONGUS AGENESIS (PLA) \n",
            "AMONG TURKISH MEDICAL STUDENTS \n",
            " \n",
            "Mukadder Sunar1 \n",
            "1(Asst. Prof, PhD) Erzincan Binali Yıldırım University,  \n",
            "e-mail: mukaddersunar@gmail.com \n",
            "                 0000-0002-6744-3848 \n",
            " \n",
            "INTRODUCTION \n",
            "The palmaris longus  (Figure 1) (1)  is a small, fusiform -shaped \n",
            "muscle located on the anterior forearm of the human upper extremity. This \n",
            "muscle belongs to the su perficial forearm flexor group with a most \n",
            "common proximal attachment at the medial epicondyle of the humerus via \n",
            "the common forearm flexor tendon and a most common distal attachment \n",
            "into the connective tissue fibers of the palmar aponeurosis and the flexor \n",
            "retinaculum, a ligamentous structure forming the roof of the carpal tunnel \n",
            "and containing the me dian nerve and digital flexor tendons ( 2, 3 ). The \n",
            "palmaris longus can be morphologically quite variable but most commonly \n",
            "has a tendinous proximal attachment, a mid-length, spindle-shaped muscle \n",
            "belly, and a long and thin tendinous distal portion. The majo rity of fibers \n",
            "in the palmaris longus tendon pass superficially to the flexor retinaculum, \n",
            "the tendon broadens into a flattened collection of fibers, and the fibers \n",
            "interweave with the palmar aponeurosis (2, 3). The functional contribution \n",
            "of the palmaris longus appears to be minimal, but it has clinical \n",
            "significance due to its frequent intraoperative harvest for many surgical \n",
            "procedures, often involving tendon repair in the upper extremity. The thin \n",
            "distal tendinous portion, superficial location, and lack of functional \n",
            "significance make the muscle easily accessible and ideal for intraoperative \n",
            "harvest for tendon reconstruction and other surgical procedures. The \n",
            "palmaris longus muscle is commonly present but may be absent in a small \n",
            "percentage of the populat ion, ranging from 2.5% to 26% of individuals, \n",
            "depending on the studied population (2, 3, 4). The palmaris longus tendon \n",
            "is located near the anatomical center of the anterior wrist, medial to the \n",
            "tendon of flexor carpi radialis, and lateral to the tendon of  flexor carpi \n",
            "ulnaris (3). The presence of the palmaris longus muscle can be determined \n",
            "through noninvasive and standard physical examination of the volar wrist \n",
            "(5, 6).\n",
            "31 \n",
            "increase the use of anthracyclines further especially in chemotherapy \n",
            "protocols with anti-VEGF agents.  \n",
            "4b. Echinomycin \n",
            "Echinomycin is a peptide antibiotic with DNA intercalating activity. \n",
            "With the aim of identifying new drugs which inhibit binding of HIF -1 to \n",
            "DNA, a high -throughput screening was conducted with National Cancer  \n",
            "Institute’s comprehensive small-molecule library. The screening identified \n",
            "echinomycin as a potent inhibitor of HIF-1/DNA binding 45.  Echinomycin \n",
            "has been tested in several Phase II trials for the indications of soft tissue \n",
            "sarcoma, endometrial carcinoma, non -small cell lung carcinoma and \n",
            "colorectal cancer 46-49. However, the clinical efficacy in these trials were \n",
            "disappointing. Therefore, echinomycin could not progress into the clinic \n",
            "with the expected speed as an anti-HIF-1 agent.  However, nano-liposomal \n",
            "formulations of echinomycin are being developed, which may offer an \n",
            "improved efficacy and pharmacokinetic profile for the agent 50,51. \n",
            "5. Drugs That Inhibit HIF-1α at Multiple Levels  \n",
            "5a. Bortezomib \n",
            "The u biquitin proteasome pathway plays a central role in protein \n",
            "homeostasis, leading to degradation of misfolded or damaged proteins. \n",
            "Proteasome is an attractive target in cancer therapy since inhibition of \n",
            "proteosome induces cell death via endoplasmic reticulum stress, inhibition \n",
            "of survival pathways and stimulation of apoptosis 52. Bortezomib is one of \n",
            "the most prominent proteasome inhibitors evaluated for clinical use in \n",
            "cancer. It was approved by FDA in the treatment of multiple myeloma in \n",
            "2003 53, and there are more than 900 different clinical trials registered that \n",
            "evaluate bortezomib, most ly in combination to conventional \n",
            "chemotherapeutics in a wide spectrum of cancers. Since proteasomal \n",
            "degradation of HIF-1α has substantial importance in regulation of HIF -1, \n",
            "bortezomib also has an anti -HIF-1 action. In the presence of bortezomib, \n",
            "ubiquitinated HIF-1α could not be degraded and accumulates in an inactive \n",
            "form. In this form HIF -1α cannot bind to p300 and induce gene \n",
            "expression54. Additionally, it was shown that b ortezomib can inhibit \n",
            "PI3K/AKT/mTOR pathway. Moreover, bortezomib was reported to \n",
            "suppress nuclear translocation of HIF-1α via inhibition of MAPK \n",
            "pathway55. With these mechanisms bortezomib exhibits anti-HIF-1 action \n",
            "at multiple levels which makes it an attractive agent in cancer therapy.  \n",
            "5b. PX-478 \n",
            "PX-478 is a melphalan derivative that downregulates the HIF-1α \n",
            "mRNA and inhibits its translation. It was also reported to inhibit de -\n",
            "ubiquitination of HIF-1α to a smaller extent 56. Due to inhibition of HIF -\n",
            "1α, PX-478 may have a potential in cancer treatment. The safety and\n",
            "103 \n",
            "pregnancy or was first diagnosed during pregnancy ( 23). This definition \n",
            "did not exclude the possibility of diabetes, which was also present before \n",
            "conception but was unknown until the first examination during pregnancy. \n",
            "Although the American Obstetrics and Gynecological Association \n",
            "still uses the same terminology, in recent years, the International Diabetic \n",
            "Working Groups Association (IADPSG), the American Diabetes \n",
            "Association (ADA), and the World Health Organization (WHO) and others \n",
            "were first diagnosed during pregnancy but probably previously thought to \n",
            "be diabetic. stated that transient diabetes due to pregnancy -related insulin \n",
            "resistance should be differentiated (17). These organizations have used the \n",
            "term gestational diabetes emerging in the second half of pregnancy: overt \n",
            "diabetes or diabetes mellitus during pregnancy, and the terms for diabetes, \n",
            "which is recognized by standard non -gestational criteria in early \n",
            "pregnancy, when insulin resistance is less (45). \n",
            "4.1. PATHOPHYSIOLOGY OF GESTATIONAL DIABETES \n",
            "A subclinical metabolic dysfunction is thought to occur in women \n",
            "who have normal glucose tolerance during normal pregnancy but develop \n",
            "GDM in the late period of pregnancy. The 60% decrease in insulin \n",
            "sensitivity that occurs during normal pregnancy has led to clinical \n",
            "hyperglycemia / GDM in these women. Materna l obesity, which is \n",
            "frequently associated with gestational diabetes, has been associated with \n",
            "increased inflammation in maternal white adipose tissue and placenta. \n",
            "Adipokines and cytokines such as leptin, adiponectin, TNF-a, interlokin-6 \n",
            "were secreted from white adipose tissue (5). The placenta showed a similar \n",
            "cytokine gene expression profile except for adinopectin. It is thought that \n",
            "inflammation caused by secreted cytokines may be related with increased \n",
            "insulin resistance in pregnant women with gestational diabetes (20). If the \n",
            "maternal pancreatic B -cells cannot provide enough insulin to meet the \n",
            "increasing insulin need, GDM has developed (2). \n",
            "4.2. FETAL AND MATERNAL EFFECTS OF \n",
            "GESTATIONAL DIABETES \n",
            "It is known that both the mother and the fetus are at man y risks \n",
            "associated with diabetes during pregnancy. There was an increase in risks \n",
            "(12). While negative consequences in the mother may be short -term \n",
            "(hypertension, preeclampsia), they have also been long-termed, such as the \n",
            "increased risk of Type 2 DM in later life ( 21). Although postpartum \n",
            "glucose levels return to normal in women with GDM, it has been known \n",
            "that the risk of developing Type 2 diabetes mellitus (DM) increases 7 times \n",
            "in later life (3, 62). \n",
            "GDM history has also been found to be a determinant for increased \n",
            "cardiovascular risk and early atherosclerosis (1 4). Hypertensive\n",
            "70 \n",
            "hyperpolarization by opening Ca +2 dependent K + channels, and also \n",
            "causes smooth muscle relaxation by providing membrane \n",
            "hyperpolarization by inhibition of calcium sensitizing pathways such as \n",
            "the Rho-kinase pathway (Figure 1) 11,17. \n",
            " \n",
            "Figure 1: cGMP-mediated smooth muscle cell relaxation in \n",
            "corpora cavernosa17 \n",
            "NO from nNOS in nitrergic nerves is responsible for most of \n",
            "smooth muscle relaxation and initiation of relaxation, while NO from \n",
            "eNOS has been shown to contribute to the maintenance of erection 18. It \n",
            "has been determined that the activity of nNOS in the penis is regulated \n",
            "by androgens. In castrated rats, it has been shown that the erectile \n",
            "response caused by cavernosal nerve stimulation and the nNOS activity \n",
            "in the penis decrease, and these effects ca n be corrected by androgen \n",
            "administration 18. Molecular oxygen, along with L -arginine, is a \n",
            "necessary substance for NO synthesis. It has been shown that NO \n",
            "synthesis in the corpus cavernosum is directly regu lated by oxygen \n",
            "concentration19. \n",
            "3. POTENTIAL GOALS FOR THE TREATMENT OF \n",
            "ERECTILE DYSFUNCTION \n",
            "3.1. Targets Associated with NO-cGMP Pathway  \n",
            "3.1.1. Increasing NO Production  \n",
            "In the treatment of erectile dysfunction, Tetra hydrobiopterin \n",
            "(BH4), a NOS cofactor, is used as a potential therapeutic agent in the\n",
            "3 \n",
            "the unique material properties. Electrospinning is an inexpensive and \n",
            "simple method to create nanoscale polymer fibers with diameter range \n",
            "from 3 –5000 nm  (11, 14).  Nanofibers are suitable to  mimic biological \n",
            "environment because they are in the same scale as biological molecules. In \n",
            "fact, nanomaterials like pa rticles, fibrous morphologies or other complex \n",
            "forms, have shown improved interactionswith cells, for example, selective \n",
            "endocytosis, adhesion and orientation (11, 15, 16). \n",
            "A useful wound healing patch should have the following properties \n",
            "(a) antibacterial, (b) able to promote rapid hemostasis and (c) having good \n",
            "biocompatibility to promote cell growth (6). Nanofibers were usually \n",
            "fabricated by incorporating antibacterial materials in the polymers. To \n",
            "date, five methods of incorporating active agents in the  fibers; including \n",
            "the active agent blending with polymer solution before electrospinning, \n",
            "fabricating core/shell structure through coaxial electrospinning, \n",
            "encapsulating the active agent before mixing them with electrospinning \n",
            "solution, posttreatment of t he fiber after electrospinning to convert a \n",
            "precursor to its active form or attaching the fiber s urface with the active \n",
            "compound (6).  \n",
            "The electrospinning process utilizes high electrostatic forces for \n",
            "nanofiber generation; generally from a polymeric solut ion or melt. The \n",
            "main assembly of the electrospinning unit comprises of electrical supply \n",
            "(for the generation of high electrical voltage), a syringe (contains solution/ \n",
            "melt/suspension to be electrospun), a metallic needle (as a capillary), and \n",
            "a grounded conductive collector (rotatable drum or static plate type) all \n",
            "enclosed within a chamber (17, 18). During the spinning process, high \n",
            "voltage (5 –15 kV) is applied between a needle capillary end and a \n",
            "collector. The polymer solution is electrically charged. At the needle tip, \n",
            "the polymer solution deforms from a spherical pendant droplet to a conical \n",
            "shape, known as “Taylor cone”. As the electric field is stronger than the \n",
            "surface tension of the polymer solution, the jet is ejected from the cone \n",
            "surface. As the jet travels, the solvent evaporates in the air, together with \n",
            "the stretching and acceleration of the polymer jet, leading to the extremely \n",
            "thin polymer fibers deposition on the collector (11, 19).  Electrical bending \n",
            "instability occurs when the distance from the tip to the collector is \n",
            "sufficiently long; in the case of a short distance, the jet is typically straight. \n",
            "Under the action of the electric field, polymer jets experience bending \n",
            "instability primarily due to mutual repulsion of the excess electric charges \n",
            "carried by electrospun jets. The electrospinning process and the formation \n",
            "of polymer fibers are affected by many parameters. Spinnability, fiber \n",
            "diameters, fiber uniformity, fiber alignment, defects control (e.g. beads, \n",
            "junctions, and pores), and  other properties are tunable by changing these \n",
            "parameters, (a) substrate -related parameters (polymer concentration,\n",
            "48 \n",
            "Figure 2. Clinical evaluation of PT and PTT results \n",
            " \n",
            "Thrombin time (TT) is a test that the patient's plasma is mixed with \n",
            "thrombin, and clotting time is measured. It is an assessment of functional \n",
            "fibrinogen. Heparin and abnormal or low fibrinogen molecules prolonges \n",
            "TT. The most performed fibrinogen assay is a modified thrombin test \n",
            "known as the Clauss fibrinogen assay. This method contains an initial (10-\n",
            "fold) dilution of the plasma sample to guarantee that fibrinogen is rate -\n",
            "limiting for clotting and the following measurement of the clotting time by \n",
            "supplementing an excess of thrombin to the sample. T he length of the \n",
            "clotting time is contrarily related to the concentration of fibrinogen. D -\n",
            "Dimer forms via fibrin degradation and contains two cross -linked D \n",
            "fragments of the fibrin protein. Elevated levels suggest increased \n",
            "fibrinolysis in DIC and thrombotic states. Antithrombin disables factor Xa \n",
            "(activated factor X) and activated factor II (thrombin). Therefore, activity \n",
            "is induced by heparin. Low ATIII levels may need additional heparin to \n",
            "obtain the desired anticoagulated state. This is called \"heparin resistance.\" \n",
            "Adipose tissue may release heparin storage back into the circulation a few \n",
            "hours after surgery. This is mentioned as rebound heparin and could result \n",
            "in bleeding. Both heparin resistance and rebound heparin can be prevented \n",
            "if low ATIII levels are corrected before surgery. Low levels of ATIII levels \n",
            "may be seen in; inherited deficiency, liver disease, nephrotic syndrome, \n",
            "DIC, and L-Asparaginase therapy.  \n",
            "Coagulation tests may include different approaches other than \n",
            "routine analysis. PT and aPT T prolongation in individuals may be due to \n",
            "factor deficiency or factor inhibitors. At this point, mixing studies come to\n",
            "CHAPTER VII \n",
            " \n",
            "POSSIBLE EFFECTS OF PREEKLAMPSY AND \n",
            "EKLAMPSY THAT MAY OCCUR WITH MATERNAL \n",
            "OBESITY ON THE HEALTH OF PREGNANCY: A \n",
            "METAANALYSIS \n",
            " \n",
            "Yılmaz Altuner \n",
            "(Asst. Prof. Dr..),Karabük University, e-mail:  ayilmaz@karabuk.edu.tr   \n",
            "                0000-0002-8162-2842 \n",
            " \n",
            "1. INTRODUCTION \n",
            "It has been determined that the prevalence of overweight \"obesity\" \n",
            "has gradually increased in women in the last 20 years (88). As a result, it \n",
            "has been suggested that it is associated with obesity during pregnancy, \n",
            "gestational diabetes, hypertensive diseases, preeclampsia -eclampsia, \n",
            "traumboeubalism diseases, preterm labo b, macrosomia, birth \n",
            "complications and increased cesarean delivery (89). In addition, \n",
            "epidemiological studies have shown that excess maternal body we ight \n",
            "increase during pregnancy causes high birth weight newborns. (90) It has \n",
            "also been reported that newborns may increase the risk of being overweight \n",
            "and obese in childhood and adulthood (91). \n",
            "According to the data of the World Health Organization (WHO) , \n",
            "it is stated that there are over 400 million obese and 1.6 billion slightly \n",
            "obese individuals in the world. It was stated that in 2015, this rate could \n",
            "reach 2.3 billion per 700 million, respectively (92). 2016 According to the \n",
            "data of the adult population in the world, approximately 13% were obese, \n",
            "and especially if the prevalence of obesity before pregnancy with an \n",
            "average 0.5 point increased knowledge of literature a year i, in 2000 \n",
            "Turkey's National Diabetes Obesity and Hypertension Epidemiology \n",
            "(TURDEP) that the obesity prevalence according to study data 22.3% It \n",
            "has been suggested (93). \n",
            "In particular, increased obesity was found to be associated with \n",
            "pregnancy loss and the risk of recurrent pregnancy in the first trimester \n",
            "(94). In overweight and obe se pregnant women, in addition to the \n",
            "increasing number of undesirable perinatal effects, obviously obesity; It \n",
            "has also been determined to increase the risk of severe gestational \n",
            "hypertension, preeclapsia-eclipse, gestational diabetes and macrosomia in \n",
            "terms of the mother and fetus (95). In a study involving 1.4 million women \n",
            "with a large sample, it was found that the risk of preeclapse doubles with\n",
            "43 \n",
            "factor), prekallikrein, and high -molecular-weight (HMW) kininogen. In \n",
            "vitro contact phase is launched by binding factor XII to negative surfaces \n",
            "of g lass and kaolin. This leads to the generation of cofactors XIIa and \n",
            "kallikrein and the release of bradykinin from HMW kininogen. Factor XIIa \n",
            "then activates factor XI, which converts factor IX to factor IXa, a reaction \n",
            "requiring calcium presence. After fact or IXa complexes with its cofactor \n",
            "protein factor VIIIa on a negatively charged membrane surface. This \n",
            "enzymatic complex, also referred to as the tenase complex, converts factor \n",
            "X to factor Xa. After both the extrinsic and intrinsic pathways generate \n",
            "factor Xa, the coagulation pathway 's ensuing reactions are the same and \n",
            "are referred to as the common pathway. Based on the discovery that the \n",
            "factor VIIa-TF complex also converts factor IX to factor IXa, that is the \n",
            "privileged reaction, a new modified concept of coagulation was proposed \n",
            "in which factor VIIa -TF complex seems to be the core initiator of \n",
            "coagulation, but the intrinsic pathway is aforethought essential to pursue \n",
            "the coagulation response. \n",
            " \n",
            "Figure 1. Coagulation pathway scheme \n",
            " \n",
            "ENDOGENOUS ANTICOAGULANTS AND FİBRİNOLYSIS \n",
            "Anticoagulant substances consist of antithrombin III (AT -III), \n",
            "protein C, protein S, and TFPI. Intact endothelium ensures that the \n",
            "formation of clots is stopped, and if endothelial repair is completed, the\n",
            "100 \n",
            "meta-analysis of randomized studies conducted for the prevention of \n",
            "preeclampsia by acetylsalicylic acid and involvin g more than 30,000 \n",
            "women, although long-term fetal effects could not be ignored, it was stated \n",
            "that it provided a small decrease in the rate and morbidity of preeclampsia \n",
            "and there was no evidence against an acute risk (70). \n",
            "Antioxidant Supplements (With V itamins C and E):  \n",
            "Antioxidant support with vitamin C or vitamin E is not recommended for \n",
            "the prevention or treatment of preeclampsia. ( 70). High-quality evidence \n",
            "of ineffectiveness has been found. In two studies in which antioxidants \n",
            "were given to women with severe preeclampsia for treatment, no clinical \n",
            "benefit was found (71, 72). In order to prevent preeclampsia and reduce its \n",
            "complications; Although a pilot study found that supplementation of \n",
            "1000mg of vitamin C and 400 IU of vitamin E daily during the second and \n",
            "third trimesters significantly reduced the risk of preeclampsia ( 73), it was \n",
            "broadly and in multiple, multicenter, randomized women with both low - \n",
            "and high-risk groups. No meaningful results have been achieved in studies \n",
            "(74, 75). \n",
            "Folic Acid Supplement: Although it has been stated that folic acid \n",
            "reduces the risk of preeclampsia, there are studies reporting the opposite \n",
            "(48, 49, 51). \n",
            "Antihypertensive Drugs:  It has not been shown in controlled \n",
            "studies that lowering blood pressure with antihyperte nsive drugs reduces \n",
            "the risk of preeclampsia or ablatio placenta or improves fetal and \n",
            "pregnancy outcomes. However, treatment has decreased the frequency of \n",
            "moderate and severe hypertension (50). \n",
            "Calcium Supplement: No benefit of routine calcium supplements \n",
            "has been observed for the prevention of preeclampsia in healthy \n",
            "nulliparous women whose dietary calcium intake is sufficient. It has been \n",
            "shown to be beneficial in the prevention of preeclampsia in the high -risk \n",
            "group, especially in societies where dieta ry calcium intake is low ( 64). \n",
            "World Health Organization (WHO) recommended 1500 -2000 mg of \n",
            "calcium supplements per day to reduce the risk of preeclampsia for \n",
            "pregnant women who are at high risk for developing hypertension in places \n",
            "where calcium intake is low ( 51). In a randomized controlled study \n",
            "conducted by WHO in the female population (n: 8325) whose daily \n",
            "calcium intake is less than 600 mg per day; calcium supplementation \n",
            "provided a small statistically insignificant reduction in preeclampsia. \n",
            "Eclampsia and severe gestational hypertension were significantly lower in \n",
            "the calcium group. At the same time, the severe maternal mortality and \n",
            "morbidity index and neonatal mortality rates decreased in the group \n",
            "receiving calcium. As a result, 1.5 g calcium supple mentation per day\n",
            "112 \n",
            "56. PRECOG: Pre -Eclampsia Community Guideline 2004. http:/ /action-\n",
            "on-pre-eclampsia.org.uk/wp-content/uploads/2012/07/PRECOG-\n",
            "Community-Guideline.pdf.   \n",
            "57. Gallos ID, Sivakumar K, Kilby M, Coomarasamy A, Thangaratinam S, \n",
            "Vatish M. Preeeclampsia is associated with, and preceded by, \n",
            "hypertriglyceridaemia: a meta-analysis. BJOG: An International \n",
            "Journal of Obstetrics & Gynaecology 2013; 120(11), 1321-1332. \n",
            "58.   Ozan YD, Ertuğrul M, Okumuş H. Preeklampsi Tanılama, \n",
            "Değerlendirme ve Hemşirelik Yönetimi. Cumhuriyet Hemşirelik \n",
            "Dergisi 2012; 2, 59-65. \n",
            "59.  Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. \n",
            "Maternal hyperlipidemia and the risk of preeclampsia: a meta -\n",
            "analysis. American journal of epidemiology 2014; 180(4), 346 -\n",
            "358.   \n",
            "60. Swank M, Nageotte M, Hatfield T. Necrotizing pancreatitis associated \n",
            "with severe preeclampsia. Obstetrics & Gynecology 2012; 120, \n",
            "453-5. \n",
            "61. Lynch TA, Dexter SC. Alcoholic Pancreatitis Masquerading as \n",
            "Preeclampsia. Obstetrics & Gynecology 2015; 126(6), 1276-8. \n",
            "62. Ødegård RA, Vatten LJ, Nilsen ST, Salvesen KÅ, Austgulen R. \n",
            "Preeclampsia and fetal growth. Obstetrics & Gynecology 2000; \n",
            "96(6), 950-5. \n",
            "63.  Townsend NS, Drummond SB. Preeclampsia: Pathophysiology and \n",
            "implications for care. The Journal of perinatal & neonatal nursing \n",
            "2011; 25(3), 245-52.  \n",
            "64. Hofmeyr GJ, Lawrie TA, Atallah ÁN, Duley L, Torloni MR. Calcium \n",
            "supplementation during pregnancy for preventing hypertensive \n",
            "disorders and related problems (Review). Cochrane Database Syst \n",
            "Rev 2014;(6): CD001059.  \n",
            "65. Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali MM, Zavaleta N. \n",
            "World Health Organization randomized trial of calcium \n",
            "supplementation among low calcium intake pregnant women. \n",
            "American journal of obstetrics and gynecology 2006; 194(3), 639-\n",
            "49. \n",
            "66. Critchfield AS, Heard AJ. Severe Preeclampsia or Eclampsia and \n",
            "Hypertensive Issues. In: Angelini DJ, LaFontaine D, editors. \n",
            "Obstetric triage and emergency care protocols. New York: \n",
            "Springer Publishing Company; 2012. pp 149-159 .\n",
            "2 \n",
            "to provide ideal scar formation by affecting factors such as inflammatory \n",
            "cells, thrombocytes, mediators and extracellular matrix (4). In this context, \n",
            "different treatment methods are tried, new treatment searches are continued \n",
            "to accelerate the healing process, prevent excessive inflammation and \n",
            "infections, and to prevent any symptoms by monitoring the healing process \n",
            "(5). \n",
            "Open wounds mean an open door for infection. Therefore, the \n",
            "wound surface should not be left open and should be covered with suitable \n",
            "materials. Wound dressings were originally fabricated from natural \n",
            "materials such as plant fibers and animal fats to simply cover the wounds. \n",
            "This has evolved to the present day whereby artificial materials can be \n",
            "fabricated by various advanced technologies to create multifunctional \n",
            "wound dressings. The two essential requirements of suitable modern \n",
            "wound dressings include rapid hemostasis property and good antibacterial \n",
            "property. The purpose of a wound dressing is to achieve rapid hemostasis \n",
            "function and it should also possess good antibacterial property to prevent \n",
            "infections from surrounding bacteria.  \n",
            "Electrospinning has att racted much interest for its versatility to \n",
            "fabricate nanofibrous membranes for a wound dressing which can create a \n",
            "moist environment around the wound area to promote healing (6). \n",
            "ELECTROSPINNING \n",
            "Historically, cells were grown and studied as monolayers on tissue \n",
            "culture plates. In recent years, advances in biomaterial synthesis and \n",
            "microfabrication have made it possible to pattern cells into complex, three-\n",
            "dimensional structures by using appropriate scaffolds as the templates  (7, \n",
            "8). \n",
            "Electrospinning is a re markably simple, robust, and versatile \n",
            "technique capable of generating fi bers with diameters down to the \n",
            "nanoscale (7, 9). A non-woven mat of electrospun nanofi bers possesses \n",
            "high porosity and spatial interconnectivity well -suited for nutrient and \n",
            "waste t ransport and cell communication  (7, 10). A scaff old based on \n",
            "electrospun nanofibers also has a large specific surface area for loading of \n",
            "bioactive molecules to facilitate efficient a nd selective cellular responses \n",
            "(9). \n",
            "Electrospinning was first being intro duced in early 1930s for \n",
            "fabrication of nanofibers as filter materials and textile yarns. Since 1990s, \n",
            "after Reneker et al. demonstrated the feasibility to produce electrospun \n",
            "nanofibers from many polymers, the number of publications about \n",
            "electrospinning has grown exponentially , especially for recent ten years  \n",
            "(11, 12, 13).  Electrospinning received  much attention for biomedical \n",
            "applications mainly due to the growing interest in nano -technologies and\n",
            "130  \n",
            "Macrophages are highly malleable and can transform into both \n",
            "proinflammatory and anti -inflammatory cells through different \n",
            "environmental mediators. 8,9 Although mast cells mainly play a role in \n",
            "allergic respon ses, their importance in immune response regulation in \n",
            "wound healing has been shown in recent studies.10  \n",
            "The proliferative phase progresses intertwined with the \n",
            "inflammatory phase and is characterized by granulation tissue formation, \n",
            "angiogenesis, epithel ization, and collagen deposition. Fibroblasts and \n",
            "endothelial cells fill the gap opened by the degredation of the fibrin plug.3 \n",
            "Macrophage-derived growth factors, mainly vascular endothelial growth \n",
            "factor (VEGF) and fibroblast growth factor (FGF), play an important role \n",
            "in angiogenesis.2 It has been shown that basal membrane pericytes involved \n",
            "in angiogenesis are able to act as mesenchymal stem cells and transform \n",
            "into bone, adipose tissue and cartilage. 11 Epithelialization process is \n",
            "characterized by the p roliferation and migration of epithelial cells. \n",
            "Migration is the rate limiting step of this process; migration disorders result \n",
            "in a chronic non-healing wound. 12  \n",
            "The function of protein -coding genes is important in the wound \n",
            "healing process. The producti on of all protein structures takes place \n",
            "through these genes. In recent studies, it has been shown that the \n",
            "transcription of mRNA from DNA and protein translation from mRNA \n",
            "takes place under the control of microRNAs (miRNA). miRNAs are \n",
            "shortchain RNAs foun d in all eukaryotic cells and not used in coding. 13 \n",
            "miRNAs have begun to be recognized as the most important regulators of \n",
            "the entire wound healing process. In the future, as the specific tasks of \n",
            "miRNAs are better understood, it is thought that miRNA -based therapies \n",
            "can be identified and may be particularly useful in chronic wound \n",
            "treatment.12  \n",
            "Wound closure for chronic wounds is defined as epithelized skin that \n",
            "does not require dressing and does not show leakage in 2 control \n",
            "examinations performed 2 weeks apart. There should be no recurrence for \n",
            "at least 3 months to accept the treatment as successful. 12 Recent studies \n",
            "have shown that biofilm -infected wounds may remain functionally open, \n",
            "despite visual closure, and fail to fulfill their barrier function. Th is \n",
            "condition is called high transepidermal water loss (TEWLhi) and is \n",
            "associated with the increase of biofilm -induced miRNAs. For this reason, \n",
            "measurements such as TEWL in addition to visual evaluation will provide \n",
            "more objective results for evaluating wound healing.14  \n",
            "WOUND DRESSING  \n",
            "The ideal dressing method should keep the wound moist, absorb \n",
            "exudate, avoid contamination and prevent dehydration while not \n",
            "traumatizing the wound. 15 For this purpose, many materials have been\n",
            "CONTENTS \n",
            "PREFACE....………………………………………………………….....I \n",
            "REFEREES……………………………………………………………..V \n",
            "Chapter I G. Naz Yazıcı & M. Sunar \n",
            "A BIOMEDICAL TREASURE: NANOFIBERS IN WOUND \n",
            "HEALING………………………………………….…...1 \n",
            "Chapter II  G. Naz Yazıcı \n",
            "BIOCHEMICAL AND HISTOPATHOLOGICAL \n",
            "PARAMETERS USED IN EXPERIMENTAL \n",
            "OVARIAN ISCHEMIA / REPERFUSION MODELS IN \n",
            "RECENT YEARS...........................................................13 \n",
            "Chapter III  G. Ozcan \n",
            "CLINICAL DEVELOPMENT OF HIF -1α INHIBITORS FOR \n",
            "CANCER THERAPY....................................................26 \n",
            "Chapter IV  M. E. Duz \n",
            "COAGULATION ANALYSES IN DIAGNOSIS AND \n",
            "TREATMENT................................................................39 \n",
            "Chapter V  M. Sunar \n",
            "PREVALENCE OF PALMARIS LONGUS AGENESIS (PLA) \n",
            "AMONG TURKISH MEDICAL STUDENTS..............55 \n",
            "Chapter VI  N. Eser \n",
            "TARGETS FOR THE TREATMENT OF ERECTILE \n",
            "DYSFUNCTION............................................................67 \n",
            "Chapter VII  Y. Altuner \n",
            "POSSIBLE EFFECTS OF PREEKLAMPSY AND EKLAMPSY \n",
            "THAT MAY OCCUR WITH MATERN AL OBESITY \n",
            "ON THE HEALTH OF PREGNANCY: A \n",
            "METAANALYSIS.........................................................89 \n",
            "Chapter VIII  E. Balcıoğlu & H. Yeşil Sarsmaz & G. S. Gürgen \n",
            "AN EXAMINATION OF THE RELATIONSHIP BETWEEN \n",
            "SMOKING DURING -BEFORE PREGNANCY AND \n",
            "NEWBORN BIRTH WEIGHT/PLACENTA WEIGHT \n",
            "AND ITS HISTOPATHOLOGICAL IMPACTS ON \n",
            "THE PLACENTA TISSUE..........................................115 \n",
            "Chapter IX  A. Demiröz & Z. G. Özünal \n",
            "EFFECTS OF LAVENDER OIL ON WOUND HEALING…129\n",
            "CHAPTER IV \n",
            " \n",
            "COAGULATION ANALYSES IN DIAGNOSIS AND \n",
            "TREATMENT \n",
            " \n",
            "Muhammed Emin Düz \n",
            "(Biochemistry Specialist, MD),. Amasya Sabuncuoğlu Şerefeddin Training and Research \n",
            "Hospital, e-mail: cerrahemin@gmail.com \n",
            "              0000-0002-1837-6415 \n",
            " \n",
            "INTRODUCTION \n",
            "In living macroorganisms, life -long expected and unexpected \n",
            "bleeding and coagulation mechanisms are activated at regular intervals. \n",
            "Excessive coagulation can lead to life -threatening damage resulting from \n",
            "a blockage in the vessels, and uncontrolled bleedin g can cause serious \n",
            "complications, especially death. To prevent bleeding, blood clotting \n",
            "(clotting) occurs a few seconds after the vessel injury. The primary purpose \n",
            "of coagulation is the vascular repair that occurs by collecting thrombocytes \n",
            "at the damage site. Coagulation is known as the clotting of blood or plasma. \n",
            "Hemostasis is the procedure that tries to stop bleeding and is the first \n",
            "component of the metabolism's response to vascular injury. As a result of \n",
            "hemostasis, a product called a hemostatic plug or hemostatic clot is formed. \n",
            "Thrombosis is an unexpected clot formation in a healthy vascular structure. \n",
            "Thrombus formation occurs as a result of thrombosis. Bloo d clotting can \n",
            "occur at an injury site (hemostasis), in a healthy vessel (thrombosis), or on \n",
            "a foreign surface such as a laboratory test tube. Still, hemostasis is a \n",
            "physiological process that can only occur in a living, bleeding organism. \n",
            "Hemostasis consists of primary hemostasis, in which platelets are attached \n",
            "and activated to a site of damage, and a fibrin network rigidly structures \n",
            "secondary hemostasis, in which the primary platelet plug formed. The \n",
            "hemostatic process represents a delicate, well -balanced chain of steps \n",
            "between regulatory mechanisms and control that prevent the efficient \n",
            "activation of local hemostatic agents and improper activation or \n",
            "prolongation of coagulation steps due to vascular damage. The interactions \n",
            "of the protein ingredients of coagulation cascade can be studied in cell-free \n",
            "plasma and characterized as a \"cascade\" of proteolytic reactions. \n",
            "Conversely, hemostasis's operation takes place on cell surfaces in a living \n",
            "organism and is dependent on regulation by various biochemical an d \n",
            "cellular mechanisms. The competence of plasma procoagulant levels can \n",
            "be defined in the routine plasma clotting assays: prothrombin time (PT) \n",
            "and activated partial thromboplastin time (aPTT). Platelet count and\n",
            "101 \n",
            "cannot prevent preeclampsia, but its severity, maternal 1 morbidity and \n",
            "neonatal mortality have been reduced (65). \n",
            "Fish Oil:  There are studies indicating that fish oil supplements \n",
            "have a protective effect on the vessels, lowers systemic b lood pressure, \n",
            "reduces the incidence of preeclampsia and pregnancy -induced \n",
            "hypertension (52, 53). On the contrary, fish oil supplementation has no \n",
            "There have been many studies stating that it has no effect (54, 55, 56). \n",
            "Nitric Oxide: There is no sufficient  level of evidence that nitric \n",
            "oxide prevents preeclampsia (35). \n",
            "Other Dietary Interventions: There have been only a few small \n",
            "randomized studies investigating the role of diet in preventing \n",
            "preeclampsia. No beneficial results were found from dietary \n",
            "recommendations such as protein and energy supplements, protein and \n",
            "energy restriction (in obese women), magnesium supplementation, and salt \n",
            "restriction (21, 55, 58, 59). \n",
            "Vitamin D Supplementation:  Some observational studies \n",
            "indicate an association between vitamin D deficiency and increased risk of \n",
            "preeclampsia ( 38) and early -onset severe preeclampsia ( 61), while no \n",
            "association was found in a prospective cohort study of women with high -\n",
            "risk preeclampsia (76). As with other nutritional interventions, evidence \n",
            "was insufficient to prevent preeclampsia (70). \n",
            "Weight Loss: Although there is an increased risk between \n",
            "maternal obesity and preeclampsia, few studies have evaluated the effect \n",
            "of weight loss on risk. In cohort studies of patients undergoing surgery for \n",
            "weight loss, weight loss was reported to significantly reduce the risk of \n",
            "preeclampsia (76). Additionally, in a cohort study, it was determined that \n",
            "the risk of recurrent preeclampsia was reduced i n women with \n",
            "preeclampsia who lost weight between pregnancies (62). \n",
            "Rest and Physical Activity:  There is no strong evidence that \n",
            "exercise or physical activity affects the risk of developing preeclampsia. \n",
            "(43). Restriction of bed rest or other physical activities is not recommended \n",
            "primarily in the prevention of preeclampsia and its complications. (80). It \n",
            "has been hypothesized that regular exercise prevents preeclampsia by \n",
            "improving vascular functions. Although bed rest is recommended as a \n",
            "preventive strategy, it has been reported that the evidence for this is limited. \n",
            "Only two small studies evaluated bed rest as a protective strategy, but did \n",
            "not evaluate perinatal -maternal morbidity and mortality and adverse \n",
            "effects of bed rest (44, 45). \n",
            "Moderate activ ity has been found to reduce the risk of \n",
            "hypertension and cardiovascular disease in non -pregnant women. In \n",
            "normal pregnancy, 30 minutes of moderate activity is not recommended on\n",
            "109 \n",
            "Development i n young Adults Study,J Am Heart Assoc \n",
            "2014;3:e00049 \n",
            "15. HAPO Study Cooperative Research Group, Matzger BE, Lowe \n",
            "LP,Dyer AR, Trimble ER, Chaovariner U,Coustan DR,et al.: \n",
            "Hyperglycemia  and adverse pregnancy outcome .N Engl J Med \n",
            "2008;358:1991-2002 \n",
            "16. Hauguel de Mouzon S,Guerre-Millom.: The placenta cytokine network \n",
            "and inflammatory signals Placenta 2006;27:794-98  \n",
            "17. International Association of Diabetes and Pregnancy study Groups \n",
            "Consensus Panel, Metzger BE, Gabbe SG, persson B,Buchanan \n",
            "TA,Catalano PA, et al.. International association of diabetes and \n",
            "pregnancy study groups recommendations on the diagnosis and \n",
            "classification of hyperglycemia in pregnancy Diabetes Care 2010; \n",
            "33:676-82 \n",
            "18.Jacobsen AF, S Kjeldstad FE, Sandset PM.: Incidence and risk patterns \n",
            "of venosus thromboembolism in pregnancy and puerperium -a \n",
            "register -based case -control study .Am I Obstet Gynecol \n",
            "2008;198:233, e-1-7 \n",
            "19. Jevitt C. pregnancy complicated by obesity: midwifery ,J Midwifery \n",
            "womens Health 2009: 54(6):445-451 \n",
            "20. Kirtzmiller J, Cloherty J, Younger MD, et al.: Diabetes Preg nancy and  \n",
            "Perinatal  Morbidity. Amj Obstet Gynecol 131:560,1978 \n",
            "21. Kitsantas P, Pawlowski LR, Maternal Obesity : health status during \n",
            "pregnancy ,and breastfeeding  initiation and duration J Matern \n",
            "Fetal Neonatal Med .2010:23(2): 135-141 \n",
            "22. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, \n",
            "Galie N, et al.: 2014 ESC guidelines on the diagnosis and \n",
            "management of acute pulmonary embolism ,Eur Heart J \n",
            "2014;35:3033-69, 3069a-3069k,doi:10.1093/eurheartj/ehu 283 \n",
            "23. Langer O, an egg bunamA, Brustman L, et al.: Management of women \n",
            "with one abnormal oral glucose tolerance test valve reduces \n",
            "adverse outcome in pregnancy .Am J Obstet Gynecol \n",
            "161:593,1989 \n",
            "24. Lauenburg J, Hansen T,Jensen DM,vestergaard, H, Mølsted -Pedersen \n",
            "L,Homnes P, et al. ıncreasing incidence of diabetes after \n",
            "gestational diabetes: a long -term follow -up in a Danish \n",
            "population Diabetes. Care 2004; 27:1194-a \n",
            "25. Lee CY, Koren G,Maternal Obesity.: effects on pregnancy  and the role \n",
            "of preconception Counselling. J Obstet Gynaecol 2010;30(2):101-\n",
            "106 \n",
            "26. Lindsay NK,Graves W, Klein L .: The  relationship of one abnormal \n",
            "glucose tolerance test value and pregnancy complications obstet. \n",
            "Gynecol 173:103,1989\n",
            "132  \n",
            "EMA.  Wound healing and related factors were studied in many in -vitro, \n",
            "in-vivo and clinical studies.  \n",
            "IN-VITRO STUDIES  \n",
            "Lavender essential oil is studied for antifungal properties and \n",
            "resulted with antifungal efficacy in Candida, Cryptococcus neoformans, \n",
            "dermatophyte and Aspergillus strains. 21 A different species of lavender is \n",
            "shown to have anti -leishmanial and antibacterial activities. 22 Bouyahya et \n",
            "al. not only showed these activities they also showed antioxidant activity \n",
            "with the essential oil. A constituent in lavender oil; Terpinen-4-ol, is found \n",
            "to inhibit in vitro growth of human melanoma cell line. 23 In many in-vitro \n",
            "cancer studies anti-proliferative effect is shown.24 In vitro scratch assay or \n",
            "wound healing assay with a prostate cancer cell line, in p arallel resulted \n",
            "reduced healing with lavender essential oil. 24 Perillyl alcohol, a \n",
            "monoterpene constituent in the lavender essential oil is showed to have \n",
            "antiangiogenic effect via VEGF.25  \n",
            "Abe et al. evaluated the anti -inflammatory effects in neutrophil \n",
            "adhesion method with various essential oils including lavender oil and \n",
            "reported that the main component in the lavender EO linalool has \n",
            "antiinflammatory effect in TNF-α -induced neutrophil adhesion in-vitro.26 \n",
            "Even the concentration is higher than the expe cted concentration of \n",
            "transdermal exposed dose of lavender EO, they supported in -vivo \n",
            "interpretation cannot exclude the potential anti-inflammatory role.  \n",
            "IN-VIVO AND CLINICAL STUDIES  \n",
            "Several clinical studies have been conducted investigating the \n",
            "effects of lavender oil in wound healing. 27 It is well known to have \n",
            "antioxidant, antibacterial, antifungal and analgesic effects. It is also known \n",
            "to accelerate wound contraction.   \n",
            "Hartman and Coetze investigated the effect of lavender and \n",
            "chamomile essential oils in their study on 8 patients with chronic wounds. \n",
            "Complete closure was achieved in 4 of the five patients who were applied \n",
            "the essential oils, and recovery was not possible in 3 patients in the control \n",
            "group until the end of the study. Although it is no t possible to make a \n",
            "statistical comparison in this small sample group, it would not be wrong to \n",
            "say that the essential oils used were effective.28  \n",
            "Kerr compared the effects of various essential oil blends created in \n",
            "aloe vera gel base on simple wounds and concluded that the most effective \n",
            "combination was lavender, German chamomile, myrrh and tea tree \n",
            "essential oils in aloe vera gel. He reported that this preparation reduced \n",
            "odor, prevented redness and inflammation, and shortened the healing \n",
            "time.29\n",
            "60 \n",
            "CONCLUSION \n",
            "In conclusion, this study demonstrates absence of palmaris longus \n",
            "(PL) muscle in Turkish students compatible with other population studies. \n",
            " \n",
            "ACKNOWLEDGEMENTS \n",
            "The authors of this work wish to thank our mentor Prof. Dr. Samet \n",
            "KAPAKİN a nd all the Students in college of Medicine, Atatürk and \n",
            "Erzincan Binali Yıldırım University for their help for collecting the sample \n",
            "and doing the research. \n",
            " \n",
            "Figure 1: Dissected cadaveric forearm with present palmaris longus \n",
            "muscle (Pękala, P. A., Henry, B. M., Pękala, J. R., Skinningsrud, B., \n",
            "Walocha, J. A., Bonczar, M., & Tomaszewski, K. A. (2017). Congenital \n",
            "absence of the palmaris longus muscle: A meta-analysis comparing \n",
            "cadaveric and functional studies. Journal of Plastic, Reconstructive & \n",
            "Aesthetic Surgery, 70(12), 1715-1724.)\n",
            "94 \n",
            "2.2. THE EFFECT OF MATERNAL OBESITY ON \n",
            "THROMBOEMBOLI DISEASES \n",
            "Physiological and anatomical changes during pregnancy were \n",
            "important factors in venous stasis and decreased venous blood flow, uterine \n",
            "pressure on inferior vena cava and pelvic veins and immobility thrombus \n",
            "formation. While some coagulation factors increased during pregnancy, \n",
            "the protein level decreased (41). Age> 35, obesity, cesarean delivery, \n",
            "severe ovarian hyperstimulation, heart disease, DM, multiparity have been \n",
            "reported to increase the risk of pulmonary embolism (PE) (18).  \n",
            "Physiological changes during pregnancy cause PE-like symptoms \n",
            "causing diagnostic difficulties. Dyspnea, tachypnea, tachycardia and leg \n",
            "swelling occurred during pregnancy. The complaint of shortness of breath \n",
            "gradually increased during pregnancy. In particular, the unusual increase \n",
            "in dyspnea and the accompanying DNT symptoms were among the \n",
            "important clues for PE. The most common symptoms were listed as \n",
            "dyspnea, pleuritic, chest pain and cough (8). \n",
            "Thrombolytic Treatment in Pregnant Women:  When \n",
            "thrombolytic therapy in pregnant women is used in patients who are not \n",
            "pregnant, it carries a similar risk to the risk of bleeding (3 1). No large \n",
            "studies have been conducted on the use of pregnancy thrombolytic drugs. \n",
            "Therefore, experience in this matter has been limited ( 33). Tissue -\n",
            "plasminogen activator (tPA) has been recommended in pregnant women \n",
            "using thrombolytics in the recently published European PE guideline (22). \n",
            "3.PREEKLAMPSİA AND EKLAMSİA \n",
            "Preeclampsia has been a common occurrence in pregnant women. \n",
            "It has been characterized by protein in the urine accompanying high blood \n",
            "pressure. Women with preeclampsia have had swelling in their feet, legs, \n",
            "and hands. If preeclampsia is present, it may occur earlier, and it is usually \n",
            "seen in the second half of pregnancy, the last part of the second trimester, \n",
            "or the third trimester. \n",
            "Eclampsia has been identified as the final and most severe stage of \n",
            "preeclampsia if left untreated. In addition to the previously mentioned \n",
            "findings of preeclampsia, it was found that women with eclampsia mostly \n",
            "had a stroke. Eclampsia caused the mother and the baby to go into a coma \n",
            "or even death. In addition, the disease was discovered before, during or \n",
            "after the birth of the child. \n",
            "It has been stated that preeclampsia can cause your baby to be born \n",
            "very small and prevent the placenta from getting enough blood. It has also \n",
            "been the main cause of difficulties such as premature birth and \n",
            "accompanying learning defects, epilepsy, cerebral palsy, and he aring and\n",
            "CHAPTER  III \n",
            " \n",
            "CLINICAL DEVELOPMENT OF HIF-1α INHIBITORS  \n",
            "FOR CANCER THERAPY \n",
            " \n",
            " \n",
            "Gülnihal Özcan \n",
            "(Asst. Prof.) Koç University School of Medicine, e-mail:guozcan@ku.edu.tr \n",
            "                  0000-0001-5354-0148 \n",
            " \n",
            " \n",
            "INTRODUCTION \n",
            "Hypoxia inducible factors (HIFs) are transcription factors that play \n",
            "a central role in adaptation of cells to hypoxia. HIFs are stabilized in the \n",
            "hypoxic environment leading to transcription of many target genes that \n",
            "induce angiogenesis to re -establish oxy gen homeostasis and regulate \n",
            "cellular energetic metabolism to adapt to hypoxic conditions 1. Cancer cells \n",
            "utilize these mechanisms in their advantage to survive despite unfavorable \n",
            "conditions, gain replicative immortality and stem cell characteristics, \n",
            "escape from apoptotic stimuli and immunosurveillance, metastasize to \n",
            "different areas and resis t anti -cancer therapy. As a result, hypoxia or \n",
            "increased activity of HIFs bring more malignant characteristics to tumors \n",
            "and worsen patient prognosis 2.  \n",
            "Among the HIF isoforms HIF -1 come forward w ith its prominent \n",
            "involvement in tumor progression and chemoresistance. HIF -1 is a \n",
            "heterodimer of HIF-1α and HIF -1β subunits. HIF -1α is overexpressed in \n",
            "several tumors and its expression is associated with poor overall survival \n",
            "3-5. HIF -1α expression was found to be more abundant at the invasive \n",
            "margins of tumor specimens 6-8. High expression of HIF -1α is also \n",
            "associated with high a risk of metastasis in cancer 9-11. Therefore, targeting \n",
            "HIF-1α is of prime importance to increase  therapeutic success in cancer \n",
            "chemotherapy. \n",
            "REGULATION OF HIF-1α ACTIVITY \n",
            "In the presence of oxygen HIF -1α is hydroxylated by prolyl \n",
            "hydroxylases (PHDs). Then hydroxylated HIF-1α is ubiquitinated and \n",
            "degraded by ubiquitin proteasome system with a reaction dependent on \n",
            "tumor suppressor protein von Hippel–Lindau (pVHL). On the other hand, \n",
            "in hypoxic conditions HIF-1α cannot be hydroxylated by PHDs and \n",
            "becomes stable. Then, it translocates to the nucleus and couples with HIF-\n",
            "1β to form HIF-1. After that, HIF-1 binds p300/CBP co-activator forming \n",
            "the HIF transcription complex which binds to hypoxia response elements\n",
            "27 \n",
            "test a synthetic locked nucleic acid form of EZN -2968 (RO7070179) in \n",
            "hepatocellular carcinoma (HCC) ( NCT02564614), since dose limiting \n",
            "toxicity in the previous studies was hepatotoxicity due to accumulation in \n",
            "liver. Study results suggested that HCC patients may benefit from \n",
            "RO7070179 and, decrease in HIF-1α mRNA during the first cycle may \n",
            "have predictive value for therapeutic effect 21.  \n",
            "2. Drugs That Inhibit HIF-1α Translation \n",
            "2a. Camptothecins \n",
            "Camptothecins which act primarily by inhibition of topoisomerase I \n",
            "enzyme, is an important group of chemotherapeutics used in the treatment \n",
            "of cancer. Camptothecin and its derivatives like topotecan has been shown \n",
            "to down -regulate HIF-1α through regulation of the HIF-1α-targeting \n",
            "miRNAs 22. After the confirmation of its anti-HIF1α activity together with \n",
            "the anti -angiogenetic and anti -tumorigenic effects in xenograft models, \n",
            "topotecan was evaluated i n a phase I study for its effectiveness in \n",
            "suppressing HIF -1α expression in advanced solid tumors refractory to \n",
            "treatment (NCT00117013). Although a median reduction of 7.5% percent \n",
            "was detected in HIF-1α expression and a correlation was observed between \n",
            "this reduction and radiological outcomes, the results were not statistically \n",
            "significant because of low patient accrual 23. \n",
            "Besides their use as single agents, inclusion of campothecins in \n",
            "combination chemotherapy where an anti -VEGF agent is involved may \n",
            "prevent the increase in HIF-1α due to inhibition of angiogenesis. With this \n",
            "notion, combination of camptothecins with anti -angiogenetic agents have \n",
            "been tested in several clinical trials. Combination of irinotecan with anti -\n",
            "VEGF monoclonal antibody bevacuzimab was tested for its efficacy in \n",
            "pediatric patients with recurrent, progressive, or refractory glioma, \n",
            "medulloblastoma, ependymoma, or low -grade glioma in a phase II trial \n",
            "started in 2006 (NCT00381797). In another phase II trial started in 2007, \n",
            "efficacy of topotecan in combination with cisplatin and bevacuzimab was \n",
            "tested in patients with recurrent or  persistent cervical can cer \n",
            "(NCT00548418). However, the toxicity profile of this combination was \n",
            "disappointing 24.  \n",
            "EZN-2208, a pegylated form of SN38, which is the active metabolite \n",
            "of irinotecan, was combined with bevacuzimab in a phase I trial to test its \n",
            "safety, efficacy and anti -HIF-1α activity in solid tumors refractory to \n",
            "treatment (NCT01251926, no posted results). CRLX101, which is a \n",
            "nanoparticle formulation of camptothecin, was tested for its safety and \n",
            "efficacy profile in combination with bevacizumab in patients with ovarian, \n",
            "tubal, and peritoneal cancers resistant to platinium -based therapy \n",
            "(NCT01652079) 25. The trial was completed in 2018 with no results posted \n",
            "yet. Although the emphasis was not on inhibition of HIF-1α, the efficacy\n",
            "6 \n",
            "dressings prepared by electrospin method; It has many prominent features \n",
            "that will provide advantag es in the wound healing process.  NFs based \n",
            "wound dresses can promote hemostasis without resorting to a haemostatic \n",
            "agent, water adsorption is 8 –92 times superior on electrospun dressings \n",
            "compared to typical film dressings . The arrangement o f the nanofibers \n",
            "results in small pores that not only allow cell respiration, oxygen exchange, \n",
            "and to control the moisture at the wounded site preventing dehydration, \n",
            "but, because of its small size, can also effectively protect the wound from \n",
            "infection pre venting microorganisms from penetrating.  These wound \n",
            "dresses also comfortable, funct ional because u nlike other commercially \n",
            "available dressings that use multi-layer technology, which tends to be more \n",
            "unpredictable and less stable, with  electrospinning it is possible to blend \n",
            "various functional mate rials simultaneously to produce an all -in-one \n",
            "wound dressing.  Use of electrospinning to produce biomimetic \n",
            "nanofibrous structures with good cell conductivity can enhance blood and \n",
            "tissue compatibility, which facil itates wound healing and tissue \n",
            "regeneration and provide scar-free healing (22, 23, 24). \n",
            "ANTIBACTERIAL PROPORTIES of NFs \n",
            "Microbes on the human skin are divided into three general \n",
            "categories: pathogens, potential pathogens, an d harmless symbiotic \n",
            "organisms (25, 26).  Bacteria are one of these cutaneous microbes. Normal \n",
            "bacteria that are commonly found on the skin include  Staphylococcus \n",
            "epidermidis, corynebacterium, propionibacterium, \n",
            "occasionally Staphylococcus aureus, and peptostreptococcus species (27). \n",
            "Some of the aforementioned cutaneous bacteria, which are known as \n",
            "opportunistic pathogens, can become pathogenic when the human immune \n",
            "system is weakened, or when there are concurrent infections and illnesses \n",
            "such as cancer. They can infect the human body and cause many diseases \n",
            "(25, 28). \n",
            "When the human skin barrier is removed or damaged, chances of \n",
            "more serious infections and issues increase (25). Usually, the polymers \n",
            "used for fabricating antibacterial nanofibers possess inherent abilities such \n",
            "as non -toxicity, goodmechanical properties, biocompatibility and \n",
            "biodegradability including PCL, PLA, PLGA, PVA and chitosan. The \n",
            "common antibacterialmaterials such as antibiotics, triclosan, \n",
            "chlorhexidine, quaternary ammonium compounds (QACs), biguanides, \n",
            "silver nanoparticles, and metal oxide nanoparticles have been reported to \n",
            "be used in fabricating antibacterial nanofibers (6). \n",
            "Sohrabi A. et al used ampicillin incorporated PMMA (polymethyl \n",
            "methacrylate)–nylon6 core/shell fibers were fabricated utilizing the coaxial \n",
            "electrospinning technique for investigate these materials antibacterial \n",
            "activity in gram-positive Listeria innocua . They confirmed their fibers\n",
            "92 \n",
            "2.1. EFFECT OF MATERNAL OBESITY ON \n",
            "HYPERTENSIVE DISEASES \n",
            "It has been suggested that hypertensive disorders are  the most \n",
            "common medical problems complicating pregnancy in developing and \n",
            "developed countries, and cause significant morbidity and mortality in \n",
            "mother, fetus and newborn, and hypertensive disorders are seen in \n",
            "approximately 10% of pregnancies worldwide (11). Previously, 30 mmHg \n",
            "systolic blood pressure (SBP) increase or 15 mmHg diastolic blood \n",
            "pressure (DBP) increase were included in the definition of hypertension \n",
            "(HT) in pregnant women, but it was no longer defined since it was found \n",
            "that it had no effect on prognosis (6). However, these pregnant women \n",
            "were followed up more closely in terms of the possibility of developing \n",
            "hypertension (HT). High blood pressure is a symptom and has been the \n",
            "result of different pathogenesis. Accordingly, its effect on the mo ther and \n",
            "fetus was also different. In addition, hypertension during pregnancy has \n",
            "varied from mild high blood pressure to severe high blood pressure causing \n",
            "multiorgan dysfunction. \n",
            "HT can be present before pregnancy as well as detected during \n",
            "pregnancy for  the first time. In some, it becomes evident only in the \n",
            "intrapartum or postpartum period. Classification is extremely important in \n",
            "terms of prognosis, management and determination of maternal fetal risks. \n",
            "The National High Blood Pressure Education Program  (NHBPEP) made \n",
            "the following classification in 2000 (34): \n",
            "1. Preeclampsia-eclampsia \n",
            "2. Chronic hypertension \n",
            "3. Preeclampsia combined with chronic hypertension \n",
            "4.Gestational hypertension \n",
            "Preeclampsia-Eclampsia: It was defined as de novo hypertension \n",
            "accompanied by proteinuria, which emerged after 20 weeks of gestation. \n",
            "Hypertension blood pressure was found to be above 140/90 mmHg in at \n",
            "least two measurements. Proteinuria is defined as 300 mg protein leakage \n",
            "in 24-hour urine. Since edema, which was included in the old definition, is \n",
            "nonspecific and is seen in most normotensive pregnant women, it has not \n",
            "been included in the new definition. It has been said that preeclampsia is \n",
            "not severe if there is no target orga n damage. The definition of severe \n",
            "preeclampsia is defined as excessive elevation in blood pressure or target \n",
            "organ damage. \n",
            "Chronic Hypertension: Known to be present before pregnancy. \n",
            "It was detected before or before the 20th week of pregnancy. In the firs t \n",
            "half of the pregnancy, despite the increase in intravascular and \n",
            "extravascular volume as well as the increase in cardiac output and\n",
            "124 \n",
            "Placenta is an organ that clinicians and pathologists do not \n",
            "generally show the required interest in. The fact t hat the number of \n",
            "placentas is high and that majority do not contain any pathology in addition \n",
            "to the lack of any relation between various placenta pathologies and \n",
            "perinatal mortality and morbidity have resulted in clinicians and \n",
            "pathologists to not evaluate the placenta sufficiently23. \n",
            "The Nicotinic acetylcholine receptor  (nAChR) expression in the \n",
            "placenta of pregnant women who are smokers and who have preeclampsia \n",
            "were examined immunohistochemically as a result of which it was \n",
            "determined in various histopathological studies in literature as well as in \n",
            "the study published by Machaa lani R et al. in 2018 that the cells in the \n",
            "decidua and the villuses, external villouses at the trophoblast are stained \n",
            "positively24. Reijnders IF et al. published a study in 2018 in which they \n",
            "evaluated 82 studies on the impact and function of maternal lif e style on \n",
            "the biomarkers and clinical characteristics of placenta development as well \n",
            "as function.  Findings of these studies have indicated that smoking in \n",
            "pregnancy affects the lower first trimester placental vascularization flow \n",
            "index, that the uterine  and umbilical arteries are more resistant in the \n",
            "second and third trimesters and that the middle cerebral arterial resistance \n",
            "is lower. Even though it was expected to determine that smoking has a \n",
            "negative impact on placenta weight, the result was not that  definitive25. \n",
            "Zhao F et al. Published a study in 2018 in which the protective effects of \n",
            "hydrogen sulfide were examined rather than the impacts of smoking during \n",
            "pregnancy. The protective effects of hydrogen sulfide against oxidative \n",
            "damage on the placenta throughout the pregnancy were evaluated. In \n",
            "addition to the  reactive oxygen species  (ROS), total antioxidant \n",
            "capacity  (T-AOC) and  Glutathione (GSH) levels, superoxide dismutase 1 \n",
            "(SOD1), superoxide dismutase 2 (SOD2), catalase (CAT) and gluta- thione \n",
            "peroxidase ( GPx) activities were examined. Nuclear factor erythroid 2 \n",
            "related factor 2 (Nrf2) was analyzed via immunohistochemical staining. \n",
            "Moreover, realtime PCR and Western Blot applications were also included. \n",
            "In the light of all these findings, it was thought that the protective effect of \n",
            "H2S on the placenta in cases of exposure to cigarette is due most probably \n",
            "to the decrease of the imbalance in the Nrf2 pathway26. Heidari Z et al. \n",
            "published a study in 2018 in which they examined the placenta tissues \n",
            "according to Cavalieri’s point counting method. Statistical analysis was \n",
            "carried out in the method secti on after applying Masson’s Trichrome \n",
            "staining and a statistically significant difference was observed. While a \n",
            "significant difference was determined between the placenta weights of \n",
            "smoker and non -smoker groups in the findings section, statistically \n",
            "significant differences were observed between the total volume in the \n",
            "placenta, intervillous gaps, fibrine and syncytiotrophoblasts (p<0.05) 27. \n",
            "Based on the histopathological findings, a statistically significant increase \n",
            "was also observed in our study in fibrinoid deposits in the intravillous and\n",
            "28 \n",
            "of anti-VEGF aflibercept in combination with the FOLFIRI (folinic acid, \n",
            "fluorouracil, and irinotecan) regimen was investigated in metastatic \n",
            "colorectal cancer (NCT02129257). The regimen was found to be tolerable. \n",
            "However, 6 months of first-line treatment with FOLFIRI + aflibercept was \n",
            "followed by aflibercept without accompanying anti-HIF1α treatment and a \n",
            "substantial increase in efficacy has not been detected 26. \n",
            "2b. PI3K/AKT/mTOR Pathway Inhibitors \n",
            "PI3K/AKT/mTOR pathway is an important intracellular signaling \n",
            "pathways that induces cell proliferation, migration, and tumor progression. \n",
            "Several anticancer drugs that inhibit this pathway at distinct molecular \n",
            "levels have been used or being tested in chemotherapy of several cancers. \n",
            "Rapamycin (sirolimus) is the first agent discovered among these, which \n",
            "gives its name to the mTOR protein, the mammalian target of rapamycin \n",
            "27. Rapamycin analogs (rapalogs), temsirolimus and everolimus are first \n",
            "approved for the treatment of advanced renal car cinoma and have been \n",
            "tested in preclinical and clinical studies for the treatment of several other \n",
            "cancers 28. Besides their primary action on inhibition of cell proliferation \n",
            "and migration, rapalogs also downregulate HIF-1α since \n",
            "PI3K/AKT/mTOR pathway is a positive regulator of  HIF-1α expression \n",
            "14,17. Due to this action, rapalogs have been started to be tested clinically in \n",
            "combination with other chemotherapeutics and anti-angiogenic agents.  \n",
            "A phase I study started in 2010  to determine maximum tolerated \n",
            "dose of everolimus (RAD001), in combination with capecitabine and \n",
            "oxaliplatin (XELOX) regimen in patients with advanced gastric  cancer \n",
            "(NCT01049620). The same year, another clinical trial started to determine \n",
            "safety of evero limus and its efficacy in combination with FOLFOX and \n",
            "bevacizumab in the first -line treatment of colorectal cancer \n",
            "(NCT01047293). The combination exhibited a tolerable profile and fair \n",
            "efficacy 29.  Combination of everolimus with sorafenib, which is an anti -\n",
            "tumorigenic and anti -angiogenic agent due to its multi -kinase inhibitor \n",
            "action, was tested in a Phase I -II study for advanced so lid tumors. \n",
            "However, the study was suspended early due to toxicity (NCT01226056). \n",
            "Combination of rapamycin and irinotecan has also been tested in refractory \n",
            "solid tumors in children for the synergistic effect in inhibition of \n",
            "angiogenesis and suppression of HIF-1α (NCT01282697, no results \n",
            "posted).  \n",
            "Perifosine is a multitarget tyrosine kinase inhibitor that has AKT \n",
            "inhibitor activity. It has been extensively tested as a single agent or \n",
            "combination in several different cancers in tens of different clinical trials \n",
            "(e.g., NCT00398879, NCT01048580, NCT00398814, NCT00060437, \n",
            "NCT00873457, NCT02238496  and NCT02238496). Due to AKT \n",
            "inhibitory action, perifosine downregulates HIF-1α 16. However, this action\n",
            "50 \n",
            "react with fibrinogen, resulting in high sensitivity and specificity of the \n",
            "test. ELISA can measure prothrombin fragments 1 and 2 (F1 + 2), \n",
            "thrombin-antithrombin complex (TAT), beta -thromboglobulin, and PF 4  \n",
            "to assess hypercoagulability in research laboratories. However, these \n",
            "assays are generally not accepted for evaluating a bleeding patient or a \n",
            "patient with thrombotic disorders. Thromboelastograp hy (TEG) is a \n",
            "method used to measure the effectiveness of blood coagulation. Although \n",
            "it is used more and more in emergency departments, intensive care units, \n",
            "and resuscitation in delivery rooms, it mainly comes to the fore in surgery \n",
            "and anesthesiology. TEG can also evaluate platelet function, clot strength, \n",
            "and fibrinolysis in addition to known coagulation tests. \n",
            "Thromboelastometry (TEM), previously known as rotational \n",
            "thromboelastography (ROTEG) or rotational thromboelastometry \n",
            "(ROTEM), is a different TE G modeling in which the rotating TEG is the \n",
            "sensor shaft instead of the container. \n",
            "COAGULATION DISORDERS  \n",
            "Laboratory tests are essential for diagnosing coagulation disorders. \n",
            "However, there are no standardized panels required for accurate diagnosis, \n",
            "and measurements can differ significantly between laboratories. Routine \n",
            "laboratory tests for coagulation disorders include platelet count, \n",
            "prothrombin time (PT), partial thromboplastin time (aPTT), international \n",
            "normalized ratio (INR), and bleeding time. Platelets should have not only \n",
            "sufficient quantity but also be functional. Bleeding time evaluates the \n",
            "function of platelets. Bleeding times may increase in VWF deficiency or \n",
            "antithrombotic substance use (NSAID, aspirin, and valproic acid). PT \n",
            "shows the function of factors II, V, VII, and X, which are vitamin K -\n",
            "dependent factors synthesized from the liver. Drugs that reduce the \n",
            "synthesis of vitamin K, such as warfarin, will cause an increase in PT and \n",
            "INR values. INR is a ratio used to predict the percentage of ac tive \n",
            "coagulation factors. For example, an INR of 2 to 3 means about 10% \n",
            "clotting factor activity. This activity should be at least 30% for standard \n",
            "coagulation. Partial thromboplastin time evaluates the von Willebrand \n",
            "factor's activity and factors VIII, IX, XI, and XII. Hemophilia patients have \n",
            "regular PT / INR, bleeding time, and thrombocyte count despite high aPTT. \n",
            "Low FVIII levels will cause prolonged aPTT values through the intrinsic \n",
            "pathway. An elevated aPTT requires investigation of factors VIII and I X. \n",
            "When evaluating the established factor levels, the amount of factor s \n",
            "present will determine the disease's severity and prognosis. When \n",
            "prolonged aPTT values raise clinical suspicion, the focus should be on the \n",
            "mother's entire family history, especially the first -degree male relatives. \n",
            "Diagnosis of von Willebrand disease is made with increased bleeding time \n",
            "and decreased vWF levels in ristocetin cofactor analysis, in addition to \n",
            "bleeding history and family history. Since vWF levels are affected by intra-\n",
            "5 \n",
            "    \n",
            "Figure 2: Diagrammatic illustration to high light the practical applications \n",
            "of E-spun NFs. (Thenmozhi, S., Dharmaraj, N., Kadirvelu, K., & Kim, H. \n",
            "Y. (2017). Electrospun nanofibers: New generation materials for advanced \n",
            "applications. Materials Science and Engineering: B, 217, 36-48.) \n",
            "NANOFIBERS (NFs) on WOUND HEALING \n",
            "Many tissues in the human body do not have sufficient \n",
            "regenerative capacity, so damage to these tissues is irreversible. In addition \n",
            "to poor healing ability, injuries to tissues such as nerves, tendons, cartilage, \n",
            "and myocardium also cause severe pain and disability. At the end of the \n",
            "healing process that is completed after the injuries, especially the formation \n",
            "of scar tissue on the skin; It is a difficult situation to overcome both in \n",
            "terms of reducing the quality of life and cosmetics. Even with surgery, the \n",
            "return of function is often limited, a nd the healing response is scar \n",
            "mediated rather than regenerative (7, 21). Patients with organ trauma, \n",
            "disease, or congenital abnormalities should rely on organ transplantation \n",
            "to regain function. Despite its tremendous clinical success, this approach \n",
            "grapples with post-surgical immune reactions and severe limitations in the \n",
            "number of donors available, leaving thousands of patients on waiting lists. \n",
            "These limitations of organ transplantation have pushed researchers to find \n",
            "solutions in different areas for decades. \n",
            "WOUND DRESSER PROPORTIES of NFs \n",
            "When the advantages and disadvantages of wound dressings are \n",
            "evaluated; A good dressing must have some distinctive features.  Wound\n",
            "15 \n",
            "ischemia / reperfusion procedures of experimental studies and agents used \n",
            "for treatment is presented in the Table 2. \n",
            "BIOCHEMICAL PARAMETERS \n",
            "Ischemic damage, which is caused by a drop in adnexal \n",
            "circulation, is one possible cause of adnexal injury resulting from torsion. \n",
            "Levels of lactic acid, hypoxanthine, and lip id peroxide in the tissues \n",
            "increase because of the hypoxia that is caused by this decreased blood flow \n",
            "(5). Removing the cause of ischemia and restoring the tissue blood supply \n",
            "(reperfusion/detosion) are significant procedures, unavoidable in cases of \n",
            "ischemia. During reperfusion, however, the return of oxygenated blood \n",
            "starts a reaction that can cause even more damage to the tissue. Reperfusion \n",
            "injury starts with the formation of reactive oxygen species, triggering a \n",
            "series of events (24). \n",
            "Among all possible pathological mechanisms of ischemia -\n",
            "reperfusion injury, free radical damage (mainly oxidative/nitrosative stress \n",
            "injury) has been found to play a key role in the process. Free radicals lead \n",
            "to protein dysfunction, DNA damage, and lipid peroxidatio n, resulting in \n",
            "cell death. Free radicals are divided into two main groups: reactive oxygen \n",
            "species (ROS) and reactive nitrogen species (RNS). ROS and RNS play \n",
            "key roles in many pathological processes during ischemia reperfusion. \n",
            "Currently, free radicals’ toxicity in ischemia -reperfusion injury is being \n",
            "intensively studied (25). Lipidoxidation results in the production of toxic \n",
            "substances, includingmalondialdehyde (MDA). MDA, a marker of tissue \n",
            "injury, is a secondary product of oxidative damage formed durin g \n",
            "lipidperoxidation (26, 27) . MDA disrupts ionic transport and \n",
            "enzymaticactivity, severely modifying cell membrane permeability and \n",
            "flu-idity to cause discontinuities and breaks that separate cel ls and \n",
            "organelle contents (7). For this reason, MDA has been chosen as the basic \n",
            "biochemical parameter among many studies we have examined in this \n",
            "review. \n",
            "The cells are protected against ROS damage by various ways \n",
            "such as scavenging enzyme systems including Catalase which converts \n",
            "hydrogen peroxide into hydrogen oxide (water) and superoxide dismutase \n",
            "(SOD). SOD catalyzes the partitioning of the superoxide (O2_) radical into \n",
            "either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2). \n",
            "Superoxide is produced as a by-product of oxygen metabolism. It needs to \n",
            "be re gulated; otherwise it causes many types of cell damage. Lipid \n",
            "peroxidation which plays a role in decreased binding of hypothalamic \n",
            "hormones to their receptors causes a decline in antioxidant systems (28). \n",
            "The concentrations of the metabolic intermediates o f ROS are \n",
            "kept under strict control by a complex defense system that includes \n",
            "enzymes such as superoxide dismutase (SOD), catalase (CAT), and\n",
            "90 \n",
            "every 5-7 kg / m2 increase in body mass index in pregnant women (96). \n",
            "Again, when compared with obese and normal body weight women, it was \n",
            "found that triglyceride, very small density lipoprotein, insulin and leptin \n",
            "levels were higher in obese pregnant women (97). It has been concluded \n",
            "that obese women, especially in the postpartum period, breastfeed less than \n",
            "those of normal weight (98). \n",
            "It is clear that maternal obesity increases a number of serious \n",
            "problems such as gestational diabetes, hypertension, preeclapse and eclipse \n",
            "during pregnancy, as it is associated with short and long -term \n",
            "complications in the mother and newborn at the end of pregnancy, delivery \n",
            "and postpartum. \n",
            "2. MATERNAL OBESITY \n",
            "The alarming increase in the prevalence of obesity worldwide has \n",
            "explained the importance of the World Health Organization (WHO) \n",
            "considering obesity as one of the most se rious global health problems of \n",
            "the 21st century (50). WHO defined obesity and obesity as abnormal or \n",
            "excessive fat accumulation that harm health and stated that the prevalence \n",
            "of obesity during pregnancy is between 1.8% and 25.3% (25). \n",
            "The Center for Disease Control (The Center for Disease Control) \n",
            "stated that the prevalence of obesity in pregnant women mirrors obesity in \n",
            "women of reproductive age (42); stated that 25% of women of childbearing \n",
            "age are obese and 25% of them are obese especially in the USA a nd \n",
            "maternal obesity is a major risk factor for maternal and perinatal mortality \n",
            "(40). \n",
            "It was found that the mother who was overweight and obese during \n",
            "pregnancy and at birth was at significant risk in terms of antenatal, \n",
            "intapartum, postpartum and neonatal  complications ( 25). Among the \n",
            "prenatal complications; It has also been determined that recurrent \n",
            "miscarriages, congenital anomalies cause pregnancy -induced \n",
            "hypertension, preeclampsia, gestational diabetes mellitus (GDM) and \n",
            "venous thromboembolism (29). The risk of induction and cesarean section \n",
            "increases in obese and obese mothers and it has been stated that the babies \n",
            "of these mothers are mostly macrosomic and stay in the hospital for a \n",
            "longer time (1).  \n",
            "It has been emphasized that obesity is a strong ris k factor for \n",
            "gestational diabetes (35) and is effective in the development of diabetes, \n",
            "cardiovascular disease and hypertension in the following years (30). \n",
            "The Royal Collage of Obstetricios and Gynecologist (2004) \n",
            "emphasizes that those with prenatal and postnatal BMI over 30 or body \n",
            "weight over 90 kg carry a significant risk for postpartum troboembolic\n",
            "17 \n",
            "A healthy evaluation of these histopathological cha nges is only \n",
            "possible with a semiquantitative scoring. A semiquantitative histological \n",
            "evaluation scoring system was used to determine histopathological \n",
            "changes. These parameterswere evaluated after scoring each individual \n",
            "criterion between 0 and 3. The cr iteria that were used to evaluate for \n",
            "ovarian injury were follicular cell degeneration, vascular congestion, \n",
            "hemorrhage, and infiltration by inflammatory cells. Each specimen was \n",
            "scored using a scale ranging from 0 to 3 (0: none; 1: mild; 2: moderate; 3: \n",
            "severe) for each criterion (35).  \n",
            "When the other strategy is examined, it is seen that the scoring is \n",
            "done as follows. Five microscopy fields were used to determine the \n",
            "presence or severity of tissue damage. The scoring system used for \n",
            "histopathologic evaluation of the ovarian tissues was the same as in Sagsöz \n",
            "et al (6). According to this system, congestion (vascular dilation), \n",
            "hemorrhage, and interstitial edema were scored from 0 to 3 according to \n",
            "their severity: 0 represented no pathologic findings; and 1,  2, and 3 \n",
            "represented pathologic findings of less than 25%, 25%  to 75%, and more \n",
            "than 75% of the ovarian section, respectively. The total tissue damage \n",
            "scores were calculated by adding the scores for each parameter, and the \n",
            "total tissue damage scores were calculated between 0 and 9 for each ovary. \n",
            "Examination and scoring of the ovarian sections were performed in a \n",
            "blinded fashion by the same pathologist (8 , 37). A healthy evaluation of \n",
            "these histopathological changes is only possible with a semiquantitativ e \n",
            "scoring. In the experimental studies reviewed in this review, the use of \n",
            "scoring system for histopathological changes is about 37%. Apart from \n",
            "studies using hematoxylin eosin staining, there are also studies evaluating \n",
            "immunohistochemical parameters, but they are in a minority ( 13, 18, 38, \n",
            "39).  \n",
            "DISCUSSION \n",
            "Ischaemia-Reperfusion injury (IRI) is defined as the paradoxical \n",
            "exacerbation of cellular dysfunction and death, following restoration of \n",
            "blood flow to previously ischaemic tissues. Reestablishment of blood flow \n",
            "is essential to salvage ischaemic tissues. However reperfusion itself \n",
            "paradoxically causes further damage, threatening function and viability of \n",
            "the organ. IRI occurs in a wide range of organs including the heart, lung, \n",
            "kidney, gut, skeletal mus cle and brain and may involve not only the \n",
            "ischaemic organ itself but may also induce systemic damage to distant \n",
            "organs (34). Medical therapies such as anti-inflammatory and antioxidant \n",
            "free radical scavengers directed toward the mediators responsible for \n",
            "ischemic damage may be used to prevent tissue damage and irreversible \n",
            "changes (5). This was observed through a reduction in oxidative stress, an \n",
            "increase in antioxidant enzymes, and less histopathologic damage. These \n",
            "results agree with earlier experimental  models showing that oxidative\n",
            "61 \n",
            " \n",
            "Figure 2: Schaffer test. (Thidar, A. M., Myint, T. T., Naing, D. K. S., & \n",
            "Mustapha, Z. A. (2013). Palmaris Longus Agenesis (PLA) among Dusun \n",
            "and Bajau ethnic groups of Northern Borneo. International Journal of \n",
            "Collaborative Research on Internal Medicine & Public Health, 5(6), 0-\n",
            "0.) \n",
            " \n",
            "Figure 3: Thompson test. (Thidar, A. M., Myint, T. T., Naing, D. K. S., \n",
            "& Mustapha, Z. A. (2013). Palmaris Longus Agenesis (PLA) among \n",
            "Dusun and Bajau ethnic groups of Northern Borneo. International \n",
            "Journal of Collaborative Research on Internal Medicine & Public \n",
            "Health, 5(6), 0-0.)\n",
            "75 \n",
            "recent years  52. The  view that drugs such as ACEI/ ARBs such as \n",
            "telmisartan, ramipril, captopril and losartan should reduce these harmful \n",
            "effects and be seen as treatment targets for ED 53–55. \n",
            "3.3.3. Endothelin and Adrenergic receptors \n",
            "Downregulation of ETA receptor expression or activity of \n",
            "Endothelin (ET-1) synthesized by the vascular endothelium in the penis \n",
            "is potentially effective in alleviating ED 26. Studies with drugs such as \n",
            "tamsulosin, doxazosin, and alfuzosin have shown that α -adrenergic \n",
            "blockade is effective in the ED treatment  56. \n",
            "3.3.4. Transient receptor potential (TRP) channels and Store \n",
            "operated calcium entry \n",
            "Intracellular Ca 2+ is playing an important role in modulating \n",
            "levels of TRP channels (TRPC6) are see n as a new molecular target for \n",
            "ED therapy 57. Recently, transfer of dominant negative genes for 2 \n",
            "proteins, named OR AI1 and STIM1 identified in cavernous smooth \n",
            "muscle cells has been shown to restore erectile function in diabetic rats \n",
            "and is seen as a new treatment target for ED 58. \n",
            "3.4. Anti-inflammatory and anti-fibrotic treatment targets \n",
            "This pathway is directed towards the pre vention of collagen \n",
            "accumulation and smooth muscle cell loss in CC  59. Upregulation of the \n",
            "TGF-β1/Smad pathway by inducing fibrous-muscle structural changes 60; \n",
            "inhibition of Poly (adenosine diphosphate ribose) polymerase (PARP), \n",
            "which is important for DNA re pair, by increasing NO -mediated \n",
            "relaxation 61; by suppressing IL -6, a pleiotropic cytokine 62. It has been \n",
            "shown to improve erectile function. \n",
            "3.5. Centrally acting drug targets \n",
            "Positive results have been developed in cli nical trials with \n",
            "centrally acting drugs such as dopamine receptor agonists and \n",
            "melanocortin receptor agonists. Apomorphine, a centrally -acting non -\n",
            "opioid dopaminergic agonist, induces penile vascular and corporal \n",
            "smooth muscle relaxation, through the acti vation of the receptors D1 and \n",
            "D2 in the MPOA (Medial Preoptic area) and PVN  (Paraventricular \n",
            "nucleus of  hypothalamus) regions, which maintain the activation of \n",
            "central neurogenic pathways in erection 63. \n",
            "Melanocortins such as m elanocyte-stimulating hormone ( MSH) \n",
            "and adrenocorticotropic hormone (ACTH) are involved in important \n",
            "homeostatic mechanisms controlled by the hypothalamus as well as \n",
            "sexual functions such as penile erection and sexual motivation 63. \n",
            "Melanocortins act on dopaminergic neurons located in the pro -erectile\n",
            "30 \n",
            "best of our knowledge, there is no registered clinical trial for ENMD-1198 \n",
            "in clinicaltrials.gov yet.  \n",
            "3. Drugs That Destabilize HIF-1α \n",
            "3a. Geldanamycin and Its Derivatives \n",
            "Geldanamycin and its derivatives are a nsamycin antibiotics with \n",
            "anti-cancer activity. They inhibit heat shock protein 90 (HSP90), leading \n",
            "to degradation of its targets which regulate the activity of several \n",
            "intracellular pathways 37. Geldanamycin and its derivative 17AAG (17-\n",
            "allylamino 17-demethoxygeldanamycin) or tanespimycin have been tested \n",
            "in clinical trials for the treatment of several cancers since the beginning of \n",
            "2000’s (e.g., NCT00003969, NCT00058253, NCT00093405, \n",
            "NCT00119236, NCT00004065, NCT00019708, NCT00093821, \n",
            "NCT00087386, and  NCT00319930). Since HSP90 takes part in the \n",
            "stabilization of HIF -1α, this makes it an important target to induce \n",
            "destabilization and degradation of HIF -1α. With the emphasis on this \n",
            "mechanism, efficacy of 17AAG was evaluated in VHL disease and renal \n",
            "tumors in a phase II trial started in 2004 (NCT00088374). The study could \n",
            "not achieve accrual goals. However, the evidence that point out to the \n",
            "potential of geldanamycin and its derivatives in cancer th erapy is \n",
            "growing38,39.  \n",
            "3b. Histone Deacetylase Inhibitors \n",
            "Histone deacetyla ses (HDAC) play important roles in epigenetic \n",
            "regulation of genes associated with cancer. HDAC inhibitors were \n",
            "approved for the treatment of several cancers such as lymphoma and \n",
            "multiple myeloma. They show antitumor effect by inducing cell cycle \n",
            "arrest, apoptosis, and anti-angiogenic response 40. HDAC is also important \n",
            "for the acetylation of HIF -1α/p300 complex and therefore HDAC \n",
            "inhibitors lead to destabilization of HIF-1α 41. Among the HDAC inhibitors \n",
            "romidepsin come forward with this action and there are more than 20 \n",
            "different active clinical trials that assess romidepsin in the treatment of \n",
            "lymphoma and several other cancers (e.g., NCT02512172, NCT04257448, \n",
            "NCT01947140, NCT01755975, and NCT01638533). \n",
            "4. Inhibitors of HIF-1/DNA Binding \n",
            "4a.   Anthracyclines \n",
            "Anthracyclines are among the most widely used and most potent \n",
            "chemotherapeutics in cancer therapy today. They show anti -tumor action \n",
            "by binding to DNA and inhibiting the progression of topoisomerase II  \n",
            "enzyme 42. They also inhibit binding of HIF-1 to DNA. Hence, they inhibit \n",
            "the expression of HIF -1α regulated genes 43,44. Even though they are \n",
            "already in use in the treatment of several cancers, their anti-HIF action may\n",
            "51 \n",
            "individual variation, stress, pregnancy, exercise, and inflammatory \n",
            "processes, the test should be repeated three times before making a \n",
            "diagnosis. It can affect gender and blood type levels. Factor multimer tests \n",
            "may be required to diagnose the specific subtype of the disease. Also, aPTT \n",
            "can be slightly elevated at second to low factor VIII levels in about 50% of \n",
            "patients with von Willebrand disease.  \n",
            "Disseminated intravascular coagulation (DIC) is a \n",
            "clinicobiological syndrome defined by excessive clotting activation \n",
            "leading to the accumulation of fibrin into the vessel, organ d isorders, \n",
            "excessive consumption of coagulation factors and platelets, and bleeding \n",
            "that can be fatal. DIC can be triggered by different clinical conditions \n",
            "(sepsis, cancer, trauma, and pregnancy complicated by eclampsia or other \n",
            "diseases). Elimination of t he activation factor and the destruction of the \n",
            "trigger mechanism are the main therapeutic approaches. DIC -specific \n",
            "treatment strategies aim to limit the activation of blood clotting and the risk \n",
            "of bleeding. Fibrin formation is accompanied by plasminogen activator \n",
            "inhibitor 1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), and \n",
            "fibrinolysis activation due to comorbid diseases and clinical conditions. If \n",
            "fibrinolysis does not occur at the required level, fibrin accumulation will \n",
            "cause diffuse bl ockages in the microvascular system. Microvascular \n",
            "thrombosis, together with hemodynamic and metabolic disorders, can lead \n",
            "to multiple organ failure. It may have clinical consequences in organ \n",
            "failure, renal failure, respiratory failure, hypotension, circu latory failure, \n",
            "or impaired brain function. Besides, intravascular coagulation activation \n",
            "may contribute to macrovascular thrombus formation, leading to venous or \n",
            "arterial thrombus and embolization. Diagnostic criteria include:  \n",
            "-Presence of additional disease that may predispose to DIC, \n",
            "-Clinical signs (bleeding or organ dysfunction) \n",
            "-Laboratory tests (platelet count, PT, fibrinogen, and \n",
            "fibrin/fibrinogen degradation products [FDPs]) \n",
            "Rapidly evolving DIC results in severe thrombocytopenia, \n",
            "prolonged PT and PTT, rapidly decreasing plasma fibrinogen levels, and \n",
            "elevated plasma D-dimer levels. \n",
            "Preanalytical requirements  for routine coagulation \n",
            "measurements \n",
            "Blue-capped tubes with a citrate concentration of 105-109 mmol / \n",
            "L (3.2%) are recommended for coagulation tests. Laboratory professionals \n",
            "should keep in mind that there may be a reference range difference \n",
            "depending on the citrate concentration in the same method and correct \n",
            "reference ranges. In ensuring the correct blood/anticoagulant ratio, care \n",
            "should be ta ken to ensure that the blood amount corresponds to the tube\n",
            "CHAPTER I \n",
            " \n",
            "A BIOMEDICAL TREASURE: NANOFIBERS IN WOUND \n",
            "HEALING \n",
            " \n",
            "Gülce Naz Yazıcı1 & Mukadder Sunar2 \n",
            "1(Asst. Prof, PhD) Erzincan Binali Yıldırım University,   \n",
            "e-mail: gulcenazyazici.ank@gmail.com \n",
            "                      0000-0002-6989-997X \n",
            "2(Asst. Prof, PhD) Binali Yıldırım University, e-mail: mukaddersunar@gmail.com \n",
            "                   0000-0002-6744-3848 \n",
            " \n",
            " \n",
            "INTRODUCTION \n",
            "The skin that covers the body from the outside, protects against \n",
            "external-environmental factors and has the largest surface;  It is also very \n",
            "prone to damage. The most important function of healthy skin is to provide \n",
            "homostasis. It acts as a barrier for exogenous substances, chemicals, \n",
            "moisture loss and pathogens. It is vitally important to quickly and \n",
            "effectively recycle any damage that may occur in the skin. \n",
            "Wound is the deterioration of normal anatomical structure and \n",
            "functional integrity. Skin; It can be damaged by the effect of many harmful \n",
            "stimuli such as trauma, surgical applications, heat, cold, radiation, \n",
            "infection and n eoplasia. In the event of injury, a complex healing and \n",
            "regeneration process occurs in the skin. The healing process firstly aims to \n",
            "restore homeostasis and within the framework of this process; It covers the \n",
            "steps of blood coagulation, inflammation, epith elium regeneration, \n",
            "granulation tissue and tissue reconstruction. \n",
            "Normal wound healing takes place through the regular and \n",
            "sequential work of many cellular and biochemical functions. Under normal \n",
            "circumstances, these steps result in repairing the damage to the injured skin \n",
            "area. However, as a result of damage repair, a permanent scar formation \n",
            "occurs in the healing area. Scar tissue, unlike normal tissue; It is a texture \n",
            "that does not contain any leather additions and has lost its appearance - \n",
            "elasticity. While wound healing continues rapidly and regularly in healthy \n",
            "individuals, it is delayed in cases such as age, infection, diabetes, use of \n",
            "systemic steroids and cancer treatment. In these cases, chronic and \n",
            "incomplete healing ulcers may occur by disrupting the healing process (1, \n",
            "2, 3). The aim of topical and systemic applications used to prevent this is\n",
            "84 \n",
            "systematic review on rho -kinase as a potential therapeutic target \n",
            "for the treatment of erectile dysfunction. Research and Reports in \n",
            "Urology. 2020;12:261-272. doi:10.2147/RRU.S255743 \n",
            "50.  Uvin P, Albersen M, Bollen I, et al. Additive effects of the Rho \n",
            "kinase inhibitor Y -27632 and vardenafil on relaxation of the \n",
            "corpus cavernosum tissue of p atients with erectile dysfunction \n",
            "and clinical phosphodiesterase type 5 inhibitor failure. BJU \n",
            "International. 2017;119(2):325-332. doi:10.1111/bju.13691 \n",
            "51.  Jin LM. Angiotensin II signaling and its implication in erectile \n",
            "dysfunction. In: Journal of Sexua l Medicine . Vol 6. Blackwell \n",
            "Publishing Ltd; 2009:302 -310. doi:10.1111/j.1743 -\n",
            "6109.2008.01188.x \n",
            "52.  Fraga-Silva RA, Montecucco F, Mach F, Santos RAS, Stergiopulos \n",
            "N. Pathophysiological role of the renin -angiotensin system on \n",
            "erectile dysfunction. European Journal of Clinical Investigation . \n",
            "2013;43(9):978-985. doi:10.1111/eci.12117 \n",
            "53.  Schlimmer N, Kratz M, Böhm M, Baumhäkel M. Telmisartan, \n",
            "ramipril and their combination improve endothelial function in \n",
            "different tissues in a murine model of cholesterol -induced \n",
            "atherosclerosis. British Journal of Pharmacology . \n",
            "2011;163(4):804-814. doi:10.1111/j.1476-5381.2011.01267.x \n",
            "54.  Kilarkaje N, Yousif MHM, El -Hashim AZ, Makki B, Akhtar S, \n",
            "Benter IF. Role of angiotensin II and angiotensin -(1-7) in \n",
            "diabetes-induced oxid ative DNA damage in the corpus \n",
            "cavernosum. Fertility and Sterility . 2013;100(1):226 -233. \n",
            "doi:10.1016/j.fertnstert.2013.02.046 \n",
            "55.  Chen Y, Cui S, Lin H, et al. Losartan improves erectile dysfunction \n",
            "in diabetic patients: A clinical trial. International Jou rnal of \n",
            "Impotence Research. 2012;24(6):217-220. doi:10.1038/ijir.2012.4 \n",
            "56.  Jo HW, Yoo DS, Ju HT, et al. Effect of Patient -Optimized Doses of \n",
            "Tamsulosin on Erectile Function in Men With Erectile \n",
            "Dysfunction and Lower Urinary Tract Symptoms. Korean Journal \n",
            "of Urology. 2013;54(2):100. doi:10.4111/kju.2013.54.2.100 \n",
            "57.  Jung JH, Kim BJ, Chae MR, et al. Gene transfer of TRPC6DN \n",
            "(Dominant negative) restores erectile function in diabetic rats. \n",
            "Journal of Sexual Medicine . 2010;7(3):1126 -1138. \n",
            "doi:10.1111/j.1743-6109.2009.01634.x \n",
            "58.  Sung HH, Kam SC, Lee JH, et al. Molecular and functional \n",
            "characterization of ORAI and STIM in human corporeal smooth\n",
            "76 \n",
            "centers of the hypothalamus, causing central and spinal oxytocin release. \n",
            "They show their effects by binding with the MC1 -R to MC5-R receptors. \n",
            "These receptors have been ide ntified in the skin, gastrointestinal tract, \n",
            "male and female reproductive system, adrenal cortex, and brain 64,65. \n",
            "Especially expressed in peripheral tissues, MC5 -R provides the \n",
            "relationship between central and peripheral control of sexual behavior 64.  \n",
            "3.6. Alternative therapy goals \n",
            "3.6.1 Herbs, Toxins and Polyphenols \n",
            "In recent years, complementary and alternative medicine has \n",
            "become increasingly popular and has been used as herbal supplements \n",
            "for ED. These plants and the  properties of active components in their \n",
            "content 66–68 and there are preclinical studies that reveal their mechanisms \n",
            "of action and significant efficacyies are promising 69–71. The mechanism \n",
            "of action of some herbs has been demonstrated by its stimulatory effect \n",
            "on the NO -cGMP signa ling pathway  71, some aphrodisiac 72 increase \n",
            "fertility and sexual function 73. It has been shown to have such effects.   \n",
            "It shows that Tx2 -6, a toxin purified from the venom of the P. \n",
            "nigriventer spider, induces erection, by activating the nNOS of the \n",
            "PnTx2-6 toxin, increasing NO production and improving vascular \n",
            "smooth muscle relaxation that animal v enoms can be potential drugs in \n",
            "ED treatment 74,75. \n",
            "There is some evidence that polyphenols, which have been \n",
            "shown to be effective in erectile dysfunction, do this by acting as \n",
            "antioxidants that improve the NO/ cGMP p athway and stimulate \n",
            "angiogenesis. Resveratrol, a polyphenol found in red wine, is reported to \n",
            "increase cGMP in corporal smooth muscle cells, activate eNOS, thereby \n",
            "improving endothelial function 76. On the other hand, Quercetin is \n",
            "beneficial on the corpus cavernosum with its anti -inflammatory, anti -\n",
            "apoptotic and antioxidant effects 77. \n",
            "3.7. Regenerative medical \n",
            "Regenerative medical especially in the last few decades has \n",
            "increased in importance, and preclinical trials have shown that growth \n",
            "factor therapy, gene transfer, stem cell therapy, and tissue engineering \n",
            "can be beneficial for the restoration of erectile function 78–81.  \n",
            "Although human growth hormone (GH) is not considered as the \n",
            "classic sex hormone, it is involved in the regulation of male reproductive \n",
            "functions and sexual maturation.  GH has physiological significance not \n",
            "only in LH and FSH secretion but also in early testosterone stimulation \n",
            "82. It is assumed that the biological effect of growth hormo ne is through \n",
            "the stimulation of endothelial NO formation mediated by \"insulin -like\n",
            "83 \n",
            "penile tissue. Journal of Sexual Medicine . 2008;5(2):336 -343. \n",
            "doi:10.1111/j.1743-6109.2007.00695.x \n",
            "40.  Hurt KJ, Sezen SF, Lagoda GF, et al. Cyclic AMP -dependent \n",
            "phosphorylation of neuronal nitric oxide synthase mediates penile \n",
            "erection. Proceedings of the National Academy of Sciences of the \n",
            "United States of America . 2012;109(41):16624 -16629. \n",
            "doi:10.1073/pnas.1213790109 \n",
            "41.  Costa P, Potempa AJ. Intraurethral alprostadil for erectile \n",
            "dysfunction: A review of the literature. Drugs. 2012;72(17):2243-\n",
            "2254. doi:10.2165/11641380-000000000-00000 \n",
            "42.  Decaluwé K, Pauwels B, Verpoest S, Van de Voorde J. New \n",
            "Therapeutic Targets for the Treatment of Erectile Dysfunction. \n",
            "Journal of Sexual Medicine . 2011;8(12):3271 -3290. \n",
            "doi:10.1111/j.1743-6109.2011.02459.x \n",
            "43.  Burian B, Ortner A, Prassl R, Zimmer A, Mosgoeller W. Clinical \n",
            "Potential of VIP by Modified Pharmaco -kinetics and Delivery \n",
            "Mechanisms. Endocrine, Metabolic & Immune Disorders -Drug \n",
            "Targets. 2012;12(4):344-350. doi:10.2174/187153012803832594 \n",
            "44.  Shukla N, Rossoni G, Hotston M, et al. Effect of hydrogen sulphide -\n",
            "donating sildenafil (ACS6) on erectile function and oxidative \n",
            "stress in rabbit isolated corpus cavernosum and in hypertensive \n",
            "rats. BJU International . 2009;103(11):1522 -1529. \n",
            "doi:10.1111/j.1464-410X.2009.08415.x \n",
            "45.  Meng J, Adaikan PG, Srilatha B. Hydrogen sulfide promotes nitric \n",
            "oxide production in corpus cavernosum by enhancing expression \n",
            "of endothelial nitric oxide synthase. International Journal of \n",
            "Impotence Research. 2013;25(3):86-90. doi:10.1038/ijir.2012.39 \n",
            "46.  Gur S, Kadowitz PJ, Hellstrom WJG. RhoA/Rho -Kinase as a \n",
            "therapeutic target for the male urogenital tract. Journal of Sexual \n",
            "Medicine. 2011;8(3):675 -687. doi:10.1111/j.1743 -\n",
            "6109.2010.02084.x \n",
            "47.  Jiang X, Chitaley K. The promise of inhibition of smooth muscle \n",
            "tone as a treatment for erectile dysfunction: Where are we now. \n",
            "International Journal of Impotence Research . 2012;24(2):49 -60. \n",
            "doi:10.1038/ijir.2011.49 \n",
            "48.  Jin L, Burnett AL. RhoA/Rho -kinase in erectile tissue: Mecha nisms \n",
            "of disease and therapeutic insights. Clinical Science . \n",
            "2006;110(2):153-165. doi:10.1042/CS20050255 \n",
            "49.  Zewdie KA, Ayza MA, Tesfaye BA, Wondafrash DZ, Berhe DF. A\n",
            "7 \n",
            "formation of the core/shell structure and the smooth surface morphology \n",
            "with TEM and SEM analysis. They design ed drug delivery system for all \n",
            "the concentrations of the encapsulated drug indicates a three stages drug \n",
            "release over a period of 31 days with a sustained manner and suppressed \n",
            "burst release, which occurred only for 6 h. Antibacterial investigations \n",
            "showed a gradual decrease in the OD (concentration of the bacteria) with \n",
            "an increase in the concentration of the encapsulated drug from 1% to 20%. \n",
            "A higher amount of drug in the fibers led to enhanced drug release after 18 \n",
            "h incubation which resulted in a higher degree of growth inhibition (29). \n",
            "Khampieng T. et al , used  electrospinning technique and post -\n",
            "spinning sorption method DOXY -h loaded -poly(acrylic acid) (PAA) \n",
            "nanofiber mats (PAA/DOXY -h nanofiber mats) at various doses: \n",
            "PAA/DOXY-h125, PAA/DOXY -h250, PAA/DOXY -h500, and \n",
            "PAA/DOXY-h1000. The morphology, drug content, release \n",
            "characteristics, and antibacterial activities of the PAA/DOXY-h nanofiber \n",
            "mats were investigated with SEM, UV–vis spectrophotometry, and disc \n",
            "diffusion methodology.  They tested these products in gram-positive \n",
            "bacteria, Staphylococcus aureus and Streptococcus agalactiae, and gram-\n",
            "negative bacteria, Pseudomonas aeruginosa . They found that;  these \n",
            "particular nanofiber mats demonstrated antibacterial properties against \n",
            "gram-positive bacteria; S. aureus and S. agalactiae , therewithal appeared \n",
            "to be mor e effective and concentration-dependent against gram-negative \n",
            "bacteria; P. aeruginosa (30). \n",
            "Kim SS. et al, producted Polyacrylonitrile (PAN) –chitosan \n",
            "double-face films an d nanofibers for investigating their antibacterial \n",
            "activity. They dissolved PAN and a chitosan salt in dimethyl sulfoxide, and \n",
            "then thin-layered on a glass plate or electro spun followed by coagulation \n",
            "in sodium hydroxide solution. The morphology of the PAN –chitosan \n",
            "double-face films and nanofibers was analyzed by SEM. The antibacterial \n",
            "efficacy was measured by a swatch test with bacterial suspensions. They \n",
            "concluded that; the PAN–chitosan nanofibers produced a 5 -log reduction \n",
            "(Log reduction is a mathematical term that is used to express the relative \n",
            "number of living microbes that are elimina ted by disinfection) against \n",
            "Escherichia coli, Staphylococcus aureus, and Micrococcus luteus (31). \n",
            "Sarhan WA and Azzazy HME, produced chitosan and honey were \n",
            "co-spun with polyvinyl alcohol (P VA) allowing the fabrication of \n",
            "nanofibers with high honey concentrations up to 40% and high chitosan \n",
            "concentrations up to 5.5% of the total weight of the fibers using \n",
            "biocompatible solvents (1% acetic acid). The fabricated nanofibers were \n",
            "further chemically crosslinked, by exposure to glutaraldehyde vapor, and \n",
            "physically crosslinked by heating and freezing/thawing. The new HP –\n",
            "chitosan nanofibers showed pronounced antibacterial activity against \n",
            "Staphylococcus aureus but weak antibacterial activity against Escherichia\n",
            "18 \n",
            "stress plays an important role in ovarian torsion (5) and the results of many \n",
            "experimental studies we gathered from this study show that antioxidants \n",
            "used for therapeutic purposes can reduce ovarian tissue damage. We hope \n",
            "that our study will be a helpful resource for the design of future ovarian \n",
            "ischemia / reperfusion studies. \n",
            "Table 1:  Anesthetics used for surgical procedure in ovaryan torsion \n",
            "studies. \n",
            " \n",
            " \n",
            "STUDY\n",
            "ANESTHETICS USEDfor THE\n",
            "SURGICALPROCEDURE\n",
            "Cemgil Awkan D.etal(2010),Bozkurt S.et\n",
            "al(2012)\n",
            "60mg/kgKetaminehydrochlorideviaIP\n",
            "Aslan MK.etal(2012)\n",
            "80 mg / kg Ketamine hydrochloride via IP\n",
            "Cadici E. et al (2010), Kurt A. et al (2011),\n",
            "Sengil O.etal(2013),BayirY.etal(2016),\n",
            "Unlubilgin E.et al(2017),Turkler C.et al\n",
            "25 mg / kg Sodium thiopental via IP\n",
            "(2018)\n",
            "Akdemir A. etal (2014), Aslan M. et al\n",
            "50mg/kgKetaminehydrochloride+7mg\n",
            "(2017),1lgen O.et al (2020)\n",
            "kgXylazinehydrochloridecombinationviaIP\n",
            "Ergwn Y.et al (2010), Sak ME.etal (2013),\n",
            "50mg/kgKetaminehydrochloride+10mg/\n",
            "Eser A.et al(2015),Incebuyuk A.et al (2015)\n",
            "MelekogluR.etal(2018)\n",
            "kgXylazinehydrochloride.combinationviaIM\n",
            "75mg/kg Ketaminehydrochloride +10mg\n",
            "Cakr Gingor AN.et al (2014)\n",
            "kgXylazinehydrochloridecombinationviaIP\n",
            "YurtcuE.etal(2015)\n",
            "40mg/kgKetaminehydrochloride+10mg/\n",
            "kgXylazine hydrochloridecombinationyia IP\n",
            "TopdagYilmazEP.etal(2020)\n",
            "45mg/kgKetaminehydrochloride+5mg\n",
            "kgXylazinehydrochloridecombinationviaIP\n",
            "Behroozi-Lak T.etal(2017)\n",
            "90mg/kgKetaminehydrochloride+5mg\n",
            "kg Xylazine hydrochloride.combination via IP\n",
            "108 \n",
            "KAYNAKÇA \n",
            "1. Athukorala C. Rumbold AR, Willson KJ, Crowther CA.: The risk of \n",
            "adverse pregnancy outcomes in women who are overweight or \n",
            "obese, BMC Pregnancy Childbirth,2010;17(10):56                  \n",
            "2. Barbour LA, Mc Curdy CE, Hernandez TL, Kirwan JP, Catalano P M, \n",
            "Friedman JE.: Cel lular mechanisms for insulin resistance in \n",
            "normal pregnancy and gestational diabetes, Diabetes Care \n",
            "2007;30(suppl 2): s112-119 \n",
            "3. Bellomy L,Casas JP, Hingorani AD, Williams D. Type 2 diabetes \n",
            "mellitus after gestational diabetes :a systematic review and meta \n",
            "analysis .Lancet 2009 ;373:1773-9 \n",
            "4. Berk MA, Mimouni F, Miodovnik M,etal: Macrosomia in infants of \n",
            "insulin - dependent diabetic mothers, Pediatrics 83(6) 1029,1989 \n",
            "5. Bion X, Gao P, Xiong X, XuH, QlanM,Lius.:  Risk     factors for \n",
            "development of diabetes mellitus in women with a history et \n",
            "gestational diabetes mellitud.Chin Med J (Engl)2000;113:759-62 \n",
            "6. Bulletins- Obstetrics  ACoP.: ACOG practice bulletin, Diognosis and \n",
            "management of preeclampsia and eclampsia. Number 33, January \n",
            "2002. Obstet Gynecol 2002;99: 159-167 \n",
            "7. Chen M, McNiff C, Madan J, Goodman E,Davis JM, Dammann O.: \n",
            "Maternal obesity and neonatal apgar scores ,J Matern Fetal \n",
            "Neonatal  Med .2010;23(1):89-95 \n",
            "8. Cherman R B, Coodwin T M, Leung B, Byrne J D Hethu mumi R, \n",
            "Montoro M,: Incidence,clinical characteristics,and timing of \n",
            "objectively diagnosed venous  thromboembolism during \n",
            "pregnancy obstet  Gynecol 1999;94:730-4 \n",
            "9. Christianson RE,: Studies on blood pressure during pregnancy .I, \n",
            "Influence of parity and age Am J Obstet Gynecol 1976;125 :509 -\n",
            "513 \n",
            "10. Constant DR: Maternal insulin to lower the risk of fetal macrosomia in \n",
            "diabetic pregnancy ,Clin Obstet Gynecol 34(2):288,1991 \n",
            "11. Duley L.: The global impact of pre -eclampsia and eclampsia. semin \n",
            "perinatol 2009;33:130-137. \n",
            "12. Ehrenberg HM,Durnwald CP,Catalone P,Mercer BM.: influence of \n",
            "pbesity and diabetes on the risk of  cesarean delivery  Am J Obstet  \n",
            "Gynecol 2004;191:969-74      \n",
            "13.Farah N, Maher N, Barry S, Kennelly M, Stuart B, Turner MJ.: \n",
            "Maternal morbid obesity and obst etric outcomes. Obes Facts \n",
            "2009;2(6):352-354  \n",
            "14.Gunders EP,chiang V, pletscher MI ,Jacobs DR, Quesenberry CP, \n",
            "Sidney S,et al.: History of gestational diabetes mellitus and future \n",
            "risk of atherosclerosis in mid -life :the Coronary Artery Risk\n",
            "57 \n",
            "0.70-1.0 very strong (14). Statistical significance was accepted as p <0.05 \n",
            "in all tests. \n",
            "RESULTS \n",
            "Study was carried out with 712 medical students. There were 283 \n",
            "(39.7%) female and 429 (60.3%) male students. The mean  age \n",
            "was19.5±1.4 and ranged from 18 to 26 years. \n",
            "For all students PLA prevalence was found 7.6% (n=54). The \n",
            "prevalence of PLA for females was 6.4% (n=18 out of 283) and for males \n",
            "8.4% (n=36 out of 429). Prevalence was not significantly different between \n",
            "males and females (p=0.316). \n",
            "Out of 54 students who had PLA was examined for sides according \n",
            "to gender. The percentage of unilateral PLA was 50.0% (n=9 out of 18) for \n",
            "female sand 61.1% (n=22 out of 36) in males. Percentage of unilaterality \n",
            "was not statistically significant for gender (p=0.436). The distribution of \n",
            "agenesis according to gender was shown in (Table 1). \n",
            "When the sides were examined for PLA, both for males andf \n",
            "emales, right and left limbs have strong positive correlation of PL agenesis \n",
            "(φ=0.576, p<0.001). For females correlation between agenesis and sides  \n",
            "was (φ=0.576, p<0.001) and (φ=0.650, p<0.001) for males. \n",
            " \n",
            " \n",
            "Table 1. PLA distribution according to gender\n",
            "49 \n",
            "the fore. In this test, the patient's plasma and normal plasma are mixed in \n",
            "equal volume, and PT, PTT, or both are evaluated at 0 and 1-2 hours. \n",
            "Prolonged PT / PTT is not shortening, despite factor addition indicates the \n",
            "presence of inhibitors. 0 and 1 -2 hour PTT results mean lupus \n",
            "anticoagulant in the same cases. Results that extend over time reveal the \n",
            "presence of the antibody (typically factor VIII inhibitor). If the PT and PTT \n",
            "are both prolonged and the mixing study shows correction, the only \n",
            "inference is common pathway problems. Plasma anti -Xa testing can be \n",
            "used to monitor patients receiving unfractionated heparin (UFH) or low \n",
            "molecular weight heparin (LMWH) therapy. LMWH primarily has anti-Xa \n",
            "activity, and UFH shows both anti -Xa and anti -IIa activity. Coagulation-\n",
            "based or chromogenic methods can measure the anti -Xa activity of AT.  \n",
            "Additionally, a patient who is bleeding but shows typical values of PT/PTT \n",
            "may be due to; thrombocytopenia and thrombocytopathia, factor XIII \n",
            "deficiency (clot is not soluble in urea), and increased primary fibrinolysis \n",
            "(e.g., lack of α2 -antiplasmin). The Factor XIII screening test is based on \n",
            "mono chloric a cid's ability to dissolve the fibrin clot in factor XIII \n",
            "deficiency. Quantitative tests depend on factor XIII transamidase \n",
            "properties. Although prolonged bleeding time is determinant for von \n",
            "Willebrand disease, it is not specific for the disease. At this p oint, \n",
            "measurements of the von Willebrand antigen amount, the functional \n",
            "capacity of VWF, and the function of the associated factor VIII molecule \n",
            "are valuable. VWF protein is measured by the ELISA method. A decrease \n",
            "in VWF levels is found in most patients. The average VWF antigenic level \n",
            "in people with blood type 0 is about 25% lower than in other blood groups. \n",
            "The functionality of VWF is evaluated by calculating the cofactor activity \n",
            "of ristocetin (standardized normal platelet suspension) in the patient \n",
            "plasma. In this assay, the agglutination capacity of VWF in ristocetin -\n",
            "added plasma is evaluated in terms of the rate or extent of platelet \n",
            "agglutination.  \n",
            "Disruption of coagulation mechanisms may cause bleeding, and \n",
            "impairment of control mechanisms may cause  thrombosis. Control \n",
            "modulators include AT, protein C and immunological and functional \n",
            "methods can measure protein S and AT. Functional tests involving \n",
            "chromogenic substrates detect AT as a heparin cofactor. For protein C, \n",
            "tests are available evaluating th e prolongation of aPTT in terms of \n",
            "inactivating activated protein C factors V and VIII. The determination of \n",
            "protein S is involved in its combination with a free protein S and C4b. Free \n",
            "protein S acts as the cofactor of active protein C. Protein S assay ca n be \n",
            "evaluated using protein S deficient plasma and activated protein C. In the \n",
            "past, various fibrin/fibrinogen degradation products were determined by \n",
            "different methods. Currently, only D -dimer is measured as a diagnostic \n",
            "parameter for DIC and other throm botic events. Monoclonal antibodies \n",
            "that can detect D-dimer in plasma were synthesized. The antibody did not\n",
            "53 \n",
            "REFERENCES \n",
            "1. Doherty TM, Kelley A. Bleeding Disorders. [Updated 2020 Aug 12]. In: \n",
            "StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; \n",
            "2020 Jan -. Available from: \n",
            "https://www.ncbi.nlm.nih.gov/books/NBK541050/ \n",
            "2. Hiller E. (2007) Basic Principles of Hemostasis. In Munker R., Hiller \n",
            "E., Glass J., Paquette R. (eds) Modern Hematology. Contemporary \n",
            "Hematology. Humana Press. https://doi.org/10.1007/978-1-\n",
            "59745-149-9_19 \n",
            "3. Harold R. Roberts, Dougald M. Monroe, Miguel A. Escobar, Richard B. \n",
            "Weiskopf; Current  Concepts of Hemostasis: Implications for \n",
            "Therapy. Anesthesiology 2004; 100:722 –730 doi: \n",
            "https://doi.org/10.1097/00000542-200403000-00036 \n",
            "4. Antonio Blanco and Gustavo Blanco. Hemostasis. In Medical \n",
            "Biochemistry, 2017 . Pages  781 – 789. doi: \n",
            "https://doi.org/10.1016/B978-0-12-803550-4.00031-8 \n",
            "5. Hoffman, Maureen, 2010. Regulation of Hemostasis and Thrombosis. \n",
            "doi: https://doi.org/10.1016/B978-1-4160-3773-6.10009-6 \n",
            "6. Nguyen, Andy & Dasgupta, Amitava & Wahed, Amer. (2016). \n",
            "Coagulation-Based Tests and Their Int erpretation. doi: \n",
            "https://doi.org/10.1016/B978-0-12-803531-3.00001-X. \n",
            "7. Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated Intravascular \n",
            "Coagulation: An Update on Pathogenesis, Diagnosis, and \n",
            "Therapeutic Strategies. Clin Appl Thromb Hemost. \n",
            "2018;24(9_suppl):8S-28S. doi: \n",
            "https://doi.org/10.1177/1076029618806424 \n",
            "8. Favaloro EJ, Funk DM, Lippi G. Pre-analytical variables in coagulation \n",
            "testing associated with diagnostic errors in hemostasis. Lab Med. \n",
            "2012;43:1-10. doi: \n",
            "https://doi.org/10.1309/LM749BQETKYPYPVM\n",
            "Medical Diagnosis and Treatment Methods  \n",
            "in  \n",
            "Basic Medical Sciences \n",
            " \n",
            " \n",
            " \n",
            " \n",
            " \n",
            "Editor \n",
            "Prof. Dr. Sıddık Keskin \n",
            " \n",
            " \n",
            " \n",
            " \n",
            "Lyon 2020\n",
            "69 \n",
            "opening of Potassium ion channels that cause smooth muscle cell \n",
            "hyperpolarization 11–13. \n",
            "Similarly; pathways mediated by VIP, CGRP, and Prostaglandin \n",
            "also cause smooth muscle cell relaxation by increasing intracellular \n",
            "cAMP levels 14. \n",
            "A feature that is very important in all these erection mechanisms \n",
            "and must be remembered is the ion channels known as gap junctions and \n",
            "located in the cavernosal smooth muscle cell membrane. Thanks to these \n",
            "channels that cause tight communication, syncytial relaxation and \n",
            "contraction can occur, which has a very important role in erectile \n",
            "physiology 13. \n",
            "The phosphodiesterase enzyme system is required for \n",
            "detumescence (reversal of erection): A series of biological events \n",
            "develop in the arterial blood, which is filled and stuck in the cavernous \n",
            "bodies, to return to the ve nous system and the penis to regain its flaccid \n",
            "state. First, the enzyme called \"phosphodiesterase 5\" in the cavernous \n",
            "structure c -GMP and possibly also enzymes called \"phosphodiesterase \n",
            "2,3,4\" break down c -AMP into GMP and AMP, respectively. Cells in \n",
            "hyperpolarized states are then depolarized, calcium channels open, and \n",
            "muscular filaments start to contract by interacting with each other as \n",
            "calcium enters the cell. Blood is pumped into the congested veins, and as \n",
            "the amount of blood in the cavernous body de creases, the pressure on the \n",
            "veins stuck in the periphery decreases, and a normal venous return begins \n",
            "15. \n",
            "Nitric oxide (NO) is a potent peripheral smooth muscle relaxant \n",
            "acting through cyclic guanosine monophosphate (cGMP ). NO released \n",
            "from nonadrenergic-noncholinergic nerve endings and endothelium is the \n",
            "main mediator that provides an erection. NO; It is synthesized from L -\n",
            "arginine by nitric oxide synthase (NOS) enzyme in many tissues in the \n",
            "body. NO synthase; endothelial  (eNOS), neuronal ( nNOS), and induced \n",
            "(iNOS), it is known that there are 3 isoforms. Mainly, eNOS and nNOS \n",
            "play a role in penile erection due to NO. NO is synthesized from the \n",
            "endothelium (eNOS) in response to shear stress, from cholinergic nerves \n",
            "as co -transmitter with acetylcholine, and nonadrenergic -noncholinergic \n",
            "(NANK) nerve endings by nNOS, and it activates intracellular guanylate \n",
            "cyclase by diffusing into smooth muscle cells 16. This causes the \n",
            "conversion of GTP to cGMP. Thus, intracellular cGMP concentrations \n",
            "increase when there is NO stimulation. Increased cGMP concentr ations \n",
            "cause cGMP -dependent protein kinase (PKG) activation and \n",
            "consequently smooth muscle relaxation. PKG; reduces intracellular Ca +2 \n",
            "levels by decreasing Ca +2 channel activity, causes smooth muscle cell\n",
            "40 \n",
            "function can be determined in the clinical laboratory. Levels of individual \n",
            "plasma coagulation inhibitors and other regulatory proteins can also be \n",
            "evaluated. However, no laboratory test can provide a general evaluation of \n",
            "hemostasis's competency or thrombosis risk. Each laboratory test offers a \n",
            "small fraction of the information required, and the assessment of \n",
            "hemostatic function always requires a comparison of laboratory results \n",
            "with patients' clinical condition.  \n",
            "HEMOSTASIS \n",
            "The hemostatic system consists of the plasma coagulation system, \n",
            "including blood vessels, platelets, fibrinolytic factors, and inhibitory \n",
            "mechanisms. When vessel damage occurs, three local agencies are \n",
            "activated to control bleeding: (1) vessel wall contraction, (2) platelet \n",
            "adhesion and aggregation (platelet plug formation), and  (3) clot to form \n",
            "fibrin. All these mechanisms need to work, and defects in one or more of \n",
            "them result in abnormal bleeding. Primary hemostasis is used for rapid \n",
            "plug formation upon damage to the vessel wall, followed by \n",
            "vasoconstriction, platelet adhesion , and aggregation. This stage is for a \n",
            "sudden and quick solution, and fibrin formation is not required. However, \n",
            "primary hemostasis is transient, and bleeding could begin again, except \n",
            "secondary hemostasis strengthens the platelet plug by forming a stable \n",
            "fibrin clot. Eventually, the fibrinolytic system 's mechanisms ensure the \n",
            "fibrin clot's dissolution and the restoration of normal blood flow.  \n",
            "Platelets cannot adhere to the healthy, smooth endothelial surface, \n",
            "and coagulation is not initiated. Endothelial thromboresistance is generated \n",
            "by various antiplatelet and anticoagulant materials produced by the \n",
            "endothelial cells like; prostacyclin (prostaglandin I2, PgI2), nitrite oxide \n",
            "(NO), thrombomodulin, heparin -like glycosaminoglycans, tissue factor \n",
            "pathway inhibitor (TFPI), tissue plasminogen activator (t-PA). Endothelial \n",
            "cells also show procoagulant activity by synthesizing and secreting von \n",
            "Willebrand factor (VWF) and PAI-1. It is crucial that blood not clot inside \n",
            "the vascular system. In the baseline state, vascular endothelial cells \n",
            "maintain a nonthrombogenic interface with the circulating blood. \n",
            "Endothelial cells do not ordinarily reveal molecules that promote platelet \n",
            "adhesion or aid activation and activity of the coagulation proteins. After \n",
            "vascular damage, procoagulant factors and tissue factor (TF) are activated, \n",
            "and thrombocyte adhesion, aggregation, and local thrombin formation are \n",
            "achieved.  \n",
            "Platelets are nucleated cells that are released by the breakdown of \n",
            "megakaryocytes in the bone marrow. They can be found in circulation for \n",
            "up to nine days. The approximate number of platelets in peripheral blood \n",
            "is between 150,000 to 400,000 per microliter. On the outer surface of \n",
            "platelets are various molecules such as integrins and leucine -rich\n",
            "110 \n",
            "27. London MB,Mela L,Spong CY Carpenter MW,Rahim SM,Casey B,et \n",
            "al.: The  relationship between maternal glycemia and perinatal \n",
            "outcome.obste.t Gynecol 2011;117 :218-24  \n",
            "28. Madan J Chen M.Goodman E, Davis J Allan W.Dammann O. Maternal  \n",
            "Obesity ,gestational hypertension and preterm deli very .J Matern \n",
            "Fetal Neonatal Med.257.   \n",
            "29. Madan JC, Davis JM, Craig WY.et al.: Maternal Obesity and markers \n",
            "of inflammation in pregnancy. Cytokine, 2009;47(1):61-64 \n",
            "30. Majumdar A, Saleh S, Candelier CK. Failure to recognise the impact \n",
            "of moderate obesity (BMİ 30-40) on adverse obstetric outcomes. J \n",
            "Obstet Gynaecol,2010;30(6):567-57040. \n",
            "31. Marik PE, Plante LA.: Venous thromboembolic disease and pregnancy. \n",
            "N Engl J Med. 2008 others and risk of preterm birth and low birth \n",
            "weight infants:systematic review and meta -analyses. BUJ. \n",
            "2010;2013(41):c3428 \n",
            "32. McGuire W, Dyson L, Renfrew M, Maternal Obesity: Consequences \n",
            "for children, challenges for clinicians and carers, Semin Fetal \n",
            "Neonatal Med .2010;15(2):108-112 \n",
            "33. Middeldorp S. How I treat pregnancy -related venous \n",
            "thromboembolism , Blood 2011;118:5394 -400. doi: 10.1182/ \n",
            "blood -2011-04-30658959.     \n",
            "34. Report of the National High Blood Pressure Education Program \n",
            "Working Group on High Blood Pressure in Pregnancy . Am I \n",
            "Obstet  Gynecol 2000;183 ;S1 -S22 \n",
            "35. Riskin. Mashiah S, Damti A, Younes G, Auslander R.: Pregestationd \n",
            "body mass index, weight gain during pregnancy and maternal \n",
            "hyperglycemia. Gynecol Endocrinol. 2011;27(7):464-467      \n",
            "36. Rosenn B, Miodovnik M, Combs CA, et al: Human versus animal \n",
            "insulin in the management of insulin -dependent  Diabetes:Lack of \n",
            "effect on fetal growth . Obstet Gynecol 78:590,1991. \n",
            "37. Saudan P, Brown MA, Buddle ML, Jones M.: Does gestational \n",
            "hypertension become preeclampsia Br J Obstet Gynaecol \n",
            "1998;105:1177-1184 \n",
            "38. Shaikh H,  Robinson S. Teah TG.: Management of maternal obesity \n",
            "prior to and during pregnancy. Cytokine. 2009:47(1):61-64 \n",
            "39. Shailch H, Robinson S, Teoh TG.Management of maternal obesity \n",
            "prior to and during pregnancy. Semin Fetal Neonatal Med. \n",
            "2010;15(2):77-82 \n",
            "40. Sheikh H. Robinson S, Teoh TG.: Management of maternal obesity \n",
            "prior to and during pregnancy. Semin Fetal Neonatal Med. 2010 \n",
            "15(2):77-82 \n",
            "41. Simic M, Wahlin A, Marsal K,Kallen K.:  Maternal Obesity is a  \n",
            "potential source of error in midtrimester ultrasound  estimation \n",
            "gestational  age .ultrasound obstet. Gynecol. 2010;35(1):48-53\n",
            "79 \n",
            "REFERENCES \n",
            "1.  Mesquita JFP, Ramos TF, Mesquita FP, Netto JMB, Bastos MG, de \n",
            "Figueiredo AA. Prevalence of erectile dysfunction in chronic \n",
            "renal disease patients on conservative treatment. Clinics. \n",
            "2012;67(2):181-183. doi:10.6061/clinics/2012(02)15 \n",
            "2.  Müller A, Mulhall JP. Cardiovascular disease, metabolic syndrome \n",
            "and erectile dysfunction. Current Opinion in Urology . \n",
            "2006;16(6):435-443. doi:10.1097/01.mou.0000250284.83108.a6 \n",
            "3.  Shamloul R, Ghanem H. Erectile dysfunction. The Lancet . \n",
            "2013;381(9861):153-165. doi:10.1016/S0140-6736(12)60520-0 \n",
            "4.  Perelman MA. Psychosocial evaluation and combination treatment \n",
            "of men with erectile dysfun ction. Urologic Clinics of North \n",
            "America. 2005;32(4):431-445. doi:10.1016/j.ucl.2005.08.010 \n",
            "5.  Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay \n",
            "JB. Impotence and its medical and psychosocial correlates: \n",
            "Results of the Massachusetts Male Aging  Study. Journal of \n",
            "Urology. 1994;151(1):54 -61. doi:10.1016/S0022 -5347(17)34871-\n",
            "1 \n",
            "6.  Lue TF. Erectile Dysfunction. Wood AJJ, ed. New England Journal \n",
            "of Medicine . 2000;342(24):1802 -1813. \n",
            "doi:10.1056/NEJM200006153422407 \n",
            "7.  Yiee JH, Baskin LS. Penile Embryol ogy and Anatomy. \n",
            "TheScientificWorldJOURNAL. 2010;10:1174 -1179. \n",
            "doi:10.1100/tsw.2010.112 \n",
            "8.  Giuliano F, Rampin O. Neural control of erection. Physiology and \n",
            "Behavior. 2004;83(2):189 -201. \n",
            "doi:10.1016/j.physbeh.2004.08.014 \n",
            "9.  PRIVIERO FBM, LEITE R, WEBB RC,  TEIXEIRA CE. \n",
            "Neurophysiological basis of penile erection. Acta \n",
            "Pharmacologica Sinica. 2007;28(6):751-755. doi:10.1111/j.1745-\n",
            "7254.2007.00584.x \n",
            "10.  Stief CG, Noack T, Andersson KE. Signal transduction in cavernous \n",
            "smooth muscle. World Journal of Urology . 1997;15(1):27-31. \n",
            "doi:10.1007/BF01275153 \n",
            "11.  Burnett AL, Lowenstein CJ, Bredt DS, Chang TSK, Snyder SH. \n",
            "Nitric oxide: A physiologic mediator of penile erection. Science. \n",
            "1992;257(5068):401-403. doi:10.1126/science.1378650 \n",
            "12.  Rajfer J, Aronson WJ, Bush P A, Dorey FJ, Ignarro LJ. Nitric Oxide\n",
            "10 \n",
            "12. Reneker, D. H., & Chun, I. (1996). Nanometre diameter fibres of \n",
            "polymer, produced by electrospinning.  Nanotechnology, 7(3), \n",
            "216. \n",
            "13. Doshi, J., & Reneker, D. H. (1995). Electrospinning process and \n",
            "applications of electrospun fibers. Journal of electrostatics, 35(2-\n",
            "3), 151-160. \n",
            "14. Subbiah, T., Bhat, G. S., Tock, R. W., Parameswaran, S., & Ramkumar, \n",
            "S. S. (2005). Electrospinning of nanofibers.  Journal of applied \n",
            "polymer science, 96(2), 557-569. \n",
            "15. Jiang, W., Kim, B. Y., Rutka, J. T., & Chan, W. C. (2008). \n",
            "Nanoparticle-mediated cellular response is size-dependent. Nature \n",
            "nanotechnology, 3(3), 145-150. \n",
            "16. Kai, D., Jin, G., Prabhakaran, M. P., & Ramakrishna, S. (20 13). \n",
            "Electrospun synthetic and natural nanofibers for regenerative \n",
            "medicine and stem cells. Biotechnology journal, 8(1), 59-72. \n",
            "17. Thakkar, S., & Misra, M. (2017). Electrospun polymeric nanofibers: \n",
            "New horizons in drug delivery.  European Journal of \n",
            "Pharmaceutical Sciences, 107, 148-167. \n",
            "18. Schiffman, J. D., & Schauer, C. L. (2008). A review: electrospinning \n",
            "of biopolymer nanofibers and their applications.  Polymer \n",
            "reviews, 48(2), 317-352. \n",
            "19. Deitzel, J. M., Kleinmeyer, J., Harris, D. E. A., & Tan, N. B. ( 2001). \n",
            "The effect of processing variables on the morphology of \n",
            "electrospun nanofibers and textiles. Polymer, 42(1), 261-272. \n",
            "20. Vilchez, A., Acevedo, F., Cea, M., Seeger, M., & Navia, R. (2020). \n",
            "Applications of electrospun nanofibers with antioxidant \n",
            "properties: A review. Nanomaterials, 10(1), 175. \n",
            "21. Vacanti, J. P., & Langer, R. (1999). Tissue engineering: the design and \n",
            "fabrication of living replacement devices for surgical \n",
            "reconstruction and transplantation. The lancet, 354, S32-S34. \n",
            "22. Felgueiras, H. P., & Amorim, M. T. P. (2017). Functionalization of \n",
            "electrospun polymeric wound dressings with antimicrobial \n",
            "peptides. Colloids and Surfaces B: Biointerfaces, 156, 133-148. \n",
            "23. Zahedi, P., Rezaeian, I., Ranaei‐Siadat, S. O., Jafari, S. H., & Supaphol, \n",
            "P. (2010). A review on wound dressings with an emphasis on \n",
            "electrospun nanofibrous polymeric bandages.  Polymers for \n",
            "Advanced Technologies, 21(2), 77-95. \n",
            "24. Zhang, Y., Lim, C. T., Ramakrishna, S., & Huang, Z. M. (2005). Recent \n",
            "development of polymer nanofiber s for biomedical and\n",
            "42 \n",
            "involved in all coagulation steps. These components accumulating on the \n",
            "phospholipid complex require calcium ions for activation, limiting the \n",
            "affected area's reactions. All of the coagulation factors, except factor IV \n",
            "(Ca + 2), are proteins, and most of them are found in the blood as inactive \n",
            "proenzymes (zymogen). Factors V and VIII, on the other hand, are not in \n",
            "the enzyme structure and are synthesized by megakaryocytes in the bone \n",
            "marrow. It is stored in platelet granule s and released after activation. \n",
            "Vitamin K is required for factor II, VII, IX, X, protein C and S synthesis \n",
            "and function. The only coagulation factor not circulating is tissue factor \n",
            "(Factor III) located in the subendothelial area. The coagulation system is a \n",
            "chain of sequential reactions in which coagulation factors activate each \n",
            "other. It is known to be initiated by two classical ways, extrinsic and \n",
            "intrinsic. The intrinsic pathway begins with Hageman factor (factor XII) \n",
            "activation, and the extrinsic path way begins with the release of tissue \n",
            "factor. Both paths provide stable clot formation as a result of burst \n",
            "reactions that activate factor X. In the coagulation cascade, many factors \n",
            "intertwine, trigger, and inhibit each other's  work under a single system \n",
            "simultaneously. The interconnected structure of the system at many points \n",
            "also allows better control of bleeding and clotting conditions.  The \n",
            "coagulation system is triggered by the tissue factor released due to \n",
            "endothelial damage or inflammation either by factor XII activated by \n",
            "collagen. TF then interacts with factor VIIa, activating factors IX and X. \n",
            "Factor Xa also produces a small amount of thrombin from prothrombin. \n",
            "Propagation of coagulation consists of when thrombin repeatedly activates \n",
            "factors XI, IX, V, and VIII. Thrombin also stimulates the aggregation and \n",
            "activation of platelets. Coagulation factors, which are frequently activated \n",
            "and multiplied in the system each time, generate too much thrombin from \n",
            "prothrombin. Finally, thrombin transforms fibri nogen into fibrin. Also, \n",
            "thrombin activates factor XIII and forms the desired stable clot with a fibrin \n",
            "fiber network.  \n",
            "The main initiating pathway of in vivo blood coagulation is the \n",
            "extrinsic system. The crucial component is TF, an intrinsic membrane \n",
            "component expressed by cells in most extravascular tissues. The \n",
            "terminology \"extrinsic\" continues to be used today in terms of education, \n",
            "although quite outdated. TF is not frequently extrinsic to the circulatory \n",
            "system, but it is also expressed by endothelia l cells and leukocytes under \n",
            "definite pathological conditions. TF serves as a cofactor to the significant \n",
            "factor VII in the extrinsic pathway. TF and factor VII complex provide \n",
            "factor VIIa activation, whereby factor X is converted into factor Xa, the \n",
            "main compartment in the common path. The factor VIIa-TF complex also \n",
            "converts factor IX to factor IXa. Also, as levels of factor Xa increase, the \n",
            "factor VIIa-TF complex is subject to inhibition by the factor Xa-dependent \n",
            "tissue factor pathway inhibitor (TFPI). The intrinsic pathway earlier begins \n",
            "with the contact phase. This phase is achieved by factor XII (contact\n",
            "88 \n",
            "2005;48(2):314-318. doi:10.1016/j.eururo.2005.05.005 \n",
            "88.  Atala A. Tissue engineering of reproductive tissues and organs. \n",
            "Fertility and Sterility . 2012;98(1):21 -29. \n",
            "doi:10.1016/j.fertnstert.2012.05.038 \n",
            "89.  Ribeiro F, Alves AJ, Duarte JA, Oliveira J. Is exercise training an \n",
            "effective therapy targeting endothelial dysfunction and vascular \n",
            "wall inflammation? International Journal of Cardiology . \n",
            "2010;141(3):214-221. doi:10.1016/j.ijcard.2009.09.548 \n",
            "90.  Morelli A, Filippi S, Comeglio P, et al. Physical activity counteracts \n",
            "metabolic syndrome -induced hypogonadotropic hypogonadism \n",
            "and erectile dysfunction in the rabbit. American Journal of \n",
            "Physiology - Endocrinology and Metabolism. 2019;316(3):E519-\n",
            "E535. doi:10.1152/ajpendo.00377.2018\n",
            "113 \n",
            "67.  Magee LA, Helewa M, Moutquin J -M, von Dadelszen P, Committee \n",
            "HG. Strategic Training Initiative in Research in the Reproductive \n",
            "Health Sciences (STTRRHS) Scholars.\" Diagnosis, evaluation, \n",
            "and management of the hypertensive disorders of pregnancy\". \n",
            "Journal of obstetrics and gynaecology Canada 2008; 30 \n",
            "68.  Endeshaw M, Abebe F, Bedimo M, Asart A. Diet and Pre-eclampsia: \n",
            "A Prospective Multicentre Case –Control Study in Ethiopia. \n",
            "Midwifery 2015; 31(6), 617-24. \n",
            "69.  Hacihasanoğlu R, Gözüm S. The effect of patient education and home \n",
            "monitoring on medication compliance, hypertension management, \n",
            "healthy lifestyle behaviours and BMI in a primary health care \n",
            "setting. Journal of clinical nursing 2011; 20, 692-705.  \n",
            "70. Hypertension in Pregnancy (Report of the ACOG Task Force on \n",
            "Hypertension in Pregnancy) Obstetrics & Gynecology 2013; 122 \n",
            "(5). \n",
            "711. Stratta P,  Canavese C, Porcu M, Dogliani M, Todros T, Garbo E. \n",
            "Vitamin E supplementation in preeclampsia. Gynecologic and \n",
            "obstetric investigation 1994; 37(4), 246-9. \n",
            "72.  Gülmezoğlu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the \n",
            "treatment of severe pre ‐eclampsis an explanatory randomised \n",
            "controlled trial. BJOG: An International Journal of Obstetrics & \n",
            "Gynaecology 1997; 104(6), 689-96.  \n",
            "73.  Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ. Effect of \n",
            "antioxidants on the occurrence of pre -eclampsia in wome n at \n",
            "increased risk: a randomised trial. The Lancet 1999; 354(9181), \n",
            "810-6. \n",
            "74. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ. \n",
            "Vitamins C and E to prevent complications of pregnancy -\n",
            "associated hypertension. New England Journal of Medicine 2010; \n",
            "362(14), 1282-91.  \n",
            "75. Villar J, Purwar M, Merialdi M, Zavaleta N, Anthony J, De Greeff A. \n",
            "World Health Organisation multicentre randomised trial of \n",
            "supplementation with vitamins C and E among pregnant women at \n",
            "high risk for pre ‐eclampsia in populations  of low Madazlı R. \n",
            "Preeklampsi. Turkiye Klinikleri J Gynecol Obst -Special Topics \n",
            "2010; 3(1):45-52.  \n",
            " 76. Mostello D,Chang JJ ,Allen J ,Luehr L, Shyken J ,Leet T,Recurrent \n",
            "preeclampsia :the effect of weight change between pregnancies \n",
            ",Obstetrics ve Gynecolo gy 2010;116(3),667 -72 \n",
            "77. World Health Organization. (2000). Obesity: preventing and\n",
            "CHAPTER VIII \n",
            " \n",
            "AN EXAMINATION OF THE RELATIONSHIP BETWEEN \n",
            "SMOKING DURING-BEFORE PREGNANCY AND \n",
            "NEWBORN BIRTH WEIGHT/PLACENTA WEIGHT AND \n",
            "ITS HISTOPATHOLOGICAL IMPACTS ON THE \n",
            "PLACENTA TISSUE \n",
            " \n",
            "Eysan Balcıoğlu1 & Hayrunnisa Yeşil Sarsmaz2 \n",
            "Gülşen Seren Gürgen3 \n",
            "1 (Expert Midwif), Manisa Celal Bayar University,  e-mail:eysanbalciogli@gmail.com  \n",
            "                 0000-0001-8159-6640 \n",
            "2 (Asst. Prof. Dr.), Manisa Celal Bayar University,  e-mail: nisalisayy@hotmail.com  \n",
            "                  0000-0002-9790-1723 \n",
            "3 (Assoc. Prof.Dr.) Manisa Celal Bayar University, e-mail: serengurgen@gmail.com \n",
            "                    0000-0002-5514-1404 \n",
            " \n",
            "1. INTRODUCTION:  \n",
            "The fact that smoking is quite common in the society leads to 90% \n",
            "of the smokers to start this habit before the age of 20  and whereas the \n",
            "number of male smokers continues to decrease, the increase in the number \n",
            "of smoking women results in an increase  in smoking during pregnancy 1. \n",
            "Increasing cigarette use among female population results in lung cancer, \n",
            "coronary obstructive lung disease, coronary diseases, osteoporosis, late \n",
            "pregnancy, early menopause, menstrual issues, infertility and cancers 2, 3.  \n",
            "It was determined based on the Turkey Population and Health \n",
            "TPHS-2008 data, these values decreased to 11,4% for pregnant women and \n",
            "16,5% for nursing mothers  4. Worryingly, then the global prevalence of \n",
            "smoking duringpregnancy is 1.7% with up to 8.1% of women smoking \n",
            "during pregnancy in Europe and 250 million women smoking during \n",
            "pregnancy worldwide5, 6 . All these findings indicate that smoking among \n",
            "pregnant women is a frequently encountered behavior and an important \n",
            "health issue. The increase of smoking among the female population in a \n",
            "community results in an increase in smoking related pregnancy risks 7. \n",
            "Fetal growth and development is characterized by fetal tissue and \n",
            "organ differe ntiation, maturation and growth 8. Fetal genetic structure, \n",
            "uteroplacental function and maternal environment are among the primary \n",
            "factors with impacts on fetal growth and development. A healthy fetus \n",
            "completes its intrauterine somatic growth under conditions for which all\n",
            "82 \n",
            "30.  Oh JS, Heo HM, Kim YG, Lee SG, Lee CK, Yoo B. The effect of \n",
            "anti-tumor necrosis factor agents on sexual dysfunction in male \n",
            "patients with ankylosing spondylitis: A pilot s tudy. International \n",
            "Journal of Impotence Research . 2009;21(6):372 -375. \n",
            "doi:10.1038/ijir.2009.44 \n",
            "31.  Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: From angina \n",
            "to erectile dysfunction to pulmonary hypertension and beyond. \n",
            "Nature Reviews Drug Discovery . 2006;5(8):689 -702. \n",
            "doi:10.1038/nrd2030 \n",
            "32.  Seidler M, Ückert S, Waldkirch E, et al. In vitro effects of a novel \n",
            "class of nitric oxide (NO) donating compounds on isolated human \n",
            "erectile tissue. European Urology . 2002;42(5):523 -528. \n",
            "doi:10.1016/S0302-2838(02)00397-4 \n",
            "33.  Friebe A, Müllershausen F, Smolenski A, Walter U, Schultz G, \n",
            "Koesling D. YC-1 potentiates nitric oxide - and carbon monoxide-\n",
            "induced cyclic GMP effects in human platelets. Molecular \n",
            "Pharmacology. 1998;54(6):962-967. doi:10.1124/mol.54.6.962 \n",
            "34.  Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson K -E. \n",
            "Nitric Oxide Independent Activation of Guanylate Cyclase by \n",
            "YC-1 Causes Erectile Responses in the Rat. Journal of Urology . \n",
            "2002;167(5):2276-2281. doi:10.1016/S0022-5347(05)65142-7 \n",
            "35.  Bischoff E, Schramm M, Straub A, Feurer A, Stasch JP. BAY 41 -\n",
            "2272: A stimulator of soluble guanylyl cyclase induces nitric \n",
            "oxide-dependent penile erection in vivo. Urology. \n",
            "2003;61(2):464-467. doi:10.1016/S0090-4295(02)02121-0 \n",
            "36.  Stasch JP, Alonso -Alija C, Apeler H, et al. Pharmacological actions \n",
            "of a novel NO-independent guanylyl cyclase stimulator, BAY 41 -\n",
            "8543: In vitro studies. British Journal of Pharmacology . \n",
            "2002;135(2):333-343. doi:10.1038/sj.bjp.0704484 \n",
            "37.  Fonteles MC, do Nascimento NRF. Guanylin pe ptide family: \n",
            "History, interactions with ANP, and new pharmacological \n",
            "perspectives. Canadian Journal of Physiology and \n",
            "Pharmacology. 2011;89(8):575-585. doi:10.1139/y11-050 \n",
            "38.  Abdel Aziz MT, El Asmer MF, Mostafa T, et al. Effects of \n",
            "Losartan, HO-1 Inducers or HO -1 inhibitors on erectile signaling \n",
            "in diabetic rats. Journal of Sexual Medicine . 2009;6(12):3254 -\n",
            "3264. doi:10.1111/j.1743-6109.2009.01517.x \n",
            "39.  Abdel Aziz MT, El-asmar MF, Mostafa T, et al. Effect of hemin and \n",
            "carbon monoxide releasing molecule ( CORM-3) on cGMP in rat\n",
            "114 \n",
            "managing the  \n",
            "global epidemic. World Health Organ Tech Rep Ser.2001/03/10 \n",
            "ed. Geneva,Switzerland:World Health Organization. \n",
            "78. Villamor, E.Cnattingius, S. (2006). Interpregnancy weight change and \n",
            "risk of adverse pregnancy outcomes a population -based \n",
            "study.Lancet.Sep30:368(9542),1164-70. \n",
            "79. Wrotniak, BH. Shults, J. Butts, S. Stettler, N. ( 2008). Gestational \n",
            "weight gain and risk of overweight in the offspring at age 7 y in a \n",
            "multicenter, multiethnic cohort study.Am J Clin Nutr. \n",
            "Jun;87(6):1818-24. \n",
            "80. Oken, E. Taveras, EM. Kleinman, KP. Rich-Edwards, JW. Gillman, \n",
            "MW.  (2007). Gestational weight gain and child adiposity at age 3 \n",
            "years. Am J Obstet  Gynecol. Apr;196(4):322.e1-8. \n",
            "81. http://www.who.int/mediacentre/factsheets/fs311/en/index.html  \n",
            "82. Satman, İ., Dinççağ, N., Karşıdağ, K., Şengül,  A., Salman, F., sargın, \n",
            "M. ve diğerleri., (2000).TURDEP Group Yayını, 50(1),142 \n",
            "83. Lashen, H., Fear, K., Sturdee, DW., (2004). Obesity is associated with  \n",
            "increased risk of first trimester and recurrent miscarriage Matched \n",
            "case-control study. Hum Re- prod19:1644. \n",
            "84. Weiss, JL., Malone, FD., Emig, D., et al; (2004). Obesity, obstetric  \n",
            "complications and cesarean delivery rate a po pulation-based \n",
            "screening study FASTER Research Consortium. Am J Obstet \n",
            "Gynecol Apr;190(4):1091-7. \n",
            "85. O'Brien, TE., Ray, JG., Chan, WS., (2003). Maternal body mass index \n",
            "and the risk of preeclampsia: a systematic \n",
            "overview.EpidemiologyMay;14(3):368-74., \n",
            "86. Ramsay, JE., Ferrell, WR., Crawford, L., Wallace, AM., Gree r, IA., \n",
            "Sattar, N., (2002). Maternal obesity is associated with \n",
            "dysregulation of metabolic, vascular, and inflammatory \n",
            "pathways.J Clin Endocrinol Metab.Sep;87(9):4231-7. \n",
            "87.  Li, R., Jewell, S., Gr ummer-Strawn,L. (2003). Maternal obesity and \n",
            "breastfeeding practices. Am J Clin Nutr 77:931 \n",
            "88. internet adresi: https:// www.hemensağlık.com>makale  (Erişim \n",
            "tarihi:24.04.2019)\n",
            "CHAPTER IX  \n",
            "  \n",
            "EFFECTS OF LAVENDER OIL ON WOUND HEALING  \n",
            "  \n",
            "Anıl Demiröz1 & Zeynep Güneş Özünal2  \n",
            "1(MD, Asst. Prof), Istanbul University-Cerrahpaşa, e-mail: anil.demiroz@istanbul.edu.tr  \n",
            "                                 0000-0001-6182-6939  \n",
            "2(MD, Assoc. Prof.) Maltepe University, e-mail: zeynep.ozunal@maltepe.edu.tr    \n",
            "                                0000-0002-3060-1507  \n",
            "  \n",
            "INTRODUCTION  \n",
            "Wound healing is one of the oldest topics in medicine. Throughout \n",
            "history, mankind has sought ways to cope with the wound, and this search \n",
            "still continues. In the 19th century, with advances such as infection control, \n",
            "hemostasis and necrosis control, an important progress has been achieved \n",
            "in this field. However, chronic wounds still constitute an important \n",
            "problem.1  \n",
            "Numerous methods have been described and many studies have been \n",
            "conducted in the field of wound care and treatment. It is important to know \n",
            "the basics of these methods in order to obtain the desired results in clinical \n",
            "practice.  \n",
            "THE WOUND HEALING PROCESS  \n",
            "Wound healing consists of many processes that are intertwined, that \n",
            "trigger or inhibit each other. Many agents play a role in the activation or \n",
            "inhibition of all these processes. 2 Wound healing phases are defined as \n",
            "hemostasis and inflammation, proliferation and remodeling.3  \n",
            "The primary purpose of the hemostasis phase is to stop bleeding, and \n",
            "this is achieved by clot formation. 4 The clot not only stops bleeding but \n",
            "also acts as a barrier against microorganisms as well as a matrix rich in \n",
            "cytokines and growth factors for inflammatory cells, stem cells and \n",
            "progenitor cells. 5 The inflammation phase begins as the clot captures \n",
            "neutrophils in the bloodstream. In recent studies, it has been shown that \n",
            "neutrophils can produce structures that are called neutrophil extracellular \n",
            "traps (NET) and that enable them to capture microorgan isms like a \n",
            "network, apart from their phagocytosis functions. 6 Monocyte derived \n",
            "macrophages, which become dominant on day 3 to 5 of injury, play a role \n",
            "in fibroblast proliferation and angiogenesis by releasing cytokines, growth \n",
            "factors and angiogenic factors in addition to their phagocytosis function. 7\n",
            "Editor • Prof. Dr. Sıddık Keskin                      0000-0001-9355-6558 \n",
            " \n",
            "Cover Design • Aruull Raja \n",
            "First Published • December 2020, Lyon \n",
            " \n",
            "ISBN: 978-2-38236-061-3 \n",
            " \n",
            " \n",
            " \n",
            " \n",
            "© copyright \n",
            "All rights reserved. No part of this publication may be reproduced, stored \n",
            "in a retrieval system, or transmitted in any form or by an means, \n",
            "electronic, mechanical, photocopying, recording, or otherwise, without \n",
            "the publisher’s permission. \n",
            " \n",
            " \n",
            " \n",
            "The chapters in this book have been checked for plagiarism by \n",
            " \n",
            "Publisher • Livre de Lyon \n",
            "Address •  37 rue marietton, 69009, Lyon France \n",
            "website •  http://www.livredelyon.com \n",
            "e-mail •  livredelyon@gmail.com\n",
            "22 \n",
            "11. Yurtcu, E., Togrul, C., Ozyer, S., Uzunlar, O., Karatas, Y. H., Seckin, \n",
            "K. D., ... & Cicek, N. (2015). Dose dependent protective effects of \n",
            "vardenafil on ischemia –reperfusion injury with biochemical and \n",
            "histopathologic evaluation in rat ovary.  Journal of pediatric \n",
            "surgery, 50(7), 1205-1209. \n",
            "12. Incebiyik, A., Seker, A., Camuzcuoglu, H., Kocaslan, S., \n",
            "Camuzcuoglu, A., Hilali, N. G., ... & Aksoy, N. (2015). Does \n",
            "sildenafil have protective effects against ovarian ischemia -\n",
            "reperfusion injury in rats?.  Archives of gynecology and \n",
            "obstetrics, 291(6), 1283-1288. \n",
            "13. Başer, B. G., Taşkın, M. İ., Adalı, E., Öztürk, E., Hısmıoğulları, A. A., \n",
            "& Yay, A. (2018). Does progesterone have protective effects on \n",
            "ovarian ischemia -reperfusion injury?.  Journal of the Turkish \n",
            "German Gynecological Association, 19(2), 87. \n",
            "14. Yilmaz, E. P. T., Un, H., Gundogdu, B., Polat, E., Askin, S., Topdagi, \n",
            "Y. E., & Halici, Z. (2020). Protective Effect of Lycopene against \n",
            "Reperfusion Injury in Rats with Ovarian Torsion: A Biochemical \n",
            "and Hist opathological Evaluation.  Journal of Laboratory \n",
            "Physicians, 12(1), 32. \n",
            "15. Erbas, O., & Karadadas, N. Effects of Methylene Blue on Ovarian \n",
            "TorsionLDetorsion Injury in a Rat Model. \n",
            "16. Cadirci, E., Oral, A., Odabasoglu, F., Kilic, C., Coskun, K., Halici, Z., \n",
            "... & Unal, B. (2010). Atorvastatin reduces tissue damage in rat \n",
            "ovaries subjected to torsion and detorsion: biochemical and \n",
            "histopathologic evaluation.  Naunyn-Schmiedeberg's archives of \n",
            "pharmacology, 381(5), 455-466. \n",
            "17. Sak, M. E., Soydinc, H. E., Sak,  S., Evsen, M. S., Alabalik, U., \n",
            "Akdemir, F., & Gul, T. (2013). The protective effect of curcumin \n",
            "on ischemia-reperfusion injury in rat ovary. International Journal \n",
            "of Surgery, 11(9), 967-970. \n",
            "18. Gungor, A. N. C., Gencer, M., Karaca, T., Hacivelioglu, S., Uysal, A., \n",
            "Korkmaz, F., ... & Cosar, E. (2014). The effect of hesperetin on \n",
            "ischemia–reperfusion injury in rat ovary.  Archives of gynecology \n",
            "and obstetrics, 290(4), 763-769. \n",
            "19. Nayki, C., Nayki, U., Keskin Cimen, F., Kulhan, M., Yapca, O. E., \n",
            "Kurt, N., & Bilgin Ozbek, A. (2018). The effect of rutin on ovarian \n",
            "ischemia-reperfusion injury in a rat model.  Gynecological \n",
            "Endocrinology, 34(9), 809-814. \n",
            "20. Eser, A., Hizli, D., Haltas, H., Namuslu, M., Kosus, A., Kosus, N., & \n",
            "Kafali, H. (2015). Effects of curcum in on ovarian ischemia -\n",
            "45 \n",
            "COAGULATION TESTS \n",
            "Numerous tests assess the risk of bleeding to guide clinical \n",
            "diagnosis and treatment approaches. Commonly used coagulation tests \n",
            "contain the following: \n",
            "-CBC \n",
            "-Bleeding time \n",
            "-Platelet function tests \n",
            "-Routine hemostasis tests as prothrombin time (PT), partial \n",
            "thromboplastin time (PTT), thrombin \n",
            "time (TT), fibrinogen level, and D-dimer \n",
            "- Antithrombin III levels \n",
            "- Private analysis suchlike anti -Xa assay, diluted thrombin time, \n",
            "and tests for heparin-induced thrombocytopenia \n",
            "- Thromboelastography (TEG) \n",
            "-Hypercoagulability and fibrinolysis tests \n",
            "Complete blood count (CBC) is one of the most common \n",
            "laboratory tests requested by clinicians, and this test is also required before \n",
            "surgery to evaluate a patient for bleeding risk. Pla telet count and mean \n",
            "platelet volume are essential parameters in predicting bleeding \n",
            "complications, especially in surgical interventions. Performing CBC is for \n",
            "diagnosing thrombocytopenia when the platelet count is less than 150,000/ \n",
            "µL. Unexpected thrombo cytopenia should be confirmed by peripheral \n",
            "blood smear. The probability of red blood cell fragments or pseudo \n",
            "thrombocytopenia may provide hints for further assessing the patient.  \n",
            "Bleeding time is defined as the time between applying a small \n",
            "standard incision and bleeding stops. Although it is a simple test, many \n",
            "factors affect bleeding time, making it difficult to standardize. Bleeding \n",
            "time measures platelets ' interaction with the vessel wall, followed by \n",
            "forming the first hemostatic plug. Bleeding time will be prolonged in cases \n",
            "of decreased platelet count, dysfunction, or vascular wall pathology. \n",
            "Besides, when there is a decrease in VWF or fibrinogen, the bleeding time \n",
            "may be prolonged. The depth, width, and position of the skin incision may \n",
            "differ for each application, so its diagnostic utility as an individual test is \n",
            "of limited value. \n",
            "Analyzers available for platelet function tests include PFA -100, \n",
            "Plateletworks, and VerifyNow. Also, a platelet aggregation test can be \n",
            "performed. These tests are used to determine platelet function and to decide \n",
            "whether a platelet transfusion is required. The PFA-100 system is a platelet\n",
            "Editor\n",
            "Prof. Dr. Sıddık Keskin\n",
            "Medical Diagnosis\n",
            "and\n",
            "Treatment Methods\n",
            "in\n",
            "Basic Medical Sciences\n",
            "Medical Diagnosis and Treatment Methods in Basic Medical Sciences\n",
            "Health\n",
            "livredelyon.com\n",
            "livredelyon\n",
            "livredelyon\n",
            "livredelyon\n",
            "ISBN: 978-2-38236-061-3\n",
            "I \n",
            "PREFACE \n",
            " \n",
            "Basic medical sciences are the entire of studies that aim to \n",
            "diagnose and treatments of diseases in order to maintain healthy life or to \n",
            "protect health and to treat disorders. Malpractices in health are still an \n",
            "important problem for many societie s even for developed societies. The \n",
            "reflection of this problem on patients, relatives of patient and doctors is \n",
            "very serious financially and morally. It is obvious that this problem can \n",
            "be reduced substantially by applying the proper diagnosis and treatmen t \n",
            "methods in Medical Sciences. Today, Evidence -Based Medicine (EBM) \n",
            "aims to minimize the problems arising from malpractices in Health \n",
            "Sciences and directly affecting the patients, doctors and institution. \n",
            "Therefore, diagnosis and treatment methods in medic al sciences are very \n",
            "important in the process of treating the patient and eliminating the \n",
            "diseases. In order to apply the proper treatment method, the proper \n",
            "diagnosis of the disease is basic prerequisite. When considering the role \n",
            "of diagnosis and treatme nt for clinicians, well -designed, accurate and \n",
            "reliable diagnostic and treatment methods are needed. Thus, many studies \n",
            "have been carried out on the diagnosis and treatment methods as well as \n",
            "efficacy and reliability of these methods used in Basic Medical Sciences. \n",
            "In this framework, the aim of this book is to gather and to present the \n",
            "studies to clinician for easy access and evaluation medical diagnosis and \n",
            "treatment methods. Thus, our book has 9 chapters. The first and second \n",
            "chapters present conceptual o verview of    biomedical and biochemical \n",
            "histopathology, respectively. The third chapter is about the review of \n",
            "cancer treatment and the fourth chapter is about the coagulation analysis \n",
            "in diagnosis and treatment. The 5 th chapter is about the prevalence of  \n",
            "Palmaris longus. The 6 th chapter is focused on Treatment of erectile \n",
            "dysfunction. The 7 th chapter describes possible effect of pre -eclampsia \n",
            "and eclampsia on pregnancy, and examination of relationship between \n",
            "smoking and pregnancy is presented in the 8 th chapter. Finally, Chapter 9 \n",
            "addresses the effect of lavender on wound healing as alternative \n",
            "medicine. \n",
            "We tried to prepare this book as carefully as possible and by \n",
            "minimizing mistakes as time and possibilities allowed. However, I \n",
            "apologize to you readers for the mistakes. I would like to thank for all my \n",
            "teammates who contributed to the preparation of this book. We hope that \n",
            "this book will be useful to our readers and researchers who want to make \n",
            "new studies. \n",
            "Prof. Dr. Sıddık KESKİN\n",
            "REFEREES \n",
            " \n",
            "Assoc. Prof. Dr. Alper Gümüş,  Başakşehir City Hospital  \n",
            "Assoc. Prof.  Dr. Kemal Sarsmaz , University of Health Sciences Etlik \n",
            "Zübeyde Hanım Gynecology Training and Research Hospital \n",
            "Asst. Prof. Dr. Ayhan Güler, Hakkari University\n",
            "120 \n",
            "Table 3: Pearson correlation analysis for all data. \n",
            " \n",
            " \n",
            "Table 4:  Statistical analysis of histopathological concentrations \n",
            "(Hematoxylin-Eosin) of smokers and non-smokers. \n",
            " \n",
            " \n",
            "Histopathological Findings:  \n",
            "Majority of the placentas in the non -smoker group were terminal \n",
            "villus based on our histopathological findings (Figure 2a). The villuses \n",
            "were located at intervillous intervals with sporadic maternal blood cells in \n",
            "between. While fetal veins and connective tissue were observed in the \n",
            "villuses, rare cytotrophoblast cells and syncytial cells and knots were \n",
            "observed on the outside (Figure 2b). Normal structure mesenchymal \n",
            "connective tissue and fibroblasts were observed in root villuses (Figure \n",
            "2c,d). Intravillous deposits at the tertiary villuses and fibrinoid deposits on \n",
            "the intervillous areas were observed when the structural differences and \n",
            "cellular average were evaluated for the placentas of the smoker group in \n",
            "addition to an increase in syncytial knots (Fig ure 3a,b). The connective \n",
            "tissue of root villuses lost its normal structure, necrotic and inflammation \n",
            "areas were determined different than the non -smokers (Figure 3c,d). The \n",
            "presence of histopathological findings in smokers increased by 76.09 % \n",
            "(Table 1). In addition, a statistically significant difference was determined \n",
            "between the smoker and non -smoker groups with regard to fibrinoid \n",
            "deposits at the intravillous and intervillous areas and necrotic and \n",
            "inflammation areas in the term placenta (p <0.05) (Figure 1,2,3) (Table 4). \n",
            " \n",
            "Group\n",
            "N\n",
            "x\n",
            "SD\n",
            "H&E\n",
            "Smokers\n",
            "35\n",
            "2,5143\n",
            ",61220\n",
            "nonsmokers\n",
            "35\n",
            ",6000\n",
            ",49705\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "<ipython-input-40-1662d5adef26>:2: LangChainDeprecationWarning: The method `BaseRetriever.get_relevant_documents` was deprecated in langchain-core 0.1.46 and will be removed in 1.0. Use :meth:`~invoke` instead.\n",
            "  all_chunks = retriever.get_relevant_documents(\"cancer\")\n"
          ]
        }
      ],
      "source": [
        "retriever = vectorstores.as_retriever()\n",
        "all_chunks = retriever.get_relevant_documents(\"cancer\")\n",
        "\n",
        "docs = vectorstores.similarity_search(\"\", k=2000)\n",
        "\n",
        "full_text = \"\\n\".join([doc.page_content for doc in docs])\n",
        "print(full_text)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 51,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 194
        },
        "id": "o8sDiU2tl5lS",
        "outputId": "6acd9c84-adc1-43bc-8cfc-cfad97c3fe71"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Based on the provided text, histopathological findings refer to the examination of tissue samples under a microscope to identify abnormalities or changes in the structure of cells and tissues. In the context of the three documents, histopathological findings would likely be related to the study of blood clots, fibrinolysis, and coagulation disorders.\\n\\nIn Document 1, histopathological findings might include an examination of blood clots and their components, such as fibrin, fibrinogen, and other proteins involved in clot formation and breakdown. The document mentions the role of plasminogen and plasmin in fibrinolysis, which suggests that histopathological findings might focus on the study of thrombi (blood clots) and the mechanisms of their degradation.\\n\\nIn Document 2, histopathological findings might include an examination of blood vessels and endothelial cells, as well as the coagulation system. The document discusses the role of antithrombin III in inhibiting serine proteases and activating protein C, which suggests that histopathological findings might focus on the study of vascular biology and thrombosis.\\n\\nIn Document 3, histopathological findings might include an examination of blood clots and their components, as well as the effects of fibrinolysis on clot structure. The document mentions the formation of fibrin degradation products (FDPs) and the role of D-dimer in assessing disease severity, which suggests that histopathological findings might focus on the study of thrombi and coagulation disorders.\\n\\nOverall, histopathological findings would likely involve a detailed examination of tissue samples to identify changes or abnormalities related to blood clots, fibrinolysis, and coagulation disorders. This might include examining tissue sections for evidence of thrombi, endothelial damage, or other signs of coagulation disorders.'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 51
        }
      ],
      "source": [
        "from operator import itemgetter\n",
        "\n",
        "chain= (\n",
        "    {\n",
        "        \"context\" : itemgetter('question') | retriever,\n",
        "        \"question\": itemgetter('question')\n",
        "    }\n",
        "    | prompt\n",
        "    | model\n",
        "    | parser\n",
        "\n",
        ")\n",
        "chain.invoke({\"question\": \"Histopathological Findings.\"})"
      ]
    }
  ],
  "metadata": {
    "accelerator": "GPU",
    "colab": {
      "gpuType": "T4",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}